PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN				Harpaz, R; VonSeidlein, L; Averhoff, FM; Tormey, MP; Sinha, SD; Kotsopoulou, K; Lambert, SB; Robertson, BH; Cherry, JD; Shapiro, CN			Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE WORKERS; SURFACE-ANTIGEN; OPERATING-ROOM; EXPOSURE; BLOOD; RISK; CONTAMINATION; OUTBREAK	Background. Although about 1 percent of surgeons are infected with hepatitis B virus (HBV), transmission from surgeons to patients is thought to be uncommon, In July 1992, a 47-year-old woman became ill with acute hepatitis B after undergoing a thymectomy in which a thoracic-surgery resident who had had acute hepatitis B six months earlier assisted. Methods. To determine whether the surgeon transmitted HBV to this patient and others, we conducted chart reviews, interviews, and serologic testing of thoracic-surgery patients at the two hospitals where the surgeon worked from July 1991 to July 1992, Hepatitis B surface antigen (HBsAg) subtypes and DNA sequences from the surgeon and from infected patients were determined. Results. Of 144 susceptible patients in whose surgery the infected surgeon participated, 19 had evidence of recent HBV infection (13 percent), One of the hospitals was selected for additional study, and none of the 124 susceptible patients of the other thoracic surgeons at this hospital had evidence of recent HBV infection (relative risk, infinity; 95 percent confidence interval, 4.7 to infinity). NO evidence was found for any common source of HBV other than the infected surgeon, The HBsAg subtype and the partial HBV DNA sequences from the surgeon were identical to those in the infected patients, Transmission of the infection was associated with cardiac transplantation (relative risk, 4.9; 95 percent confidence interval, 1,5 to 15.5) but not with other surgical procedures, The surgeon was positive for hepatitis B e antigen and had a high serum HBV DNA concentration (15 ng per milliliter), Our investigations identified no deficiencies in the surgeon's infection-control practices. Conclusions. In this outbreak there was surgeon-to-patient HBV transmission despite apparent compliance with recommended infection-control practices, We could not identify any specific events that led to transmission.	CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA 30333; UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA	Centers for Disease Control & Prevention - USA; University of California System; University of California Los Angeles								ALTER HJ, 1975, NEW ENGL J MED, V292, P454, DOI 10.1056/NEJM197502272920904; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BELL DM, 1995, SURG CLIN N AM, V75, P1189; CARL M, 1982, LANCET, V1, P731; COUTINHO RA, 1982, LANCET, V1, P345; Dean A. G., 1990, EPI INFO VERSION 5 W; DODD RY, 1973, AM J EPIDEMIOL, V97, P111, DOI 10.1093/oxfordjournals.aje.a121487; FELL M, 1989, ANN ROY COLL SURG, V71, P7; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HARPAZ R, 1994, INFECT CONT HOSP EP, V15, P352; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HOSIE KB, 1988, LANCET, V2, P1500; Johnston B L, 1992, Can Commun Dis Rep, V18, P89; LABRECQUE DR, 1986, HEPATOLOGY, V6, P205, DOI 10.1002/hep.1840060209; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; MEYERS JD, 1978, JAMA-J AM MED ASSOC, V240, P1725, DOI 10.1001/jama.240.16.1725; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; PATE JW, 1990, ANN THORAC SURG, V50, P248, DOI 10.1016/0003-4975(90)90743-P; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; PRENDERGAST TJ, 1991, WESTERN J MED, V154, P353; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; QUEBBEMAN EJ, 1992, ARCH SURG-CHICAGO, V127, P213; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; ROBERTSON BH, 1991, J INFECT DIS, V163, P286, DOI 10.1093/infdis/163.2.286; ROSE DA, 1994, INFECT CONT HOSP EP, V15, P349; SHAFRITZ DA, 1982, P NATL ACAD SCI-BIOL, V79, P5675, DOI 10.1073/pnas.79.18.5675; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; WELCH J, 1989, LANCET, V1, P205; WILLIAMS SV, 1975, JAMA-J AM MED ASSOC, V232, P1231, DOI 10.1001/jama.232.12.1231; WONG PS, 1993, ANN THORAC SURG, V56, P108, DOI 10.1016/0003-4975(93)90412-B; 1994, HOSP STAT AHA PROFIL; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, PROGRAM MANUAL GCG P	36	170	174	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					549	554		10.1056/NEJM199602293340901	http://dx.doi.org/10.1056/NEJM199602293340901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569821				2022-12-28	WOS:A1996TW69600001
J	Jentsch, S				Jentsch, S			When proteins receive deadly messages at birth	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI				Jentsch, S (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY.							ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; GUARNEROS G, 1988, CURR TOP MICROBIOL, V136, P1; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KEILER KC, 1995, PROTEIN SCI, V4, P1505; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	19	36	37	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					955	956		10.1126/science.271.5251.955	http://dx.doi.org/10.1126/science.271.5251.955			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584931				2022-12-28	WOS:A1996TV70400038
J	Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M				Melcher, T; Maas, S; Herb, A; Sprengel, R; Seeburg, PH; Higuchi, M			A mammalian RNA editing enzyme	NATURE			English	Article							MOLECULAR-CLONING; CHANNELS; RECEPTOR	EDITING of RNA(1) by site-selective adcnosine deamination alters codons in brain-expressed pre-messenger RNAs for glutamate receptor (GluR) subunits(2-4) including a codon for a channel determinant (Q/R site) in GluR-B, which controls the Ca2+ permeability of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors(5,6). Editing of GluR pre-mRNAs requires a double-stranded RNA (dsRNA) structure formed by esonic and intronic sequences(4,7) and is catalysed by an unknown dsRNA adenosine deaminase. Here we report the cloning of complementary DNA for RED1, a dsRNA adenosine deaminase expressed in brain and peripheral tissues that efficiently edits the Q/R site in GluR-B pre-mRNA in vitro. This site is poorly edited by DRADA, which is distantly sequence related to RED1. Both deaminases edit the R/G site in GluR-B pre-mRNA, indicating that members of an emerging gene family catalyse adenosine deamination in nuclear transcripts with distinct but overlapping substrate specificities.	UNIV HEIDELBERG, ZMBH, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; CHENG JF, 1994, GENOMICS, V23, P75, DOI 10.1006/geno.1994.1461; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	29	426	438	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 1	1996	379	6564					460	464		10.1038/379460a0	http://dx.doi.org/10.1038/379460a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559253				2022-12-28	WOS:A1996TT30400063
J	Kopelman, P				Kopelman, P			Gestational diabetes and beyond	LANCET			English	Editorial Material							GLUCOSE-INTOLERANCE; MELLITUS; WOMEN				Kopelman, P (corresponding author), ROYAL LONDON HOSP,MED UNIT,LONDON E1 1BB,ENGLAND.							ALES KL, 1989, LANCET, V1, P1187; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; DORNHORST A, 1993, DIABETIC MED, V10, P897, DOI 10.1111/j.1464-5491.1993.tb00004.x; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; KUHL C, 1991, BAILLIERE CLIN OB GY, V5, P279, DOI 10.1016/S0950-3552(05)80098-7; MANSON JE, 1992, AM J MED, V93, P13, DOI 10.1016/0002-9343(92)90674-Z; NASRAT HA, 1990, METABOLISM, V39, P51, DOI 10.1016/0026-0495(90)90147-5; NELSONPIERCY C, 1994, DIABETIC MED, V11, P493, DOI 10.1111/j.1464-5491.1994.tb00313.x; OSULLIVAN JB, 1982, JAMA-J AM MED ASSOC, V248, P949, DOI 10.1001/jama.248.8.949; OSULLIVAN JB, 1991, DIABETES, V40, P131, DOI 10.2337/diab.40.2.S131; 1985, WHO TECH REP SER, V729, P9	11	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					208	209		10.1016/S0140-6736(96)90397-9	http://dx.doi.org/10.1016/S0140-6736(96)90397-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551874				2022-12-28	WOS:A1996TT06900003
J	Chant, J				Chant, J			Septin scaffolds and cleavage planes in Saccharomyces	CELL			English	Review							CELL-CYCLE; GENETIC-CONTROL; BUDDING YEAST; CEREVISIAE; MORPHOGENESIS; CYTOKINESIS; ACTIN; SITE				Chant, J (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; FARES H, 1996, IN PRESS MOL CELL BI; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1977, GENETICS, V85, P395; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NOTTENBURG C, 1990, GENE, V95, P279, DOI 10.1016/0378-1119(90)90372-X; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; SNYDER M, 1991, J CELL BIOL, V114, P515, DOI 10.1083/jcb.114.3.515; TRAAS J, 1995, NATURE, V375, P676, DOI 10.1038/375676a0; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; ZAHNER J, 1996, IN PRESS MOL CELL BI	22	80	84	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					187	190		10.1016/S0092-8674(00)80972-1	http://dx.doi.org/10.1016/S0092-8674(00)80972-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565063	Bronze			2022-12-28	WOS:A1996TR59500004
J	Fang, F; Orend, G; Watanabe, N; Hunter, T; Ruoslahti, E				Fang, F; Orend, G; Watanabe, N; Hunter, T; Ruoslahti, E			Dependence of cyclin E-CDK2 kinase activity on cell anchorage	SCIENCE			English	Article							INDEPENDENT GROWTH; PROTEIN-KINASE; FIBROBLASTS; P40(MO15); P34(CDC2); ADHESION	Most nonmalignant cells are anchorage-dependent; they require substrate attachment for growth and, in some instances, survival. This requirement is lost on oncogenic transformation. The cyclin E-CDK2 complex, which is required for the G(1)-S transition of the cell cycle, was activated in late G(1) phase in attached human fibroblasts, but not in fibroblasts maintained in suspension. In transformed fibroblasts the complex was active regardless of attachment, The lack of cyclin E-CDK2 activity in suspended cells appeared to result from increased expression of CDK2 inhibitors and a concomitant decrease in phosphorylation of CDK2 on threonine-160. Suppression of cyclin E-CDK2 activity may thus underlie the anchorage dependence of cell growth.	SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA	Salk Institute	Fang, F (corresponding author), LA JOLLA CANC RES FDN, CTR CANC, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Watanabe, Nobumoto/N-6959-2015; Orend, Gertraud/E-8446-2015	Watanabe, Nobumoto/0000-0002-2130-1334; Orend, Gertraud/0000-0003-2522-1195	NATIONAL CANCER INSTITUTE [R01CA060725, R01CA067224, P01CA028896] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60725, CA 67224, CA 28896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPISI J, 1983, J CELL PHYSIOL, V114, P53, DOI 10.1002/jcp.1041140109; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG FF, UNPUB; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KOFF A, 1995, J CELL BIOL, V130, P755; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHILIPPE M, 1991, CELL, V66, P1217; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, CURR BIOL, V5, P1243; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; POON RYC, UNPUB; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	47	347	356	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					499	502		10.1126/science.271.5248.499	http://dx.doi.org/10.1126/science.271.5248.499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560263				2022-12-28	WOS:A1996TR32200040
J	Kinomura, S; Larsson, J; Gulyas, B; Roland, PE				Kinomura, S; Larsson, J; Gulyas, B; Roland, PE			Activation by attention of the human reticular formation and thalamic intralaminar nuclei	SCIENCE			English	Article							NEURONS; WAKING; STATES; BRAIN; CORE; CAT	It has been known for over 45 years that electrical stimulation of the midbrain reticular formation and of the thalamic intralaminar nuclei of the brain alerts animals. However, lesions of these sectors fail to impair arousal and vigilance in some cases, making the role of the ascending activating reticular system controversial. Here, a positron emission tomographic study showed activation of the midbrain reticular formation and of thalamic intralaminar nuclei when human participants went from a relaxed awake state to an attention-demanding reaction-time task. These results confirm the role of these areas of the brain and brainstem in arousal and vigilance.	KAROLINSKA INST,DEPT NEUROSCI,DIV HUMAN BRAIN RES,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Gulyas, Balazs/F-9508-2015					[Anonymous], 1993, BRAIN ACTIVATION; BERGSTROM M, 1981, J COMPUT ASSIST TOMO, V5, P136, DOI 10.1097/00004728-198102000-00027; DECETY J, 1992, NEUROREPORT, V3, P761, DOI 10.1097/00001756-199209000-00010; DENOYER M, 1991, BRAIN RES, V539, P287, DOI 10.1016/0006-8993(91)91633-C; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GLENN LL, 1982, J NEUROSCI, V2, P1387; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; HU B, 1989, NEUROSCIENCE, V31, P1, DOI 10.1016/0306-4522(89)90026-2; INGVAR DH, 1964, ARCH NEUROL-CHICAGO, V11, P13, DOI 10.1001/archneur.1964.00460190017002; KAWASHIMA R, 1995, CEREB CORTEX, V2, P111; KETY SS, 1950, AM J MED, V8, P205, DOI 10.1016/0002-9343(50)90363-9; KITSIKIS A, 1981, BEHAV BRAIN RES, V3, P361, DOI 10.1016/0166-4328(81)90005-X; LINDSLEY DB, 1950, ELECTROEN CLIN NEURO, V2, P483, DOI 10.1016/0013-4694(50)90086-1; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OSULLIVAN BT, 1994, EUR J NEUROSCI, V6, P137, DOI 10.1111/j.1460-9568.1994.tb00255.x; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Roland P E, 1994, Hum Brain Mapp, V1, P173, DOI 10.1002/hbm.460010303; ROLAND P E, 1976, Archives of Neurology, V33, P551; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SALLANON M, 1988, ARCH ITAL BIOL, V126, P87; Schaltenbrand G., 1959, EINFUHRUNG STEREOTAK; Scheibel ME, 1958, RETICULAR FORMATION, P31; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; STERIADE M, 1982, BRAIN RES, V238, P13, DOI 10.1016/0006-8993(82)90767-3; STERIADE M, 1982, EXP BRAIN RES, V46, P37; WEBSTER HH, 1988, BRAIN RES, V458, P285, DOI 10.1016/0006-8993(88)90471-4	28	460	478	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					512	515		10.1126/science.271.5248.512	http://dx.doi.org/10.1126/science.271.5248.512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560267				2022-12-28	WOS:A1996TR32200044
J	Nightingale, SL				Nightingale, SL			Progress in international harmonization of drug approval requirements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, JAMA-J AM MED ASSOC, V270, P302	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-28	WOS:A1996TP96500007
J	Horton, R				Horton, R			The infected metropolis	LANCET			English	Editorial Material																		[Anonymous], 1995, WORLD URBANIZATION P; Barrera R, 1995, Bull Pan Am Health Organ, V29, P193; Bellow S., 1995, IT ALL ADDS UP; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; Karlen A., 1995, PLAGUES PROGR SOCIAL; ROHTER L, 1995, NY TIMES INT    0923, P5; STEERE AC, 1995, INFECTIOUS DISEASES IN AN AGE OF CHANGE, P1; 1995, LANCET, V346, P809	8	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					134	135		10.1016/S0140-6736(96)90333-5	http://dx.doi.org/10.1016/S0140-6736(96)90333-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544541	Bronze			2022-12-28	WOS:A1996TQ24400002
J	Shennan, A; Gupta, M; Halligan, A; Taylor, DJ; deSwiet, M				Shennan, A; Gupta, M; Halligan, A; Taylor, DJ; deSwiet, M			Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry	LANCET			English	Article							DIASTOLIC BLOOD-PRESSURE; HYPERTENSION; DEFINITION	Background Since hypertensive disorders of pregnancy are common, blood pressure is frequently measured in all pregnant women. Many authorities recommend that Korotkoff phase IV (K4, muffling of sound) is taken as the diastolic identification point measured on mercury sphygomanometry in pregnancy because of reports that phase V (K5, disappearance of sound) is at or near to zero cuff pressure in some pregnant women, We compared the identification and reproducibility of K4 and K5 by observers unaware of each other's results. Methods In the first part of the study, two pairs of observers each took 340 measurements in 85 pregnant women. The second part of the study consisted of 1120 measurements in 80 pregnant and 80 non-pregnant women by five pairs of observers. Measurements were taken simultaneously by sphygmomanometry with a shared cuff and diaphragm; the observers were in separate booths. Findings K5 was identified in all measurements by both observers and never approached zero. K4 was heard in only 52% of measurements; in 33% of cases it was heard by only one of the pair of observers, so the pair agreed on its detection in only 19% of readings. Visual analogue scores used to assess Korotkoff sound quality indicated that systolic blood pressure was perceived significantly more clearly than diastolic blood pressure (K4 or K5). Even when K4 was heard by both observers, agreement an its value was poor (78% within 5 mm Hg vs 86% for K5, p<0.05). K4 was heard significantly less often in non-pregnant women (32% of measurements). There was also no consistency in the identification of K4 within individual women. Interpretation K4 has little value in clinical management because it cannot be reproduced accurately. We recommend that K4 should be replaced by K5 as the measure of diastolic blood pressure in pregnancy.	UNIV LEICESTER, LEICESTER ROYAL INFIRM, DEPT OBSTET & GYNAECOL, LEICESTER, LEICS, ENGLAND	University of Leicester	Shennan, A (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP, ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W6 0XG, ENGLAND.			Shennan, Andrew/0000-0001-5273-3132				[Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; BLANK SG, 1994, HYPERTENSION, V24, P234, DOI 10.1161/01.HYP.24.2.234; BROWN MA, 1994, AM J OBSTET GYNECOL, V171, P661, DOI 10.1016/0002-9378(94)90079-5; BROWN MA, 1991, BRIT MED J, V303, P120, DOI 10.1136/bmj.303.6794.120-d; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; ETTINGER W, 1907, WEIN KLIN WOCHENSCHR, V58, P243; GALLERY EDM, 1995, 9TH P INT SOC STUD H, P74; JOHENNING AR, 1992, AM J OBSTET GYNECOL, V167, P577, DOI 10.1016/S0002-9378(11)91552-X; KIRKENDALL W M, 1981, Hypertension (Dallas), V3, p510A; Korotkoff NS, 1905, IZV IMP VOENNO MED A, VXI, P365, DOI DOI 10.1097/00004872-200501000-00001; LOPEZ MC, 1994, AM J OBSTET GYNECOL, V170, P574, DOI 10.1016/S0002-9378(94)70230-6; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; NELSON TR, 1955, J OBSTET GYNAECOL, V62, P48; OBRIEN E, 1993, J HYPERTENS, V11, P677, DOI 10.1097/00004872-199306000-00013; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; PERRY IJ, 1990, BRIT MED J, V301, P1198, DOI 10.1136/bmj.301.6762.1198; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; RAFTERY EB, 1968, CARDIOVASC RES, V2, P210, DOI 10.1093/cvr/2.2.210; REDMAN CWG, 1988, LANCET, V1, P809; SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/j.1471-0528.1993.tb15104.x; TERVILA L, 1973, ACTA OBSTET GYN SCAN, V52, P235, DOI 10.3109/00016347309158320; WICHMAN K, 1984, ACTA OBSTET GYN SCAN, P25; WILKINSON LS, 1991, J ROY COLL PHYS LOND, V25, P116; 1987, WHO TECH REP SER, V758	25	97	98	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					139	142		10.1016/S0140-6736(96)90338-4	http://dx.doi.org/10.1016/S0140-6736(96)90338-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544546				2022-12-28	WOS:A1996TQ24400007
J	Doniach, T				Doniach, T			Basic FGF as an inducer of anteroposterior neural pattern	CELL			English	Review							CENTRAL-NERVOUS-SYSTEM; XENOPUS				Doniach, T (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.							ALTABA ARI, 1994, TRENDS NEUROSCI, V17, P233, DOI 10.1016/0166-2236(94)90006-X; ALVARADOMALLART RM, 1993, J NEUROBIOL, V24, P1341, DOI 10.1002/neu.480241007; Cox WG, 1995, DEVELOPMENT, V121, P4349; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KENGAKU M, 1993, DEVELOPMENT, V119, P1067; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LAMB TM, 1995, DEVELOPMENT, V121, P3627; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; NIEUWKOOP PD, 1990, DEV GROWTH DIFFER, V32, P23; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK H, 1994, GENE DEV, V4, P116; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958	20	123	125	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1067	1070		10.1016/0092-8674(95)90133-7	http://dx.doi.org/10.1016/0092-8674(95)90133-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548794	Bronze			2022-12-28	WOS:A1995TM76200003
J	Bagatell, CJ; Bremner, WJ				Bagatell, CJ; Bremner, WJ			Drug therapy - Androgens in men - Uses and abuses	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GONADOTROPIN-RELEASING-HORMONE; DENSITY-LIPOPROTEIN CHOLESTEROL; ANABOLIC-STEROID USE; HYPOGONADAL MEN; TESTOSTERONE REPLACEMENT; SEXUAL-BEHAVIOR; BONE-CELLS; DANAZOL; PREVALENCE; ANTAGONIST		UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Bagatell, CJ (corresponding author), VET AFFAIRS MED CTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							ALEN M, 1985, INT J SPORTS MED, V6, P139, DOI 10.1055/s-2008-1025827; ALEN M, 1985, MED SCI SPORT EXER, V17, P354; ALEN M, 1987, AM J SPORT MED, V15, P357, DOI 10.1177/036354658701500411; Ammus S S, 1989, Adv Intern Med, V34, P191; ANDERSON RA, 1992, J CLIN ENDOCR METAB, V75, P1503, DOI 10.1210/jc.75.6.1503; [Anonymous], 1987, Med Sci Sports Exerc, V19, P534; [Anonymous], 1990, Lancet, V336, P955; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P711, DOI 10.1210/jc.78.3.711; BAGATELL CJ, 1993, J CLIN ENDOCR METAB, V77, P427, DOI 10.1210/jc.77.2.427; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V79, P561, DOI 10.1210/jc.79.2.561; BAHRKE MS, 1990, SPORTS MED, V10, P303, DOI 10.2165/00007256-199010050-00003; BARBIERI RL, 1981, AM J OBSTET GYNECOL, V141, P453, DOI 10.1016/0002-9378(81)90611-6; Bebb RA, 1996, J CLIN ENDOCR METAB, V81, P757, DOI 10.1210/jc.81.2.757; BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341; BEHRE HM, 1992, J CLIN ENDOCR METAB, V75, P1204, DOI 10.1210/jc.75.5.1204; BHASIN S, 1992, J CLIN ENDOCR METAB, V74, P75, DOI 10.1210/jc.74.1.75; BHASIN S, 1992, J CLIN ENDOCR METAB, V74, P1221, DOI 10.1210/jc.74.6.1221; BIZZARRO A, 1987, J CLIN ENDOCR METAB, V64, P32, DOI 10.1210/jcem-64-1-32; BREMNER WJ, 1983, J CLIN ENDOCR METAB, V56, P1278, DOI 10.1210/jcem-56-6-1278; BROWER KJ, 1989, J CLIN PSYCHIAT, V50, P31; BUCKLEY WE, 1988, JAMA-J AM MED ASSOC, V260, P3441; DAVIDSON JM, 1982, CLIN ENDOCRINOL META, V11, P599, DOI 10.1016/S0300-595X(82)80003-0; DAVIDSON JM, 1979, J CLIN ENDOCR METAB, V48, P955, DOI 10.1210/jcem-48-6-955; DICKINSON P, 1969, J CLIN ENDOCR METAB, V29, P837, DOI 10.1210/jcem-29-6-837; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; ELASHOFF JD, 1991, ANN INTERN MED, V115, P387, DOI 10.7326/0003-4819-115-5-387; FERENCHICK G, 1992, AM J MED SCI, V303, P78, DOI 10.1097/00000441-199202000-00002; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1990, TESTOSTERONE ACTION, P204; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FRANKLE MA, 1988, ARCH PHYS MED REHAB, V69, P632; FRIEDL KE, 1990, METABOLISM, V39, P69, DOI 10.1016/0026-0495(90)90150-B; GARDNER FH, 1968, BRIT J HAEMATOL, V14, P611, DOI 10.1111/j.1365-2141.1968.tb00367.x; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GILSANZ V, 1988, RADIOLOGY, V166, P847, DOI 10.1148/radiology.166.3.3340782; GOOREN LJG, 1987, ARCH SEX BEHAV, V16, P463, DOI 10.1007/BF01541711; GRAY A, 1991, J CLIN ENDOCR METAB, V73, P1016, DOI 10.1210/jcem-73-5-1016; GROSSMAN CJ, 1991, J STEROID BIOCHEM, V40, P649, DOI 10.1016/0960-0760(91)90287-F; Gurakar A, 1994, J Okla State Med Assoc, V87, P399; HANDELSMAN DJ, 1990, J CLIN ENDOCR METAB, V71, P216, DOI 10.1210/jcem-71-1-216; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805; HUBERT W, 1990, TESTOSTERONE ACTION, P51; ISHAK KG, 1987, SEMIN LIVER DIS, V7, P230, DOI 10.1055/s-2008-1040579; JACKSON JA, 1990, MEDICINE, V69, P137, DOI 10.1097/00005792-199005000-00002; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; Joss E E, 1994, Curr Ther Endocrinol Metab, V5, P299; KANTOR MA, 1985, MED SCI SPORT EXER, V17, P462, DOI 10.1249/00005768-198508000-00010; KASPERK C, 1990, J CLIN ENDOCR METAB, V71, P1322, DOI 10.1210/jcem-71-5-1322; KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo-124-3-1576; KIRKLAND RT, 1987, JAMA-J AM MED ASSOC, V257, P502, DOI 10.1001/jama.257.4.502; KWAN M, 1983, J CLIN ENDOCR METAB, V57, P557, DOI 10.1210/jcem-57-3-557; LEMAY A, 1991, CLIN ENDOCRINOL, V35, P305, DOI 10.1111/j.1365-2265.1991.tb03541.x; Luke MC, 1994, PHYSL REPROD, P1435; MANNI A, 1985, J CLIN ENDOCR METAB, V61, P705, DOI 10.1210/jcem-61-4-705; MATSUMOTO AM, 1985, CLIN ENDOCRINOL, V22, P713, DOI 10.1111/j.1365-2265.1985.tb00161.x; MATSUMOTO AM, IN PRESS CECIL TXB M; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; MEIKLE AW, 1992, J CLIN ENDOCR METAB, V74, P623, DOI 10.1210/jc.74.3.623; MICHAEL RP, 1978, PSYCHONEUROENDOCRINO, V3, P217, DOI 10.1016/0306-4530(78)90011-2; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; MORLEY JE, 1993, J AM GERIATR SOC, V41, P149, DOI 10.1111/j.1532-5415.1993.tb02049.x; OCARROLL R, 1985, CLIN ENDOCRINOL, V23, P527, DOI 10.1111/j.1365-2265.1985.tb01113.x; PATANELLI DJ, 1977, DHEW PUBLICATION; PAULSEN CA, 1982, ADV FERTILITY RES, V1, P157; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; POPE HG, 1988, AM J PSYCHIAT, V145, P487; ROOT A, 1972, J PEDIATR-US, V80, P264, DOI 10.1016/S0022-3476(72)80588-2; SALMIMIES P, 1982, ARCH SEX BEHAV, V11, P345, DOI 10.1007/BF01541595; SANTULLI R, 1990, ENDOCRINOLOGY, V126, P95, DOI 10.1210/endo-126-1-95; SCHALLY AV, 1971, SCIENCE, V173, P1036, DOI 10.1126/science.173.4001.1036; SEE KL, 1992, LIVER, V12, P73; Sharpe Richard M., 1994, P1363; SKAKKEBAEK NE, 1981, CLIN ENDOCRINOL, V14, P49, DOI 10.1111/j.1365-2265.1981.tb00364.x; SNYDER PJ, 1984, ANNU REV MED, V35, P207, DOI 10.1146/annurev.med.35.1.207; SORVA R, 1988, ATHEROSCLEROSIS, V69, P191, DOI 10.1016/0021-9150(88)90014-7; STRAUSS RH, 1991, ANNU REV MED, V42, P449, DOI 10.1146/annurev.me.42.020191.002313; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; TOM L, 1992, J CLIN ENDOCR METAB, V75, P476, DOI 10.1210/jc.75.2.476; UZYCH L, 1992, CAN J PSYCHIAT, V37, P23, DOI 10.1177/070674379203700106; WEBER JP, 1991, AM J HEMATOL, V36, P190, DOI 10.1002/ajh.2830360306; WHEELER MJ, 1993, CLIN ENDOCRINOL, V38, P351, DOI 10.1111/j.1365-2265.1993.tb00513.x; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; WILSON JD, 1980, METABOLISM, V29, P1278, DOI 10.1016/0026-0495(80)90159-6; WU FCW, 1992, BAILLIERE CLIN ENDOC, V6, P373, DOI 10.1016/S0950-351X(05)80155-7; YESALIS CE, 1993, JAMA-J AM MED ASSOC, V270, P1217, DOI 10.1001/jama.270.10.1217; YOUNG NR, 1993, J CLIN ENDOCR METAB, V77, P1028, DOI 10.1210/jc.77.4.1028; ZMUDA JM, 1993, METABOLISM, V42, P446, DOI 10.1016/0026-0495(93)90101-S	91	302	318	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					707	714		10.1056/NEJM199603143341107	http://dx.doi.org/10.1056/NEJM199603143341107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594431				2022-12-28	WOS:A1996TZ52800007
J	vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M				vonBartheld, CS; Byers, MR; Williams, R; Bothwell, M			Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system	NATURE			English	Article							NERVE GROWTH-FACTOR; RETROGRADE TRANSPORT; AXONAL-TRANSPORT; RECEPTORS; BRAIN; INTERNALIZATION; EXPRESSION; SYNAPSES; NEURONS; DEATH	Neurotrophic factors support the differentiation and survival of neurons(1,2) and influence properties of synaptic transmission(3,4). The neurotrophic hypothesis postulates a retrograde action of trophic factors: their production and release by target cells and their uptake by innervating axons(5). Besides the retrograde route of trophic messengers, the survival of neurons and the development of synapses is thought to be also regulated by anterograde, afferent trophic signals(6-10). We now show that exogenous neurotrophins are transported in the anterograde direction, from cell bodies to the axon terminals, and that the intact neurotrophin is released after anterograde transport, taken up and utilized by second-order visual neurons in the developing chick brain. These results suggest that anterogradely transported neurotrophins may play a role in synaptic plasticity and may have effects at more than one synapse beyond the initial release site.	UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; KAROLINSKA INST,DEPT DEV BIOL,S-17177 STOCKHOLM,SWEDEN	University of Washington; University of Washington Seattle; Karolinska Institutet	vonBartheld, CS (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							[Anonymous], [No title captured]; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BYERS MR, 1974, BRAIN RES, V75, P97, DOI 10.1016/0006-8993(74)90773-2; CATSICAS M, 1992, J NEUROSCI, V12, P4642; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; CLAUDE P, 1982, J NEUROSCI, V2, P431; Cowan W. M., 1970, CONT RES METHODS NEU, P217, DOI 10.1007/978-3-642-85986-1_11; EMFORS P, 1990, NEURON, V5, P511; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; HAMMERSCHLAG R, 1982, TRENDS NEUROSCI, V5, P12, DOI 10.1016/0166-2236(82)90009-1; HERZOG KH, 1994, DEVELOPMENT, V120, P1643; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; NIETOBONA MP, 1993, J NEUROSCI RES, V36, P520, DOI 10.1002/jnr.490360504; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RICHARDSON PM, 1986, J NEUROSCI, V6, P2312; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SMITH RS, 1994, J NEUROCHEM, V62, P1698; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; VONBARTHELD CS, 1991, J COMP NEUROL, V310, P103, DOI 10.1002/cne.903100110; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; WAYNE DB, 1990, DEV BIOL, V138, P484, DOI 10.1016/0012-1606(90)90214-4; WILLIAMS R, 1995, EUR J NEUROSCI, V7, P116, DOI 10.1111/j.1460-9568.1995.tb01026.x; ZHOU XF, IN PRESS NEUROSCIENC	31	256	256	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					830	833		10.1038/379830a0	http://dx.doi.org/10.1038/379830a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587607				2022-12-28	WOS:A1996TX50100060
J	Chopra, I; Hodgson, J; Metcalf, B; Poste, G				Chopra, I; Hodgson, J; Metcalf, B; Poste, G			New approaches to the control of infections caused by antibiotic-resistant bacteria - An industry perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,EPSOM KT18 5X0,SURREY,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,UPPER MERION,PA	GlaxoSmithKline; GlaxoSmithKline								ALLEN NE, 1985, ANNU REP MED CHEM, V20, P155; CASADEVALL A, 1994, ANTIMICROB AGENTS CH, V38, P1695, DOI 10.1128/AAC.38.8.1695; DALE DC, 1994, CLIN INFECT DIS   S2, V18, P180; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DeMarsh PL, 1996, J INFECT DIS, V173, P203, DOI 10.1093/infdis/173.1.203; DOUGAN G, 1994, MICROBIOL-SGM, V140, P215, DOI 10.1099/13500872-140-2-215; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett L., 1994, COMING PLAGUE NEWLY; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; JACOB L, 1994, CIBA F SYMP, V186, P197; LAMBERT HP, 1984, BRIT MED BULL, V40, P102, DOI 10.1093/oxfordjournals.bmb.a071938; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1992, EMERGING TARGETS ANT, P205; Podzorski Raymond P., 1993, Clinical Microbiology Newsletter, V15, P137, DOI 10.1016/0196-4399(93)90042-L; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Russell A.D., 1990, UNDERSTANDING ANTIBA; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; SPARLING PF, 1994, P NATL ACAD SCI USA, V91, P2456, DOI 10.1073/pnas.91.7.2456; STAGER CE, 1992, CLIN MICROBIOL REV, V5, P302, DOI 10.1128/CMR.5.3.302-327.1992; SUTCLIFFE JA, 1988, ANNU REP MED CHEM, V23, P141; TALLY FT, 1995, J ANTIMICROB CHEMOTH, V35, P449, DOI 10.1093/jac/35.4.449; UTT EA, 1995, CAN J MICROBIOL, V41, P152, DOI 10.1139/m95-020	25	53	53	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					401	403		10.1001/jama.275.5.401	http://dx.doi.org/10.1001/jama.275.5.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569021				2022-12-28	WOS:A1996TT30300035
J	Berridge, V				Berridge, V			Drug policy: Should the law take a back seat?	LANCET			English	Article											Berridge, V (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			berridge, virginia/0000-0001-8011-8348				ANDERSON W, 1993, AIDS CONT HISTORY; BERRIDGE V, 1979, SOC SCI MED-MED SOC, V13, P351, DOI 10.1016/0160-7979(79)90072-9; BERRIDGE V, 1978, J SOC POLICY, V7, P285, DOI 10.1017/S004727940000790X; BERRIDGE V, 1984, BRIT J ADDICT, V79, P17; Berridge V., 1987, OPIUM PEOPLE; BERRIDGE V, 1996, ASHES ASHES; Berridge Virginia., 1993, AIDS CONT HIST; Bruun K., 1975, GENTLEMENS CLUB INT; Courtwright DT., 1982, DARK PARADISE OPIATE; DOWNES D, 1988, CONTRACTS TOLERANCE; EDWARDS G, 1983, DRUG USE MISUSE CULT; Edwards G., 1994, ALCOHOL POLICY PUBLI; EDWARDS G, 1995, MAR T OKEY ANN LECT; GOODMAN J, 1995, CONSUMING HABITS; KYVIG DE, 1979, REPEALING NATIONAL P; LEVINE HG, 1991, MILBANK Q, V69, P461, DOI 10.2307/3350105; Marsh A, 1994, POOR SMOKERS, VPolicy Studies Institute; McKeganey NP., 1992, AIDS DRUGS SEXUAL RI; MUNSTO D, 1973, AM DISEASE ORIGINS N; PARKE RH, 1994, DRUGS ED PREVENTION, V1, P5; Pollock John., 1977, WILBERFORCE; SIMSON GV, 1982, HEROIN ADDICTION TRE; SPEAR HB, 1969, BRIT J ADDICT, V64, P245; STEIN SD, 1985, INT DIPLOMACY STATE; 1994, DRUGLINK, V9, P6; 1919, HO45399514 HOM OFF P; 1857, MED TIMES GAZ, V14, P426; 1919, MH5851 MIN HLTH PAP; 1995, TACKING DRUGS TOGETH; 1995, GUARDIN         0429, V1, P3; 1992, DAEDALUS         SUM	31	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					301	305		10.1016/S0140-6736(96)90471-7	http://dx.doi.org/10.1016/S0140-6736(96)90471-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569367	Bronze			2022-12-28	WOS:A1996TT48500014
J	Bonn, D				Bonn, D			What prospects for hormonal contraceptives for men?	LANCET			English	News Item																			0	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					316	316		10.1016/S0140-6736(96)90482-1	http://dx.doi.org/10.1016/S0140-6736(96)90482-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569371				2022-12-28	WOS:A1996TT48500023
J	Buckwalter, JA				Buckwalter, JA			Joint distraction for osteoarthritis	LANCET			English	Editorial Material											Buckwalter, JA (corresponding author), UNIV IOWA HOSP & CLIN,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242, USA.							ABDO RV, 1992, FOOT ANKLE, V13, P307, DOI 10.1177/107110079201300602; BUCKWALTER JA, 1994, J BONE JOINT SURG AM, V76A, P1405, DOI 10.2106/00004623-199409000-00019; KITAOKA HB, 1994, J BONE JOINT SURG AM, V76A, P974, DOI 10.2106/00004623-199407000-00003; OGILVIEHARRIS DJ, 1993, J BONE JOINT SURG AM, V75A, P1167, DOI 10.2106/00004623-199308000-00006; TAKAKURA Y, 1995, J BONE JOINT SURG BR, V77B, P50, DOI 10.1302/0301-620X.77B1.7822395; VANVALBURG AA, 1995, J BONE JOINT SURG BR, V77, P720, DOI 10.1302/0301-620X.77B5.7559696	6	20	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					279	280		10.1016/S0140-6736(96)90463-8	http://dx.doi.org/10.1016/S0140-6736(96)90463-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569359				2022-12-28	WOS:A1996TT48500006
J	Sheng, ZH; Rettig, J; Cook, T; Catterall, WA				Sheng, ZH; Rettig, J; Cook, T; Catterall, WA			Calcium-dependent interaction of N-type calcium channels with the synaptic core complex	NATURE			English	Article							TRANSMITTER RELEASE; MEMBRANE-PROTEIN; ACTIVE ZONES; SYNAPTOTAGMIN; SYNTAXIN; VESICLES; DOCKING	NEUROTRANSMITTER release is initiated by influx of Ca2+ through voltage-gated Ca2+ channels(1,2), within 200 mu s of the action potential arriving at the synaptic terminal(3), as the Ca2+ concentration increases from 100 nM to >200 mu M(4). Exocytosis requires high Ca2+ concentration, with a threshold of 20-50 mu M and half-maximal activation at 190 mu M(5,6). The synaptic membrane syntaxin(7,8), 25K synaptosome-associated protein (SNAP25)9, and vesicle-associated membrane protein (VAMP)/synaptobrevin(10-12), are thought to form a synaptic core complex which mediates vesicle docking and membrane fusion(13-19) Synaptotagmin may be the low-affinity Ca2+-sensor(20-24), but other Ca2+-sensors are involved(25-27) as residual neurotransmission persists in synaptotagmin-null mutants. Syntaxin binds to N-type Ca2+ channels(7,8,28,29) at a site in the intracellular loop connecting domains II and III30. Here we describe Ca2+ dependent interaction of this site with syntaxin and SNAP25 which has a biphasic dependence on Ca2+, with maximal binding at 20 mu M free Ca2+, near the threshold for transmitter release. Ca2+-dependent interaction of Ca2+ channels with the synaptic core complex may be important for Ca2+-dependent docking and fusion of synaptic vesicles.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Rettig, Jens/K-5103-2013	Rettig, Jens/0000-0001-6160-3954				BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6309; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHENG ZH, 1994, NEURON, V13, P1301; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	30	300	307	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					451	454		10.1038/379451a0	http://dx.doi.org/10.1038/379451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559250				2022-12-28	WOS:A1996TT30400060
J	Yudkin, PL; Stratton, IM				Yudkin, PL; Stratton, IM			How to deal with regression to the mean in intervention studies	LANCET			English	Article							VARIABILITY; SUBJECT; DIET		UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT OBSTET & GYNAECOL,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford			stratton, irene/AAZ-3627-2020	stratton, irene/0000-0003-1172-7865				ARMITAGE P, 1987, STATISTICAL METHODS, P152; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; DAVIS CE, 1976, AM J EPIDEMIOL, V104, P493, DOI 10.1093/oxfordjournals.aje.a112321; DENKE MA, 1993, AM J MED, V94, P637; EDERER F, 1972, J CHRON DIS, V25, P277, DOI 10.1016/0021-9681(72)90164-6; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HANNAN PJ, 1994, AM J EPIDEMIOL, V139, P422, DOI 10.1093/oxfordjournals.aje.a117015; HJERMANN I, 1981, LANCET, V2, P1303; JAMES KE, 1973, BIOMETRICS, V29, P121, DOI 10.2307/2529681; JOHNSON WD, 1991, STAT MED, V10, P1295, DOI 10.1002/sim.4780100812; JOHNSTON HJ, 1995, MED J AUSTRALIA, V162, P524, DOI 10.5694/j.1326-5377.1995.tb138510.x; KLEPP KI, 1993, EUR J PUBLIC HEALTH, V3, P38; NEWELL D, 1990, MED J AUSTRALIA, V153, P166, DOI 10.5694/j.1326-5377.1990.tb136839.x; Prospective U. K., 1991, DIABETOLOGIA, V34, P877; ROSE G, 1980, BRIT MED J, V1, P747; Senn S J, 1988, Stat Med, V7, P1203, DOI 10.1002/sim.4780071114; SENN SJ, 1985, BIOMETRICS, V41, P555, DOI 10.2307/2530881; SHEPARD DS, 1983, PREV MED, V12, P304, DOI 10.1016/0091-7435(83)90239-6; SMITH SJ, 1993, CLIN CHEM, V39, P1012; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; 1985, BRIT MED J, V291, P97; 1990, SAS LANGUAGE, P1042	22	145	147	1	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					241	243		10.1016/S0140-6736(96)90410-9	http://dx.doi.org/10.1016/S0140-6736(96)90410-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551887				2022-12-28	WOS:A1996TT06900016
J	Feldman, DE; Brainard, MS; Knudsen, EI				Feldman, DE; Brainard, MS; Knudsen, EI			Newly learned auditory responses mediated by NMDA receptors in the owl inferior colliculus	SCIENCE			English	Article							LONG-TERM POTENTIATION; OPTIC TECTUM; BARN OWL; VISUAL RESPONSES; SPACE; MAPS; NEURONS; CORTEX; ANTAGONIST; PLASTICITY	Alignment of auditory and visual receptive fields in the optic tectum of the barn owl (Tyto alba) is maintained through experience-dependent modification of auditory responses in the external nucleus of the inferior colliculus (ICX), which provides auditory input to the tectum. Newly learned tectal auditory responses, induced by altered visual experience, were found to be pharmacologically distinct from normal responses expressed at the same tectal sites. N-methyl-D-aspartate (NMDA) receptor antagonists administered systemically or applied locally in the ICX reduced learned responses more than normal responses. This differential blockade was not observed with non-NMDA or broad-spectrum antagonists. Thus, NMDA receptors preferentially mediate the expression of novel neuronal responses induced by experience during development.			Feldman, DE (corresponding author), STANFORD UNIV, SCH MED, DEPT NEUROBIOL, FAIRCHILD SCI BLDG, STANFORD, CA 94305 USA.			Brainard, Michael/0000-0002-9425-9907	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC00155-14] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BEAR MF, 1990, J NEUROSCI, V10, P909; BRAINARD MS, 1995, J NEUROPHYSIOL, V73, P595, DOI 10.1152/jn.1995.73.2.595; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; BRAINARD MS, 1993, INT CONGR SER, V1036, P113; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAW NW, 1993, ANNU REV NEUROSCI, V16, P207, DOI 10.1146/annurev.ne.16.030193.001231; DUNIA R, 1989, HEARING RES, V37, P241, DOI 10.1016/0378-5955(89)90025-7; Feldman D. P., UNPUB; FELDMAN DE, 1994, J NEUROSCI, V14, P5939; FOX K, 1989, J NEUROSCI, V9, P2443; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017, DOI 10.1152/jn.1994.72.6.3017; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KNUDSEN EI, 1983, J COMP NEUROL, V218, P187, DOI 10.1002/cne.902180206; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; KNUDSEN EI, 1991, J NEUROSCI, V11, P1727; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KOHR G, 1993, J NEUROSCI, V13, P3612; KWON YH, 1991, J NEUROPHYSIOL, V66, P414, DOI 10.1152/jn.1991.66.2.414; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOONEY R, 1992, J NEUROSCI, V12, P2464; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; NETER J, 1990, APPLIED LINEAR STATI; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; OLSEN JF, 1989, J NEUROSCI, V9, P2591; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SILLAR KT, 1991, BRAIN RES, V545, P24, DOI 10.1016/0006-8993(91)91265-3; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	36	72	72	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					525	528		10.1126/science.271.5248.525	http://dx.doi.org/10.1126/science.271.5248.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560271				2022-12-28	WOS:A1996TR32200048
J	Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B				Visa, N; AlzhanovaEricsson, AT; Sun, X; Kiseleva, E; Bjorkroth, B; Wurtz, T; Daneholt, B			A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes	CELL			English	Article							PREMESSENGER RIBONUCLEOPROTEIN PARTICLE; ELECTRON-MICROSCOPE TOMOGRAPHY; SALIVARY-GLAND CELLS; CHIRONOMUS-TENTANS; DROSOPHILA-MELANOGASTER; HNRNP PROTEINS; HEAT-SHOCK; COMPLEXES; INVIVO; VISUALIZATION	In the larval salivary glands of C. tentans, it is possible to visualize by electron microscopy how Balbiani ring (BR) pre-mRNA associates with proteins to form pre-mRNP particles, how these particles move to and through the nuclear pore, and how the BR RNA is engaged in the formation of giant polysomes in the cytoplasm. Here, we study C. tentans hrp36, an abundant protein in the BR particles, and establish that it is similar to the mammalian hnRNP A1. By immunoelectron microscopy it is demonstrated that hrp36 is added to BR RNA concomitant with transcription, remains in nucleoplasmic BR particles, and is translocated through the nuclear pore still associated with BR RNA. It appears in the giant BR RNA-containing polysomes, where it remains as an abundant protein in spite of ongoing translation.			Visa, N (corresponding author), KAROLINSKA INST, MED NOBEL INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN.		Visa, Neus/C-9459-2016; Visa, Neus/R-8037-2019	Visa, Neus/0000-0003-3145-3953; Visa, Neus/0000-0003-3145-3953; Kiseleva, Elena/0000-0001-6949-182X				AMERO SA, 1991, GENE DEV, V5, P188, DOI 10.1101/gad.5.2.188; ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3093, DOI 10.1093/nar/21.13.3093; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEYER AL, 1990, EUKARYOTIC NUCLEUS, V2, P431; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CASE ST, 1978, J MOL BIOL, V124, P223, DOI 10.1016/0022-2836(78)90157-2; DANEHOLT B, 1977, J CELL BIOL, V73, P149, DOI 10.1083/jcb.73.1.149; Daneholt B., 1982, P382; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE D, 1969, J CELL BIOL, V40, P61, DOI 10.1083/jcb.40.1.61; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EDSTROM JE, 1978, CHROMOSOMA, V66, P33, DOI 10.1007/BF00285814; FRANCKE C, 1982, EMBO J, V1, P59, DOI 10.1002/j.1460-2075.1982.tb01124.x; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KISELEVA EV, 1989, FEBS LETT, V257, P251, DOI 10.1016/0014-5793(89)81545-5; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR A, 1975, J MOL BIOL, V96, P353, DOI 10.1016/0022-2836(75)90165-5; LEZZI M, 1981, CHROMOSOMA, V83, P327, DOI 10.1007/BF00327356; LONNROTH A, 1992, EXP CELL RES, V199, P292, DOI 10.1016/0014-4827(92)90437-D; MARTIN TE, 1980, CELL BIOL COMPREHENS, P137; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; MINIKH V B, 1985, Biokhimiya, V50, P604; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAYCHAUDHURI G, 1992, MOL CELL BIOL, V12, P847, DOI 10.1128/MCB.12.2.847; RICE CM, 1993, NUCLEIC ACIDS RES, V21, P2967, DOI 10.1093/nar/21.13.2967; RISAU W, 1983, CELL, V33, P529, DOI 10.1016/0092-8674(83)90434-8; SHEN J, 1995, P NATL ACAD SCI USA, V92, P1822, DOI 10.1073/pnas.92.6.1822; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN AS, 1985, TRENDS BIOCHEM SCI, V10, P162, DOI 10.1016/0968-0004(85)90158-6; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; THOMAS JO, 1983, J MOL BIOL, V171, P439, DOI 10.1016/0022-2836(83)90039-6; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WIESLANDER L, 1994, PROG NUCLEIC ACID RE, V48, P275, DOI 10.1016/S0079-6603(08)60858-2; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; WURTZ T, 1996, IN PRESS MOL CELL BI; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5	60	208	214	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					253	264		10.1016/S0092-8674(00)80980-0	http://dx.doi.org/10.1016/S0092-8674(00)80980-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565071	Bronze			2022-12-28	WOS:A1996TR59500012
J	Carpenter, PB; Mueller, PR; Dunphy, WG				Carpenter, PB; Mueller, PR; Dunphy, WG			Role for a Xenopus Orc2-related protein in controlling DNA replication	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; CELL-CYCLE; INVITRO; SYSTEM; EGGS; PHOSPHORYLATION; INITIATION; MITOSIS	THE six-subunit origin recognition complex (ORC) is essential for the initiation of DNA replication at specific origins in the budding yeast Saccharomyces cerevisiae(1-9). An important issue is whether DNA replication in higher eukaryotes, in which the characteristics of replication origins are poorly defined(10), occurs by an ORC-dependent mechanism, We have identified a Xenopus laevis Orc2-related protein (XORC2) by its ability to rescue a mitotic-catastrophe mutant of the fission yeast Schizosaccharomyces pombe, We show that immunodepletion of XORC2 from Xenopus egg extracts(11-13) abolishes the replication of chromosomal DNA but not elongation synthesis on a single-stranded DNA template, Indirect immunofluorescence indicates that XORC2 binds to chromatin well before the commencement of DNA synthesis, and even under conditions that prevent the association of replication licensing factor(s) with the DNA. These findings suggest that Orc2 plays an important role at an early step of chromosomal replication in animal cells.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012					ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ALLSHIRE RC, 1990, P NATL ACAD SCI USA, V87, P4043, DOI 10.1073/pnas.87.11.4043; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FANG F, 1993, J CELL SCI, V106, P983; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLS AD, 1989, J CELL SCI, V94, P471; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZUBER M, 1989, EXP CELL RES, V182, P384, DOI 10.1016/0014-4827(89)90243-7	30	180	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					357	360		10.1038/379357a0	http://dx.doi.org/10.1038/379357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552193				2022-12-28	WOS:A1996TR32300062
J	Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV				Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV			Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice	NATURE			English	Article							IMMUNOGLOBULIN; LYMPHOCYTES; RECEPTORS; CELLS	DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immunoglobulin-G receptor, Fc gamma RII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production(1-6). We now report that Fc gamma RII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice, Mast cells from Fc gamma RII(-/-) are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts, Fc gamma RII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by Fc gamma RIII crosslinking, These results demonstrate that Fc gamma RII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response, Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.	MEM SLOAN KETTERING CANC CTR,DIV MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Takai, T (corresponding author), OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,TSUSHIMA NAKA,OKAYAMA 700,JAPAN.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				AMIGORENA S, 1992, SCIENCE, V243, P378; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON S, 1995, IMMUNITY, V3, P635; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PHILIPPS NE, 1984, J IMMUNOL, V132, P327; QUI WQ, 1990, SCIENCE, V248, P732; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WILSON HA, 1987, J IMMUNOL, V138, P1712	17	685	754	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					346	349		10.1038/379346a0	http://dx.doi.org/10.1038/379346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552190				2022-12-28	WOS:A1996TR32300059
J	Carr, AM				Carr, AM			Checkpoints take the next step	SCIENCE			English	Editorial Material											Carr, AM (corresponding author), UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND.			Carr, Antony Michael/0000-0002-2028-2389				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; CARR AG, UNPUB; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	13	41	45	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					314	315		10.1126/science.271.5247.314	http://dx.doi.org/10.1126/science.271.5247.314			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553064				2022-12-28	WOS:A1996TQ52800029
J	Walworth, NC; Bernards, R				Walworth, NC; Bernards, R			rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; ATAXIA-TELANGIECTASIA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; GENE; REPAIR; CANCER; FAMILIES; MUTANTS; INSTABILITY	Exposure of eukaryotic cells to agents that generate DNA damage results in transient arrest of progression through the cell cycle. In fission yeast, the DNA damage checkpoint associated with cell cycle arrest before mitosis requires the protein kinase p56(chk1). DNA damage induced by ultraviolet light, gamma radiation, or a DNA-alkylating agent has now been shown to result in phosphorylation of p56(chk1). This phosphorylation decreased the mobility of p56(chk1) on SDS-polyacrylamide gel electrophoresis and was abolished by a mutation in the p56(chk1) catalytic domain, suggesting that it might represent autophosphorylation. Phosphorylation of p56(chk1) did not occur when other checkpoint genes were inactive. Thus, p56(chk1) appears to function downstream of several of the known Schizosaccharomyces pombe checkpoint gene products, including that encoded by rad3(+), a gene with sequence similarity to the ATM gene mutated in patients with ataxia telangiectasia. The phosphorylation of p56(chk1) provides an assayable biochemical response to activation of the DNA damage checkpoint in the G(2) phase of the cell cycle.	NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Walworth, Nancy/0000-0001-5940-8236; Bernards, Rene/0000-0001-8677-3423				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BASI G, 1993, GENE, V114, P59; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; Carr Andrew, COMMUNICATION; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KUNKEL TA, 1987, METHOD ENZYMOL, V155, P166; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCCREADY S, 1993, MOL MICROBIOL, V10, P885, DOI 10.1111/j.1365-2958.1993.tb00959.x; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1981, NATURE, V292, P448; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WALWORTH NC, UNPUB; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P662; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	39	351	358	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					353	356		10.1126/science.271.5247.353	http://dx.doi.org/10.1126/science.271.5247.353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553071	Green Submitted			2022-12-28	WOS:A1996TQ52800042
J	Leahy, DJ; Aukhil, I; Erickson, HP				Leahy, DJ; Aukhil, I; Erickson, HP			2.0 angstrom crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region	CELL			English	Article							3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; PLASMA FIBRONECTIN; ANOMALOUS DIFFRACTION; CELL-ADHESION; HUMAN CD4; PROTEIN; BINDING; MOLECULE; TENASCIN	We have determined the 2.0 Angstrom crystal structure of a fragment of human fibronectin encompassing the seventh through the RGD-containing tenth type III repeats (FN7-10). The structure reveals an extended rod-like molecule with a long axis of similar to 140 Angstrom and highly variable relationships between adjacent domains, An unusually small rotation between domains 9 and 10 creates a distinctive binding site, in which the RGD loop from domain 10 and the ''synergy'' region from domain 9 are on the same face of FN7-10 and thus easily accessible to a single integrin molecule. The cell-binding RGD loop is well-ordered in this structure and extends similar to 10 Angstrom away from the FN7-10 core.	UNIV N CAROLINA, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University	Leahy, DJ (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21218 USA.				NCI NIH HHS [CA47056] Funding Source: Medline; NHLBI NIH HHS [HL51202] Funding Source: Medline; NIDCR NIH HHS [DE7801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DOOLITTLE RF, 1986, URFS ORFS; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; ERICKSON HP, 1981, J CELL BIOL, V91, P673, DOI 10.1083/jcb.91.3.673; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Hynes RO, 1990, FIBRONECTINS; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI P, 1993, J CELL SCI, V106, P389; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOSSIAKOFF AA, 1992, PROTEINS, V14, P65, DOI 10.1002/prot.340140108; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI CS, 1993, J MOL BIOL, V230, P625, DOI 10.1006/jmbi.1993.1174; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LITVINOVICH SV, 1995, J MOL BIOL, V248, P611, DOI 10.1006/jmbi.1995.0246; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCCO M, 1983, J BIOL CHEM, V258, P4545; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMADA T, 1995, J BIOL CHEM, V270, P5687, DOI 10.1074/jbc.270.11.5687	58	580	605	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					155	164		10.1016/S0092-8674(00)81002-8	http://dx.doi.org/10.1016/S0092-8674(00)81002-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548820	hybrid			2022-12-28	WOS:A1996TQ17000018
J	Engel, J				Engel, J			Current concepts - Surgery for seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SURGICAL-TREATMENT; EPILEPSY		UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								[Anonymous], 1995, NEUROLOGY, V45, P224; APUZZO MLJ, 1991, NEUROSURGICAL ASPECT; BAILEY P, 1951, JAMA-J AM MED ASSOC, V145, P365, DOI 10.1001/jama.1951.02920240001001; BARKOVICH AJ, 1995, AM J NEURORADIOL, V16, P339; BEGLEY CE, 1994, EPILEPSIA, V35, P1230, DOI 10.1111/j.1528-1157.1994.tb01794.x; CHUGANI HT, 1993, EPILEPSIA, V34, P764, DOI 10.1111/j.1528-1157.1993.tb00459.x; DAM M, 1994, ACTA NEUROL SCAND, V89, P1; DEONNA TW, 1991, J CLIN NEUROPHYSIOL, V8, P288, DOI 10.1097/00004691-199107010-00005; DEVINSKY O, 1993, EPILEPSIA, V34, pS1, DOI 10.1111/j.1528-1157.1993.tb05910.x; Duchowny M, 1990, J EPILEPSY S1, V3; Ebersole J S, 1995, Neuroimaging Clin N Am, V5, P267; ENGEL J, 1993, NEUROLOGY, V43, P1612, DOI 10.1212/WNL.43.8.1612; ENGEL J, 1994, CURR OPIN NEUROL, V7, P140, DOI 10.1097/00019052-199404000-00010; ENGEL J, 1993, ELECTROEN CLIN NEURO, V87, P437, DOI 10.1016/0013-4694(93)90158-R; ENGEL J, 1990, NEUROLOGY, V40, P1670, DOI 10.1212/WNL.40.11.1670; ENGEL J, 1987, SURGICAL TREATMENT E; ENGEL J, 1993, SURGICAL TREATMENT E; Engel Jerome Jr., 1993, P609; Engel Jerome Jr., 1993, P23; Hauser W, 1990, EPILEPSY FREQUENCY C; Horsely V., 1886, BMJ-BRIT MED J, V2, P670; JASPER H, 1951, AMA ARCH NEUROL PSY, V65, P272, DOI 10.1001/archneurpsyc.1951.02320030009002; KALE R, 1994, BRIT MED J, V309, P939, DOI 10.1136/bmj.309.6959.939; Kuzniecky R., 1995, MAGNETIC RESONANCE E; Luders Hans O., 1993, P137; LUDERS HO, 1992, EPILEPSY SURGERY; MORRELL F, 1989, J NEUROSURG, V70, P231, DOI 10.3171/jns.1989.70.2.0231; MORRIS GL, 1994, ELECTROEN CLIN NEURO, V91, P229, DOI 10.1016/0013-4694(94)90073-6; NEWTON MR, 1995, J NEUROL NEUROSUR PS, V59, P26, DOI 10.1136/jnnp.59.1.26; Pilcher W H, 1993, Neurosurg Clin N Am, V4, P311; PURPURA DP, 1975, ADV NEUROLOGY, V8; SANKAR R, 1995, AM J NEURORADIOL, V16, P1265; Shields W. Donald, 1993, P35; SILBERGELD DL, 1993, NEUROSURG CLIN N AM, P4; SPENCER SS, 1994, EPILEPSIA, V35, pS72, DOI 10.1111/j.1528-1157.1994.tb05990.x; SPENCER SS, 1993, EPILEPSIA, V34, P561, DOI 10.1111/j.1528-1157.1993.tb02596.x; SPENCER SS, 1991, SURGERY EPILEPSY; THEODORE WH, 1992, EPILEPSY RES S, V5; TUXHORN I, IN PRESS PAEDIATRIC; VELASCO F, 1995, EPILEPSIA, V36, P63, DOI 10.1111/j.1528-1157.1995.tb01667.x; VICKREY BG, 1994, EPILEPSIA, V35, P597, DOI 10.1111/j.1528-1157.1994.tb02480.x; VICKREY BG, 1995, LANCET, V346, P1445, DOI 10.1016/S0140-6736(95)92470-1; Villemure Jean-Guy, 1993, P511; Wieser Heinz-Gregor, 1993, P49; WIESER HG, 1987, PRESURGICAL EVALUATI; WYLER AR, 1994, SURGICAL MANAGEMENT	46	658	666	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					647	652		10.1056/NEJM199603073341008	http://dx.doi.org/10.1056/NEJM199603073341008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592530				2022-12-28	WOS:A1996TX69300008
J	Delbanco, TL; Daley, J				Delbanco, TL; Daley, J			A 35-year-old man with epigastric pain, 1 year later - Discussion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion																		GLICKMAN R, 1995, JAMA-J AM MED ASSOC, V274, P495, DOI 10.1001/jama.274.6.495	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					722	722						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594272				2022-12-28	WOS:A1996TX17400030
J	Smith, PL; Baukrowitz, T; Yellen, G				Smith, PL; Baukrowitz, T; Yellen, G			The inward rectification mechanism of the HERG cardiac potassium channel	NATURE			English	Article							K+ CHANNELS; INACTIVATION; CELLS	A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel(1). The HERG K+ channel is unusual in that it seems to have the architectural plan of the depolarization-activated K+ channel family (six putative transmembrane segments), yet it exhibits rectification like that of the inward-rectifying K+ channels, a family with different molecular structure (two transmembrane segments)(2-4). We have studied HERG channels expressed in mammalian cells and find that this inward rectification arises from a rapid and voltage-dependent inactivation process that reduces conductance at positive voltages. The inactivation gating mechanism resembles that of C-type inactivation, often considered to be the 'slow inactivation' mechanism of other K+ channels. The characteristics of this gating suggest a specific role for this channel in the normal suppression of arrhythmias.	MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Yellen, Gary/0000-0003-4228-7866; Baukrowitz, Thomas/0000-0003-4562-0505	NINDS NIH HHS [R01 NS029693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Baukrowitz T, 1996, SCIENCE, V271, P653, DOI 10.1126/science.271.5249.653; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; JUNNAN ME, 1994, BIOTECHNIQUES, V17, P876; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	640	651	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					833	836		10.1038/379833a0	http://dx.doi.org/10.1038/379833a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587608				2022-12-28	WOS:A1996TX50100061
J	Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV				Lloyd, SE; Pearce, SHS; Fisher, SE; Steinmeyer, K; Schwappach, B; Scheinman, SJ; Harding, B; Bolino, A; Devoto, M; Goodyer, P; Rigden, SPA; Wrong, O; Jentsch, TJ; Craig, IW; Thakker, RV			A common molecular basis for three inherited kidney stone diseases	NATURE			English	Article							LINKED RECESSIVE NEPHROLITHIASIS; MUSCLE CHLORIDE CHANNEL; EXPRESSION; MUTATIONS; GENE	KIDNEY stones (nephrolithiasis), which affect 12% of males and 5% of females in the western world, are familial in 45% of patients(1,2) and are most commonly associated with hypercalciuria(1). Three disorders of hypercalciuric nephrolithiasis (Dent's disease(3), X-linked recessive nephrolithiasis (XRN)(4), and X-linked recessive hypophosphataemic rickets (XLRH)(5)) have been mapped to Xp11.22 (refs 5-7). A microdeletion(6) in one Dent's disease kindred allowed the identification of a candidate gene, CLCN5 (refs 8,9) which encodes a putative renal chloride channel. Here we report the investigation of 11 kindreds with these renal tubular disorders for CLCN5 abnormalities; this identified three nonsense, four missense and two donor splice site mutations, together with one intragenic deletion and one microdeletion encompassing the entire gene. Heterologous expression of wild-type CLCN5 in Xenopus oocytes yielded outwardly rectifying chloride currents, which were either abolished or markedly reduced by the mutations. The common aetiology for Dent's disease, XRN and XLRH indicates that CLCN5 may be involved in other renal tubular disorders associated with kidney stones.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; UNIV OXFORD,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY 13210; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP MONTREAL ENFANTS,MONTREAL,PQ H3H 1P3,CANADA; GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND; MIDDLESEX HOSP,DEPT NEPHROL,LONDON W1N 8AA,ENGLAND	Imperial College London; University of Oxford; University of Hamburg; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London			Pearce, Simon/AAB-3692-2019; Fisher, Simon E./E-9130-2012; Bolino, Alessandra/O-2933-2013; Bolino, Alessandra/AAN-5442-2020; Devoto, Marcella/AAP-7595-2021; Craig, Ian/AAF-9167-2019	Pearce, Simon/0000-0001-8384-8063; Fisher, Simon E./0000-0002-3132-1996; Bolino, Alessandra/0000-0002-8980-4878; Schwappach, Blanche/0000-0003-0225-6432; Jentsch, Thomas/0000-0002-3509-2553; DEVOTO, MARCELLA/0000-0002-4431-5114; Craig, Ian/0000-0002-4063-1005; Thakker, Rajesh/0000-0002-1438-3220				ADACHI S, 1994, J BIOL CHEM, V269, P17677; Bolino A., 1993, European Journal of Human Genetics, V1, P269; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/geno.1995.9960; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; HIGGINS JT, 1977, PFLUG ARCH EUR J PHY, V371, P87, DOI 10.1007/BF00580776; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POOK MA, 1993, HUM MOL GENET, V2, P2129, DOI 10.1093/hmg/2.12.2129; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; SAMBROOK J, 1989, LABORATORY MANUAL; SCHEINMAN SJ, 1993, J CLIN INVEST, V91, P2351, DOI 10.1172/JCI116467; SMITH LH, 1989, J UROLOGY, V141, P707, DOI 10.1016/S0022-5347(17)40990-6; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; THAKKER RV, 1993, J CLIN INVEST, V91, P2815, DOI 10.1172/JCI116524; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; WRONG OM, 1994, Q J MED, V87, P473	28	580	595	0	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					445	449		10.1038/379445a0	http://dx.doi.org/10.1038/379445a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559248	Green Submitted			2022-12-28	WOS:A1996TT30400058
J	Delamothe, T; Smith, R				Delamothe, T; Smith, R			Redesigning the journal: Having your say	BRITISH MEDICAL JOURNAL			English	Article																		CROSSAN L, 1995, BRIT MED J, V310, P5, DOI 10.1136/bmj.310.6971.5; DELAMOTHE T, 1995, BRIT MED J, V311, P966; 1995, BRIT MED J, V310, P660	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					232	235						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563592				2022-12-28	WOS:A1996TT48600033
J	Iyengar, R				Iyengar, R			Gating by cyclic AMP: Expanded role for an old signaling pathway	SCIENCE			English	Editorial Material							ISOLATED RAT HEPATOCYTES; ADENYLATE-CYCLASE; RP DIASTEREOMER; 3',5'-PHOSPHOROTHIOATE; INHIBITION; GLYCOGENOLYSIS; PHOSPHORYLASE; MEMBRANES				Iyengar, R (corresponding author), CUNY, MT SINAI SCH MED, DEPT PHARMACOL, NEW YORK, NY 10029 USA.							ABRAMS TW, 1991, J NEUROSCI, V11, P2655; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KREBS EG, 1956, J BIOL CHEM, V218, P483; LI W, 1995, SCIENCE, V80, P553; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1977, J BIOL CHEM, V252, P6966; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P8151; ROTHERMEL JD, 1984, J BIOL CHEM, V259, P5294; ROTHERMEL JD, 1983, J BIOL CHEM, V258, P2125; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SUTHERLAND EW, 1955, NATURE, V175, P169, DOI 10.1038/175169a0; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	30	112	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					461	463		10.1126/science.271.5248.461	http://dx.doi.org/10.1126/science.271.5248.461			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560257				2022-12-28	WOS:A1996TR32200028
J	Lukowitz, W; Mayer, U; Jurgens, G				Lukowitz, W; Mayer, U; Jurgens, G			Cytokinesis in the Arabidopsis embryo involves the syntaxin-related KNOLLE gene product	CELL			English	Article							VESICULAR TRANSPORT; THALIANA; EXPRESSION; DROSOPHILA; EPIMORPHIN; PROTEINS; CLONING; FAMILY; GENOME; LIGHT	The embryo of the flowering plant Arabidopsis develops by a regular pattern of cell divisions and cell shape changes. Mutations in the KNOLLE (KN) gene affect the rate and plane of cell divisions as well as cell morphology, resulting in mutant seedlings with a disturbed radial organization of tissue layers. At the cellular level, mutant embryos are characterized by incomplete cross walls and enlarged cells with polyploid nuclei, The KN gene was isolated by positional cloning. The predicted KN protein has similarity to syntaxins, a protein family involved in vesicular trafficking. During embryogenesis, KN transcripts are detected in patches of single cells or small cell groups. Our results suggest a function for KN in cytokinesis.	UNIV MUNICH, LEHRSTUHL GENET, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich								AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ASADA T, 1994, J CELL SCI, V107, P2249; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; GEBHARDT C, 1989, THEOR APPL GENET, V78, P65, DOI 10.1007/BF00299755; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Goodbody K. C., 1994, V139, P221; GUNNING BES, 1982, CYTOSKELETON PLANT G, P230; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRIS SD, 1994, GENETICS, V136, P517; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HEPLER PK, 1990, PROTOPLASMA, V157, P182, DOI 10.1007/BF01322651; HEPLER PK, 1967, J ULTRA MOL STRUCT R, V19, P498, DOI 10.1016/S0022-5320(67)80076-5; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIME G, 1992, DEVELOPMENT, V114, P165; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; INOUE A, 1992, J BIOL CHEM, V267, P10613; JANTTI J, 1994, J CELL SCI, V107, P3623; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kimura M., 1983, NEUTRAL THEORY MOL E; KONING AJ, 1991, PLANT CELL, V3, P657, DOI 10.1105/tpc.3.7.657; KOOMNEEF M, 1983, ARABID INFO SERV, V20, P89; Lambert AM, 1993, CURR OPIN CELL BIOL, V5, P116, DOI 10.1016/S0955-0674(05)80016-X; LEHNER CF, 1992, J CELL SCI, V103, P1021; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LIU CM, 1995, DEV GENET, V16, P321, DOI 10.1002/dvg.1020160405; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAHEWSHWARI P, 1950, INTRO EMBRYOLOGY ANG; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Matallana E., 1992, Methods in Arabidopsis research., P144; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MCINTOSH K, 1995, INT J PLANT SCI, V156, P1, DOI 10.1086/297222; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OWEN HA, 1995, PROTOPLASMA, V185, P7, DOI 10.1007/BF01272749; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; ROPER W, 1977, PROTOPLASMA, V93, P89, DOI 10.1007/BF01276284; Sambrook J, 1989, MOL CLONING LABORATO; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Swofford D., 1998, PAUP PHYLOGENETIC AN; TIMBERLAKE W E, 1986, P343; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Wick SM, 1991, CURR OPIN CELL BIOL, V3, P253, DOI 10.1016/0955-0674(91)90149-S	69	398	424	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					61	71		10.1016/S0092-8674(00)80993-9	http://dx.doi.org/10.1016/S0092-8674(00)80993-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548827	Bronze			2022-12-28	WOS:A1996TQ17000009
J	Baud, FJ; Borron, SW; Bavoux, E; Astier, C; Hoffman, JR				Baud, FJ; Borron, SW; Bavoux, E; Astier, C; Hoffman, JR			Relation between plasma lactate and blood cyanide concentrations in acute cyanide poisoning	BRITISH MEDICAL JOURNAL			English	Article									HOP HENRI MONDOR, TOXICOL LAB, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Baud, FJ (corresponding author), UNIV PARIS 07, HOP FERNAND WIDAL, F-75010 PARIS, FRANCE.							BAUD FJ, 1991, NEW ENGL J MED, V325, P1761, DOI 10.1056/NEJM199112193252502; MARBACH EP, 1967, CLIN CHEM, V13, P314; Marrs T., 1987, CLIN EXPT TOXICOLOGY, P217; Rieders F, 1975, METHODOLOGY ANAL TOX, VI, P113; Vogel S, 1987, CLIN EXPT TOXICOLOGY, P451	5	35	36	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					26	27		10.1136/bmj.312.7022.26	http://dx.doi.org/10.1136/bmj.312.7022.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555853	Green Published			2022-12-28	WOS:A1996TP20900019
J	Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA				Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA			Phosphorylation by p34(cdc2) regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo	CELL			English	Article							CELL-FREE-EXTRACTS; MITOTIC SPINDLE; MICROTUBULE DYNAMICS; ASPERGILLUS-NIDULANS; P34CDC2 KINASE; PROTEIN-KINASE; FISSION YEAST; GENE; CYCLE; IDENTIFICATION	We have isolated a human homolog of Xenopus Eg5, a kinesin-related motor protein implicated in the assembly and dynamics of the mitotic spindle. We report that microinjection of antibodies against human Eg5 (HsEg5) blocks centrosome migration and causes HeLa cells to arrest in mitosis with monoastral microtubule arrays. Furthermore, an evolutionarily conserved cdc2 phosphorylation site (Thr-927) in HsEg5 is phosphorylated specifically during mitosis in HeLa cells and by p34(cdc2)/cyclin B in vitro. Mutation of Thr-927 to nonphosphorylatable residues prevents HsEg5 from binding to centrosomes, indicating that phosphorylation controls the association of th is motor with the spindle apparatus. These results indicate that HsEg5 is required for establishing a bipolar spindle and that p34(cdc2) protein kinase directly regulates its localization.	CNRS, INST RECH CANC, F-94801 VILLEJUIF, FRANCE; UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva	Blangy, A (corresponding author), SWISS INST EXPTL CANC RES, 155 CHEM BOVERESSES, CH-1066 EPALINGES, SWITZERLAND.			BLANGY, Anne/0000-0001-7043-0784; nigg, erich/0000-0003-4835-5719				AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Hunt T, 1991, Semin Cell Biol, V2, P213; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; Karsenti E, 1991, Semin Cell Biol, V2, P251; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUDJOU M, 1991, J CELL BIOL, V115, P129, DOI 10.1083/jcb.115.1.129; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; THOMAS D, 1990, GENET ANAL-BIOMOL E, V7, P87, DOI 10.1016/0735-0651(90)90033-C; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; TIHY F, 1992, GENOMICS, V13, P1371, DOI 10.1016/0888-7543(92)90075-4; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	69	746	796	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1159	1169		10.1016/0092-8674(95)90142-6	http://dx.doi.org/10.1016/0092-8674(95)90142-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548803	Bronze			2022-12-28	WOS:A1995TM76200012
J	Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW				Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW			The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination	CELL			English	Article							HAMSTER OVARY CELL; PRE-B CELLS; CYCLE-DEPENDENT REPAIR; RAY-SENSITIVE MUTANTS; LIGHT CHAIN GENES; IONIZING-RADIATION; SCID MUTATION; MOUSE THYMOCYTES; MICE; REARRANGEMENT	The XR-1 Chinese hamster ovary cell line is impaired in DNA double-strand break repair (DSBR) and in ability to support V(D)J recombination of transiently introduced substrates. We now show that XR-1 cells support recombination-activating gene 1- and 2-mediated initiation of V(D)J recombination within chromosomally integrated substrate, but are highly impaired in ability to complete the process by forming coding and recognition sequence joins. On this basis, we isolated a human cDNA sequence, termed XRCC4, whose expression confers normal V(D)J recombination ability and significant restoration of DSBR activity to XR-1, clearly demonstrating that this gene product is involved in both processes. The XRCC4 gene maps to the previously identified locus on human chromosome 5, is deleted in XR-1 cells, and encodes a ubiquitously expressed product unrelated to any described protein.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; LANKENAU MED RES CTR,WYNNEWOOD,PA 19096	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Lankenau Medical Center; Lankenau Institute for Medical Research	Li, ZY (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115, USA.				NCI NIH HHS [CA58301] Funding Source: Medline; NIAID NIH HHS [AI20047, AI35714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, P01AI035714, R01AI020047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, NATURE, V296, P325, DOI 10.1038/296325a0; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; FAIRMAN MP, 1992, NUCLEIC ACIDS RES, V20, P4145, DOI 10.1093/nar/20.16.4145; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINIE NJ, 1995, P NATL ACAD SCI USA, V92, P320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1995, PHILOS T ROY SOC B, V347, P43, DOI 10.1098/rstb.1995.0007; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GLIMCHER LH, 1982, NATURE, V298, P283, DOI 10.1038/298283a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; JONES NJ, 1988, MUTAT RES, V193, P139, DOI 10.1016/0167-8817(88)90044-2; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANSFORD R, 1995, IN PRESS MOL IMMUNOL; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; MALYAPA RS, 1994, RADIAT RES, V140, P321; MALYNN BA, 1995, INT IMMUNOL, V7, P1637, DOI 10.1093/intimm/7.10.1637; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MILLER RD, 1995, P NATL ACAD SCI US, V92; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OTEVREL T, 1995, GENOMICS, V27, P211, DOI 10.1006/geno.1995.1029; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SELIG S, 1995, P NATL ACAD SCI USA, V92, P3702, DOI 10.1073/pnas.92.9.3702; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; STAMATO TD, 1987, MUTAT RES, V183, P61, DOI 10.1016/0167-8817(87)90046-0; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1990, MOL CELL BIOL, V10, P1697, DOI 10.1128/MCB.10.4.1697; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	79	376	386	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1079	1089		10.1016/0092-8674(95)90135-3	http://dx.doi.org/10.1016/0092-8674(95)90135-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548796	Bronze			2022-12-28	WOS:A1995TM76200005
J	Southwick, FS; Purich, DL				Southwick, FS; Purich, DL			Mechanisms of disease - Intracellular pathogenesis of listeriosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACTIN POLYMERIZATION; MONOCYTOGENES MENINGITIS; SURFACE PROTEIN; F-ACTIN; ADULTS; CELLS; INFECTION; PROFILIN; SPREAD; RHOMBENCEPHALITIS		UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	Southwick, FS (corresponding author), UNIV FLORIDA, COLL MED, DIV INFECT DIS, DEPT MED, BOX 100277, GAINESVILLE, FL 32610 USA.				NIAID NIH HHS [R01 AI023262, R01 AI034276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262, R01AI034276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANAISSIE E, 1992, ANN INTERN MED, V117, P466, DOI 10.7326/0003-4819-117-6-466; ARMSTRONG RW, 1993, CLIN INFECT DIS, V16, P689, DOI 10.1093/clind/16.5.689; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BOUVET E, 1982, SCAND J INFECT DIS, V14, P267, DOI 10.3109/inf.1982.14.issue-4.04; BROOME CV, 1993, ASM NEWS, V59, P444; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HANSEN PB, 1987, SCAND J INFECT DIS, V19, P55, DOI 10.3109/00365548709032378; HAVELL EA, 1986, INFECT IMMUN, V54, P787, DOI 10.1128/IAI.54.3.787-792.1986; HEARMON CJ, 1989, POSTGRAD MED J, V65, P74, DOI 10.1136/pgmj.65.760.74; HEINZEN RA, 1993, INFECT IMMUN, V61, P1926, DOI 10.1128/IAI.61.5.1926-1935.1993; JURADO RL, 1993, CLIN INFECT DIS, V17, P224, DOI 10.1093/clinids/17.2.224; KASAHARA K, 1994, J INFECT DIS, V170, P1238, DOI 10.1093/infdis/170.5.1238; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KOCKS C, 1993, J CELL SCI, V105, P699; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; MACKANESS GB, 1969, J EXP MED, V129, P993, DOI 10.1084/jem.129.5.993; MERLMELET M, 1994, 34 INT C ANT AG CHEM, P260; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; NIEMAN RE, 1980, REV INFECT DIS, V2, P207; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; RACZ P, 1972, LAB INVEST, V26, P694; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; SOUTHWICK FS, 1994, BIOESSAYS, V16, P885, DOI 10.1002/bies.950161206; SOUTHWICK FS, 1989, CLIN RES, V37, pA567; SPENCER JAD, 1987, BMJ-BRIT MED J, V295, P349, DOI 10.1136/bmj.295.6594.349; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; ULDRY PA, 1993, J NEUROL, V240, P235, DOI 10.1007/BF00818711; WATSON GW, 1978, ARCH INTERN MED, V138, P83, DOI 10.1001/archinte.138.1.83	47	185	194	2	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					770	776		10.1056/NEJM199603213341206	http://dx.doi.org/10.1056/NEJM199603213341206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592552				2022-12-28	WOS:A1996TZ97900006
J	Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK				Nelson, KB; Dambrosia, JM; Ting, TY; Grether, JK			Uncertain value of electronic fetal monitoring in predicting cerebral palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WESTERN-AUSTRALIA; ANTECEDENTS; RISK	Background. Electronic monitoring of the fetal heart rate is commonly performed, in part to detect hypoxia during delivery that may result in brain injury: It is not known whether specific abnormalities on electronic fetal monitoring are related to the risk of cerebral palsy. Methods. Among 155,636 children born from 1983 through 1985 in four California counties, we identified singleton infants with birth weights of at least 2500 g who survived to three years of age and had moderate or severe cerebral palsy. The children with cerebral palsy were compared with randomly selected control children with respect to characteristics noted in the birth records. Results. Seventy-eight of 95 children with cerebral palsy and 300 of 378 controls underwent intrapartum fetal monitoring. Characteristics found to be associated with an increased risk of cerebral palsy were multiple late decelerations in the heart rate, commonly defined as slowing of the heart rate well after the onset of uterine contractions (odds ratio, 3.9; 95 percent confidence interval, 1.7 to 9.3), and decreased beat-to-beat variability of the heart rate (odds ratio, 2.7; 95 percent confidence interval, 1.1 to 5.8); there was no association between the highest or lowest fetal heart rate recorded for each child and the risk of cerebral palsy. Even after adjustment for other risk factors, the association of abnormalities on fetal monitoring with an increased risk of cerebral palsy persisted (adjusted odds ratio, 2.7; 95 percent confidence interval, 1.4 to 5.4). The 21 children with cerebral palsy who had multiple late decelerations or decreased variability in heart rate on fetal monitoring represented only 0.19 percent of singleton infants with birth weights of 2500 g or more who had these fetal-monitoring findings, for a false positive rate of 99.8 percent. Conclusions. Specific abnormal findings on electronic monitoring of the fetal heart rate were associated with an increased risk of cerebral palsy. However, the false positive rate was extremely high. Since cesarean section is often performed when such abnormalities are noted and is associated with risk to the mother, our findings arouse concern that, if these indications were widely used, many cesarean sections would be performed without benefit and with the potential for harm. (C) 1996, Massachusetts Medical Society.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892; NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892; HOWARD HUGHES MED INST,BETHESDA,MD 20817; UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA 94608	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Howard Hughes Medical Institute; University of Pennsylvania; California Department of Health Care Services								BADER TJ, 1995, OBSTET GYNECOL, V85, P643; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Cohen A B, 1982, Med Decis Making, V2, P79, DOI 10.1177/0272989X8200200111; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; CUNNINGHAM GC, 1979, INTRAUTERINE GROWTH; GRANT A, 1989, EFFECTIVE CARE PREGN, V2, P846; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; KRAGELOHMANN I, 1995, DEV MED CHILD NEUROL, V37, P191; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; Lumley J, 1988, Paediatr Perinat Epidemiol, V2, P299, DOI 10.1111/j.1365-3016.1988.tb00223.x; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MACGILLIVRAY I, 1995, PAEDIATR PERINAT EP, V9, P146, DOI 10.1111/j.1365-3016.1995.tb00130.x; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NEILSON JP, 1994, BIRTH-ISS PERINAT C, V21, P101, DOI 10.1111/j.1523-536X.1994.tb00242.x; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; NIELSEN TF, 1984, ACTA OBSTET GYN SCAN, V63, P103, DOI 10.3109/00016348409154643; NIELSEN TF, 1995, REPRODUCTIVE HLTH CA, P279; PANETH N, 1993, CLIN INVEST MED, V16, P159; Paul R H, 1994, J Perinatol, V14, P393; ROSTOW VP, 1989, NEW ENGL J MED, V321, P1057, DOI 10.1056/NEJM198910123211526; SCHELLER JM, 1994, OBSTET GYNECOL, V83, P624, DOI 10.1097/00006250-199404000-00025; SHY KK, 1987, ANNU REV PUBL HEALTH, V8, P165, DOI 10.1146/annurev.publhealth.8.1.165; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; VINTZILEOS AM, 1995, OBSTET GYNECOL, V85, P149, DOI 10.1016/0029-7844(94)00320-D; YUDKIN PL, 1995, PAEDIATR PERINAT EP, V9, P156, DOI 10.1111/j.1365-3016.1995.tb00131.x	31	299	305	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					613	618		10.1056/NEJM199603073341001	http://dx.doi.org/10.1056/NEJM199603073341001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592523				2022-12-28	WOS:A1996TX69300001
J	King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A				King, GE; Markowitz, LE; Heath, J; Redd, SC; Coleman, S; Bellini, WJ; Sievert, A			Antibody response to measles mumps rubella vaccine of children with mild illness at the time of vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENZYME IMMUNOASSAYS; OPPORTUNITIES; INFANTS	Objective.-To examine the response to measles-mumps-rubella (MMR) vaccine among children with and without mild illness. Design.-Prospective cohort. Participants.-A total of 386 children aged 15 to 23 months. Main Outcome Measures.-Seroconversion rates to measles, mumps, and rubella in ill and well children. Setting.-Six public health immunization clinics in two counties in the greater metropolitan Atlanta, Ga, area from February 1992 to April 1993. Results.-Acute upper respiratory tract infection, otitis media, and diarrhea were observed in 128 (33%), 41 (11%), and 13 (3%) of the children (groups are not mutually exclusive); 157 children had one of these mild illnesses and 229 were well. Overall seroconversion rates were 98% for measles, 83% for mumps, and 98% for rubella antigens, Measles seroconversion rates for ill children compared with well children, respectively, were as follows: upper respiratory tract infection, 99% vs 97%; mild fever, 98% vs 97%; otitis media, 98% vs 98%; diarrhea, 100% vs 98%; and any mild illness, 99% vs 97%. Estimates of the magnitude of antibody response to measles, mumps, and rubella antigens were the same for children with and without mild illness. There was no association of mild illness with increased rates and severity of adverse events reported in the 2 weeks after vaccination. Conclusions.-Vaccinating children who present with mild illnesses with MMR vaccine is a safe and efficacious practice. These results support recommendations of the Advisory Committee on Immunization Practices and the American Academy of Pediatrics.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30333; DEKALB CTY BOARD HLTH,DECATUR,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ATKINSON WL, 1992, 32 INT C ANT AG CHEM; DENNEHY PH, 1994, PEDIATRICS, V94, P514; FARIZO KM, 1992, PEDIATRICS, V89, P589; FORGHANI B, 1979, J CLIN MICROBIOL, V9, P657; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HUMMEL KB, 1992, J CLIN MICROBIOL, V30, P2874, DOI 10.1128/JCM.30.11.2874-2880.1992; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; NDIKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448, DOI 10.1093/ije/17.2.448; PETER G, 1994, REPORT COMMITTEE INF, P35; Ratman S, 1995, J PEDIATR, V127, P432; 1987, MMWR-MORBID MORTAL W, V36, P45; 1994, MMWR-MORBID MORTAL W, V43, P57; 1994, MMWR-MORBID MORTAL W, V43, P26; 1993, MMWR-MORBID MORTAL W, V42, P5; 1989, MMWR-MORBID MORTAL W, V38, P9	18	16	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					704	707		10.1001/jama.275.9.704	http://dx.doi.org/10.1001/jama.275.9.704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594268				2022-12-28	WOS:A1996TX17400026
J	Nightingale, SL				Nightingale, SL			New tuberculosis test approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-28	WOS:A1996TW62700005
J	Chiles, BW; Cooper, PR				Chiles, BW; Cooper, PR			Current concepts - Acute spinal injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEUROGENIC PULMONARY-EDEMA; CORD INJURY; CERVICAL-SPINE; ENDOTRACHEAL INTUBATION; TRACHEAL INTUBATION; TRAUMA; FRACTURES; METHYLPREDNISOLONE; MANAGEMENT; NALOXONE				Chiles, BW (corresponding author), NYU, MED CTR, DEPT NEUROSURG, 550 1ST AVE, NEW YORK, NY 10016 USA.							BAUER RD, 1991, SPINAL TRAUMA, P195; BERCZELLER PH, 1986, MED COMPLICATIONS QU, P95; BOHLMAN HH, 1979, J BONE JOINT SURG AM, V61, P1119, DOI 10.2106/00004623-197961080-00001; BOHLMAN HH, 1985, J BONE JOINT SURG AM, V67A, P360, DOI 10.2106/00004623-198567030-00002; BOHLMAN HH, 1985, J BONE JOINT SURG AM, V67A, P165, DOI 10.2106/00004623-198567010-00024; Bohlman HH, 1989, CERVICAL SPINE, P355; BRAAKMAN R, 1976, HDB CLIN NEUROLOGY, V25, P227; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRIGHTMAN RP, 1988, CONT NEUROSURG, V10, P1; Casas E R, 1976, Paraplegia, V14, P178; CLARK CR, 1988, SPINE, V13, P742, DOI 10.1097/00007632-198807000-00006; COHEN M, 1990, BIOL EFFECTS HEAVY M, V2, P19; COOPER PR, 1979, J NEUROSURG, V50, P603, DOI 10.3171/jns.1979.50.5.0603; Crutchfield WG, 1933, S SURG, V2, P156; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; ELKHOURY GY, 1993, AM J ROENTGENOL, V160, P95, DOI 10.2214/ajr.160.1.8416656; FRIED LC, 1974, JAMA-J AM MED ASSOC, V229, P181, DOI 10.1001/jama.229.2.181; FRNAKEL HL, 1989, PARAPLEGIA, V27, P163; GORE RM, 1981, SPINE, V6, P538, DOI 10.1097/00007632-198111000-00002; Gunby I, 1981, JAMA, V245, P1201; Guttmann L, 1973, SPINAL CORD INJURIES; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; Harris JH, 1987, RADIOLOGY ACUTE CERV; KEWALRAMANI LS, 1979, J TRAUMA, V19, P259, DOI 10.1097/00005373-197904000-00008; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; LARSON SJ, 1986, UNSTABLE SPINE, P127; MACKENZIE CF, 1985, J NEUROSURG, V62, P843, DOI 10.3171/jns.1985.62.6.0843; MARSHALL LF, 1987, J NEUROSURG, V66, P400, DOI 10.3171/jns.1987.66.3.0400; MESCHINO A, 1992, CAN J ANAESTH, V39, P114, DOI 10.1007/BF03008639; MEYER PR, 1991, NEUROL CLIN, V9, P625, DOI 10.1016/S0733-8619(18)30271-8; MULDER DS, 1975, J TRAUMA, V15, P638, DOI 10.1097/00005373-197508000-00003; OSEBOLD WR, 1981, SPINE, V6, P13, DOI 10.1097/00007632-198101000-00004; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; REISS SJ, 1986, NEUROSURGERY, V18, P327, DOI 10.1227/00006123-198603000-00012; ROBERTS JB, 1970, J BONE JOINT SURG AM, VA 52, P1115, DOI 10.2106/00004623-197052060-00004; ROMANICK PC, 1985, J BONE JOINT SURG AM, V67A, P1195, DOI 10.2106/00004623-198567080-00008; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; SCHNEIDER RC, 1955, J NEUROSURG, V12, P95, DOI 10.3171/jns.1955.12.2.0095; SILVER JR, 1983, BRIT J HOSP MED, V29, P412; Sonntag V, 1990, MANAGEMENT POSTTRAUM, P99; SONNTAG VKH, 1991, NEUROSURGERY UPDATE, V2, P222; STAUFFER ES, 1979, J BONE JOINT SURG AM, V61, P389, DOI 10.2106/00004623-197961030-00013; SUDERMAN VS, 1991, CAN J ANAESTH, V38, P785, DOI 10.1007/BF03008461; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; THEODORE J, 1975, LANCET, V2, P749; THOMPSON H, 1962, J BONE JOINT SURG BR, V44, P655, DOI 10.1302/0301-620X.44B3.655; VENGER BH, 1989, J NEUROSURG, V70, P514, DOI 10.3171/jns.1989.70.4.0514; WRIGHT SW, 1992, AM J EMERG MED, V10, P104, DOI 10.1016/0735-6757(92)90039-Z; YASHON D, 1970, J NEUROSURG, V32, P163, DOI 10.3171/jns.1970.32.2.0163; YOUNG JS, 1978, PARAPLEGIA, V16, P39, DOI 10.1038/sc.1978.6; ZWERLING MT, 1974, SURG GYNECOL OBSTET, V138, P189	54	40	41	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					514	520		10.1056/NEJM199602223340807	http://dx.doi.org/10.1056/NEJM199602223340807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559206				2022-12-28	WOS:A1996TV68600007
J	Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J				Hubbard, R; Lewis, S; Richards, K; Johnston, I; Britton, J			Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis	LANCET			English	Article							PULMONARY FIBROSIS; RESPIRATORY-TRACT; WORKERS; DISEASES; LUNG; POLISHER	Background We have previously suggested that cryptogenic fibrosing alveolitis (CFA) may be caused by occupational exposures, particularly to metal or wood dust. We have specifically investigated this hypothesis in a case-control study of patients with CFA. Methods We obtained lifetime occupational histories by postal questionnaire from 218 patients with CFA and 569 controls matched for age, sex, and community, living in the Trent region of the UK. Information was subsequently verified by telephone interview in 165 cases and 408 controls. Serum IgE, rheumatoid factor, and antinuclear antibodies and skin sensitivity to common allergens were measured in cases and in one matched control for each. Findings The relative risk of CFA, after adjustment for smoking, was significantly increased in relation to questionnaire-reported exposure to metal dust (odds ratio 1.68 [95% CI 1.07-2.65], p=0.024) or to wood dust (1.71 [1.01-2.92], p=0.048). Similar results were obtained with the telephone interview data. Significant exposure-response effects were found for both metal-dust and wood-dust exposure. CFA was also associated with the presence of rheumatoid factor or antinuclear antibodies, but not with positive allergen skin tests or raised IgE concentrations. There was no evidence of interaction between the effects of rheumatoid factor, antinuclear antibodies, positive shin allergen tests, or IgE concentrations and exposure to metal or wood dust. The combined aetiological fraction attributable to exposure to metal or wood dust was of the order of 20%. Interpretation Occupational exposures to metal or wood dust are independent risk factors for CFA. Avoidance or limitation of these exposures may provide an opportunity to prevent the disease.	UNIV NOTTINGHAM, CITY HOSP, DIV RESP MED, NOTTINGHAM NG5 1PB, ENGLAND; QUEENS MED CTR, QUEENS RESP UNIT, NOTTINGHAM NG7 2UH, ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham			Britton, John R/G-9705-2011					[Anonymous], 1994, Respir Med, V88, P165; BARTTER T, 1991, ARCH INTERN MED, V151, P1197, DOI 10.1001/archinte.151.6.1197; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; CAROSSO A, 1987, BRIT J IND MED, V44, P53; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CUGELL DW, 1992, CLIN CHEST MED, V13, P269; DEVUYST P, 1986, EUR J RESPIR DIS, V68, P131; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; JEDERLINIC PJ, 1990, AM REV RESPIR DIS, V142, P1179, DOI 10.1164/ajrccm/142.5.1179; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; LILIS R, 1985, CHEST, V88, P306, DOI 10.1378/chest.88.2.306; MARSH P, 1994, RESP MED, V88, P369, DOI 10.1016/0954-6111(94)90043-4; NEMERY B, 1990, AM REV RESPIR DIS, V141, P1373, DOI 10.1164/ajrccm/141.5_Pt_1.1373; NEMERY B, 1990, EUR RESPIR J, V3, P202; RAMAGE JE, 1988, AM REV RESPIR DIS, V137, P1229, DOI 10.1164/ajrccm/137.5.1229; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; TOWNSHEND RH, 1982, BRIT J IND MED, V39, P411; Turner-Warwick M, 1971, Clin Allergy, V1, P83; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; VALLYATHAN V, 1982, CHEST, V81, P372, DOI 10.1378/chest.81.3.372; VANASSENDELFT AH, 1985, CHEST, V87, P394, DOI 10.1378/chest.87.3.394; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; WALDRON HA, 1994, OCCUPATIONAL LUNG DI, P593	29	241	248	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1996	347	8997					284	289		10.1016/S0140-6736(96)90465-1	http://dx.doi.org/10.1016/S0140-6736(96)90465-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569361				2022-12-28	WOS:A1996TT48500008
J	vanDijk, MR; Janse, CJ; Waters, AP				vanDijk, MR; Janse, CJ; Waters, AP			Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes	SCIENCE			English	Article							SIZE POLYMORPHISM; FALCIPARUM; BREAKAGE; DNA	Targeted integration of exogenous DNA into the genome of malaria parasites will allow their phenotype to be modulated by means of gene disruption or the stable expression of foreign and mutated genes. Described here is the site-specific integration through reciprocal exchange, and subsequent expression, of a selectable marker gene into the genome of the pathogenic, bloodstage forms of the rodent malaria parasite Plasmodium berghei. Stable integration of a single copy of the marker gene (retained for more than 70 generations in the absence of drug pressure) into a nontranscribed subtelomeric repeat array of different chromosomes was observed. Expression of the gene within the subtelomeres indicated that the previously recorded absence of transcription in these regions could be due to a corresponding absence of genes rather than active silencing mechanisms.	LEIDEN UNIV, DEPT PARASITOL, 2300 AL LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1992, NUCLEIC ACIDS RES, V20, P581, DOI 10.1093/nar/20.3.581; LANZER M, 1993, NATURE, V361, P654, DOI 10.1038/361654a0; LANZER M, 1996, MOL BIOCHEM PARASIT, V70, P1; PACE T, 1990, MOL CELL BIOL, V10, P6759, DOI 10.1128/MCB.10.12.6759; POLOGE LG, 1990, MOL CELL BIOL, V10, P3243, DOI 10.1128/MCB.10.6.3243; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; PONZI M, 1992, NUCLEIC ACIDS RES, V20, P4491, DOI 10.1093/nar/20.17.4491; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; SCHERF A, 1992, EMBO J, V11, P2293, DOI 10.1002/j.1460-2075.1992.tb05288.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; WU Y, IN PRESS P NATL ACAD; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973	18	76	76	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					662	665		10.1126/science.271.5249.662	http://dx.doi.org/10.1126/science.271.5249.662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571132				2022-12-28	WOS:A1996TT87000051
J	Dai, G; Levy, O; Carrasco, N				Dai, G; Levy, O; Carrasco, N			Cloning and characterization of the thyroid iodide transporter	NATURE			English	Article							EXPRESSION; PROTEIN	IODIDE (I-) is an essential constituent of the thyroid hormones T-3 and T-4, and is accumulated by the thyroid. The transport of iodide, the first step in thyroid hormogenesis, is catalysed by the Na+/I- symporter, an intrinsic membrane protein that is crucial for the evaluation, diagnosis and treatment of thyroid disorders. Although several other important thyroid proteins involved in hormogenesis have been characterized, the Na+/I- symporter has not. Here we report the isolation of a complementary DNA clone that encodes this symporter, as a result of functional screening of a cDNA library from a rat thyroid derived cell line (FRTL-5) in Xenopus laevis oocytes. Oocyte microinjection of an RNA transcript made in vitro from this cDNA clone elicited a more than 700-fold increase in perchlorate-sensitive Na+/I- symport activity over background. To our knowledge, this is the first iodide-transporting molecule to have its cDNA cloned, providing a missing link in the thyroid hormone biosynthetic pathway.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162				CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAI G, 1996, IN PRESS HDB BIOL PH, V2; DEGROOT LJ, 1995, ENDOCRINOLOGY, P507; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Surratt C K, 1993, Curr Opin Nephrol Hypertens, V2, P744; VILIJN F, 1989, J BIOL CHEM, V264, P11901; VULSMA T, 1991, ACTA ENDOCRINOL-COP, V124, P405, DOI 10.1530/acta.0.1240405; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WERNER SC, 1991, THYROID FUNDAMENTAL, P1; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	19	871	933	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					458	460		10.1038/379458a0	http://dx.doi.org/10.1038/379458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559252				2022-12-28	WOS:A1996TT30400062
J	Davenport, M				Davenport, M			ABC of general surgery in children - Surgically correctable causes of vomiting in infancy	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					236	239						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563593				2022-12-28	WOS:A1996TT48600034
J	Rawles, J				Rawles, J			Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: New evidence from Grampian region early anistreplase trial (GREAT)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; PATIENT	Objective-To generalise from the results of the Grampian region early anistreplase trial (GREAT) and to express the benefit of earlier thrombolysis in terms of lives saved per hour of earlier treatment. Design-Multivariate analysis of a randomised double blind trial. Setting-29 rural practices in Grampian region and teaching hospitals in Aberdeen. Subjects-311 patients with suspected acute myocardial infarction and without contraindications to thrombolysis who were seen by their general practitioners within four hours of the start of symptoms. Interventions-Anistreplase 30 units given intravenously, either by general practitioners before hospitalisation or later in hospital. Main outcome measure-Death within 30 months of entry into trial. Results-Death within 30 months was positively related to age (P<0.0001) and to delay between start of symptoms and thrombolytic treatment (P=0.0004). However, the probability of dying rose exponentially with earlier presentation, so death within 30 months was negatively related to the logarithm of the time of randomisation (P=0.0163). In patients presenting two hours after start of symptoms each hour's delay in receiving thrombolysis led to the loss of 21 lives per 1000 within 30 days (95% confidence interval 1 to 94 lives per 1000) (P=0.03) and 69 lives per 1000 within 30 months(16 to 14l livers per 1000) (P=0.0004). Conclusions-The magnitude of the benefit from earlier thrombolysis is such that giving thrombolytic treatment to patients with acute myocardial infarction should be accorded the same degree of urgency as the treatment of cardiac arrest.			Rawles, J (corresponding author), UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BAIGENT C, 1993, CIRCULATION, V88, P291; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HILLIS WS, 1992, BRIT HEART J, V68, P89; HOFGREN K, 1988, HEART LUNG, V17, P274; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MAYNARD C, 1989, AM J CARDIOL, V63, P1296, DOI 10.1016/0002-9149(89)91038-2; RAWLES J, 1995, BRIT MED J, V310, P465, DOI 10.1136/bmj.310.6977.465a; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; TRENT R, 1995, INT J CARDIOL, V49, P33, DOI 10.1016/0167-5273(95)02271-W; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; WILCOX RG, 1990, LANCET, V335, P1175	17	59	61	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	1996	312	7025					212	215						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563585				2022-12-28	WOS:A1996TT48600024
J	Hicke, L; Riezman, H				Hicke, L; Riezman, H			Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis	CELL			English	Article							PHEROMONE RECEPTOR; INSULIN-RECEPTOR; ALPHA-FACTOR; PROTEIN; DEGRADATION; INTERNALIZATION; VACUOLE; GENE; CEREVISIAE; SUBUNIT	Binding of alpha factor to Ste2p, a G protein-coupled plasma membrane receptor, activates a signal transduction pathway and stimulates endocytosis of the receptor-ligand complex. Ligand binding also induces ubiquitination of the Ste2p cytoplasmic tail. Protein ubiquitination is required for stimulated endocytosis of Steep, as internalization is 5- to 15-fold slower in ubc mutants that lack multiple ubiquitin-conjugating enzymes. In a C-terminal truncated form of Ste2p that is rapidly ubiquitinated and endocytosed in response to ligand binding, a single lysine to arginine substitution in its cytoplasmic tail eliminates both ubiquitination and internalization. Thus, ubiquitination of Ste2p itself is required for ligand-stimulated endocytosis. We propose that ubiquitination mediates degradation of receptor-ligand complexes, not via the proteasome, but by acting as a signal for endocytosis leading to subsequent degradation in the lysosome/vacuole.			Hicke, L (corresponding author), UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DULIC V, 1991, METHOD ENZYMOL, V194, P697; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	52	642	656	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					277	287		10.1016/S0092-8674(00)80982-4	http://dx.doi.org/10.1016/S0092-8674(00)80982-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565073	Bronze			2022-12-28	WOS:A1996TR59500014
J	Struthers, MD; Cheng, RP; Imperiali, B				Struthers, MD; Cheng, RP; Imperiali, B			Design of a monomeric 23-residue polypeptide with defined tertiary structure	SCIENCE			English	Article							ZINC-FINGER PEPTIDE; 4-HELIX BUNDLE; CRYSTAL-STRUCTURE; METAL-BINDING; PROTEIN ZFY; SPECTROSCOPY; DOMAIN; MOTIFS; PROBE	Small proteins or protein domains generally require disulfide bridges or metal sites for their stabilization. Here it is shown that the beta beta alpha architecture of zinc fingers can be reproduced in a 23-residue polypeptide in the absence of metal ions. The sequence was obtained through an iterative design process. A key feature of the final design is the incorporation of a type II' beta turn to aid in beta-hairpin formation. Nuclear magnetic resonance analysis reveals that the alpha helix and beta hairpin are held together by a defined hydrophobic core. The availability of this structural template has implications for the development of functional polypeptides.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	California Institute of Technology				Imperiali, Barbara/0000-0002-5749-7869				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; EIS PS, 1993, BIOCHEMISTRY-US, V32, P7981, DOI 10.1021/bi00082a020; Fasman GD, 1989, PREDICTION PROTEIN S, P193; FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GOODSELL DS, 1993, TRENDS BIOCHEM SCI, V18, P65, DOI 10.1016/0968-0004(93)90153-E; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; IMPERIALI B, 1992, J AM CHEM SOC, V114, P3182, DOI 10.1021/ja00035a002; KURODA Y, 1995, PROTEIN ENG, V8, P97, DOI 10.1093/protein/8.2.97; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIEBERMAN M, 1991, J AM CHEM SOC, V113, P1470, DOI 10.1021/ja00004a090; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RALEIGH DP, 1995, J AM CHEM SOC, V117, P7558, DOI 10.1021/ja00133a035; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SMITH DDS, 1995, PROTEIN ENG, V8, P13, DOI 10.1093/protein/8.1.13; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRUTHERS MS, UNPUB; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P5660, DOI 10.1021/bi00476a002; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; WETLAUFER DB, 1990, TRENDS BIOCHEM SCI, V15, P414, DOI 10.1016/0968-0004(90)90275-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAN YB, 1994, PROTEIN SCI, V3, P1069, DOI 10.1002/pro.5560030709	38	278	284	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					342	345		10.1126/science.271.5247.342	http://dx.doi.org/10.1126/science.271.5247.342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553067				2022-12-28	WOS:A1996TQ52800038
J	Quon, KC; Marczynski, GT; Shapiro, L				Quon, KC; Marczynski, GT; Shapiro, L			Cell cycle control by an essential bacterial two-component signal transduction protein	CELL			English	Article							GRAM-NEGATIVE BACTERIA; CAULOBACTER-CRESCENTUS; BACILLUS-SUBTILIS; DNA-REPLICATION; GENE-EXPRESSION; DIVISION; MUTAGENESIS; PROMOTER; DIFFERENTIATION; IDENTIFICATION	Dividing cells must coordinate cell cycle events to ensure genetic stability. Here we identify an essential two-component signal transduction protein that controls multiple events in the Caulobacter cell cycle, including cell division, stalk synthesis, and cell cycle-specific transcription. This protein, CtrA, is homologous to response regulator transcription factors and controls transcription from a group of cell cycle-regulated promoters critical for DNA replication, DNA methylation, and flagellar biogenesis. CtrA activity in the cell cycle is controlled both transcriptionally and by phosphorylation. As purified CtrA binds an essential DNA sequence motif found within its target promoters, we propose that CtrA acts in a phosphorelay signal transduction system to control bacterial cell cycle events directly at the transcriptional level.			Quon, KC (corresponding author), STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM5 1426, GM 32506/512OMZ] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1991, GENETICS, V129, P333; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELY B, 1991, METHOD ENZYMOL, V204, P372; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FISHER JA, 1988, J BACTERIOL, V170, P4706, DOI 10.1128/jb.170.10.4706-4713.1988; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GUENZI E, 1994, MOL MICROBIOL, V12, P505, DOI 10.1111/j.1365-2958.1994.tb01038.x; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; IRETON K, 1992, P NATL ACAD SCI USA, V89, P8808, DOI 10.1073/pnas.89.18.8808; IRETON K, 1994, EMBO J, V13, P1566, DOI 10.1002/j.1460-2075.1994.tb06419.x; JENAL U, 1994, J MOL BIOL, V243, P227, DOI 10.1006/jmbi.1994.1650; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOKJOHN TA, 1987, J BACTERIOL, V169, P1499, DOI 10.1128/jb.169.4.1499-1508.1987; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUTSUKAKE K, 1994, MOL GEN GENET, V243, P605, DOI 10.1007/BF00279569; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; Miller J.H., 1972, EXPT MOL GENETICS; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEWTON A, 1989, P NATL ACAD SCI USA, V86, P6651, DOI 10.1073/pnas.86.17.6651; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; OSLEY MA, 1977, P NATL ACAD SCI USA, V74, P124, DOI 10.1073/pnas.74.1.124; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAMAKRISHNAN G, 1994, J BACTERIOL, V176, P7587, DOI 10.1128/JB.176.24.7587-7600.1994; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; RIZZO MF, 1993, J BACTERIOL, V175, P6970, DOI 10.1128/jb.175.21.6970-6981.1993; RUDOLPH J, 1995, EMBO J, V14, P667, DOI 10.1002/j.1460-2075.1995.tb07045.x; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT JM, 1966, J CELL BIOL, V28, P423, DOI 10.1083/jcb.28.3.423; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STEPHENS CM, 1995, J BACTERIOL, V177, P1662, DOI 10.1128/jb.177.7.1662-1669.1995; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VANWAY SM, 1993, J BACTERIOL, V175, P367, DOI 10.1128/JB.175.2.367-376.1993; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZHUANG WY, 1992, J BACTERIOL, V177, P34; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	59	384	388	0	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					83	93		10.1016/S0092-8674(00)80995-2	http://dx.doi.org/10.1016/S0092-8674(00)80995-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548829	Bronze			2022-12-28	WOS:A1996TQ17000011
J	Stern, MP				Stern, MP			Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; IMPAIRED GLUCOSE-TOLERANCE; NON-HISPANIC WHITES; RISK-FACTORS; PIMA-INDIANS; MEXICAN-AMERICANS; ARTERY DISEASE; MYOCARDIAL-INFARCTION; FOLLOW-UP	Recent evidence suggests that non-insulin-dependent diabetes mellitus (NIDDM) and cardiovascular disease, rather than being related as underlying disease and complication, share common genetic and environmental antecedents, that is, they ''spring from the same soil.'' Fetal and early-life nutritional deficiencies appear to predispose persons to both NIDDM and cardiovascular disease in later life. The insulin resistance syndrome, including abdominal obesity, may constitute the intermediate link between fetal and early-life nutritional deficiency and later disease. The insulin resistance syndrome includes insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia with high triglyceride and low high-density lipoprotein cholesterol levels, and hypertension. Each element of the insulin resistance syndrome has been firmly established as a risk factor for development of diabetes. In addition, most of these elements are also well-recognized cardiovascular risk factors, although the weight of evidence now suggests that hyperinsulinemia itself is not. This last point is significant because of concern that aggressive insulinization of diabetic patients, which has been proved to reduce microvascular complications, might paradoxically increase the risk for large-vessel atherosclerosis. Available clinical trials suggest that this fear is unwarranted, but definitive trials are needed to resolve this important clinical question.			Stern, MP (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.							AMER DIABET ASSOC, 1993, DIABETES CARE, V16, P1517; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; [Anonymous], 1983, Diabetologia, V24, P404; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BERNE C, 1994, DIABETOLOGIA, V37, pA57; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CHAKRABORTY R, 1986, GENET EPIDEMIOL, V3, P435, DOI 10.1002/gepi.1370030608; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; CROUSE JR, 1985, J LIPID RES, V26, P566; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; FERRARA A, 1994, AM J EPIDEMIOL, V140, P857, DOI 10.1093/oxfordjournals.aje.a117174; FONTBONNE A, 1994, DIABETOLOGIA, V37, P953, DOI 10.1007/s001250050203; Goff David C. Jr., 1993, Ethnicity and Disease, V3, P55; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, ANN INTERN MED, V87, P393, DOI 10.7326/0003-4819-87-4-393; HAFFNER SM, 1993, ARTERIOSCLER THROMB, V13, P1623, DOI 10.1161/01.ATV.13.11.1623; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HAFFNER SM, 1994, DIABETES, V43, P1490, DOI 10.2337/diabetes.43.12.1490; HAFFNER SM, IN PRESS DIABETES; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HERMAN JB, 1977, DIABETOLOGIA, V13, P229, DOI 10.1007/BF01219704; HOWARD BV, 1995, AM J EPIDEMIOL, V142, P254, DOI 10.1093/oxfordjournals.aje.a117632; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; Jarrett R J, 1984, Diabet Med, V1, P279; JARRETT RJ, 1984, DIABETOLOGIA, V26, P99; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; JARRETT RJ, 1994, DIABETOLOGIA, V37, P945, DOI 10.1007/BF00400952; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KAHN SE, 1995, DIABETES, V44, P173, DOI 10.2337/diabetes.44.2.173; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LIU QZ, 1992, DIABETES, V41, P1141, DOI 10.2337/diabetes.41.9.1141; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519; MEDALIE JH, 1975, ARCH INTERN MED, V135, P811, DOI 10.1001/archinte.135.6.811; MEHTA J, 1987, J AM COLL CARDIOL, V9, P263, DOI 10.1016/S0735-1097(87)80373-X; MEINERT CL, 1970, DIABETES, V19, P789; MITCHELL BD, 1991, CIRCULATION, V83, P45, DOI 10.1161/01.CIR.83.1.45; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; MYKKANEN L, 1993, DIABETOLOGIA, V36, P553, DOI 10.1007/BF02743273; MYKKANEN L, 1994, DIABETOLOGIA, V37, pA74; NELSON RG, 1990, CIRCULATION, V81, P987, DOI 10.1161/01.CIR.81.3.987; Nichaman M Z, 1993, Ann Epidemiol, V3, P42; NIELSEN NV, 1985, HORM METAB RES, V15, P19; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; Orchard Trevor J., 1994, Annals of Epidemiology, V4, P40; PELL S, 1967, J AMER MED ASSOC, V202, P10, DOI 10.1001/jama.1967.03130140068008; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1994, DIABETOLOGIA, V37, P948, DOI 10.1007/s001250050202; REWERS M, 1992, CIRCULATION, V85, P865; SAAD MF, 1990, J CLIN ENDOCR METAB, V70, P1247, DOI 10.1210/jcem-70-5-1247; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STERN MP, 1990, DIABETES METAB REV, V6, P29, DOI 10.1002/dmr.5610060102; STERN MP, 1994, DIABETOLOGIA, V37, P956, DOI 10.1007/s001250050204; STERN MP, 1987, CIRCULATION, V76, P1245, DOI 10.1161/01.CIR.76.6.1245; STERN MP, 1993, DIABETES, V42, P706, DOI 10.2337/diabetes.42.5.706; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; TEMPLE RC, 1990, CLIN ENDOCRINOL, V32, P689, DOI 10.1111/j.1365-2265.1990.tb00915.x; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WELIN L, 1992, DIABETOLOGIA, V35, P766; WELTY TK, 1995, AM J EPIDEMIOL, V142, P269, DOI 10.1093/oxfordjournals.aje.a117633; YOSHIOKA N, 1988, DIABETOLOGIA, V31, P355, DOI 10.1007/BF02341503; 1980, BUILD STUDY 1979	90	88	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				110	116		10.7326/0003-4819-124-1_Part_2-199601011-00006	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554201				2022-12-28	WOS:A1996TL94400006
J	Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H				Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H			The 3' enhancer region determines the B/T specificity and pro-B pre-B specificity of immunoglobulin V-kappa-J(kappa) joining	CELL			English	Article							CHAIN INTRON ENHANCER; V(D)J RECOMBINATION; GENE REARRANGEMENT; CONSTANT REGION; LOCUS CONTAINS; ETS ONCOGENE; BONE-MARROW; CELL; HEAVY; EXPRESSION	Using transgenic substrates, we found that the immunoglobulin kappa gene 3' enhancer (E3') acts as a negative regulator in V-kappa-J(kappa) joining. Although the E3' was originally identified as a transcriptional enhancer, it acts in a suppressive manner for recombinational regulation. Base substitution analysis has shown that the PU.1-binding site within the E3' regulates the B/T specificity of V-kappa-J(kappa) joining. In a substrate with a mutated PU.1-binding site (GAGGAA to TCTTCG), V-kappa-J(kappa) joining occurred not only in B cells, but also in T cells. The E3' region is also responsible for determining the pro-B/pre-B specificity of V-kappa-J(kappa) joining. When the E3' region was deleted, kappa gene rearrangement actively occurred at the early pro-B stage of B cell development: nongermline (N) nucleotides were common at recombination junctions.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT DEV GENET, KUMAMOTO 862, JAPAN; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kumamoto University; Mayo Clinic; Fox Chase Cancer Center; University of Tokyo	Hiramatsu, R (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV IMMUNOL, BERKELEY, CA 94720 USA.		Sakumi, Kunihiko/G-4808-2011	Matsuoka, Masao/0000-0002-0473-754X				AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOODHARDT M, 1987, P NATL ACAD SCI USA, V84, P4229, DOI 10.1073/pnas.84.12.4229; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEINRICH G, 1984, J EXP MED, V159, P417, DOI 10.1084/jem.159.2.417; HROMAS R, 1993, BLOOD, V82, P2998; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HSIEH CL, 1992, J BIOL CHEM, V22, P15963; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KUNG JT, 1981, J IMMUNOL, V127, P873; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; ROSS IL, 1994, ONCOGENE, V9, P121; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; WATRIN F, 1994, TRANSGENESIS TARGETE, P1; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	53	55	55	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1113	1123		10.1016/0092-8674(95)90138-8	http://dx.doi.org/10.1016/0092-8674(95)90138-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548799	Bronze			2022-12-28	WOS:A1995TM76200008
J	GALLAGHER, EJ; LOMBARDI, G; GENNIS, P				GALLAGHER, EJ; LOMBARDI, G; GENNIS, P			EFFECTIVENESS OF BYSTANDER CARDIOPULMONARY-RESUSCITATION AND SURVIVAL FOLLOWING OUT-OF-HOSPITAL CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIENCE; SYSTEM; CPR	Objective.-To examine the independent relationship between effectiveness of bystander cardiopulmonary resuscitation (CPR) and survival following out-of-hospital cardiac arrest. Design.-Prospective observational cohort. Setting.-New York City. Participants.-A total of 2071 consecutive out-of-hospital cardiac arrests meeting Utstein criteria. Intervention.-Trained prehospital personnel assessed the quality of bystander CPR on arrival at the scene. Satisfactory execution of CPR required performance of both adequate compressions and ventilations in conformity with current American Heart Association guidelines. Main Outcome Measure.-Adjusted association between CPR effectiveness and survival. Survival was defined as discharge from hospital to home. Results.-Outcome was determined on all members of the inception cohort-none were lost to follow-up. When the association between bystander CPR and survival was adjusted for effectiveness of CPR in the parent data set (N=2071), only effective CPR was retained in the logistic model (adjusted odds ratio [OR]=5.7; 95% confidence interval [CI], 2.7 to 12.2; P<.001). Of the subset of 662 individuals (32%) who received bystander CPR, 305 (46%) had it performed effectively. Of these, 4.6% (14/305) survived vs 1.4% (5/357) of those with ineffective CPR (OR=3.4; 95% CI, 1.1 to 12.1; P<.02). After adjustment for witness status, initial rhythm, interval from collapse to CPR, and interval from collapse to advanced life support, effective CPR remained independently associated with improved survival (adjusted OR=3.9; 95% CI, 1.1 to 14.0; P<.04). Conclusion.-The association between bystander CPR and survival in out-of-hospital cardiac arrest appears to be confounded by CPR quality. Effective CPR is independently associated with a quantitatively and statistically significant improvement in survival.	ALBERT EINSTEIN COLL MED,DEPT EMERGENCY MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; YALE UNIV,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,NEW HAVEN,CT	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University								BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; CHANDRA NC, 1992, CURR EMERG CARDIAC C, V3, P5; COBB LA, 1980, ANNU REV MED, V31, P454; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GENNIS P, 1994, ANN EMERG MED, V24, P194, DOI 10.1016/S0196-0644(94)70130-X; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; LUND I, 1976, LANCET, V2, P702; NEWMAN MM, 1994, CURR EMERG CARDIAC C, V17, P11; STUEVEN H, 1986, ANN EMERG MED, V15, P707, DOI 10.1016/S0196-0644(86)80430-9; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WHITE BC, 1985, JAMA-J AM MED ASSOC, V254, P3308; 1994, ADV CARDIAC LIFE SUP; 1992, JAMA-J AM MED ASSOC, V268, P2184	22	377	381	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1922	1925		10.1001/jama.274.24.1922	http://dx.doi.org/10.1001/jama.274.24.1922			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568985				2022-12-28	WOS:A1995TL16900033
J	Marmot, M				Marmot, M			A not-so-sensible drinks policy	LANCET			English	Editorial Material											Marmot, M (corresponding author), UCL, INT CTR HLTH & SOC, MORTIMER ST, LONDON, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BOFETTA P, 1990, EPIDEMIOLOGY, V1, P342; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Edwards G., 1994, ALCOHOL POLICY PUBLI; 1995, SENSIBLE DRINKING RE; 1995, ROYAL COLLEGES REPOR	5	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1643	1644		10.1016/S0140-6736(95)92833-2	http://dx.doi.org/10.1016/S0140-6736(95)92833-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551817				2022-12-28	WOS:A1995TL42300003
J	Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M				Lehtinen, M; Dillner, J; Knekt, P; Luostarinen, T; Aromaa, A; Kimbauer, R; Koskela, P; Paavonen, J; Peto, R; Schiller, JT; Hakama, M			Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To study human papillomavirus type 16 in the aetiology of cervical c Design-Within a cohort of 18 814 Finnish women followed for up to 23 years a nested case-control study was conducted based on serological diagnosis of past infection with human papillomavirus type 16. Subjects-72 women (27 with invasive carcinoma and 45 with in situ carcinoma) and 143 matched controls were identified during the follow up. Main outcome measure- Relative risk of cervical carcinoma in presence of IgG antibodies to human papillomavirus type 16. Results-After adjustment for smoking and for antibodies to various other agents of sexually transmitted disease, such as herpes simplex virus type 2 and Chlamydia trachomatis, the only significant association was with infection with human papillomavirus type 16 (odds ratio 12.5; 95% confidence interval 2.7 to 57, 2P < 0.001). Conclusion-This prospective study provides epidemiological evidence that infection with human papillomavirus type 16 confers an excess risk for subsequent development of cervical carcinoma.	TAMPERE UNIV, TAMPERE SCH PUBL HLTH, SF-33101 TAMPERE, FINLAND; NATL PUBL HLTH INST, OULU, FINLAND; NATL PUBL HLTH INST, DEPT CHRON VIRAL DIS, SF-00300 HELSINKI, FINLAND; KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, STOCKHOLM, SWEDEN; SOCIAL INSURANCE INST, CTR RES & DEV, SF-00381 HELSINKI, FINLAND; FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; UNIV VIENNA, SCH MED, DEPT IMMUNODERMATOL, VIENNA, AUSTRIA; HELSINKI UNIV, HELSINKI, FINLAND; UNIV OXFORD, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND; UNIV OXFORD, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD, ENGLAND; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	Tampere University; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Karolinska Institutet; Finnish Cancer Registry; University of Vienna; University of Helsinki; University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Schiller, John/ABK-8287-2022	Luostarinen, Tapio/0000-0003-3231-8550; lehtinen, matti/0000-0002-9481-0535				Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Chabaud Martine, 1994, P59; DILLNER J, 1994, CANCER RES, V54, P134; DILLNER J, 1995, INT J CANCER, V60, P377; HAKAMA M, 1993, AM J EPIDEMIOL, V137, P166, DOI 10.1093/oxfordjournals.aje.a116656; HANNA L, 1980, J CLIN MICROBIOL, V12, P409, DOI 10.1128/JCM.12.3.409-412.1980; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; KIMBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494; LEHTINEN M, 1986, EUR J CLIN MICROBIOL, V5, P596, DOI 10.1007/BF02017713; MARDH PA, 1989, CHLAMYDIA, P1; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; NONNENMACHER B, 1995, J INFECT DIS, V172, P19, DOI 10.1093/infdis/172.1.19; PAAVONEN J, 1996, SEXUALLY TRANSMITTED; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958	14	132	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1996	312	7030					537	539		10.1136/bmj.312.7030.537	http://dx.doi.org/10.1136/bmj.312.7030.537			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595281	Green Published			2022-12-28	WOS:A1996TY88500021
J	Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL				Chua, SC; Chung, WK; WuPeng, XS; Zhang, YY; Liu, SM; Tartaglia, L; Leibel, RL			Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; HUMAN DNA; OBESITY; YEAST; CONSTRUCTION; INSERTS; CLONING; MODEL; MICE	Mice harboring mutations in the obese (ob) and diabetes (db) genes display similar phenotypes, and it has been proposed that these genes encode the ligand and receptor, respectively, for a physiologic pathway that regulates body weight. The cloning of ob, and the demonstration that it encodes a secreted protein (leptin) that binds specifically to a receptor (OB-R) in the brain, have validated critical aspects of this hypothesis. Here it is shown by genetic mapping and genomic analysis that mouse db, rat fatty (a homolog of db), and the gene encoding the OB-R are the same gene.	ROCKEFELLER UNIV,HUMAN BEHAV & METAB LAB,NEW YORK,NY 10021; MILLENNIUM PHARMACEUT,CAMBRIDGE,MA 02139	Rockefeller University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals					NICHD NIH HHS [HD28047] Funding Source: Medline; NIDDK NIH HHS [DK26687, DK47473] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047473, P30DK026687] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUBERT R, 1985, J NUTR, V115, P327, DOI 10.1093/jn/115.3.327; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHUA SJ, UNPUB; CHUNG WK, 1995, 2ND CHROM ONE M VIEN; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KERSHAW EE, 1995, GENOMICS, V27, P149, DOI 10.1006/geno.1995.1017; KOLETSKY S, 1973, EXP MOL PATHOL, V19, P53, DOI 10.1016/0014-4800(73)90040-3; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEITER EH, 1980, DIABETOLOGIA, V19, P66, DOI 10.1007/BF00258314; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093	28	955	992	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					994	996		10.1126/science.271.5251.994	http://dx.doi.org/10.1126/science.271.5251.994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584938				2022-12-28	WOS:A1996TV70400051
J	Takahashi, Y; Kaji, H; Okimura, Y; Goji, K; Abe, H; Chihara, K				Takahashi, Y; Kaji, H; Okimura, Y; Goji, K; Abe, H; Chihara, K			Brief report: Short stature caused by a mutant growth hormone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING PROTEIN-COMPLEX; RECEPTOR; GH; CHILDREN; SERUM; CELLS; FAILURE; PLASMA; DNA		KOBE CHILDRENS HOSP, DEPT ENDOCRINOL & METAB, KOBE, HYOGO, JAPAN		Takahashi, Y (corresponding author), KOBE UNIV, SCH MED,DEPT MED,DIV 3,CHUO KU, 7-5-1 KUSUNOKI CHO, KOBE 650, JAPAN.							ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1989, METABOLISM, V38, P330, DOI 10.1016/0026-0495(89)90119-4; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BRIGHT GM, 1983, PEDIATRICS, V71, P576; CARLSSON LMS, 1993, J CLIN ENDOCR METAB, V77, P356, DOI 10.1210/jc.77.2.356; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMARTYNOFF G, 1980, BIOCHEM BIOPH RES CO, V93, P645, DOI 10.1016/0006-291X(80)91127-4; FRAZER T, 1982, J PEDIATR-US, V101, P12, DOI 10.1016/S0022-3476(82)80171-6; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAYEK A, 1978, PEDIATR RES, V12, P413, DOI 10.1203/00006450-197804001-00304; HERINGTON AC, 1991, ACTA ENDOCRINOL-COP, V124, P14; KOWARSKI AA, 1978, J CLIN ENDOCR METAB, V47, P461, DOI 10.1210/jcem-47-2-461; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; Maniatis T., 1982, MOL CLONING; OKIMURA Y, 1988, J CLIN ENDOCR METAB, V67, P1074, DOI 10.1210/jcem-67-5-1074; PLOTNICK LP, 1983, PEDIATRICS, V71, P324; ROSENBLOOM AL, 1992, ACTA PAEDIATR, V81, P117; RUDMAN D, 1981, NEW ENGL J MED, V305, P123, DOI 10.1056/NEJM198107163050302; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVA CM, 1994, J BIOL CHEM, V269, P27532; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TSVETNITSKY V, 1995, BIOCHEM J, V307, P239, DOI 10.1042/bj3070239; VALENTA LJ, 1985, NEW ENGL J MED, V312, P214, DOI 10.1056/NEJM198501243120405	27	94	108	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					432	436		10.1056/NEJM199602153340704	http://dx.doi.org/10.1056/NEJM199602153340704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552145				2022-12-28	WOS:A1996TU69600004
J	Weissberg, PL; Clesham, GJ; Bennett, MR				Weissberg, PL; Clesham, GJ; Bennett, MR			Is vascular smooth muscle cell proliferation beneficial?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; PATHOGENESIS; ATHEROSCLEROSIS; ANGIOPLASTY; ATHERECTOMY; RESTENOSIS; PREVENTION; DISEASE; THERAPY				Weissberg, PL (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, LEVEL 5, CAMBRIDGE CB2 2QQ, ENGLAND.			Bennett, Martin/0000-0002-2565-1825				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BENNETT MR, IN RESS CIRCULATION; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1990, CIRCULATION, V82, P47; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; MOSSE PRL, 1985, LAB INVEST, V53, P556; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1994, LANCET, V344, P1383; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STRAUSS BH, 1992, J AM COLL CARDIOL, V20, P1465, DOI 10.1016/0735-1097(92)90438-S; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36	22	104	109	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1996	347	8997					305	307		10.1016/S0140-6736(96)90472-9	http://dx.doi.org/10.1016/S0140-6736(96)90472-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569368				2022-12-28	WOS:A1996TT48500015
J	Alguire, PC; Anderson, WA; Albrecht, RR; Poland, GA				Alguire, PC; Anderson, WA; Albrecht, RR; Poland, GA			Resident research in internal medicine training programs	ANNALS OF INTERNAL MEDICINE			English	Article							PSYCHIATRY; RECOMMENDATIONS; VIEWS	Objective: To determine how well medical residency programs are prepared to meet the new Accreditation Council of Graduate Medical Education (ACGME) accreditation guidelines for resident scholarly activity. Design: Cross-sectional study using a mailed survey. Participants: Program directors of all ACGME-accredited internal medicine residency programs. Measurements: Program directors were asked to list the scholarly activities and products of their residents and their programs' minimal expectations for resident research; available academic, faculty, technical, and personnel support for resident research; perceived barriers to resident research; and the desired educational and skill outcomes of resident research. The responses of university-based training programs were compared with those of non-university-based programs. Results: 271 program directors returned the survey, yielding a response rate of 65%. Ninety-seven percent of all programs have established scholarly guidelines consistent with accreditation requirements. Although only 37% of programs reported having an organized, comprehensive research curriculum 70% taught skills important to research. Technical support and resources were generally available for resident research; the most frequently cited barrier to resident research was lack of resident time. University-based and non-university-based training programs differed in important ways. Generally, non-university-based programs had more research activity and structure, and they exceeded university-based programs in the number of oral and poster presentations given at local, state, and national professional meetings. Conclusions: Most programs have in place the basic elements conducive to resident research. Program directors have identified and teach educational outcomes and skills that are likely to have lifelong benefits for most of their graduates.	MICHIGAN STATE UNIV, OFF MED EDUC RES & DEV, E LANSING, MI 48824 USA; MAYO CLIN & MAYO FDN, VACCINE RES GRP, ROCHESTER, MN 55905 USA	Michigan State University; Mayo Clinic	Alguire, PC (corresponding author), UNIV FLORIDA, HLTH SCI CTR, POB 100277, GAINESVILLE, FL 32610 USA.							ABRAMSON M, 1977, T AM ACAD OPHTHALMOL, V84, P984; Alguire PC, 1993, TEACH LEARN MED, V5, P37; APPLEGATE WB, 1990, AM J MED, V88, P263, DOI 10.1016/0002-9343(90)90152-4; BAKER SL, 1969, MED ANN DIST COLUMBI, V37, P273; BLAKE DJ, 1994, AM J PHYS MED REHAB, V73, P245, DOI 10.1097/00002060-199407000-00004; BLAND CJ, 1992, ACTA MED, V67, P685; CROWLEY AE, 1993, DIRECTORY GRADUATE M; DEMERS RY, 1981, J FAM PRACTICE, V12, P675; Eisenberg J M, 1986, J Gen Intern Med, V1, pS8; Fletcher R H, 1986, J Gen Intern Med, V1, pS50; FOGELMAN AM, 1994, ANN INTERN MED, V120, P579, DOI 10.7326/0003-4819-120-7-199404010-00009; Gaspar M J, 1987, Fam Med, V19, P463; GEYMAN JP, 1978, J FAM PRACTICE, V7, P69; GEYMAN JP, 1977, J FAM PRACTICE, V5, P245; GIBSON K, 1989, CAN J PSYCHIAT, V34, P182, DOI 10.1177/070674378903400304; GOLDMAN L, 1986, CLIN RES, V34, P1; GRABOIS M, 1988, AM J PHYS MED REHAB, V67, P171, DOI 10.1097/00002060-198808000-00008; HAYWARD RA, 1993, J GEN INTERN MED, V8, P140, DOI 10.1007/BF02599759; HERSHBERG RI, 1980, J MED EDUC, V55, P540; HILLMAN BJ, 1990, INVEST RADIOL, V25, P587, DOI 10.1097/00004424-199005000-00020; HILLMAN BJ, 1989, INVEST RADIOL, V24, P849, DOI 10.1097/00004424-198911000-00003; Hitchcock M A, 1990, Fam Med, V22, P191; Holloway R L, 1986, Fam Med, V18, P133; JONES J, 1987, ANN EMERG MED, V16, P149; Kane W J, 1976, J Fam Pract, V3, P668; KANTOR SM, 1981, J MED EDUC, V56, P748; KERN DC, 1985, JAMA-J AM MED ASSOC, V254, P70, DOI 10.1001/jama.254.1.70; KUZEL AJ, 1984, FAM MED, V16, P1; Liese B S, 1988, Kans Med, V89, P143; McDonald C J, 1986, J Gen Intern Med, V1, pS19; MCWHINNEY IR, 1966, LANCET, V1, P419; Morris B A, 1994, Fam Med, V26, P579; MORRISON JC, 1994, AM J OBSTET GYNECOL, V170, P777, DOI 10.1016/S0002-9378(94)70281-0; NEINSTEIN LS, 1989, ACAD MED, V64, P32, DOI 10.1097/00001888-198901000-00014; PANIAGUA FA, 1993, J AM ACAD CHILD PSY, V32, P446, DOI 10.1097/00004583-199303000-00029; PERKOFF GT, 1985, J FAM PRACTICE, V21, P389; Philpott G W, 1984, Curr Surg, V41, P433; Pollack C V Jr, 1994, J Emerg Med, V12, P75, DOI 10.1016/0736-4679(94)90019-1; ROWLEY BD, 1991, JAMA-J AM MED ASSOC, V266, P933, DOI 10.1001/jama.266.7.933; STOLOV WC, 1983, ARCH PHYS MED REHAB, V64, P1; STRAUSS GD, 1980, AM J PSYCHIAT, V137, P727; SULAK PJ, 1992, AM J OBSTET GYNECOL, V167, P498, DOI 10.1016/S0002-9378(11)91437-9; TANIGUCHI MH, 1994, AM J PHYS MED REHAB, V73, P240, DOI 10.1097/00002060-199407000-00003; Temte J L, 1994, Fam Med, V26, P93; THIER SO, 1980, CLIN RES, V28, P85; WILSON JL, 1980, J FAM PRACTICE, V10, P479; WINTER BJ, 1993, TEACH LEARN MED, V5, P96; 1984, POLICIES PROCEDURES; 1983, ANN INTERN MED, V99, P840	49	71	71	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					321	328		10.7326/0003-4819-124-3-199602010-00007	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554228				2022-12-28	WOS:A1996TR59600007
J	RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG				RoelkeParker, ME; Munson, L; Packer, C; Kock, R; Cleaveland, S; Carpenter, M; OBrien, SJ; Pospischil, A; HofmannLehmann, R; Lutz, H; Mwamengele, GLM; Mgasa, MN; Machange, GA; Summers, BA; Appel, MJG			A canine distemper virus epidemic in Serengeti lions (Panthera leo)	NATURE			English	Article								CANINE distemper virus (CDV) is thought to have caused several fatal epidemics in canids within the Serengeti-Mara ecosystem of East Africa, affecting silver-backedjackals (Canis mesomelas) and bat-cared foxes (Otocyon megalotis) in 1978 (ref. 1), and African wild dogs (Lycaon pictus) in 1991 (refs 2, 3). The large, closely monitored Serengeti lion population(4,5) was not affected in these epidemics. However, an epidemic caused by a morbillivirus closely related to CDV emerged abruptly in the lion population of the Serengeti National Pack, Tanzania, in early 1994, resulting in fatal neurological disease characterized by grand mal seizures and myoclonus; the lions that died had encephalitis and pneumonia. Here we report the identification of CDV from these lions, and the close phylogenetic relationship between CDV isolates from lions and domestic dogs. By August 1994, 85% of the Serengeti lion population had anti-CDV antibodies, and the epidemic spread north to lions in the Maasai Mara National reserve, Kenya, and uncounted hyaenas, bat-eared foxes, and leopards were also affected.	UNIV TENNESSEE,COLL VET MED,DEPT PATHOL,KNOXVILLE,TN 37901; SERENGETI WILDLIFE RES INST,TANZANIA NATL PARKS,ARUSHA,TANZANIA; MESSERLI FDN,ZURICH,SWITZERLAND; UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108; KENYA WILDLIFE SERV,NAIROBI,KENYA; INST ZOOL,LONDON NW1 4RY,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV ZURICH,INST VET PATHOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,DEPT VET INTERNAL MED,CH-8057 ZURICH,SWITZERLAND; SOKOINE UNIV AGR,DEPT VET PATHOL,MOROGORO,TANZANIA; VET INVEST CTR,ARUSHA,TANZANIA; CORNELL UNIV,COLL VET MED,DEPT PATHOL,ITHACA,NY 14853; CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Minnesota System; University of Minnesota Twin Cities; University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zurich; University of Zurich; Sokoine University of Agriculture; Cornell University; Cornell University			OBRIEN, STEPHEN/ABD-1346-2020; Hofmann-Lehmann, Regina/C-6528-2009	Hofmann-Lehmann, Regina/0000-0001-9750-4296; Carpenter, Margaret/0000-0003-1606-1986; OBRIEN, STEPHEN/0000-0001-7857-0757; Kock, Richard/0000-0002-6561-3209				ALEXANDER KA, 1994, J WILDLIFE DIS, V30, P481, DOI 10.7589/0090-3558-30.4.481; APPEL M, 1973, AM J VET RES, V34, P1459; APPEL MJ, 1987, VIRUS INFECT CARNIVO, P00133; APPEL MJG, 1992, J VET DIAGN INVEST, V4, P258, DOI 10.1177/104063879200400306; APPEL MJG, 1994, J VET DIAGN INVEST, V6, P277, DOI 10.1177/104063879400600301; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BROWN EW, 1993, J ZOO WILDLIFE MED, V24, P357; BROWN EW, 1994, J VIROL, V68, P5953, DOI 10.1128/JVI.68.9.5953-5968.1994; CARMICHAEL LE, 1980, AM J VET RES, V41, P784; FELSTEINSTEIN J, 1995, PHYLOGENY INFERENCE; GILBERT DA, 1991, J HERED, V82, P378, DOI 10.1093/oxfordjournals.jhered.a111107; Hofer Heribert, 1993, Symposia of the Zoological Society of London, V65, P347; MACDONALD DW, 1992, NATURE, V360, P633, DOI 10.1038/360633b0; Moehlman PD, 1983, RECENT ADV STUDY MAM, P423; MONTALI RJ, 1991, VIRUS INFECTIONS CAR, P437; ORVELL C, 1985, J GEN VIROL, V66, P443, DOI 10.1099/0022-1317-66-3-443; Packer C., 1988, P363; PACKER C, 1995, AM NAT, V145, P833, DOI 10.1086/285771; SWAFFORD DL, 1984, PHYLOGENETIC ANAL US; WILDT DE, 1987, NATURE, V329, P328, DOI 10.1038/329328a0	20	521	549	3	163	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					441	445		10.1038/379441a0	http://dx.doi.org/10.1038/379441a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559247	Green Published, Bronze			2022-12-28	WOS:A1996TT30400057
J	Kitange, HM; Machibya, H; Black, J; Mtasiwa, DM; Masuki, G; Whiting, D; Unwin, N; Moshiro, C; Klima, PM; Lewanga, M; Alberti, KGMM; McLarty, DG				Kitange, HM; Machibya, H; Black, J; Mtasiwa, DM; Masuki, G; Whiting, D; Unwin, N; Moshiro, C; Klima, PM; Lewanga, M; Alberti, KGMM; McLarty, DG			Outlook for survivors of childhood in sub-Saharan Africa: Adult mortality in Tanzania	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure age and sex specific mortality in adults (15-59 years) in one urban and two rural areas of Tanzania. Design-Reporting of all deaths occurring between 1 June 1992 and 31 May 1995. Setting-Eight branches in Dar es Salaam (Tanzania's largest city), 59 villages in Morogoro rural district (a poor rural area), and 47 villages in Hai district (a more prosperous rural area). Subjects-40 304 adults in Dar es Salaam, 69 964 in Hai, 50 465 in Morogoro rural. Main outcome measures-Mortality and probability of death between 15 and 59 years of age ((45)Q(15)). Results-During the three year observation period a total of 4929 deaths were recorded in adults aged 15-59 years in all areas. Crude mortalities ranged from 6.1/1000/year for women in Hai to 15.9/1000/year for men in Morogoro rural. Age specific mortalities were up to 43 times higher than rates in England and Wales. Rates were higher in men at all ages in the two rural areas except in the age group 25 to 29 years in Hai and 20 to 34 years in Morogoro rural. In Dar es Salaam rates in men were higher only in the 40 to 59 year age group. The probability of death before age 60 of a 15 year old man ((45)Q(15)) was 47% in Dar es Salaam, 37% in Hai, and 58% in Morogoro; for women these figures were 45%, 26%, and 48%, respectively. (The average (45)Q(15)s for men and women in established market economies are 15% and 7%, respectively.) Conclusion-Survivors of childhood in Tanzania continue to show high rates of mortality throughout adult life. As the health of adults is essential for the wellbeing of young and old there is an urgent need to develop policies that deal with the causes of adult mortality.	MUHIMBILI MED CTR,DAR ES SALAAM,TANZANIA; MINIST HLTH,DAR ES SALAAM,TANZANIA; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; DAR ES SALAAM URBAN HLTH PROJECT,DAR ES SALAAM,TANZANIA	Newcastle University - UK; Newcastle University - UK			Black, James FP/E-1526-2013	Black, James FP/0000-0002-9287-8712; Whiting, David/0000-0001-9827-2896; Unwin, Nigel/0000-0002-1368-1648; Moshiro, Candida/0000-0001-7606-2361				[Anonymous], 1983, REGIONAL MODEL LIFE; BLACK JFP, 1994, BRIT MED J, V308, P531; FEACHEM RGA, 1992, HLTH ADULTS DEV WORL, P1; GARDNER MJ, 1989, STATISTICS CONFIDENC, P61; HILL AB, 1971, LANCET; Murray CJL, 1994, GLOBAL COMP ASSESSME, P21; MURRAY CJL, 1992, HLTH ADULTS DEV WORL, P23; NAKAJIMA H, 1992, HLTH ADULTS DEV WORL, pR9; PHILLIPS M, 1993, AM J PUBLIC HEALTH, V83, P1527, DOI 10.2105/AJPH.83.11.1527; SHRYOCK HS, 1976, METHODS MATERIALS DE, P503; TARIMO E, 1991, DIS MORTALITY SUBSAH, P243; 1988 POPULATION CENS; 1994, WORLD HLTH STATISTIC; 1993, MORTALITY STATIST DH, V2; 1994, AUG P E AFR BURD DIS	15	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					216	220						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563587	Green Published			2022-12-28	WOS:A1996TT48600026
J	Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH				Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH			Chronic granulomatous disease in adults	LANCET			English	Article							HUMAN-NEUTROPHILS; INFECTION; PHAGOCYTE; VARIANT	Background Chronic granulomatous disease (CGD), an inherited disorder of granulocyte function caused by failure of intracellular superoxide production, normally presents in the first years of life with severe recurrent bacterial and fungal infections. Methods From the files of two children's hospitals we identified 11 CGD patients who were remarkable for an unusually late diagnosis, at 13-43 years of age. Their clinical and laboratory features were examined. Findings The first clinical manifestation occurred at a median age of 3.6 years but CGD was not diagnosed until a median age of 22 years. Pneumonias and abscesses caused by Staphylococcus aureus and Aspergillus species were the most frequent infections. Granulomas, often leading to chronic complications, occurred in 7 of the patients. With 1.1 severe infections in 100 patient months, the 11 patients had a lower frequency of severe infections than patients with classic CGD; however, such infections could be equally life-threatening. 8 of the patients had X-linked CGD with small but detectable quantities of cytochrome b(558), normally absent in X-linked CGD; and 3 had autosomal-recessive CGD. 9 patients had residual production of reactive oxygen metabolites, a feature that could explain the low incidence of infections. Interpretation CGD in adults may be more common than previously assumed. In view of the possibility of timely treatment, infection prophylaxis, and genetic counselling for affected families, CGD should be excluded in any patient with unexplained infections or granulomas.	UNIV GOTTINGEN,KINDERKLIN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	Liese, JG (corresponding author), UNIV MUNICH,KINDERKLIN,LINDWURMSTR 4,D-80337 MUNICH,GERMANY.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; CAZZOLA M, 1985, HAEMATOLOGICA, V76, P1581; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; CURNUTTE JT, 1986, ADV HUM GENET, V19, P229; DILWORTH JA, 1977, AM J MED, V63, P233, DOI 10.1016/0002-9343(77)90237-6; FINN A, 1990, ARCH DIS CHILD, V65, P942, DOI 10.1136/adc.65.9.942; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; JENDROSSEK V, 1993, BLOOD, V81, P211; JOHNSTON RB, 1977, PEDIATR CLIN N AM, V24, P365; LANDING BH, 1957, PEDIATRICS, V20, P431; LUTTER R, 1984, J BIOL CHEM, V259, P9603; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; MOUY R, 1991, NEW ENGL J MED, V325, P1516; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; NAKAMURA M, 1987, BLOOD, V69, P1404; NERURKAR LS, 1987, SOUTHERN MED J, V80, P1296, DOI 10.1097/00007611-198710000-00022; NEWBURGER PE, 1980, BLOOD, V55, P85; NEWBURGER PE, 1986, BLOOD, V68, P914; PREISIG E, 1971, EUR J CLIN INVEST, V1, P409, DOI 10.1111/j.1365-2362.1971.tb00550.x; ROOS D, 1992, J LEUKOCYTE BIOL, V51, P164, DOI 10.1002/jlb.51.2.164; SCHAPIRO BL, 1991, NEW ENGL J MED, V325, P1786, DOI 10.1056/NEJM199112193252506; SMITH RM, 1991, BLOOD, V77, P673; STYRT B, 1984, PEDIATR INFECT DIS J, V3, P556, DOI 10.1097/00006454-198411000-00015; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; 1991, NEW ENGL J MED, V324, P509	26	106	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					220	223		10.1016/S0140-6736(96)90403-1	http://dx.doi.org/10.1016/S0140-6736(96)90403-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551880				2022-12-28	WOS:A1996TT06900009
J	Graur, D; Duret, L; Gouy, M				Graur, D; Duret, L; Gouy, M			Phylogenetic position of the order Lagomorpha (rabbits, hares and allies)	NATURE			English	Article							RODENTIA	EVER since they have been classified as ruminants in the Old Testament (Leviticus 11:6, Deuteronomy 14:7) and equated with hyraxes in the vulgate Latin translation, rabbits and their relatives (order Lagomorpha) have frequently experienced radical changes in taxonomic rank By using 91 orthologous protein sequences, we have attempted to answer the classical question ''What, if anything, is a rabbit?''(1). Here we show that Lagomorpha is significantly more closely related to Primates and Scandentia (tree shrews) than it is to rodents. This newly determined phylogenetic position invalidates the superordinal taxon Glires (Lagomorpha + Rodentia), and indicates that the morphological 'synapomorphies' previously used to cluster rodents and lagomorphs into Glires(2,3), may actually represent symplesiomorphies or homoplasies that are of no phylogenetic value. This raises the possibility that the ancestral eutherian morphotype may have possessed many rodent-like morphological characters.	UNIV LYON 1,LAB BIOMETRIE GENET & BIOL POPULAT,CNRS,URA 2055,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Graur, D (corresponding author), TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT ZOOL,IL-69978 RAMAT AVIV,ISRAEL.			Duret, Laurent/0000-0003-2836-3463				BAILEY WJ, 1992, SCIENCE, V256, P86, DOI 10.1126/science.1301735; CASANE D, 1994, GENETICS, V138, P471; DEJONG WW, 1993, MAMMAL PHYLOGENY : PLACENTALS, P5; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; EASTEAL S, 1990, GENETICS, V124, P165; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GEORGE DG, 1994, NUCLEIC ACIDS RES, V22, P3569; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; Kimura M., 1983, NEUTRAL THEORY MOL E; KISHINO H, 1990, J MOL EVOL, V30, P151; LI WH, 1989, MOL BIOL EVOL, V6, P424; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; Luckett W. P., 1993, Journal of Mammalian Evolution, V1, P127, DOI 10.1007/BF01041591; McKenna M. C., 1975, PHYLOGENY PRIMATES, P21, DOI DOI 10.1007/978-1-4684-2166-8_2; MIGNOTTE F, 1990, EUR J BIOCHEM, V194, P561, DOI 10.1111/j.1432-1033.1990.tb15653.x; MILINKOVITCH MC, 1995, TRENDS ECOL EVOL, V10, P328, DOI 10.1016/S0169-5347(00)89120-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOOD AE, 1957, EVOLUTION, V11, P417, DOI 10.1111/j.1558-5646.1957.tb02913.x	25	222	228	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					333	335		10.1038/379333a0	http://dx.doi.org/10.1038/379333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552186				2022-12-28	WOS:A1996TR32300055
J	Lip, GYH; Beevers, DG; Coope, JR				Lip, GYH; Beevers, DG; Coope, JR			ABC of atrial fibrillation - Atrial fibrillation in general and hospital practice	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham	Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							LIP GYH, IN PRESS HEART; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153; 1990, J CLIN PATHOL, V43, P177	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					175	178						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563542				2022-12-28	WOS:A1996TR32500031
J	Spitzer, WO; Lewis, MA; Heinemann, LAJ; Thorogood, M; MacRae, KD				Spitzer, WO; Lewis, MA; Heinemann, LAJ; Thorogood, M; MacRae, KD			Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ETHINYLESTRADIOL	Objective - To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of venous thromboembolism. Design - Matched case-control study. Setting - 10 centres in Germany and United Kingdom. Subjects - Cases were 471 women aged 16-44 who had a venous thromboembolism. Controls were 1772 women (at least 3 controls per case) unaffected by venous thromboembolism who were matched with corresponding case for age and for hospital or community setting. Main outcome measures - Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. Results - Odds ratios (95% confidence intervals) for venous thromboembolism were: for any oral contraceptives versus no use, 4.0 (3.1 to 5.3); for second generation products (low dose ethinyloestradiol, no gestodene or desogestrel) versus no use, 3.2 (2.3 to 4.3); for third generation products (low dose ethinyloestradiol, gestodene or desogestrel) versus no use, 4.8 (3.4 to 6.7); for third generation products versus second generation products, 1.5 (1.1 to 2.1); for products containing gestodene versus second generation products, 1.5 (1.0 to 2.2); and for products containing desogestrel versus second generation products, 1.5 (1.1 to 2.2). Probability of death due to venous thromboembolism for women using third generation products is about 20 per million users per year, for women using second generation products it is about 14 per million users per year, and for non-users it is five per million per year. Conclusions - Risk of venous thromboembolism was slightly increased in users of third generation oral contraceptives compared with users of second generation products.	MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA; CTR EPIDEMIOL & HLTH RES,ZEPERNICK BERLIN,GERMANY; LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,LONDON,ENGLAND	McGill University; University of London; London School of Hygiene & Tropical Medicine; Imperial College London			Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002				COLE P, 1971, BRIT J PREV SOC MED, V25, P242; GOLDZIEHER JW, 1983, J REPROD MED, V28, P53; JUNGHOFFMANN C, 1989, CONTRACEPTION, V40, P299, DOI 10.1016/0010-7824(89)90094-2; KUHL H, 1988, CONTRACEPTION, V38, P477, DOI 10.1016/0010-7824(88)90088-1; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; LEWIS MA, IN PRESS PHARMACOEPI; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; POULTER N, IN PRESS J CLIN EPID; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; VESSEY MP, 1993, METHOD INFORM MED, V32, P222	13	486	494	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					83	88						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555935				2022-12-28	WOS:A1996TQ16800022
J	Tait, DR; Ward, KN; Brown, DWG; Miller, E				Tait, DR; Ward, KN; Brown, DWG; Miller, E			Measles and rubella misdiagnosed in infants as Exanthem subitum (roseola infantum)	BRITISH MEDICAL JOURNAL			English	Article							HUMAN HERPESVIRUS-6		UNIV LONDON,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,ENTER & RESP VIRUS DIV,LONDON NW9 5HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND	Imperial College London; University of London; Public Health England; Public Health England								BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; JURETIC M, 1963, HELVETICA PAEDIATRIC, V1, P80; Miller E, 1994, Commun Dis Rep CDR Rev, V4, pR146; WARD KN, 1993, J MED VIROL, V39, P131, DOI 10.1002/jmv.1890390209; YAMANISHI K, 1988, LANCET, V1, P1065	5	42	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					101	102						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555893				2022-12-28	WOS:A1996TQ16800030
J	Henry, RR				Henry, RR			Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			HYPERGLYCEMIA; THERAPY; OBESE	Chronic hyperglycemia is implicated in the pathogenesis of microvascular, neurologic, and macrovascular complications of diabetes. Recent studies prove that near-normal glycemic control in insulin-dependent diabetes mellitus (IDDM) reduces the risk for the development and progression of microvascular and neurologic complications. With the expectation of comparable benefits, similar glycemic goals have been advocated for the management of non-insulin-dependent diabetes mellitus (NIDDM). However, using intensified insulin therapy to achieve near-normal glycemia in NIDDM may be problematic because of basic differences in the pathophysiology of the two types of diabetes. Insulin resistance is a major contributor to the development of hyperglycemia in NIDDM and may prevent attainment of normoglycemia in most patients who are using the conventional approaches of diet, exercise, and oral hypoglycemic therapy. Near-normal glycemia in patients with NIDDM can usually be achieved with exogenous insulin but often requires large doses to overcome the insulin resistance. Intensive insulin therapy normalizes glycemia by decreasing hepatic glucose output and improving peripheral glucose uptake and may also improve insulin resistance and insulin secretion by reducing hyperglycemic glucotoxicity. However, large doses of exogenous insulin are associated with hyperinsulinemia and weight gain, but these effects may be minimized by combining insulin with other forms of therapy, for example, oral antidiabetic agents. When intensive management is instituted, the dose of exogenous insulin should be kept as low as possible. To do this, therapy for NIDDM must be part of a multifaceted approach combining insulin therapy with other effective forms of treatment such as counseling on diet and exercise therapy and the use of oral antidiabetic agents.	UNIV CALIF SAN DIEGO, LA JOLLA, CA USA	University of California System; University of California San Diego	Henry, RR (corresponding author), VET AFFAIRS MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.							BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; BLOOMGARDEN ZT, 1995, DIABETES CARE, V18, P1215, DOI 10.2337/diacare.18.8.1215; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DONNELLY R, 1994, BRIT J CLIN PHARMACO, V37, P311, DOI 10.1111/j.1365-2125.1994.tb04283.x; GARVEY WT, 1985, DIABETES, V34, P222, DOI 10.2337/diabetes.34.3.222; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; MARRERO DG, 1994, DIABETES REV, V2, P292; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OLEFSKY JM, 1985, AM J MED, V79, P1, DOI 10.1016/S0002-9343(85)80001-2; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; 1994, MED MANAGEMENT NON I, P26; 1988, PHYSICIANS GUIDE NON, P25; 1981, DIABETOLOGIA, V34, P877	19	46	49	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				97	103		10.7326/0003-4819-124-1_Part_2-199601011-00004	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554221				2022-12-28	WOS:A1996TL94400004
J	YOUNG, TK; GELSKEY, DE				YOUNG, TK; GELSKEY, DE			IS NONCENTRAL OBESITY METABOLICALLY BENIGN - IMPLICATIONS FOR PREVENTION FROM A POPULATION SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; MEN BORN; PARTICIPANTS; LIPIDS; FOLLOW; MASS	Objective.-To determine if individuals who are overall obese but have low waist-to-hip ratios have unfavorable lipid profiles, blood pressures, and glucose statuses. Design.-Cross-sectional study. Setting.-The Manitoba Heart Health Survey surveyed a representative sample of residents of the Canadian province of Manitoba. Participants.-A total of 2792 adults aged 18 to 74 years were interviewed, 2339 of whom underwent clinical examinations. Main Outcome Measures.-Blood pressure, fasting plasma glucose, total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein measurements were compared across categories of body mass index (BMI) and waist-to-hip ratio (WHR). Main Results.--Manitobans with noncentral obesity tend to occupy positions between those of the nonobese and the centrally obese in terms of the effect on blood pressure, plasma lipids, and glucose. In multiple linear regression models involving age, BMI, and WHR as independent variables and one of the metabolic variables as dependent variables, both BMI and WHR are significant independent predictors of most metabolic variables. Where both are significant, BMI tends to be the stronger predictor, with a larger standardized regression coefficient. Conclusions.-Noncentral obesity is not metabolically benign; BMI as an overall measure of obesity is as important as, and sometimes more important than, WHR in predicting metabolic effects. The recognition of the epidemiological significance of the WHR as a centrality measure of obesity should not divert attention from the metabolic risk status of noncentrally obese individuals who require continued health education to reduce weight.	CADHAM PROV LAB,WINNIPEG,MB,CANADA		YOUNG, TK (corresponding author), UNIV MANITOBA,FAC MED,DEPT COMMUNITY HLTH SCI,7509 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							CONNELLY PW, 1992, CAN MED ASSOC J, V146, P1977; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GELSKEY DE, 1994, J CLIN EPIDEMIOL, V47, P547, DOI 10.1016/0895-4356(94)90301-8; HODGE AM, 1993, INT J OBESITY, V17, P399; ISO H, 1991, INT J EPIDEMIOL, V20, P88, DOI 10.1093/ije/20.1.88; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; YOUNG TK, 1989, AM J CLIN NUTR, V49, P786, DOI 10.1093/ajcn/49.5.786	10	41	43	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1939	1941		10.1001/jama.274.24.1939	http://dx.doi.org/10.1001/jama.274.24.1939			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568989				2022-12-28	WOS:A1995TL16900037
J	Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA				Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA			Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody	LANCET			English	Article							MONOCLONAL-ANTIBODIES; TUMOR-LOCALIZATION; NEOPLASMS; THERAPY; ANALOG	Specific tumour imaging with radiolabelled monoclonal antibodies has been extensively investigated. Although some success has been reported, there are many limitations due to the slow kinetics, poor extravasation, catabolism by the reticuloendothelial system, and nonspecific uptake of macromolecules such as antibodies. We have tried to overcome some of the problems associated with monoclonal antibodies while retaining their specificity by using an antibody-derived synthetic peptide. A synthetic pentadecapeptide (alpha M2) derived from the third heavy-chain complementarity-determining region (CDR-3H) of a tumour-associated monoclonal antibody was produced and shown to retain its specificity against the pan-carcinoma cell-surface antigen, polymorphic epithelial mucin, detected by the parent antibody. The peptide was radiolabelled with technetium-99m and injected intravenously to image malignant lesions in 26 women with primary, recurrent, or metastatic breast cancer. Visualisation of breast tumours and their metastases was obtained shortly after administration of alpha M2, and was optimum by 3 h. Overall, 57 (77%) of 74 sites were visualised. Successful imaging was achieved in 14 of 15 primary tumour sites and all of eight local recurrences. Five of six metastases in the opposite breast, eight of 15 metastatic axillary lymph nodes, and all of six metastatic supraclavicular lymph nodes were imaged. Metastatic sites in the lungs, mediastinum, chest wall, and liver were poorly visualised because of background cardiac blood pool, alpha M2 detected small lesions (<2 cm) as efficiently as larger ones. The peptide was rapidly (3 h) cleared from the circulation. No acute or chronic adverse reactions due to the alpha M2 were observed. Specific tumour targeting with the radiolabelled anticancer peptide alpha M2 offers new opportunities for breast cancer imaging and possibly therapy.	SAMARITAN HOSP,ANTISOMA LTD,LONDON,ENGLAND; ENCEPHALOS RES & THERAPEUT INST,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,ICRF,ONCOL UNIT,LONDON W12 0NN,ENGLAND; METAXA CANC HOSP,PIRAES,GREECE; AGII ANARGIRI CANC HOSP,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Sivolapenko, Gregory/0000-0003-2388-362X				BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BOVEN E, 1991, EUR J CANCER, V27, P1430, DOI 10.1016/0277-5379(91)90025-9; BUCHSBAUM DJ, 1985, INT J NUCL MED BIOL, V12, P79, DOI 10.1016/0047-0740(85)90160-3; COURTENAYLUCK NS, 1986, CANCER RES, V46, P6489; EPENETOS AA, 1986, CANCER RES, V46, P3183; EPENETOS AA, 1989, BRIT J CANCER, V59, P152, DOI 10.1038/bjc.1989.32; ESTEBAN JM, 1987, INT J CANCER, V39, P50, DOI 10.1002/ijc.2910390110; HALPERN SE, 1990, J NUCL MED, V31, P1436; HIRD V, 1991, BRIT J CANCER, V64, P911, DOI 10.1038/bjc.1991.425; HUSSAIN R, IN PRESS PEPTIDES; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KALOFONOS HP, 1988, CANCER RES, V48, P1977; KRENNING EP, 1989, LANCET, V1, P242; SCHATTEN C, 1991, LANCET, V337, P395, DOI 10.1016/0140-6736(91)91169-U; SCHROFF RW, 1985, CANCER RES, V45, P879; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; VIRGOLINI I, 1994, NEW ENGL J MED, V331, P1116, DOI 10.1056/NEJM199410273311703	17	49	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1662	1666		10.1016/S0140-6736(95)92839-1	http://dx.doi.org/10.1016/S0140-6736(95)92839-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551823				2022-12-28	WOS:A1995TL42300009
J	Sung, JJY; Chung, SCS; Yung, MY; Lai, CW; Lau, JYW; Lee, YT; Leung, VKS; Li, MKK; Li, AKC				Sung, JJY; Chung, SCS; Yung, MY; Lai, CW; Lau, JYW; Lee, YT; Leung, VKS; Li, MKK; Li, AKC			Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation	LANCET			English	Article							BLEEDING ESOPHAGEAL-VARICES; INJECTION SCLEROTHERAPY; CONTROLLED TRIAL; HEMORRHAGE; SOMATOSTATIN	Up to a third of patients have early rebleeding from oesophageal varices after endoscopic variceal ligation. Octreotide infusion is effective for control of variceal bleeding. We investigated the efficacy of octreotide infusion as an adjunct to endoscopic variceal ligation to prevent early rebleeding from varices. 100 consecutive patients admitted with endoscopically confirmed oesophageal varices and active bleeding or signs of recent haemorrhage were randomly assigned endoscopic variceal ligation alone or octreotide (50 mu g intravenous bolus injection followed by intravenous infusion at 50 mu g per h for 5 days) plus endoscopic variceal ligation. Three patients in each group were excluded. Bleeding was controlled in 44 of 47 patients who received variceal ligation alone and in 45 of 47 who received combined treatment (p=1 . 0). Recurrent bleeding was documented in 18 (38% [24-52]) patients who received variceal ligation alone and in four (9% [3-21] who received combined treatment (p=0 . 0007). The relative risk of rebleeding was lower (0 . 22 [0 . 08-0 . 60]) in the combined therapy group. Ten patients in the variceal ligation group and one in the combined therapy group required balloon tamponade for massive haematesis and haemodynamic instability (p=0 . 0039). The in-hospital and 30-day mortality rates were higher in the variceal ligation group than in the combined therapy group (19 vs 9% and 23 vs 11%), but the differences did not reach significance. The relative risks of in-hospital (0 . 5 [0 . 04-5 . 3]) and 30-day (0 . 45 [0 . 17-1 . 2]) mortality were lower in the combined therapy group. Octreotide significantly reduces recurrent bleeding and the need for balloon tamponade in patients with variceal haemorrhage treated by endoscopic variceal ligation.	CHINESE UNIV HONG KONG,DEPT SURG,SHA TIN,HONG KONG	Chinese University of Hong Kong	Sung, JJY (corresponding author), CHINESE UNIV HONG KONG,DEPT MED,SHA TIN,HONG KONG.		Sung, Joseph J. Y./R-3203-2018; Lau, James Y. W./O-2612-2016	Sung, Joseph J. Y./0000-0003-3125-5199; Lau, James Y. W./0000-0003-0122-4068				AVGERINOS A, 1994, GASTROENTEROLOGY, V106, pA861; BORMAN PC, 1994, LANCET, V343, P1079; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; HASHIZUME M, 1993, GASTROINTEST ENDOSC, V39, P123, DOI 10.1016/S0016-5107(93)70050-4; JENSEN DM, 1995, GASTROINTEST ENDOSC, V41, P351, DOI 10.1016/S0016-5107(05)80258-5; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; LAINE L, 1995, GASTROINTEST ENDOSC, V41, P353, DOI 10.1016/S0016-5107(05)80268-8; LO GH, 1993, GASTROENTEROLOGY, pA943; MCCORMICK PA, 1990, EUR J GASTROEN HEPAT, V2, P489; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SILVAIN C, 1993, HEPATOLOGY, V18, P61, DOI 10.1016/0270-9139(93)90507-J; SODERLUND C, 1990, SCAND J GASTROENTERO, V25, P622, DOI 10.3109/00365529009095539; SONNENBERG GE, 1981, GASTROENTEROLOGY, V80, P526; STIEGMANN GV, 1988, AM SURGEON, V55, P124; STIEGMANN GV, 1992, NEW ENGL J MED, V32, P152; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; WILLIAMS SGJ, 1994, BRIT MED J, V308, P1213	19	160	162	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1666	1669		10.1016/S0140-6736(95)92840-5	http://dx.doi.org/10.1016/S0140-6736(95)92840-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551824				2022-12-28	WOS:A1995TL42300010
J	Tunkel, AR; Scheld, WM				Tunkel, AR; Scheld, WM			Acute bacterial meningitis	LANCET			English	Article							RESISTANT PNEUMOCOCCAL MENINGITIS; STREPTOCOCCUS-PNEUMONIAE; PENICILLIN-RESISTANT; UNITED-STATES; ANTIMICROBIAL RESISTANCE; DEXAMETHASONE THERAPY; CEREBROSPINAL-FLUID; CHILDREN; DIAGNOSIS; PATHOPHYSIOLOGY	Acute meningitis may be caused by a variety of infectious agents. Of greatest concern, however, is bacterial meningitis, which can be fatal if treatment is delayed. Here, we review the clinical presentation of patients with acute community-acquired bacterial meningits (for example, caused by Haemophilus influenzae type b, Neisseria meningitis or Streptococcus pneumoniae), the approaches to diagnosis, and the early, emergency management, including empirical antimicrobial regimens	HAHNEMANN UNIV,SCH MED,PHILADELPHIA,PA 19102; UNIV VIRGINIA,SCH MED,DEPT MED & NEUROSURG,CHARLOTTESVILLE,VA 22908	Drexel University; University of Virginia	Tunkel, AR (corresponding author), MED COLL PENN,DEPT MED,DIV INFECT DIS,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; ASENI F, 1991, J CHEMOTHER, V5, P133; ASHWAL S, 1992, NEUROLOGY, V42, P739, DOI 10.1212/WNL.42.4.739; ASHWAL S, 1994, CURR PROB PEDIATR, P267; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P423, DOI 10.1097/00006454-199206000-00001; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CATALAN MJ, 1994, CLIN INFECT DIS, V18, P766, DOI 10.1093/clinids/18.5.766; FEIGIN RD, 1992, PEDIATR INFECT DIS J, V11, P785, DOI 10.1097/00006454-199209000-00039; FENOLL A, 1991, REV INFECT DIS, V13, P56; FRIEDLAND IR, 1993, ANTIMICROB AGENTS CH, V37, P1630, DOI 10.1128/AAC.37.8.1630; FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002; FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GARY N, 1989, AM J DIS CHILD, V143, P307, DOI 10.1001/archpedi.1989.02150150061018; GEISELER PJ, 1980, REV INFECT DIS, V2, P725; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; GRAY LD, 1992, CLIN MICROBIOL REV, V5, P130, DOI 10.1128/CMR.5.2.130-145.1992; JACKSON LA, 1994, J INFECT DIS, V169, P438, DOI 10.1093/infdis/169.2.438; JONES RN, 1994, 34 INT C ANT AG CHEM, P87; KALLIO MJT, 1994, JAMA-J AM MED ASSOC, V272, P787, DOI 10.1001/jama.272.10.787; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; KAPLAN SL, 1987, PEDIATR INFECT DIS J, V6, P670, DOI 10.1097/00006454-198707000-00011; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; KILPI T, 1995, PEDIATR INFECT DIS J, V14, P270, DOI 10.1097/00006454-199504000-00005; KING SM, 1994, CAN J INFECT DIS, V5, P219; LEBEL MH, 1989, AM J DIS CHILD, V143, P301, DOI 10.1001/archpedi.1989.02150150055017; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEBEL MH, 1989, J PEDIATR-US, V114, P1049, DOI 10.1016/S0022-3476(89)80462-7; LOPEZ E, 1995, 33RD INT C ANT AG CH, P326; LYONS MK, 1990, MAYO CLIN PROC, V65, P684, DOI 10.1016/S0025-6196(12)65131-3; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MARTON KI, 1986, ANN INTERN MED, V104, P840, DOI 10.7326/0003-4819-104-6-840; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MEADOW WL, 1993, AM J DIS CHILD, V147, P40, DOI 10.1001/archpedi.1993.02160250042014; NI HL, 1992, LANCET, V340, P1432, DOI 10.1016/0140-6736(92)92622-M; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; PELTOLA H, 1989, LANCET, V1, P1281; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; RADETSKY M, 1992, PEDIATR INFECT DIS J, V11, P694, DOI 10.1097/00006454-199209000-00002; Saez-Llorens X, 1990, Infect Dis Clin North Am, V4, P623; SAEZNIETO JA, 1992, CLIN INFECT DIS, V14, P394, DOI 10.1093/clinids/14.2.394; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P622; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; SYROGIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853, DOI 10.1093/infdis/169.4.853; TAN TQ, 1994, ANTIMICROB AGENTS CH, V38, P918, DOI 10.1128/AAC.38.5.918; Tunkel Allan R., 1994, P163; TUNKEL AR, 1990, ANN INTERN MED, V112, P610, DOI 10.7326/0003-4819-112-8-610; TUNKEL AR, 1993, CLIN MICROBIOL REV, V6, P118, DOI 10.1128/CMR.6.2.118-136.1993; TUNKEL AR, 1995, PRINCIPLES PRACTICE, P831; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; WALD ER, 1995, PEDIATRICS, V95, P21; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	60	97	98	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1675	1680		10.1016/S0140-6736(95)92844-8	http://dx.doi.org/10.1016/S0140-6736(95)92844-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551828				2022-12-28	WOS:A1995TL42300014
J	Worthington, P				Worthington, P			Another Christmas carol	BRITISH MEDICAL JOURNAL			English	Article											Worthington, P (corresponding author), MID GLAMORGAN HLTH AUTHOR,SERV DEV,PONTYPRIDD CF37 1LA,M GLAM,WALES.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1702	1704		10.1136/bmj.311.7021.1702	http://dx.doi.org/10.1136/bmj.311.7021.1702			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541766	Green Published			2022-12-28	WOS:A1995TL94200028
J	Lowin, MH; Lowitt, NR				Lowin, MH; Lowitt, NR			Recent advances - Dermatology	BRITISH MEDICAL JOURNAL			English	Article							KAPOSIS-SARCOMA		UNIV MARYLAND,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21201; JOHNS HOPKINS BAYIEW MED CTR,DIV GEN INTERNAL MED,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine								BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERARDESCA E, 1994, ACTA DERM-VENEREOL, V74, P302; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CARBE C, 1995, CANCER, V75, P2492; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P613, DOI 10.1016/S0190-9622(94)70225-X; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; GARBE C, 1995, CANCER-AM CANCER SOC, V75, P2484, DOI 10.1002/1097-0142(19950515)75:10<2484::AID-CNCR2820751014>3.0.CO;2-U; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; HIDE M, 1994, CLIN EXP ALLERGY, V24, P624, DOI 10.1111/j.1365-2222.1994.tb00965.x; HIGHTON A, 1995, J AM ACAD DERMATOL, V32, P67, DOI 10.1016/0190-9622(95)90186-8; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; RAMSAY CA, 1994, DERMATOLOGY, V189, P260, DOI 10.1159/000246851; TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z; THAN SN, 1994, BRIT J DERMATOL, V131, P673; 1995, PEDIATRICS, V95, P791	19	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1615	1617		10.1136/bmj.311.7020.1615	http://dx.doi.org/10.1136/bmj.311.7020.1615			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555807	Green Published			2022-12-28	WOS:A1995TL42200026
J	Cerin, A; Heldaas, K; Moeller, B				Cerin, A; Heldaas, K; Moeller, B			Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									TELEMARK CENT HOSP, N-3900 PORSGRUNN, NORWAY; ODENSE HOSP, DK-5000 ODENSE, DENMARK	University of Southern Denmark; Odense University Hospital	Cerin, A (corresponding author), KAROLINSKA HOSP, S-17176 STOCKHOLM, SWEDEN.							DAVID A, 1994, I C S S, V8, P463; ELLERINGTON MC, 1992, BRIT MED BULL, V48, P401, DOI 10.1093/oxfordjournals.bmb.a072553; HAMMARBACK S, 1985, ACTA OBSTET GYN SCAN, V64, P393, DOI 10.3109/00016348509155154; HIRVONEN E, 1995, MATURITAS, V21, P39, DOI 10.1016/0378-5122(94)00862-2; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X	5	33	34	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					668	669		10.1056/NEJM199603073341018	http://dx.doi.org/10.1056/NEJM199603073341018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592546				2022-12-28	WOS:A1996TX69300029
J	Greenberg, ER; Baron, JA; Karagas, MR; Stukel, TA; Nierenberg, DW; Stevens, MM; Mandel, JS; Haile, RW				Greenberg, ER; Baron, JA; Karagas, MR; Stukel, TA; Nierenberg, DW; Stevens, MM; Mandel, JS; Haile, RW			Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-E; CANCER PREVENTION; CLINICAL-TRIAL; RISK; ANTIOXIDANTS; VEGETABLES; FRUIT; SKIN	Objective.-To examine the relationship between beta carotene plasma concentration and beta carotene supplementation and risk of death from major disease causes. Design.-Cohort study of plasma concentrations; randomized, controlled clinical trial of supplementation. Setting.-Medical school-affiliated dermatology practices. Patients.-A total of 1188 men and 532 women with mean age of 63.2 years, who had enrolled in a randomized clinical trial of beta carotene supplementation to prevent nonmelanoma skin cancer. Intervention.-Oral beta carotene, 50 mg per day for a median of 4.3 years. Main Outcome Measures.-All-cause mortality and mortality from cardiovascular disease and cancer. Results.-During a median follow-up period of 8.2 years, there were 285 deaths. Persons whose initial plasma beta carotene concentrations were in the highest quartile (>0.52 mu mol/L [27.7 mu g/dL]) had a lower risk of death from all causes (adjusted relative rate [RR], 0.52; 95% confidence interval [CI] 0.44 to 0.87) and from cardiovascular diseases (adjusted RR, 0.57; 95% CI, 0.34 to 0.95) compared with persons with initial concentrations in the lowest quartile (<0.21 mu mol/L [11.2 mu g/dl]). Patients randomly assigned to beta carotene supplementation showed no reduction in relative mortality rates from all causes (adjusted RR, 1.03; 95% CI, 0.82 to 1.30) or from cardiovascular disease (adjusted RR, 1.16; 95% CI, 0.82 to 1.64). There was no evidence of lower mortality following supplementation among patients with initial beta carotene concentrations below the median for the study group. Conclusions.-These analyses provide no support for a strong effect of supplemental beta carotene in reducing mortality from cardiovascular disease or other causes. Although the possibility exists that beta carotene supplementation produces benefits that are too small or too delayed to have been detected in this study, noncausal explanations should be sought for the association between plasma concentrations of beta carotene and diminished risk of death.	DARTMOUTH COLL SCH MED,LEBANON,NH; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90089	Dartmouth College; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Greenberg, ER (corresponding author), NORRIS COTTON CANC CTR,1 MED CTR DR,LEBANON,NH 03756, USA.			Stukel, Therese/0000-0002-2951-1360	NCI NIH HHS [CA23108, CA32934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA032934, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CAMPBELL DR, 1994, CANCER EPIDEM BIOMAR, V3, P493; CANTILENA LR, 1992, AM J CLIN NUTR, V55, P659, DOI 10.1093/ajcn/55.3.659; Cox D. R., 1984, ANAL SURVIVAL DATA; DWYER JT, 1988, AM J CLIN NUTR, V48, P712, DOI 10.1093/ajcn/48.3.712; GAZIANO JM, 1993, ANN NY ACAD SCI, V691, P148, DOI 10.1111/j.1749-6632.1993.tb26166.x; GERSTER H, 1991, INT J VITAM NUTR RES, V61, P277; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; GREENBERG ER, 1993, ANN NY ACAD SCI, V691, P120, DOI 10.1111/j.1749-6632.1993.tb26163.x; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HALLIWELL B, 1995, AM J CLIN NUTR, V61, p670S, DOI 10.1093/ajcn/61.3.670S; HANKINSON SE, 1994, JAMA-J AM MED ASSOC, V272, P1455; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HENNEKENS CH, 1994, NEW ENGL J MED, V330, P1080, DOI 10.1056/NEJM199404143301510; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KOHLMEIER L, 1995, AM J CLIN NUTR, V62, P1370, DOI 10.1093/ajcn/62.6.1370S; LEE ET, 1980, STATISTICAL METHODS; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; NIERENBERG D, 1985, J CHROMATOGR, V339, P278; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; VANPOPPEL G, 1995, AM J CLIN NUTR, V62, P1393, DOI 10.1093/ajcn/62.6.1393S; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; 1994, NEW ENGL J MED, V330, P1029	30	203	206	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					699	703		10.1001/jama.275.9.699	http://dx.doi.org/10.1001/jama.275.9.699			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594267				2022-12-28	WOS:A1996TX17400025
J	Miller, RS; Jonas, HS; Whitcomb, ME				Miller, RS; Jonas, HS; Whitcomb, ME			The initial employment status of physicians completing training in 1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To gain information about the career status of residents who completed graduate medical education training programs in selected specialties and subspecialties during the 1993-1994 academic year. Design.--A descriptive one-page survey of residency program directors, including two mailed follow-up surveys, was conducted from January 1, 1995, to June 1, 1995. Setting.-Directors of residency programs in 26 specialties and subspecialties accredited by the Accreditation Council for Graduate Medical Education, totaling 4369 programs. Main Outcome Measures.-Program directors identified the number of resident physicians who completed the program, the known career status of those physicians, the number of physicians who had experienced difficulty finding a practice position, the characteristics of the full-time clinical practice positions, and the number of physicians who could not find full-time employment. The perceptions about likely trends in the availability of practice opportunities for graduates in the future and the likely change in the number of resident positions were also assessed. Results.-A total of 3090 program directors (70.7%) completed the survey. Respondents reported that 15 999 resident physicians completed training in one of the 26 specialties and subspecialties, and 63.2% of these graduates were potentially seeking a professional position. Most of those not seeking a position were pursuing additional training (92.9%). Of those seeking employment, the percentage who did not find a full-time position in their specialty or subspecialty ranged between none in urology to 10.8% in pathology. Across all specialties, about 70% of graduates looking for full-time positions entered clinical practice in their specialty of training. Physicians pursuing generalist careers had fewer problems finding preferred positions than those pursuing nongeneralist specialties. Finally, program directors in most nongeneralist specialties believed that the degree of difficulty their graduates will experience in finding a full-time practice position will increase during the next year. Conclusions.-Physicians attempting to enter practice in some specialties and in some regions of the country are experiencing difficulty. In some cases up to 10% of the resident physicians did not find full-time positions in their specialty or subspecialty. The differences noted between the generalist and nongeneralist specialties are consistent with widespread perceptions about the current market. These data establish the baseline for analyzing trends.	AMER MED ASSOC,MED EDUC GRP,CHICAGO,IL 60610; ASSOC AMER MED COLL,DIV MED EDUC,WASHINGTON,DC 20036	American Medical Association; Association of American Medical Colleges	Miller, RS (corresponding author), AMER MED ASSOC,DEPT RES & DATA ANAL,DIV GRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							ANDERS G, 1995, WALL STREET J   0317, pA1; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; ROSENTHAL E, 1995, NY TIMES        0816, P1; SCHWARTZ WB, 1980, NEW ENGL J MED, V303, P1032, DOI 10.1056/NEJM198010303031803; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1995, NEW ENGL J MED, V333, P454, DOI 10.1056/NEJM199508173330712	6	80	80	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					708	712		10.1001/jama.275.9.708	http://dx.doi.org/10.1001/jama.275.9.708			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594269				2022-12-28	WOS:A1996TX17400027
J	Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J				Esteban, JI; Gomez, J; Martell, M; Cabot, B; Quer, J; Camps, J; Gonzalez, A; Otero, T; Moya, A; Esteban, R; Guardia, J			Transmission of hepatitis C virus by a cardiac surgeon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRANSFUSION HEPATITIS; NEEDLESTICK INJURY; DENTAL PRACTICE; INFECTION; RNA; HCV; ANTIBODIES; REGIONS; ASSAY	Background. In the course of a study conducted from 1992 through 1994 of the efficacy of screening blood donors for antibodies to hepatitis C virus (HCV), we found that two patients had acquired hepatitis C after cardiac surgery, with the transmission apparently unrelated to blood transfusions, Because their surgeon had chronic hepatitis C, we sought to determine whether he was transmitting the virus to his patients. Methods. Of 222 of the surgeon's patients who participated in studies of post-transfusion hepatitis between 1988 and 1994, 6 contracted postoperative hepatitis C, despite the use of only seronegative blood for transfusions, All six patients had undergone valve-replacement surgery, Analyses were performed to compare nucleotide sequences encompassing the hypervariable region at the junction between the coding regions for envelope glycoproteins E1 and E2 in the surgeon, the patients, and 10 controls infected with the same HCV genotype. Results. The surgeon and five of the six patients with hepatitis C unrelated to transfusion were infected with HCV genotype 3; the sixth patient had genotype 1 and was considered to have been infected from another source, Thirteen other patients of the surgeon had transfusion associated hepatitis C and were also infected with genotype 1. The average net genetic distance between the sequences from the five patients with HCV genotype 3 and those from the surgeon was 2.1 percent (range, 1.1 to 2.5 percent; P<0,001), as compared with an average distance of 7.6 percent (range, 6.1 to 8.3 percent) between the sequences from the patients and those from the controls, The results of a phylogenetic-tree analysis indicated a common epidemiologic origin of the viruses from the surgeon and the five patients. Conclusions. Our findings provide evidence that a cardiac surgeon with chronic hepatitis C may have transmitted HCV to five of his patients during open-heart surgery.	UNIV AUTONOMA BARCELONA,HOSP GEN VALLE HEBRON,LIVER UNIT,DEPT MED,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,DEPT GENET,VALENCIA,SPAIN	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Valencia			Martell, Maria/J-8191-2013; Quer, Josep/A-6741-2012; Moya, Andrés/A-8190-2008; Jordi, Gómez/L-6112-2015	Martell, Maria/0000-0002-0935-0029; Quer, Josep/0000-0003-0014-084X; Moya, Andrés/0000-0002-2867-1119; Gomez, Jordi/0000-0002-7806-1503; esteban, rafael/0000-0001-5280-392X				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; [Anonymous], VIRAL HEPATITIS LIVE; Brown AJL, 1994, EVOLUTIONARY BIOL VI, P75; CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; CHUNG HT, 1993, HEPATOLOGY, V18, P1045; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GONZALEZ A, 1995, HEPATOLOGY, V22, P439, DOI 10.1016/0270-9139(95)90563-4; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; HOSIE KB, 1988, LANCET, V2, P1500; HUANG YY, 1994, TRANSFUSION, V34, P661, DOI 10.1046/j.1537-2995.1994.34894353459.x; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; NEI M, 1989, MOL BIOL EVOL, V6, P290; NELSON KE, 1992, NEW ENGL J MED, V327, P1601; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PRENTICE MB, 1992, BRIT MED J, V304, P761, DOI 10.1136/bmj.304.6829.761; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; WANG YJ, 1994, VOX SANG, V67, P187, DOI 10.1111/j.1423-0410.1994.tb01657.x; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, LANCET, V338, P1040	37	296	302	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					555	560		10.1056/NEJM199602293340902	http://dx.doi.org/10.1056/NEJM199602293340902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569822				2022-12-28	WOS:A1996TW69600002
J	Cook, DJ; Simel, DL				Cook, DJ; Simel, DL			Does this patient have abnormal central venous pressure?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE HEART-FAILURE; CRITICALLY ILL; HEPATOJUGULAR REFLUX; CATHETERIZATION; DIAGNOSIS		MCMASTER UNIV,FAC HLTH SCI,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,FAC HLTH SCI,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8N 3Z5,CANADA; DUKE UNIV,MED CTR,VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC	McMaster University; McMaster University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BRAUNWALD E, 1988, HEART DISEASE TXB CA, P13; BRISCOE CE, 1973, BRIT J ANAESTH, V45, P173, DOI 10.1093/bja/45.2.173; BURCH GE, 1954, AM HEART J, V48, P373, DOI 10.1016/0002-8703(54)90025-3; COHN JN, 1964, ANN INTERN MED, V66, P1283; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; CONSTANT J, 1964, AM HEART J, V67, P701, DOI 10.1016/0002-8703(64)90343-6; COOK DJ, 1990, AM J MED SCI, V299, P175, DOI 10.1097/00000441-199003000-00006; DAVISON R, 1974, AM HEART J, V87, P279, DOI 10.1016/0002-8703(74)90064-7; DUCAS J, 1983, AM J CARDIOL, V52, P1299, DOI 10.1016/0002-9149(83)90592-1; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; EWY GA, 1988, ANN INTERN MED, V109, P456, DOI 10.7326/0003-4819-109-6-456; MAISEL AS, 1984, ANN INTERN MED, V101, P781, DOI 10.7326/0003-4819-101-6-781; MARANTZ PR, 1990, CHEST, V97, P776, DOI 10.1378/chest.97.4.776; MATTHEWS MB, 1958, LANCET, V1, P873; MATTHEWS MB, 1982, CLIN EXAMINATION, P99; OROURKE RA, 1989, HEART ARTERIES VEINS, P157; PASTEUR W, 1885, LANCET, V2, P524; Sapira JD, 1990, ART SCI BEDSIDE DIAG, P355; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SINGH SP, 1973, POSTGRAD MED J, V49, P10, DOI 10.1136/pgmj.49.567.10; STOELTING RK, 1983, ANESTHESIOLOGY, V38, P291	21	72	73	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					630	634		10.1001/jama.275.8.630	http://dx.doi.org/10.1001/jama.275.8.630			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594245				2022-12-28	WOS:A1996TW62700024
J	Nightingale, SL				Nightingale, SL			Fat substitute Olestra approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-28	WOS:A1996TW62700031
J	Kennedy, S; ChanYeung, M				Kennedy, S; ChanYeung, M			Taking ''cryptogenic'' out of fibrosing alveolitis	LANCET			English	Editorial Material							IDIOPATHIC PULMONARY FIBROSIS; EXPOSURE		UNIV BRITISH COLUMBIA,OCCUPAT HYG PROGRAM,VANCOUVER,BC V5Z 1M9,CANADA	University of British Columbia	Kennedy, S (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,OCCUPAT LUNG DIS RES UNIT,VANCOUVER,BC V5Z 1M9,CANADA.							ABRAMSON MJ, 1989, AM REV RESPIR DIS, V139, P1042, DOI 10.1164/ajrccm/139.4.1042; BILLINGS CG, 1994, EUR RESPIR J, V7, P1172; Chan-Yeung Moira, 1993, P299; CHANYEUNG M, 1994, EUR J RESPIR DIS, V7, P969; CHERNIACK RM, 1991, AM REV RESPIR DIS, V143, P680, DOI 10.1164/ajrccm/143.3.680; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; MONSO E, 1990, ARCH ENVIRON HEALTH, V45, P185, DOI 10.1080/00039896.1990.9936714; OWENS GR, 1988, AM J MED, V85, P114, DOI 10.1016/0002-9343(88)90515-3; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; TESCHKE K, 1994, AM J IND MED, V26, P327, DOI 10.1002/ajim.4700260306; 1992, WORKERS HLTH INT DEC, V34	13	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					276	277		10.1016/S0140-6736(96)90459-6	http://dx.doi.org/10.1016/S0140-6736(96)90459-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569355				2022-12-28	WOS:A1996TT48500002
J	Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I				Rozenberg, P; Goffinet, F; Philippe, HJ; Nisand, I			Ultrasonographic measurement of lower uterine segment to assess risk of defects of scarred uterus	LANCET			English	Article							PREVIOUS CESAREAN-SECTION; X-RAY PELVIMETRY; VAGINAL DELIVERY; RUPTURE; DEHISCENCE; PREGNANCY; DIAGNOSIS; BIRTH	Background Ultrasonography has been used to examine the scarred uterus in women who have had previous caesarean sections in an attempt to assess the risk of rupture of the scar during subsequent labour. The predictive value of such measurements has not been adequately assessed, however. We aimed to evaluate the usefulness of sonographic measurement of the lower uterine segment before labour in predicting the risk of intrapartum uterine rupture. Methods In this prospective observational study, the obstetricians were not told the ultrasonographic findings and did not use them to make decisions about type of delivery. Eligible patients were those with previous caesarean sections booked for delivery at our hospital. 642 patients underwent ultrasound examination at 36-38 weeks' gestation, and were allocated to four groups according to the thickness of the lower uterine segment. Ultrasonographic findings were compared with those of physical examination at delivery. Findings The overall frequency of defective scars was 4.0% (15 ruptures, 10 dehiscences). The frequency of defects rose as the thickness of the lower uterine segment decreased: there were no defects among 278 women with measurements greater than 4.5 mm, three (2%) among 177 women with values of 3.6-4.5 mm, 14 (10%) among 136 women with values of 2.6-3.5 mm, and eight (16%) among 51 women with values of 1.6-2.5 mm. With a cutoff value of 3.5 mm, the sensitivity of ultrasonographic measurement was 88.0%, the specificity 73.2%, positive predictive value 11.8%, and negative predictive value 99.3%. Interpretation Our results show that the risk of a defective scar is directly related to the degree of thinning of the lower uterine segment at around 37 weeks of pregnancy. The high negative predictive value of the method may encourage obstetricians in hospitals where routine repeat elective caesarean is the norm to offer a trial of labour to patients with a thickness value of 3.5 mm or greater.			Rozenberg, P (corresponding author), CTR HOSP INTERCOMMUNAL,DEPT OBSTET & GYNAECOL,LEON TOUHLADJIAN,F-78303 POISSY,FRANCE.			GOFFINET, Francois/0000-0001-9643-0299				ACTON CM, 1978, AUSTRALAS RADIOL, V22, P254, DOI 10.1111/j.1440-1673.1978.tb02068.x; ARAKI T, 1982, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V34, P738; AVRECH OM, 1994, ULTRASOUND OBST GYN, V4, P151, DOI 10.1046/j.1469-0705.1994.04020151.x; BEDI DG, 1986, J CLIN ULTRASOUND, V14, P529, DOI 10.1002/jcu.1870140706; BROWN JE, 1986, AM J OBSTET GYNECOL, V155, P4; CHAPMAN K, 1994, BRIT J OBSTET GYNAEC, V101, P549, DOI 10.1111/j.1471-0528.1994.tb13163.x; CHAZOTTE C, 1990, AM J OBSTET GYNECOL, V163, P738, DOI 10.1016/0002-9378(90)91059-L; COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; FLAMM BL, 1988, AM J OBSTET GYNECOL, V158, P1079, DOI 10.1016/0002-9378(88)90224-4; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; GALE JT, 1986, J ULTRAS MED, V5, P713; KRISHNAMURTHY S, 1991, BRIT J OBSTET GYNAEC, V98, P716, DOI 10.1111/j.1471-0528.1991.tb13462.x; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945, DOI 10.1016/0002-9378(93)90032-E; MEEHAN FP, 1990, INT J GYNECOL OBSTET, V31, P249, DOI 10.1016/0020-7292(90)91019-M; MICHAELS WH, 1988, OBSTET GYNECOL, V71, P112; NIELSEN TF, 1989, AM J OBSTET GYNECOL, V160, P569, DOI 10.1016/S0002-9378(89)80029-8; OSMERS R, 1988, INT J GYNECOL OBSTET, V26, P279, DOI 10.1016/0020-7292(88)90274-3; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; THUBISI M, 1993, BRIT J OBSTET GYNAEC, V100, P421, DOI 10.1111/j.1471-0528.1993.tb15265.x; 1981, NIH8220967 PUBL	21	175	194	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					281	284		10.1016/S0140-6736(96)90464-X	http://dx.doi.org/10.1016/S0140-6736(96)90464-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569360				2022-12-28	WOS:A1996TT48500007
J	Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M				Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M			Clinical algorithm for treatment of Plasmodium falciparum malaria in children	LANCET			English	Article							DIAGNOSIS; ANEMIA; INFECTIONS; THERAPY; AFRICA	Background Identification of children who need antimalarial treatment is difficult in settings where confirmatory laboratory testing is not available, as in much of sub-Saharan Africa. The current national policy in Malawi is to treat all children with fever, usually defined as the mother's report of fever in the child, for presumed malaria. To assess this policy and to find out whether a better clinical case definition could be devised, we studied acutely ill children presenting to two hospital outpatient departments in Malawi. Methods The parent or guardian of each enrolled child (n=1124) was asked a standard series of questions about the symptoms and duration of the child's illness. Each child was examined, axillary and rectal temperatures and blood haemoglobin concentrations were measured, and a giemsa-stained thick smear was examined for malaria parasites. Logistic regression procedures were used to identify clinical predictors of parasitaemia. Findings High temperature (37.7 degrees C or above), nailbed palter, enlarged spleen, and being seen at one of the clinics rather than the other were associated with an increased risk of malaria parasitaemia in univariate analyses. A revised malaria case definition of rectal temperature of 37.7 degrees C or higher, spienomegaly, or nailbed pallor was 85% sensitive in identifying parasitaemic children and 41% specific; the corresponding sensitivity and specificity for the nationally recommended definition that equates mother's history of fever with malaria were 93% and 21%. The revised case definition had 89% sensitivity in identifying parasitaemic children with concentration below g/L and 89% sensitivity in identifying children with parasite density greater than 10 000/mu L, characteristics that indicate a clear need for antimalarial treatment. Interpretation These results suggest that better clinical definitions are feasible, that splenomegaly and pallor are helpful in identifying children with malaria, and that much overtreatment of children without parasitaemia could be avoided.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341; KAMUZU CENT HOSP,DEPT PAEDIAT,LILONGWE,MALAWI; MALAWI MINIST HLTH,COMMUNITY HLTH SCI UNIT,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,CHICHIRI,MALAWI	Centers for Disease Control & Prevention - USA; University of Malawi								BASSETT MT, 1991, J TROP MED HYG, V94, P65; BJORCK M, 1992, HEALTH POLICY PLANN, V7, P290, DOI 10.1093/heapol/7.3.290; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BJORKMAN A, 1991, B WORLD HEALTH ORGAN, V69, P297; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; DELFINI LF, 1973, J TROP MED HYG, V76, P111; Field J. W., 1937, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V30, P569, DOI 10.1016/S0035-9203(37)90070-1; GJORUP T, 1986, AM J EPIDEMIOL, V124, P657, DOI 10.1093/oxfordjournals.aje.a114438; GREENWOOD BM, 1987, PARASITOL TODAY, V3, P206, DOI 10.1016/0169-4758(87)90061-5; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; NARDONE DA, 1990, ARCH INTERN MED, V150, P201, DOI 10.1001/archinte.150.1.201; OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X; PETERSEN E, 1991, J INFECT DIS, V164, P949, DOI 10.1093/infdis/164.5.949; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; SANCHEZCARRILLO CI, 1989, J CLIN EPIDEMIOL, V42, P751, DOI 10.1016/0895-4356(89)90071-1; SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; STROBACH RS, 1988, ARCH INTERN MED, V148, P831, DOI 10.1001/archinte.148.4.831; SUTRISNA B, 1991, LANCET, V338, P471, DOI 10.1016/0140-6736(91)90544-Y; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TRAORE M, 1991, EVALUATION IMPACT FO, P1; WURAPA FK, 1986, J TROP MED HYG, V89, P33; 1992, AFRO22 TECHN PAP, P1	26	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					223	227		10.1016/S0140-6736(96)90404-3	http://dx.doi.org/10.1016/S0140-6736(96)90404-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551881	Green Submitted			2022-12-28	WOS:A1996TT06900010
J	Steinberg, D				Steinberg, D			A docking receptor for HDL cholesterol esters	SCIENCE			English	Editorial Material							HIGH-DENSITY LIPOPROTEIN; APOPROTEIN-A-I; SELECTIVE UPTAKE; ADRENAL-CELLS; HEPATOCYTES; CD36				Steinberg, D (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; PITAS RE, 1992, ARTERIOSCLER THROMB, V12, P1235, DOI 10.1161/01.ATV.12.11.1235; PITTMAN RC, 1984, J LIPID RES, V25, P1577; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; PLKUMP AS, COMMUNICATION; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019	15	65	68	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					460	461		10.1126/science.271.5248.460	http://dx.doi.org/10.1126/science.271.5248.460			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560256				2022-12-28	WOS:A1996TR32200027
J	Thompson, NP; Driscoll, R; Pounder, RE; Wakefield, AJ				Thompson, NP; Driscoll, R; Pounder, RE; Wakefield, AJ			Genetics versus environment in inflammatory bowel disease: Results of a British twin study	BRITISH MEDICAL JOURNAL			English	Article							CROHNS-DISEASE		ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON NW3 2PF,ENGLAND; NATL ASSOC COLITIS & CROHNS DIS,ST ALBANS AL1 1AB,HERTS,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; JABLON S, 1967, AM J HUM GENET, V19, P133; LYKKEN DT, 1987, BEHAV GENET, V17, P343, DOI 10.1007/BF01068136; MONSEN U, 1991, SCAND J GASTROENTERO, V26, P302, DOI 10.3109/00365529109025046; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990	5	244	247	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					95	96						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555939				2022-12-28	WOS:A1996TQ16800026
J	Boleti, H; Karsenti, E; Vernos, I				Boleti, H; Karsenti, E; Vernos, I			Xklp2, a novel Xenopus centrosomal kinesin-like protein required for centrosome separation during mitosis	CELL			English	Article							SPINDLE FORMATION; EXTRACTS; SEQUENCES; CELLS	We describe a novel Xenopus plus end-directed kinesin-like protein (KLP), Xklp2, localized on centrosomes throughout the cell cycle and on spindle pole microtubules during metaphase. Using mitotic spindles assembled in Xenopus egg extracts and different recombinant GST-Xklp2 mutants, we show that this motor is targeted to spindle poles through its C-terminal domain. Xklp2-truncated polypeptides lacking the motor domain block centrosome separation and disrupt preassembled metaphase spindles. Antibodies directed against the tail of Xklp2 have a similar effect. These results show that Xklp2 protein is required for centrosome separation and maintenance of spindle bipolarity. This study is an example of the application of the dominant negative mutant effect on spindle assembly in Xenopus egg extracts, demonstrating the usefulness of this approach in probing the function of proteins in this system.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	Boleti, H (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Vernos, Isabelle/C-1687-2015	Vernos, Isabelle/0000-0003-1469-9214				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1994, PROTEIN PROFILE, V1; CHANDRA R, 1993, METHODS CELL BIOL; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GARD DL, 1994, DEV BIOL, V161, P131, DOI 10.1006/dbio.1994.1015; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERINGA J, 1993, PROTEINS, V17, P391, DOI 10.1002/prot.340170407; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1991, J CELL SCI S, V14, P125; Karsenti E, 1991, Semin Cell Biol, V2, P251; KISHINIO A, 1988, NATURE, V293, P566; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCINTOSJH RJ, 1994, MICROTUBULES; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN ES, 1995, P NATL ACAD SCI USA, V92, P4289; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; SELLERS JR, 1993, METHODS CELL BIOL; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SINARD JH, 1990, J CELL BIOL, V111, P2417, DOI 10.1083/jcb.111.6.2417; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1026, P146; SULLIVAN W, 1990, DEVELOPMENT, V110, P311; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361	47	131	134	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					49	59		10.1016/S0092-8674(00)80992-7	http://dx.doi.org/10.1016/S0092-8674(00)80992-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548825	Bronze			2022-12-28	WOS:A1996TQ17000008
J	WilsonMacDonald, J				WilsonMacDonald, J			Controversies in management - Should backache be treated with spinal fusion? The case for spinal fusion is unproved	BRITISH MEDICAL JOURNAL			English	Article							PAIN				WilsonMacDonald, J (corresponding author), NUFFIELD ORTHOPAED CTR,SPINAL UNIT,OXFORD OX3 7LD,ENGLAND.							CHERKIN D, 1993, INT COMP BACK SURGER; ESSES SI, 1993, SPINE, V18, P2231, DOI 10.1097/00007632-199311000-00015; FRANKLIN GM, 1994, SPINE, V19, P1897, DOI 10.1097/00007632-199409000-00005; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002; JOHNSON JR, 1983, J BONE JOINT SURG BR, V65, P43; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; KOHLES S, 1990, SPINE, V15, P1321, DOI 10.1097/00007632-199012000-00016; MITCHELL RI, 1990, SPINE, V15, P514, DOI 10.1097/00007632-199006000-00016; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; ZDEBLICK TA, 1993, SPINE, V18, P983, DOI 10.1097/00007632-199306150-00006	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					39	40		10.1136/bmj.312.7022.39	http://dx.doi.org/10.1136/bmj.312.7022.39			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555862	Green Published			2022-12-28	WOS:A1996TP20900028
J	Manske, CL; Wang, Y; Thomas, W				Manske, CL; Wang, Y; Thomas, W			Mortality of cadaveric kidney transplantation versus combined kidney-pancreas transplantation in diabetic patients	LANCET			English	Article							RENAL-TRANSPLANTATION; DISEASE; MORBIDITY	In the United States diabetes is now the principal cause of end-stage renal disease. For diabetic patients undergoing cadaveric kidney transplantation, a combined kidney-pancreas (KP) transplant is often recommended because this option is perceived to carry no additional risk. However, most transplant centres have restricted KP transplantation to patients with few diabetic complications and no coronary artery disease. We compared survival rates after KP transplantation with those after kidney transplantation alone in clinically similar though non-randomised patient groups. In 173 consecutive diabetic renal transplant candidates, 3-year patient survival in 54 KP recipients was 68%, versus 90% in 46 patients who received a cadaveric kidney alone (p=0 . 01). The remaining patients had a living-related-donor kidney transplant, either alone (65) or followed 4-20 months later by a pancreas transplant (8), with survival similar to that with a cadaveric kidney. Independent variables associated with early death were age, history of congestive heart failure, and pancreas transplantation. A serious complication of pancreas transplantation was infection, for which 14 of 54 recipients required pancreatectomy; KP recipients had a higher death rate from infection in the first 12 months (p=0 . 034). In view of the excess mortality associated with KP transplantation, we suggest that the combined operation should be reserved for young patients with no history of congestive heart failure, or for patients in whom hypoglycaemia is life-threatening. A randomised trial is needed to compare the long-term outcomes of these procedures.	UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,DEPT BIOSTAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [MOIRR004400] Funding Source: Medline; NIDDK NIH HHS [DK13038] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT WM, 1978, AM J MED, V65, P779, DOI 10.1016/0002-9343(78)90796-9; CHEUNG AHS, 1992, KIDNEY INT, V41, P924, DOI 10.1038/ki.1992.141; CHEUNG AHS, 1993, TRANSPLANT P, V25, P1184; GREWAL HP, 1993, TRANSPLANTATION, V56, P1609; GRUESSNER RWG, 1994, TRANSPLANTATION, V57, P1598; LEMMER MJ, 1991, DIABETES CARE, V14, P310; LEMMERS MJ, 1991, DIABETES CARE, V14, P295, DOI 10.2337/diacare.14.4.295; LORDER MI, 1987, TRANSPLANT P, V19, P1539; Manske C. L., 1993, Journal of the American Society of Nephrology, V4, P947; MANSKE CL, 1992, LANCET, V340, P998, DOI 10.1016/0140-6736(92)93010-K; OZAKI CF, 1992, AM J SURG, V164, P546, DOI 10.1016/S0002-9610(05)81198-5; REMUZZI G, 1994, LANCET, V343, P27, DOI 10.1016/S0140-6736(94)90880-X; ROBERTSON RP, 1992, NEW ENGL J MED, V327, P1861; ROSEN CB, 1991, TRANSPLANTATION, V51, P123, DOI 10.1097/00007890-199101000-00019; SCHULAK JA, 1992, TRANSPLANTATION, V53, P685; SOLLINGER HW, 1991, ANN SURG, V214, P703, DOI 10.1097/00000658-199112000-00010; STRATTA RJ, 1993, SURG GYNECOL OBSTET, V177, P163; STRATTA RJ, 1993, TRANSPLANT P, V25, P1184; WEINRAUCH LA, 1978, ANN INTERN MED, V88, P346, DOI 10.7326/0003-4819-88-3-346; 1994, 1994 USRDS NIH NAT I	20	73	73	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1658	1662		10.1016/S0140-6736(95)92838-3	http://dx.doi.org/10.1016/S0140-6736(95)92838-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551822				2022-12-28	WOS:A1995TL42300008
J	Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J				Agrawal, RK; Penczek, P; Grassucci, RA; Li, YH; Leith, A; Nierhaus, KH; Frank, J			Direct visualization of A-, P-, and E-site transfer RNAs in the Escherichia coli ribosome	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; ANTICODON INTERACTION SITE; CRYSTAL-STRUCTURE; A-SITES; LOCALIZATION; RESOLUTION; TOPOGRAPHY; BINDING; SUBUNIT	Transfer RNA (tRNA) molecules play a crucial role in protein biosynthesis in all organisms. Their interactions with ribosomes mediate the translation of genetic messages into polypeptides. Three tRNAs bound to the Escherichia coli 70S ribosome were visualized directly with cryoelectron microscopy and three-dimensional reconstruction, The detailed arrangement of A- and P-site tRNAs inferred from this study allows localization of the sites for anticodon interaction and peptide bond formation on the ribosome.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA; SUNY ALBANY, DEPT BIOMED SCI, ALBANY, NY 12222 USA; MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Max Planck Society			Leith', Ardean/AAI-5163-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR01219] Funding Source: Medline; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER D, 1994, J BIOL CHEM, V269, P30713; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BURMA DP, 1986, STRUCTURE FUNCTION G, P438; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KILL R, 1984, BIOCHEMISTRY-US, V25, P3245; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LULJAS A, 1991, BIOCHIMIE, V73, P1093; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NOLLER HF, 1990, RIBOSOME, P73; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Silberklang M, 1979, Methods Enzymol, V59, P58; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; SUSSMAN JL, 1976, BIOCHEM BIOPH RES CO, V68, P89, DOI 10.1016/0006-291X(76)90014-0; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1994, BIOCHIMIE, V76, P1235, DOI 10.1016/0300-9084(94)90054-X; Zhu J. N, UNPUB; ZIMMERMANN RA, 1990, RIBOSOME, P331	35	189	194	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					1000	1002		10.1126/science.271.5251.1000	http://dx.doi.org/10.1126/science.271.5251.1000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584922				2022-12-28	WOS:A1996TV70400053
J	Laudanna, C; Campbell, JJ; Butcher, EC				Laudanna, C; Campbell, JJ; Butcher, EC			Role of Rho in chemoattractant-activated leukocyte adhesion through integrins	SCIENCE			English	Article							GTP-BINDING-PROTEIN; HUMAN-NEUTROPHILS; ADP-RIBOSYLATION; CALPHOSTIN-C; GENE-PRODUCT; KINASE-C; BOTULINUM; STIMULATION; INHIBITION; VENULES	Heterotrimeric guanine nucleotide binding protein (G protein)-linked receptors of the chemoattractant subfamily can trigger adhesion through leukocyte integrins, and in this role they are thought to regulate immune cell-cell interactions and trafficking. In lymphoid cells transfected with formyl peptide or interleukin-8 receptors, agonist stimulation activated nucleotide exchange on the small guanosine triphosphate-binding protein RhoA in seconds. Inactivation of Rho by C3 transferase exoenzyme blocked agonist-induced lymphocyte alpha 4 beta 1 adhesion to vascular cell adhesion molecule-1 and neutrophil beta 2 integrin adhesion to fibrinogen. These findings suggest that Rho participates in signaling from chemoattractant receptors to trigger rapid adhesion in leukocytes.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS HLTH CARE SYST,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Laudanna, C (corresponding author), STANFORD UNIV,DEPT PATHOL,LAB IMMUNOL & VASC BIOL,STANFORD,CA 94305, USA.			Campbell, James/0000-0003-4252-5182	NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008930] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09302] Funding Source: Medline; NIAID NIH HHS [1F32 AI08930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CAMPBELL JC, UNPUB; CLARKE MSF, 1992, J CELL SCI, V102, P533; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HONDA S, 1994, J IMMUNOL, V152, P4026; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAUDANNA C, UNPUB; LEY K, 1993, J IMMUNOL, V151, P6347; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034	23	420	431	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					981	983		10.1126/science.271.5251.981	http://dx.doi.org/10.1126/science.271.5251.981			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584934				2022-12-28	WOS:A1996TV70400047
J	Abbott, A				Abbott, A			DNA chips intensify the sequence search	NATURE			English	Editorial Material																		1995, NATURE, V373, P372	1	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					392	392						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559237				2022-12-28	WOS:A1996TT30400017
J	Edmond, MB; Wenzel, RP; Pasculle, AW				Edmond, MB; Wenzel, RP; Pasculle, AW			Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							AMBULATORY PERITONEAL-DIALYSIS; HYGIENIC HAND DISINFECTION; LONG-TERM HEMODIALYSIS; NASAL CARRIAGE; MUPIROCIN OINTMENT; INFECTION; ELIMINATION; EFFICACY; COLONIZATION; EMERGENCE	Given the dramatic increase in the incidence of vancomycin resistance among the enterococci and experimental evidence for the transfer of vancomycin resistance from enterococci to Staphylococcus aureus, there is concern that strains of S. aureus will emerge that are resistant to vancomycin. The result would be a highly virulent pathogen for which effective antimicrobial therapy would not be available. To prevent the nosocomial transmission of such an organism, stringent infection control policies need to be developed and implemented. We offer proposals that are based on the limited data available on the transmission and control of S. aureus and that may be used as starting points for the development of formal guidelines for the isolation of colonized and infected patients and for microbiology laboratory precautions.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT INTERNAL MED, RICHMOND, VA 23298 USA; UNIV PITTSBURGH, MED CTR, PITTSBURGH, PA 15213 USA	Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Edmond, MB (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV QUAL HLTH CARE, POB 980019, RICHMOND, VA 23298 USA.			Edmond, Michael/0000-0002-4144-8974				AYLIFFE GAJ, 1978, J CLIN PATHOL, V31, P923, DOI 10.1136/jcp.31.10.923; AYLIFFE GAJ, 1974, LANCET, V2, P1573; BAIRD D, 1987, LANCET, V2, P387; BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; CALIA FM, 1969, J HYG-CAMB, V67, P49, DOI 10.1017/S0022172400041413; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V18, P1; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V17, P365, DOI 10.1093/jac/17.3.365; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P597; COHEN SH, 1991, AM J MED, V91, pS233, DOI 10.1016/0002-9343(91)90374-7; COOKSON BD, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92667-7; COOKSON BD, 1990, J ANTIMICROB CHEMOTH, V25, P497, DOI 10.1093/jac/25.4.497; DAVIES SJ, 1989, PERITON DIALYSIS INT, V9, P61; DOEBBELING BN, 1994, ARCH INTERN MED, V154, P1505, DOI 10.1001/archinte.154.13.1505; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DOEBBELING BN, 1993, CLIN INFECT DIS, V17, P466, DOI 10.1093/clinids/17.3.466; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; FEKETY FR, 1964, MEDICINE, V43, P593, DOI 10.1097/00005792-196409000-00003; GANESH R, 1989, LANCET, V2, P558; GILBART J, 1993, ANTIMICROB AGENTS CH, V37, P32, DOI 10.1128/AAC.37.1.32; HALEY RW, 1995, J INFECT DIS, V171, P614, DOI 10.1093/infdis/171.3.614; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P171, DOI 10.1017/S0022172400046349; KIRMANI N, 1978, ARCH INTERN MED, V138, P1657, DOI 10.1001/archinte.138.11.1657; KJOLEN H, 1992, J HOSP INFECT, V21, P61, DOI 10.1016/0195-6701(92)90154-E; LAYTON MC, 1993, INFECT CONT HOSP EP, V14, P369; LILLY HA, 1978, J CLIN PATHOL, V31, P919, DOI 10.1136/jcp.31.10.919; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; LOWBURY EJL, 1964, BMJ-BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5403.230; MURO K, 1991, Journal of the American Society of Nephrology, V2, P340; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; OJAJARVI J, 1980, J HYG-CAMBRIDGE, V85, P193, DOI 10.1017/S0022172400063221; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; RAHMAN M, 1987, LANCET, V2, P387; RANSJO U, 1978, SCAND J INFECT DIS, P3; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; SANFORD MD, 1994, CLIN INFECT DIS, V19, P1123, DOI 10.1093/clinids/19.6.1123; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SESSO R, 1989, CLIN NEPHROL, V31, P264; SMITH GE, 1988, J ANTIMICROB CHEMOTH, V21, P141, DOI 10.1093/jac/21.1.141; TANNER EI, 1980, J HYG-CAMBRIDGE, V85, P219, DOI 10.1017/S0022172400063257; TUAZON CU, 1975, JAMA-J AM MED ASSOC, V231, P1272, DOI 10.1001/jama.231.12.1272; TUAZON CU, 1974, J INFECT DIS, V129, P725, DOI 10.1093/infdis/129.6.725; TULLOCH LG, 1954, BMJ-BRIT MED J, V2, P912, DOI 10.1136/bmj.2.4893.912; VEACH LA, 1990, J CLIN MICROBIOL, V28, P2064, DOI 10.1128/JCM.28.9.2064-2068.1990; WADE JJ, 1991, J HOSP INFECT, V18, P211, DOI 10.1016/0195-6701(91)90145-X; WADE JJ, 1991, J HOSP INFECT, V18, P23, DOI 10.1016/0195-6701(91)90259-B; WATANAKUNAKORN C, 1992, AM J INFECT CONTROL, V20, P138, DOI 10.1016/S0196-6553(05)80180-4; WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787; WHITE A, 1961, J LAB CLIN MED, V58, P273; WILLIAMS RE, 1966, BACTERIOL REV, V30, P660, DOI 10.1128/MMBR.30.3.660-674.1966; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204; 1995, INFECT CONT HOSP EP, V16, P105; 1991, PROTECTION LABORATOR, P31	53	106	110	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					329	334		10.7326/0003-4819-124-3-199602010-00008	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554229				2022-12-28	WOS:A1996TR59600008
J	Leizorovicz, A				Leizorovicz, A			Benefit from earlier thrombolytic therapy is certain, but what is the magnitude of benefit?	BRITISH MEDICAL JOURNAL			English	Editorial Material											Leizorovicz, A (corresponding author), SERV PHARMACOL CLIN,INSERM,BP 3041,F-69394 LYON 03,FRANCE.							Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; Rawles J, 1996, BMJ-BRIT MED J, V312, P212; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; 1993, NEW ENGL J MED, V329, P383; 1992, BRIT MED J, V305, P548	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					215	216						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563586				2022-12-28	WOS:A1996TT48600025
J	Weeks, KM; Cech, TR				Weeks, KM; Cech, TR			Assembly of a ribonucleoprotein catalyst by tertiary structure capture	SCIENCE			English	Article							16-S RIBOSOMAL-RNA; PRE-MESSENGER RNA; GROUP-I INTRON; ESCHERICHIA-COLI; CBP2 PROTEIN; YEAST; INVITRO; BINDING; SUBSTRATE; SEQUENCE	CBP2 is an RNA tertiary structure binding protein required for efficient splicing of a yeast mitochondrial group I intron. CBP2 must wait for folding of the two RNA domains that make up the catalytic core before it can bind. In a subsequent step, association of the 5' domain of the RNA is stabilized by additional interactions with the protein. Thus, CBP2 functions primarily to capture otherwise transient RNA tertiary structures. This simple one-RNA, one-protein system has revealed how the kinetic pathway of RNA folding can direct the assembly of a specific ribonucleoprotein complex. There are parallels to steps in the formation of a much more complex ribonucleoprotein, the 30S ribosomal subunit,			Weeks, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							ALBERTY RA, 1957, J PHYS CHEM-US, V62, P154; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CAREY J, 1993, BIOCHEMISTRY-US, V2, P2610; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GESTELAND RF, 1993, RNA WORLD; GU XG, 1992, BIOCHEMISTRY-US, V31, P10295, DOI 10.1021/bi00157a017; HELD WA, 1974, J BIOL CHEM, V249, P3103; HELD WA, 1973, BIOCHEMISTRY-US, V12, P3273, DOI 10.1021/bi00741a020; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; LI Y, 1995, BIOCHEMISTRY-US, V34, P14394, DOI 10.1021/bi00044a016; LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041; MANDIYAN V, 1989, J MOL BIOL, V210, P323, DOI 10.1016/0022-2836(89)90334-3; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOMURA M, 1969, COLD SPRING HARB SYM, V34, P49, DOI 10.1101/SQB.1969.034.01.009; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PINGOUD A, 1973, FEBS LETT, V30, P1, DOI 10.1016/0014-5793(73)80605-2; POWERS T, 1993, J MOL BIOL, V232, P362, DOI 10.1006/jmbi.1993.1396; POWERS T, 1995, RNA, V1, P194; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SIEBER G, 1978, BIOCHEMISTRY-US, V17, P3505, DOI 10.1021/bi00610a013; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WEEKS KM, UNPUB; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	36	105	109	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					345	348		10.1126/science.271.5247.345	http://dx.doi.org/10.1126/science.271.5247.345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553068				2022-12-28	WOS:A1996TQ52800039
J	Turner, R; Cull, C; Holman, R				Turner, R; Cull, C; Holman, R			United Kingdom prospective diabetes study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; FOLLOW-UP; PLASMA-GLUCOSE; RISK FACTOR; MORTALITY; POPULATION; HYPERGLYCEMIA; RESISTANCE	Purpose: To report the progress (after 9-year follow-up) of a study designed to determine whether improved glucose control in patients with newly diagnosed non-insulin-dependent diabetes mellitus (NIDDM) is effective in reducing the incidence of clinical complications. Data Source: A multicenter, randomized, controlled trial of different therapies for NIDDM. After initial diet therapy, 4209 asymptomatic patients who remained hyperglycemic (fasting plasma glucose levels, 6.0 to 15.0 mmol/L) were assigned to either a conventional therapy policy, primarily with diet alone, or to an intensive therapy policy, aiming for fasting plasma glucose levels of less than 6.0 mmol/L, with assignment to primary therapy with sulfonylurea or insulin (which increased insulin supply) or metformin (which enhanced insulin sensitivity). Results: All three modes of pharmacologic therapy in the intensively treated group-sulfonylurea, insulin, and metformin-had similar efficacy in reducing the fasting plasma glucose and glycated hemoglobin levels. Over 9 years, patients assigned to intensive therapy with sulfonylurea or insulin had lower fasting plasma glucose levels (median, 7.3 and 9.0 mmol/L, respectively) and lower hemoglobin A(1c) levels (6.7% and 7.5%, respectively) than patients assigned to conventional therapy. Regardless of the assigned therapy, however, the fasting plasma glucose and hemoglobin A(1c) levels increased, and maintaining near-normal glycemia was, in general, not feasible. Even insulin therapy did not achieve the therapeutic goal of near-normal glycemia because of the difficulty in treating marked hyperglycemia and the risk for hypoglycemic episodes. Nine years after the diagnosis of diabetes, 29% of the patients had had a diabetes-related clinical end point, 20% had had a macrovascular complication, and 9% had had a microvascular complication. Conclusions: A report will be published in 1998 after a median duration from randomization of 11 years (range, 6 to 20 years) with an 81% power at a 1% level of significance of detecting whether the obtained improvement in glucose control causes a 15% decrease or increase in the incidence of major complications and whether any specific therapy is advantageous or disadvantageous.	GEN HOSP, BIRMINGHAM, W MIDLANDS, ENGLAND; ROYAL INFIRM, ABERDEEN, SCOTLAND; UNIV LONDON ST GEORGES HOSP, LONDON, ENGLAND; HAMMERSMITH HOSP, LONDON, ENGLAND; CITY HOSP, BELFAST, ANTRIM, NORTH IRELAND; N STAFFORDSHIRE ROYAL INFIRM, STOKE ON TRENT, STAFFS, ENGLAND; ROYAL VICTORIA HOSP, BELFAST, ANTRIM, NORTH IRELAND; ST HELIER HOSP, CARSHALTON, SURREY, ENGLAND; WHITTINGTON HOSP, LONDON, ENGLAND; NORFOLK & NORWICH HOSP, NORWICH, NORFOLK, ENGLAND; LISTER HOSP, STEVENAGE, HERTS, ENGLAND; IPSWICH HOSP, IPSWICH, SUFFOLK, ENGLAND; NINEWELLS HOSP, DUNDEE, SCOTLAND; NORTHAMPTON HOSP, NORTHAMPTON, ENGLAND; TORBAY HOSP, TORQUAY, ENGLAND; PETERBOROUGH GEN HOSP, PETERBOROUGH, ENGLAND; SCARBOROUGH GEN HOSP, SCARBOROUGH, ENGLAND; DERBYSHIRE ROYAL INFIRM, DERBY, ENGLAND; MANCHESTER ROYAL INFIRM, MANCHESTER, LANCS, ENGLAND; HOPE HOSP, SALFORD, LANCS, ENGLAND; LEICESTER GEN HOSP, LEICESTER, LEICS, ENGLAND; ROYAL DEVON & EXETER HOSP, EXETER, DEVON, ENGLAND	Royal Infirmary of Edinburgh; St Georges University London; Imperial College London; Keele University; University Hospital of North Staffordshire NHS Trust; St Helier Hospital; University of London; University College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Lister Hospital; Ipswich Hospital NHS Trust; Ipswich Hospital; University of Dundee; University of Manchester; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Exeter	Turner, R (corresponding author), RADCLIFFE INFIRM, DIABET RES LABS, UNITED KINGDOM PROSPECT DIABET STUDY GRP, WOODSTOCK RD, OXFORD OX2 6HE, ENGLAND.							[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R; [Anonymous], 1995, BMJ, V310, P83; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BALLAGIPORDANY G, 1990, DIABETES RES CLIN PR, V8, P109, DOI 10.1016/0168-8227(90)90020-T; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; FULLER JH, 1980, LANCET, V1, P1373; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GREENE DA, 1988, DIABETES, V37, P688, DOI 10.2337/diabetes.37.6.688; Holman R R, 1985, Diabet Med, V2, P45; HOLMAN RR, 1977, LANCET, V1, P469; JARRETT RJ, 1976, LANCET, V2, P1009; JARRETT RJ, 1988, DIABETOLOGIA, V31, P71, DOI 10.1007/BF00395550; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAING W, 1989, DIABETES MODEL HLTH, P32; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MEINERT CL, 1970, DIABETES, V19, P789; MEYER LC, 1994, DIABETIC MED, V11, P670; NATHAN DM, 1995, DIABETES CARE, V18, P251, DOI 10.2337/diacare.18.2.251; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PETTITT DJ, 1980, LANCET, V2, P1050; POGATSA G, 1992, ACTA MED HUNG, V49, P39; PYORALA K, 1979, J CHRON DIS, V32, P729, DOI 10.1016/0021-9681(79)90052-3; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STAMLER R, 1979, J CHRON DIS, V32, P683, DOI 10.1016/0021-9681(79)90047-X; STOUT RW, 1992, DIABETES ATHEROSCLER, P165; TURNER RC, 1993, J HYPERTENS, V11, P319; TURNER RC, 1991, DIABETOLOGIA, V34, P877; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; 1995, IN PRESS DIABETES; 1994, DIABETIC MED, V11, P773; 1985, WHO TECHNICAL SERIES, V727; 1959, STATISTICAL B METROP, V40, P1; 1975, DIABETES S1, V24, P65	42	380	399	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				136	145		10.7326/0003-4819-124-1_Part_2-199601011-00011	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554206				2022-12-28	WOS:A1996TL94400011
J	KATZEL, LI; BLEECKER, ER; COLMAN, EG; ROGUS, EM; SORKIN, JD; GOLDBERG, AP				KATZEL, LI; BLEECKER, ER; COLMAN, EG; ROGUS, EM; SORKIN, JD; GOLDBERG, AP			EFFECTS OF WEIGHT-LOSS VS AEROBIC EXERCISE TRAINING ON RISK-FACTORS FOR CORONARY-DISEASE IN HEALTHY, OBESE, MIDDLE-AGED AND OLDER MEN - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; BODY-FAT DISTRIBUTION; PRECIPITATION PROCEDURE; CARDIOVASCULAR-DISEASE; ABDOMINAL OBESITY; OVERWEIGHT MEN; BLOOD-LIPIDS; PLASMA; WOMEN; GLUCOSE	Objective.-To compare the effects of weight loss vs aerobic exercise training on coronary artery disease risk factors in healthy sedentary, obese, middle-aged and older men. Design.-Randomized controlled trial. Subjects.-A total of 170 obese (body mass index, 30+/-1 kg/m(2) [mean+/-SEM]), middle-aged and older (61+/-1 years) men. Interventions.-A g-month diet-induced weight loss intervention, 9-month aerobic exercise training program, and a weight-maintenance control group. Main Outcome Measures.-Change in body composition, maximal aerobic capacity (VO(2)max), blood pressure, lipoprotein concentrations, and glucose tolerance. Results.-Forty-four of 73 men randomized to weight loss completed the intervention and had a 10% mean reduction in weight (-9.5+/-0,.7 kg; P<.001), with no change in VO(2)max, Forty-nine of 71 men randomized to aerobic exercise completed the intervention, increased their VO(2)max by a mean of 17% (P<.001), and did not change their weight, whereas the 18 men who completed in the control group had no significant changes in body composition or VO(2)max. Weight loss decreased fasting glucose concentrations by 2%, insulin by 18%, and glucose and insulin areas during the oral glucose tolerance test (OGTT) by 8% and 26%, respectively (P<.01). By contrast, aerobic exercise did not improve fasting glucose or insulin concentrations or glucose responses during the OGTT but decreased insulin areas by 17% (P<.001). In analysis of variance, the decrement in fasting glucose and insulin levels and glucose areas with intervention differed between weight loss and aerobic exercise when compared with the control group (P<.05). Similarly, weight loss but not aerobic exercise increased high-density lipoprotein cholesterol levels (+13%) and decreased blood pressure compared with the control group. In multiple regression analyses, the improvement in lipoproteins and glucose metabolism was related primarily to the reduction in obesity. Conclusions.-These results suggest that weight loss is the preferred treatment to improve coronary artery disease risk factors in overweight, middle-aged and older men.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GERONTOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV PULM MED,BALTIMORE,MD 21201; VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,BALTIMORE,MD; NIA,GERONTOL RES CTR,METAB SECT,CLIN PHYSIOL LAB,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NATIONAL INSTITUTE ON AGING [K08AG000497, P01AG004402] Funding Source: NIH RePORTER; NIA NIH HHS [5-K08-AG00497, P01 AG04402, T32 AG002109] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BLUMENTHAL JA, 1991, AM J CARDIOL, V67, P633, DOI 10.1016/0002-9149(91)90904-Y; BORKAN GA, 1977, HUM BIOL, V3, P495; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; CASASSUS P, 1992, ARTERIOSCLER THROMB, V12, P1387, DOI 10.1161/01.ATV.12.12.1387; COON PJ, 1989, METABOLISM, V12, P1201; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DENNIS KE, 1993, ARTERIOSCLER THROMB, V13, P1487, DOI 10.1161/01.ATV.13.10.1487; FORTMANN SP, 1988, AM J CARDIOL, V62, P89, DOI 10.1016/0002-9149(88)91370-7; FRAZE E, 1987, J AM GERIATR SOC, V35, P224, DOI 10.1111/j.1532-5415.1987.tb02313.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GIDEZ LI, 1982, J LIPID RES, V23, P1206; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; HUGHES VA, 1994, AM J CLIN NUTR, V59, P820, DOI 10.1093/ajcn/59.4.820; KATZEL LI, 1992, ARTERIOSCLER THROMB, V12, P814, DOI 10.1161/01.ATV.12.7.814; KING AC, 1991, JAMA-J AM MED ASSOC, V266, P1535, DOI 10.1001/jama.266.11.1535; KLIMT C R, 1969, Diabetes, V18, P299; KOHRT WM, 1993, DIABETES, V42, P273, DOI 10.2337/diabetes.42.2.273; KOKKINOS PF, 1995, ARCH INTERN MED, V155, P415; MEYERS DA, 1991, J GERONTOL, V46, pM57, DOI 10.1093/geronj/46.2.M57; MILLAR JS, 1995, J LIPID RES, V36, P1155; MOREY MC, 1991, J AM GERIATR SOC, V39, P986, DOI 10.1111/j.1532-5415.1991.tb04045.x; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; SCHWARTZ RS, 1987, METABOLISM, V36, P165, DOI 10.1016/0026-0495(87)90012-6; SCHWARTZ RS, 1993, METABOLISM, V40, P545; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SIRI W E, 1956, Adv Biol Med Phys, V4, P239; SPARROW D, 1986, DIABETES, V35, P411, DOI 10.2337/diabetes.35.4.411; TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; WOOD PD, 1983, METABOLISM, V32, P31, DOI 10.1016/0026-0495(83)90152-X; 1985, CIRCULATION, V62, pA449; 1988, ARCH INTERN MED, V148, P36	36	230	231	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1915	1921		10.1001/jama.274.24.1915	http://dx.doi.org/10.1001/jama.274.24.1915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TL169	8568984				2022-12-28	WOS:A1995TL16900032
J	Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L				Mazzaferro, V; Regalia, E; Doci, R; Andreola, S; Pulvirenti, A; Bozzetti, F; Montalto, F; Ammatuna, M; Morabito, A; Gennari, L			Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; RESECTION; CANCER; MALIGNANCY; RECURRENCE	Background. The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma is controversial, and determining which patients are likely to have a good outcome after liver transplantation is difficult. Methods. We studied 48 patients with cirrhosis who had small, unresectable hepatocellular carcinomas and who underwent liver transplantation. In 94 percent of the patients, the cirrhosis was related to infection with hepatitis B virus, hepatitis C virus, or both. The presence of tumor was confirmed by biopsy or serum alpha-fetoprotein assay. The criteria for eligibility for transplantation were the presence of a tumor 5 cm or less in diameter in patients with single hepatocellular carcinomas and no more than three tumor nodules, each 3 cm or less in diameter, in patients with multiple tumors. Twenty-eight patients with sufficient hepatic function underwent treatment for the tumor, mainly chemoembolization, before transplantation. After liver transplantation, the patients were followed prospectively for a median of 26 months (range, 9 to 54), No anticancer treatment was given after transplantation. Results. The overall mortality rate was 17 percent. After four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent. Hepatocellular carcinoma recurred in four patients (8 percent). The overall and recurrence-free survival rates at four years among the 35 patients (73 percent of the total) who met the predetermined criteria for the selection of small hepatocellular carcinomas at pathological review of the explanted liver were 85 percent and 92 percent, respectively, whereas the rates in the 13 patients (27 percent) whose tumors exceeded these limits were 50 percent and 59 percent, respectively (P=0.01 for overall survival; P=0.002 for recurrence-free survival). In this group of 48 patients with early-stage tumors, tumor-node-metastasis status, the number of tumors, the serum alphafetoprotein concentration, treatment received before transplantation, and 10 other variables were not significantly correlated with survival. Conclusions. Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis.	NATL CANC INST,DEPT PATHOL,I-20133 MILAN,ITALY; NATL CANC INST,DEPT ANESTHESIA,I-20133 MILAN,ITALY; UNIV MILAN,INST MED STAT & BIOMETRY,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan			Regalia, Enrico/L-9933-2017; Mazzaferro, Vincenzo/C-2726-2017; Mazzaferro, Vincenzo/AAL-4707-2020	Regalia, Enrico/0000-0002-9528-5859; Mazzaferro, Vincenzo/0000-0002-4013-8085; 				BARBARA L, 1992, HEPATOLOGY, V16, P132, DOI 10.1002/hep.1840160122; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; *EUR LIV TRANSPL R, 1994, REP EUR LIV TRANSPL; HAUG CE, 1992, TRANSPLANTATION, V53, P376, DOI 10.1097/00007890-199202010-00021; HERMANEK P, 1987, TNM CLASSIFICATION M, P53; ISMAIL T, 1990, BRIT J SURG, V77, P983, DOI 10.1002/bjs.1800770908; IWATSUKI S, 1985, ANN SURG, V202, P401, DOI 10.1097/00000658-198510000-00001; IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAZZAFERRO V, 1994, TRANSPLANT P, V26, P3557; MORENO E, 1992, AM J SURG, V163, P395; OGRADY JG, 1988, ANN SURG, V207, P373, DOI 10.1097/00000658-198804000-00002; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; OKUDA K, 1991, OXFORD TXB CLIN HEPA, V2, P1019; OLTHOFF KM, 1990, ARCH SURG-CHICAGO, V125, P1261; PENN I, 1991, SURGERY, V110, P726; RINGE B, 1989, ANN SURG, V209, P88, DOI 10.1097/00000658-198901000-00013; RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064; SELBY R, 1995, WORLD J SURG, V19, P53, DOI 10.1007/BF00316980; SPREAFICO C, 1994, RADIOLOGY, V192, P687, DOI 10.1148/radiology.192.3.8058934; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1985, J PEDIATR-US, V106, P604, DOI 10.1016/S0022-3476(85)80081-0; STEVES MA, 1992, AM SURGEON, V58, P608; TAN KC, 1995, BRIT J SURG, V82, P253, DOI 10.1002/bjs.1800820239; TREY C, 1966, NEW ENGL J MED, V274, P473, DOI 10.1056/NEJM196603032740901; TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013; UTSUNOMIYA T, 1992, HEPATOLOGY, V16, P694, DOI 10.1002/hep.1840160313; YOKOYAMA I, 1990, HEPATO-GASTROENTEROL, V37, P188; YOKOYAMA I, 1991, CANCER, V68, P2095, DOI 10.1002/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y	33	5107	5360	7	438	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					693	699		10.1056/NEJM199603143341104	http://dx.doi.org/10.1056/NEJM199603143341104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594428	Bronze			2022-12-28	WOS:A1996TZ52800004
J	Rapola, JM; Virtamo, J; Haukka, JK; Heinonen, OP; Albanes, D; Taylor, PR; Huttunen, JK				Rapola, JM; Virtamo, J; Haukka, JK; Heinonen, OP; Albanes, D; Taylor, PR; Huttunen, JK			Effect of vitamin E and beta carotene on the incidence of angina pectoris - A randomized, double-blind, controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; DENSITY-LIPOPROTEIN; ROSE QUESTIONNAIRE; ALPHA-TOCOPHEROL; E CONSUMPTION; RISK; CHOLESTEROL; INHIBITION; HUMANS	Objective.-To examine the effect of supplementation with vitamin E (alpha tocopherol), beta carotene, or both on the incidence of angina pectoris in men without known previous coronary heart disease. Design.-Randomized, double-blind, placebo-controlled trial. Setting and Participants.-Participants in the Alpha Tocopherol, Beta Carotene Cancer Prevention Study (N=29 133) were male smokers aged 50 through 69 years who were living in southern and western Finland. Of these men, 22 269 were considered free of coronary heart disease at baseline and were followed up for the incidence of angina pectoris. Intervention.-Participants were randomized to receive 50 mg/d of alpha tocopherol, 20 mg/d of beta carotene, both, or placebo in a 2x2 design. Outcome Measures.-An incident case was defined as the first occurrence of typical angina pectoris identified in administering the annually repeated World Health Organization (Rose) Chest Pain Questionnaire. Results.-During a median follow-up time of 4.7 years (96 427 person-years), 1983 new cases of angina pectoris were detected. Comparing alpha tocopherol-supplemented subjects with non-alpha tocopherol-supplemented subjects showed a relative risk (RR) of angina pectoris incidence of 0.91 (95% confidence interval [CI], 0.83 to 0.99; P=.04). The RR for incidence of angina pectoris for the beta carotene-supplemented subjects compared with those not receiving beta carotene was 1.06 (95% CI, 0.97 to 1.16; P=.19). Compared with those receiving placebo, the RRs for incidence of angina pectoris were 0.97 (95% CI, 0.85 to 1.10) and 0.96 (95% CI, 0.85 to 1.09) in the alpha tocopherol and alpha tocopherol plus beta carotene groups respectively, and 1.13 (95% CI, 1.00 to 1.27) in the beta carotene group (P=.06). Baseline dietary intakes and serum levels of alpha tocopherol and beta carotene did not predict incidence of angina pectoris. Conclusions.-Supplementation with alpha tocopherol was associated with only a minor decrease in the incidence of angina pectoris. Beta carotene had no preventive effect and was associated with a slight increase in the incidence of angina.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rapola, JM (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.		Albanes, Demetrius/B-9749-2015; Haukka, Jari/G-1484-2014	Haukka, Jari/0000-0003-1450-6208	DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045165] Funding Source: NIH RePORTER; NCI NIH HHS [N0I-CN-45165] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKESON AL, 1991, ATHEROSCLEROSIS, V86, P261, DOI 10.1016/0021-9150(91)90222-O; ANDERSON TW, 1974, CAN MED ASSOC J, V110, P401; [Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1; BELLIZZI MC, 1994, EUR J CLIN NUTR, V48, P822; CHATELAIN E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P83, DOI 10.1016/0167-4889(93)90181-N; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ERIKSSEN J, 1976, CIRCULATION, V54, P371, DOI 10.1161/01.CIR.54.3.371; FLEISS JL, 1973, STATISTICAL METHODS, P130; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; GAZIANO JM, 1990, CIRCULATION, V82, P201; GAZIANO JM, 1995, ATHEROSCLEROSIS, V112, P187, DOI 10.1016/0021-9150(94)05414-E; GAZIANO JM, 1993, ANN NY ACAD SCI, V691, P148, DOI 10.1111/j.1749-6632.1993.tb26166.x; Gey K. Fred, 1993, American Journal of Clinical Nutrition, V57, p787S, DOI 10.1093/ajcn/57.5.787S; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; GILLILAN RE, 1977, AM HEART J, V93, P444, DOI 10.1016/S0002-8703(77)80406-7; HENSE HW, 1993, ATHEROSCLEROSIS, V103, P21, DOI 10.1016/0021-9150(93)90036-T; HEYDEN S, 1971, ARCH INTERN MED, V128, P961, DOI 10.1001/archinte.128.6.961; JIALAL I, 1993, CIRCULATION, V88, P2780, DOI 10.1161/01.CIR.88.6.2780; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; JIALAL I, 1991, BIOCHIM BIOPHYS ACTA, V1086, P134, DOI 10.1016/0005-2760(91)90164-D; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; KOSTNER GM, 1976, CLIN CHEM, V22, P695; MILNE DB, 1986, CLIN CHEM, V32, P874; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; PIETINEN P, 1988, AM J EPIDEMIOL, V128, P655, DOI 10.1093/oxfordjournals.aje.a115013; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; REAVEN PD, 1994, ARTERIOSCLER THROMB, V14, P1162, DOI 10.1161/01.ATV.14.7.1162; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; REUNANEN A, 1983, SOCIAL INSURANCE I C; REUNANEN A, 1977, PREVALENCE PROGRNOSI, P8; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1971, BRIT J PREV SOC MED, V25, P94; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; ROSE GA, 1965, MILBANK FUND Q, V43, P32, DOI 10.2307/3348873; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1991, J AM COLL NUTR, V10, P466; STREET DA, 1994, CIRCULATION, V90, P1154, DOI 10.1161/01.CIR.90.3.1154; ZEINERHENRIKSEN T, 1972, J CHRON DIS, V25, P407, DOI 10.1016/0021-9681(72)90033-1; 1989, RECOMMENDED DIETARY; 1994, NEW ENGL J MED, V330, P1029	46	169	175	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					693	698		10.1001/jama.275.9.693	http://dx.doi.org/10.1001/jama.275.9.693			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594266				2022-12-28	WOS:A1996TX17400024
J	Bailey, CJ; Turner, RC				Bailey, CJ; Turner, RC			Drug therapy - Metformin	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INSULIN-INDUCED TRANSLOCATION; DEPENDENT DIABETES-MELLITUS; RAT ADIPOCYTES; CARDIOVASCULAR-DISEASE; GLUCOSE TRANSPORTERS; INTRACELLULAR POOL; PLASMA-MEMBRANE; LACTIC-ACIDOSIS; NIDDM; RESISTANCE		RADCLIFFE INFIRM, DIABET RES LABS, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford	Bailey, CJ (corresponding author), UNIV ASTON, DEPT PHARMACEUT & BIOL SCI, ASTON TRIANGLE, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND.							[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, BMJ, V310, P83; [Anonymous], 1994, Diabetes Care, V17, P616; BAILEY CJ, 1993, GEN PHARMACOL, V24, P1299, DOI 10.1016/0306-3623(93)90411-P; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; BAILEY CJ, 1986, DIABETES METAB, V12, P212; BAILEY CJ, 1989, DIABETES CARE, V12, P553, DOI 10.2337/diacare.12.8.553; BAILEY CJ, 1988, BAILLIERE CLIN ENDOC, V2, P455, DOI 10.1016/S0950-351X(88)80043-0; BAILEY CJ, 1992, DIABETIC MED, V9, P482, DOI 10.1111/j.1464-5491.1992.tb01822.x; BAILEY CJ, 1992, BRIT J PHARMACOL, V105, P1009, DOI 10.1111/j.1476-5381.1992.tb09093.x; Beckmann R., 1971, ORAL WIRKSAME ANTIDI, P439, DOI [10.1007/978-3-642-65265-3_8, DOI 10.1007/978-3-642-65265-3_8]; BOYD K, 1992, DIABETES RES CLIN EX, V19, P69; CAMPBELL IW, 1984, BRIT MED J, V289, P289, DOI 10.1136/bmj.289.6440.289; CIGOLINI M, 1984, DIABETES METAB, V10, P311; CLARKE BF, 1977, BRIT MED J, V2, P1576, DOI 10.1136/bmj.2.6102.1576; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; DANDONA P, 1983, DIABETES CARE, V6, P472, DOI 10.2337/diacare.6.5.472; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; GALUSKA D, 1994, DIABETOLOGIA, V37, P826, DOI 10.1007/BF00404340; GAN SC, 1992, ARCH INTERN MED, V152, P2333, DOI 10.1001/archinte.152.11.2333; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GRANT PJ, 1991, DIABETIC MED, V8, P361, DOI 10.1111/j.1464-5491.1991.tb01610.x; GROOP L, 1989, DIABETOLOGIA, V32, P599; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HERMANN LS, 1990, DIABETES CARE, V13, P37, DOI 10.2337/diacare.13.3.37; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; Hermann LS, 1992, INT TXB DIABETES MEL, V1, P773; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; JACKSON RA, 1987, DIABETES, V36, P632, DOI 10.2337/diabetes.36.5.632; KOZKA IJ, 1993, DIABETES, V42, P1159, DOI 10.2337/diabetes.42.8.1159; KRENTZ AJ, 1994, DRUG SAFETY, V11, P223, DOI 10.2165/00002018-199411040-00002; LALAU JD, 1989, INT J CLIN PHARM TH, V27, P285; MATTHAEI S, 1991, DIABETES, V40, P850, DOI 10.2337/diabetes.40.7.850; MATTHAEI S, 1993, ENDOCRINOLOGY, V133, P304, DOI 10.1210/en.133.1.304; MEINERT CL, 1970, DIABETES, V19, P789; MELIN B, 1990, METABOLISM, V39, P1089, DOI 10.1016/0026-0495(90)90171-8; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NATTRASS M, 1978, DIABETOLOGIA, V14, P71, DOI 10.1007/BF01263443; OATES NS, 1983, CLIN PHARMACOL THER, V34, P827, DOI 10.1038/clpt.1983.257; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PANZRAM G, 1987, DIABETOLOGIA, V30, P364; PENICAUD L, 1989, BIOCHEM J, V262, P881, DOI 10.1042/bj2620881; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; REAVEN GM, 1992, J CLIN ENDOCR METAB, V74, P1020, DOI 10.1210/jc.74.5.1020; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICCIO A, 1991, DIABETES METAB, V17, P180; ROSSETTI L, 1990, METABOLISM, V39, P425, DOI 10.1016/0026-0495(90)90259-F; RUDENSKI AS, 1988, DIABETIC MED, V5, P36, DOI 10.1111/j.1464-5491.1988.tb00938.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SOMOGYI A, 1987, BRIT J CLIN PHARMACO, V23, P545, DOI 10.1111/j.1365-2125.1987.tb03090.x; Sterne J., 1969, ORAL HYPOGLYCEMIC AG, P193; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1	67	1527	1606	1	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					574	579		10.1056/NEJM199602293340906	http://dx.doi.org/10.1056/NEJM199602293340906			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569826				2022-12-28	WOS:A1996TW69600006
J	Nutting, PA; Main, DS; Fischer, PM; Stull, TM; Pontious, M; Seifert, M; Boone, DJ; Holcomb, S				Nutting, PA; Main, DS; Fischer, PM; Stull, TM; Pontious, M; Seifert, M; Boone, DJ; Holcomb, S			Problems in laboratory testing in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To examine the frequency and characteristics of problems in laboratory testing in primary care physicians' offices and their impact on health care. Design. - Prospective descriptive study in which participating office-based primary care clinicians reported each occurrence of any laboratory incident during a 6-month study. Each identified problem was reported on a structured data collection instrument with an open-ended description of the problem. Setting. - Primary care physicians' offices in North America. Participants. - One hundred twenty-four primary care clinicians in 49 practices of the Ambulatory Sentinel Practice Network (ASPN). Main Results. - A total of 180 problems were reported, yielding a crude rate of 1.1 problems per 1000 patient visits. Problems involving test ordering and specimen handling were the most common (56%), while those attributable to the test analysis itself accounted for 13% of the total. In the judgment of the practice staff, 27% of the reported problems had an impact on patient care. Of the 24 cases for which the specific impact was known and reported, half of the impacts were minor and about half were significant, as judged by whether or not the diagnosis and/or treatment of the patient was measurably affected. Conclusions. - Clinically apparent problems with laboratory testing in primary care were found at a rate of 1.1 problems per 1000 patient visits. Of the laboratory problems that occurred in this study, 27% were judged by the physician to have an effect on patient care.	CTR DIS CONTROL & PREVENT,DIV LAB SYST,PUBL HLTH PRACTICE PROGRAM,ATLANTA,GA 30341; UNIV COLORADO,HLTH SCI CTR,DEPT FAMILY MED,DENVER,CO; UNIV OKLAHOMA,DEPT FAMILY MED,ENID,OK	Centers for Disease Control & Prevention - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Oklahoma System; University of Oklahoma Health Sciences Center	Nutting, PA (corresponding author), ABULATORY SENTINEL PRACTICE NETWORK,1650 PIERCE ST,DENVER,CO 80214, USA.				PHS HHS [U47/CCU810643-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOONE DJ, 1992, ARCH PATHOL LAB MED, V116, P681; FERRIS DG, 1992, JAMA-J AM MED ASSOC, V268, P766; FINN AF, 1988, JAMA-J AM MED ASSOC, V259, P2549, DOI 10.1001/jama.259.17.2549; FISCHER PM, 1991, P 1989 CDC I CRIT IS, P1126; Green L A, 1988, Fam Med, V20, P185; Green L A, 1993, Arch Fam Med, V2, P939, DOI 10.1001/archfami.2.9.939; Green L A, 1988, Fam Med, V20, P182; HOWANITZ PJ, 1994, CAP TODAY        JUL, P41; ROSS JW, 1991, 1989 I CRITICAL ISSU; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V253; TUCKERMAN JF, 1985, COMPUT METH PROG BIO, V20, P103, DOI 10.1016/0169-2607(85)90050-1; 1988, 52477 SEN COMM LAB H	12	77	78	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					635	639		10.1001/jama.275.8.635	http://dx.doi.org/10.1001/jama.275.8.635			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594246				2022-12-28	WOS:A1996TW62700025
J	Levitt, MD; Furne, J; Olsson, S				Levitt, MD; Furne, J; Olsson, S			The relation of passage of gas and abdominal bloating to colonic gas production	ANNALS OF INTERNAL MEDICINE			English	Article							CARBOHYDRATE	Objective: To determine the relation of gas passage and abdominal bloating to the production of gas in the colon. Design: Randomized, double-blind, crossover study of gaseous symptoms during a 1-week period. Setting: A Veterans Affairs medical center. Participants: 25 healthy medical center employees. Intervention: Participants' diets were supplemented with either a placebo (10 g of lactulose, a nonabsorbable sugar), psyllium (a fermentable fiber), or methylcellulose (a nonfermentable fiber). Measurements: All participants were polled for gaseous symptoms (including number of gas passages, impression of increased rectal gas, and abdominal bloating), and five were examined for breath hydrogen excretion. Results: Participants passed gas 10 +/- 5.0 times per day (mean +/- SD) during the placebo period. A significant increase in gas passages (to 19 +/- 12 times per day) and a subjective impression of increased rectal gas were reported with lactulose but not with either of the two fiber preparations. Breath hydrogen excretion, an indicator of hydrogen production in the colon, did not increase after ingestion of either of the fibers. However, a statistically significant (P < 0.05) increase in feelings of abdominal bloating (which the participants perceived as excessive gas in the bower) was reported with both fiber preparations and with lactulose. Conclusions: The physician should distinguish between excessive rectal gas (which indicates excessive gas production) and feelings of bloating (which are usually unrelated to excessive gas production). Treatment of the former consists of limiting the supply of fermentable material to the colonic bacteria, Symptoms of bloating usually indicate the irritable bowel syndrome, and therapy should be directed accordingly.			Levitt, MD (corresponding author), VET AFFAIRS MED CTR, RES SERV 151, 1 VET DR, MINNEAPOLIS, MN 55417 USA.				NIDDK NIH HHS [R01 DK 13309-25] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013309] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOND JH, 1972, J CLIN INVEST, V51, P1219, DOI 10.1172/JCI106916; CHRISTL SU, 1992, GASTROENTEROLOGY, V102, P1269; LASSER RB, 1975, NEW ENGL J MED, V293, P524, DOI 10.1056/NEJM197509112931103; LEVITT MD, 1976, NEW ENGL J MED, V295, P260, DOI 10.1056/NEJM197607292950507; LEVITT MD, 1974, J LAB CLIN MED, V84, P163; STEGGERDA FR, 1968, ANN NY ACAD SCI, V150, P57, DOI 10.1111/j.1749-6632.1968.tb19031.x; STROCCHI A, 1993, GASTROENTEROLOGY, V105, P1404, DOI 10.1016/0016-5085(93)90145-3; TOMLIN J, 1991, GUT, V32, P665, DOI 10.1136/gut.32.6.665	9	65	66	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					422	424		10.7326/0003-4819-124-4-199602150-00006	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554251				2022-12-28	WOS:A1996TV22000006
J	Swartz, K; Brennan, TA				Swartz, K; Brennan, TA			Integrated health care, capitated payment, and quality: The role of regulation	ANNALS OF INTERNAL MEDICINE			English	Article							FINANCIAL INCENTIVES; PHYSICIANS; HMOS	Concerns about the effect of managed care techniques on the quality of medical care have been raised in many quarters. Physicians have advocated the reiteration of professional ethics or even the prohibition of market incentives in health care as solutions to the problem of cost-quality tradeoffs in managed care systems. However, few recognize the existing systems for the regulation of managed care or consider how additional regulation could alleviate some of the potential problems posed by market-based competition. We review the evolution and growth of managed care organizations and the payment techniques that could cause a conflict between patient welfare and physician income. We then discuss the existing types of federal and state regulation of managed care and suggest some new incentives that could buttress the ethical practice of medicine in the medical marketplace.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health								Angell M, 1993, Kennedy Inst Ethics J, V3, P279; BRENNAN TA, 1995, REGULATING IMPROVEME; Burns L R, 1993, Health Care Manage Rev, V18, P7; CHIRBAMARTIN MA, 1994, HEALTH AFFAIR, V13, P142, DOI 10.1377/hlthaff.13.2.142; CLANCY CM, 1995, JAMA-J AM MED ASSOC, V273, P338, DOI 10.1001/jama.273.4.338; CLARK RC, 1980, HARVARD LAW REV, V93, P1416, DOI 10.2307/1340606; CORCORAN JD, 1993, NGMJ             JUL, P15; COSTOLITZ J, 1993, NATIONAL J, V25, P2704; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; HALL MA, 1994, WAKE FOREST LAW REV, V24, P1; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HIGGINS DB, 1993, HLTH LAW REPORTER, V2, P586; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; INGELHART JK, 1994, NEW ENGL J MED, V331, P63; JOHNSSON J, 1994, AM MED NEWS     1212, P36; JOHNSSON J, 1994, AM MED NEWS     1024, P1; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; LAPUMA J, 1993, MANAGED CARE SURVIVA; MEYER H, 1995, AM MED NEWS     0123, P9; MICK SS, 1988, HOSP HEALTH SERV ADM, V33, P345; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Morreim E. H., 1991, BALANCING ACT NEW ME; Newhouse JP, 1993, FREE ALL LESSONS RAN; PHILBIN PW, 1993, HOSPITALS HLTH  0605; REIMAN AS, 1987, NEW ENGL J MED, V316, P1150; Rodwin M. A., 1993, MED MONEY MORALS PHY; Sharrott D, 1992, BROOK L REV, V58, P85; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; WELCH WP, 1990, MILBANK Q, V68, P221, DOI 10.2307/3350097; ZABLOCKI E, 1992, HMO MAGAZINE     JUL, P48; 1994, FED REGISTER, V53, P4601; 1994, J HLTH CARE PERFORMA, V1, P8; 1993, HLTH PLAN EMPLOYER D; 1996, JAMA-J AM MED ASSOC, V273, P330	39	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					442	448		10.7326/0003-4819-124-4-199602150-00009	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554254				2022-12-28	WOS:A1996TV22000009
J	Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV				Davie, AP; Francis, CM; Love, MP; Caruana, L; Starkey, IR; Shaw, TRD; Sutherland, GR; McMurray, JJV			Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; FRANCIS CM, 1995, BRIT MED J, V310, P634, DOI 10.1136/bmj.310.6980.634; MACALLAN DC, 1990, J ROY SOC MED, V83, P559, DOI 10.1177/014107689008300909; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; WHEELDON NM, 1993, Q J MED, V86, P17	5	185	189	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					222	222						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563589				2022-12-28	WOS:A1996TT48600029
J	Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA				Margossian, SP; Li, HL; Zassenhaus, HP; Butow, RA			The DExH box protein Suv3p is a component of a yeast mitochondrial 3'-to-5' exoribonuclease that suppresses group I intron toxicity	CELL			English	Article							CONSERVED DODECAMER SEQUENCE; TETRAHYMENA-THERMOPHILA RIBOZYME; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL PROCESSES; KINETIC DESCRIPTION; ENCODED PROTEIN; MESSENGER-RNAS; ACTIVE-SITE; GENE; PURIFICATION	The yeast mitochondrial protein Suv3p is a putative NTP-dependent RNA helicase. Here we report that in cells lacking Suv3p, there is an similar to 50-fold increase in the excised form of the group I intron omega of the mitochondrial 21S rRNA gene. Surprisingly, little mature 21S rRNA accumulates in those cells; instead, unligated 21S rRNA exons appear. Intron overaccumulation could lead to spliced exon reopening via a reaction known to be catalyzed by group I introns in vitro. We also show that Suv3p is a functional component of a novel mitochondrial NTP-dependent 3'-to-5' exoribonuclease activity that can degrade group I intron RNAs. These findings account for group I intron overaccumulation in cells lacking Suv3p and define a novel function for putative RNA helicases in direct RNA degradation.	ST LOUIS UNIV, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, ST LOUIS, MO 63104 USA	Saint Louis University	Margossian, SP (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM22525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; CONRAD H, 1987, THESIS OHIO STATE U; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; DAKE E, 1988, J BIOL CHEM, V263, P7691; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOCKER J, 1981, PLASMID, V6, P302, DOI 10.1016/0147-619X(81)90038-X; MAHESHWARI KK, 1984, BIOCHIM BIOPHYS ACTA, V781, P153, DOI 10.1016/0167-4781(84)90133-7; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; OSINGA KA, 1984, EMBO J, V3, P829, DOI 10.1002/j.1460-2075.1984.tb01892.x; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; ROSE MD, 1988, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEPIEN PP, 1995, CURR GENET, V27, P234, DOI 10.1007/BF00326154; TABAK HF, 1984, CELL, V39, P623, DOI 10.1016/0092-8674(84)90469-0; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VONTIGERSTROM RG, 1982, BIOCHEMISTRY-US, V21, P6397, DOI 10.1021/bi00268a012; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZHU H, 1987, MOL CELL BIOL, V7, P2530, DOI 10.1128/MCB.7.7.2530; ZHU H, 1989, MOL CELL BIOL, V9, P1507, DOI 10.1128/MCB.9.4.1507	44	102	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					199	209		10.1016/S0092-8674(00)80975-7	http://dx.doi.org/10.1016/S0092-8674(00)80975-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565066	Bronze			2022-12-28	WOS:A1996TR59500007
J	Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC				Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC			Pregnancy termination in relation to risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FULL TERM PREGNANCY; REPRODUCTIVE FACTORS; SPONTANEOUS-ABORTION; WOMEN; PROGESTERONE; INCREASE	Objective. - To evaluate the association between pregnancy terminations and of breast cancer. Design and Setting. - Population-based case-control study in Wisconsin, Massachusetts, Maine, and New Hampshire. Study Participants. - Cases were women younger than 75 years with a new diagnosis of breast cancer (n=6888), identified from statewide tumor registries. Controls younger than 65 years (n=9529) were randomly selected from lists of licensed drivers, or for older subjects, from lists of Medicare beneficiaries. Exposures and Outcomes. - Breast cancer risk in relation to spontaneous or induced abortions. Results.- After adjustment for parity, age at first birth, and other risk factors, pregnancy termination (induced or spontaneous) was associated with a relative risk (RR) of breast cancer of 1.12 (95% confidence interval [CI], 1.04 to 1.21), compared with the risk among women who had never had a termination, Induced terminations were associated with a RR of 1.23 (95% CI, 1.00 to 1.51), which was somewhat greater than the risk associated with spontaneous terminations (RR, 1.21, 95% CI, 1.02 to 1.20). The association with induced abortions was stronger for those performed before legalization of abortion in 1973 (RR, 1.35; 95% CI, 1.01 to 1.80) than after this time (RR, 1.12; 95% CI, 0.84 to 1.49), suggesting a bias in reporting this sensitive procedure. Conclusions. - A weak positive association was observed between abortion-whether induced or spontaneous - and risk of breast cancer. The increase in risk of breast cancer was somewhat greater among women with a history of induced terminations. However, this association may be due to reporting bias and was not significantly different than the slight risk for spontaneous terminations.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA; UNIV CHICAGO, CHICAGO LYING IN HOSP, DEPT OBSTET & GYNECOL, CHICAGO, IL USA; DARTMOUTH HITCHCOCK MED SCH, NORRIS COTTON CANC CTR, HANOVER, NH USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Fred Hutchinson Cancer Center; University of California System; University of California Los Angeles; University of Chicago; Dartmouth College; Norris Cotton Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Newcomb, RA (corresponding author), UNIV WISCONSIN, CTR COMPREHENS CANC, MED SCI CTR, ROOM 4780, 1300 UNIV AVE, MADISON, WI 53706 USA.			Longnecker, Matthew/0000-0001-6073-5322	NCI NIH HHS [CA 47305, CA 47147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047147, R01CA047305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; ANDERSON BA, 1994, DEMOGRAPHY, V31, P115, DOI 10.2307/2061911; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; CALLE EE, 1995, CANCER CAUSE CONTROL, V6, P460, DOI 10.1007/BF00052187; CUMMINGS P, 1994, BRIT MED J, V308, P1672, DOI 10.1136/bmj.308.6945.1672; CUNNINGHAM DS, 1993, J REPROD MED, V38, P301; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; HELMRICH SP, 1983, AM J EPIDEMIOL, V117, P35, DOI 10.1093/oxfordjournals.aje.a113513; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; KRIEGER N, 1989, BREAST CANCER RES TR, V13, P205, DOI 10.1007/BF02106571; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P347, DOI 10.1093/ije/16.3.347; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; LONGNECKER MP, 1992, EPIDEMIOLOGY, V3, P535, DOI 10.1097/00001648-199211000-00014; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MICHELS KB, 1995, CANCER CAUSE CONTROL, V6, P75, DOI 10.1007/BF00051683; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; Rebar RW, 1994, MATERNAL FETAL MED P, P144; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SELLERS TA, 1993, CANCER CAUSE CONTROL, V4, P21, DOI 10.1007/BF00051710; TALAMINI R, 1985, AM J EPIDEMIOL, V4, P70; VESSEY MP, 1982, BRIT J CANCER, V45, P327, DOI 10.1038/bjc.1982.58; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WITT BR, 1990, FERTIL STERIL, V53, P1029; 1977, MANUAL INT CLASSIFIC	43	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					283	287						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544267				2022-12-28	WOS:A1996TP96500023
J	Mathews, D				Mathews, D			The semantics of pressure	LANCET			English	Editorial Material							BLOOD-PRESSURE; PREGNANCY				Mathews, D (corresponding author), ALL ST HOSP,CHATHAM,KENT,ENGLAND.							BROWN MA, 1991, BRIT MED J, V303, P120, DOI 10.1136/bmj.303.6794.120-d; CHAMBERLAIN GVP, 1978, BRIT MED J, V1, P626, DOI 10.1136/bmj.1.6113.626; PERRY I, 1991, BRIT MED J, V302, P179, DOI 10.1136/bmj.302.6769.179-e; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; RAFTERY EB, 1968, CARDIOVASC RES, V2, P210, DOI 10.1093/cvr/2.2.210; TERVILA L, 1973, ACTA OBSTET GYN SCAN, V52, P235, DOI 10.3109/00016347309158320; THEOBALD GW, 1955, PREGNANCY TOXAEMIAS, P419; 1990, AM J OBSTET GYNECOL, V163, P1689	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					135	136		10.1016/S0140-6736(96)90334-7	http://dx.doi.org/10.1016/S0140-6736(96)90334-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544542	Bronze			2022-12-28	WOS:A1996TQ24400003
J	Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R				Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R			A genetic test of the effects of mutations in PKA on mossy fiber LTP and its relation to spatial and contextual learning	CELL			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; HIPPOCAMPAL-FORMATION; ANATOMICAL DATA; MUTANT MICE; MEMORY; RAT; ORGANIZATION; LOCALIZATION; ENHANCEMENT	Using a genetic approach, we assessed the effects of mutations in protein kinase A (PKA) on long-term potentiation (LTP) in the messy fiber pathway and its relationship to spatial and contextual learning. Ablation by gene targeting of the C beta(1) or the RI beta isoform of PKA produces a selective defect in messy fiber LTP, providing genetic evidence for the role of these isoforms in the messy fiber pathway. Despite the elimination of messy fiber LTP, the behavioral responses to novelty, spatial learning, and conditioning to context are unaffected. Thus, contrary to current theories about hippocampal function, messy fiber LTP does not appear to be required for spatial or contextual learning. In the absence of messy fiber LTP, adequate spatial and contextual information might reach the CA1 region via other pathways from the entorhinal cortex.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	Columbia University; University of Washington; University of Washington Seattle	Huang, YY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BACH ME, 1995, CELL, V81, P905; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BERGER TW, 1991, LONG TERM POTENTIATI, P327; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CRUSIO WE, 1989, BEHAV BRAIN RES, V32, P81, DOI 10.1016/S0166-4328(89)80075-0; DOUGLAS RJ, 1969, J COMP PHYSIOL PSYCH, V69, P473, DOI 10.1037/h0028163; DOUGLAS RJ, 1990, SPONTANEOUS ALTERNAT, P73; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLM IE, 1991, J COMP NEUROL, V308, P409, DOI 10.1002/cne.903080308; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Huang Y Y, 1994, Learn Mem, V1, P74; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; HUANG YY, 1994, LEARN MEMORY, V79, P69; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JARRARD LE, 1976, J COMP PHYSIOL PSYCH, V90, P1035, DOI 10.1037/h0078659; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; JONES B, 1972, EXP NEUROL, V36, P362, DOI 10.1016/0014-4886(72)90030-1; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1989, NEUROSCIENCE, V9, P3040; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHWEGLER H, 1988, BEHAV GENET, V18, P153, DOI 10.1007/BF01067837; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SPENCER WA, 1962, PHYSL HIPPOCAMPE, P71; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SWANSON LW, 1982, NEUROSCI RES PROG B, V20, P613; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; YECKEL MF, 1995, HIPPOCAMPUS, V5, P108, DOI 10.1002/hipo.450050204; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	52	219	222	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1211	1222		10.1016/0092-8674(95)90146-9	http://dx.doi.org/10.1016/0092-8674(95)90146-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548807	Bronze			2022-12-28	WOS:A1995TM76200016
J	Davies, S; Thornicroft, G; Leese, M; Higgingbotham, A; Phelan, M				Davies, S; Thornicroft, G; Leese, M; Higgingbotham, A; Phelan, M			Ethnic differences in risk of compulsory psychiatric admission among representative cases of psychosis in London	BRITISH MEDICAL JOURNAL			English	Article							AFRO-CARIBBEAN PATIENTS; SEVERE MENTAL DISORDER; HOSPITAL ADMISSIONS; SCHIZOPHRENIA; CAMBERWELL; DETENTION; BRISTOL; ILLNESS; ASIANS	Objective-To compare the risk of detention under the Mental Health Act 1983 in a representative group of people with psychotic disorders from different ethnic groups. Setting-Two defined geographical areas in south London. Design-Annual period prevalent cases of psychosis were identified in 1993 in the study areas from hospital and community data. Standardised criteria were applied to case notes to establish diagnosis and detention under the act. Subjects-535 patients were identified, of whom 439 fulfilled ICD-10 criteria for psychosis. Main outcome measures-Risk of ever having been detained under the Mental Health Act 1983, risk of detention under specific sections of the act during the study year, and risk of contact with forensic services for the different ethnic groups. Results-439 patients with a psychotic illness were identified. Nearly half of the white patients had been detained under the act compared with 70% and 69% of black Caribbean and black African patients, respectively. Black Caribbean and black African patients were more likely than white patients to have been involuntarily detained (adjusted odds ratio 3.67; 95% confidence interval 2.07 to 6.50 and 2.88; 1.04 to 7.95, respectively). Rates of use of sections 2, 3, and 136 in the study year were higher for black than for white patients, and black patients were more likely than white patients to have been admitted to a psychiatric intensive care facility or prison. Conclusion-Independent of psychiatric diagnosis and sociodemographic differences. black African and black Caribbean patients with psychosis in south London were more likely than white patients to have ever been detained under the Mental Health Act 1983.			Davies, S (corresponding author), INST PSYCHIAT,PSYCHIAT RES SERV MEASUREMENT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010; Leese, Morven N/E-4195-2010	Thornicroft, Graham/0000-0003-0662-0879; 				Audit Commission, 1994, FIND PLAC REV MENT H; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; BEBBINGTON PE, 1994, BRIT J PSYCHIAT, V165, P743, DOI 10.1192/bjp.165.6.743; BEBBINGTON PE, 1981, SOC PSYCHIATR, V16, P43, DOI 10.1007/BF00578068; CASTLE D, 1991, BRIT J PSYCHIAT, V159, P790, DOI 10.1192/bjp.159.6.790; Dale A, 1993, 1991 CENSUS USERS GU; FULOP N, 1995, ONE DAY CENSUS ADULT; HARRISON G, 1984, BRIT J PSYCHIAT, V145, P605, DOI 10.1192/bjp.145.6.605; HARRISON G, 1988, PSYCHOL MED, V18, P643, DOI 10.1017/S0033291700008321; HARRISON G, 1989, PSYCHOL MED, V19, P683, DOI 10.1017/S0033291700024284; Ineichen B, 1991, Int J Soc Psychiatry, V37, P227, DOI 10.1177/002076409103700401; INEICHEN B, 1990, BRIT MED J, V300, P1669, DOI 10.1136/bmj.300.6741.1669; INEICHEN B, 1984, BRIT J PSYCHIAT, V145, P600, DOI 10.1192/bjp.145.6.600; KING M, 1994, BMJ-BRIT MED J, V309, P1115, DOI 10.1136/bmj.309.6962.1115; LITTLEWOOD R, 1981, PSYCHOL MED, V11, P303, DOI 10.1017/S0033291700052120; LITTLEWOOD R, 1985, PSYCHIAT B, V10, P306; LONDON M, 1986, BRIT J PSYCHIAT, V149, P265, DOI 10.1192/bjp.149.3.265; MCGOVERN D, 1991, SOC PSYCH PSYCH EPID, V26, P95, DOI 10.1007/BF00791535; MCGOVERN D, 1987, BRIT J PSYCHIAT, V150, P505, DOI 10.1192/bjp.150.4.505; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MCKENZIE K, IN PRESS BMJ; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; MOODLEY P, 1988, MED SCI LAW, V28, P324, DOI 10.1177/002580248802800412; OWENS D, 1991, PSYCHOL MED, V21, P185, DOI 10.1017/S003329170001477X; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; SZMUKLER GI, 1981, PSYCHOL MED, V11, P617, DOI 10.1017/S0033291700052909; THOMAS CS, 1993, BRIT J PSYCHIAT, V163, P91, DOI 10.1192/bjp.163.1.91; TURNER TH, 1992, PSYCHOL MED, V22, P765, DOI 10.1017/S0033291700038204; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458; WESSELY S, 1991, BRIT J PSYCHIAT, V159, P795, DOI 10.1192/bjp.159.6.795; World Health Organization, 1992, 10 REV INT CLASS DIS	31	115	115	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					533	537		10.1136/bmj.312.7030.533	http://dx.doi.org/10.1136/bmj.312.7030.533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TY885	8595280	Green Published			2022-12-28	WOS:A1996TY88500020
J	Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL				Quinn, J; Fyrberg, AM; Ganster, RW; Schmidt, MC; Peterson, CL			DNA-binding properties of the yeast SWI/SNF complex	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATOR; CRUCIFORM DNA; PROTEIN; GENES; ENHANCERS; HMG1	The SWI/SNF complex is required for the enhancement of transcription by many transcriptional activators in yeast(1,2) Genetic and biochemical studies indicate that the complex facilitates activator function by antagonizing chromatin-mediated transcriptional repression(3-6). The absence of known DNA-binding motifs in several SWI/SNF subunits and the failure to identify SWI/SNF-dependent DNA-binding activities in crude yeast extracts have led to the belief that the complex does not bind DNA(7,8). Here we show that the SWI/SNF complex has a high affinity for DNA and that its DNA-binding properties are similar to those of proteins containing HMG-box domains(9). The complex interacts with the minor groove of the DNA helix, binds synthetic four-way junction DNA, and introduces positive supercoils into relaxed plasmid DNA. These properties are likely to be important in the remodelling of chromatin structure by the SWI/SNF complex.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Janet/AAR-9957-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049650, R37 GM049650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CAIMS BR, 1994, P NATL ACAD SCI USA, V91, P1950; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HIRSCHHORN JN, 1992, GENE DEV, V6, P228; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; PETERSON CL, 1988, MOL CELL BIOL, V8, P4972, DOI 10.1128/MCB.8.11.4972; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TREICH I, 1995, MOL CELL BIOL, V15, P4240; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEMER MH, 1995, CELL, V81, P705; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	27	176	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					844	847		10.1038/379844a0	http://dx.doi.org/10.1038/379844a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587611				2022-12-28	WOS:A1996TX50100064
J	Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR				Hinchey, J; Chaves, C; Appignani, B; Breen, J; Pao, L; Wang, A; Pessin, MS; Lamy, C; Mas, JL; Caplan, LR			A reversible posterior leukoencephalopathy syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVOUS-SYSTEM TOXICITY; BONE-MARROW TRANSPLANTATION; HUMAN-ENDOTHELIAL-CELLS; WHITE-MATTER LESIONS; HYPERTENSIVE ENCEPHALOPATHY; LIVER-TRANSPLANTATION; CORTICAL BLINDNESS; RENAL ARTERIOPATHY; CYCLOSPORINE; ECLAMPSIA	Background and Methods. In some patients who are hospitalized for acute illness, we have noted a reversible syndrome of headache, altered mental functioning, seizures, and loss of vision associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies, To elucidate this syndrome, we searched the log books listing computed tomographic (CT) and magnetic resonance imaging (MRI) studies performed at the New England Medical Center in Boston and Hopital Sainte Anne in Paris; we found 15 such patients who were evaluated from 1988 through 1994. Results. Of the 15 patients, 7 were receiving immunosuppressive therapy after transplantation or as treatment for aplastic anemia, 1 was receiving interferon for melanoma, 3 had eclampsia, and 4 had acute hypertensive encephalopathy associated with renal disease (2 with lupus nephritis, 1 with acute glomerulonephritis, and 1 with acetaminophen-induced hepatorenal failure), Altogether, 12 patients had abrupt increases in blood pressure, and 8 had some impairment of renal function. The clinical findings included headaches, vomiting, confusion, seizures, cortical blindness and other visual abnormalities, and motor signs, CT and MRI studies showed extensive bilateral white-matter abnormalities suggestive of edema in the posterior regions of the cerebral hemispheres, but the changes often involved other cerebral areas, the brain stem, or the cerebellum. The patients were treated with antihypertensive medications, and immunosuppressive therapy was withdrawn or the dose was reduced, In all 15 patients, the neurologic deficits resolved within two weeks. Conclusions. Reversible, predominantly posterior leukoencephalopathy may develop in patients who have renal insufficiency or hypertension or who are immunosuppressed, The findings on neuroimaging are characteristic of subcortical edema without infarction. (C) 1996, Massachusetts Medical Society.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT NEUROL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HOP ST ANNE, SERV NEUROL, F-75674 PARIS, FRANCE	Tufts Medical Center; Tufts University; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite								ABUELMAGD KM, 1991, TRANSPLANT P, V23, P3190; ANTONOVYCH TT, 1988, TRANSPL P, V20, P951; BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BHATT BD, 1988, NEW ENGL J MED, V318, P788; BROWN Z, 1987, TRANSPLANT P, V19, P1178; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; BYROM FB, 1954, LANCET, V2, P201; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; COHEN RB, 1993, ANN INTERN MED, V118, P114, DOI 10.7326/0003-4819-118-2-199301150-00007; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; DEGROEN PC, 1988, NEW ENGL J MED, V318, P789; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DEKLIPPEL N, 1992, LANCET, V339, P1114, DOI 10.1016/0140-6736(92)90707-A; DIGRE KB, 1993, ARCH NEUROL-CHICAGO, V50, P399, DOI 10.1001/archneur.1993.00540040055015; DINSDALE HB, 1971, EUR NEUROL, V6, P29, DOI 10.1159/000114461; DINSDALE HB, 1974, ARCH NEUROL-CHICAGO, V31, P80, DOI 10.1001/archneur.1974.00490380028002; DONALDSON JO, 1993, LANCET, V342, P504; DONALDSON JO, 1993, LANCET, V341, P1447; DUNCAN R, 1989, J NEUROL NEUROSUR PS, V52, P899, DOI 10.1136/jnnp.52.7.899; EIDELMAN BH, 1991, TRANSPLANT P, V23, P3175; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; FOGO A, 1990, TRANSPLANTATION, V49, P1190, DOI 10.1097/00007890-199006000-00038; FREISE CE, 1991, TRANSPLANT P, V23, P3173; GOTTRAND F, 1991, NEW ENGL J MED, V324, P1744; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; HERZOG TJ, 1990, OBSTET GYNECOL, V76, P980; HOLLER E, 1989, BLOOD, V73, P2018; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; HUMPHREYS TR, 1993, J AM ACAD DERMATOL, V29, P490, DOI 10.1016/S0190-9622(08)82005-1; IGARASHI T, 1994, ANN RHEUM DIS, V53, P350, DOI 10.1136/ard.53.5.350; JACOBS BC, 1992, MAGNETIC RESONANCE I, P636; JOHANSSON BB, 1983, ACTA MED SCAND, P107; KUPFERSCHMIDT H, 1995, ANN INTERN MED, V123, P598, DOI 10.7326/0003-4819-123-8-199510150-00006; MERIMSKY O, 1992, ANTI-CANCER DRUG, V3, P567, DOI 10.1097/00001813-199212000-00002; MOUTABARRIK A, 1991, TRANSPLANT P, V23, P3137; MUELLER AR, 1994, TRANSPLANTATION, V58, P155, DOI 10.1097/00007890-199407270-00006; RAPS EC, 1993, ANN NEUROL, V33, P222, DOI 10.1002/ana.410330215; RAROQUE HG, 1990, NEUROLOGY, V40, P167, DOI 10.1212/WNL.40.1.167; REMUZZI G, 1989, AM J KIDNEY DIS, V13, P261, DOI 10.1016/S0272-6386(89)80032-0; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; RUBIN AM, 1987, NEUROLOGY, V37, P1072, DOI 10.1212/WNL.37.6.1072; SANDERS TG, 1991, RADIOLOGY, V180, P475, DOI 10.1148/radiology.180.2.2068315; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P379, DOI 10.2214/ajr.159.2.1632361; Sheth RD, 1996, EUR NEUROL, V36, P25, DOI 10.1159/000117195; SHUTTER LA, 1993, NEUROLOGY, V43, P2417, DOI 10.1212/WNL.43.11.2417; SIBAI BM, 1980, OBSTET GYNECOL, V55, P74; SLOANE JP, 1985, LANCET, V2, P280; SOMMER BG, 1986, TRANSPLANT P, V18, P151; SOMMER BG, 1985, AM J SURG, V149, P756, DOI 10.1016/S0002-9610(85)80181-1; STEIN DP, 1992, ANN NEUROL, V31, P644, DOI 10.1002/ana.410310612; TOLLEMAR J, 1988, NEW ENGL J MED, V318, P788; TROMMER BL, 1988, STROKE, V19, P326, DOI 10.1161/01.STR.19.3.326; TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651; VAUGHN DJ, 1993, AM J NEURORADIOL, V14, P1014; VERBEKE M, 1994, CARDIOVASC RES, V28, P1152, DOI 10.1093/cvr/28.8.1152; WEINGARTEN K, 1994, AM J ROENTGENOL, V162, P665, DOI 10.2214/ajr.162.3.8109519; WIJDICKS EFM, 1994, ANN NEUROL, V35, P498, DOI 10.1002/ana.410350422; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555; ZOJA C, 1986, LAB INVEST, V55, P455	60	2261	2439	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					494	500		10.1056/NEJM199602223340803	http://dx.doi.org/10.1056/NEJM199602223340803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559202				2022-12-28	WOS:A1996TV68600003
J	Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M				Wilm, M; Shevchenko, A; Houthaeve, T; Breit, S; Schweigerer, L; Fotsis, T; Mann, M			Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry	NATURE			English	Article							PEPTIDES	MOLECULAR analysis of complex biological structures and processes increasingly requires sensitive methods far protein sequencing. Electrospray mass spectrometry(1) has been applied to the high-sensitivity sequencing of short peptides(2), but technical difficulties have prevented similar success with gel-isolated proteins. Here we report a simple and robust technique for the sequencing of proteins isolated by polyacrylamide gel electrophoresis, using nano-electrospray(3,4) tandem mass spectrometry(5,6). As little as 5 ng protein starting material on Coomassie- or silver-stained gels can be sequenced. Multiple-sequence stretches of up to 16 amino acids are obtained, which identify the protein unambiguously if already present in databases or provide information to clone the corresponding gene. We have applied this method to the sequencing and cloning of a protein which inhibits the proliferation of capillary endothelial cells in vitro and thus may have potential antiangiogenic effects on solid tumours.	EUROPEAN MOLEC BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,DIV ONCOL & HAEMATOL,D-69120 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUNKAPILLER M, 1984, NATURE, V310, P105, DOI 10.1038/310105a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JENO P, 1995, ANAL BIOCHEM, V224, P451; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	16	1465	1530	5	179	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					466	469		10.1038/379466a0	http://dx.doi.org/10.1038/379466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559255				2022-12-28	WOS:A1996TT30400065
J	Li, TG; Janda, KD; Lerner, RA				Li, TG; Janda, KD; Lerner, RA			Cationic cyclopropanation by antibody catalysis	NATURE			English	Article							BIOSYNTHESIS; SQUALENE	REACTIONS involving highly reactive carbocations play a central role in many important chemical processes, such as cyclization reactions(1,2). However, the potential for controlling the pathways of such reactions to obtain energetically disfavoured (but desirable) products has been hard to realize because of the difficulties inherent in controlling the conformation and chemical environment of the carbocation intermediates. Antibody catalysts, with their high specificity and binding energies, can provide the degree of conformational and chemical control necessary for directing such reactions(3,4). Here we show how antibody catalysis can guide cationic cyclization reactions selectively to form products (in high yield) that would otherwise be highly disfavoured. Most notable is the formation of a strained bicyclic compound containing a rare cyclopropane group. To explain our results, we propose a common reaction scheme in which the key step is the formation of a highly reactive protonated cyclopropane intermediate; subtle structural modifications to the substrate (the compound on which the catalytic antibody acts) lead to dramatic differences in the structure of the final product.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P6174, DOI 10.1021/ja00487a037; BAYLESS JH, 1967, J AM CHEM SOC, V89, P147, DOI 10.1021/ja00977a029; BEATON JM, 1955, J CHEM SOC, P3992, DOI 10.1039/jr9550003992; BROWN HC, 1982, PURE APPL CHEM, V54, P1783, DOI 10.1351/pac198254101783; COLLINS CJ, 1969, CHEM REV, V69, P543, DOI 10.1021/cr60260a004; DJERASSI C, 1990, NEW J CHEM, V14, P713; FLEMING I, 1976, J CHEM SOC CHEM COMM, P182, DOI 10.1039/c39760000182; GUILFORD WJ, 1982, J AM CHEM SOC, V104, P3506, DOI 10.1021/ja00376a045; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JOHNSON WS, 1968, ACCOUNTS CHEM RES, V1, P1, DOI 10.1021/ar50001a001; Lee C. C., 1970, PROGR PHYS ORG CHEM, V7, P129; LEWINSOHN E, 1993, ARCH BIOCHEM BIOPHYS, V94, P2189; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; LI TY, 1995, J AM CHEM SOC, V117, P3308, DOI 10.1021/ja00116a050; LOGRASSO PV, 1993, ARCH BIOCHEM BIOPHYS, V307, P193, DOI 10.1006/abbi.1993.1578; MARCH J, 1985, ADV ORG CHEM, P673; OLAH GA, 1995, ANGEW CHEM INT EDIT, V34, P1393, DOI 10.1002/anie.199513931; OLAH GA, 1970, CARBONIUM IONS; RUZICKA L, 1947, HELV CHIM ACTA, V30, P140, DOI 10.1002/hlca.19470300117; SAUNDERS M, 1973, ACCOUNTS CHEM RES, V6, P53, DOI 10.1021/ar50062a003; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SILVER MS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a079; SKELL PS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a078	25	41	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					326	327						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552185				2022-12-28	WOS:A1996TR32300052
J	Lewis, MA; Spitzer, WO; Heinemann, LAJ; MacRae, KD; Bruppacher, R; Thorogood, M				Lewis, MA; Spitzer, WO; Heinemann, LAJ; MacRae, KD; Bruppacher, R; Thorogood, M			Third generation oral contraceptives and risk of myocardial infarction: An international case-control study	BRITISH MEDICAL JOURNAL			English	Article								Objective - To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of myocardial infarction. Design - Matched case-control study. Setting - 16 centres in Austria, France, Germany, Switzerland, and the United Kingdom. Subjects - Cases were 153 women aged 16-44 with a myocardial infarction event. Controls were 498 women (at least 3 controls per case) unaffected by myocardial infarction who were matched with their corresponding case for age and for hospital or community setting within four months of the index infarction. Main outcome measures - Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. Results - The estimated odds ratio for myocardial infarction of third compared with second generation oral contraceptives among all 651 study subjects was 0.36 (95% confidence interval 0.1 to 1.2) (P=0.11). The odds ratio for the United Kingdom and Germany alone was 0.45 (0.1 to 1.8) (P=0.26). Other odds ratios for the five countries were 3.1 (1.5 to 6.3) (P=0.003) for use of second generation products v no current use and 1.1 (0.4 to 3.4) (P=0.9) for use of third generation products v no current use. Among the confounding variables the independent contribution of smoking (for which adjustment was made in the above estimates) proved to be important (10.1 (5.7 to 17.9), P<0.001). Conclusion - An odds ratio of 0.45 with wide confidence intervals shows that third generation oral contraceptives compared with second generation products are associated with a reduced risk of myocardial infarction or with no difference. This finding from an interim analysis should be interpreted with extreme caution. However, the excess risk of venous thromboembolism associated with the use of third generation products may be balanced by the reduced risk of myocardial infarction associated with the same products.	PIPTA,D-14482 POTSDAM,GERMANY				Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002				COLE P, 1971, BRIT J PREV SOC MED, V25, P242; ENGEL HJ, 1987, HERZ, V12, P290; KJAER A, 1989, CONTRACEPTION, V40, P665, DOI 10.1016/0010-7824(89)90070-X; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; LEWIS MA, IN PRESS PHARMACOEPI; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; POULTER N, IN PRESS J CLIN EPID; Spitzer WO, 1996, BRIT MED J, V312, P83; Spitzer WO, 1993, PHARMACOEPIDEM DR S, V2, P21; THOROGOOD M, 1993, PHARMACOEPIDEM DR S, V2, P21; 1974, ORAL CONTRACEPTIVES	11	155	155	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					88	90						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555936				2022-12-28	WOS:A1996TQ16800023
J	Guadagno, TM; Newport, JW				Guadagno, TM; Newport, JW			Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity	CELL			English	Article							CYCLIN-DEPENDENT KINASE-2; HUMAN CELL-CYCLE; PROTEIN-KINASE; DNA-REPLICATION; CATALYTIC SUBUNIT; CDC25 PROTEIN; S-PHASE; XENOPUS; PHOSPHORYLATION; YEAST	In higher eukaryotes, Cdk2 kinase plays an essential role in regulating the G1-S transition. Here, we use cycling Xenopus egg extracts to examine the requirement of Cdk2 kinase on progression into mitosis. Interestingly, when Cdk2 kinase activity is inhibited by the Cdk-specific inhibitor, p21(Clp1), a block to mitosis occurs, and inactive Cdc2-cyclin B accumulates. This block occurs in the absence of nuclei and is not due to direct inhibition of Cdc2 by Cip. Importantly, this block to mitosis is reversible by restoring Cdk2-cyclin E kinase activity to a Cip-treated cycling extract. Moreover, immunodepletion of Cdk2 from interphase extracts prevents activation of Cdc2 upon the addition of exogenous cyclin B. Thus, our data show that Cdk2 kinase is a positive regulator of Cdc2-cyclin B complexes and establish a link between Cdk2 kinase and cell cycle progression into mitosis.			Guadagno, TM (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NICHD NIH HHS [HD07721-03] Funding Source: Medline; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, R01GM033523] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1995, MOL BIOL CELL, V6, P3877; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEICHMAN KA, 1994, CELL, V79, P556; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUNTER T, 1994, CELL, V79, P673; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1	57	197	200	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					73	82		10.1016/S0092-8674(00)80994-0	http://dx.doi.org/10.1016/S0092-8674(00)80994-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548828	Bronze			2022-12-28	WOS:A1996TQ17000010
J	Omran, M; Russell, G				Omran, M; Russell, G			Continuing increase in respiratory symptoms and atopy Aberdeen schoolchildren	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen								ANDERSON PG, 1993, CARDIOVASC PATHOL, V2, P6; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171	5	117	118	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					34	34		10.1136/bmj.312.7022.34	http://dx.doi.org/10.1136/bmj.312.7022.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555858	Green Published			2022-12-28	WOS:A1996TP20900024
J	Savage, PJ				Savage, PJ			Cardiovascular complications of diabetes mellitus: What we know and what we need to know about their prevention	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			CORONARY HEART-DISEASE; RISK-FACTORS; POPULATION; MORTALITY; FRAMINGHAM; PROGRAM; ONSET; MEN	Cardiovascular disease is a major cause of morbidity and mortality in patients with non-insulin-dependent diabetes mellitus (NIDDM). With an increase in the number of older diabetic persons, an increase in U.S. minority populations with high rates of diabetes, and the proven success of new methods to reduce microvascular complications, the importance of diabetic macrovascular complications will increase. The relative effectiveness of different treatments to reduce the incidence of diabetic cardiovascular complications is poorly understood. In addition to relative efficacy, issues related to patient burden and the economic cost of different treatments must be considered. Some of the information needed to improve therapy will be available soon from ongoing clinical trials. Obtaining definitive answers to other questions, especially those related to the relative benefit of intensive glucose level control compared with control of other known cardiovascular disease risk factors, will require additional studies. Although several questions unique to diabetic patients remain unanswered, results of previous clinical trials done among largely nondiabetic participants can be used to develop interim recommendations for cardiovascular disease prevention. Until definitive guidelines for prevention are established, combining aggressive therapy for known cardiovascular disease risk factors with efforts to normalize the glucose level offers the best chance to reduce the higher risk for cardiovascular disease associated with NIDDM.			Savage, PJ (corresponding author), NHLBI, EPIDEMIOL & BIOMETRY PROGRAM,DECA,2 ROCKLEDGE CTR, RM 8154, 6701 ROCKLEDGE DR, BETHESDA, MD 20892 USA.							ABBOTT RD, 1987, JAMA-J AM MED ASSOC, V257, P949, DOI 10.1001/jama.257.7.949; ABRAIRA C, IN PRESS DIABETES CA; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, DIABETES CARE, V12, P573; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GETZ GS, 1993, ARTERIOSCLER THROMB, V13, P459, DOI 10.1161/01.ATV.13.3.459; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HARRIS MI, 1994, DIABETES CARE, V17, P761, DOI 10.2337/diacare.17.7.761; HARRIS MI, 1985, NIH851468 PUBL, P1; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MELTON LJ, 1980, DIABETES CARE, V3, P650, DOI 10.2337/diacare.3.6.650; National Cholesterol Education Program, 1994, CIRCULATION, V89, P1333, DOI [10.1161/01.CIR.89.3.1333, DOI 10.1161/01.CIR.89.3.1333]; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; RE RN, 1994, HYPERTENSION, V23, P159; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMITH DA, 1986, DIABETES CARE, V9, P601, DOI 10.2337/diacare.9.6.601; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; SOWERS JR, 1994, HYPERTENSION, V23, P145; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; TURNER RC, 1991, DIABETOLOGIA, V34, P877; WETTERHALL SF, 1992, DIABETES CARE, V15, P960, DOI 10.2337/diacare.15.8.960; 1979, J CHRON DIS, V32, P829	30	88	93	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				123	126		10.7326/0003-4819-124-1_Part_2-199601011-00008	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554203				2022-12-28	WOS:A1996TL94400008
J	Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S				Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S			Impaired motor coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CEREBELLAR PURKINJE-CELLS; INFERIOR OLIVARY NEURONS; VESTIBULO-OCULAR REFLEX; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; GLUTAMATE SENSITIVITY; INVITRO	It is generally believed that a smooth execution of a compound movement, or motor coordination, requires learning of component movements as well as experience-based refinement of the motor program as a whole. PKC gamma mutant mice display impaired motor coordination but intact eyeblink conditioning, a form of component movement learning. Cerebellar long-term depression, a putative cellular mechanism for component motor learning, is also unimpaired. Thus, PKC gamma mutant mice are defective in refinement of the motor program. In the accompanying paper, we demonstrate that innervation of multiple climbing fibers onto Purkinje cells persists in adulthood in these mutant mice. We propose that this defective elimination of surplus climbing fibers underlies motor discoordination.	MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Jichi Medical University; University of Southern California	Chen, C (corresponding author), MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Hashimoto, Kouichi/0000-0002-3884-8213; Kano, Masanobu/0000-0002-0725-3292; Chen, Lu/0000-0002-8097-2699; Kim, Jeansok/0000-0001-7964-106X	NINDS NIH HHS [R01 NS32925] Funding Source: Medline; ACF HHS [NIA AF05142] Funding Source: Medline; OMHHE CDC HHS [1F32MN10521-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); ACF HHS; OMHHE CDC HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; CHEN C, 1995, IN PRESS LTP CURRE 3; CHEN C, 1995, LEARN MEMORY, V2, P18; CHEN S, 1993, NEUROSCIENCE, V56, P177, DOI 10.1016/0306-4522(93)90572-W; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAUM I, 1993, BEHAV NEUROSCI, V107, P748, DOI 10.1037/0735-7044.107.5.748; Dow R. S., 1958, PHYSL PATHOLOGY CERE; DUFOSSE M, 1978, BRAIN RES, V150, P611, DOI 10.1016/0006-8993(78)90825-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Fetz E E, 1993, Curr Opin Neurobiol, V3, P932, DOI 10.1016/0959-4388(93)90165-U; GELLMAN R, 1985, J NEUROPHYSIOL, V54, P40, DOI 10.1152/jn.1985.54.1.40; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HUANG FL, 1988, J NEUROSCI, V8, P4734; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1984, CEREBELLUM NEURAL CO; ITO M, 1994, CELLULAR MOL MECHANI, P25; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KOSE A, 1988, J NEUROSCI, V8, P4262; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1985, BRAIN RES, V326, P179, DOI 10.1016/0006-8993(85)91400-3; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LISBERGER SG, 1992, NATURE, V360, P159, DOI 10.1038/360159a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MERCHENTHALER I, 1993, J COMP NEUROL, V336, P378, DOI 10.1002/cne.903360306; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NAGAO S, 1989, EXP BRAIN RES, V77, P531; SAITO N, 1988, J NEUROSCI, V8, P369; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P8383; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; THOMPSON RF, 1993, SYNAPTIC PLASTICITY, P230; WATANABE E, 1984, BRAIN RES, V297, P169, DOI 10.1016/0006-8993(84)90555-9; WELSH JP, 1995, NATURE, V374, P453, DOI 10.1038/374453a0; YEO CH, 1984, BEHAV BRAIN RES, V13, P261, DOI 10.1016/0166-4328(84)90168-2	61	276	281	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1233	1242		10.1016/0092-8674(95)90148-5	http://dx.doi.org/10.1016/0092-8674(95)90148-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548809	Bronze			2022-12-28	WOS:A1995TM76200018
J	Strick, R; Laemmli, UK				Strick, R; Laemmli, UK			SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein	CELL			English	Article							TOPOISOMERASE-II SITES; ATTACHMENT SITES; HISTONE H-1; BINDING; CHROMATIN; EXTRACTS; SCAFFOLD; REGIONS; LOOP; CONDENSATION	SARs are candidate DNA elements for defining the bases of chromatin loops and possibly for serving as cis elements of chromosome dynamics. SARs contain numerous A tracts, whose altered DNA structure is recognized by cooperatively interacting proteins such as topoisomerase II. We constructed multi-AT hook (MATH) proteins and demonstrate that they specifically bind the clustered A tracts of SARs in chromatin and chromosomes. They are also potent inhibitors of chromosome assembly in mitotic Xenopus extracts, demonstrating the importance of SARs in this process. Titration of SARs with MATH20 (20 hooks) blocks shape determination of chromatids but not chromatin condensation per se. SARs are also required for shape maintenance of chromosomes. If MATH20 is added after formation of chromatids, they collapse and are reshaped by an active, mitotic process into spherical chromatid balls.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Strick, R (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GOTO T, 1982, J BIOL CHEM, V257, P5866; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1984, J CELL BIOL, V98, P122; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Sambrook J, 1989, MOL CLONING LABORATO; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	41	131	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1137	1148		10.1016/0092-8674(95)90140-X	http://dx.doi.org/10.1016/0092-8674(95)90140-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548801	Bronze			2022-12-28	WOS:A1995TM76200010
J	GARFIN, SR; DELBANCO, TL				GARFIN, SR; DELBANCO, TL			A 50-YEAR-OLD WOMAN WITH DISABLING SPINAL STENOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							LOW-BACK-PAIN; NERVE ROOT COMPRESSION; CAUDA-EQUINA ANATOMY; LUMBAR SPINE; CORTICOSTEROIDS; FIBROMYALGIA; SURGERY; FUSION; SENSE		UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego								BENNETT RM, 1993, RHEUM DIS CLIN N AM, V19, P45; Bigos S, 1994, ACUTE LOW BACK PAIN; BLOCK SR, 1993, RHEUM DIS CLIN N AM, V19, P61; BOGDUK N, 1993, EPIDURAL STEROIDS MA; CAPUTY AJ, 1992, J NEUROSURG, V77, P669, DOI 10.3171/jns.1992.77.5.0669; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; COHEN MS, 1990, SPINE, V15, P1248, DOI 10.1097/00007632-199012000-00003; CUCKLER JM, 1985, J BONE JOINT SURG AM, V67A, P63, DOI 10.2106/00004623-198567010-00009; DEYO RA, 1991, NEW ENGL J MED, V325, P1039, DOI 10.1056/NEJM199110033251411; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1993, SPINE, V18, P1463; DILKE TFW, 1973, BRIT MED J, V2, P635, DOI 10.1136/bmj.2.5867.635; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GARFIN SR, 1995, SPINE, V20, P1810, DOI 10.1097/00007632-199508150-00012; GARFIN SR, 1992, SPINE, P857; GARFIN SR, 1990, LUMBAR SPINE; GREGG R, 1994, SEMIN SPINE SURG, V6, P156; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002; HERRON LD, 1991, J SPINAL DISORD, V4, P26; JOHNSSON KE, 1989, SPINE, V14, P591, DOI 10.1097/00007632-198906000-00008; JOHNSSON KE, 1992, CLIN ORTHOP RELAT R, V279, P82; KANA SM, 1994, SEMIN SPINE SURG, V6, P109; KANTROWITZ F, 1975, NATURE, V258, P737, DOI 10.1038/258737a0; KATZ JN, 1991, J BONE JOINT SURG AM, V73A, P809, DOI 10.2106/00004623-199173060-00003; KIRKALDY-WILLIS W H, 1978, Spine, V3, P319, DOI 10.1097/00007632-197812000-00004; KORKALA O, 1985, SPINE, V10, P156, DOI 10.1097/00007632-198503000-00009; LEHMANN TR, 1987, SPINE, V12, P97, DOI 10.1097/00007632-198703000-00004; LIPSON SJ, 1989, SEMIN SPINE SURG, V1, P143; MARDJETKO SM, 1994, SPINE, V19, pS2256, DOI 10.1097/00007632-199410151-00002; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MAYER TG, 1992, SPINE, P1929; MAYER TG, 1991, CONT CONSERVATIVE CA; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; OLMARKER K, 1990, J SPINAL DISORD, V3, P25; PENTA M, 1995, SPINE, V20, P743, DOI 10.1097/00007632-199503150-00018; RAPP SE, 1994, ANESTHESIOLOGY, V81, pA923; RINEHART JJ, 1974, J CLIN INVEST, V54, P1337, DOI 10.1172/JCI107880; RYDEVIK B, 1984, SPINE, V9, P7, DOI 10.1097/00007632-198401000-00004; RYDEVIK B, 1990, ACTA PHYSIOL SCAND, V138, P247, DOI 10.1111/j.1748-1716.1990.tb08843.x; SANDERSON PL, 1993, J BONE JOINT SURG BR, V75, P393, DOI 10.1302/0301-620X.75B3.8496206; SCHONSTROM NSR, 1985, SPINE, V10, P806, DOI 10.1097/00007632-198511000-00005; SCHREIBER AD, 1975, J CLIN INVEST, V56, P1189, DOI 10.1172/JCI108196; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SILVERS HR, 1993, J NEUROSURG, V78, P695, DOI 10.3171/jns.1993.78.5.0695; SPENGLER DM, 1987, J BONE JOINT SURG AM, V69A, P305, DOI 10.2106/00004623-198769020-00027; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; TUITE GF, 1994, J NEUROSURG, V81, P699, DOI 10.3171/jns.1994.81.5.0699; Van Horn J R, 1992, Acta Orthop Belg, V58, P280; WALL EJ, 1990, SPINE, V15, P1244, DOI 10.1097/00007632-199012000-00002; WEINSTEIN J, 1991, ORTHOP CLIN N AM, V22, P235; WEINSTEIN JN, 1991, ADULT SPINE, P29; YUAN HA, 1994, SPINE, V19, pS2279	54	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1949	1954						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568991				2022-12-28	WOS:A1995TL16900039
J	Gobel, EJAM; Hautvast, RWM; vanGilst, WH; Spanjaard, JN; Hillege, HL; DeJongste, MJL; Molhoek, GP; Lie, KI				Gobel, EJAM; Hautvast, RWM; vanGilst, WH; Spanjaard, JN; Hillege, HL; DeJongste, MJL; Molhoek, GP; Lie, KI			Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris	LANCET			English	Article							MYOCARDIAL-ISCHEMIA; REFRACTORY ANGINA; NITROGLYCERIN; NIFEDIPINE; PROPRANOLOL; THERAPY; REST; EFFICACY	The effect of dihydropyridines in patients with unstable angina is discouraging. To find out the effect of the non- dihydropyridine-like calcium-channel blocker diltiazem, a randomised, double-blind trial was conducted comparing diltiazem with glyceryl trinitrate. both given intravenously, in 129 patients with unstable angina. The endpoints were refractory angina or myocardial infarction, individually and as a composite endpoint. Refractory angina alone or together with myocardial infarction occurred significantly less commonly in the diltiazem group. While patients were on the trial drugs the numbers with refractory angina were 6 (10%) in the diltiazem group versus 17 (28%) in the glyceryl trinitrate group (relative risk 0 . 36, p=0 . 02), and the numbers with refractory angina and myocardial infarction were 9 (15%) versus 23 (38%) (relative risk 0 . 40, p=0 . 007). Over 48 h the numbers were: refractory angina 8 (13%) versus 18 (30%), relative risk 0 . 45, p=0 . 03, and refractory angina and myocardial infarction 12 (20 . 0%) versus 25 (41%), relative risk 0 . 49, p=0 . 02. Patients in the diltiazem group had better (p<0 . 05) event-free survival while taking the drugs. Heart-rate pressure product was reduced significantly only by diltiazem (p<0 . 05). The incidence of bradyarrhythmias did not differ significantly. Atrioventricular conduction disturbances occurred in 5 (8%) patients in the diltiazem group but were not seen in the glyceryl trinitrate group (p=0 . 03). These disturbances could be reversed by decreasing the dose of the drug or withdrawing it. No temporary pacemakers were required. Headache requiring an analgesic or dose adjustment occurred significantly less in the diltiazem group: 3 (5%) versus 15 (25%), relative risk 0 . 20 (p<0 . 004). These results indicate that intravenous diltiazem, compared with intravenous glyceryl trinitrate, significantly reduces ischaemic events and can be used safely in patients with unstable angina.	MED SPECTRUM TWENTE,DEPT CARDIOL,ENSCHEDE,NETHERLANDS	Medical Spectrum Twente	Gobel, EJAM (corresponding author), UNIV GRONINGEN HOSP,DEPT CARDIOL,HANZEPLEIN 1,POB 30001,9700 RB GRONINGEN,NETHERLANDS.		van Gilst, Wiek/R-1806-2019; van Gilst, Wiek H/C-3828-2008	van Gilst, Wiek/0000-0003-2968-8585; 				ANDREFOUET X, 1983, EUR HEART J, V4, P691, DOI 10.1093/oxfordjournals.eurheartj.a061380; BELLER GA, 1989, CIRCULATION, V80, P78; BODEN WE, 1985, JAMA-J AM MED ASSOC, V253, P1131, DOI 10.1001/jama.253.8.1131; COLOMBO G, 1987, CLIN THER, V9, P536; CURFMAN GD, 1983, CIRCULATION, V67, P276, DOI 10.1161/01.CIR.67.2.276; DAUWE F, 1979, AM J CARDIOL, V43, P416; FANG ZY, 1991, AM J CARDIOL, V68, pC42; GERSTENBLITH G, 1982, NEW ENGL J MED, V306, P885, DOI 10.1056/NEJM198204153061501; GOTTLIEB SO, 1986, CIRCULATION, V73, P331, DOI 10.1161/01.CIR.73.2.331; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; KAPLAN K, 1983, AM J CARDIOL, V51, P694, DOI 10.1016/S0002-9149(83)80117-9; KERN MJ, 1990, AM HEART J, V119, P47, DOI 10.1016/S0002-8703(05)80080-8; MAURI F, 1988, European Heart Journal, V9, P158; MIKOLICH JR, 1980, CHEST, V77, P375, DOI 10.1378/chest.77.3.375; MULLER JE, 1984, CIRCULATION, V69, P728, DOI 10.1161/01.CIR.69.4.728; PARODI O, 1986, AM J CARDIOL, V57, P899, DOI 10.1016/0002-9149(86)90727-7; SQUIRE A, 1982, CIRCULATION, V66, P120; THANDANI U, 1987, CIRCULATION S4, V76, P128; THANDANI U, 1988, CURR PROB CARDIOLOGY, V13, P725; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1986, BRIT HEART J, V56, P400	22	34	40	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1653	1657		10.1016/S0140-6736(95)92837-5	http://dx.doi.org/10.1016/S0140-6736(95)92837-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551821				2022-12-28	WOS:A1995TL42300007
J	Harper, PS				Harper, PS			Genetic testing, common diseases, and health service provision	LANCET			English	Editorial Material											Harper, PS (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,INST MED GENET,CARDIFF,S GLAM,WALES.							Bernstein T, 1994, RADON RENTAL HOUSING; CORDELL HJ, 1995, TRENDS GENET, V11, P499, DOI 10.1016/S0168-9525(00)89160-X; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; MCGUFFIN P, 1995, LANCET, V346, P678, DOI 10.1016/S0140-6736(95)92285-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236; 1993, GENETIC SCREENING ET; 1993, BIOTECHNOLOGY RELATE; 1995, HOUSE COMMONS SCI TE; 1994, J MED GENET, V31, P785; 1995, 1ST NHS CENTR RES DE; 1995, 2ND NHS CEN RES DEV; 1994, GENETIC SCREENING RE; 1995, AM J HUM GENET, V57, P1233; 1994, AM J HUM GENET, V55, P1; 1995, GENOMICS IMPACT NEW	16	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1645	1646		10.1016/S0140-6736(95)92835-9	http://dx.doi.org/10.1016/S0140-6736(95)92835-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551819				2022-12-28	WOS:A1995TL42300005
J	Polonsky, KS; Sturis, J; Bell, GI				Polonsky, KS; Sturis, J; Bell, GI			Non-insulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; HUMAN SKELETAL-MUSCLE; OBESE SUBJECTS; CIRCULATING PROINSULIN; CHRONIC HYPERGLYCEMIA; GLYCOGEN-SYNTHASE; PLASMA-INSULIN; RECEPTOR GENE; SECRETION; SENSITIVITY		UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Polonsky, KS (corresponding author), UNIV CHICAGO,DEPT MED,5841 S MARYLAND AVE,MC 1027,CHICAGO,IL 60637, USA.		Sturis, Jeppe/GQY-6476-2022; Sturis, Jeppe/ABA-6183-2020	Sturis, Jeppe/0000-0001-9938-5278; Sturis, Jeppe/0000-0001-9938-5278				BECKNIELSEN H, 1978, DIABETES, V27, P1175, DOI 10.2337/diab.27.12.1175; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BERGMAN RN, 1981, J CLIN INVEST, V68, P1456, DOI 10.1172/JCI110398; BYRNE M, 1995, DIABETES, V44, pA195; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CIARALDI TP, 1982, DIABETES, V31, P1016, DOI 10.2337/diacare.31.11.1016; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DEFRONZO R, 1979, J CLIN INVEST, V63, P939, DOI 10.1172/JCI109394; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; ERIKSSON J, 1992, DIABETOLOGIA, V35, P143, DOI 10.1007/BF00402546; ERIKSSON J, 1992, DIABETOLOGIA, V35, P594; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1992, NATURE, V357, P607, DOI 10.1038/357607c0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOLAY A, 1988, DIABETES METAB REV, V4, P727, DOI 10.1002/dmr.5610040803; GOLAY A, 1988, DIABETOLOGIA, V31, P585, DOI 10.1007/BF00264764; GORDEN P, 1972, J CLIN ENDOCR METAB, V34, P235, DOI 10.1210/jcem-34-1-235; GROOP LC, 1993, NEW ENGL J MED, V328, P10, DOI 10.1056/NEJM199301073280102; GULLI G, 1992, DIABETES, V41, P1575, DOI 10.2337/diabetes.41.12.1575; GUMBINER B, 1990, J CLIN ENDOCR METAB, V70, P1594, DOI 10.1210/jcem-70-6-1594; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; HEATON DA, 1988, DIABETOLOGIA, V31, P182, DOI 10.1007/BF00276853; HERMAN WH, 1994, DIABETES, V43, P40, DOI 10.2337/diabetes.43.1.40; HERMAN WH, 1994, DIABETES, V43, P1171; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; KHAN A, 1995, AM J PHYSIOL-ENDOC M, V269, pE623, DOI 10.1152/ajpendo.1995.269.4.E623; KNOWLER WC, 1995, DIABETES, V44, P483, DOI 10.2337/diabetes.44.5.483; LANG DA, 1981, DIABETES, V30, P435, DOI 10.2337/diabetes.30.5.435; LARSSON H, 1995, J CLIN ENDOCR METAB, V80, P1778, DOI 10.1210/jc.80.6.1778; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; LEAHY JL, 1988, J CLIN INVEST, V81, P1407, DOI 10.1172/JCI113470; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MAEGAWA H, 1991, DIABETES, V40, P815, DOI 10.2337/diabetes.40.7.815; MAKO ME, 1977, AM J MED, V63, P865, DOI 10.1016/0002-9343(77)90538-1; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; OLEFSKY JM, 1977, DIABETES, V26, P680, DOI 10.2337/diab.26.7.680; OLEFSKY JM, 1974, J CLIN INVEST, V54, P1323, DOI 10.1172/JCI107878; OMEARA NM, 1993, J CLIN INVEST, V92, P262, DOI 10.1172/JCI116560; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; OSEI K, 1991, DIABETES CARE, V14, P890, DOI 10.2337/diacare.14.10.890; PIMENTA W, 1995, JAMA-J AM MED ASSOC, V273, P1855, DOI 10.1001/jama.273.23.1855; POLONSKY KS, 1988, NEW ENGL J MED, V318, P1231, DOI 10.1056/NEJM198805123181903; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; POLONSKY KS, 1988, J CLIN INVEST, V81, P442, DOI 10.1172/JCI113339; POLONSKY KS, 1988, J CLIN INVEST, V81, P435, DOI 10.1172/JCI113338; RAMACHANDRAN A, 1990, DIABETIC MED, V7, P331, DOI 10.1111/j.1464-5491.1990.tb01400.x; REAVEN GM, 1994, J INTERN MED, V236, P13; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSSETTI L, 1987, J CLIN INVEST, V80, P1037, DOI 10.1172/JCI113157; STURIS J, 1991, AM J PHYSIOL, V260, pE801, DOI 10.1152/ajpendo.1991.260.5.E801; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; VELHO G, 1992, LANCET, V340, P448; VESTERGAARD H, 1993, J CLIN INVEST, V91, P2342, DOI 10.1172/JCI116466; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARD WK, 1987, DIABETOLOGIA, V30, P698, DOI 10.1007/BF00296991; WEIR GC, 1982, AM J MED, V73, P461, DOI 10.1016/0002-9343(82)90321-7	71	466	490	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					777	783		10.1056/NEJM199603213341207	http://dx.doi.org/10.1056/NEJM199603213341207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592553				2022-12-28	WOS:A1996TZ97900007
J	Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D				Reiman, EM; Caselli, RJ; Yun, LS; Chen, KW; Bandy, D; Minoshima, S; Thibodeau, SN; Osborne, D			Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; AMYLOID-BETA-PEPTIDE; TYPE-4 ALLELE; RISK; METABOLISM; BINDING; BRAIN	Background. Variants of the apolipoprotein pared regional rates of glucose metabolism in the two groups. E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain In which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease, We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment. Methods. Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease, Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 E4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups. Results. The epsilon 4 homozygotes were cognitively normal, They had significantly reduced rates of glucose metabolism In the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease, They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging. Conclusions. In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease, These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease, PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease. (C) 1996, Massachusetts Medical Society.	UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ USA; UNIV ARIZONA, DEPT RADIOL, TUCSON, AZ 85724 USA; MAYO CLIN, DEPT NEUROL, SCOTTSDALE, AZ USA; MAYO CLIN, DEPT PSYCHOL, SCOTTSDALE, AZ USA; ARIZONA STATE UNIV, DEPT COMP SCI, TEMPE, AZ 85287 USA; UNIV MICHIGAN, DIV NUCL MED, ANN ARBOR, MI 48109 USA; MAYO CLIN, DEPT LAB MED & PATHOL, ROCHESTER, MN USA	University of Arizona; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; University of Michigan System; University of Michigan; Mayo Clinic	Reiman, EM (corresponding author), GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, 1111 E MCDOWELL RD, PHOENIX, AZ 85006 USA.		Chen, kewei/P-6304-2015	Chen, kewei/0000-0001-8497-3069				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRUN A, 1976, ARCH PSYCHIAT NERVEN, V223, P15, DOI 10.1007/BF00367450; CASELLI RJ, 1995, ARCH NEUROL-CHICAGO, V52, P1004, DOI 10.1001/archneur.1995.00540340096018; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; COFFEY CE, 1992, NEUROLOGY, V42, P527, DOI 10.1212/WNL.42.3.527; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; First M.B., 1990, USERS GUIDE STRUCTUR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFTON ST, 1992, ARCH NEUROL-CHICAGO, V49, P1161, DOI 10.1001/archneur.1992.00530350075022; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HIXSON JE, 1990, J LIPID RES, V31, P545; KAPLITT MG, 1995, ABSTR SOC NEUROSCI, V21, P1008; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; KUHL DE, 1982, J CEREBR BLOOD F MET, V2, P163, DOI 10.1038/jcbfm.1982.15; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, V5; LOESSNER A, 1995, J NUCL MED, V36, P1141; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCGEER EG, 1990, CAN J NEUROL SCI, V17, P1; MIELKE R, 1994, DEMENTIA, V5, P36, DOI 10.1159/000106692; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; MINOSHIMA S, 1995, J COMPUT ASSIST TOMO, V19, P541, DOI 10.1097/00004728-199507000-00006; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PIETRINI P, 1993, DEMENTIA, V4, P94, DOI 10.1159/000107349; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; RIGGS JE, 1994, ARCH NEUROL-CHICAGO, V51, P750, DOI 10.1001/archneur.1994.00540200024011; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SALMON E, 1991, ACTA NEUROL BELG, V91, P288; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHWARTZ WJ, 1979, SCIENCE, V205, P723, DOI 10.1126/science.462184; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SMITH GS, 1992, ARCH NEUROL-CHICAGO, V49, P1142, DOI 10.1001/archneur.1992.00530350056020; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; Talairach J., 1988, COPLANAR STEREOTAXIC; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]	50	1084	1111	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					752	758		10.1056/NEJM199603213341202	http://dx.doi.org/10.1056/NEJM199603213341202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592548	Bronze			2022-12-28	WOS:A1996TZ97900002
J	OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ				OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ			Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; CONTROLLED TRIAL; CLINICAL-TRIALS; END-POINTS; REVERSE-TRANSCRIPTASE; P24 ANTIGEN; ZIDOVUDINE; MARKER; NEOPTERIN; RESISTANCE	Background. Clinical trials of antiretroviral drugs can take years to complete because the outcomes measured are progression to the acquired immunodeficiency syndrome (AIDS) or death. Trials could be accelerated by the use of end points such as changes in CD4+ lymphocyte counts and plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and beta(2)-microglobulin, but there is uncertainty about whether these surrogate measures are valid predictors of disease progression. Methods. We analyzed data from the Veterans Affairs Cooperative Study on AIDS, which compared immediate with deferred zidovudine therapy. Patients' plasma levels of HIV-1 RNA and beta(2)-microglobulin were measured in stored plasma. Results. Among the 129 patients in the immediate-treatment group, 34 had disease that progressed to AIDS, as compared with 57 of the 141 patients in the deferred-treatment group (P=0.03). Progression to AIDS correlated strongly with base-line CD4+ lymphocyte counts (P=0.001) and plasma levels of HIV-1 RNA (P<0.001), but not with base-line levels of beta(2)-microglobulin (P=0.14). A decrease of at least 75 percent in the plasma level of HIV-1 RNA over the first six months of zidovudine therapy accounted for 59 percent of the benefit of treatment, defined as the absence of progression to AIDS (95 percent confidence interval, 13 to 112 percent). Plasma beta(2)-microglobulin levels and CD4+ lymphocyte counts explained less of the effect of treatment. A 75 percent decrease in the plasma HIV-1 RNA level plus a 10 percent increase in the CD4+ lymphocyte count could explain 79 percent of the treatment effect (95 percent confidence interval, 27 to 145 percent). Conclusions. Treatment-induced changes in the plasma HIV-1 RNA level and the CD4+ lymphocyte count, taken together, are valid predictors of the clinical progression of HIV-related disease and can be used to assess the efficacy of zidovudine and possibly other antiretroviral drugs as well. (C) 1996, Massachusetts Medical Society.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; VET AFFAIRS COOPERAT STUDIES PROGRAM, COORDINATING CTR, W HAVEN, CT USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; GLAXO INC, RES TRIANGLE PK, NC 27709 USA; VET AFFAIRS MED CTR, NEW YORK, NY USA; NYU, SCH MED, NEW YORK, NY USA; DUKE UNIV, MED CTR, DURHAM, NC USA; VET AFFAIRS MED CTR, DURHAM, NC 27705 USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; VET ADM MED CTR, MIAMI, FL 33125 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC USA; VET ADM MED CTR, WASHINGTON, DC 20422 USA; DUKE UNIV, VIROL CTR, DURHAM, NC 27706 USA; UNIV MARYLAND, PHARMACOL LAB, COLLEGE PK, MD 20742 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University System of Maryland; University of Maryland College Park	OBrien, WA (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, DEPT MED, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.		Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COX DR, 1979, THEORETICAL STATISTI; CUNNINGHAM AL, 1993, J ACQ IMMUN DEF SYND, V6, pS32; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; GRAHAM NMH, 1993, J ACQ IMMUN DEF SYND, V6, P1258; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; LACEY CJN, 1987, AIDS, V1, P123; LAGAKOS SW, 1993, CLIN INFECT DIS, V16, pS22, DOI 10.1093/clinids/16.Supplement_1.S22; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Simberkoff MS, 1996, J ACQ IMMUN DEF SYND, V11, P142, DOI 10.1097/00042560-199602010-00005; SPECTOR SA, 1989, J INFECT DIS, V159, P822, DOI 10.1093/infdis/159.5.822; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1, V36, pS1	40	638	645	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					426	431		10.1056/NEJM199602153340703	http://dx.doi.org/10.1056/NEJM199602153340703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552144	Bronze			2022-12-28	WOS:A1996TU69600003
J	Utz, JP; Swensen, SJ; Gertz, MA				Utz, JP; Swensen, SJ; Gertz, MA			Pulmonary amyloidosis - The Mayo Clinic experience from 1980 to 1993	ANNALS OF INTERNAL MEDICINE			English	Article						amyloidosis; biopsy; bronchoscopy; amyloid; respiratory tract diseases	LOWER RESPIRATORY-TRACT; TRANS-BRONCHIAL BIOPSY; TRACHEOBRONCHOPATHIA OSTEOPLASTICA; LOCALIZED AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; HILAR ADENOPATHY; PLEURAL DISEASE; NEEDLE-BIOPSY; MANIFESTATIONS; DIAGNOSIS	Objective: To define the prognosis for and radiographic presentation of patients with pulmonary amyloidosis. Design: Retrospective review of the Mayo Clinic experience with biopsy-proven pulmonary amyloidosis from 1980 to 1993. Setting: Tertiary care center. Patients: Patients with pulmonary biopsy specimens showing amyloid deposition. Measurements: Medical records were reviewed, and pertinent information was recorded, including demographic data, type of pulmonary biopsy, results of biopsies of nonpulmonary sites and of immunoelectrophoresis, and other clinical, radiographic, and laboratory information necessary for distinguishing localized pulmonary amyloidosis, primary systemic amyloidosis, secondary amyloidosis, and familial amyloidosis. Results: 35 of 55 patients with pulmonary amyloidosis had primary systemic amyloidosis that presented radiographically as an interstitial or reticulonodular pattern with or without pleural effusion. The median survival after diagnosis was 16 months. Nodular pulmonary ''amyloidomas'' (nodular amyloid lesions) were not associated with systemic disease and were associated with a benign prognosis. Three of 4 patients with localized tracheobronchial amyloidosis required Nd:YAC (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive symptoms. ''Senile'' amyloid deposition was an incidental finding in some patients at autopsy. Conclusions: Localized amyloidomas are characterized by a benign course and are not associated with systemic amyloidosis. Despite its localized nature, tracheobronchial amyloid deposition may be asymptomatic or may result in significant morbidity due to obstructive phenomena. Pulmonary amyloidosis associated with primary systemic amyloidosis generally presents as a diffuse interstitial pattern with or without pleural effusion. Complete survival data indicate that long-term outcome is poor after diagnosis. We describe the largest series of patients diagnosed by bronchoscopic lung biopsy. Despite reports to the contrary, we have found bronchoscopic lung biopsy to be a safe and effective diagnostic technique.	MAYO MED CTR, ROCHESTER, MN USA	Mayo Clinic	Utz, JP (corresponding author), MAYO CLIN & MAYO FDN, MAYO MED SCH, 200 1ST ST SW, E-18, ROCHESTER, MN 55905 USA.		Gertz, Morie/K-2873-2019					ALROY GG, 1972, CHEST, V61, P465, DOI 10.1378/chest.61.5.465; BIERNY JP, 1978, AM J ROENTGENOL, V131, P1082; BREUER R, 1985, THORAX, V40, P870, DOI 10.1136/thx.40.11.870; BUXBAUM JN, 1988, CECIL TXB MED, P1198; CANDEIRA SR, 1991, CHEST, V100, P292, DOI 10.1378/chest.100.1.292-a; CELLI BR, 1978, CHEST, V74, P543, DOI 10.1378/chest.74.5.543; CORDIER JF, 1986, CHEST, V90, P827, DOI 10.1378/chest.90.6.827; DAHLGREN SE, 1970, ACTA PATH MICRO IM A, VA 78, P1; DAHLIN DC, 1950, MED CLIN N AM, P1107; DAIL DH, 1988, PULMONARY PATHOLOGY, P535; DESAI RA, 1979, CHEST, V76, P170, DOI 10.1378/chest.76.2.170; FLEMMING AFS, 1980, BRIT J DIS CHEST, V74, P183, DOI 10.1016/0007-0971(80)90032-7; GALLEGO FG, 1974, NEW ENGL J MED, V291, P531; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; GOTTLIEB LS, 1972, AM REV RESPIR DIS, V105, P425; GROSS BH, 1981, RADIOLOGY, V138, P11, DOI 10.1148/radiology.138.1.7455070; HOLMES S, 1988, BRIT J DIS CHEST, V82, P414, DOI 10.1016/0007-0971(88)90097-6; HUI AN, 1986, ARCH PATHOL LAB MED, V110, P212; JONES AW, 1977, BRIT J DIS CHEST, V71, P268, DOI 10.1016/0007-0971(77)90124-3; KAMBERG S, 1962, NEW ENGL J MED, V266, P587, DOI 10.1056/NEJM196203222661204; KAVURU MS, 1990, CHEST, V98, P20, DOI 10.1378/chest.98.1.20; KAW YT, 1991, DIAGN CYTOPATHOL, V7, P628, DOI 10.1002/dc.2840070617; KHAN JA, 1996, CLIN PULM MED, V2, P66; KIDD CR, 1974, NEW ENGL J MED, V290, P972; KIM C H, 1990, Korean Journal of Internal Medicine, V5, P63; KLINE LR, 1985, AM REV RESPIR DIS, V132, P191; KNAPP MJ, 1988, ARCH PATHOL LAB MED, V112, P57; KUNZE WP, 1979, PATHOL RES PRACT, V164, P413, DOI 10.1016/S0344-0338(79)80058-8; KYLE RA, 1983, MAYO CLIN PROC, V58, P665; LEWINSOHN G, 1976, CHEST, V69, P682, DOI 10.1378/chest.69.5.682; MARTIN CJ, 1974, ARCH OTOLARYNGOL, V100, P290; NIENHUIS DM, 1990, ANN OTO RHINOL LARYN, V99, P689, DOI 10.1177/000348949009900903; OSNOSS KL, 1980, CHEST, V78, P786, DOI 10.1378/chest.78.5.786; PETERMANN W, 1987, EUR J RESPIR DIS, V71, P210; PITKANEN P, 1984, AM J PATHOL, V117, P391; POH SC, 1975, THORAX, V30, P186, DOI 10.1136/thx.30.2.186; RUBINOW A, 1978, AM REV RESPIR DIS, V118, P603; SAKULA A, 1968, THORAX, V23, P105, DOI 10.1136/thx.23.1.105; SHINOI K, 1962, DIS CHEST, V42, P442, DOI 10.1378/chest.42.4.442; SIONGCHUAN L, 1975, THORAX, V30, P178; SMITH RRL, 1979, AM J MED, V66, P96, DOI 10.1016/0002-9343(79)90488-1; STRANGE C, 1987, CHEST, V92, P367, DOI 10.1378/chest.92.2.367; THOMPSON PJ, 1983, THORAX, V38, P84, DOI 10.1136/thx.38.2.84; TOMASHEFSKI JF, 1980, ACTA CYTOL, V24, P224; WEISMANN RE, 1947, J THORAC SURG, V16, P269; WEISS L, 1960, AM J CLIN PATHOL, V33, P318; WILSON SR, 1976, RADIOLOGY, V120, P283, DOI 10.1148/120.2.283; YOOD RA, 1983, JAMA-J AM MED ASSOC, V249, P1322, DOI 10.1001/jama.249.10.1322	48	241	259	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					407	+		10.7326/0003-4819-124-4-199602150-00004	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554249				2022-12-28	WOS:A1996TV22000004
J	Baba, S; Taniguchi, H; Nambu, S; Tsuboi, S; Ishihara, K; Osato, S				Baba, S; Taniguchi, H; Nambu, S; Tsuboi, S; Ishihara, K; Osato, S			The great Hanshin earthquake	LANCET			English	Article									KOBE UNIV,SCH MED,KOBE 657,JAPAN; HYOGO INST CLIN RES,KOBE,JAPAN; PUBL HLTH BUR,KOBE,HYOGO,JAPAN; HYOGO REHABIL CTR HOSP,KOBE,HYOGO,JAPAN; IDF WPR,KOBE,HYOGO,JAPAN	Kobe University	Baba, S (corresponding author), HYOGO MED CTR ADULTS,13-17 KITAOJI CHO,AKASHI,HYOGO 673,JAPAN.								0	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					307	309		10.1016/S0140-6736(96)90473-0	http://dx.doi.org/10.1016/S0140-6736(96)90473-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569369				2022-12-28	WOS:A1996TT48500016
J	Chen, HW; Sandler, DP; Taylor, JA; Shore, DL; Liu, E; Bloomfield, CD; Bell, DA				Chen, HW; Sandler, DP; Taylor, JA; Shore, DL; Liu, E; Bloomfield, CD; Bell, DA			Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect	LANCET			English	Article							EXPOSURE; CARCINOGENESIS; SUSCEPTIBILITY; CANCER	Background The glutathione S-transferases (GST) mediate exposure to various cytotoxic and genotoxic agents, including those associated with increased risk of the myelodysplastic syndromes (MDS). Both GST M1 (GSTM1) and GST theta 1 (GSTT1) genes have a ''null'' variant allele, in which the entire gene is absent. We tested whether the homozygous null genotype of GSTM1 and GSTT1 altered the risk for MDS. Methods In a hospital-based case-control study we analysed lymphocyte or bone-marrow DNA samples from 96 patients with MDS and 201 cancer-free controls of similar, age, race, and sex. We have restricted our report to the 92 white MDS patients. We analysed GSTM1 and GSTT1 genotypes by PCR. Findings The frequency of the GSTT1 null genotype was higher among MDS cases (46%) than among controls (16%). Inheritance of the GSTT1 null genotype conferred a 4.3-fold risk of MDS (odds ratio 4.3, 95% CI 2.5-7.4, p<0.00001). The GSTM1 null genotype was not associated with increased risk of MDS (odds ratio 0.8, 0.5-1.3). Interpretation Individuals with the GSTT1 null genotype may have enhanced susceptibility to MDS. The mechanism might involve decreased detoxification of environmental or endogenous carcinogens.	NIEHS, RES TRIANGLE PK, NC 27709 USA; WESTAT CORP, RES TRIANGLE PK, NC USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; ROSWELL PK CANC INST, BUFFALO, NY 14263 USA; CANC & LEUKEMIA GRP B, DURHAM, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Westat; University of North Carolina; University of North Carolina Chapel Hill; Roswell Park Cancer Institute			Bell, Douglas A/C-7687-2019; Liu, Edison/C-4141-2008; taylor, jack a/C-7154-2019	Bell, Douglas A/0000-0001-7700-0840; taylor, jack a/0000-0001-5303-6398; Sandler, Dale/0000-0002-6776-0018				BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655; CHESON BD, 1990, ANN INTERN MED, V112, P932, DOI 10.7326/0003-4819-112-12-932; FARROW A, 1989, LEUKEMIA, V3, P33; GOASGUEN JE, 1992, SEMIN ONCOL, V19, P4; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; IDLE JR, 1991, MUTAT RES, V247, P259, DOI 10.1016/0027-5107(91)90021-F; KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; NELSON HH, 1995, CARCINOGENESIS, V16, P1243, DOI 10.1093/carcin/16.5.1243; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; TAN KL, 1995, GENOMICS, V25, P381, DOI 10.1016/0888-7543(95)80037-M; VERWILGHEN R L, 1987, Blood Reviews, V1, P34, DOI 10.1016/0268-960X(87)90017-8; WARHOLM M, 1995, PHARMACOGENETICS, V5, P252, DOI 10.1097/00008571-199508000-00010; WARWICK A, 1994, CARCINOGENESIS, V15, P2841, DOI 10.1093/carcin/15.12.2841; WEST RR, 1995, LEUKEMIA RES, V19, P127, DOI 10.1016/0145-2126(94)00141-V; WIENCKE JK, 1995, CANCER EPIDEM BIOMAR, V4, P253	20	248	261	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	1996	347	8997					295	297		10.1016/S0140-6736(96)90468-7	http://dx.doi.org/10.1016/S0140-6736(96)90468-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569364				2022-12-28	WOS:A1996TT48500011
J	Alappan, R; Perazella, MA; Buller, GK				Alappan, R; Perazella, MA; Buller, GK			Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To determine the effect of standard-dose trimethoprim-sulfamethoxazole on serum potassium concentration in hospitalized patients. Design: Prospective chart review. Setting: Community-based teaching hospital. Patients: 105 patients with various infections were hospitalized and treated. Eighty patients treated with standard-dose trimethoprim-sulfamethoxazole (trimethoprim, less than or equal to 320 mg/d; sulfamethoxazole, less than or equal to 1600 mg/d) composed the treatment group; 25 patients treated with other antibiotic agents served as the control group. Measurements: Serum sodium, potassium, and chloride concentrations; serum carbon dioxide content; anion gap; blood urea nitrogen level; and serum creatinine level. Results: The serum potassium concentration in the treatment group (mean +/- SD) was 3.89 +/- 0.46 mmol/L (95% CI, 3.79 to 3.99 mmol/L), and it increased by 1.21 mmol/L (CI, 1.09 to 1.32 mmol/L) 4.6 +/- 2.2 days after trimethoprim-sulfamethoxazole therapy was initiated. Blood urea nitrogen levels increased from 7.92 +/- 5.7 mmol/L (CI, 6.67 to 9.16 mmol/L) to 9.2 +/- 5.8 mmol/L (CI, 7.9 to 10.5 mmol/L), and serum creatinine levels increased from 102.5 +/- 49.5 mu mol/L (CI, 91.4 to 113.6 mu mol/L) to 126.1 +/- 70.7 mu mol/L (CI, 110.3 to 141.9 mu mol/L). Patients with a serum creatinine level of 106 mu mol/l (1.2 mg/dL) or more developed a higher peak potassium concentration (5.37 +/- 0.59 mmol/L [CI, 5.15 to 5.59 mmol/L]) than patients with a serum creatinine level of less than 106 mu mol/L (4.95 +/- 0.48 mmol/L [CI, 4.80 to 5.08 mmol/L]). Patients with diabetes had a slightly higher peak potassium concentration (5.14 +/- 0.45 mmol/L [CI, 4.93 to 5.35 mmol/L]) than did patients without diabetes (5.08 +/- 0.59 mmol/L [CI, 4.93 to 5.23 mmol/L]), but the difference was not statistically significant. The serum potassium concentration in the control group was 4.33 +/- 0.45 mmol/L (CI, 4.15 to 4.51 mmol/L), and it decreased nonsignificantly over 5 days of therapy. Conclusions: Standard-dose trimethoprim-sulfamethoxazole therapy used to treat various infections leads to an increase in serum potassium concentration. A peak serum potassium concentration greater than 5.0 mmol/L developed in 62.5% of patients; severe hyperkalemia (peak serum potassium concentration greater than or equal to 5.5 mmol/L) occurred in 21.2% of patients. Patients treated with standard-dose trimethoprim-sulfamethoxazole should be monitored closely for the development of hyperkalemia, especially if they have concurrent renal insufficiency (serum creatinine level greater than or equal to 106 mu mol/L).	YALE UNIV, SCH MED, DEPT MED, NEPHROL SECT, NEW HAVEN, CT 06510 USA; ST MARYS HOSP, DEPT MED, YALE PRIMARY CARE PROGRAM, WATERBURY, CT 06706 USA; ST MARYS HOSP, DEPT MED, NEPHROL SECT, WATERBURY, CT 06706 USA	Yale University; Yale University								BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; CANADAY DH, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00017; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CRYST C, 1988, AM J NEPHROL, V8, P483, DOI 10.1159/000167666; GREENBERG S, 1993, ANN INTERN MED, V119, P291, DOI 10.7326/0003-4819-119-4-199308150-00007; JICK H, 1982, REV INFECT DIS, V4, P426; MODEST GA, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00015; PENNYPACKER LC, 1994, ANN INTERN MED, V120, P437, DOI 10.7326/0003-4819-120-5-199403010-00016; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; VELAZQUEZ H, 1993, ANN INTERN MED, V119, P296, DOI 10.7326/0003-4819-119-4-199308150-00008; 1992, MED ECONOMICS	12	80	82	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					316	320		10.7326/0003-4819-124-3-199602010-00006	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554227				2022-12-28	WOS:A1996TR59600006
J	Vinjamuri, S; Hall, AV; Solanki, KK; Bomanji, J; Siraj, Q; OShaughnessy, E; Das, SS; Britton, KE				Vinjamuri, S; Hall, AV; Solanki, KK; Bomanji, J; Siraj, Q; OShaughnessy, E; Das, SS; Britton, KE			Comparison of Tc-99m Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection	LANCET			English	Article								Background Bacterial infection can pose a substantial diagnostic dilemma. Techniques involving radiolabelled leucocytes can pinpoint the site of inflammation. However, previous radiolabelling techniques have failed to distinguish between bacterial-mediated infection and non-bacterial inflammation. To overcome this difficulty, we have studied a radiopharmaceutical, technetium-99m (Tc-99m) Infecton, which is based on the antibiotic ciprofloxacin. Methods We used this agent to image bacterial infection in 56 patients (one twice) with known or suspected sites of infection. We then compared the imaging results of these patients with those from a radiolabelled leucocyte study. Findings The concordance rate was 68% (39 out of 57 images). In 18 discordant results Tc-99m Infecton was correctly positive in 8 out of 9 positive studies and correctly negative in 4 out of 9 negative studies. 4 out of 5 of the falsely negative studies were in patients who had taken antibiotics for over 7 days. We found that Tc-99m Infecton gave better imaging results than radiolabelled leucocytes. Comparison between Tc-99m infecton and leucocyte imaging gave sensitivities of 84% and 81%, and specificities of 96% and 77%, respectively. Interpretation We believe that the specificity Tc-99m Infecton confers for bacterial infection and its ease of administration are the main advantages of this new agent.	ST BARTHOLOMEWS HOSP,DEPT NUCL MED,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MICROBIOL,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								HOOPER DC, 1987, AM J MED, V82, P12; PETERS AM, 1986, LANCET, V2, P945; RODDIE ME, 1988, RADIOLOGY, V166, P767, DOI 10.1148/radiology.166.3.3340775; SOLANKI KK, 1993, J NUCL MED, V34, pP119; SOLANKI KK, 1988, NUCL MED COMMUN, V9, P753, DOI 10.1097/00006231-198810000-00012; THAKUR ML, 1987, J NUCL MED, V22, P1011; TUDOR RG, 1988, ARCH SURG-CHICAGO, V123, P1487	7	220	230	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					233	235		10.1016/S0140-6736(96)90407-9	http://dx.doi.org/10.1016/S0140-6736(96)90407-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551884				2022-12-28	WOS:A1996TT06900013
J	Licht, S; Gerfen, GJ; Stubbe, JA				Licht, S; Gerfen, GJ; Stubbe, JA			Thiyl radicals in ribonucleotide reductases	SCIENCE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; REDUCTION; ELECTRON; COENZYME-B12; MECHANISM; COBAMIDES; STATE; DNA	The ribonucleoside triphosphate reductase (RTPR) from Lactobacillus leichmannii catalyzes adenosylcobalamin (AdoCbl)-dependent nucleotide reduction, as well as exchange of the 5' hydrogens of AdoCbl with solvent. A protein-based thiyl radical is proposed as an intermediate in both of these processes. In the presence of RTPR containing specifically deuterated cysteine residues, the electron paramagnetic resonance (EPR) spectrum of an intermediate in the exchange reaction and the reduction reaction, trapped by rapid freeze quench techniques, exhibits narrowed hyperfine features relative to the corresponding unlabeled RTPR. The spectrum was interpreted to represent a thiyl radical coupled to cob(II)alamin. Another proposed intermediate, 5'-deoxyadenosine, was detected by rapid acid quench techniques, Similarities in mechanism between RTPR and the Escherichia coli ribonucleotide reductase suggest that both enzymes require a thiyl radical for catalysis.	MIT, FRANCIS BITTER MAGNET LAB, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Licht, S (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029595, R01GM029595] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NIGMS NIH HHS [GM 29595] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1967, J BIOL CHEM, V242, P3589; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; GERFEN GJ, UNPUB; HAMILTON JA, 1971, BIOCHEMISTRY-US, V10, P347, DOI 10.1021/bi00778a023; HIBLER DW, 1989, METHOD ENZYMOL, V177, P74; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; HOGENKAMP HP, 1968, J BIOL CHEM, V243, P799; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; NSLLOU FP, 1970, SNSL VHRM, V46, P1248; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SANDO GN, 1975, J BIOL CHEM, V250, P8774; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; THELANDER L, 1974, J BIOL CHEM, V249, P4858; TSAI AL, 1995, J BIOL CHEM, V250, P1053; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WERTZ JE, 1986, ELECT SPIN RESONANCE, P498; WILLING A, 1988, EUR J BIOCHEM, V175, P167, DOI 10.1111/j.1432-1033.1988.tb14179.x	30	274	278	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					477	481		10.1126/science.271.5248.477	http://dx.doi.org/10.1126/science.271.5248.477			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560260				2022-12-28	WOS:A1996TR32200032
J	Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM				Pfaff, SL; Mendelsohn, M; Stewart, CL; Edlund, T; Jessell, TM			Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a motor neuron-dependent step in interneuron differentiation	CELL			English	Article							LARVAL FROG RETINA; CELL PATTERN; SPINAL-CORD; FLOOR PLATE; HOMEODOMAIN; EXPRESSION; NOTOCHORD; ELEGANS; LINEAGE; MOUSE	Motor neuron differentiation is accompanied by the expression of a LIM homeodomain transcription factor, Islet1 (ISL1). To assess the involvement of ISL1 in the generation of motor neurons, we analyzed cell differentiation in the neural tube of embryos in which ISL1 expression has been eliminated by gene targeting. Motor neurons are not generated without ISL1, although many other aspects of cell differentiation in the neural tube occur normally. A population of interneurons that express Engrailed1 (EN1), however, also fails to differentiate in Isl1 mutant embryos. The differentiation of EN1(+) interneurons can be induced in both wild-type and mutant neural tissue by regions of the neural tube that contain motor neurons. These results show that ISL1 is required for the generation of motor neurons and suggest that motor neuron generation is required for the subsequent differentiation of certain interneurons.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University	Pfaff, SL (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.							[Anonymous], 1977, HDB PHYSL NERVOUS SY; Appel B, 1995, DEVELOPMENT, V121, P4117; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Brown AG, 1981, ORG SPINAL CORD; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; NEGISHI K, 1982, SCIENCE, V216, P747, DOI 10.1126/science.7079736; NOMES WO, 1978, BRAIN RES, V159, P1; REH TA, 1987, J NEUROSCI, V7, P3317; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHENG H, 1996, IN PRESS SCIENCE; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TOKUMOTO M, 1995, DEV BIOL, V171, P578, DOI 10.1006/dbio.1995.1306; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	38	635	653	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					309	320		10.1016/S0092-8674(00)80985-X	http://dx.doi.org/10.1016/S0092-8674(00)80985-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565076	hybrid			2022-12-28	WOS:A1996TR59500017
J	Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE				Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE			The definition and preoperative prediction of clinically insignificant prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLING TIME; ADENOCARCINOMA; VOLUME; CARCINOMA; ANTIGEN; PROGRESSION; PROGNOSIS	Objectives. - To define clinically insignificant prostate cancer according to cancer volume, grade, cancer doubling time, and life expectancy; and to determine how many insignificant cancers are removed by radical prostatectomy. Design and Patients. - Clinically insignificant cancer was defined as a tumor that would give rise to no more than 20 cm(3) of cancer within the prostate by the time of expected patient death (1990 life tables) and whose Gleason score was less than 4 in 40- to 49-year-olds, 5 in 50- to 59-year-olds, 6 in 60- to 69-year-olds, and 7 in 70- to 79-year-olds. Four definitions were formulated based on assumed cancer volume doubling times of 2, 3, 4, and 6 years. Using these four definitions, we reviewed 337 totally embedded prostates removed at Mayo Clinic between 1991 and 1993 for clinical stage T1c through T3 cancer to determine how many contained clinically insignificant cancer. Main Outcome Measures. - Clinically significant vs clinically insignificant prostate cancer. Results. - For cancer volume doubling time of 2, 3, 4, and 6 years, clinically insignificant cancer was identified in one (0.3%), 13 (3.9%), 25 (7.4%), and 49 (14.5%) of 337 prostatectomy specimens, respectively. Conclusions. - Clinically insignificant prostate cancer can be defined by cancer volume, grade, cancer volume doubling time, and life expectancy of the patient. According to our definitions, most men treated with radical prostatectomy have clinically significant cancer.	MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								BLACKWELL KL, 1994, J UROLOGY, V151, P1565, DOI 10.1016/S0022-5347(17)35303-X; BOSTWICK DG, 1993, UROLOGY, V41, P403, DOI 10.1016/0090-4295(93)90497-X; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CSAPO Z, 1988, J UROLOGY, V140, P1032, DOI 10.1016/S0022-5347(17)41921-5; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; DAMICO AV, 1993, CANCER-AM CANCER SOC, V72, P2638, DOI 10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HUMPHREY PA, 1990, HUM PATHOL, V21, P799, DOI 10.1016/0046-8177(90)90048-A; IRWIN MB, 1994, UROLOGY, V44, P862, DOI 10.1016/S0090-4295(94)80171-1; KLEE GG, 1994, J UROLOGY, V151, P94, DOI 10.1016/S0022-5347(17)34879-6; KRAMER SA, 1980, J UROLOGY, V124, P223, DOI 10.1016/S0022-5347(17)55381-1; LOWE BA, 1988, J UROLOGY, V140, P1340, DOI 10.1016/S0022-5347(17)42039-8; MCNEAL JE, 1986, LANCET, V1, P60; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1992, HUM PATHOL, V23, P258, DOI 10.1016/0046-8177(92)90106-D; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q; SCHRODER FH, 1992, PROSTATE S, V4, P129; STAMEY TA, 1988, J UROLOGY, V139, P1235; STAMEY TA, 1993, CANCER, V71, P993; TERRIS MK, 1995, UROLOGY, V45, P75, DOI 10.1016/S0090-4295(95)96858-X; VILLERS AA, 1990, J UROLOGY, V143, P1183, DOI 10.1016/S0022-5347(17)40220-5; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; 1989, VITAL STATISTICS US, P22; 1981, NCI MONOGRAPH, V57; 1990, VITAL STATISTICS US, P22	28	134	136	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					288	294		10.1001/jama.275.4.288	http://dx.doi.org/10.1001/jama.275.4.288			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544268				2022-12-28	WOS:A1996TP96500024
J	Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P				Forrester, TE; Wilks, RJ; Bennett, FI; Simeon, D; Osmond, C; Allen, M; Chung, AP; Scott, P			Fetal growth and cardiovascular risk factors in Jamaican schoolchildren	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ADULT LIFE; SERUM-CHOLESTEROL; CHILDHOOD; LIPOPROTEINS; CHILDREN; DISEASE; LIPIDS; HYPERTENSION; ADOLESCENCE	Objective-To determine relation between schoolchildren's blood pressure, glycated haemoglobin level, and cholesterol concentration and their anthropometry, socioeconomic status, and birth measurements. Design-Retrospective cohort study. Setting-27 schools closest to University Hospital of the West Indies, Kingston, Jamaica. Subjects-2337 children aged 6-16 years who were born at university hospital were recruited, and their birth records were recovered: 1610 had suitable records, 659 had records including birth length, and 610 of these were prepubertal. Main outcome measures-Blood pressure, haemoglobin level, serum cholesterol concentration, anthropometry at birth, current anthropometry, and socioeconomic status. Results-Multiple regression analysis showed that children's systolic blood pressure was inversely related to their birth weight (P < 0.0001) and directly related to their current weight. Glycated haemoglobin level was higher in children with thicker triceps skinfolds (P < 0.001) and who had been shorter at birth (P = 0.003). Serum cholesterol concentration was inversely related to current height (P = 0.001) and to length at birth (P = 0.09) and was directly related to triceps skinfold thickness and higher socioeconomic status (P < 0.001). Conclusions-Blood pressure in childhood was inversely related to birth weight and directly to current weight. Glycaemic control and serum cholesterol were related to short length at birth, height deficit in childhood, and childhood obesity.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	Forrester, TE (corresponding author), UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA.			SIMEON, DONALD/0000-0002-6197-9369; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON AJ, 1988, ARTERIOSCLEROSIS, V8, P88, DOI 10.1161/01.ATV.8.1.88; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ANTIA AU, 1990, W INDIAN MED J, V24, P110; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1994, FETAL MATERNAL MED R, V6, P71, DOI DOI 10.1017/S0965539500001005; BEAGLEHOLE R, 1977, AM J EPIDEMIOL, V105, P87, DOI 10.1093/oxfordjournals.aje.a112359; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BURNS TL, 1989, AM J EPIDEMIOL, V129, P973, DOI 10.1093/oxfordjournals.aje.a115229; CAMPOS H, 1991, ARTERIOSCLER THROMB, V11, P1077, DOI 10.1161/01.ATV.11.4.1077; CLARKE WR, 1978, CIRCULATION, V58, P626, DOI 10.1161/01.CIR.58.4.626; FREEDMAN DS, 1987, PEDIATRICS, V80, P789; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALL PM, 1983, ANN CLIN BIOCHEM, V20, P129, DOI 10.1177/000456328302000301; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LAUER RM, 1984, CIRCULATION, V69, P242, DOI 10.1161/01.CIR.69.2.242; LAUER RM, 1991, HYPERTENSION, V18, P74, DOI 10.1161/01.HYP.18.3_Suppl.I74; LAUER RM, 1988, PEDIATRICS, V75, P1081; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW CM, IN PRESS DIABET MED; LIU K, 1989, HYPERTENSION, V14, P218, DOI 10.1161/01.HYP.14.2.218; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARGETTS BM, 1991, INT J EPIDEMIOL, V20, P938, DOI 10.1093/ije/20.4.938; Martorell R, 1989, ANTHROPOMETRIC STAND; MILLER GJ, 1976, CLIN SCI MOL MED, V51, P475, DOI 10.1042/cs0510475; MUELLER WH, 1984, AM J PHYS ANTHROPOL, V64, P389, DOI 10.1002/ajpa.1330640404; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; STERN MP, 1986, ARTERIOSCLEROSIS, V6, P123, DOI 10.1161/01.ATV.6.2.123; WARD R, 1990, HYPERTENSION PATHOPH, P81; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1992, J EPIDEMIOL COMMUNIT, V46, P1640; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	39	175	176	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					156	160						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563535				2022-12-28	WOS:A1996TR32500023
J	Kumar, A; Edward, N; White, MI; Johnston, PW; Catto, GRD				Kumar, A; Edward, N; White, MI; Johnston, PW; Catto, GRD			Lesson of the week - Allopurinol, erythema multiforme, and renal insufficiency	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HYPERSENSITIVITY REACTIONS; CREATININE CLEARANCE		ABERDEEN MED SCH,DEPT PATHOL,ABERDEEN,SCOTLAND	University of Aberdeen	Kumar, A (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,FORSTERHILL AB9 2ZD,ABERDEEN,SCOTLAND.							ARELLANO F, 1993, ANN PHARMACOTHER, V27, P337, DOI 10.1177/106002809302700317; AUBOCK J, 1985, BMJ-BRIT MED J, V290, P1969, DOI 10.1136/bmj.290.6486.1969; CAMERON JS, 1987, BRIT MED J, V294, P1504, DOI 10.1136/bmj.294.6586.1504; CHAN HL, 1977, AUST NZ J MED, V7, P518, DOI 10.1111/j.1445-5994.1977.tb03375.x; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; GELBART DR, 1977, ANN INTERN MED, V86, P197; GRUSSENDORF M, 1981, AM J NEPHROL, V1, P105, DOI 10.1159/000166504; HANDE KR, 1984, AM J MED, V76, P47, DOI 10.1016/0002-9343(84)90743-5; JARZOBSKI J, 1970, AM HEART J, V79, P116, DOI 10.1016/0002-8703(70)90401-1; LANG PG, 1979, SOUTHERN MED J, V72, P1361, DOI 10.1097/00007611-197911000-00004; LUPTON GP, 1979, J AM ACAD DERMATOL, V1, P365, DOI 10.1016/S0190-9622(79)70031-4; MCINNES GT, 1901, ANN RHEUM DIS, V40, P245; MCMENAMIN RA, 1976, AUST NZ J MED, V6, P583, DOI 10.1111/j.1445-5994.1976.tb04001.x; MILLS RM, 1971, J AMER MED ASSOC, V216, P799, DOI 10.1001/jama.216.5.799; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; RUNDLES RW, 1966, ANN INTERN MED, V64, P229, DOI 10.7326/0003-4819-64-2-229; YOUNG JL, 1974, ARCH INTERN MED, V134, P553, DOI 10.1001/archinte.134.3.553	17	38	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					173	174						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563541				2022-12-28	WOS:A1996TR32500030
J	Curcio, MJ; Belfort, M				Curcio, MJ; Belfort, M			Retrohoming: cDNA-mediated mobility of group II introns requires a catalytic RNA	CELL			English	Review							TRANSPOSITION; YEAST		SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Curcio, MJ (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR,MOLEC GENET PROGRAM,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618; Curcio, M. Joan/0000-0001-5361-3909	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052072] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM052072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Eickbush Thomas H., 1994, P121; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; WANG J, 1993, CELL, V76, P1071; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	15	58	62	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					9	12		10.1016/S0092-8674(00)80987-3	http://dx.doi.org/10.1016/S0092-8674(00)80987-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548830	Bronze			2022-12-28	WOS:A1996TQ17000003
J	Genuth, S				Genuth, S			Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			CORONARY HEART-DISEASE; COMPLICATIONS TRIAL; MORTALITY; POPULATION	Purpose: It is currently unknown whether intensive insulin treatment of diabetes decreases the risk for cardiovascular complications by lowering glucose levels or increases the risk by postulated direct atherogenic effects. This article reviews published data from two long-term,randomized clinical trials that compared cardiovascular outcomes associated with different exogenous insulin treatment regimens. Study Selection and Data Sources: The University Group Diabetes Program (UGDP) and the Diabetes Control and Complications Trial (DCCT) were selected as the only available randomized intervention trials with longterm follow-up results. Data reviewed were from the major publications of these two trials. Results: The UGDP compared the effects of a fixed-dose standard insulin regimen, a variable-dose insulin regimen, and a diet plus oral placebo regimen in over 600 patients with non-insulin-dependent diabetes mellitus (NIDDM) who were followed for up to 13 years (1962 to 1975). Plasma glucose levels were 1.7 to 2.2 mmol/L lower in the variable-dose insulin regimen group than in the other two treatment groups. No significant differences were found in the final prevalence or the cumulative incidence of total deaths, cardiovascular disease deaths, or myocardial infarctions among the three treatment groups, even when outcomes were adjusted for pertinent baseline cardiovascular risk factors. There was a slight suggestion only from post hoc analysis that patients in both insulin treatment groups, who were defined as having good glucose control, had fewer cardiovascular events than those with fair or poor control. The DCCT compared intensive insulin treatment with conventional insulin treatment (the mean hemoglobin Al, [HbA(1c)] level was 7.2% and 9.0%, respectively) in over 1400 patients with insulin-dependent diabetes (IDDM) followed for up to 10 years (1983 to 1993). Three major cardiovascular events occurred in the intensive treatment group as compared with 14 in the conventional treatment group (P > 0.05), and low-density lipoprotein cholesterol and triglyceride levels were substantially lower in the intensive treatment group. However, body mass index increased substantially more with intensive than with conventional therapy. Conclusions: The UGDP trial was flawed by inadequate power, uncertainties in compliance with treatment regimens, insufficient separation of glycemic levels, and ignorance of smoking history as a possible confounder. In the DCCT, the number of cardiovascular events was few because the patients were young and had a relatively short duration of diabetes at baseline. In addition, total daily insulin doses were similar in the two DCCT treatment groups. For these reasons, neither trial provides a definitive answer to the question about the effects of intensive insulin therapy. A better designed clinical trial is needed to determine whether insulin treatment has beneficial or adverse effects, or even offsetting beneficial and adverse effects, on the risk for cardiovascular disease in NIDDM and IDDM.	CASE WESTERN RESERVE UNIV, CLEVELAND, OH USA	Case Western Reserve University	Genuth, S (corresponding author), MT SINAI MED CTR, 1 MT SINAI DR, CLEVELAND, OH 44106 USA.							[Anonymous], 1982, Diabetes, V31 Suppl 5, P1; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; EASTMAN RC, 1993, J CLIN ENDOCR METAB, V77, P1105, DOI 10.1210/jc.77.5.1105; ELLIOTT TG, 1993, BAILLIERE CLIN ENDOC, V7, P1079, DOI 10.1016/S0950-351X(05)80246-0; GENUTH S, 1990, DIABETES CARE, V13, P1240, DOI 10.2337/diacare.13.12.1240; HARRIS M, 1979, DIABETES, V28, P1039; JARRETT RJ, 1984, DIABETOLOGIA, V26, P99; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; KILO C, 1980, DIABETOLOGIA, V18, P179, DOI 10.1007/BF00251913; KILO C, 1980, JAMA-J AM MED ASSOC, V243, P450, DOI 10.1001/jama.243.5.450; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; LASKER RD, 1993, NEW ENGL J MED, V329, P1035, DOI 10.1056/NEJM199309303291410; Lebovitz Harold E., 1994, Clinical Diabetes, V12, P3; MEINERT CL, 1970, DIABETES, V19, P789; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; SHAMOON H, 1995, DIABETES CARE, V18, P361; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STERN MP, 1985, ARTERIOSCLEROSIS, V5, P311, DOI 10.1161/01.ATV.5.4.311; TURNER RC, 1991, DIABETOLOGIA, V34, P877; YAMASAKI Y, 1995, DIABETOLOGIA, V38, P585, DOI 10.1007/s001250050323; 1975, JAMA-J AM MED ASSOC, V231, P583	25	79	81	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				104	109		10.7326/0003-4819-124-1_Part_2-199601011-00005	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554200				2022-12-28	WOS:A1996TL94400005
J	Javitt, JC; Aiello, LP				Javitt, JC; Aiello, LP			Cost-effectiveness of detecting and treating diabetic retinopathy	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			4-YEAR INCIDENCE; MELLITUS; DIAGNOSIS; AGE; PHOTOCOAGULATION; PROGRESSION; GUIDELINES; PREVALENCE; MORTALITY; SEVERITY	Objective: To determine, from the health insurer's perspective, the cost of preventing vision loss in patients with diabetes mellitus through ophthalmologic screening and treatment and to calculate the cost-effectiveness of these interventions as compared with that of other medical interventions. Design: Computer modeling, incorporating data from population-based epidemiologic studies and multicenter clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. Results: Screening and treatment of eye disease in patients with diabetes mellitus costs $3190 per quality-adjusted life-year (QALY) saved. This average cost is a weighted average (based on prevalence of disease) of the cost-effectiveness of detecting and treating diabetic eye disease in those with insulin-dependent diabetes mellitus ($1996 per QALY), those with non-insulin-dependent diabetes mellitus (NIDDM) who use insulin for glycemic control ($2933 per QALY), and those with NIDDM who do not use insulin for glycemic control ($3530 per QALY). Conclusions: Our analysis indicates that prevention programs aimed at improving eye care for diabetic persons not only result in substantial federal budgetary savings but are highly cost-effective health investments for society. Ophthalmologic screening for diabetic persons is more cost-effective than many routinely provided health interventions. Because diabetic eye disease is the leading cause of new cases of blindness among working-age Americans, these results support the widespread use of screening and treatment for diabetic eye disease.	JOSLIN DIABET CTR, BEETHAM EYE INST, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Javitt, JC (corresponding author), GEORGETOWN UNIV, MED CTR, CTR SIGHT, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NATIONAL EYE INSTITUTE [R01EY008805, R21EY007744] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EYO8805, R21-EY07744] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1979, Arch Ophthalmol, V97, P654; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], DIABETIC RETINOPATHY; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BRADFORD DF, 1983, PUBLIC EXPENDITURE P, P129; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CANNER JK, 1992, WIN P SIM C, V25, P1041; CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; Davis M D, 1979, Trans Am Ophthalmol Soc, V77, P144; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; DRUMMOND M, 1987, CNSULTANT REPORT NAT; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EVERHART J, 1985, NIH851468 US DEP HLT, P1; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; Johannesson M, 1992, Int J Technol Assess Health Care, V8, P359; Kenny S.J., 1995, NIH PUBLICATION, P47; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN HA, 1970, US DHEW73427; KLEIN R, 1985, DIABETES CARE, V8, P71, DOI 10.2337/diacare.8.1.S71; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1987, OPHTHALMOLOGY, V94, P747; KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1984, NIH851468 PUBLICATIO, P1; KNATTERUD GL, 1983, ISRAEL J MED SCI, V19, P424; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MARTIN DB, 1985, NIH851468 PHS US DEP, pR24; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; RING A, 1991, CLIN DIABETES MELLIT, P728; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; VANDER JF, 1991, OPHTHALMOLOGY, V98, P1575; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1993, MMWR-MORBID MORTAL W, V42, P191; 1989, DIABETES 2000 ELIMIN; 1992, LANCET, V340, P148; 1987, VITAL STATISTICS US, V2; ANAL EARLY TREATMENT; 1980, VISION PROBLEMS US S; 1988, VITAL STATISTICS US, V1, P17; 1990, AVERAGE MEDICARE ALL	54	270	274	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				164	169		10.7326/0003-4819-124-1_Part_2-199601011-00017	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554212				2022-12-28	WOS:A1996TL94400017
J	McDonald, CJ; Overhage, M; Tierney, WM; Abernathy, GR; Dexter, PR				McDonald, CJ; Overhage, M; Tierney, WM; Abernathy, GR; Dexter, PR			The promise of computerized feedback systems for diabetes care	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			SODIUM-NITROPRUSSIDE INFUSION; CONTROLLED TRIAL; INSULIN DELIVERY; MEDICAL-RECORD; PATIENT-CARE; MANAGEMENT; PHYSICIANS; REMINDERS; PRESSURE; PROTOCOL	Feedback control is an important mechanism for reaching a targeted goal. Biologic examples range from achieving the appropriate blood pressure level to glycemia control. Computer-based feedback control systems have many potential applications in medicine. Closed-loop systems directly sense the state of the patient and then deliver an intervention without human action. Closed-loop systems have been used to control postoperative fluid infusion, reduce malignant hypertension to a reasonable range through nitroprusside infusions, and control continuous insulin infusions-in effect, an artificial pancreas. Sensory problems have limited the direct application of closed-loop systems to date; most current medical uses of computer-based feedback control are open loop, where a human is interposed between the suggested intervention and the delivered treatment. Because many variables important to the management of diabetes are objective, many opportunities exist for open-loop control in diabetes management. Open-loop systems have already been used to suggest insulin dosage adjustments and treatments for hypercholesterolemia and to remind physicians of various interventions to reduce the complications of diabetes mellitus. However, existing applications have only scratched the surface. Many more facets of diabetes management could be standardized and assisted by open-loop control systems if the management rules could be more exactly specified, a task requiring substantial time commitments by diabetologists. Efforts to translate existing knowledge bases into precise guidelines will be helpful, but new primary studies and decision analyses are needed to define the optimal use of some interventions.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis	McDonald, CJ (corresponding author), REGENSTRIEF INST HLTH CARE, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.			Overhage, Joseph/0000-0003-0223-0195	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM043510] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS07719-01] Funding Source: Medline; NLM NIH HHS [N01-LM-4-3510] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		[Anonymous], 1992, MANUAL ASSESSING HLT; BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BERGER MP, 1990, COMPUT BIOMED RES, V23, P346, DOI 10.1016/0010-4809(90)90026-9; Buchwald H, 1992, ASAIO J, V38, P3, DOI 10.1097/00002480-199201000-00002; CHIARELLI F, 1990, DIABETES CARE, V13, P1080, DOI 10.2337/diacare.13.10.1080; DEUTSCH T, 1989, COMPUT METH PROG BIO, V29, P75, DOI 10.1016/0169-2607(89)90076-X; EAST TD, 1992, CHEST, V101, P697, DOI 10.1378/chest.101.3.697; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HAUG PJ, 1994, COMPUT BIOMED RES, V27, P396, DOI 10.1006/cbmr.1994.1030; HUBBELL FA, 1985, NEW ENGL J MED, V312, P209, DOI 10.1056/NEJM198501243120404; JELLIFFE RW, 1994, INT J BIOMED COMPUT, V36, P1, DOI 10.1016/0020-7101(94)90091-4; LANDEFELD CS, 1992, ANN INTERN MED, V116, P829, DOI 10.7326/0003-4819-116-10-829; LEVY P, 1994, DIABETES REV, V2, P368; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; Marrero D G, 1991, J Community Health, V16, P259, DOI 10.1007/BF01320334; MARRERO DG, 1989, DIABETES CARE, V12, P345, DOI 10.2337/diacare.12.5.345; MARRERO DG, 1995, DIABETES EDUCATOR, V21, P313, DOI 10.1177/014572179502100409; MARRERO DG, 1993, CONCEPTS IDEAL DIABE, P375; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MELINE LJ, 1985, ANESTH ANALG, V64, P38; PETERSON CM, 1986, AM J MED, V81, P69, DOI 10.1016/0002-9343(86)90184-1; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; RUBENSTEIN LZ, 1980, JAMA-J AM MED ASSOC, V244, P2536, DOI 10.1001/jama.244.22.2536; SAUDEK CD, 1993, DIABETES CARE, V16, P122, DOI 10.2337/diacare.16.3.122; SHEPPARD LC, 1977, MED INSTRUM, V11, P296; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; TIERNEY WM, 1994, J AM MED INFORM ASSN, V1, P353, DOI 10.1136/jamia.1994.95236170; WESTENSKOW DR, 1986, M D COMPUT, V3, P14; YING H, 1990, MED PROG TECHNOL, V16, P69; ZIPES DP, 1994, MAYO CLIN PROC, V69, P395, DOI 10.1016/S0025-6196(12)62229-0; 1993, DIABETES CARE S2, V16, P10; 1982, J MED ENG TECHNOL, V6, P89	36	19	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				170	174		10.7326/0003-4819-124-1_Part_2-199601011-00018	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00018			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554213				2022-12-28	WOS:A1996TL94400018
J	MOHER, D; OLKIN, I				MOHER, D; OLKIN, I			METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS - A CONCERN FOR STANDARDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METAANALYSIS		OTTAWA CIVIC HOSP,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; STANFORD UNIV,DEPT STAT,STANFORD,CA 94305	University of Ottawa; Ottawa Hospital Research Institute; Stanford University	MOHER, D (corresponding author), OTTAWA CIVIC HOSP,LOEB MED RES INST,CLIN EPIDEMIOL UNIT,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.			Moher, David/0000-0003-2434-4206				[Anonymous], 1995, LANCET, V345, P669; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Chalmers I, 1995, SYSTEMATIC REV; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; GLESER LJ, 1995, 100 STANF U DEP STAT; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; Iyengar S., 1988, STAT SCI, V3, P109, DOI DOI 10.1214/SS/1177013012; JADAD AR, IN PRESS CONTROLLED; JADAD AR, IN PRESS J CLIN EPID; KOON KT, 1991, BRIT MED J, V303, P1499; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOHER D, IN PRESS INT J TECHN; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STERLING TD, 1995, AM STAT, V49, P108, DOI 10.2307/2684823; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; 1994, JAMA-J AM MED ASSOC, V272, P1926	28	99	99	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1962	1964		10.1001/jama.274.24.1962	http://dx.doi.org/10.1001/jama.274.24.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568993				2022-12-28	WOS:A1995TL16900041
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ON THE INTERNET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-28	WOS:A1995TL16900011
J	GAN, SS; AMASINO, RM				GAN, SS; AMASINO, RM			INHIBITION OF LEAF SENESCENCE BY AUTOREGULATED PRODUCTION OF CYTOKININ	SCIENCE			English	Article							TOBACCO PLANTS	Controlling expression of IPT, a gene encoding isopentenyl transferase (the enzyme that catalyzes the rate-limiting step in cytokinin biosynthesis), with a senescence-specific promoter results in the suppression of leaf senescence. Transgenic tobacco plants expressing this chimeric gene do not exhibit the developmental abnormalities usually associated with IPT expression because the system is autoregulatory. Because sufficient cytokinin is produced to retard senescence, the activity of the senescence-specific promoter is attenuated. Senescence-retarded leaves exhibit a prolonged, photosynthetically active life-span. This result demonstrates that endogenously produced cytokinin can regulate senescence and provides a system to specifically manipulate the senescence program.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								Duvick D. N., 1984, Genetic contributions to yield gains of five major crop plants. Proceedings of a symposium sponsored by Division C-1 of the Crop Science Society of America, 2 December 1981, in Atlanta, Georgia, P15; GAN S, UNPUB; GARNER RJ, 1988, GRAFTERS HDB; HEWELT A, 1994, PLANT J, V6, P879, DOI 10.1046/j.1365-313X.1994.6060879.x; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; LI Y, 1992, DEV BIOL, V153, P386, DOI 10.1016/0012-1606(92)90123-X; LOHMAN KN, 1994, PHYSIOL PLANTARUM, V92, P322, DOI 10.1111/j.1399-3054.1994.tb05343.x; MARTINEAU B, 1994, PLANT J, V5, P11, DOI 10.1046/j.1365-313X.1994.5010011.x; NOODEN LD, 1979, SCIENCE, V206, P841, DOI 10.1126/science.206.4420.841; NOODEN LD, 1978, PHYTOHORMONES RELATE, V2, P329; RICHMOND AE, 1957, SCIENCE, V125, P650, DOI 10.1126/science.125.3249.650-a; SINGH S, 1992, PHYSIOL PLANTARUM, V86, P388, DOI 10.1111/j.1399-3054.1992.tb01334.x; SMART CM, 1991, PLANT CELL, V3, P647, DOI 10.1105/tpc.3.7.647; THOMAS H, 1980, ANNU REV PLANT PHYS, V31, P83, DOI 10.1146/annurev.pp.31.060180.000503	14	774	977	9	231	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1986	1988		10.1126/science.270.5244.1986	http://dx.doi.org/10.1126/science.270.5244.1986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8592746				2022-12-28	WOS:A1995TL42000040
J	Butler, RN				Butler, RN			On behalf of older women - Another reason to protect Medicare and Medicaid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Butler, RN (corresponding author), INT LONGEV CTR US,NEW YORK,NY 10029, USA.							BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; *BUR CENS, 1995, CURR POP REP P23, V178, P14; Corning Peter A, 1969, EVOLUTION MEDICARE; DAVIS K, 1995, AM J PUBLIC HEALTH, V85, P1051, DOI 10.2105/AJPH.85.8_Pt_1.1051; DAVIS K, 1993, UNFINISHED AGENDA IM; Harris Richard, 1966, SACRED TRUST; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805	8	14	14	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					794	796		10.1056/NEJM199603213341211	http://dx.doi.org/10.1056/NEJM199603213341211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592557				2022-12-28	WOS:A1996TZ97900011
J	Andersen, HS; Godwin, JH				Andersen, HS; Godwin, JH			Multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Andersen, HS (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.								0	0	0	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					513	513		10.1056/NEJM199602223340806	http://dx.doi.org/10.1056/NEJM199602223340806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559205				2022-12-28	WOS:A1996TV68600006
J	Lips, P; Graafmans, WC; Ooms, ME; Bezemer, PD; Bouter, LM				Lips, P; Graafmans, WC; Ooms, ME; Bezemer, PD; Bouter, LM			Vitamin D supplementation and fracture incidence in elderly persons - A randomized, placebo-controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article						vitamin D; fractures; aged; osteoporosis; hip fractures	POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; HIP-FRACTURES; BONE-DENSITY; OSTEOPOROSIS; CALCIUM; PEOPLE	Objective: To determine whether vitamin D supplementation decreases the incidence of hip fractures and other peripheral bone fractures. Design: Prospective, double-blind trial. Setting: Community setting (Amsterdam and surrounding area). Patients: 2578 persons (1916 women, 662 men) 70 years of age and older (mean age +/- SD, 80 +/- 6 years) living independently, in apartments for elderly persons, or in homes for elderly persons. Intervention: Participants were randomly assigned to receive either vitamin D-3, 400 IU in one tablet daily, or placebo for a maximum of 3.5 years. Measurements: Dietary calcium intake and serum 25-hydroxyvitamin D [25(OH)D] were estimated in a subset of participants. During follow-up, attention was concentrated on hip fractures and other peripheral fractures. The maximal follow-up period was 4 years. The results were evaluated by survival analysis. Results: Mean dietary calcium intake from dairy products was 868 mg/d. Mean serum 25(OH)D concentration in the third year of the study was 23 nmol/L in the placebo group and 60 nmol/L in the vitamin D group. Median follow-up was 3.5 years, and total follow-up was 8450 patient-years. During follow-up, 306 persons in the placebo group and 282 persons in the vitamin D group died (P = 0.20). Hip fractures occurred in 48 persons in the placebo group and 58 persons in the vitamin D group (P = 0.39, intention-to-treat analysis). Other peripheral fractures occurred in 74 persons in the placebo group and 77 persons in the vitamin D group (P = 0.86). Conclusion: Our results do not show a decrease in the incidence of hip fractures and other peripheral fractures in Dutch elderly persons after vitamin D supplementation.			Lips, P (corresponding author), VRIJE UNIV AMSTERDAM, ACAD ZIEKENHUIS, DEPT ENDOCRINOL, POB 7057, 1007 MB AMSTERDAM, NETHERLANDS.			Bouter, Lex/0000-0002-2659-5482				ARMITAGE P, 1987, STATISTICAL METHODS; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; CHAPUY MC, 1987, AM J CLIN NUTR, V46, P324, DOI 10.1093/ajcn/46.2.324; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; HIMMELSTEIN S, 1990, AM J CLIN NUTR, V52, P701, DOI 10.1093/ajcn/52.4.701; Holick M. F., 1990, BONE MINERAL RES ANN, P313; JONGEN MJ, 1988, J CLIN CHEM CLIN BIO, V26, P25; KANIS JA, 1984, LANCET, V1, P27; KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; Lips P, 1991, Osteoporos Int, V1, P218; LIPS P, 1990, BONE MINER, V9, P49, DOI 10.1016/0169-6009(90)90099-2; LIPS P, 1983, J CLIN ENDOCR METAB, V57, P204, DOI 10.1210/jcem-57-1-204; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; LIPS P, 1995, J BONE MINER RES, V10, pS496; LIPS P, 1991, VITAMIN D, P757; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MOSEKILDE L, 1987, BONE, V8, P79, DOI 10.1016/8756-3282(87)90074-3; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; OOMS ME, 1995, J BONE MINER RES, V10, P1177; OOMS ME, 1994, THESIS VRIJE U AMSTE; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203	30	486	491	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					400	+		10.7326/0003-4819-124-4-199602150-00003	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554248	Green Submitted			2022-12-28	WOS:A1996TV22000003
J	Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K				Amano, M; Mukai, H; Ono, Y; Chihara, K; Matsui, T; Hamajima, Y; Okawa, K; Iwamatsu, A; Kaibuchi, K			Identification of a putative target for Rho as the serine-threonine kinase protein kinase N	SCIENCE			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; MOLECULAR-WEIGHT	Rho, a Ras-like small guanosine triphosphatase, has been implicated in cytoskeletal responses to extracellular signals such as lysophosphatidic acid (LPA) to form stress fibers and focal contacts. The form of RhoA bound to guanosine triphosphate directly bound to and activated a serine-threonine kinase, protein kinase N (PKN). Activated RhoA formed a complex with PKN and activated it in COS-7 cells. PKN was phosphorylated in Swiss 3T3 cells stimulated with LPA, and this phosphorylation was blocked by treatment of cells with botulinum C3 exoenzyme. Activation of Rho may be linked directly to a serine-threonine kinase pathway.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Kobe University; Kirin Brewery Company Limited			Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Mukai, Hideyuki/0000-0002-0167-8695				AMANO M, UNPUB; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3	20	387	407	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					648	650		10.1126/science.271.5249.648	http://dx.doi.org/10.1126/science.271.5249.648			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571127				2022-12-28	WOS:A1996TT87000046
J	Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A				Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A			Normal host prion protein necessary for scrapie-induced neurotoxicity	NATURE			English	Article							CELL-SURFACE; PRP	ACCUMULATION of the prion protein PrPSc, a pathological and protease-resistant isoform of the normal host protein PrPC, is a feature of prion disease such as scrapie(1,2). It is still unknown whether scrapie pathology comes about by neurotoxicity of PrPSc, acute depletion of PrPC, or some other mechanism. Here we investigate this question by grafting neural tissue overexpressing PrPC into the brain of PrP-deficient mice which are scrapie-resistant and do not propagate infectivity(3-5). After intracerebral inoculation with scrapie prions, the grafts accumulated high levels of PrPSc and infectivity and developed the severe histopathological changes characteristic of scrapie. Moreover, substantial amounts of graft-derived PrPSc migrated into the host brain. Even 16 months after inoculation no pathological changes were seen in PrP-deficient tissue, not even in the immediate vicinity of the grafts. Therefore, in addition to being resistant to scrapie infection, brain tissue devoid of PrPC is not damaged by exogenous PrPSc.	UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOLEC BIOL,DEPT 1,ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich			Brandner, Sebastian/J-4562-2014; Aguzzi, Adriano/A-3351-2008; Isenmann, Stefan/AAJ-3788-2020; Sailer, Andreas/M-9913-2016	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708; Sailer, Andreas/0000-0002-9015-7946; Marino, Silvia/0000-0002-9612-2883				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; FISCHER M, IN PRESS EMBO J; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; ISENMANN S, IN PRESS NEUROPATHOL; JEFFREY M, 1994, BRAIN RES, V656, P329, DOI 10.1016/0006-8993(94)91477-X; JEFFREY M, 1994, NEUROSCI LETT, V174, P39, DOI 10.1016/0304-3940(94)90113-9; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUISINER SBA, 1994, REV MICROBIOL, V48, P655; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9	23	641	659	0	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					339	343		10.1038/379339a0	http://dx.doi.org/10.1038/379339a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552188				2022-12-28	WOS:A1996TR32300057
J	Coast, J; Inglis, A; Frankel, S				Coast, J; Inglis, A; Frankel, S			Alternatives to hospital care: What are they and who should decide?	BRITISH MEDICAL JOURNAL			English	Article							BEDS	Objective-To examine potential for alternatives to care in hospitals for acute admissions, and to compare the decisions about these alternatives made by clinicians with different backgrounds. Design-Standardised tool was used to identify patients who could potentially be treated in an alternative form of care. Information about such patients was assessed by three panels of clinicians: general practitioners without experience of general practitioner beds, general practitioners with experience of general practitioner beds, and consultants. Setting-One hospital for acute admissions in a rural area of the South and West region of England. Subjects-Of 620 patients admitted to specialties of general medicine and care of the elderly, details of 112 were assessed by panels. Main outcome measures-Proportion of hospitalised patients who could have received alternative care and identification of most appropriate alternative form of care. Results-Both general practitioner panels estimated that between 51 and 89 of the hospitalised patients could have received alternative care (equivalent to 8-14% of all admissions). Consultants estimated that between 25 and 55 patients could have had alternative care (5.5-9% of all admissions). General practitioner bed and urgent outpatient appointment were the main alternatives chosen by all three panels. Conclusion-About 10% of admissions to general hospital might be suitable for alternative forms of care. Doctors with different backgrounds made similar overall assessments of most appropriate forms of care.			Coast, J (corresponding author), UNIV BRISTOL,DEPT MED SOCIOL,BRISTOL BS8 2PR,AVON,ENGLAND.			Coast, Joanna/0000-0002-3537-5166				ANDERSON P, 1988, BRIT MED J, V297, P910, DOI 10.1136/bmj.297.6653.910; BEECH R, 1987, BRIT MED J, V294, P685, DOI 10.1136/bmj.294.6573.685; Cox D., 1958, PLANNING EXPT; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; INGLIS AL, 1995, MED CARE, V33, P952, DOI 10.1097/00005650-199509000-00006; JACOBS CM, 1992, ISD A REV SYSTEM ADU; LAURANCE J, 1993, TIMES           0111, P7; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; Torrance N, 1972, J R Coll Gen Pract, V22, P211; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; 1992, INDEPENDENT     0330, P9	12	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					162	166						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563538				2022-12-28	WOS:A1996TR32500026
J	Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E				Gough, A; Chapman, S; Wagstaff, K; Emery, P; Elias, E			Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome	BRITISH MEDICAL JOURNAL			English	Article							FAILURE; ACNE	Monocycline is the most widely prescribed systemic antibiotic for acne largely because it needs to be given only once or twice a day and seems not to induce resistance. Up to April 1994 11 cases of minocycline induced systemic erythematosus and cases of hepatitis been reported to Committee on Safety of Medicines. An analysis of these cases together with seven other cases shows the severity of some of these reactions. Two patients died while taking the drug for acne and a further patient needed a liver transplant. Acne itself can induce arthritis and is often seen in association with autoimmine liver disease, but the clinical and biochemical resolution seen after withdrawal of the drug, despite deterioration of the acne, suggests a drug reaction. In five cases re-exposure led to recurrence. Because reactions may be severe early recognition is important to aid recovery and also to avoid invasive investigations and treatments such as corticosteroids and immunosuppresants. Safer alternatives should be considered for treating acne.	UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND; HARROGATE DIST HOSP,DEPT RHEUMATOL,HARROGATE HG2 7SX,W YORKSHIRE,ENGLAND; UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND; SELLY OAK HOSP,DRUG INFORMAT UNIT,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,LIVER UNIT,DEPT HEPATOBILIARY MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Leeds; Keele University; University of Birmingham			emery, paul/B-3560-2013					BOCKER R, 1991, ANTIMICROB AGENTS CH, V35, P1434, DOI 10.1128/AAC.35.7.1434; BOUDREAUX JP, 1993, TRANSPLANT P, V25, P1873; BURETTE A, 1984, ARCH INTERN MED, V144, P1491, DOI 10.1001/archinte.144.7.1491; BYRNE PAC, 1994, BRIT J RHEUMATOL, V33, P674; DAVIES MG, 1989, BRIT MED J, V298, P1523, DOI 10.1136/bmj.298.6686.1523-c; DOLLERY C, 1991, THERAPEUTIC DRUGS; DOMZ CA, 1959, ANN INTERN MED, V50, P1217, DOI 10.7326/0003-4819-50-5-1217; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; GORARD DA, 1990, POSTGRAD MED J, V66, P404, DOI 10.1136/pgmj.66.775.404; HEALY E, 1994, BRIT MED J, V308, P831, DOI 10.1136/bmj.308.6932.831; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KNITZER RH, 1991, SEMIN ARTHRITIS RHEU, V20, P247, DOI 10.1016/0049-0172(91)90020-Z; MACDONALD H, 1973, CLIN PHARMACOL THER, V14, P852; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; MIN DI, 1992, PHARMACOTHERAPY, V12, P68; NELIS HJCF, 1981, LANCET, V2, P938; OTERO M, 1983, JAMA-J AM MED ASSOC, V250, P2602, DOI 10.1001/jama.1983.03340190016010; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; PUYANA J, 1990, ALLERGY, V45, P313, DOI 10.1111/j.1398-9995.1990.tb00502.x; ROBINSON MJ, 1970, AM J DIG DIS, V15, P857, DOI 10.1007/BF02236049; RUTENBURG AM, 1952, NEW ENGL J MED, V247, P797, DOI 10.1056/NEJM195211202472104; SCHULTZ JC, 1963, NEW ENGL J MED, V269, P999, DOI 10.1056/NEJM196311072691903; SOLDINGER AM, 1988, RHEUM CLIN N AM, V14, P187	23	235	235	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					169	172						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563540				2022-12-28	WOS:A1996TR32500028
J	Reichman, LB				Reichman, LB			How to ensure the continued resurgence of tuberculosis	LANCET			English	Editorial Material							NEW-YORK-CITY		UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07107	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT MED,GB1,65 BERGEN ST,NEWARK,NJ 07107, USA.							BINYA T, 1992, CHINESE J ANTIBIOTIC, V7, P313; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P299; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; MOULDING T, 1995, ANN INTERN MED, V122, P951, DOI 10.7326/0003-4819-122-12-199506150-00010; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIDZON R, 1995, AM J RESP CRIT CARE, V151, pA665; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; WARING JJ, 1956, JAMA-J AM MED ASSOC, V161, P1368, DOI 10.1001/jama.1956.02970140024007; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, OTR H574 US C OFF TE, P91; 1961, DHEW PHS ML784 PUBL; 1995, MMWR-MORBID MORTAL W, V44, P835; 1995, WHO TUBERCULOSIS PRO; 1995, GAOHEHS9511 US GEN A; 1993, WORLD HEALTH FORUM, V14, P438	21	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					175	177		10.1016/S0140-6736(96)90348-7	http://dx.doi.org/10.1016/S0140-6736(96)90348-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544556				2022-12-28	WOS:A1996TQ24400017
J	Stratmann, R; Lehner, CF				Stratmann, R; Lehner, CF			Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase anaphase transition	CELL			English	Article							DNA TOPOISOMERASE-II; CYCLIN-A; MELANOGASTER; CHROMOSOME; GENE; MUTATIONS; SEQUENCE; EMBRYOS; PROGRESSION; SEGREGATION	Mutations in the Drosophila genes pimples and three rows result in a defect of sister chromatid separation during mitosis. As a consequence, cytokinesis is also defective. However, cell cycle progression including the mitotic degradation of cyclins A and B is not blocked by the failure of sister chromatid separation, and as a result, metaphase chromosomes with twice the normal number of chromosome arms still connected in the centromeric region are observed in the following mitosis. pimples encodes a novel protein that is rapidly degraded in mitosis. Our observations suggest that Pimples and Three rows act during mitosis to release the cohesion between sister centromeres.			Stratmann, R (corresponding author), MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,SPEMANNSTR 37-39,D-72076 TUBINGEN,GERMANY.							ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARMENA M, 1993, J CELL SCI, V105, P41; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOE VE, 1989, DEVELOPMENT, V107, P1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GHOSH S, 1992, EXP CELL RES, V200, P215, DOI 10.1016/S0014-4827(05)80091-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUACCI V, 1993, S QYANT BIOL, V58, P677; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HOLLOWAY SL, 1995, CURR OPIN GENET DEV, V5, P243, DOI 10.1016/0959-437X(95)80015-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IMIGER S, 1995, CELL, V81, P269; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MATSUMOTO K, 1994, CHROMOSOMA, V103, P338, DOI 10.1007/BF00417881; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PHILP AV, 1993, J CELL SCI, V106, P87; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; STEM B, 1993, DEVELOPMENT, V117, P219; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	59	116	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					25	35		10.1016/S0092-8674(00)80990-3	http://dx.doi.org/10.1016/S0092-8674(00)80990-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548823	Bronze			2022-12-28	WOS:A1996TQ17000006
J	Henry, RR; Genuth, S				Henry, RR; Genuth, S			Forum one: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			PROGRESSION; NEPHROPATHY; TRIAL	Purpose: To review issues about intensive management of non-insulin-dependent diabetes mellitus (NIDDM) and to formulate recommendations for goals and general approaches to implementation of intensive management. Method: A panel of clinical scientists and practitioners specializing in diabetes initially used a formal nominal process to identify the points of agreement on major issues. These points were further refined in a general conference discussion. Conclusions: 1) On the basis of data from intervention trials in IDDM that prove that intensive glycemic control reduces microvascular and neuropathic complications, coupled with epidemiologic and basic scientific data that support the strong likelihood of a similar benefit in NIDDM, the goal of treatment in NIDDM should be near-normal glycemia (glycohemoglobin level no higher than 1.0% above the upper normal limit); 2) glycemic targets should be adjusted individually according to clinical factors such as increased risk for hypoglycemia, advanced age, or reduced life expectancy from comorbid conditions; 3) some degree of comprehensive and repetitive instruction about diet and exercise and the use of blood glucose self-monitoring for all patients is essential to achieve the chosen targets; 4) intensive management of hyperglycemia should be instituted early and should initially emphasize diet and exercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of increasing complexity are recommended as needed to achieve glycemic targets; 5) comprehensive care must also include aggressive attempts to reduce cardiovascular risk factors (particularly hypertension, smoking, dyslipidemia, and obesity) as well as prevention of nephropathy and neuropathy; 6) the complex interaction among treatment regimens for hyperglycemia, dyslipidemia, obesity, and hypertension ideally requires a team approach, using a physician, diabetes educator, nurse, dietitian, and other health professionals; health insurers should make these resources available to generalists who currently care for most diabetic patients.	UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA USA; MT SINAI MED CTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH USA	University of California System; University of California San Diego; Case Western Reserve University	Henry, RR (corresponding author), VET AFFAIRS MED CTR, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.							[Anonymous], 1994, Diabetes Care, V17, P616; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; Genuth S M, 1995, Adv Intern Med, V40, P573; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; 1994, MED MANAGEMENT NON I, P26	12	37	38	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				175	177		10.7326/0003-4819-124-1_Part_2-199601011-00019	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554214				2022-12-28	WOS:A1996TL94400019
J	Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S				Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S			Impaired synapse elimination during cerebellar development in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; PURKINJE-CELLS; CLIMBING FIBERS; RAT-BRAIN; MULTIPLE INNERVATION; POSTNATAL-DEVELOPMENT; EXPRESSION; LOCALIZATION	PKC gamma is highly expressed in Purkinje cells (PCs) but not in other types of neurons in the cerebellum. The expression of PKC gamma changes markedly during cerebellar development, being very low at birth and reaching a peak around the third postnatal week. This temporal pattern of PKC gamma expression coincides with the developmental transition from multiple to single climbing fiber innervation onto each PC. In adult mutant mice deficient in PKC gamma, we found that 41% of PCs are still innervated by multiple climbing fibers, while other aspects of the cerebellum including the morphology and excitatory synaptic transmission of PCs appear normal. Thus, elimination of multiple climbing fiber innervation appears to be specifically impaired in the mutant cerebellum. We suggest that the developmental role of PKC gamma may be to act as a downstream element in the signal cascade necessary for the elimination of surplus climbing fiber synapses.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 606,JAPAN	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Hokkaido University	Kano, M (corresponding author), JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		WATANABE, Masahiko/A-4055-2012; Watanabe, Masahiko/S-3614-2019	WATANABE, Masahiko/0000-0001-5037-7138; Watanabe, Masahiko/0000-0001-5037-7138; Hashimoto, Kouichi/0000-0002-3884-8213; Aiba, Atsu/0000-0002-8192-0778; Kano, Masanobu/0000-0002-0725-3292	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ASE K, 1988, J NEUROSCI, V8, P3850; BRANDT SJ, 1987, CELL, V49, P57, DOI 10.1016/0092-8674(87)90755-0; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1979, J PHYSIOL-LONDON, V290, P97, DOI 10.1113/jphysiol.1979.sp012762; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARCIASEGURA LM, 1984, BRAIN RES, V296, P75, DOI 10.1016/0006-8993(84)90512-2; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1990, DEV BRAIN RES, V52, P121, DOI 10.1016/0165-3806(90)90227-P; HUANG FL, 1988, J NEUROSCI, V8, P4734; HUANG FL, 1987, J BIOL CHEM, V262, P15714; Ito M, 1984, CEREBELLUM NEURAL CO; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KITANO T, 1987, J NEUROSCI, V7, P1520; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KOSE A, 1988, J NEUROSCI, V8, P4262; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1992, J NEUROSCI, V12, P3601; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARANI E, 1979, ACTA MORPHOL NEER SC, V17, P33; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLEARY JL, 1971, J COMP NEUROL, V142, P377, DOI 10.1002/cne.901420307; Palay S. L., 1974, CEREBELLAR CORTEX CY; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAITO N, 1988, J NEUROSCI, V8, P369; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	52	284	286	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1223	1231		10.1016/0092-8674(95)90147-7	http://dx.doi.org/10.1016/0092-8674(95)90147-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548808	Bronze			2022-12-28	WOS:A1995TM76200017
J	Zhou, QY; Palmiter, RD				Zhou, QY; Palmiter, RD			Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic	CELL			English	Article							BASAL GANGLIA; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; RAT NEOSTRIATUM; NEONATAL RATS; FOOD REWARD; NEURONS; LESIONS; NEUROTRANSMITTERS; RECEPTOR	Mice unable to synthesize dopamine (DA) specifically in dopaminergic neurons were created by inactivating the tyrosine hydroxylase (TH) gene then by restoring TH function in noradrenergic cells. These DA-deficient (DA(-/-)) mice were born at expected frequency but became hypoactive and stopped feeding a few weeks after birth. Midbrain dopaminergic neurons, their projections, and most characteristics of their target neurons in the striatum appeared normal. Within a few minutes of being injected with L-dihydroxyphenylalanine (L-DOPA), the product of TH, the DA(-/-) mice became more active and consumed more food than control mice. With continued administration of L-DOPA, nearly normal growth was achieved. These studies indicate that DA is essential for movement and feeding, but is not required for the development of neural circuits that control these behaviors.			Zhou, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				NICHD NIH HHS [HD-09172] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANAND BK, 1951, YALE J BIOL MED, V24, P123; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ARNT J, 1987, DOPAMINE RECEPTORS, P199; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BAYER SA, 1984, INT J DEV NEUROSCI, V2, P163, DOI 10.1016/0736-5748(84)90008-X; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; BUNNEY BS, 1976, BRAIN RES, V117, P423, DOI 10.1016/0006-8993(76)90751-4; CARLSSON A, 1959, PHARMACOL REV, V11, P490; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; Cooper SJ, 1993, D1 D2 DOPAMINE RECEP, P203; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DOURISH CT, 1993, BIOL PSYCHIAT, V7, P487; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FIBIGER HC, 1973, BRAIN RES, V55, P135, DOI 10.1016/0006-8993(73)90493-9; FIBIGER HC, 1988, ANN NY ACAD SCI, V537, P206, DOI 10.1111/j.1749-6632.1988.tb42107.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GROSSMAN SP, 1978, SCIENCE, V202, P537, DOI 10.1126/science.705344; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; HEMMINGS HC, 1986, PROG BRAIN RES, V69, P149; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7; HERNANDEZ L, 1966, PHARMACOL REV, V18, P925; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JICHA GA, 1991, J NEUROSCI, V11, P3822; JOSEPH MH, 1990, J NEUROSCI METH, V34, P143, DOI 10.1016/0165-0270(90)90052-H; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1992, J NEUROSCI, V12, P4281; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LUDECKE B, 1995, HUM GENET, V95, P123; LYTLE LD, 1978, SCIENCE, V200, P1175; MARROCCO RT, 1994, CURR OPIN NEUROBIOL, V4, P166, DOI 10.1016/0959-4388(94)90067-1; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORGANE PJ, 1961, AM J PHYSIOL, V201, P420, DOI 10.1152/ajplegacy.1961.201.3.420; NYGAARD TG, 1995, CURR OPIN NEUROL, V8, P310, DOI 10.1097/00019052-199508000-00011; ONN SP, 1990, BRAIN RES, V518, P274, DOI 10.1016/0006-8993(90)90980-P; PARKER SW, 1967, EXP NEUROL, V17, P313, DOI 10.1016/0014-4886(67)90109-4; PHILLIPS AG, 1975, NATURE, V258, P750, DOI 10.1038/258750a0; PHILLIPSON OT, 1979, J COMP NEUROL, V187, P117, DOI 10.1002/cne.901870108; RODRIGUES PD, 1990, P NATL ACAD SCI USA, V87, P9693, DOI 10.1073/pnas.87.24.9693; ROGERS DC, 1990, EXP BRAIN RES, V80, P172; ROLLS ET, 1981, HDB HYPOTHALAMUS, V3, P439; SALAMONE JD, 1990, NEUROSCIENCE, V39, P17, DOI 10.1016/0306-4522(90)90218-S; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SCHWARZ SS, 1987, EXP BRAIN RES, V65, P449; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SKUTELLA T, 1994, NEUROSCI LETT, V167, P55, DOI 10.1016/0304-3940(94)91026-X; SMITH GP, 1988, ANN NY ACAD SCI, V537, P254, DOI 10.1111/j.1749-6632.1988.tb42111.x; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P95; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WELF DW, 1995, ANNU REV NEUROSCI, V18, P463; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WINN P, 1984, NEUROSCIENCE, V12, P225, DOI 10.1016/0306-4522(84)90149-0; WISE RA, 1992, SYNAPSE, V10, P247, DOI 10.1002/syn.890100307; WISE RA, 1978, SCIENCE, V201, P262, DOI 10.1126/science.566469; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; WRIGHT AK, 1980, APPETITE, V1, P43, DOI 10.1016/S0195-6663(80)80007-9; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1; ZIGMOND MJ, 1972, SCIENCE, V177, P1211	77	575	585	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1197	1209		10.1016/0092-8674(95)90145-0	http://dx.doi.org/10.1016/0092-8674(95)90145-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548806	Bronze			2022-12-28	WOS:A1995TM76200015
J	Kenny, D				Kenny, D			Analysis of the bureaucratic unsolicited mountainous paper heap (BUMPH) that general practitioners received in 1994	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To record and analyse the bureaucratic unsolicited mountainous paper heap (BUMPH) received by general practitioners; to make some suggestions for coping with the ensuing workload. Design-Daily record of all BUMPH landing on the desk of a general practitioner in one year. Setting-Mixed practice with one full time and two job sharing principals. Results-5100 pages of BUMPH arrived during the year. The most prolific source of origin was health authorities (1549 pages). Fridays, Mondays, and the day after a holiday were the days BUMPH was most frequently seen. Conclusions-BUMPH is a major source of workload. One way of avoiding it is not to work on the day after a day off.			Kenny, D (corresponding author), WESTGATE SURG,40 PARSONAGE ST,DURSLEY GL11 4AA,GLOS,ENGLAND.							CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; ROUT U, 1994, FAM PRACT, V11, P300, DOI 10.1093/fampra/11.3.300	2	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1705	1706		10.1136/bmj.311.7021.1705	http://dx.doi.org/10.1136/bmj.311.7021.1705			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541768	Green Published			2022-12-28	WOS:A1995TL94200030
J	Hensel, WA				Hensel, WA			My living will	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					588	588		10.1001/jama.275.8.588	http://dx.doi.org/10.1001/jama.275.8.588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594232				2022-12-28	WOS:A1996TW62700007
J	Mayaux, MJ; Burgard, M; Teglas, JP; Cottalorda, J; Krivine, A; Simon, F; Puel, J; Tamalet, C; Dormont, D; Masquelier, B; Doussin, A; Rouzioux, C; Blanche, S				Mayaux, MJ; Burgard, M; Teglas, JP; Cottalorda, J; Krivine, A; Simon, F; Puel, J; Tamalet, C; Dormont, D; Masquelier, B; Doussin, A; Rouzioux, C; Blanche, S			Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; INFANTS; TYPE-1; TRANSMISSION; CHILDREN; REPLICATION	Objective. - To identify clinical and laboratory parameters at birth that are associated with the rapidly progressive form of human immunodeficiency virus type 1 (HIV-1) disease in children born to infected mothers. Design. - Multicenter, prospective study of infants born to HIV-seropositive mothers. Setting. - A total of 62 obstetric and pediatric centers in France. Participants. - Of 1386 children born to HIV-1-seropositive mothers at least 18 months before the cutoff date, 267 were infected. Infection was defined as serological positivity at 18 months or death from HIV disease before this age. Main Outcome Measure. - Category C events (including opportunistic infections, recurrent severe bacterial infections, cancers, specific encephalopathy, and wasting syndrome) in the new pediatric Centers for Disease Control and Prevention classification during the first year of life, according to clinical, immunological, and virological findings at birth. Results. - The risk of category C manifestations at 12 months was significantly higher when an infected newborn had liver and/or spleen enlargement and/or adenopathies (38.1% vs 15.1%; relative risk [RR], 2.5; 95% confidence interval [CI], 1.4 to 6.0; P<.02) or a low proportion (<30%) of CD4(+) cells at birth (45.5% vs 15.0%; RR, 3.0; 95% CI, 1.4 to 6.4; P<.005). Similarly, HIV-1 culture and/or polymerase chain reaction positivity during the first week of life was associated with a higher risk of the early, severe form of HIV infection (26.4% vs 9.3%; RR, 2.8; 95% CI, 1.3 to 6.1; P<.006). In case of positive antigenemia at birth, the risk was 50.0% vs 14.4% (RR, 3.5; 95% CI, 1.9 to 6.2; P<.001). These parameters, determined at birth, were strongly interrelated and could reflect active disease onset in utero in some cases of early, severe HIV-1 disease in childhood. Conclusions. - These prognostic markers, particularly virological parameters, are of value in monitoring children infected by HIV and might serve as a basis for early therapeutic intervention.	HOP NECKER ENFANTS MALAD,VIROL LAB,PARIS,FRANCE; HOP LOUIS PASTEUR,VIROL LAB,NICE,FRANCE; HOP PORT ROYAL,VIROL LAB,PARIS,FRANCE; HOP BICHAT,VIROL LAB,F-75877 PARIS,FRANCE; HOP PURPAN,VIROL LAB,TOULOUSE,FRANCE; HOP ENFANTS LA TIMONE,VIROL LAB,MARSEILLE,FRANCE; CEA,FONTENAY ROSES,FRANCE; HOP PELLEGRIN TRIPODE,VIROL LAB,BORDEAUX,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U429,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; CHU de Toulouse; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CEA; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mayaux, MJ (corresponding author), HOP BICETRE,INSERM,U292,SECTEUR BLEU PIERRE MARIE-PORTE 26,82 RUE GEN LEC,F-94276 LE KREMLIN BICETR,FRANCE.							AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1986, J PEDIATR-US, V109, P965, DOI 10.1016/S0022-3476(86)80277-3; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BORKOWSKY W, 1994, J PEDIATR-US, V125, P345, DOI 10.1016/S0022-3476(05)83274-3; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; Caldwell MB, 1994, MMWR-MORBID MORTAL W, V43, P1; Delfraissy J F, 1992, Immunodefic Rev, V3, P305; DEROSSI A, 1993, J PEDIATR-US, V123, P929, DOI 10.1016/S0022-3476(05)80389-0; GABIANO C, 1992, PEDIATRICS, V90, P369; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JONES DS, 1992, PEDIATRICS, V89, P123; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LEPAGE P, 1992, AIDS, V6, P882, DOI 10.1097/00002030-199208000-00021; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; PIZZO PA, 1995, J ACQ IMMUN DEF SYND, V8, P30; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROUZIOUX C, 1991, VIRAL QUANTITATION IN HIV INFECTION, P187; ROUZIOUX C, 1993, 1 NAT C HUM RETR REL; SCHUPBACH J, 1994, J INFECT DIS, V170, P318, DOI 10.1093/infdis/170.2.318; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SPINILLO A, 1994, EUR J OBSTET GYN R B, V57, P13, DOI 10.1016/0028-2243(94)90103-1; TOVO PA, 1994, J INFECT DIS, V170, P1000, DOI 10.1093/infdis/170.4.1000; 1994, BRIT J OBSTET GYNAEC, V101, P136; 1982, LANCET, V2, P1043	29	106	110	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					606	610		10.1001/jama.275.8.606	http://dx.doi.org/10.1001/jama.275.8.606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594241				2022-12-28	WOS:A1996TW62700020
J	Latronico, AC; Anasti, J; Arnhold, IJP; Rapaport, R; Mendonca, BB; Bloise, W; Castro, M; Tsigos, C; Chrousos, GP				Latronico, AC; Anasti, J; Arnhold, IJP; Rapaport, R; Mendonca, BB; Bloise, W; Castro, M; Tsigos, C; Chrousos, GP			Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN		NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA; CHILDRENS HOSP NEW JERSEY, DEPT PEDIAT ENDOCRINOL & METAB, NEWARK, NJ USA; UNIV & MED DENT NEW JERSEY, NEW JERSEY MED SCH, NEWARK, NJ USA; UNIV SAO PAULO, HOSP CLIN, DIV ENDOCRINOL, BR-05508 SAO PAULO, BRAZIL	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidade de Sao Paulo			Mendonca, Berenice/AAS-3742-2021; de Castro, Margaret/A-4918-2009; Latronico, Ana Claudia/AAC-5112-2019; Latronico, Ana Claudia/E-1198-2012; Mendonca, Berenice B/J-6917-2015; Mendonca, Berenice B/C-2827-2012; ARNHOLD, IVO JORGE PRADO/D-2672-2012	Mendonca, Berenice/0000-0003-1762-1084; de Castro, Margaret/0000-0003-4932-4623; Latronico, Ana Claudia/0000-0001-6782-693X; Latronico, Ana Claudia/0000-0001-6782-693X; Mendonca, Berenice B/0000-0003-1762-1084; ARNHOLD, IVO JORGE PRADO/0000-0003-1739-1354				AARONSON IA, 1994, J UROLOGY, V152, P4, DOI 10.1016/S0022-5347(17)32804-5; ANASTI JN, 1995, J CLIN ENDOCR METAB, V80, P276, DOI 10.1210/jc.80.1.276; ARNHOLD IJP, 1988, J UROLOGY, V140, P1549, DOI 10.1016/S0022-5347(17)42104-5; BERTHEZENE F, 1976, NEW ENGL J MED, V295, P969, DOI 10.1056/NEJM197610282951801; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; DAVID R, 1984, J CLIN ENDOCR METAB, V59, P156, DOI 10.1210/jcem-59-1-156; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; KOSUGI S, 1991, J BIOL CHEM, V266, P19413; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; MAGOFFIN DA, 1994, INT CONGR SER, V1046, P25; MERENDINO JJ, 1993, NEW ENGL J MED, V328, P1538, DOI 10.1056/NEJM199305273282106; MINEGISH T, 1994, BIOCHEM BIOPH RES CO, V201, P1057, DOI 10.1006/bbrc.1994.1809; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SALDANHA PH, 1987, AM J MED GENET, V26, P337, DOI 10.1002/ajmg.1320260212; SCHWARTZ M, 1981, J CLIN ENDOCR METAB, V53, P123, DOI 10.1210/jcem-53-1-123; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; TSIGOS C, 1995, J CLIN ENDOCR METAB, V80, P2186, DOI 10.1210/jc.80.7.2186; TSIGOS C, 1993, J CLIN INVEST, V92, P2458, DOI 10.1172/JCI116853	25	248	261	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					507	512		10.1056/NEJM199602223340805	http://dx.doi.org/10.1056/NEJM199602223340805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559204				2022-12-28	WOS:A1996TV68600005
J	Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR				Warriner, HE; Idziak, SHJ; Slack, NL; Davidson, P; Safinya, CR			Lamellar biogels: Fluid-membrane-based hydrogels containing polymer lipids	SCIENCE			English	Article							SYNCHROTRON X-RAY; DIBLOCK COPOLYMERS; MULTIMEMBRANE; PHASES; SEGREGATION; CURVATURE; RIGIDITY; VESICLES; SYSTEM; GELS	A class of lamellar biological hydrogels comprised of fluid membranes of lipids and surfactants with small amounts of low molecular weight poly(ethylene glycol)-derived polymer lipids (PEG-lipids) were studied by x-ray diffraction, polarized light microscopy, and rheometry, In contrast to isotropic hydrogels of polymer networks, these membrane-based birefringent liquid crystalline biogels, labeled L(alpha,g), form the gel phase when water is added to the liquid-like lamellar L(alpha) phase, which reenters a liquid-like mixed phase upon further dilution. Furthermore, gels with larger water content require less PEG-lipid to remain stable, Although concentrated (similar to 50 weight percent) mixtures of free PEG (molecular weight, 5000) and water do not gel, gelation does occur in mixtures containing as little as 0.5 weight percent PEG-lipid, A defining signature of the L(alpha,g) regime as it sets in from the fluid lamellar L(alpha) phase is the proliferation of layer-dislocalion-type defects, which are stabilized by the segregation of PEG-lipids to the defect regions of high membrane curvature that connect the membranes.	UNIV CALIF SANTA BARBARA,DEPT MAT,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,INTERDEPT BIOCHEM,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,PROGRAM MOLEC BIOL,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Davidson, Patrick/F-7874-2017; Davidson, Patrick/Q-6691-2019	Davidson, Patrick/0000-0002-1363-6062; Davidson, Patrick/0000-0002-1363-6062				ALEXANDER S, 1977, J PHYS-PARIS, V38, P977, DOI 10.1051/jphys:01977003808097700; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ASHER SA, 1979, BIOPHYS J, V27, P393, DOI 10.1016/S0006-3495(79)85225-X; Bailey F. E., 1976, POLYETHYLENE OXIDE; BENSHAUI A, 1994, MICELLES MEMBRANES M; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAO BH, 1994, FARADAY DISCUSS, V98, P245, DOI 10.1039/fd9949800245; DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; DEGENNES PG, 1976, J PHYS LES ULIS, V37, P1443; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HELFRICH W, 1985, CHEM SCR, V25, P2; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; KAWAKATSU T, 1993, J PHYS II, V3, P971, DOI 10.1051/jp2:1993177; KAWASAKI K, 1990, PHYS REV A, V42, P3664, DOI 10.1103/PhysRevA.42.3664; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KUHL TL, BIOPHYS J, V6619, P94; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1993, LIPOSOMES PHYSICS AP; Lasic DD, 1995, STEALTH LIPOSOMES; MACKINTOSH FC, COMMUNICATION; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MATSUO ES, 1992, NATURE, V358, P482, DOI 10.1038/358482a0; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y; OSADA Y, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0593-82; Osada Y., 1991, POLYM GELS FUNDAMENT; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; PINCUS P, UNPUB; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P273, DOI 10.1051/jphys:01984004502027300; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; Small D.M., 1986, HDB LIPID RES, V4; SMITH GS, 1990, J CHEM PHYS, V92, P4519, DOI 10.1063/1.457764; SMITH GS, 1988, PHYS REV LETT, V60, P813, DOI 10.1103/PhysRevLett.60.813; TARDIEU A, 1973, J MOL BIOL, V75, P711, DOI 10.1016/0022-2836(73)90303-3; WANG ZG, 1990, J PHYS-PARIS, V51, P185, DOI 10.1051/jphys:01990005102018500; WARRINER HE, UNPUB; [No title captured]	44	160	169	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					969	973		10.1126/science.271.5251.969	http://dx.doi.org/10.1126/science.271.5251.969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584932				2022-12-28	WOS:A1996TV70400043
J	Kraemer, KH				Kraemer, KH			Xeroderma pigmentosum knockouts	LANCET			English	Editorial Material											Kraemer, KH (corresponding author), NCI,MOLEC CARCINOGENESIS LAB,BLDG 37,BETHESDA,MD 20892, USA.			Kraemer, Kenneth/0000-0002-2689-3316	Intramural NIH HHS [Z01 BC004517-31] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; GASPARI AA, 1993, J CLIN INVEST, V92, P1135, DOI 10.1172/JCI116682; HANAWALT PC, 1995, MUTAT RES-DNA REPAIR, V336, P101, DOI 10.1016/0921-8777(94)00061-A; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; NAKANE T, 1995, NATURE, V377, P165; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					278	279		10.1016/S0140-6736(96)90462-6	http://dx.doi.org/10.1016/S0140-6736(96)90462-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569358	Bronze			2022-12-28	WOS:A1996TT48500005
J	Smith, PM; Torrey, BB				Smith, PM; Torrey, BB			The future of the behavioral and social sciences	SCIENCE			English	Editorial Material									NATL RES COUNCIL,COMMISS BEHAV & SOCIAL SCI & EDUC,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	Smith, PM (corresponding author), MCGEARY & SMITH,464 M ST SW,WASHINGTON,DC 20024, USA.							[Anonymous], 1995, RESHAPING GRADUATE E; [Anonymous], 1988, MAPPING SEQUENCING H; DEUTSCH KW, 1971, SCIENCE, V171, P450, DOI 10.1126/science.171.3970.450; FOGEL RW, 1994, AM ECON REV, V84, P369; LUCE D, 1989, LEADING EDGES SOCIAL; Martin L. G., 1994, DEMOGRAPHY AGING; Ross Dorothy, 1992, ORIGINS AM SOCIAL SC; SMEEDING TM, 1988, SCIENCE, V242, P873, DOI 10.1126/science.242.4880.873; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Thelen L. B., 1994, DYNAMIC SYSTEMS APPR; Young CH, 1991, INVENTORY LONGITUDIN; 1994, FEDERAL FUNDS RES DE, P94; 1993, SCI ENG INDICATORS 1	13	14	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					611	612		10.1126/science.271.5249.611	http://dx.doi.org/10.1126/science.271.5249.611			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571121				2022-12-28	WOS:A1996TT87000030
J	Turek, FW				Turek, FW			Melatonin hype hard to swallow	NATURE			English	Editorial Material							ENTRAINMENT; RHYTHMS; SLEEP				Turek, FW (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							Aschoff J., 1982, VERTEBRATE CIRCADIAN, P129; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; EBIHARA S, 1986, SCIENCE, V231, P491, DOI 10.1126/science.3941912; GASTON S, 1968, SCIENCE, V160, P1125, DOI 10.1126/science.160.3832.1125; HOFFMAN RA, 1965, SCIENCE, V148, P1609, DOI 10.1126/science.148.3677.1609; JAMES SP, 1987, NEUROPSYCHOPHARMACOL, V1, P41, DOI 10.1016/0893-133X(87)90008-X; MADDOX J, 1995, NATURE, V378, P435, DOI 10.1038/378435a0; Pierpaoli W, 1995, MELATONIN MIRACLE; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R., 1995, MELATONIN; SACK RL, 1991, J BIOL RHYTHM, V6, P249, DOI 10.1177/074873049100600305; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; TUREK FW, 1976, SCIENCE, V194, P1441, DOI 10.1126/science.1006311; VANCOEVORDEN A, 1991, AM J PHYSIOL, V260, pE651, DOI 10.1152/ajpendo.1991.260.4.E651	14	40	41	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					295	296		10.1038/379295a0	http://dx.doi.org/10.1038/379295a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552179				2022-12-28	WOS:A1996TR32300027
J	Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW				Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW			Psychometric scores and persistence of irritable bowel after infectious diarrhoea	LANCET			English	Article							LIFE EVENTS; COMMUNITY; SYMPTOMS; ANXIETY; RAT	Background Although previous studies have shown that psychological disturbances are frequently associated with the irritable bowel syndrome (IBS), the relation was not necessarily cause and effect. The development of chronic bowel symptoms resembling IBS after an episode of acute gastroenteritis has allowed us to examine prospectively the role of psychological factors. Methods 75 patients with acute gastroenteritis completed a series of psychometric tests soon after admission to hospital. Of these, 22 had persistent symptoms compatible with IBS after the acute illness, and in 20 of these the symptoms were still present at six months. Findings At the time of their initial illness, patients who subsequently developed IBS symptoms had higher scores for anxiety, depression, somatisation, and neurotic trait than those who returned to normal bowel function. The psychometric scores had not changed when remeasured three months after the acute illness. Lactose malabsorption was not an important factor. Interpretation These results support the hypothesis that psychological factors are important in IBS.	UNIV SHEFFIELD, NO GEN HOSP, GI MOTIL UNIT, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT INFECT DIS & MED, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; MCMASTER UNIV, INTESTINAL DIS RES UNIT, HAMILTON, ON, CANADA; UNIV SHEFFIELD, SHEFFIELD CTR HLTH & RELATED RES, SHEFFIELD, S YORKSHIRE, ENGLAND	Northern General Hospital; University of Sheffield; University of Sheffield; McMaster University; University of Sheffield				Marshall, Jean S./0000-0002-5642-1379; Walters, Stephen/0000-0001-9000-8126				[Anonymous], 1992, GASTROENTEROL INT; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHAUDHARY NA, 1962, Q J MED, V31, P307; COLLINS SM, 1992, ANN NY ACAD SCI, V664, P415, DOI 10.1111/j.1749-6632.1992.tb39780.x; COLLINS SM, 1989, STRESS DIGESTIVE MOT, P151; CRAIG TKJ, 1984, J PSYCHOSOM RES, V28, P411, DOI 10.1016/0022-3999(84)90073-4; CREED F, 1981, LANCET, V1, P1381; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; Efron B., 1994, MONOGRAPHS STAT APPL; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; Eysenck H.J., 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; KHAN I, 1994, GASTROENTEROLOGY, V106, pA523; MACDONALD AJ, 1980, BRIT J PSYCHIAT, V136, P276, DOI 10.1192/bjp.136.3.276; MCHUGH KJ, 1993, GASTROENTEROLOGY, V104, pA1051; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; METZ G, 1975, LANCET, V1, P1155; PALMER RL, 1974, POSTGRAD MED J, V50, P416, DOI 10.1136/pgmj.50.585.416; Rubio C A, 1992, In Vivo, V6, P81; SAUNDERS PR, 1993, GASTROENTEROLOGY, V104, pA1061; STEWART GT, 1950, BMJ-BRIT MED J, V1, P405, DOI 10.1136/bmj.1.4650.405; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165, DOI 10.1093/oxfordjournals.aje.a116483; TALLEY NJ, 1991, EUR J GASTROEN HEPAT, V3, P71; VALLANCE BA, 1994, GASTROENTEROLOGY, V106, pA582; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	417	427	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					150	153		10.1016/S0140-6736(96)90341-4	http://dx.doi.org/10.1016/S0140-6736(96)90341-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544549				2022-12-28	WOS:A1996TQ24400010
J	Buhl, EH; Otis, TS; Mody, I				Buhl, EH; Otis, TS; Mody, I			Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model	SCIENCE			English	Article							PAIRED-PULSE DEPRESSION; DENTATE GRANULE CELLS; FIBER SYNAPTIC REORGANIZATION; RAT HIPPOCAMPAL SLICES; A-RECEPTOR COMPLEX; FASCIA-DENTATA; MOSSY FIBERS; PATCH-CLAMP; GYRUS; NEURONS	In the kindling model of temporal robe epilepsy, several physiological indicators of inhibition by gamma-aminobutyric acid (GABA) in the hippocampal dentate gyrus are consistent with an augmented, rather than a diminished, inhibition. In brain slices obtained from epileptic (kindled) rats, the excitatory drive onto inhibitory interneurons was increased and was paralleled by a reduction in the presynaptic autoinhibition of GABA release. This augmented inhibition was sensitive to zinc most likely after a molecular reorganization of GABA(A) receptor subunits. Consequently, during seizures, inhibition by GABA may be diminished by the zinc released from aberrantly sprouted messy fiber terminals of granule cells, which are found in many experimental models of epilepsy and in human temporal robe epilepsy.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL RNRC 3131,LOS ANGELES,CA 90095; UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; UNIV WISCONSIN,SCH MED,CTR MED SCI,DEPT NEUROPHYSIOL,MADISON,WI 53706	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; University of Wisconsin System; University of Wisconsin Madison					NINDS NIH HHS [NS 12151, NS 30549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030549, R01NS030549, P50NS012151, P01NS012151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; AVOLI M, 1991, EPILEPSY RES, V10, P33, DOI 10.1016/0920-1211(91)90092-T; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CLARK M, 1994, MOL BRAIN RES, V26, P309, DOI 10.1016/0169-328X(94)90104-X; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Frederickson C. J., 1994, Biological Signals, V3, P127; FREDERICKSON CJ, COMMUNICATION; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; ISOKAWA M, 1993, J NEUROSCI, V13, P1511, DOI 10.1523/jneurosci.13-04-01511.1993; KAMPHUIS W, 1994, NEUROSCI LETT, V174, P5, DOI 10.1016/0304-3940(94)90105-8; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KOHR G, 1993, J NEUROSCI, V13, P3612; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KRAUS JE, 1994, J NEUROSCI, V14, P4196; LAMBERT NA, 1994, J NEUROPHYSIOL, V72, P121, DOI 10.1152/jn.1994.72.1.121; LEGENDRE P, 1991, MOL PHARMACOL, V39, P267; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; MOTT DD, 1993, J NEUROPHYSIOL, V69, P674, DOI 10.1152/jn.1993.69.3.674; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; OLIVER MW, 1985, EXP BRAIN RES, V57, P443; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; Ribak C E, 1991, Hippocampus, V1, P355, DOI 10.1002/hipo.450010403; SAXENA NC, 1994, J NEUROSCI, V14, P7077; Schwartzkroin PA, 1993, EPILEPSY MODELS MECH; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SOLLESZ I, 1995, NEURON, V14, P1273; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SUTULA TP, 1991, EPILEPSY RES, V10, P62, DOI 10.1016/0920-1211(91)90096-X; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TITULAER MNG, 1995, J NEUROCHEM, V64, P2615; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; URNO K, 1994, HIPPOCAMPUS, V4, P583; VALDES F, 1982, P NATL ACAD SCI-BIOL, V79, P193, DOI 10.1073/pnas.79.1.193; WANG YX, 1990, PFLUG ARCH EUR J PHY, V415, P582, DOI 10.1007/BF02583509; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WHITE G, 1995, NEUROREPORT, V6, P461, DOI 10.1097/00001756-199502000-00014	66	329	333	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					369	373		10.1126/science.271.5247.369	http://dx.doi.org/10.1126/science.271.5247.369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553076				2022-12-28	WOS:A1996TQ52800047
J	Levy, ML				Levy, ML			Asthmatic patients with psychosis need special care - Commentary	BRITISH MEDICAL JOURNAL			English	Article																		SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P361, DOI 10.1016/0091-6749(87)90047-9	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					82	83						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ168	8555934				2022-12-28	WOS:A1996TQ16800021
J	Lip, GYH; Watson, RDS; Singh, SP				Lip, GYH; Watson, RDS; Singh, SP			ABC of atrial fibrillation - Cardioversion of atrial fibrillation	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham	Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							CLARK A, 1991, BRIT J HOSP MED, V46, P114; LAUPACIS A, 1995, CHEST S, V108, P352; LIP GYH, 1995, POSTGRAD MED J, V71, P457, DOI 10.1136/pgmj.71.838.457; 1993, J AM COLL CARDIOL, V22, P336	4	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					112	115						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555897				2022-12-28	WOS:A1996TQ16800036
J	Lilford, RJ; Thornton, JG; Braunholtz, D				Lilford, RJ; Thornton, JG; Braunholtz, D			Clinical trials and rare diseases: A way out of a conundrum	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Currently, clinical trials tend to be individually funded and applicants must include a power calculation in their grant request. However, conventional levels of statistical precision are unlikely to be obtainable prospectively if the trial is required to evaluate treatment of a rare disease. This means that clinicians treating such diseases remain in ignorance and must form their judgments solely on the basis of (potentially biased) observational studies, experience, and anecdote. Since some unbiased evidence is clearly better than none, this state of affairs should not continue. However, conventional (frequentist) confidence limits are unlikely to exclude a null result, even when treatments differ substantially. Bayesian methods utilise all available data to calculate probabilities that may be extrapolated directly to clinical practice. Funding bodies should therefore fund a repertoire of small trials, which need have no predetermined end, alongside standard larger studies.	UNIV LEEDS, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND	University of Leeds	Lilford, RJ (corresponding author), W MIDLANDS HLTH AUTHOR, ARTHUR THOMSON HOUSE, BIRMINGHAM B16 9PA, W MIDLANDS, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				BERRY DA, 1993, STAT MED, V12, P1377, DOI 10.1002/sim.4780121504; BURTON PR, 1994, STAT MED, V13, P1699, DOI 10.1002/sim.4780131702; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FREEDMAN LS, 1992, STAT MED, V11, P23, DOI 10.1002/sim.4780110105; GRANT AM, 1988, BRIT J OBSTET GYNAEC, V95, P437; GREENHOUSE JB, 1992, STAT MED, V11, P37, DOI 10.1002/sim.4780110106; HUGHES MD, 1993, STAT MED, V12, P1651, DOI 10.1002/sim.4780121802; JOHNSON N, 1991, J MED ETHICS, V17, P30, DOI 10.1136/jme.17.1.30; KADANE JB, 1986, J MED PHILOS, V11, P385, DOI 10.1093/jmp/11.4.385; LEUSCHNER U, 1994, SCAND J GASTROENTERO, V29, P40, DOI 10.3109/00365529409103624; LILFORD R, 1994, BMJ-BRIT MED J, V308, P111, DOI 10.1136/bmj.308.6921.111; Lilford R J, 1989, Int J Technol Assess Health Care, V5, P459; LILFORD RJ, 1990, LANCET, V335, P483; Lilford RJ, 1995, J ROY SOC MED, V88, P552; LILFORD RJ, 1990, NEW ENGL J MED, V322, P780; LILFORD RJ, 1992, J ROY COLL PHYS LOND, V26, P400; SACHS H, 1982, AM J MED, V72, P233; SCHAFFNER F, 1985, BRIT MED J, V290, P1353, DOI 10.1136/bmj.290.6478.1353-c; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527	19	175	178	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	1995	311	7020					1621	1625		10.1136/bmj.311.7020.1621	http://dx.doi.org/10.1136/bmj.311.7020.1621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555809	Green Published			2022-12-28	WOS:A1995TL42200032
J	Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH				Kitahata, MM; Koepsell, TD; Deyo, RA; Maxwell, CL; Dodge, WT; Wagner, EH			Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MULTICENTER AIDS COHORT; IN-HOSPITAL MORTALITY; VIRUS INFECTION; ZIDOVUDINE; PROPHYLAXIS; VOLUME; CARE; OUTCOMES; MEN	Background. Previous studies have found that patients with the acquired immunodeficiency syndrome (AIDS) who are admitted to hospitals that admit many such patients have lower mortality rates than patients in hospitals with less experience with AIDS. We examined the relation between physicians' experience with AIDS and the survival of their patients with AIDS. Methods. We studied 403 adult male patients enrolled in a staff-model health maintenance organization in whom first AIDS-defining illnesses were diagnosed from 1984 through mid-1994; we determined that these illnesses met the 1987 case definition of the Centers for Disease Control. We defined three levels of experience for the patients' 125 primary care physicians according to their experience with AIDS during residency training and the cumulative number of patients with AIDS they had cared for in their practices. Results. The median survival of the patients of physicians with the least experience in the management of AIDS was 14 months, as compared with 26 months for the patients of physicians with the most experience (P<0.001). Controlling for the severity of illness and the year of diagnosis, we found that the patients cared for by physicians with the most experience had a 31 percent lower risk of death than the patients cared for by physicians with the least experience (P<0.02). Among 244 patients with an AIDS-defining illness diagnosed from 1989 through 1994, after adjustment for the CD4+ cell count and the severity of illness, the risk of death was 43 percent lower for patients of the most experienced physicians than for patients of the least experienced (P<0.02). Conclusions. The experience of primary care physicians in the management of AIDS is significantly associated with survival among their patients.	UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Kitahata, MM (corresponding author), UNIV WASHINGTON,CTR AIDS & STD,DEPT MED,1001 BROADWAY,SUITE 215,SEATTLE,WA 98122, USA.							BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P856; BROWN BW, 1977, STATISTICS BIOMEDICA; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, ARCH INTERN MED, V155, P1613, DOI 10.1001/archinte.155.15.1613; GRAHAM NM, 1994, J CLIN EPIDEMIOL, V447, P1003; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HOLMBERG SD, 1993, AIDS, V7, P699, DOI 10.1097/00002030-199305000-00014; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LANG W, 1991, J ACQ IMMUN DEF SYND, V4, P713; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MAKADON HJ, 1990, J GEN INTERN MED, V5, P446, DOI 10.1007/BF02599436; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; RAMSEY PG, 1994, PRIMARY CARE PATIENT; SHAPIRO MF, 1992, JAMA-J AM MED ASSOC, V268, P2698; SMITH MD, 1991, J GEN INTERN MED S1, V16, pS56; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P214; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P978; VELLA S, 1994, JAMA-J AM MED ASSOC, V271, P1197, DOI 10.1001/jama.271.15.1197; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1S, V36; 1992, MMWR-MORBID MORTAL W, V41, P1	40	392	396	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					701	706		10.1056/NEJM199603143341106	http://dx.doi.org/10.1056/NEJM199603143341106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594430				2022-12-28	WOS:A1996TZ52800006
J	Koopman, MMW; Prandoni, P; Piovella, F; Ockelford, PA; Brandjes, DPM; vanderMeer, J; Gallus, AS; Simonneau, G; Chesterman, CH; Prins, MH; Bossuyt, PMM; deHaes, H; vandenBelt, AGM; Sagnard, L; DAzemar, P; Buller, HR				Koopman, MMW; Prandoni, P; Piovella, F; Ockelford, PA; Brandjes, DPM; vanderMeer, J; Gallus, AS; Simonneau, G; Chesterman, CH; Prins, MH; Bossuyt, PMM; deHaes, H; vandenBelt, AGM; Sagnard, L; DAzemar, P; Buller, HR			Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; QUALITY-OF-LIFE; INITIAL TREATMENT; ANTICOAGULANT; THERAPY; CANCER; TRIAL	Background. An intravenous course of standard (unfractionated) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the standard initial in-hospital treatment for patients with deep-vein thrombosis, but fixed-dose subcutaneous low-molecular-weight heparin appears to be as effective and safe. Because the latter treatment can be given on an outpatient basis, we compared the two treatments in symptomatic outpatients with proximal-vein thrombosis but no signs of pulmonary embolism. Methods. We randomly assigned patients to adjusted-dose intravenous standard heparin administered in the hospital (198 patients) or fixed-dose subcutaneous low-molecular-weight heparin administered at home, when feasible (202 patients). We compared the treatments with respect to recurrent venous thromboembolism, major bleeding, quality of life, and costs. Results. Seventeen of the 198 patients who received standard heparin (8.6 percent) and 14 of the 202 patients who received low-molecular-weight heparin (6.9 percent) had recurrent thromboembolism (difference, 1.7 percentage points; 95 percent confidence interval, -3.6 to 6.9). Major bleeding occurred in four patients assigned to standard heparin (2.0 percent) and one patient assigned to low-molecular-weight heparin 10.5 percent; difference, 1.5 percentage points; 95 percent confidence interval, -0.7 to 2.7). Quality of life improved in both groups, Physical activity and social functioning were better in the patients assigned to low-molecular-weight heparin. Among the patients in that group, 36 percent were never admitted to the hospital at all, and 40 percent were discharged early. This treatment was associated with a mean reduction in hospital days of 67 percent, ranging from 29 percent to 86 percent in the various study centers. Conclusions. In patients with proximal-vein thrombosis, treatment with low-molecular-weight heparin at home is feasible, effective, and safe.	SLOTERVAART HOSP,AMSTERDAM,NETHERLANDS; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY; AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; ACAD HOSP GRONINGEN,GRONINGEN,NETHERLANDS; FLINDERS MED CTR,ADELAIDE,SA,AUSTRALIA; PRINCE WALES HOSP,SYDNEY,NSW,AUSTRALIA; HOP CLAMART,PARIS,FRANCE; SANOFI WINTHROP,PARIS,FRANCE; MED INTERNA & ONCOL MED,PAVIA,ITALY	Slotervaart Hospital; University of Padua; Auckland City Hospital; University of Groningen; Flinders Medical Centre; Sanofi-Aventis	Koopman, MMW (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLAMMAT RES,RM F4-133,1105 AZ AMSTERDAM,NETHERLANDS.		Simonneau, Gerald/ABE-6614-2020; Bossuyt, Patrick M./B-4557-2016; Piovella, Franco/AAM-8305-2020; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; Gallus, Alexander/0000-0001-7347-9989				BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; GALLUS A, 1986, LANCET, V2, P1293; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HIRSCH J, 1991, NEW ENGL J MED, V324, P165; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HOLMER E, 1982, THROMB RES, V25, P475, DOI 10.1016/0049-3848(82)90089-5; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; HURNY C, 1992, EUR J CANCER, V28A, P118, DOI 10.1016/0959-8049(92)90399-M; KEMPEN GIJM, 1992, PSYCHOL REP, V70, P608, DOI 10.2466/PR0.70.2.608-610; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRANDONI P, 1993, CIRCULATION, V88, P17; Stewart AL, 1992, MEASURING FUNCTIONIN; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639; 1990, JAMA-J AM MED ASSOC, V263, P2753	28	956	965	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					682	687		10.1056/NEJM199603143341102	http://dx.doi.org/10.1056/NEJM199603143341102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594426				2022-12-28	WOS:A1996TZ52800002
J	Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON				Catchpole, MA; Mercey, DE; Nicoll, A; Rogers, PA; Simms, J; Newham, J; Mahoney, A; Parry, JV; Joyce, C; Gill, ON			Continuing transmission of sexually transmitted diseases among patients infected with HIV-1 attending genitourinary medicine clinics in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether those who are aware of being infected with HIV continue to adopt behaviours that place others at risk of HIV infection. Design-Ongoing survey of current diagnosis of sexually transmitted disease and awareness of HIV infection among patients attending genitourinary medicine clinics. Setting-Six genitourinary medicine clinics in England and Wales (two in London and four outside) participating in unlinked anonymous HIV serosurveillance during 1990-3. Subjects-All attenders having blood drawn for syphilis serology for the first time during the calendar quarter of attendance. Main outcome measures-The proportion of syphilis serology specimens with antibody to HIV-1 detected by unlinked anonymous testing of the residue. The proportion of attenders infected with HIV-1 who remained clinically undetected, and the proportion who had another recently acquired sexually transmitted disease, Results-Of 85441 specimens tested, 2328 (2.7%) were positive for antibodies to HIV-1, About 30% of these specimens were from attenders whose HIV-1 infection remained clinically undetected, HIV-1 infection was found to coexist with another recently acquired sexually transmitted disease in 651 attenders, of whom 522 were homosexual or bisexual men. Of these, 245 (47%) already knew themselves to be infected with HIV-1, This proportion increased between 1990 and 1993. Conclusions-A considerable proportion of patients infected with HIV-1 are not identified by voluntary confidential HIV testing in genitourinary medicine clinics. Substantial numbers of homosexual or bisexual men attending genitourinary medicine clinics continue to practise unsafe sex despite being aware of their infection with HIV-1.	ACAD DEPT GENITOURINARY MED,MORTIMER MARKET CTR,LONDON WC 6AY,ENGLAND; PUBL HLTH LAB SERV,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND	Public Health England	Catchpole, MA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.							DAY NE, 1996, CDR REV, V6, pR1; EVANS BG, 1993, BRIT MED J, V306, P426, DOI 10.1136/bmj.306.6875.426; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; GROSECLOSE SL, 1994, SEX TRANSM DIS, V21, P31, DOI 10.1097/00007435-199401000-00007; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; *HLTH ED AUTH, 1994, HLTH UPD, V4; JONES JL, 1993, SEX TRANSM DIS, V20, P334, DOI 10.1097/00007435-199320060-00006; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; NARDONE A, 1995, P MED RES COUNC 9 AN; Noone A, 1992, Commun Dis Rep CDR Rev, V2, pR21; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; TOMLINSON DR, 1991, LANCET, V337, P501, DOI 10.1016/0140-6736(91)93447-H; *UNL AN HIV SURV S, 1995, UNL AN HIV PREV MON; 1993, COMMUN DIS REP CDR R, V3, pR1; 1993, LANCET, V341, P863	15	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1996	312	7030					539	542		10.1136/bmj.312.7030.539	http://dx.doi.org/10.1136/bmj.312.7030.539			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY885	8595282	Green Published			2022-12-28	WOS:A1996TY88500022
J	Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M				Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M			Medical evacuation from Mostar	LANCET			English	Article											Southall, DP (corresponding author), KEELE UNIV,N STAFFS HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							[Anonymous], 1991, CONVENTION RIGHTS CH; MORLEY D, 1986, MY NAME IS TODAY; Ressler Everett M., 1992, EVACUATION CHILDREN; SOUTHALL D, IN PRESS PROGRAMME I; 1994, INTRO IOM SPECIAL ME	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					244	245		10.1016/S0140-6736(96)90411-0	http://dx.doi.org/10.1016/S0140-6736(96)90411-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551888				2022-12-28	WOS:A1996TT06900017
J	Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR				Okuda, T; vanDeursen, J; Hiebert, SW; Grosveld, G; Downing, JR			AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; DROSOPHILA SEGMENTATION GENE; ACUTE MYELOGENOUS LEUKEMIA; SL3-3 VIRUS ENHANCER; FUSION TRANSCRIPT; RECEPTOR-DELTA; NUCLEAR FACTOR; DNA-BINDING; RUNT	The AML1-CBF beta transcription factor is the most frequent target of chromosomal rearrangements in human leukemia. To investigate its normal function, we generated mice lacking AML1. Embryos with homozygous mutations in AML1 showed normal morphogenesis and yolk sac-derived erythropoiesis, but lacked fetal liver hematopoiesis and died around E12.5. Sequentially targeted AML1(-/-) ES cells retained their capacity to differentiate into primitive erythroid cells in vitro; however, no myeloid or erythroid progenitors of definitive hematopoietic origin were detected in either the yolk sac or fetal livers of mutant embryos. Moreover, this hematopoietic defect was intrinsic to the stem cells in that AML1(-/-) ES cells failed to contribute to hematopoiesis in chimeric animals. These results suggest that AML1-regulated target genes are essential for definitive hematopoiesis of all lineages.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Okuda, T (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Downing, James R./N-8102-2018; Hiebert, Scott W/C-9979-2010		NCI NIH HHS [CA-21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; ERICKSON P, 1992, BLOOD, V80, P1825; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GERGEN JP, 1986, CELL, V45, P289, DOI 10.1016/0092-8674(86)90393-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HAJRA A, 1995, MOL CELL BIOL, V15, P4980; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIESCHKE GJ, 1994, BLOOD, V84, P27; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LOSARDO JE, 1990, J VIROL, V64, P1756, DOI 10.1128/JVI.64.4.1756-1763.1990; MANLEY NR, 1993, J VIROL, V67, P1967, DOI 10.1128/JVI.67.4.1967-1975.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1996, IN PRESS CRIT REV EU; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SHURTLEFF SA, 1995, IN PRESS LEUKEMIA; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SONODA Y, 1990, BLOOD, V75, P1615; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; SUN WW, 1993, J VIROL, V67, P1976, DOI 10.1128/JVI.67.4.1976-1986.1993; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1992, GENOMICS, V12, P340, DOI 10.1016/0888-7543(92)90383-4; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZHU X, MOL CELL BIOL, V15, P1136; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	79	1546	1584	0	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					321	330		10.1016/S0092-8674(00)80986-1	http://dx.doi.org/10.1016/S0092-8674(00)80986-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565077	Bronze			2022-12-28	WOS:A1996TR59500018
J	Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR				Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR			Roles for FGF8 in the induction, initiation, and maintenance of chick limb development	CELL			English	Article							BUD; OUTGROWTH; GROWTH; EMBRYO; MOUSE	We provide evidence that FGF8 serves as an endogenous inducer of chick limb formation and that its expression in the intermediate mesoderm at the appropriate time and place to trigger forelimb development is directly linked to the mechanism of embryonic kidney differentiation. One function of the limb inducer is to initiate Fgf8 gene expression in the ectoderm overlying the prospective limb-forming territories. FGF8 secreted by the ectoderm then appears to initiate limb bud formation by promoting outgrowth of and Sonic hedgehog expression in the underlying lateral plate mesoderm. FGF8 also maintains mesoderm outgrowth and Sonic hedgehog expression in the established limb bud. Our data thus point to FGF8 as a key regulator of limb development that not only induces and initiates the formation of a limb bud, but also sustains its subsequent development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of California System; University of California San Francisco; Washington University (WUSTL)	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURNS RK, 1955, ANAL DEV, P462; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GEDUSPAN JS, 1992, DEV BIOL, V151, P212; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIENY M, 1971, Annales d'Embryologie et de Morphogenese, V4, P281; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; MUCHMORE WB, 1957, J EXP ZOOL, V134, P293, DOI 10.1002/jez.1401340205; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PINOT M, 1970, Journal of Embryology and Experimental Morphology, V23, P109; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; STEPHENS TD, 1981, J EMBRYOL EXP MORPH, V61, P191; STRECKER TR, 1983, TERATOLOGY, V27, P159, DOI 10.1002/tera.1420270204; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZWILLING E, 1956, COLD SPRING HARB SYM, V21, P349, DOI 10.1101/SQB.1956.021.01.028	38	510	524	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					127	136		10.1016/S0092-8674(00)80999-X	http://dx.doi.org/10.1016/S0092-8674(00)80999-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548816	Bronze			2022-12-28	WOS:A1996TQ17000015
J	Walczak, CE; Mitchison, TJ; Desai, A				Walczak, CE; Mitchison, TJ; Desai, A			XKCM1: A Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly	CELL			English	Article							CELL-FREE-EXTRACTS; EGG EXTRACTS; CYTOPLASMIC DYNEIN; TOPOISOMERASE-II; KINETOCHORES; INSTABILITY; ORGANIZATION; MICROSCOPY; ANAPHASE; MITOSIS	We isolated a cDNA clone encoding a kinesin-related protein, which we named XKCM1. Antibodies to XKCM1 stain mitotic centromeres and spindle poles. Immunodepletion and antibody addition experiments in an in vitro spindle assembly assay show that XKCM1 is required for both establishment and maintenance of mitotic spindles, The structures that form in the absence of XKCM1 contain abnormally long microtubules. This long microtubule defect can be rescued by the addition of purified XKCM1 protein. Analysis of microtubule dynamics in a clarified mitotic extract reveals that loss of XKCM1 function causes a 4-fold suppression in the catastrophe frequency, XKCM1 thus exhibits a novel activity for a kinesin-related protein by promoting microtubule depolymerization during mitotic spindle assembly.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Walczak, CE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM39565-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039565, R01GM039565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1995, MOL BIOL CELL, P16319; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; Sambrook J, 1989, MOL CLONING LABORATO; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	44	447	469	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					37	47		10.1016/S0092-8674(00)80991-5	http://dx.doi.org/10.1016/S0092-8674(00)80991-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548824	Bronze			2022-12-28	WOS:A1996TQ17000007
J	Colwell, JA; Clark, CM				Colwell, JA; Clark, CM			Forum two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				The participants of Forum Two addressed the unanswered research questions about metabolic control and noninsulin-dependent diabetes mellitus (NIDDM). The most compelling issue was the effect of metabolic control on both the development and progression of macrovascular disease in patients with NIDDM. Associated questions that could be answered by a well-controlled clinical trial related to the goal of blood glucose control in NIDDM in the elderly and in persons with clinical vascular disease. The specific suggestion was a trial similar to the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Another important research issue that was discussed was the benefit of treating other risk factors such as hypertension and hyperlipidemia in diabetic patients. Yet another area discussed was the study of health services delivery to-examine the best care-delivery methods for diabetes and other chronic diseases. Other areas of discussion centered on basic research, that is, the fundamental cause of insulin resistance and the genetics of NIDDM and the loss of protection against atherosclerosis in postmenopausal women with diabetes.	REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Colwell, JA (corresponding author), MED UNIV S CAROLINA, 171 ASHLEY AVE, CHARLESTON, SC 29401 USA.								0	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				178	179		10.7326/0003-4819-124-1_Part_2-199601011-00020	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554215				2022-12-28	WOS:A1996TL94400020
J	denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR				denHeijer, M; Koster, T; Blom, HJ; Bos, GMJ; Briet, E; Reitsma, PH; Vandenbroucke, JP; Rosendaal, FR			Hyperhomocysteinemia as a risk factor for deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA HOMOCYSTEINE; PROTEIN-C; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Background. Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis, To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels In patients with a first episode of deep-vein thrombosis and in normal control subjects. Methods. We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex, Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control group (18.5 mu mol per liter). Results. Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2), The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age, The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially affect the risk estimates. Conclusions. High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general population. (C) 1996, Massachusetts Medical Society.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS; UNIV NIJMEGEN HOSP,LAB PEDIAT & NEUROL,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen	denHeijer, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,POB 40551,2504 LN THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Vandenbroucke, Jan/AAM-3928-2020; Martinelli, ida/J-2287-2015	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716; Martinelli, ida/0000-0001-9218-3622; Blom, Henk/0000-0001-5202-9241				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BIENVENU T, 1991, PRESSE MED, V20, P985; BLOM HJ, 1994, FIBRINOLYSIS, V8, P86, DOI 10.1016/0268-9499(94)90257-7; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DENHEIJER M, 1994, FIBRINOLYSIS S2, V8, P291; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	25	881	894	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					759	762		10.1056/NEJM199603213341203	http://dx.doi.org/10.1056/NEJM199603213341203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592549	Green Published			2022-12-28	WOS:A1996TZ97900003
J	Shuldiner, AR				Shuldiner, AR			Transgenic animals	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MICE				Shuldiner, AR (corresponding author), JOHNS HOPKINS UNIV, SCH MED,DEPT MED,DIV GERONTOL & GERIATR MED, 5501 HOPKINS BAYVIEW CIR, RM 5A42, BALTIMORE, MD 21224 USA.			Shuldiner, Alan/0000-0001-9921-4305				BRINSTER RL, 1986, HARVEY LECT, V80, P1; GOSSEN JA, 1994, MUTAT RES, V307, P451, DOI 10.1016/0027-5107(94)90256-9; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; PATTENGALE PK, 1989, AM J PATHOL, V135, P39	4	22	22	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					653	655		10.1056/NEJM199603073341009	http://dx.doi.org/10.1056/NEJM199603073341009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592531				2022-12-28	WOS:A1996TX69300009
J	Altman, RB; Merino, JE				Altman, RB; Merino, JE			Knotted umbilical cord	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Altman, RB (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.								0	2	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					573	573		10.1056/NEJM199602293340905	http://dx.doi.org/10.1056/NEJM199602293340905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569825				2022-12-28	WOS:A1996TW69600005
J	Creticos, PS; Reed, CE; Norman, PS; Khoury, J; Adkinson, NF; Buncher, CR; Busse, WW; Bush, RK; Gadde, J; Li, JT; Richerson, HB; Rosenthal, RR; Solomon, WR; Steinberg, P; Yunginger, JW				Creticos, PS; Reed, CE; Norman, PS; Khoury, J; Adkinson, NF; Buncher, CR; Busse, WW; Bush, RK; Gadde, J; Li, JT; Richerson, HB; Rosenthal, RR; Solomon, WR; Steinberg, P; Yunginger, JW			Ragweed immunotherapy in adult asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPONSES; CHALLENGE; ALLERGEN; EXTRACTS	Background. Although allergen immunotherapy is effective for allergic rhinitis, its role in treating asthma is unclear. Methods. We examined the efficacy of immunotherapy for asthma exacerbated by seasonal ragweed exposure. During an observation phase, adults with asthma who were sensitive to ragweed kept daily diaries and recorded peak expiratory flow rates between July End October. Those who reported seasonal asthma symptoms and medication use as well as decreased peak expiratory flow were randomly assigned to receive placebo or ragweed-extract immunotherapy in doses that increased weekly for an additional two years. Results. During the observation phase, the mean (+/-SE) peak expiratory flow rate measured in the morning during the three weeks representing the height of the pollination season was 454+/-20 liters per minute in the immunotherapy group and 444+/-16 liters per minute in the placebo group. Of the 77 patients who began the treatment phase, 64 completed one year of the study treatment and 53 completed two years. During the two treatment years, the mean peak expiratory flow rate was higher in the immunotherapy group (489+/-16 liters per minute, vs. 453+/-17 in the placebo group [P=0.06] during the first year, and 480+/-12 liters per minute, vs. 461+/-13 in the placebo group [P=0.03] during the second). Medication use was higher in the immunotherapy group than in the placebo group during observation and lower during the first treatment year (P=0.01) but did not differ in the two groups during the second year (P=0.7). Asthma-symptom scores were similar in the two groups (P=0.08 in year 1 and P=0.3 in year 2). The immunotherapy group had reduced hay-fever symptoms, skin-test sensitivity to ragweed, and sensitivity to bronchial challenges and increased IgG antibodies to ragweed as compared with the placebo group; there was no longer a seasonal increase in IgE antibodies to ragweed allergen in the immunotherapy group after two years of treatment, Reduced medication costs were counterbalanced by the costs of immunotherapy. Conclusions. Although immunotherapy for adults with asthma exacerbated by seasonal ragweed exposure had positive effects on objective measures of asthma and allergy, the clinical effects were limited and many were not sustained for two years. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; MAYO CLIN, ROCHESTER, MN USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; UNIV HOSP, CTR CLIN SCI, MADISON, WI USA; ASTHMA & ALLERGY SPECIALISTS, GREENBELT, MD USA; UNIV HOSP, IOWA CITY, IA USA; LAB APPL IMMUNOL, FAIRFAX, VA USA; UNIV HOSP, ANN ARBOR, MI USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA	Johns Hopkins University; Mayo Clinic; University System of Ohio; University of Cincinnati; Hennepin County Medical Center			Khoury, Jane/O-2068-2015		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI021992, U01AI021976] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21992, AI-21976] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRETICOS PS, 1992, JAMA-J AM MED ASSOC, V268, P2834, DOI 10.1001/jama.268.20.2834; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; DEJONG JW, 1994, AM J RESP CRIT CARE, V149, P91, DOI 10.1164/ajrccm.149.1.8111606; Hamilton RG, 1992, MANUAL CLIN LABORATO, P702; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; MALLING HJ, 1993, ALLERGY S35, V48; NORMAN PS, 1985, CHEST, V87, pS62, DOI 10.1378/chest.87.1.62S; NORMAN PS, 1992, MANUAL CLIN LABORATO, P685; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Sokal R.R., 2011, BIOMETRY, V4th; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; 1991, J ALLERGY CLIN IMMUN, V88, P425	19	182	185	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					501	506		10.1056/NEJM199602223340804	http://dx.doi.org/10.1056/NEJM199602223340804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559203	Bronze			2022-12-28	WOS:A1996TV68600004
J	Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A				Lois, C; GarciaVerdugo, JM; AlvarezBuylla, A			Chain migration of neuronal precursors	SCIENCE			English	Article							DEVELOPING CEREBRAL-CORTEX; FIBRILLARY ACIDIC PROTEIN; RADIAL GLIAL FIBERS; RAT OLFACTORY-BULB; ADULT AVIAN BRAIN; CELL-MIGRATION; MONOCLONAL-ANTIBODY; SUBEPENDYMAL LAYER; GRANULE CELLS; OPTIC TECTUM	In the brain of adult mice, cells that divide in the subventricular zone of the lateral ventricle migrate up to 5 millimeters to the olfactory bulb where they differentiate into neurons. These migrating cells were found to move as chains through a well-defined pathway, the rostral migratory stream. Electron microscopic analysis of serial sections showed that these chains contained only closely apposed, elongated neuroblasts connected by membrane specializations. A second cell type, which contained glial fibrillary acidic protein, ensheathed the chains of migrating neuroblasts. Thus, during chain migration, neural precursors moved associated with each other and were not guided by radial glial or axonal fibers.	ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV VALENCIA,FAC BIOL,E-46100 VALENCIA,SPAIN	Rockefeller University; University of Valencia			García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Alvarez-Buylla, Arturo/0000-0003-4426-8925	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028478, R29NS028478, R37NS028478] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32116] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; BONFANTI L, 1994, NEUROSCIENCE, V62, P291, DOI 10.1016/0306-4522(94)90333-6; BOURRAT F, 1990, J COMP NEUROL, V294, P1, DOI 10.1002/cne.902940102; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CULICAN SM, 1990, J NEUROSCI, V10, P684; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; GADISSEUX JF, 1992, J COMP NEUROL, V322, P246, DOI 10.1002/cne.903220210; GARCIAVERDUGO JM, 1986, J MORPHOL, V189, P189, DOI 10.1002/jmor.1051890209; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; Herrup Karl, 1994, Current Opinion in Neurobiology, V4, P108, DOI 10.1016/0959-4388(94)90039-6; Jacobson M., 1991, DEV NEUROBIOLOGY; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI K, 1990, ARCH HISTOL CYTOL, V53, P219, DOI 10.1679/aohc.53.219; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOPEZGARCIA C, 1988, DEV BRAIN RES, V43, P167, DOI 10.1016/0165-3806(88)90096-X; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; ONO K, 1990, ANAT EMBRYOL, V182, P11; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAYMOND PA, 1983, J NEUROSCI, V3, P1077; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; STAHELIN LA, 1974, INT REV CYTOL, V39, P191; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; 1970, ANAT REC, V166, P257	48	1030	1073	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					978	981		10.1126/science.271.5251.978	http://dx.doi.org/10.1126/science.271.5251.978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584933				2022-12-28	WOS:A1996TV70400046
J	Leor, J; Poole, WK; Kloner, RA				Leor, J; Poole, WK; Kloner, RA			Sudden cardiac death triggered by an earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CIRCADIAN VARIATION; ISCHEMIC DEATH; STRESS; WAR; FREQUENCY; MORTALITY	Background. The earthquake that struck the Los Angeles area at 4:31 a.m. on January 17, 1994, was one of the strongest earthquakes ever recorded in a major city in North America. Once the life-threatening situation was over, the Northridge earthquake, so called because its epicenter was near Northridge, California, just north of Los Angeles, provided investigators an unusual opportunity to examine the relation between emotional stress and sudden cardiac death. Methods. We reviewed the records of the Department of Coroner of Los Angeles County for the week before the earthquake, the day of the earthquake, the six days after the earthquake, and corresponding control periods in 1991, 1992, and 1993. Results. On the day of the earthquake, there was a sharp increase in the number of sudden deaths from cardiac causes that were related to atherosclerotic cardiovascular disease, from a daily average (+/-SD) of 4.6+/-2.1 in the preceding week to 24 on the day of the earthquake (z=4.41, P<0.001). Sixteen victims of sudden death either died or had premonitory symptoms, usually chest pain, within the first hour after the initial tremor. Only three sudden deaths occurred during or immediately after unusual physical exertion. During the six days after the earthquake, the number of sudden deaths declined to below the base-line value, to an average of 2.7+/-1.2 per day. Conclusions. The Northridge earthquake was a significant trigger of sudden death due to cardiac causes, independently of physical exertion. This finding, along with the unusually low incidence of such deaths in the week after the earthquake, suggests that emotional stress may precipitate cardiac events in people who are predisposed to such events. (C) 1996, Massachusetts Medical Society.	UNIV SO CALIF,HOSP GOOD SAMARITAN,INST HEART,LOS ANGELES,CA 90017; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Southern California; Research Triangle Institute			Kloner, Robert A/B-2971-2012; Leor, Jonathan/T-8038-2019					DANENBERG HD, 1991, ISRAEL J MED SCI, V27, P627; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757, DOI 10.5694/j.1326-5377.1991.tb94029.x; Hall JF., 1994, NORTHRIDGE EARTHQUAK; KARK JD, 1995, JAMA-J AM MED ASSOC, V273, P2108; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LEOR J, 1995, J AM COLL CARDIOL, V25, pA105; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; Muller J E, 1992, Ann Epidemiol, V2, P393; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MYERBURG RJ, 1992, HEART DIS TXB CARDIO, P756; NISHIYAMA Y, 1995, CIRCULATION S1, V92, P606; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RUMBOLDT Z, 1993, LANCET, V341, P965, DOI 10.1016/0140-6736(93)91260-S; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TOFLER GH, 1995, CIRCULATION, V92, P1203, DOI 10.1161/01.CIR.92.5.1203; TRICHOPOULOS D, 1983, LANCET, V1, P441; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; 1994, SCIENCE, V266, P389	26	561	573	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					413	419		10.1056/NEJM199602153340701	http://dx.doi.org/10.1056/NEJM199602153340701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552142	Bronze			2022-12-28	WOS:A1996TU69600001
J	Masood, E; Lehrman, S; Schiermeier, Q; Butler, D; Nathan, R				Masood, E; Lehrman, S; Schiermeier, Q; Butler, D; Nathan, R			Gene tests: Who benefits from risk?	NATURE			English	Editorial Material																		1995, NATURE, V379, P195	1	16	16	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					389	&		10.1038/379389a0	http://dx.doi.org/10.1038/379389a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559235				2022-12-28	WOS:A1996TT30400015
J	Bolland, S; Kleckner, N				Bolland, S; Kleckner, N			The three chemical steps of Tn10/IS10 transposition involve repeated utilization of a single active site	CELL			English	Article							DNA STRAND TRANSFER; TN10 TRANSPOSITION; TN7 TRANSPOSITION; INVITRO PROCEEDS; TARGET SITE; MU-DNA; MECHANISM; RECOMBINATION; INTERMEDIATE; CATALYSIS	Nonreplicative transposition by Tn10/IS10 involves three chemical steps at each transposon end: cleavage of the two strands plus joining of one strand to target DNA. These steps occur within a synaptic complex comprising two transposon ends and monomers of IS10 transposase. We report four transposase mutations that individually abolish each of the three chemical steps without affecting the synaptic complex. We conclude that a single constellation of residues, the ''active site,'' directly catalyzes each of the three steps. Analyses of reactions containing mixtures of wild-type and catalysis-defective transposases indicate that a single transposase monomer at each end catalyzes the cleavage of two strands and that strand transfer is carried out by the same monomers that previously catalyzed cleavage. These and other data suggest that one active site unit carries out all three reactions in succession at one transposon end.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [R01 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7314; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COEN ES, 1989, MOBILE DNA, P227; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; HUISMAN O, 1987, GENETICS, V116, P185; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWON D, 1995, P NATL ACAD SCI USA, V92, P8234, DOI 10.1073/pnas.92.18.8234; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596	38	85	86	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					223	233		10.1016/S0092-8674(00)80977-0	http://dx.doi.org/10.1016/S0092-8674(00)80977-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565068	Bronze			2022-12-28	WOS:A1996TR59500009
J	Chang, F; Nurse, P				Chang, F; Nurse, P			How fission yeast fission in the middle	CELL			English	Review							CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; CYTOKINESIS		IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; CHANG F, 1996, IN PRESS J CELL SCI, V109; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Fankhauser Christian, 1994, Trends in Cell Biology, V4, P96, DOI 10.1016/0962-8924(94)90182-1; GIRBARDT M, 1979, EXP MYCOL, V3, P215, DOI 10.1016/S0147-5975(79)80047-X; HAGAN IM, 1988, J CELL SCI, V89, P343; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MARKS J, 1987, SPATIAL ORG EUKARYOT, P119; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; MITCHISON JM, 1985, J CELL SCI, V75, P357; MURATA T, 1991, PLANTA, V183, P391, DOI 10.1007/BF00197738; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; SMITH LG, 1996, IN PRESS DEVELOPMENT; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; VERDE F, 1995, IN PRESS J CELL BIOL; WORDEMAN L, 1990, ANN NY ACAD SCI, V582, P252	20	117	117	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					191	194		10.1016/S0092-8674(00)80973-3	http://dx.doi.org/10.1016/S0092-8674(00)80973-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565064	Bronze			2022-12-28	WOS:A1996TR59500005
J	Reddi, AH				Reddi, AH			BMP-1: Resurrection as procollagen C-proteinase	SCIENCE			English	Editorial Material							BONE		JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	Reddi, AH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ORTHOPED SURG,BALTIMORE,MD 21205, USA.							CUNNINGHAM NS, 1995, GROWTH FACTORS, V12, P99, DOI 10.3109/08977199509028956; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Piez K.A., 1984, EXTRACELLULAR MATRIX; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	9	16	19	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					463	463		10.1126/science.271.5248.463	http://dx.doi.org/10.1126/science.271.5248.463			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560258				2022-12-28	WOS:A1996TR32200029
J	Rothfield, LI; Zhao, CR				Rothfield, LI; Zhao, CR			How do bacteria decide where to divide?	CELL			English	Review							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CELL-DIVISION; TOPOLOGICAL SPECIFICITY; SEPTUM PLACEMENT; LOCUS; MINCD; FTSZ				Rothfield, LI (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA.							ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; CANALEPAROLA E, 1970, BACTERIOL REV, V34, P82, DOI 10.1128/MMBR.34.1.82-97.1970; COOK WR, 1994, MOL MICROBIOL, V14, P497, DOI 10.1111/j.1365-2958.1994.tb02184.x; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DONACHIE WD, 1995, BIOESSAYS, V17, P569, DOI 10.1002/bies.950170616; KOTANI H, 1995, DNA RES, V2, P153; LEE SY, 1993, MOL MICROBIOL, V7, P601, DOI 10.1111/j.1365-2958.1993.tb01151.x; LEVIN PA, 1992, J BACTERIOL, V174, P6717, DOI 10.1128/JB.174.21.6717-6728.1992; MURRAY RGE, 1984, BERGEYS MANUAL SYSTE, P402; PICHOFF S, 1995, MOL MICROBIOL, V18, P321, DOI 10.1111/j.1365-2958.1995.mmi_18020321.x; REEVE JN, 1973, J BACTERIOL, V114, P860, DOI 10.1128/JB.114.2.860-873.1973; RYTER A, 1965, ANN I PASTEUR PARIS, V108, P40; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; VARLEY AW, 1992, J BACTERIOL, V174, P6729, DOI 10.1128/JB.174.21.6729-6742.1992; WOLDRINGH CL, 1991, RES MICROBIOL, V142, P309, DOI 10.1016/0923-2508(91)90046-D; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4313, DOI 10.1073/pnas.92.10.4313	20	55	55	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					183	186		10.1016/S0092-8674(00)80971-X	http://dx.doi.org/10.1016/S0092-8674(00)80971-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565062	Bronze			2022-12-28	WOS:A1996TR59500003
J	White, J; Strome, S				White, J; Strome, S			Cleavage plane specification in C-elegans: How to divide the spoils	CELL			English	Review							CAENORHABDITIS-ELEGANS; EMBRYOS		INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	White, J (corresponding author), UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN VW, 1992, DEVELOPMENT, V115, P873; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; CHENG NN, 1995, GENETICS, V139, P549; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1993, DEVELOPMENT S, V119, P279; HIRD SN, 1996, IN PRESS DEVELOPMENT; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KROBLICH JA, 1995, NATURE, V377, P624; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; STROME S, 1995, DEVELOPMENT, V121, P2961; WADDLE JA, 1994, DEVELOPMENT, V120, P2317	17	69	78	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					195	198		10.1016/S0092-8674(00)80974-5	http://dx.doi.org/10.1016/S0092-8674(00)80974-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565065	Bronze			2022-12-28	WOS:A1996TR59500006
J	Gillis, CR; Hole, DJ				Gillis, CR; Hole, DJ			Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare survival outcome for patients with breast cancer cared for by specialist and non-specialist surgeons in a geographically defined area. Design-Retrospective study of all female patients aged under 75 years in the area treated between 1980 and June 1988 (before breast screening began). Patients were identified from the cancer registry and from pathology records of all hospitals in the area. Specialist surgeons were identified by one author. All other surgeons caring for patients from the area were considered non-specialists. Setting-A geographically defined population in urban west of Scotland. Subjects-3786 patients with histologically verified breast cancer operated on between 1 January 1980 and 30 June 1988 and followed to 31 December 1993. Main outcome measures-Five and 10 year survival rates for specialists and non-specialists; relative hazard ratios derived from Cox's proportional hazards model adjusted for prognostic factors-age, socioeconomic status, tumour size, and nodal involvement. Results-The five year survival rate was 9% higher and the 10 year survival 8% higher for patients cared for by specialist surgeons. A reduction in risk of dying of 16% (95% confidence interval 6% to 25%) was found after adjustment for age, tumour size, socioeconomic status, and nodal involvement. The benefit of specialist care was apparent for all age groups, for small and large tumours, and for tumours that did and did not affect the nodes and was consistent across all socioeconomic categories. Conclusions-Survival differences of the magnitude demonstrated have implications for the provision of services for the treatment of women with breast cancer. There is a need to improve equity in the treatment of breast cancer.			Gillis, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND.							BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CARSTAIRS V, 1988, DEPRIVATION HLTH SCO; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; JUNOR EJ, 1994, BRIT J CANCER, V70, P363, DOI 10.1038/bjc.1994.307; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; OLIVOTTO IA, 1994, NEW ENGL J MED, V330, P805, DOI 10.1056/NEJM199403243301201; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SHARP L, 1993, CANCER REGISTRATION; 1992, LANCET, V339, P71; 1986, BRIT MED J, V293, P946	15	254	257	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					145	148		10.1136/bmj.312.7024.145	http://dx.doi.org/10.1136/bmj.312.7024.145			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563532	Green Published			2022-12-28	WOS:A1996TR32500019
J	Valentine, JP; Martin, CJ				Valentine, JP; Martin, CJ			Job sharing at a children's hospital: Evaluation by medical staff	BRITISH MEDICAL JOURNAL			English	Article								Objective - To evaluate job sharing for registrars at Princess Margaret Hospital for Children, Perth, by seeking responses from members of the relevant medical teams. Design - A questionnaire was sent to all 126 medical staff within the hospital (and three managers in medical administration) asking their views on job sharing for registrars. Outcome measures - Whether job sharing should continue, who should do it, at what stage of training, and the effects on patient care. Results - Among the 77 respondents (60%) there was broad support for the continuation of job sharing at the hospital: only 5 of 37 consultants and 2 of 19 non-job sharing registrars rejected the idea (with a further 4 consultants uncertain). 43% Of the consultants who had worked with job sharing registrars thought continuity of care was adversely affected. Conclusion - The committee for physician training of the Royal Australasian College of Physicians emphasises that advanced training should be flexible, with a wide range of opportunities for individuals to plan an appropriate training programme in line with their personal goals. This study has shown that job sharing for registrars at Princess Margaret Hospital for Children allows this choice. Action on concerns over any adverse effects on patient care should resolve any persisting disquiet.			Valentine, JP (corresponding author), PRINCESS MARGARET HOSP CHILDREN,POB D184,PERTH,WA 6001,AUSTRALIA.		valentine, jane/B-5875-2017	valentine, jane/0000-0003-1854-7381				GIBB S, 1994, FELLOWSHIP AFFAIRS, V13, P30; HILDICKSMITH M, 1987, PRACTITIONER, V231, P9; OLMSTED B, 1983, JOB SHARE HDB; SEWELL J, 1994, FELLOWSHIP AFFAIRS, V13, P31; STACE J, 1992, GUIDELINES JOB SHARI; THORNICROFT G, 1992, BRIT MED J, V305, P1413, DOI 10.1136/bmj.305.6866.1413; 1981, JOB SHARING IMPROVIN	7	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					115	116						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555898				2022-12-28	WOS:A1996TQ16800037
J	Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA				Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA			The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein	CELL			English	Article							DOMAINS; BINDING; GAP		ONYX PHARMACEUT,RICHMOND,CA 94806; SUGEN INC,REDWOOD CITY,CA 94063		Lock, P (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY.		FUMAGALLI, Stefano/C-2914-2019	Fumagalli, Stefano/0000-0001-5832-8680; Lock, Peter/0000-0003-4421-3609				Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OGAWA W, 1994, J BIOL CHEM, V269, P29602; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	11	74	75	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					23	24		10.1016/S0092-8674(00)80989-7	http://dx.doi.org/10.1016/S0092-8674(00)80989-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548822	Bronze			2022-12-28	WOS:A1996TQ17000005
J	Falvo, JV; Thanos, D; Maniatis, T				Falvo, JV; Thanos, D; Maniatis, T			Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y)	CELL			English	Article							NF-KAPPA-B; CRYSTAL-STRUCTURE; TATA ELEMENT; BINDING; COMPLEX; ACTIVATION; PROMOTER; AFFINITY; ADENINE; DOMAIN	In this paper, we investigate DNA bending induced by proteins required for virus induction of the human interferon-beta (IFN beta) gene. We show that NF-kappa B-DNA complexes that are functionally distinct in the context of the IFN beta enhancer are also conformationally distinct and that two sites in the enhancer contain in-phase bends that are counteracted or reversed by the binding of NF-kappa B, ATF-2/c-Jun, and HMG I(Y). Strikingly, this modulation of intrinsic enhancer architecture results in an orientation that favors predicted protein-protein interactions in a functional nucleoprotein complex, the enhanceosome. Furthermore, the subtle modulation of DNA structure by HMG I(Y) in this process distinguishes it from other architectural factors.			Falvo, JV (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI 20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AZ, 1995, NATURE, V374, P371; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HAMM MK, 1995, BIOORG MED CHEM LETT, V5, P1621, DOI 10.1016/0960-894X(95)00266-V; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KUPRASH DV, 1995, NUCLEIC ACIDS RES, V23, P427, DOI 10.1093/nar/23.3.427; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHN DA, 1988, BIOCHEM INT, V16, P963; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MEACOCK S, 1994, J BIOL CHEM, V269, P31759; MENDOZA R, 1990, BIOCHEMISTRY-US, V29, P5035, DOI 10.1021/bi00473a006; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	63	271	273	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1101	1111		10.1016/0092-8674(95)90137-X	http://dx.doi.org/10.1016/0092-8674(95)90137-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548798	Bronze			2022-12-28	WOS:A1995TM76200007
J	Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C				Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C			Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory	LANCET			English	Note								Secondary transmission of Ebola virus infection in humans is known to be caused by direct contact with infected patients or body fluids. We report transmission of Ebola virus (Zaire strain) to two of three control rhesus monkeys (Macaca mulatta) that did not have direct contact with experimentally inoculated monkeys held in the same room. The two control monkeys died from Ebola virus infections at 10 and 11 days after the last experimentally inoculated monkey had died. The most likely route of infection of the control monkeys was aerosol, oral, or conjunctival exposure to virus-laden droplets secreted or excreted from the experimentally inoculated monkeys. These observations suggest approaches to the study of routes of transmission to and among humans.			Jaax, N (corresponding author), USA, MED RES INST INFECT DIS, FREDERICK, MD 21702 USA.							BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOWEN ETW, 1978, T ROY SOC TROP MED H, V72, P188, DOI 10.1016/0035-9203(78)90058-5; Breman J, 1976, EBOLA VIRUS HAEMORRH, P103; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; GEISBERT TW, 1990, J CLIN PATHOL, V43, P813, DOI 10.1136/jcp.43.10.813; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; PROPHET EB, 1992, LABORATORY METHODS H	9	133	144	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1669	1671		10.1016/S0140-6736(95)92841-3	http://dx.doi.org/10.1016/S0140-6736(95)92841-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551825				2022-12-28	WOS:A1995TL42300011
J	Kahn, NB; Schmittling, G; Ostergaard, D; Graham, R				Kahn, NB; Schmittling, G; Ostergaard, D; Graham, R			Specialty practice of family practice residency graduates, 1969 through 1993 - A national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNAL-MEDICINE; CARE	Objective.-To describe demographic and practice characteristics of physicians who graduated from family practice residency training programs. Design.-Information was obtained from the databases of the American Academy of Family Physicians, the American Board of Family Practice (ABFP), and the American Medical Association. Data sets were cross-referenced, and quantitative data from medical membership organizations and the certifying board were summarized. Information regarding medical school graduation and family practice residency completion was reported by the participating residency programs, and data on practice specialty were self-designated by the participating physicians. Subjects.-Physician graduates of Accreditation Council for Graduate Medical Education-accredited family practice residency programs from 1969 through 1993. Main Outcome Measures.-Practice specialty designation by graduates of family practice residency programs. Results.-Of the 38 659 physicians who graduated from family practice residency programs from 1969 through 1993, 8780 (23%) were women, 2181 (6%) were graduates of colleges of osteopathic medicine, 4777 (12%) were international medical graduates, and 33 484 (87%) were certified by the ABFP. Of the 36 088 family practice residency graduates who designated a practice specialty, 32 764 (91%) identified their specialty as family practice, including 32 608 physicians who identified family practice, 129 general practice, 21 family practice-geriatric medicine, and six family practice-sports medicine. Among the 3324 family practice residency graduates (9%) who identified themselves as practicing in another specialty, the most common specialties were emergency medicine (1446 physicians [4%]) and preventive medicine (386 physicians [1%]). No other practice specialty was designated by more than 0.5% of family practice residency graduates. Conclusion.-The vast majority of family practice residency graduates are self-designated as practicing family medicine. These data suggest that family practice residency programs are an effective mechanism for the production of generalist physicians.	AMER ACAD FAMILY PHYSICIANS,DIV RES & INFORMAT SERV,KANSAS CITY,MO 64114; AMER ACAD FAMILY PHYSICIANS,OFF EDUC & SCI AFFAIRS,KANSAS CITY,MO 64114; AMER ACAD FAMILY PHYSICIANS,OFF EXECUT VICE PRESIDENT,KANSAS CITY,MO 64114		Kahn, NB (corresponding author), AMER ACAD FAMILY PHYSICIANS,DIV EDUC,8880 WARD PKWY,KANSAS CITY,MO 64114, USA.							Bowman M A, 1990, J Am Board Fam Pract, V3, P43; CHERKIN DC, 1986, MED CARE, V24, P1136, DOI 10.1097/00005650-198612000-00006; Kahn N B Jr, 1994, Fam Med, V26, P478; KAHN NB, 1994, COMMUNICATION   0330; NOBLE J, 1992, ANN INTERN MED, V116, P482, DOI 10.7326/0003-4819-116-6-482; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCHMITTLING G, 1987, FACTS FAMILY PRACTIC, P67; WECHSLER H, 1978, NEW ENGL J MED, V298, P15, DOI 10.1056/NEJM197801052980104; 1992, IMPROVING ACCESS HLT; 1980, REPORT GRADUATE MED, P2; 1992, HOSP PRIVILEGES RECE, P3	11	24	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					713	715		10.1001/jama.275.9.713	http://dx.doi.org/10.1001/jama.275.9.713			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594270				2022-12-28	WOS:A1996TX17400028
J	Soll, AH				Soll, AH			Medical treatment of peptic ulcer disease - Practice guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI INFECTION; BENIGN GASTRIC-ULCER; GASTRODUODENAL MUCOSAL DAMAGE; RANDOMIZED CONTROLLED TRIAL; RESISTANT DUODENAL-ULCERS; LONG-TERM TREATMENT; DOUBLE-BLIND; CAMPYLOBACTER-PYLORI; MAINTENANCE THERAPY	Objective. - To integrate the realization that peptic ulcer most commonly reflects infection with Helicobacter pylori or use of aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) into a disease management approach. Participants. - Guidelines were outlined by the author and presented for review to the American College of Gastroenterology (ACG) Practice Parameters Committee, selected by the president of the ACG, and a panel of experts in peptic ulcer, selected by the committee. Evidence and Consensus Process. - These guidelines were formulated following extensive review of the literature obtained by a MEDLINE search and presented for detailed review and revision to unpublicized committee meetings on three occasions and to experts by mail, These recommendations are an official statement of the ACG and have been approved by the American Gastroenterological Association and the American Society for Gastroenterological Endoscopy. Firm recommendations are discriminated from reasonable suppositions pending definitive data. Conclusions. - Since cure of H pylori infection decreases recurrence rates and facilitates healing, antibiotic therapy is indicated for all H pylori-infected ulcer patients. No optimal, simple antibiotic regimen has yet emerged. Simultaneous conventional ulcer therapy is recommended to facilitate symptom relief and healing. For refractory ulcers, only maximal acid inhibition offers advantage over continued conventional therapy; cure of H pylori infection is likely to facilitate healing of refractory ulcers. Only with complicated or refractory ulcers should conventional maintenance therapy be continued, at least until successful H pylori eradication is confirmed. A search for NSAID use is indicated for all ulcer patients. For NSAID-associated ulcers these drugs should be discontinued if possible and H pylori, if present, should be cured.			Soll, AH (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, CURE DIGEST DIS RES CTR, BLDG 115, ROOM 215, LOS ANGELES, CA 90073 USA.							ALASSI MT, 1994, ALIMENT PHARM THERAP, V8, P453; BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; BARDHAN KD, 1991, GUT, V32, P435, DOI 10.1136/gut.32.4.435; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BORODY TJ, 1992, SCAND J GASTROENTERO, V27, P281, DOI 10.3109/00365529209000075; BOYD HK, 1994, AM J GASTROENTEROL, V89, P1505; BRUNNER GHG, 1990, DIGESTION, V47, P64, DOI 10.1159/000200520; BURGET DW, 1990, GASTROENTEROLOGY, V99, P345, DOI 10.1016/0016-5085(90)91015-X; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CHERNER JA, 1989, AM J GASTROENTEROL, V84, P769; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; COGHLAN JG, 1987, LANCET, V2, P1109; CUTLER AF, 1995, GASTROENTEROLOGY, V109, P136, DOI 10.1016/0016-5085(95)90278-3; DEBOER W, 1995, LANCET, V345, P817, DOI 10.1016/S0140-6736(95)92962-2; DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993; DEBOER WA, IN PRESS EUR J GASTR; DELCHIER JC, 1989, GUT, V30, P1173, DOI 10.1136/gut.30.9.1173; DOOLEY CP, 1984, ANN INTERN MED, V101, P538, DOI 10.7326/0003-4819-101-4-538; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FARINATI F, 1987, J SURG ONCOL, V36, P263, DOI 10.1002/jso.2930360410; FENDRICK AM, 1995, ANN INTERN MED, V123, P260, DOI 10.7326/0003-4819-123-4-199508150-00003; FRESTON JW, 1982, ANN INTERN MED, V97, P573, DOI 10.7326/0003-4819-97-4-573; FRESTON JW, 1987, AM J GASTROENTEROL, V82, P1242; FRIES JF, 1991, AM J MED, V91, P213, DOI 10.1016/0002-9343(91)90118-H; FULLERTON S, 1995, GASTROENTEROLOGY, V108, pA15; GENTA RM, 1994, HUM PATHOL, V25, P221, DOI 10.1016/0046-8177(94)90191-0; Gitlin N, 1987, GASTROENTEROLOGY, V92, P48, DOI 10.1016/0016-5085(87)90838-9; GLUPCZYNSKI Y, 1992, EUR J CLIN MICROBIOL, V11, P777; GOODMAN AJ, 1987, BRIT J SURG, V74, P897, DOI 10.1002/bjs.1800741009; GOODSON JD, 1989, J GEN INTERN MED, V4, P367, DOI 10.1007/BF02599683; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P493, DOI 10.1016/0016-5085(92)90095-G; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; GRAHAM DY, 1990, GASTROENTEROL CLIN N, V19, P171; GRAY GR, 1982, LANCET, V1, P787; GUDMANDHOYER E, 1978, BRIT MED J, V1, P1095, DOI 10.1136/bmj.1.6120.1095; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HIRSCHOWITZ B I, 1992, Gastroenterology, V102, pA84; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; HOWDEN CW, 1988, DIGEST DIS SCI, V33, P619, DOI 10.1007/BF01798367; JASPERSEN D, 1995, GASTROINTEST ENDOSC, V41, P5, DOI 10.1016/S0016-5107(95)70267-9; JAUP BH, 1995, AM J GASTROENTEROL, V90, P943; JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; Kochman M L, 1993, Gastroenterology, V105, P1583; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; KURATA JH, 1990, J CLIN GASTROENTEROL, V12, P260, DOI 10.1097/00004836-199006000-00005; LABENZ J, 1995, EUR J GASTROEN HEPAT, V7, P9; LAINE L, 1992, AM J GASTROENTEROL, V87, P1398; LANCASTERSMITH MJ, 1991, GUT, V32, P252, DOI 10.1136/gut.32.3.252; LAURITSEN K, 1991, GASTROENTEROLOGY, V100, P663, DOI 10.1016/0016-5085(91)80009-X; LEGERTON CW, 1984, AM J MED, V77, P2; LICHTENSTEIN JL, 1980, J CLIN GASTROENTEROL, V2, P31, DOI 10.1097/00004836-198003000-00006; MANTZARIS GJ, 1993, DIGEST DIS SCI, V38, P1132, DOI 10.1007/BF01295732; MARSHALL BJ, 1988, LANCET, V2, P1437; MATON PN, 1991, NEW ENGL J MED, V324, P965; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; PODOLSKY I, 1988, DIGEST DIS SCI, V33, P1057, DOI 10.1007/BF01535778; PORRO GB, 1991, DRUGS, V41, P38, DOI 10.2165/00003495-199141010-00004; Poynard T, 1989, AUCTE TREATMENT DUOD, P7; PYM B, 1990, GASTROENTEROLOGY, V99, P27, DOI 10.1016/0016-5085(90)91225-U; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; ROKKAS T, 1995, GASTROINTEST ENDOSC, V41, P1, DOI 10.1016/S0016-5107(95)70266-0; ROTH SH, 1993, ARCH INTERN MED, V153, P2565, DOI 10.1001/archinte.153.22.2565; SCHEIMAN JM, 1990, SEMIN ARTHRITIS RHEU, V20, P121, DOI 10.1016/0049-0172(90)90025-B; SEPPALA K, 1995, GUT, V36, P834, DOI 10.1136/gut.36.6.834; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; SOLL AH, 1993, GASTROINTESTINAL DIS, P580; SONTAG SJ, 1988, AM J GASTROENTEROL, V83, P607; Sox HC, 1988, MED DECISION MAKING; STRUM WB, 1986, ANN INTERN MED, V105, P757, DOI 10.7326/0003-4819-105-5-757; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TEARE JP, 1995, EUR J GASTROEN HEPAT, V7, P275; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; VANDERHULST RWM, IN PRESS HELICOBACTE; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; WAGNER S, 1992, GUT, V33, P179, DOI 10.1136/gut.33.2.179; WALAN A, 1989, NEW ENGL J MED, V320, P69, DOI 10.1056/NEJM198901123200201; WALAN A, 1987, SCAND J GASTROENTERO, V22, P397, DOI 10.3109/00365528708991481; WEBERG R, 1985, SCAND J GASTROENTERO, V20, P1041, DOI 10.3109/00365528509088868; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; YEOMANS ND, IN PRESS GASTROENTER; YOUSFI MM, 1995, ALIMENT PHARM THERAP, V9, P209	98	276	285	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					622	629						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594244				2022-12-28	WOS:A1996TW62700023
J	Ifudu, O; Feldman, J; Friedman, EA				Ifudu, O; Feldman, J; Friedman, EA			The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AMBULATORY PERITONEAL-DIALYSIS; ANEMIA; FAILURE; UREMIA	Background. Anemia (characterized by a hematocrit of 30 percent or lower) persists in 40 to 60 percent of patients treated for end-stage renal disease with maintenance hemodialysis, despite concomitant erythropoietin (epoetin) therapy. We tested the hypothesis that inadequate dialysis is a key reason for the insufficient response to erythropoietin in patients with end-stage renal disease who are receiving hemodialysis. Methods. We prospectively studied 135 randomly selected patients undergoing hemodialysis who had been receiving intravenous erythropoietin for at least four months. The adequacy of dialysis was assessed by measuring the percent reduction in the blood urea nitrogen concentration and the serum albumin concentration. The hematocrit was measured weekly for four weeks, transferrin saturation was measured, and coexisting illnesses were documented. To determine the effect of an increased level of dialysis on the hematocrit, the thrice-weekly schedule of dialysis was increased to raise the mean urea-reduction value from 60.7 to 72.0 percent for six weeks in 20 consecutive patients whose base-line urea-reduction value was less than 65 percent. The change in the hematocrit in these patients was compared with that observed in the next 20 patients who had an equivalent base-line urea-reduction value but whose level of dialysis was not altered. Results. The mean (+/-SD) hematocrit of the entire group was 29.2+/-4 percent, and the mean thrice-weekly dose of erythropoietin was 59+/-29 U per kilogram of body weight. The mean serum albumin concentration was 3.8+/-0.4 g per deciliter, the mean urea-reduction value was 62+/-4.8 percent, and the mean transferrin saturation was 20+/-9 percent. Multiple regression analysis revealed direct correlations between the hematocrit and the serum albumin concentration (P=0.009) and between the hematocrit and the urea-reduction value (P=0.012) after adjustment for other factors. A logistic-regression analysis indicated that an 11 percent increase in the urea-reduction value doubled the odds that a patient would have a hematocrit above 30 percent. After six weeks of increased intensity of dialysis in 20 patients with base-line urea-reduction values of less than 65 percent, the mean (+/-SE) hematocrit rose from 28.4+/-0.78 percent to 32.3+/-0.71 percent (P=0.002); there was no significant change in a control group of 20 patients with equivalent base-line urea-reduction values in whom the dialysis level was not altered (28.2+/-0.84 percent to 26.3+/-0.85 percent; P=0.175). Conclusions. In patients with end-stage renal disease, inadequate hemodialysis is associated with a suboptimal response to erythropoietin therapy, Increasing the intensity of dialysis in patients with anemia who are receiving inadequate dialysis results in a significant increase in the hematocrit. (C) 1996, Massachusetts Medical Society.	SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,RENAL DIS DIV,450 CLARKSON AVE,BOX 52,BROOKLYN,NY 11203, USA.							BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; CARO J, 1979, J LAB CLIN MED, V93, P449; ESCHBACH JW, 1992, KIDNEY INT, V42, P407, DOI 10.1038/ki.1992.302; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCHBACH JW, 1970, ARCH INTERN MED, V126, P812, DOI 10.1001/archinte.126.5.812; ESSERS U, 1974, P EUR DIAL TRANS, V11, P389; GOODNOUGH LT, 1994, CLIN NEPHROL, V41, P303; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; IFUDU O, 1994, JAMA-J AM MED ASSOC, V271, P29, DOI 10.1001/jama.271.1.29; IFUDU O, 1995, ASAIO J, V41, pM426, DOI 10.1097/00002480-199507000-00045; IFUDU O, 1994, CLIN RES, V42, pA263; INGELFINGER JA, 1994, BIOSTATISTICS CLIN M, P166; KOCH KM, 1974, NEPHRON, V12, P405, DOI 10.1159/000180353; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LUNDIN AP, 1989, SEMIN NEPHROL, V9, P22; MARKSON J L, 1956, Scott Med J, V1, P320; MCGONIGLE RJS, 1984, KIDNEY INT, V25, P430, DOI 10.1038/ki.1984.35; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; ORTEGA JA, 1977, AM J HEMATOL, V2, P299, DOI 10.1002/ajh.2830020312; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; POWE NR, 1993, KIDNEY INT, V43, P1125, DOI 10.1038/ki.1993.158; RADTKE HW, 1981, J CLIN INVEST, V67, P1623, DOI 10.1172/JCI110197; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WALLNER SF, 1981, J LAB CLIN MED, V97, P170; ZAPPACOSTA AR, 1982, AM J MED, V72, P53, DOI 10.1016/0002-9343(82)90577-0; 1992, 1992 SE KIDN COUNC A; 1994, ANN INTERN MED, V121, P62	30	230	237	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					420	425		10.1056/NEJM199602153340702	http://dx.doi.org/10.1056/NEJM199602153340702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552143				2022-12-28	WOS:A1996TU69600002
J	Poland, GA				Poland, GA			Acellular pertussis vaccines: New vaccines for an old disease	LANCET			English	Editorial Material											Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,200 1ST ST SW,ROCHESTER,MN 55905, USA.							DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; EDWARDS KM, 1995, PEDIATRICS, V96, P548; EDWARDS KM, 1993, J INFECT DIS, V168, P15, DOI 10.1093/infdis/168.1.15; Folkers G, 1995, NIAID AIDS Agenda, P14; GRECO D, 1995, 35TH ANN ICAAC M, V11, pLB22; PLOTKIN SL, 1994, VACCINES, P1; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					209	210		10.1016/S0140-6736(96)90398-0	http://dx.doi.org/10.1016/S0140-6736(96)90398-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551875				2022-12-28	WOS:A1996TT06900004
J	Dieci, G; Sentenac, A				Dieci, G; Sentenac, A			Facilitated recycling pathway for RNA polymerase III	CELL			English	Article							TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING PROTEIN; YEAST; INITIATION; COMPLEXES; INTERMEDIATE; REINITIATION; TERMINATION; CEREVISIAE	We show that the high in vitro transcription efficiency of yeast RNA poI III is mainly due to rapid recycling. Kinetic analysis shows that RNA polymerase recycling on preassembled tDNA . TFIIIC . TFIIIB complexes is much faster than the initial transcription cycle. High efficiency of RNA poI III recycling is favored at high UTP concentrations and requires termination at the natural termination signal. Runoff transcription does not allow efficient recycling. The reinitiation process shows increased resistance to heparin as compared with the primary initiation cycle, as if RNA polymerase was not released after termination. Indeed, template competition assays show that RNA poI III is committed to reinitiate on the same gene. A model is proposed where the polymerase molecule is directly transferred from the termination site to the promoter.	UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY	University of Parma	Dieci, G (corresponding author), CEA SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.		Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961				ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHAMBERLIN MJ, 1974, ENZYMES, V10, P333; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LINMARQ N, 1995, J MOL BIOL, V245, P81, DOI 10.1006/jmbi.1994.0008; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	37	147	147	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					245	252		10.1016/S0092-8674(00)80979-4	http://dx.doi.org/10.1016/S0092-8674(00)80979-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565070	Bronze			2022-12-28	WOS:A1996TR59500011
J	Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E				Doolittle, RF; Feng, DF; Tsang, S; Cho, G; Little, E			Determining divergence times of the major kingdoms of living organisms with a protein clock	SCIENCE			English	Article							PHYLOGENETIC TREES; RIBOSOMAL-RNA; EVOLUTION; EUKARYOTES; SEQUENCE; GENE; ARCHAEBACTERIA; EUBACTERIA; ALIGNMENT; ORIGINS	Amino acid sequence data from 57 different enzymes were used to determine the divergence times of the major biological groupings. Deuterostomes and protostomes split about 670 million years ago and plants, animals, and fungi last shared a common ancestor about a billion years ago. With regard to these protein sequences, plants are slightly more similar to animals than are the fungi. In contrast, phylogenetic analysis of the same sequences indicates that fungi and animals shared a common ancestor more recently than either did with plants, the greater difference resulting from the fungal lineage changing faster than the animal and plant lines over the last 965 million years. The major protist lineages have been changing at a somewhat faster rate than other eukaryotes and split off about 1230 million years ago. If the rate of change has been approximately constant, then prokaryotes and eukaryotes last shared a common ancestor about 2 billion years ago, archaebacterial sequences being measurably more similar to eukaryotic ones than are eubacterial ones.			Doolittle, RF (corresponding author), UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL-26873] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026873, R01HL026873] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Carroll RL, 1988, VERTEBRATE PALEONTOL; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOOLITTLE RF, 1964, NATURE, V202, P147, DOI 10.1038/202147a0; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOOLITTLE RF, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P241; DOOLITTLE RF, UNPUB; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FITCH WM, 1994, P NATL ACAD SCI USA, V91, P6802, DOI 10.1073/pnas.91.15.6802; FITCH WM, 1970, BIOCHEM GENET, V4, P579, DOI 10.1007/BF00486096; FITCH WM, 1976, FED PROC, V35, P2092; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GUPTA RS, 1993, J MOL EVOL, V37, P573; HAN TM, 1992, SCIENCE, V257, P232, DOI 10.1126/science.1631544; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JOHNSON R, 1984, ELEMENTARY STATISTIC; JUKES T H, 1969, P21; JUKES TH, 1969, SPACE LIFE SCI, V1, P469, DOI 10.1007/BF00924238; KIMURA M, 1973, NATURE-NEW BIOL, V243, P199, DOI 10.1038/newbio243199a0; KIMURA M, 1972, J MOL EVOL, V2, P87, DOI 10.1007/BF01653945; Kimura M, 1971, Journal Molec Evol, V1, P1, DOI 10.1007/BF01659390; KLOTZ LC, 1981, J THEOR BIOL, V91, P261, DOI 10.1016/0022-5193(81)90233-2; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LANGLEY CH, 1974, J MOL EVOL, V3, P161, DOI 10.1007/BF01797451; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; MARGOLIASH E., 1965, P221; MARSHALL CR, 1990, J MOL EVOL, V30, P400, DOI 10.1007/BF02101112; MCLAUGHLIN PJ, 1970, SCIENCE, V168, P1469, DOI 10.1126/science.168.3938.1469; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nei M., 1987, MOL EVOLUTIONARY GEN; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; SARICH VM, 1973, SCIENCE, V179, P1144, DOI 10.1126/science.179.4078.1144; SCHOPF JW, 1976, SCIENCE, V193, P47, DOI 10.1126/science.193.4247.47; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; SOGIN ML, 1991, WIST SYMP S, V4, P175; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WOESE CR, 1991, EVOLUTION MOL MEN, P175; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL EMILE, 1965, P97; 1987, J MOL EVOL, V26, P1; 1992, ENZYME NOMENCLATURE	57	462	484	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	1996	271	5248					470	477		10.1126/science.271.5248.470	http://dx.doi.org/10.1126/science.271.5248.470			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560259				2022-12-28	WOS:A1996TR32200031
J	Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP				Linnen, J; Wages, J; ZhangKeck, ZY; Fry, KE; Krawczynski, KZ; Alter, H; Koonin, E; Gallagher, M; Alter, M; Hadziyannis, S; Karayiannis, P; Fung, K; Nakatsuji, Y; Shih, JWK; Young, L; Piatak, M; Hoover, C; Fernandez, J; Chen, S; Zou, JC; Morris, T; Hyams, KC; Ismay, S; Lifson, JD; Hess, G; Foung, SKH; Thomas, H; Bradley, D; Margolis, H; Kim, JP			Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent	SCIENCE			English	Article							NON-B-HEPATITIS; C VIRUS; NON-A; CDNA LIBRARIES; ANTIBODY; RNA; IDENTIFICATION; CONSTRUCTION; PROTEINASE; SEQUENCES	An RNA virus, designated hepatitis G virus (HGV), was identified from the plasma of a patient with chronic hepatitis. Extension from an immunoreactive complementary DNA clone yielded the entire genome (9392 nucleotides) encoding a polyprotein of 2873 amino acids. The virus is closely related to GB virus C (GBV-C) and distantly related to hepatitis C virus, GBV-A, and GBV-B. HGV was associated with acute and chronic hepatitis. Persistent viremia was detected for up to 9 years in patients with hepatitis. The virus is transfusion-transmissible. It has a global distribution and is present within the volunteer blood donor population in the United States.	GENELABS TECHNOL,REDWOOD CITY,CA 94063; CTR DIS CONTROL & PREVENT,HEPATITIS BRANCH,ATLANTA,GA 30333; NIH,DEPT TRANSFUS MED,BETHESDA,MD 20205; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; HIPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE; ST MARYS HOSP,SCH MED,DEPT MED,LONDON,ENGLAND; USN,MED RES INST,ROCKVILLE,MD 20852; NEW S WALES RED CROSS BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; BOEHRINGER MANNHEIM GMBH,D-68305 MANNHEIM,GERMANY	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Hippokration General Hospital; Imperial College London; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Australian Red Cross Blood Service			Thomas, Howard C/A-3152-2009	Karayiannis, Peter/0000-0001-5195-7863; Foung, Steven/0000-0001-7149-6160				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DECKER RH, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P795; DEKA N, 1994, J VIROL, V68, P7810, DOI 10.1128/JVI.68.12.7810-7815.1994; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HAYASHI N, 1993, J HEPATOL, V17, pS94, DOI 10.1016/S0168-8278(05)80432-5; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lim MY, UNPUB; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PURCELL RH, 1976, J IMMUNOL, V116, P349; REYES GR, 1991, MOL CELL PROBE, V5, P473, DOI 10.1016/S0890-8508(05)80020-9; RIZETTO M, 1980, LANCET, V1, P1215; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WAGES J, UNPUB; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	31	1298	1395	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					505	508		10.1126/science.271.5248.505	http://dx.doi.org/10.1126/science.271.5248.505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560265				2022-12-28	WOS:A1996TR32200042
J	Cook, DJ; Reeve, BK; Guyatt, GH; Heyland, DK; Griffith, LE; Buckingham, L; Tryba, M				Cook, DJ; Reeve, BK; Guyatt, GH; Heyland, DK; Griffith, LE; Buckingham, L; Tryba, M			Stress ulcer prophylaxis in critically ill patients - Resolving discordant meta-analyses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INTENSIVE-CARE UNIT; UPPER GASTROINTESTINAL HEMORRHAGE; RANDOMIZED TRIAL; NOSOCOMIAL PNEUMONIA; GASTRIC COLONIZATION; INTUBATED PATIENTS; ANTACID TITRATION; CLINICAL-TRIALS; MECHANICAL VENTILATION; CIMETIDINE PROPHYLAXIS	Purpose. - To resolve discrepancies in previous systematic overviews and provide estimates of the effect of stress ulcer prophylaxis on gastrointestinal bleeding, pneumonia, and mortality in critically ill patients. Data Identification. - Computerized search of published and unpublished research, bibliographies, pharmaceutical and personal files, and conference abstract reports. Study Selection. - Independent review of 269 articles identified 63 relevant randomized trials for inclusion. Data Abstraction. - We made independent, duplicate assessment of the methodologic quality, population, intervention, and outcomes of each trial. Results. - The source of discrepancies between prior meta-analyses included incomplete identification of relevant studies, differential inclusion of non-English language and nonrandomized trials, different definitions of bleeding, provision of additional information through direct correspondence with authors, and different statistical methods. The current overview demonstrates that prophylaxis with histamine(2)-receptor antagonists decreases the incidence of overt gastrointestinal bleeding (odds ratio [OR], 0.58; 95% confidence interval [CI], 0.42 to 0.79) and clinically important bleeding (OR, 0.44; 95% CI, 0.22 to 0.88). There is a trend toward decreased overt bleeding when antacids are compared with no therapy (OR, 0.66; 95% CI, 0.37 to 1.17). Histamine(2)-receptor antagonists and antacids are associated with a trend toward lower clinically important bleeding rates than sucralfate is. There is a trend toward an increased risk of pneumonia associated with histamine(2)-receptor antagonists as compared with no prophylaxis (OR, 1.25; 95% CI, 0.78 to 2.00). Sucralfate is associated with a lower incidence of nosocomial pneumonia when compared with antacids (OR, 0.80; 95% CI, 0.56 to 1.15) and histamine(2)-receptor antagonists (OR, 0.77; 95% CI, 0.60 to 1.01). Sucralfate is also associated with a reduced mortality rate (OR, 0.73; 95% CI, 0.54 to 0.97) relative to antacids and to histamine(2)-receptor antagonists (OR, 0.83; 95% CI, 0.63 to 1.09). Conclusions. - Our results emphasize the need for registries to include all randomized trials and demonstrate the importance of explicit methodology for systematic reviews. There is strong evidence of reduced clinically important gastrointestinal bleeding with histamine(2)-receptor antagonists, Sucralfate may be as effective in reducing bleeding as gastric pH-altering drugs and is associated with lower rates of pneumonia and mortality. However, the data are insufficient to determine the net effect of sucralfate compared with no prophylaxis.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA; UNIV HOSP BERGMANNSHEIL, DEPT ANAESTHESIOL INTENS CARE MED & PAIN THERAPY, BOCHUM, GERMANY; ONTARIO MINIST HLTH, TORONTO, ON M5W 1R5, CANADA	McMaster University; McMaster University; Ruhr University Bochum								AERDTS SJA, 1993, BRIT MED J, V307, P525; ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; APTE NM, 1992, CRIT CARE MED, V20, P590, DOI 10.1097/00003246-199205000-00008; BARANDUN J, 1985, SCHWEIZ MED WSCHR, V115, P1022; BASSO N, 1981, AM J SURG, V141, P339, DOI 10.1016/0002-9610(81)90191-4; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BENMENACHEM T, 1994, ANN INTERN MED, V121, P568, DOI 10.7326/0003-4819-121-8-199410150-00003; BERLIN JA, 1992, ONLINE J CURR CLIN T; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, P254, DOI 10.1016/0197-2456(89)90067-6; BORRERO E, 1984, AM J SURG, V148, P809, DOI 10.1016/0002-9610(84)90443-4; BORRERO E, 1986, ARCH SURG-CHICAGO, V121, P810; BORRERO E, 1985, AM J MED, V79, P62, DOI 10.1016/0002-9343(85)90575-3; BRANDAO A, 1991, GASTROINTEST ESOPHAG, V10, P105; BRESALIER RS, 1987, AM J MED, V83, P110, DOI 10.1016/0002-9343(87)90839-4; BREUCHA G, 1987, RATIONALE STRESSBLUT, P81; CANNON LA, 1987, ARCH INTERN MED, V147, P2101, DOI 10.1001/archinte.147.12.2101; CARTIER F, 1980, INTENS CARE MED, V6, P54; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1992, ACP J CLUB       JUL, P1; CHEADLE WG, 1985, ANN SURG, V202, P361, DOI 10.1097/00000658-198509000-00014; CIOFFI WG, 1994, J TRAUMA, V36, P541, DOI 10.1097/00005373-199404000-00014; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; COOK DJ, 1992, CHEST, V102, pS305; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; COOK DJ, 1991, CHEST, V100, P7, DOI 10.1378/chest.100.1.7; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; DITSCHUNEIT H, 1982, MED WELT, V33, P34; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; EASTERBROOK PJ, 1992, STAT MED, V11, P345, DOI 10.1002/sim.4780110307; EDDLESTON JM, 1991, CRIT CARE MED, V19, P1491, DOI 10.1097/00003246-199112000-00009; EDDLESTON JM, 1994, CRIT CARE MED, V22, P1949; ENGELHARDT D, 1985, DEUT MED WOCHENSCHR, V110, P908, DOI 10.1055/s-2008-1068930; EPHGRAVE K, 1993, CRIT CARE MED S, V21, pS253; FABIAN TC, 1993, ARCH SURG-CHICAGO, V128, P185; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FRIEDMAN CJ, 1982, CRIT CARE MED, V10, P316; GARCIALABATTUT A, 1990, INTENS CARE MED, V16, P519; GRAU JM, 1993, SCAND J GASTROENTERO, V28, P244, DOI 10.3109/00365529309096080; GROLL A, 1986, GUT, V27, P135, DOI 10.1136/gut.27.2.135; HALLORAN LG, 1980, AM J SURG, V139, P44, DOI 10.1016/0002-9610(80)90228-7; HASTINGS PR, 1978, NEW ENGL J MED, V298, P1041, DOI 10.1056/NEJM197805112981901; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; HOLZAPFEL L, 1988, INTENS CARE MED, V6, P54; HOLZAPFEL L, 1990, REAN SOINS INTENS ME, V6, P141; ISRASENA S, 1987, Journal of the Medical Association of Thailand, V70, P678; JMELNITZKY AC, 1986, DIGEST DIS SCI, V31, pS206; JONES RH, 1978, BMJ-BRIT MED J, V1, P398, DOI 10.1136/bmj.1.6110.398; KAHN F, 1981, CHEST, V79, P409; KAPPSTEIN I, 1991, AM J MED, V91, pS125, DOI 10.1016/0002-9343(91)90464-9; KARLSTADT R, 1989, AM J GASTROENTEROL, V84, pA93; KARLSTADT RG, 1990, J INTENSIVE CARE MED, V5, P26, DOI DOI 10.1177/088506669000500106; KINGSLEY AN, 1985, AM SURGEON, V51, P545; KLEIN HJ, 1987, RATIONALE STRESSBLUT, P66; KNIGHTGEORGE AB, 1990, CLIN INTENSIVE CARE, V1, P249; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; LABATTUT AG, 1992, CLIN INTENSIVE CARE, V3, P519; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LACROIX J, 1986, J PEDIATR-US, V108, P1015, DOI 10.1016/S0022-3476(86)80952-0; LACROIX J, 1989, CRIT CARE MED, V17, P862, DOI 10.1097/00003246-198909000-00003; LAGGNER AN, 1988, ANAESTHESIST, V37, P704; LAGGNER AN, 1989, AM J MED, V86, P81, DOI 10.1016/0002-9343(89)90164-2; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEVY MM, 1993, CRIT CARE MED S, V21, pS181; LOPEZHERCE J, 1992, CRIT CARE MED, V20, P1082, DOI 10.1097/00003246-199208000-00003; LUK GD, 1982, GASTROENTEROLOGY, V82, P1121; MACDOUGALL BRD, 1977, LANCET, V1, P617; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MAIER RV, 1994, ANN SURG, V220, P353; MARTIN LF, 1993, CRIT CARE MED, V21, P19, DOI 10.1097/00003246-199301000-00009; MARTIN LF, 1980, SURGERY, V88, P59; MARTIN LF, 1994, AM SURGEON, V60, P169; MARTIN LF, 1992, ANN SURG, V215, P332, DOI 10.1097/00000658-199204000-00005; MATTES P, 1980, Z GASTROENTEROL, V18, P325; MCALHANY JC, 1976, J TRAUMA, V16, P645, DOI 10.1097/00005373-197608000-00009; MCELWEE HP, 1979, SURGERY, V86, P620; METZ CA, 1993, CRIT CARE MED, V21, P1844, DOI 10.1097/00003246-199312000-00010; MORE DG, 1985, CRIT CARE MED, V13, P651, DOI 10.1097/00003246-198508000-00008; MOSCONA R, 1985, BURNS, V12, P65, DOI 10.1016/0305-4179(85)90185-8; MUNDINGER GH, 1985, SURG FORUM, V36, P121; MUSTAFA NA, 1995, INTENS CARE MED, V21, P287, DOI 10.1007/BF01701491; NAYLOR AF, 1967, BIOMETRICS, V23, P349, DOI 10.2307/2528167; NOSEWORTHY TW, 1987, CRIT CARE MED, V15, P817, DOI 10.1097/00003246-198709000-00003; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PALOMAR M, 1992, INTENS CARE MED, V18, pS58; PEURA DA, 1985, ANN INTERN MED, V103, P173, DOI 10.7326/0003-4819-103-2-173; PICKWORTH KK, 1992, CRIT CARE MED S, V20, P595; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PINILLA JC, 1985, CRIT CARE MED, V13, P646, DOI 10.1097/00003246-198508000-00007; POLESKI MH, 1986, AM J GASTROENTEROL, V81, P107; PRIEBE HJ, 1980, NEW ENGL J MED, V302, P426, DOI 10.1056/NEJM198002213020802; PRODHOM G, 1994, ANN INTERN MED, V120, P653, DOI 10.7326/0003-4819-120-8-199404150-00005; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; REUSSER P, 1990, CRIT CARE MED, V18, P270, DOI 10.1097/00003246-199003000-00004; RUIZSANTANA S, 1991, CRIT CARE MED, V19, P887, DOI 10.1097/00003246-199107000-00011; RYAN P, 1993, ARCH SURG-CHICAGO, V128, P1353; SCHIESSEL R, 1981, SURGERY, V90, P456; SHUMAN RB, 1987, ANN INTERN MED, V106, P562, DOI 10.7326/0003-4819-106-4-562; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; SIRVENT JM, 1992, INTENS CARE MED, pS186; SKILLMAN JJ, 1984, AM J SURG, V147, P451, DOI 10.1016/0002-9610(84)90004-7; STOTHERT JC, 1980, ANN SURG, V192, P169, DOI 10.1097/00000658-198008000-00006; THOMASON M, 1995, CRIT CARE MED, V23, pA93; TRYBA M, 1985, AM J MED, V79, P55, DOI 10.1016/0002-9343(85)90574-1; TRYBA M, 1988, DEUT MED WOCHENSCHR, V113, P930, DOI 10.1055/s-2008-1067744; TRYBA M, 1991, AM J MED, V91, pS135, DOI 10.1016/0002-9343(91)90466-B; TRYBA M, 1991, J CLIN GASTROENTEROL, V13, pS44; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; VANDENBERG B, 1985, DIGESTION, V31, P1, DOI 10.1159/000199170; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANESSEN HA, 1985, CRIT CARE MED, V13, P957, DOI 10.1097/00003246-198511000-00036; WEIGELT JA, 1981, ARCH SURG-CHICAGO, V116, P597; ZINNER MJ, 1989, ANN SURG, V210, P590, DOI 10.1097/00000658-198911000-00004; ZINNER MJ, 1981, SURG GYNECOL OBSTET, V153, P214	117	376	395	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					308	314						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544272				2022-12-28	WOS:A1996TP96500028
J	Koretz, RL				Koretz, RL			Polyp surveillance in patients with limited life expectancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Koretz, RL (corresponding author), OLIVE VIEW UCLA MED CTR,DIV GASTROENTEROL,14445 OLIVE VIEW DR,SYLMAR,CA 91342, USA.							DAY DW, 1984, SCAND J GASTROENTE S, V104, P99; KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011; MINAMOTO T, 1994, GASTROENTEROLOGY, V106, P1436, DOI 10.1016/0016-5085(94)90395-6; SPRATT JS, 1958, ANN SURG, V148, P682, DOI 10.1097/00000658-195810000-00014	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					327	327		10.1001/jama.275.4.327	http://dx.doi.org/10.1001/jama.275.4.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544278				2022-12-28	WOS:A1996TP96500035
J	Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P				Eckstein, MB; Brown, DWG; Foster, A; Richards, AF; Gilbert, CE; Vijayalakshmi, P			Congenital rubella in south India: Diagnosis using saliva from infants with cataract	BRITISH MEDICAL JOURNAL			English	Article									PHLS VIRUS REFERENCE DIV,ENTER & RESP VIRUS LAB,LONDON NW9 5HT,ENGLAND; ARAVIND EYE HOSP,MADURAI,TAMIL NADU,INDIA; POSTGRAD INST OPHTHALMOL,MADURAI,TAMIL NADU,INDIA		Eckstein, MB (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436				Banatvala JE, 1990, TOPLEY WILSONS PRINC, P502; FARACLEGAN H, 1987, J INFECT DIS, V155, P1073; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; SETH P, 1985, REV NFECT DIS, V7, P64	4	36	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					161	161						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563537				2022-12-28	WOS:A1996TR32500025
J	Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS				Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS			Bone morphogenetic protein-1: The type I procollagen C-proteinase	SCIENCE			English	Article							POLYACRYLAMIDE GELS; MOUSE FIBROBLASTS; PURIFICATION; QUANTITIES; CLEAVAGE; SEQUENCE; PATTERN; DOMAIN; EMBRYO; BMP-1	Bone morphogenetic proteins (BMPs) are bone-derived factors capable of inducing ectopic bone formation. Unlike other BMPs, BMP-1 is not like transforming growth factor-beta (TGF-beta), but it is the prototype of a family of putative proteases implicated in pattern formation during development in diverse organisms. Although some members of this group, such as Drosophila tolloid (TLD), are postulated to activate TGF-beta-like proteins, actual substrates are unknown, Procollagen C-proteinase (PCP) cleaves the COOH-propeptides of procollagens I, II, and III to yield the major fibrous components of vertebrate extracellular matrix. Here it is shown that BMP-1 and PCP are identical. This demonstration of enzymatic activity for a BMP-1/TLD-like protein links an enzyme involved in matrix deposition to genes involved in pattern formation.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Kessler, E (corresponding author), TEL AVIV UNIV, SACKLER FAC MED, CHAIM SHEBA MED CTR, MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST, IL-52621 TEL HASHOMER, ISRAEL.			Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [GM46846] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FINELLI L, 1995, GENETICS, V141, P271; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KESSLER E, 1978, ANAL BIOCHEM, V86, P463, DOI 10.1016/0003-2697(78)90770-4; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KESSLER EM, UNPUB; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ST, 1990, J BIOL CHEM, V265, P21992; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	436	459	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					360	362		10.1126/science.271.5247.360	http://dx.doi.org/10.1126/science.271.5247.360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553073				2022-12-28	WOS:A1996TQ52800044
J	Harris, T; Silver, T; Rink, E; Hilton, S				Harris, T; Silver, T; Rink, E; Hilton, S			Vocational training for general practice in inner London. Is there a dearth? And if so what's to be done?	BRITISH MEDICAL JOURNAL			English	Article								Objective - To identify the nature and extent of any vocational training deficit within the London initiative zone and investigate the reasons. Design - Collation of statistics and postal questionnaire surveys. Setting - Thames regions inside and outside the London initiative zone. Subjects - General practice registrars, trainers, principals from non-training practices, and vocational training course organisers. Main outcome measures - Trends in numbers of general practice registrars, proportions of trainers, views on current vocational training in inner London. Results - Numbers of general practice registrars fell significantly between 1988 and 1993 within the London initiative zone and in England overall. The number of registrars within the zone fell by more than in the rest of the Thames regions, where the decline was not statistically significant. A lower proportion of principals were approved as trainers within the zone than in the rest of the Thames regions and England overall. In their responses to the survey (88% of inner London registrars responded and 81% of outer Thames registrars) registrars suggested that improving remuneration and personal safety would make training in London more attractive. Trainers and non-trainers (response rates 89% and 66% respectively) also suggested increasing remuneration for trainers together with more protected time for training. Conclusions - Less vocational training takes place within the London initiative zone than in the rest of the Thames regions and England overall, although there are discrepancies in official statistics. As well as specific recommendations for improving recruitment to vocational training in inner London, measures to tackle inner city deprivation should also remain high on the political agenda.			Harris, T (corresponding author), ST GEORGE HOSP,DIV GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND.							BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; BEARDOW R, 1993, BRIT J GEN PRACT, V43, P449; BURROWS D, 1994, PULSE, V54, P2; DONALD AG, 1990, BRIT MED J, V301, P1060, DOI 10.1136/bmj.301.6760.1060; LORENTZON M, 1994, REPORT INNER CITY TA; MORRIS JA, 1989, STATISTICS CONFIDENC; NICHOLSON A, 1995, BRIT MED J, V311, P514, DOI 10.1136/bmj.311.7003.514; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1993, MAKING LONDON BETTER; 1993, RESPONSE TOMLINSON R; 1993, GENERAL MED SERVICES; 1994, GENERAL MED SERVICES; 1988, GENERAL MED SERVICES	13	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					97	101						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555940				2022-12-28	WOS:A1996TQ16800029
J	Robinson, MS; Watts, C; Zerial, M				Robinson, MS; Watts, C; Zerial, M			Membrane dynamics in endocytosis	CELL			English	Article							VESICLES		UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; EUROPEAN MOLEC BIOL LAB,D-69017 HEIDELBERG,GERMANY	University of Dundee; European Molecular Biology Laboratory (EMBL)	Robinson, MS (corresponding author), UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND.			Watts, Colin/0000-0001-6183-2087				BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; GUGLIATTI TA, 1973, MOL GENET, V120, P107; HOFLECK B, 1995, P NATL ACAD SCI USA, V92, P8656; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MITCHELL RN, 1995, J EXP MED, V181, P1705, DOI 10.1084/jem.181.5.1705; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	21	153	153	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					13	21		10.1016/S0092-8674(00)80988-5	http://dx.doi.org/10.1016/S0092-8674(00)80988-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548817	Bronze			2022-12-28	WOS:A1996TQ17000004
J	Reid, CJD; Marsh, MJ; Murdoch, IM; Clark, G				Reid, CJD; Marsh, MJ; Murdoch, IM; Clark, G			Lesson of the week - Nephrotic syndrome in childhood complicated by life threatening pulmonary oedema	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN		GUYS HOSP, DEPT PAED INTENS CARE, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Reid, CJD (corresponding author), GUYS HOSP, DEPT PAEDIAT NEPHROL, LONDON SE1 9RT, ENGLAND.							[Anonymous], 1984, Pediatrics, V73, P497; BARRATT TM, 1994, ARCH DIS CHILD, V70, P151; HAWS RM, 1993, PEDIATRICS, V91, P1142; HOUTMAN PN, 1990, LANCET, V336, P1454, DOI 10.1016/0140-6736(90)93167-N; HUMPHREYS MH, 1994, KIDNEY INT, V45, P266, DOI 10.1038/ki.1994.33; LEUTSCHER JA, 1949, J CLIN INVEST, V28, P700, DOI 10.1172/JCI102121; WEISS RA, 1984, NEW YORK STATE J MED, V84, P384	7	11	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					36	38		10.1136/bmj.312.7022.36	http://dx.doi.org/10.1136/bmj.312.7022.36			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555860	Green Published			2022-12-28	WOS:A1996TP20900026
J	Grindley, NDF; Leschziner, AE				Grindley, NDF; Leschziner, AE			DNA transposition: From a black box to a color monitor	CELL			English	Review							RIBONUCLEASE-H; MU				Grindley, NDF (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.			Leschziner, Andres/0000-0002-7732-7023				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BUJACZ G, 1996, IN PRESS STRUCTURE; BUJACZ G, 1995, IN PRESS J MOL BIOL; DAOK TG, 1994, P NATL ACAD SCI USA, V91, P942; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; GUTFREUND H., 1967, ESSAYS BIOCHEM, VVol. 3-3, P25; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KIM K, 1995, J BIOL CHEM, V270, P1; KUKOIJ G, 1995, GENE DEV, V9, P556; KULKOSKY J, 1992, MOL CELL BIOL, V12, P231; MCCLINTOCK B, 1992, DYNAMIC GENOME, P361; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; RICE R, 1995, CELL, V82, P209; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; YANG W, 1995, CELL, V82, P93	26	68	69	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1063	1066		10.1016/0092-8674(95)90132-9	http://dx.doi.org/10.1016/0092-8674(95)90132-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548793	Bronze			2022-12-28	WOS:A1995TM76200002
J	Krek, W; Xu, GF; Livingston, DM				Krek, W; Xu, GF; Livingston, DM			Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint	CELL			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; COMPLEX-FORMATION; GENE-PRODUCT; PROTEIN; IDENTIFICATION; EXPRESSION; TRANSACTIVATION; REPLICATION; COMPONENT	Commitment of mammalian cells to enter S phase enables the transcription factor E2F-1 to activate certain genes whose products mediate cell cycle advance. In S phase, E2F-1 forms stable complexes with cyclin A-kinase, which in turn eliminates E2F-1 DNA binding function. Here, we show that suppression of E2F-1 DNA-binding activity by cyclin A-kinase is linked to orderly S phase progression. Disruption of this linkage resulted in S phase delay/arrest followed by regrowth or apoptosis, depending upon whether the DNA-bound E2F-1 could transactivate. Hence, the unscheduled presence of E2F-1 on specific DNA sequences during S phase can activate a specific S phase checkpoint, thereby linking transcription, DNA replication, and cell cycle control.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, IN PRESS P NATL ACAD; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	43	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1149	1158		10.1016/0092-8674(95)90141-8	http://dx.doi.org/10.1016/0092-8674(95)90141-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548802	Bronze			2022-12-28	WOS:A1995TM76200011
J	Reppert, SM; Weaver, DR				Reppert, SM; Weaver, DR			Melatonin madness	CELL			English	Review											Reppert, SM (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEV CHRONOBIOL LAB,BOSTON,MA 02114, USA.			Weaver, David/0000-0001-7941-6719				Arendt J., 1995, MELATONIN MAMMALIAN; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; CAHILL GM, 1995, RETINAL EYE RES, V14, P267; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; DAVIS FC, 1988, AM J PHYSIOL, V255, pR439, DOI 10.1152/ajpregu.1988.255.3.R439; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; GOTO M, 1994, MOL BRAIN RES, V21, P349, DOI 10.1016/0169-328X(94)90266-6; LINCOLN GA, 1994, J NEUROENDOCRINOL, V6, P251, DOI 10.1111/j.1365-2826.1994.tb00580.x; MAYWOOD ES, 1995, ENDOCRINOLOGY, V136, P144, DOI 10.1210/en.136.1.144; PIERPAOLI W, 1994, P NATL ACAD SCI USA, V91, P787, DOI 10.1073/pnas.91.2.787; PIERPAOLKI W, 1995, P NATL ACAD SCI US; Reiter R., 1995, MELATONIN; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327	19	173	180	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1059	1062		10.1016/0092-8674(95)90131-0	http://dx.doi.org/10.1016/0092-8674(95)90131-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548792	Bronze			2022-12-28	WOS:A1995TM76200001
J	Dequeker, J; Vanopdenbosch, L; Ojugas, AC				Dequeker, J; Vanopdenbosch, L; Ojugas, AC			Early evidence of scleroderma	BRITISH MEDICAL JOURNAL			English	Article									HOSP 12 OCTUBRE,RHEUMATOL UNIT,E-28041 MADRID,SPAIN	Hospital Universitario 12 de Octubre	Dequeker, J (corresponding author), KATHOLIEKE UNIV LEUVEN,UNIV ZIEKENHUIS PELLENBERG,ARTHRITIS & METAB BONE DIS RES UNIT,B-3212 PELLENBERG,BELGIUM.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1714	1715		10.1136/bmj.311.7021.1714	http://dx.doi.org/10.1136/bmj.311.7021.1714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541773	Green Published			2022-12-28	WOS:A1995TL94200035
J	Lambe, M; Ekbom, A				Lambe, M; Ekbom, A			Cancers coinciding with childbearing: Delayed diagnosis during pregnancy?	BRITISH MEDICAL JOURNAL			English	Article											Lambe, M (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.			Lambe, Mats/0000-0002-4624-3767				HAAS JF, 1984, INT J CANCER, V34, P229, DOI 10.1002/ijc.2910340214; JOHANSSON I, 1993, FERTILITY SWEDISH WO; MUSEY VC, 1986, J CLIN ENDOCR METAB, V64, P111; WALLACE N, 1983, FEDERAL RESERVE BANK, V7, P1; 1993, CANCER INCIDENCE SWE	5	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1607	1608		10.1136/bmj.311.7020.1607	http://dx.doi.org/10.1136/bmj.311.7020.1607			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555804	Green Published			2022-12-28	WOS:A1995TL42200021
J	Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U				Mandel, H; Brenner, B; Berant, M; Rosenberg, N; Lanir, N; Jakobs, C; Fowler, B; Seligsohn, U			Coexistence of hereditary homocystinuria and Factor V Leiden - Effect on thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; PROTEIN-C ACTIVATION; CULTURED HUMAN-CELLS; VASCULAR-DISEASE; HOMOCYSTEINE	Background. Venous and arterial thromboembolism occurs in only about one third of patients homozygous for homocystinuria, which suggests that other, contributory factors are necessary for the development of thrombosis in these patients, Factor V Leiden, an R506Q mutation in the gene coding for factor V, is the most common cause of familial thrombosis and could be a potentiating factor. Methods. We determined activated partial-thromboplastin times in the presence and absence of activated protein C and tested for the factor V Leiden mutation in 45 members of seven unrelated consanguineous kindreds in which at least 1 member was homozygous for homocystinuria. Results. Thrombosis (venous, arterial, or both) occurred in 6 of 11 patients with homocystinuria (age, 0.2 to 8 years), All six also had the factor V Leiden mutation. One patient with prenatally diagnosed homocystinuria who was also heterozygous for factor V Leiden has received warfarin therapy since birth and has not had thrombosis (age, 18 months), Of four patients with homocystinuria who did not have factor V Leiden, none had thrombosis (ages at this writing, 1 to 17 years). Three women who were heterozygous for both homocystinuria and factor V Leiden had recurrent fetal loss and placental infarctions. Conclusions. Patients with concurrent homocystinuria and factor V Leiden can have an increased risk of thrombosis, Screening for factor V Leiden may be indicated in patients with homocystinuria and their family members. (C) 1996, Massachusetts Medical Society.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,THROMBOSIS & HEMOSTASIS UNIT,IL-31096 HAIFA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,INST THROMBOSIS & HEMOSTASIS,DEPT HEMATOL,SHEBA MED CTR,IL-69978 TEL AVIV,ISRAEL; FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,1081 HV AMSTERDAM,NETHERLANDS; UNIV BASEL,CHILDRENS HOSP,BASEL,SWITZERLAND	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Basel	Mandel, H (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,RAMBAM MED CTR,DEPT PEDIAT,IL-31096 HAIFA,ISRAEL.							BAUER KA, 1995, THROMB HAEMOSTASIS, V74, P94; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOSS GR, 1985, J CLIN INVEST, V76, P213, DOI 10.1172/JCI111948; BURKE G, 1994, NEW ENGL J MED, V326, P69; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CUTZ E, 1989, NEW ENGL J MED, V320, P646, DOI 10.1056/NEJM198903093201006; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; Fenton W. A., 1995, METABOLIC MOL BASES, P3129; FOWLER B, 1994, ENZYME PROTEIN, V47, P180; GANDRILLE S, 1995, BLOOD, V86, P219, DOI 10.1182/blood.V86.1.219.bloodjournal861219; GRASBECK R, 1972, NEW ENGL J MED, V287, P358; GREENGARD JS, 1994, NEW ENGL J MED, V331, P1559, DOI 10.1056/NEJM199412083312305; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LINDBLAD B, 1994, LANCET, V343, P917, DOI 10.1016/S0140-6736(94)90035-3; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROSENBLATT DS, 1977, PEDIATR RES, V11, P1141, DOI 10.1203/00006450-197711000-00005; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; ROSENBLATT DS, 1987, AM J MED GENET, V26, P377, DOI 10.1002/ajmg.1320260216; Rosenblatt DS., 1995, METABOLIC MOL BASES, VSeventh, P3111; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Sweetman L, 1991, TECHNIQUES DIAGNOSTI, P143; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; UHLENDORF BW, 1968, SCIENCE, V160, P1007, DOI 10.1126/science.160.3831.1007; VANBOVEN HH, 1995, THROMB HAEMOSTASIS, V73, P1256; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	42	245	255	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					763	768		10.1056/NEJM199603213341204	http://dx.doi.org/10.1056/NEJM199603213341204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592550				2022-12-28	WOS:A1996TZ97900004
J	Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G				Hugot, JP; LaurentPuig, P; GowerRousseau, C; Olson, JM; Lee, JC; Beaugerie, L; Naom, I; Dupas, JL; VanGossum, A; Orholm, M; BonaitiPellie, C; Weissenbach, J; Mathew, CG; LennardJones, JE; Cortot, A; Colombel, JF; Thomas, G			Mapping of a susceptibility locus for Crohn's disease on chromosome 16	NATURE			English	Article							INFLAMMATORY BOWEL-DISEASE; COMPLEX SEGREGATION ANALYSIS; LINKAGE ANALYSIS; EPIDEMIOLOGY	Crohn's disease (CD) and ulcerative colitis are the major forms of chronic inflammatory bowel diseases in the western world, and occur in young adults with an estimated prevalence of more than one per thousand inhabitants'. The causes of inflammatory bowel diseases remain unknown, but genetic epidemiology studies(2-5) suggest that inherited factors may contribute in part to variation in individual susceptibility to Crohn's disease. A genome-wide search performed on two consecutive and independent panels of families with multiple affected members, using a non-parametric two-point sibling-pair linkage method, identified a putative CD-susceptibility locus on chromosome 16 (P < 0.01 for each panel). The localization was centred around loci D16S409 and D16S419 by using multipoint sibpair analysis (ref. 6, and J.M.O., manuscript submitted) (P < 1.5 x 10(-5)). This region of the genome contains candidate genes which may be relevant to the pathogenic mechanism of inflammatory bowel diseases.	INST CURIE,LAB GENET TUMEURS,INSERM,U434,F-75231 PARIS,FRANCE; CTR HOSP REG & UNIV LILLE,REGISTRE MALAD INFLAMMATOIRES TUBE DIGEST NORD QU,F-59037 LILLE,FRANCE; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44109; ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; HOP ROTHSCHILD,SERV GASTROENTEROL & HEPTAOL,F-75571 PARIS,FRANCE; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; HOP NORD AMIENS,SERV HEPATOGASTROENTEROL,F-80054 AMIENS,FRANCE; HOP ERASME,SERV GASTROENTEROL & HEPATOPANCREATOL,B-1070 BRUSSELS,BELGIUM; GRP ETUD THERAPEUT AFFECT INFLAMMATORIES DIGEST,F-75012 PARIS,FRANCE; HERLEV HOSP,DEPT MED GASTROENTEROL,COPENHAGEN,DENMARK; INST GUSTAVE ROUSSY,CANC EPIDEMIOL UNIT,F-94805 VILLEJUIF,FRANCE; GENETHON,CNRS,URA 1922,F-91002 EVRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Lille - ISITE; CHU Lille; Case Western Reserve University; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Universite Libre de Bruxelles; University of Copenhagen; Herlev & Gentofte Hospital; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Mathew, Christopher G/G-3434-2015; laurent-puig, pierre/B-2226-2013; CORTOT, ANTOINE/I-7739-2016; Gower-Rousseau, Corinne/I-2553-2018; CORTOT, Antoine/I-5796-2015; Hugot, Jean-Pierre/F-6594-2012; Laurent-Puig, Pierre/K-3641-2019	Mathew, Christopher G/0000-0003-4178-1838; laurent-puig, pierre/0000-0001-8475-5459; CORTOT, ANTOINE/0000-0002-1067-8996; Gower-Rousseau, Corinne/0000-0002-3925-5364; Laurent-Puig, Pierre/0000-0001-8475-5459; Hugot, Jean-Pierre/0000-0002-8446-6056				BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; CALKINS BM, 1986, EPIDEMIOL REV, V8, P60, DOI 10.1093/oxfordjournals.epirev.a036296; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DOGGETT NA, 1995, NATURE, V377, P335; GOWERROUSSEAU C, 1994, GUT, V35, P1433, DOI 10.1136/gut.35.10.1433; GREEN P, 1992, CYTOGENET CELL GENET, V59, P122, DOI 10.1159/000133221; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HETLAND G, 1994, IMMUNOLOGY, V82, P445; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MALONEY MD, 1994, J EXP MED, V180, P191, DOI 10.1084/jem.180.1.191; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; ORHOLM M, 1993, BRIT MED J, V306, P20, DOI 10.1136/bmj.306.6869.20; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; RISCH N, 1987, AM J HUM GENET, V40, P1; RISH N, 1990, AM J HUM GENET, V46, P229; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; 1994, STATISTICAL ANAL GEN	27	791	826	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					821	823		10.1038/379821a0	http://dx.doi.org/10.1038/379821a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587604				2022-12-28	WOS:A1996TX50100057
J	Grubmuller, H; Heymann, B; Tavan, P				Grubmuller, H; Heymann, B; Tavan, P			Ligand binding: Molecular mechanics calculation of the streptavidin biotin rupture force	SCIENCE			English	Article							DYNAMICS; PROTEIN; PROGRAM; ENERGY	The force required to rupture the streptavidin-biotin complex was calculated here by computer simulations. The computed force agrees well with that obtained by recent single molecule atomic force microscope experiments. These simulations suggest a detailed multiple-pathway rupture mechanism involving five major unbinding steps. Binding forces and specificity are attributed to a hydrogen bond network between the biotin ligand and residues within the binding pocket of streptavidin. During rupture, additional water bridges substantially enhance the stability of the complex and even dominate the binding interactions. In contrast, steric restraints do not appear to contribute to the binding forces, although conformational motions were observed.			Grubmuller, H (corresponding author), UNIV MUNICH,INST MED OPT,THERESIENSTR 37,D-80333 MUNICH,GERMANY.							BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Brunger A.T., 1988, X PLOR; EICHINGER M, UNPUB; EICHINGER M, 1995, E COMMUNICATION; ELBER R, IN PRESS NEW DEV THE; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GRUBMULLER H, 1995, PHYS REV E, V52, P2893, DOI 10.1103/PhysRevE.52.2893; Heller H, 1990, MOL SIMULAT, V5, P133, DOI 10.1080/08927029008022127; JORGENSON WL, 1983, J CHEM PHYS, V79, P927; KITAO A, 1993, J PHYS CHEM-US, V97, P10223, DOI 10.1021/j100141a052; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; NIEDERMEIER C, 1994, J CHEM PHYS, V101, P734, DOI 10.1063/1.468129; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722	23	739	744	15	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					997	999		10.1126/science.271.5251.997	http://dx.doi.org/10.1126/science.271.5251.997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584939	Green Submitted			2022-12-28	WOS:A1996TV70400052
J	Lyckholm, LJ; Edmond, MB				Lyckholm, LJ; Edmond, MB			Seasonal hemolysis due to cold-agglutinin syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Lyckholm, LJ (corresponding author), UNIV IOWA,IOWA CITY,IA 52242, USA.			Edmond, Michael/0000-0002-4144-8974; Lyckholm, Laurel/0000-0003-0963-3675					0	11	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					437	437		10.1056/NEJM199602153340705	http://dx.doi.org/10.1056/NEJM199602153340705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552146				2022-12-28	WOS:A1996TU69600005
J	Bradbury, AW; Ruckley, CV				Bradbury, AW; Ruckley, CV			Angioplasty for lower-limb ischaemia: Time for randomised controlled trials	LANCET			English	Editorial Material									UNIV EDINBURGH,VASC SURG OFF,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Bradbury, AW (corresponding author), ST MARYS HOSP,PRAED ST,LONDON,ENGLAND.							BAKER SR, 1995, AUST NZ J SURG, V65, P166, DOI 10.1111/j.1445-2197.1995.tb00600.x; BUCKENHAM TM, 1993, EUR J VASCULAR SURG, V7, P21, DOI 10.1016/S0950-821X(05)80538-9; Creasy T S, 1990, Eur J Vasc Surg, V4, P135, DOI 10.1016/S0950-821X(05)80427-X; CURRIE IC, 1994, BRIT J SURG, V81, P191, DOI 10.1002/bjs.1800810209; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; HUNINK MGM, 1994, ADV VASC SURG, V2, P135; LONDON NJM, 1994, EUR J VASCULAR SURG, V8, P148, DOI 10.1016/S0950-821X(05)80450-5; LONDON NJM, 1995, BRIT J SURG, V82, P1232, DOI 10.1002/bjs.1800820925; Pell J P, 1995, Health Bull (Edinb), V53, P34; PELL JP, 1994, BRIT J SURG, V81, P832, DOI 10.1002/bjs.1800810613; PORTER JM, 1995, J VASC SURG, V21, P995, DOI 10.1016/S0741-5214(95)70229-6; RAY SA, 1995, BRIT J SURG, V82, P1217, DOI 10.1002/bjs.1800820921; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; VROEGINDEWEIJ D, 1995, EUR J VASC ENDOVASC, V10, P40, DOI 10.1016/S1078-5884(05)80197-2; WHITE GH, 1995, J VASC SURG, V21, P270, DOI 10.1016/S0741-5214(95)70268-7; WHYMAN MR, 1991, BRIT J SURG, V78, P643, DOI 10.1002/bjs.1800780603	16	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					277	278		10.1016/S0140-6736(96)90460-2	http://dx.doi.org/10.1016/S0140-6736(96)90460-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569356	Bronze			2022-12-28	WOS:A1996TT48500003
J	Collier, J				Collier, J			Medicines mismatch	LANCET			English	Editorial Material							DRUG				Collier, J (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN PHARMACOL,CRANMER TERRACE,LONDON,ENGLAND.							CHANDRA S, 1995, OCT NAT MED DRUG POL; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; KRISHNASWAMY K, 1985, EUR J CLIN PHARMACOL, V29, P363, DOI 10.1007/BF00544095; PHADKE A, 1995, STUDY SUPPLY USE PHA, P152	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					212	212		10.1016/S0140-6736(96)90400-6	http://dx.doi.org/10.1016/S0140-6736(96)90400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551877				2022-12-28	WOS:A1996TT06900006
J	Phillips, AN				Phillips, AN			Reduction of HIV concentration during acute infection: Independence from a specific immune response	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; DYNAMICS; VIREMIA; PLASMA	After infection with the human immunodeficiency virus (HIV), the concentration of the virus in the person's plasma increases. The subsequent decrease in concentration a few weeks later was thought to result from an HIV-specific immune response. This purported causal relation is investigated with a model of the dynamics of early HIV infection that incorporates no increase in the rate of removal of free virions or virus-infected cells. A pattern of changes in virus concentration similar to that observed in patients is predicted by the model. Thus, the reduction in virus concentration during acute infection may not reflect the ability of the HIV-specific immune response to control virus replication.			Phillips, AN (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,HIV RES UNIT,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; GOWDA SD, 1989, J IMMUNOL, V142, P773; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KATZENSTEIN TL, UNPUB; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P40; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; MCLEAN AR, 1991, AIDS, V5, P485, DOI 10.1097/00002030-199105000-00002; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PEAKMAN M, 1995, CELL ACTIVATION APOP; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PERELSON AS, 1989, LECTURE NOTES BIOMAT, V82, P350; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SHENZLE D, 1994, STAT MED, V13, P2067; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	22	255	260	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					497	499		10.1126/science.271.5248.497	http://dx.doi.org/10.1126/science.271.5248.497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560262				2022-12-28	WOS:A1996TR32200039
J	McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P				McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P			A presynaptic inositol-5-phosphatase	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; YEAST GOLGI; IDENTIFICATION; MUTATIONS	SYNAPTOJANIN is a nerve terminal protein of relative molecular mass 145,000 which appears to participate with dynamin in synaptic vesicle recycling(1,2). The central region of synaptojanin defines it as a member of the inositol-5-phosphatase family, which includes the product of the gene that is defective in the oculocerebrorenal syndrome of Lowe(3-7). Synaptojanin has 5-phosphatase activity and its amino-terminal domain is homologous with the yeast protein Sac1 (Rsd1), which is genetically implicated in phospholipid metabolism and in the function of the actin cytoskeleton(8-10). The carboxy terminus, which is of different lengths in adult and developing neurons owing to the alternative use of two termination sites, is proline-rich, consistent,vith the reported interaction of synaptojanin with the SH3 domains of Grb2 (refs 1, 2), Synaptojanin is the only other major brain protein besides dynamin that binds the SH3 domain of amphiphysin, a presynaptic protein with a putative function in endocytosis(11-14). Our results suggest a link between phosphoinositide metabolism and synaptic vesicle recycling.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	Yale University; Howard Hughes Medical Institute; Yale University; McGill University								ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DAVID C, IN PRESS P NATN ACAD; GAIDAROV IO, 1995, MOL BIOL CELL, V6, P407; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	30	482	491	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					353	357		10.1038/379353a0	http://dx.doi.org/10.1038/379353a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552192				2022-12-28	WOS:A1996TR32300061
J	Nightingale, SL				Nightingale, SL			Guidance on industry dissemination of textbooks and reprints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-28	WOS:A1996TP96500006
J	Cheung, B; Lam, FM; Kumana, CR				Cheung, B; Lam, FM; Kumana, CR			Lesson of the week - Insidiously evolving, occult drug interaction involving warfarin and amiodarone	BRITISH MEDICAL JOURNAL			English	Article											Cheung, B (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,DIV CLIN PHARMACOL,POKFULAM,HONG KONG.		/E-9829-2010	/0000-0001-9106-7363				HAMER A, 1982, CIRCULATION, V65, P1025, DOI 10.1161/01.CIR.65.5.1025; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HEIMARK LD, 1992, CLIN PHARMACOL THER, V51, P398, DOI 10.1038/clpt.1992.39; LATINI R, 1984, CLIN PHARMACOKINET, V9, P136, DOI 10.2165/00003088-198409020-00002; LESKO LJ, 1989, CLIN PHARMACOKINET, V17, P130, DOI 10.2165/00003088-198917020-00005; MARTINOWITZ U, 1981, NEW ENGL J MED, V304, P671; REES A, 1981, BRIT MED J, V282, P1756, DOI 10.1136/bmj.282.6278.1756-a	7	13	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					107	108						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555895				2022-12-28	WOS:A1996TQ16800033
J	Hunt, GM; Oakeshott, P; Whitaker, RH				Hunt, GM; Oakeshott, P; Whitaker, RH			Fortnightly Review: Intermittent catheterisation: Simple, safe, and effective but underused	BRITISH MEDICAL JOURNAL			English	Article							SPINAL-CORD INJURY; SELF-CATHETERIZATION; URINARY-TRACT; NEUROPATHIC BLADDER; NEUROGENIC BLADDER; CHILDREN; MANAGEMENT; MYELOMENINGOCELE; INCONTINENCE; ADULTS		ADDENBROOKES HOSP,DEPT UROL,CAMBRIDGE CB2 2QQ,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; St Georges University London				Oakeshott, Pippa/0000-0003-2568-8211				ANDERSON JB, 1991, BMJ-BRIT MED J, V302, P894, DOI 10.1136/bmj.302.6781.894; [Anonymous], 1991, DRUG THER B, V29, P37; BAUER SB, 1984, JAMA-J AM MED ASSOC, V252, P650, DOI 10.1001/jama.252.5.650; BLOOM DA, 1994, J UROLOGY, V151, P317, DOI 10.1016/S0022-5347(17)34937-6; DIOKNO AC, 1983, J UROLOGY, V129, P1120, DOI 10.1016/S0022-5347(17)52599-9; GRUNDY D, 1986, BRIT MED J, V292, P249, DOI 10.1136/bmj.292.6515.249; HARRISS DR, 1994, BRIT J UROL, V74, P790, DOI 10.1111/j.1464-410X.1994.tb07127.x; HILL VB, 1988, PARAPLEGIA, V26, P405, DOI 10.1038/sc.1988.62; HUNT G, 1993, USERS GUIDE INTERMIT; HUNT GM, 1990, BRIT J UROL, V66, P162, DOI 10.1111/j.1464-410X.1990.tb14895.x; HUNT GM, 1984, BRIT MED J, V289, P467, DOI 10.1136/bmj.289.6443.467; HUNT GM, 1993, GERIATRIC MED, V23, P17; KASS EJ, 1981, J UROLOGY, V126, P223, DOI 10.1016/S0022-5347(17)54453-5; KORNHUBER HH, 1990, EUR NEUROL, V30, P260, DOI 10.1159/000117359; LAPIDES J, 1976, J UROLOGY, V116, P169, DOI 10.1016/S0022-5347(17)58730-3; LAPIDES J, 1972, Journal of Urology, V107, P458; LINDEHALL B, 1991, BRIT J UROL, V67, P415, DOI 10.1111/j.1464-410X.1991.tb15169.x; MAYNARD FM, 1984, J UROLOGY, V132, P943, DOI 10.1016/S0022-5347(17)49959-9; MITROFANOFF P, 1980, CHIR PEDIATR, V21, P297; MURRAY K, 1984, BRIT J UROL, V56, P379, DOI 10.1111/j.1464-410X.1984.tb05825.x; Norton C, 1986, NURSING CONTINENCE; NOUR S, 1994, EUR J PEDIATR SURG, V4, P22, DOI 10.1055/s-2008-1066148; OAKESHOTT P, 1992, BRIT J GEN PRACT, V42, P253; ROBINSON RO, 1985, ARCH DIS CHILD, V60, P760, DOI 10.1136/adc.60.8.760; SCOTT JES, 1982, ARCH DIS CHILD, V57, P253, DOI 10.1136/adc.57.4.253; TAYLOR CED, 1986, BRIT J UROL, V58, P64, DOI 10.1111/j.1464-410X.1986.tb05430.x; UEHLING DT, 1985, PEDIATRICS, V76, P892; van Gool J D, 1990, Z Kinderchir, V45 Suppl 1, P10; VANGOOL JD, 1986, SPINA BIFIDA NEUROGE; WEBB RJ, 1990, BRIT J UROL, V65, P20, DOI 10.1111/j.1464-410X.1990.tb14653.x; WHITELAW S, 1987, BRIT J UROL, V60, P125, DOI 10.1111/j.1464-410X.1987.tb04947.x; WITHYCOMBE J, 1978, LANCET, V2, P981; WYNDAELE JJ, 1990, J UROLOGY, V143, P906, DOI 10.1016/S0022-5347(17)40132-7; YADAV A, 1993, PARAPLEGIA, V31, P380, DOI 10.1038/sc.1993.63; 1979, LANCET, V2, P448	35	21	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					103	107						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555894				2022-12-28	WOS:A1996TQ16800032
J	Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI				Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI			Identification and expression cloning of a leptin receptor, OB-R	CELL			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA-INHIBITORY FACTOR; SIGNAL TRANSDUCER; MOLECULAR-CLONING; GP130; EFFICIENT; OBESITY; DOMAINS; MICE	The ob gene product, leptin, is an important circulating signal for the regulation of body weight. To identify high affinity leptin-binding sites, we generated a series of leptin-alkaline phosphatase (AP) fusion proteins as well as [I-125]leptin. After a binding survey of cell lines and tissues, we identified leptin-binding sites in the mouse choroid plexus. A cDNA expression library was prepared from mouse choroid plexus and screened with a leptin-AP fusion protein to identify a leptin receptor (OB-R). OB-R is a single membrane-spanning receptor most related to the gp130 signal-transducing component of the IL-6 receptor, the G-CSF receptor, and the LIF receptor. OB-R mRNA is expressed not only in choroid plexus, but also in several other tissues, including hypothalamus. Genetic mapping of the gene encoding OB-R shows that it is within the 5.1 cM interval of mouse chromosome 4 that contains the db locus.	ROCHE RES GENT, B-9000 GHENT, BELGIUM; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding	Tartaglia, LA (corresponding author), MILLENNIUM PHARMACEUT INC, 640 MEM DR, CAMBRIDGE, MA 02139 USA.		sheng, jian/E-9474-2012					BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEBONS AF, 1977, FED PROC, V36, P143; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	2934	3140	1	147	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1263	1271		10.1016/0092-8674(95)90151-5	http://dx.doi.org/10.1016/0092-8674(95)90151-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548812	Bronze			2022-12-28	WOS:A1995TM76200021
J	Galanakis, E; Leveidiotou, S; Siamopoulou, A; Lapatsanis, P				Galanakis, E; Leveidiotou, S; Siamopoulou, A; Lapatsanis, P			A 3-month-old girl with fever and respiratory distress	LANCET			English	Note									IOANNINA UNIV,DEPT CHILD HLTH,GR-45110 IOANNINA,GREECE; IOANNINA UNIV,MICROBIOL LAB,GR-45110 IOANNINA,GREECE	University of Ioannina; University of Ioannina								ABUGHALI N, 1994, PEDIATR INFECT DIS J, V13, P738, DOI 10.1097/00006454-199408000-00012; MILLER FJW, 1982, TUBERCULOSIS CHILDRE, P55; SCHAAF HS, 1993, ARCH DIS CHILD, V69, P371, DOI 10.1136/adc.69.3.371; SPENCER RC, 1991, LANCET, V338, P1018, DOI 10.1016/0140-6736(91)91879-Y	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1674	1674		10.1016/S0140-6736(95)92843-X	http://dx.doi.org/10.1016/S0140-6736(95)92843-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551827				2022-12-28	WOS:A1995TL42300013
J	Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M				Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M			Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; CEREBRAL INFARCTION; CIVIL-SERVANTS; BRITISH MEN; FOLLOW-UP; MORTALITY; POPULATION	Individual studies of stroke have not clearly answered two questions: on the relation, if any, between total blood cholesterol and stroke; and on how the strength of the relation between diastolic blood pressure and stroke varies with age. The associations of blood cholesterol and diastolic blood pressure with subsequent stroke rates were investigated by review of 45 prospective observational cohorts involving 450 000 individuals with 5-30 years of follow-up (mean 16 years, total 7 . 3 million person-years of observation), during which 13 397 participants were recorded as having had a stroke. Most of these were fatal strokes in studies that recorded only mortality and not incidence, but about one-quarter were from studies that recorded both fatal and non-fatal strokes. After standardisation for age, there was no association between blood cholesterol and stroke except, perhaps, in those under 45 years of age when screened. This lack of association was not influenced by adjustment for sex, diastolic blood pressure, history of coronary heart disease, or ethnicity (Asian or non-Asian). However, because the types of the strokes were not centrally available, the lack of any overall relation might conceal a positive association with ischaemic stroke together with a negative association with haemorrhagic stroke. When the highest and the lowest of the six blood pressure categories were compared, the difference in usual diastolic blood pressure was 27 mm Hg (102 vs 75 mm Hg), and there was a fivefold difference in stroke risk. This fivefold difference was seen both in those with a preexisting history of coronary heart disease and in those without it. The proportional difference stroke risk, was more extreme in middle in old age. Among those aged <45, 45-64, and 65+ when screened, the differences in the relative risks of stroke (between the highest diastolic blood pressure category and a combination of the lowest two categories) were tenfold, fivefold, and twofold, respectively. However, because the absolute stroke risks are greater in old age, the absolute differences in the annual stroke rates showed an opposite pattern, being 2, 5, and 8 per thousand, respectively. This suggests that the effects of therapeutic blood pressure reductions should be assessed separately in middle age and in old age.	GOTHENBURG WOMEN, GOTHENBURG, SWEDEN; HONOLULU HEART PROGRAM, HONOLULU, HI USA		Qizilbash, N (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN GERATOL, OXFORD OX2 6HE, ENGLAND.		Knuiman, Matthew W/I-5549-2013; Davey Smith, George/A-7407-2013; Kromhout, Daan/A-8566-2014; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419; Carstensen, John/0000-0003-2256-8089; Seccareccia, Fulvia/0000-0003-4135-2806	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BAINTON D, 1992, BRIT HEART J, V68, P60; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOLTONSMITH C, 1993, BRIT J NUTR, V69, P315, DOI 10.1079/BJN19930036; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX CS, 1992, VITAL HLTH STAT, P27; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GILKS WR, 1993, J R STAT SOC B, V55, P39; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; Keil J E, 1992, Ann Epidemiol, V2, P93; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; KNUIMAN MW, 1994, AUST J PUBLIC HEALTH, V18, P129; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LIN CH, 1984, STROKE, V15, P653, DOI 10.1161/01.STR.15.4.653; LINDENSTROM E, 1994, BMJ-BRIT MED J, V309, P11, DOI 10.1136/bmj.309.6946.11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEATON JD, 1995, HYPERTENSION PATHOPH, V1, P127; PEDERSEN TR, 1994, LANCET, V344, P1383; PSATY BM, 1990, J CLIN EPIDEMIOL, V43, P961, DOI 10.1016/0895-4356(90)90079-5; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; REID DD, 1974, LANCET, V1, P469; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Speizer, 1976, NATURAL HIST CHRONIC, P218; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TANAKA H, 1985, STROKE, V16, P773, DOI 10.1161/01.STR.16.5.773; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; TUOMILEHTO J, 1991, STROKE, V22, P7, DOI 10.1161/01.STR.22.1.7; Wolf P A, 1983, Neurol Clin, V1, P317; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	53	706	729	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1647	1653						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551820				2022-12-28	WOS:A1995TL42300006
J	Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M				Kimura, T; Yokoi, H; Nakagawa, Y; Tamura, T; Kaburagi, S; Sawada, Y; Sato, Y; Yokoi, H; Hamasaki, N; Nosaka, H; Nobuyoshi, M			Three-year follow-up after implantation of metallic coronary-artery stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; RESTENOSIS; EXPERIENCE; MULTICENTER; OCCLUSION	Background. Coronary-artery stents are known to reduce rates of restenosis after coronary angioplasty, but it is uncertain how long this benefit is maintained. Methods. We evaluated clinical and angiographic follow-up information for up to three years after the implantation of Palmaz-Schatz metallic coronary-artery stents in 143 patients with 147 lesions of native coronary arteries. Results, The rate of survival free of myocardial infarction, bypass surgery, and repeated coronary angioplasty for stented lesions was 74.6 percent at three years. After 14 months, revascularization of the stented lesion was necessary in only three patients (2.1 percent), In contrast, coronary angioplasty for a new lesion was required in 11 patients (7.7 percent), Follow-up coronary angiography of 137 lesions at six months, 114 lesions at one year, and 72 lesions at three years revealed a decrease in minimal luminal diameter from 2.54+/-0.44 mm immediately after stent implantation to 1.87+/-0.56 mm at six months, but no further decrease in diameter at one year (in patients with paired angiograms, 1.95+/-0.49 mm at both six months and one year), Significant late improvement in luminal diameter was observed at three years (in patients with paired angiograms, 1.94+/-0.48 mm at six months and 2.09+/-0.48 mm at three years; P<0.001). Conclusions. Clinical and angiographic outcomes up to three years after coronary-artery stenting were favorable, with a low rate of revascularization of the stented lesions. Late improvement in luminal diameter appears to occur between six months and three years.	KOKURA MEM HOSP,DEPT CARDIOL,KOKURAKITA KU,KITAKYUSHU,FUKUOKA 802,JAPAN	Kokura Memorial Hospital								CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GORDON PC, 1994, AM J CARDIOL, V74, P26, DOI 10.1016/0002-9149(94)90486-3; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; KASTRATI A, 1993, CIRCULATION, V87, P1498, DOI 10.1161/01.CIR.87.5.1498; KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B; King SB, 1993, J AM COLL CARDIOL, V22, P353, DOI 10.1016/0735-1097(93)90037-2; MATTHEWS DE, 1988, USING UNDERSTANDING; MINTZ GS, 1995, J AM COLL CARDIOL, V25, pA36; NAKAMURA S, 1994, CIRCULATION, V89, P2026, DOI 10.1161/01.CIR.89.5.2026; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; PAINTER JA, 1994, CIRCULATION, V90, P163; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1987, CIRCULATION, V76, P450, DOI 10.1161/01.CIR.76.2.450; SCHOMIG A, 1994, CIRCULATION, V90, P2716, DOI 10.1161/01.CIR.90.6.2716; Serruys P.W., 1994, QUANTITATIVE CORONAR; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; WHITE CJ, 1992, J AM COLL CARDIOL, V19, P870, DOI 10.1016/0735-1097(92)90534-T; 1985, NEW ENGL J MED, V312, P932	29	431	445	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					561	566		10.1056/NEJM199602293340903	http://dx.doi.org/10.1056/NEJM199602293340903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569823				2022-12-28	WOS:A1996TW69600003
J	Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA				Stiell, IG; Greenberg, GH; Wells, GA; McDowell, I; Cwinn, AA; Smith, NA; Cacciotti, TF; Sivilotti, MLA			Prospective validation of a decision rule for the use of radiography in acute knee injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ANKLE INJURIES; RECURSIVE PARTITION; PREDICTION RULES; SURVIVAL-DATA; EMERGENCY; FRACTURE; AVULSION; PROGRAM	Objective. - To validate a previously derived decision rule for the use of radiography in patients with acute knee injury. Design. - Prospectively administered survey. Setting. - Emergency departments of two university hospitals serving adults. Patients. - Convenience sample of 1096 of 1251 eligible adults with acute knee injuries; 124 patients were examined by two physicians. Main Outcome Measures. - Attending emergency physicians assessed each patient for standardized clinical variables and determined the need for radiography according to the decision rule. Patients who did not have radiography underwent a structured telephone interview at day 14 to determine the possibility of a fracture. The rule was assessed for ability to correctly identify the criterion standard, fracture of the knee, An attempt was made to refine the rule by means of univariate and recursive partitioning analyses. Results. - The decision rule had a sensitivity of 1.0 (95% confidence interval [CI], 0.94 to 1.0) for identifying 63 clinically important fractures. Physicians correctly interpreted the rule in 96% of cases, and the kappa value for interpretation was 0.77 (95% CI, 0.65 to 0.89). The potential relative reduction in use of radiography was estimated to be 28%, The probability of fracture, if the decision rule were ''negative, is estimated to be 0% (95% CI, 0% to 0.4%). Attempts to refine the rule led to a model with improved specificity but with an unacceptable loss of sensitivity. Conclusion. - Prospective validation has shown this decision rule to be 100% sensitive for identifying fractures of the knee, to be reliable and acceptable, and to have the potential to allow physicians to reduce the use of radiography in patients with acute knee injury.	UNIV OTTAWA,FAC MED,DEPT EMERGENCY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa			Sivilotti, Marco L.A./AAR-8892-2020	Sivilotti, Marco L.A./0000-0001-6641-1118; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; Bauer Steven J., 1995, Journal of Emergency Medicine, V13, P611, DOI 10.1016/0736-4679(95)00064-H; Baugher W H, 1984, Emerg Med Clin North Am, V2, P347; CALLAHAM ML, 1987, CURRENT THERAPY EMER; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; CIAMPI A, 1986, COMPUT STAT DATA AN, V4, P185, DOI 10.1016/0167-9473(86)90033-2; CIAMPI A, 1987, TIME SERIES ECONOMET, V5, P23; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DIETZ GW, 1986, RADIOLOGY, V159, P467, DOI 10.1148/radiology.159.2.3961179; FAIRCLOUGH JA, 1988, INJURY, V19, P79, DOI 10.1016/0020-1383(88)90077-0; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; FRIEDMAN JH, 1977, IEEE T COMPUT, V16, P404; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GOLDMAN AB, 1988, AM J ROENTGENOL, V151, P1163, DOI 10.2214/ajr.151.6.1163; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARWOODNUSS A, 1991, CLIN PRACTICE EMERGE; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MATTHEWS MG, 1986, BRIT MED J, V293, P959; McCaig L F, 1994, Adv Data, P1; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; ROSEN P, 1992, EMERGENCY MED CONCEP; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAXENA AC, 1992, ANN EMERG MED, V21, P658; SEABERG DC, 1994, AM J EMERG MED, V12, P541, DOI 10.1016/0735-6757(94)90274-7; SIMON RR, 1995, EMERGENCY ORTHOPEDIC; Sox HC, 1988, MED DECISION MAKING; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; SVENSON J, 1988, LANCET, V1, P244; TINTINALLI JE, 1992, EMERGENCY MED COMPRE; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEBER JE, 1995, ANN EMERG MED, V26, P429, DOI 10.1016/S0196-0644(95)70109-5; 1994, NATL HOSPITAL AMBULA; 1992, 1991 92 ONT MIN HLTH	50	167	167	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					611	615		10.1001/jama.275.8.611	http://dx.doi.org/10.1001/jama.275.8.611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594242				2022-12-28	WOS:A1996TW62700021
J	Emmerson, BT				Emmerson, BT			Drug therapy - The management of gout	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MONOSODIUM URATE CRYSTALS; ANTI-INFLAMMATORY DRUGS; DIURETIC-INDUCED GOUT; URIC-ACID; ANTIHYPERURICEMIC THERAPY; ALLOPURINOL THERAPY; STEROID-THERAPY; COLCHICINE; ARTHRITIS; INDOMETHACIN				Emmerson, BT (corresponding author), UNIV QUEENSLAND, PRINCESS ALEXANDRA HOSP, DEPT MED, IPSWICH RD, BRISBANE, QLD 4102, AUSTRALIA.							AGUDELO CA, 1979, ARTHRITIS RHEUM, V22, P559, DOI 10.1002/art.1780220521; AHERN MJ, 1987, AUST NZ J MED, V17, P301, DOI 10.1111/j.1445-5994.1987.tb01232.x; ALLOWAY JA, 1993, J RHEUMATOL, V20, P111; ALTMAN RD, 1988, J RHEUMATOL, V15, P1422; ANDREOLI SP, 1986, J PEDIATR-US, V109, P292, DOI 10.1016/S0022-3476(86)80387-0; ARNOLD MH, 1988, BRIT J CLIN PHARMACO, V26, P488, DOI 10.1111/j.1365-2125.1988.tb03412.x; AXELROD D, 1988, ARTHRITIS RHEUM-US, V31, P803, DOI 10.1002/art.1780310618; BISHOP C, 1951, J CLIN INVEST, V30, P889, DOI 10.1172/JCI102505; BLUESTONE RH, 1982, AM J MED, V72, P66; BOMALASKI JS, 1986, ARTHRITIS RHEUM, V29, P1480, DOI 10.1002/art.1780291209; BROCHNERMORTENS.K, 1937, ACTA MED SCAND, V84, P127; BULL PW, 1989, J RHEUMATOL, V16, P1246; CALABRO JJ, 1974, ACTA REUMATOL PORT, V2, P163; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; CARACO Y, 1992, J RHEUMATOL, V19, P494; DAY RO, 1988, BRIT J CLIN PHARMACO, V26, P423, DOI 10.1111/j.1365-2125.1988.tb03401.x; DAYTON PG, 1971, ANN NY ACAD SCI, V179, P399, DOI 10.1111/j.1749-6632.1971.tb46916.x; DIETERLE W, 1975, EUR J CLIN PHARMACOL, V9, P135, DOI 10.1007/BF00614010; EMMERSON BT, 1987, BRIT J RHEUMATOL, V26, P445; EMMERSON BT, 1992, ANN RHEUM DIS, V51, P375, DOI 10.1136/ard.51.3.375; EMMERSON BT, 1988, ARTHRITIS RHEUM, V31, P436, DOI 10.1002/art.1780310318; EMMERSON BT, 1973, Q J MED, V42, P423; EMMERSON BT, 1991, LANCET, V337, P1461, DOI 10.1016/0140-6736(91)93141-U; EMMERSON BT, 1987, J RHEUMATOL, V14, P335; EMMERSON BT, 1967, BMJ-BRIT MED J, V2, P272, DOI 10.1136/bmj.2.5547.272; EMMERSON BT, 1973, NZ J MED, V3, P410; EMMERSON BT, 1978, URIC ACID HDB EXPT P, V51, P287; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; FAM AG, 1992, AM J MED, V93, P299, DOI 10.1016/0002-9343(92)90236-5; FESSEL WJ, 1979, AM J MED, V67, P74, DOI 10.1016/0002-9343(79)90076-7; FINDLING JW, 1980, JAMA-J AM MED ASSOC, V244, P1127, DOI 10.1001/jama.244.10.1127; FOX IH, 1981, METABOLISM, V30, P616, DOI 10.1016/0026-0495(81)90142-6; GIBSON T, 1984, BRIT J RHEUMATOL, V23, P203; GRAY RG, 1981, SEMIN ARTHRITIS RHEU, V10, P231, DOI 10.1016/0049-0172(81)90001-9; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GROFF GD, 1990, SEMIN ARTHRITIS RHEU, V19, P329, DOI 10.1016/0049-0172(90)90070-V; GUTMAN AB, 1957, AM J MED, V23, P600, DOI 10.1016/0002-9343(57)90231-0; HANDE K, 1978, CLIN PHARMACOL THER, V23, P598; HANDE KR, 1984, AM J MED, V76, P47, DOI 10.1016/0002-9343(84)90743-5; HAWKEY C, 1990, BRIT MED J, V300, P764; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; KOT TV, 1993, MED J AUSTRALIA, V159, P182, DOI 10.5694/j.1326-5377.1993.tb137784.x; KOVALCHIK MT, 1981, CONN MED, V45, P423; KUNCL RW, 1987, NEW ENGL J MED, V316, P1562, DOI 10.1056/NEJM198706183162502; LEARY W P, 1987, Cardiovascular Drugs and Therapy, V1, P29, DOI 10.1007/BF02125830; LECAILLON JB, 1979, CLIN PHARMACOL THER, V26, P611; MACFARLANE DG, 1985, BRIT J RHEUMATOL, V24, P155; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1489; MCPHAUL JJ, 1968, METABOLISM, V17, P430, DOI 10.1016/0026-0495(68)90065-6; MEYRIER A, 1976, BRIT MED J, V2, P458, DOI 10.1136/bmj.2.6033.458; MODAN M, 1987, DIABETES METAB, V13, P375; PASCUAL E, 1992, J RHEUMATOL, V19, P600; PUSEY CD, 1983, Q J MED, V52, P194; RAMAN GV, 1990, J INTERN MED, V228, P525, DOI 10.1111/j.1365-2796.1990.tb00273.x; ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759; ROBERTS WN, 1987, JAMA-J AM MED ASSOC, V257, P1920, DOI 10.1001/jama.257.14.1920; ROCHDI M, 1992, HUM EXP TOXICOL, V11, P510, DOI 10.1177/096032719201100612; ROTH SH, 1988, J RHEUMATOL, V15, P912; ROUBENOFF R, 1991, JAMA-J AM MED ASSOC, V266, P3004, DOI 10.1001/jama.266.21.3004; RUNDLES RW, 1963, T ASSOC AM PHYSICIAN, V76, P126; RUNDLES RW, 1966, ANN RHEUM DIS, V25, P655, DOI 10.1136/ard.25.Suppl_6.655; SCHIFF D, 1992, ARTHRITIS RHEUM, V35, P1535, DOI 10.1002/art.1780351218; SCHWEITZ MC, 1978, JAMA-J AM MED ASSOC, V239, P34, DOI 10.1001/jama.239.1.34; SCOTT JT, 1992, ANN RHEUM DIS, V51, P259, DOI 10.1136/ard.51.2.259; SIMMONDS HA, 1986, CLIN CHIM ACTA, V160, P189, DOI 10.1016/0009-8981(86)90141-5; SMITH MJV, 1969, J UROLOGY, V102, P750, DOI 10.1016/S0022-5347(17)62244-4; SORENSEN LB, 1976, ARTHRITIS RHEUM, V19, P183, DOI 10.1002/art.1780190209; SPECTOR T, 1977, BIOCHEM PHARMACOL, V26, P355, DOI 10.1016/0006-2952(77)90191-5; SPILBERG I, 1979, J CLIN INVEST, V64, P775, DOI 10.1172/JCI109523; UNSWORTH J, 1987, ANN RHEUM DIS, V46, P233, DOI 10.1136/ard.46.3.233; UNSWORTH J, 1987, ANN RHEUM DIS, P46; VANLIESHOUTZUIDEMA MF, 1993, J RHEUMATOL, V20, P1383; WALLACE SL, 1991, J RHEUMATOL, V18, P264; WALLACE SL, 1988, J RHEUMATOL, V15, P495; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; WERNICK R, 1992, ARCH INTERN MED, V152, P873, DOI 10.1001/archinte.152.4.873; Widmark P., 1982, AM J MED, V72, P63; WILCOX RG, 1980, BRIT MED J, V281, P531, DOI 10.1136/bmj.281.6239.531; YAMASHITA S, 1986, INT J OBESITY, V10, P255; YOUNG JL, 1974, ARCH INTERN MED, V134, P553, DOI 10.1001/archinte.134.3.553; YU T, 1982, SEMIN ARTHRITIS RHEU, V12, P256, DOI 10.1016/0049-0172(82)90065-8; YU TF, 1955, P SOC EXP BIOL MED, V90, P542; YUE TF, 1961, ANN INTERN MED, V55, P179, DOI 10.7326/0003-4819-55-2-179; 1972, NEW ENGL J MED, V286, P505; 1976, J CHRON DIS, V29, P557	86	341	368	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					445	451		10.1056/NEJM199602153340707	http://dx.doi.org/10.1056/NEJM199602153340707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552148				2022-12-28	WOS:A1996TU69600007
J	Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB				Needleman, HL; Riess, JA; Tobin, MJ; Biesecker, GE; Greenhouse, JB			Bone lead levels and delinquent behavior	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE	Objective.-To evaluate the association between body lead burden and social adjustment. Design.-Retrospective cohort study. Setting.-Public school community. Participants.-From a population of 850 boys in the first grade at public schools, 503 were selected on the basis of a risk scale for antisocial behavior. All of the 850 boys who scored in the upper 30th percentile of the distribution on a self-reported antisocial behavior scale were matched with an equal number drawn by lot from the lower 70% of the distribution. From this sample, 301 students accepted the invitation to participate. Exposure Measure.-K x-ray fluorescence spectroscopy of tibia at subjects' age of 12 years. Main Outcome Measures.-Child Behavior Checklist (CBCL), teachers' and parents' reports, and subjects' self-report of antisocial behavior and delinquency at 7 and 11 years of age. Results.-Subjects, teachers, and parents were blind to the bone lead measurements. At 7 years of age, borderline associations between teachers' aggression, delinquency, and externalizing scores and lead levels were observed after adjustment for covariates. At 11 years of age, parents reported a significant lead-related association with the following CBCL cluster scores: somatic complaints and delinquent, aggressive, internalizing, and externalizing behavior. Teachers reported significant associations of lead with somatic complaints, anxious/depressed behavior, social problems, attention problems, and delinquent, aggressive, internalizing, and externalizing behavior. High-lead subjects reported; higher scores in subjects' self-reports of delinquency at 11 years. High-lead subjects were more likely to obtain worse scores on all items of the CBCL during the 4-year period of observation. High bone lead levels were associated with an increased risk of exceeding the clinical score (T>70) for attention, aggression, and delinquency. Conclusion.-Lead exposure is associated with increased risk for antisocial and delinquent behavior, and the effect follows a developmental course.	UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,PITTSBURGH,PA; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University			Greenhouse, Joel/W-2132-2019; Klishevych, Nataliia/ABB-2500-2021	Greenhouse, Joel/0000-0001-5087-9648; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005015] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 05015-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACHENBACH TM, 1995, J AM ACAD CHILD PSY, V34, P488, DOI 10.1097/00004583-199504000-00016; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; [Anonymous], 1988, NATURE EXTENT LEAD P; BELLINGER D, 1994, ENVIRON RES, V66, P12, DOI 10.1006/enrs.1994.1041; Byers RK, 1943, AM J DIS CHILD, V66, P471; DENNO DW, 1990, BIOL VIOLENCE; FARRINGTON DP, 1991, DEV TREATMENT CHILDH, P189; FERGUSSON DM, 1993, J CHILD PSYCHOL PSYC, V34, P215, DOI 10.1111/j.1469-7610.1993.tb00980.x; GOLDSTEIN GW, 1992, HUMAN LEAD EXPOSURE; HATZAKIS A, 1987, INT C HEAVY METALS E, P204; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; LANSDOWN R, 1983, LEAD VERSUS HLTH; LANTHONY P, 1987, J FR OPHTALMOL, V10, P579; LAUGHLIN NK, 1991, NEUROTOXICOL TERATOL, V13, P429, DOI 10.1016/0892-0362(91)90092-B; Letz R, 1988, NES2 NEUROBEHAVIORAL; LOEBER R, 1991, J CRIM LAW CRIM, V82, P36; LOEBER R, 1983, PSYCHOL BULL, V94, P68, DOI 10.1037/0033-2909.94.1.68; LOEBER R, 1989, CROSS NATIONAL RES S; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; OFFORD DR, 1979, J NERV MENT DIS, V167, P734, DOI 10.1097/00005053-197912000-00003; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; Raven JC, 1988, MANUAL RAVENS PROGR; REYNOLDS CR, 1990, HDB PSYCHOL ED ASSES, P370; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; SATTERFIELD JH, 1987, CAUSES CRIME; SCIARILLO WG, 1992, AM J PUBLIC HEALTH, V82, P1356, DOI 10.2105/AJPH.82.10.1356; TAYLOR D, 1978, J PHARMACOL EXP THER, V206, P371; THOMSON GOB, 1989, J CHILD PSYCHOL PSYC, V30, P515, DOI 10.1111/j.1469-7610.1989.tb00265.x; TODD AC, 1991, ENVIRON RES, V57, P117; Tonry ML, 1991, HUMAN DEV CRIMINAL B, DOI DOI 10.1007/978-1-4613-9055-8; WATKINS CE, 1986, PROF PSYCHOL-RES PR, V17, P36; Wilson James, 1986, CRIME HUMAN NATURE	35	444	459	0	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					363	369		10.1001/jama.275.5.363	http://dx.doi.org/10.1001/jama.275.5.363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT303	8569015				2022-12-28	WOS:A1996TT30300029
J	Bertoli, A; DiDaniele, N; Troisi, A; Lauro, R				Bertoli, A; DiDaniele, N; Troisi, A; Lauro, R			A woman with bone pain, fractures, and malabsorption	LANCET			English	Article									UNIV CATTOLICA SACRO CUORE,IST MED INTERNA,ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bertoli, A (corresponding author), UNIV ROMA TOR VERGATA,CATTEDRA MED INTERNA,ROME,ITALY.			Bertoli, Aldo/0000-0001-8995-2582				HEATH DA, 1989, ENDOCRIN METAB CLIN, V18, P631, DOI 10.1016/S0889-8529(18)30357-8; KRUSE HP, 1987, DEUT MED WOCHENSCHR, V112, P1155, DOI 10.1055/s-2008-1068212; PAUL R, 1990, J INTERN MED, V228, P401, DOI 10.1111/j.1365-2796.1990.tb00252.x	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					300	300		10.1016/S0140-6736(96)90470-5	http://dx.doi.org/10.1016/S0140-6736(96)90470-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569366				2022-12-28	WOS:A1996TT48500013
J	Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC				Dacey, DM; Lee, BB; Stafford, DK; Pokorny, J; Smith, VC			Horizontal cells of the primate retina: Cone specificity without spectral opponency	SCIENCE			English	Article							MACAQUE GANGLION-CELLS; MONKEY RETINA; PHOTORECEPTORS; SENSITIVITY; CONNECTIONS; RESPONSES	The chromatic dimensions of human color vision have a neural basis in the retina. Ganglion cells, the output neurons of the retina, exhibit spectral opponency; they are excited by some wavelengths and inhibited by others. The hypothesis that the opponent circuitry emerges from selective connections between horizontal cell interneurons and cone photoreceptors sensitive to long, middle, and short wavelengths (L-, M-, and S-cones) was tested by physiologically and anatomically characterizing cone connections of horizontal cell mosaics in macaque monkeys. H1 horizontal cells received input only from L- and M-cones, whereas H2 horizontal cells received a strong input from S-cones and a weaker input from L- and M-cones. All cone inputs were the same sign, and both horizontal cell types lacked opponency. Despite cone type selectivity, the horizontal cell cannot be the locus of an opponent transformation in primates, including humans.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY; UNIV CHICAGO,CTR VISUAL SCI,CHICAGO,IL 60637	Max Planck Society; University of Chicago	Dacey, DM (corresponding author), UNIV WASHINGTON,DEPT BIOL STRUCT,BOX 357420,SEATTLE,WA 98195, USA.			Dacey, Dennis/0000-0001-8476-5585				AHNELT P, 1994, J COMP NEUROL, V343, P406, DOI 10.1002/cne.903430306; [Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; BURKHARDT DA, 1993, VISUAL NEUROSCI, V10, P981, DOI 10.1017/S0952523800010087; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; DEVALOIS RL, 1964, SCIENCE, V146, P1184, DOI 10.1126/science.146.3648.1184; DEVALOIS RL, 1958, SCIENCE, V127, P238, DOI 10.1126/science.127.3292.238; Goodchild A. K., 1995, Society for Neuroscience Abstracts, V21, P1645; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; KAMERMANS M, 1995, PROG RETIN EYE RES, V14, P313, DOI 10.1016/1350-9462(94)00003-2; KOLB H, 1980, J COMP NEUROL, V189, P31; LEE BB, 1995, COLOR VISION DEFICIE, V11, P177; MANGEL SC, 1991, J PHYSIOL-LONDON, V442, P211, DOI 10.1113/jphysiol.1991.sp018790; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; SCHNEEWEIS DM, 1995, SCIENCE, V268, P1053, DOI 10.1126/science.7754386; SMITH RG, 1995, VISUAL NEUROSCI, V12, P545, DOI 10.1017/S0952523800008440; SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5; SMITH VC, 1992, J PHYSIOL-LONDON, V458, P191, DOI 10.1113/jphysiol.1992.sp019413; SMITH VC, 1995, J OPT SOC AM A, V12, P241, DOI 10.1364/JOSAA.12.000241; SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992; VALBERG A, 1992, J PHYSIOL-LONDON, V458, P579, DOI 10.1113/jphysiol.1992.sp019435; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; Wyszecki G., 1982, COLOR SCI, V8	28	184	187	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					656	659		10.1126/science.271.5249.656	http://dx.doi.org/10.1126/science.271.5249.656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571130				2022-12-28	WOS:A1996TT87000049
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Rubison, M; Chandra, N; Rogers, WJ			Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							ELDERLY PATIENTS; MORTALITY; PROGNOSIS; OUTCOMES; WOMEN; CARE	Objective: To examine recent trends in the use of thrombolytic therapy in elderly patients who have had acute myocardial infarction and to determine whether failure to meet time-to-hospital presentation and electrocardiographic criteria might explain age-related differences in the use of thrombolytic therapy. Design: A national registry of patients who have had acute myocardial infarction. Setting: 1249 U.S. hospitals. Patients: 350 755 patients who had an acute myocardial infarction from 1 July 1990 to 30 September 1994. Measurements: Trends in the proportions of patients who received thrombolytic therapy were examined according to age and sex. The association between age and treatment with a thrombolytic agent was determined by crude and multivariable-adjusted analyses. Results: Use of a thrombolytic agent was inversely related to patient age: Almost 51% of patients younger than age 55 years received a thrombolytic agent during hospitalization for acute myocardial infarction; this proportion decreased to 43.6% for patients aged 55 to 64 years, 33.0% for those aged 65 to 74 years, 19.0% for those aged 75 to 84 years, and 7.4% for those aged 85 years or older. However, relative increases in the use of thrombolytic therapy over time were greatest for patients in the oldest age groups. Between 1 July 1990 and 30 June 1991, 16.0% of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 1993 and 30 September 1994 (a 33.8% relative increase in use). Among persons aged 85 years or older, the proportion of treated patients increased from 5.3% to 9.1% over this same period (a 71.7% relative increase in use). Increases in thrombolytic use were most prominent for older women. After adjustment for sex, diagnosis by initial electrocardiogram, electrocardiogram-based infarction description, time from symptom onset to hospital presentation, and period of the acute myocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patients in the older age groups compared with the odds for patients younger than age 55 years (for patients aged 75 to 84 years, the adjusted odds ratio was 0.27 [95% CI, 0.26 to 0.28]; for patients aged 85 years or older, the odds ratio was 0.09 [CI, 0.08 to 0.10]). Conclusions: Although older patients who have had acute myocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this population is expanding. However, substantial differences across age groups persist in the likelihood of receiving treatment, even after adjustment for potentially confounding factors. Age-related differences in thrombolytic use may not be completely explained by the degree to which older patients do not meet conventional eligibility criteria for thrombolytic therapy.	UNIV MASSACHUSETTS, MED CTR, DEPT MED, WORCESTER, MA 01655 USA; CLINTRIALS RES INC, LEXINGTON, KY 40504 USA; JOHNS HOPKINS UNIV, BAYVIEW MED CTR, DIV CARDIOL, BALTIMORE, MD 21224 USA; UNIV ALABAMA, MED CTR, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Gurwitz, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 341, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CHAMBERLAIN DA, 1988, LANCET, V1, P545; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; GURWITZ JH, 1993, INCLUSION ELDERLY IN, P205; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEDALIE JH, 1976, ANN INTERN MED, V84, P526, DOI 10.7326/0003-4819-84-5-526; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1995, AM J MED, V99, P195, DOI 10.1016/S0002-9343(99)80140-5; SIGURDSSON E, 1995, ANN INTERN MED, V122, P96, DOI 10.7326/0003-4819-122-2-199501150-00003; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4; 1992, CARDIOLOGY, V21, P5	37	118	121	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					283	+		10.7326/0003-4819-124-3-199602010-00001	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554222				2022-12-28	WOS:A1996TR59600001
J	Amar, K; Wilcock, G				Amar, K; Wilcock, G			Fortnightly review - Vascular dementia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE CEREBRAL INFARCTS; MATTER LOW ATTENUATION; ALZHEIMERS-DISEASE; RISK-FACTORS; CLINICAL-DIAGNOSIS; COMPUTED-TOMOGRAPHY; COGNITIVE FUNCTION; SENILE DEMENTIA; LEUKO-ARAIOSIS; BLOOD-PRESSURE		UNIV BRISTOL, DEPT CARE ELDERLY, FRENCHAY HOSP, BRISTOL BS16 1LE, AVON, ENGLAND	University of Bristol								ALMKVIST O, 1992, ARCH NEUROL-CHICAGO, V49, P626, DOI 10.1001/archneur.1992.00530300062011; AMAR K, 1995, AGE AGEING, V24, P411, DOI 10.1093/ageing/24.5.411; AMAR K, IN PRESS AGE AGEING; AMAR KA, 1995, NEUROLOGY, V45, P1423, DOI 10.1212/WNL.45.7.1423-a; AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; BENNETT DA, 1990, J NEUROL NEUROSUR PS, V53, P961, DOI 10.1136/jnnp.53.11.961; BENSON DF, 1982, ARCH NEUROL-CHICAGO, V39, P616, DOI 10.1001/archneur.1982.00510220014003; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; BRUST JCM, 1988, ARCH NEUROL-CHICAGO, V45, P799, DOI 10.1001/archneur.1988.00520310117026; CAPLAN LR, 1995, NEUROLOGY, V45, P626, DOI 10.1212/WNL.45.4.626; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; CORSELLIS JAN, 1965, 5TH P INT C NEUR, P546; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; DESMOND DW, 1993, ARCH NEUROL-CHICAGO, V50, P162, DOI 10.1001/archneur.1993.00540020040015; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; GEORGE AE, 1986, AM J NEURORADIOL, V7, P561; GILLEARD CJ, 1992, ACTA PSYCHIAT SCAND, V85, P264, DOI 10.1111/j.1600-0447.1992.tb01467.x; GORELICK PB, 1993, ARCH NEUROL-CHICAGO, V50, P714, DOI 10.1001/archneur.1993.00540070034011; HACHINSKI VC, 1974, LANCET, V2, P207; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; INZITARI D, 1987, ARCH NEUROL-CHICAGO, V44, P42, DOI 10.1001/archneur.1987.00520130034014; JELLINGER K, 1990, J NEUROL SCI, V95, P239, DOI 10.1016/0022-510X(90)90072-U; JUNG HH, 1995, J NEUROL NEUROSUR PS, V59, P138, DOI 10.1136/jnnp.59.2.138; KATZ DI, 1987, ARCH NEUROL-CHICAGO, V44, P1127, DOI 10.1001/archneur.1987.00520230017007; LIU CK, 1992, NEUROLOGY, V42, P138, DOI 10.1212/WNL.42.1.138; LOEB C, 1988, STROKE, V19, P560, DOI 10.1161/01.STR.19.5.560; LOEB HH, 1994, HEART DISEASE STROKE, P110; MARDER K, 1995, ARCH NEUROL-CHICAGO, V52, P695, DOI 10.1001/archneur.1995.00540310069018; Marie P, 1901, REV MED-PARIS, V21, P281; MCKEITH IG, 1992, PSYCHOL MED, V22, P911, DOI 10.1017/S0033291700038484; MCKEITH IG, 1994, NEUROLOGY, V44, P872, DOI 10.1212/WNL.44.5.872; MENEILLY GS, 1993, J GERONTOL, V48, pM117, DOI 10.1093/geronj/48.4.M117; MEYER JS, 1986, JAMA-J AM MED ASSOC, V256, P2203, DOI 10.1001/jama.256.16.2203; OBRIEN MD, 1988, ARCH NEUROL-CHICAGO, V45, P797, DOI 10.1001/archneur.1988.00520310115025; ONEILL D, 1995, AGE AGEING, V24, P242, DOI 10.1093/ageing/24.3.242; ORTIZ JS, 1994, AGE AGEING, V23, P75, DOI 10.1093/ageing/23.1.75; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; PRINCE M, 1994, NEUROLOGY, V44, P97; RAIHA I, 1993, ACTA NEUROL SCAND, V87, P286; ROCCA WA, 1991, ANN NEUROL, V30, P817, DOI 10.1002/ana.410300611; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; SCHELTENS P, 1995, NEUROLOGY, V45, P883, DOI 10.1212/WNL.45.5.883; SCHMIDT R, 1993, NEUROLOGY, V43, P2490, DOI 10.1212/WNL.43.12.2490; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; TATEMICHI TK, 1993, ANN NEUROL, V33, P568, DOI 10.1002/ana.410330603; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; TODOROV AB, 1975, J NEUROL SCI, V26, P81, DOI 10.1016/0022-510X(75)90116-1; TOLOSA E, 1994, J NEURAL TRANSM-SUPP, P15; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; WADE JPH, 1987, ARCH NEUROL-CHICAGO, V44, P24, DOI 10.1001/archneur.1987.00520130016010; WALLIN A, 1989, ACTA NEUROL SCAND, V80, P518, DOI 10.1111/j.1600-0404.1989.tb03920.x; WALLIN A, 1994, DEMENTIA, V5, P181, DOI 10.1159/000106719; WENNING GK, 1995, J NEUROL NEUROSUR PS, V58, P160, DOI 10.1136/jnnp.58.2.160; WOLFE N, 1994, ARCH NEUROL-CHICAGO, V51, P211, DOI 10.1001/archneur.1994.00540140129022; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171; YLIKOSKI R, 1993, ARCH NEUROL-CHICAGO, V50, P818, DOI 10.1001/archneur.1993.00540080029009; 1994, DIAGNOSTIC STATISTIC; 1993, ICD 10 CLASSIFICATIO, P36	65	48	51	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	1996	312	7025					227	231						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563591				2022-12-28	WOS:A1996TT48600032
J	Newell, ML; Dunn, D; DeMaria, A; Ferrazin, A; DeRossi, A; Giaquinto, C; Levy, J; Alimenti, A; Ehrnst, A; Bohlin, AB; Ljung, R; Peckham, C				Newell, ML; Dunn, D; DeMaria, A; Ferrazin, A; DeRossi, A; Giaquinto, C; Levy, J; Alimenti, A; Ehrnst, A; Bohlin, AB; Ljung, R; Peckham, C			Detection of virus in vertically exposed HIV-antibody-negative children	LANCET			English	Article								Background HIV-infected mothers can transmit their infection to their children in utero or at delivery (vertical transmission). There have been cases of children who were reported as acquiring infection vertically and later clearing the infection. We report the frequency of this phenomenon in a European cohort study. Methods In four centres of the European Collaborative Study of children born to HIV-infected mothers, 299 children became HIV-antibody-negative and 264 of these had been followed up with virus culture and PCR for viral DNA at least once. Findings Nine of the 264 children were positive by virus culture or PCR, and subsequently seroreverted. Two of the nine tested virus-positive after they became antibody-negative, Six cases were virus-positive early in life and became negative thereafter, which is consistent with clearance of infection. The pattern was less clear in the other three. The nine cases had had their last virus test at age 16-101 months. All nine children had been bottlefed only. Eight had been delivered vaginally. The children had no HIV-related symptoms and received no anti-HIV treatments. Based on only those children who had two or more positive virological tests, we estimate that 2.7% (6/219) cleared or ''tolerated'' the virus. Interpretation The detection of virus or viral DNA in ''uninfected'' children born to HIV-infected mothers was rare and was not associated with clinical disease or immunological abnormalities. The timing of samples will affect the documentation of clearance since, in uninfected children of HIV-positive mothers who cleared the virus, viraemia was intermittent. Current paediatric opinion is to inform parents of children who serorevert that the child is not HIV-infected.	UNIV GENOA,DEPT INFECT DIS,GENOA,ITALY; UNIV GENOA,ADV BIOTECHNOL CTR,GENOA,ITALY; UNIV PADUA,DEPT PAEDIAT,PADUA,ITALY; UNIV PADUA,INST ONCOL,PADUA,ITALY; HOSP ST PIERRE,DEPT PAEDIAT,BRUSSELS,BELGIUM; KAROLINSKA INST,HUDDINGE HOSP,DEPT VIROL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,HUDDINGE HOSP,DEPT PAEDIAT,S-10401 STOCKHOLM,SWEDEN; LUND UNIV,DEPT PAEDIAT,MALMO,SWEDEN	University of Genoa; University of Genoa; University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University of Padua; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Karolinska Institutet; Karolinska Institutet; Lund University	Newell, ML (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		De Rossi, A./L-3128-2015; De Rossi, Anita/Q-4845-2019; Newell, Marie-Louise/AAE-8222-2019; de maria, andrea/F-7116-2016; Giaquinto, Carlo/AAB-5016-2020	De Rossi, A./0000-0001-6435-7509; De Rossi, Anita/0000-0001-6435-7509; Newell, Marie-Louise/0000-0002-1074-7699; de maria, andrea/0000-0001-5782-333X; Dunn, David/0000-0003-1836-4446; GIAQUINTO, CARLO/0000-0001-9365-0413; Alimenti, Ariane/0000-0003-4999-8230				BAUR A, 1989, LANCET, V2, P1045; BORKOWSKY W, 1987, LANCET, V1, P1168; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; DEMARIA A, 1994, J INFECT DIS, V170, P1296, DOI 10.1093/infdis/170.5.1296; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; GIAQUINTO C, 1995, LANCET, V346, P963, DOI 10.1016/S0140-6736(95)91582-6; LOCHE M, 1988, LANCET, V2, P418; NEWELL ML, 1989, 5 INT C AIDS MONTR C, P71; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; 1991, LANCET, V337, P253; 1992, J PEDIATR INFECT DIS, V11, P1019	12	60	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					213	215		10.1016/S0140-6736(96)90401-8	http://dx.doi.org/10.1016/S0140-6736(96)90401-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551878				2022-12-28	WOS:A1996TT06900007
J	Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA				Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA			Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; PIMA-INDIANS; FOLLOW-UP; PARITY; CELL	Background Pregnancy is associated with marked insulin resistance that seems to have little, if any, impact on the long-term risk of non-insulin-dependent diabetes mellitus (NIDDM) in the general population. The aim of this study was to test whether pregnancy would alter the risk of NIDDM among women with a high prevalence of pancreatic beta-cell dysfunction, as indicated by a history of gestational diabetes mellitus. Methods The cohort consisted of 666 Latino women with gestational diabetes attending a high-risk family planning clinic. They were followed up for up to 7.5 years, during which lime they were weighed and underwent an oral glucose-tolerance test annually. The effect of an additional pregnancy, and of other risk factors for diabetes, was examined. Findings 87 (13%) of the women completed an additional pregnancy. 80 of those women did not have NIDDM immediately after the additional pregnancy and their subsequent annual incidence rate of NIDDM was 30.9% (95% CI 12.7-49.1), more than 2.5 times the annual incidence rate of NIDDM in the cohort overall (11.9%; 95% CI 10.0-13.8). Proportional hazards regression analysis using the presence or absence of an additional pregnancy as a time-dependent variable confirmed that an additional pregnancy increased the rate ratio of NIDDM to 3.34(95% CI 1.80-6.19), compared with women without an additional pregnancy after adjustment for other potential diabetes risk factors during the index pregnancy (antepartum oral glucose tolerance, highest fasting glucose, gestational age at diagnosis of gestational diabetes) and during follow-up (postpartum body mass index [BMI], and glucose tolerance, weight change, breast feeding, and months of contraceptive use). Weight gain also was independently associated with an increased risk of NIDDM; the rate ratio was 1.95 (95% CI 1.63-2.33) for each 10 lb (4.5 kg) gained during follow-up after adjustment for the additional pregnancy and the other potential risk factors. Interpretation The study showed that a single pregnancy, independent of the well-known effect of weight gain, accelerated the development of NIDDM in a group of women with a high prevalence of pancreatic beta-cell dysfunction. This finding implies that episodes of insulin resistance may contribute to the decline in beta-cell function that leads to NIDDM in many high-risk individuals.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-43] Funding Source: Medline; NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BLEICHER SJ, 1964, NEW ENGL J MED, V271, P866, DOI 10.1056/NEJM196410222711702; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; CATALANO PM, 1991, AM J OBSTET GYNECOL, V165, P1667, DOI 10.1016/0002-9378(91)90012-G; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COX DR, 1972, J R STAT SOC B, V34, P187; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DONG ZG, 1993, AUST NZ J OBSTET GYN, V33, P350, DOI 10.1111/j.1479-828X.1993.tb02107.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GAUDIER FL, 1992, OBSTET GYNECOL, V80, P755; GRANT PT, 1986, AUST NZ J OBSTET GYN, V26, P17, DOI 10.1111/j.1479-828X.1986.tb01521.x; HANSON RL, 1995, DIABETES, V43, P261; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, AM J MED, V93, P13, DOI 10.1016/0002-9343(92)90674-Z; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; PYKE DA, 1956, LANCET, V270, P818; RYAN EA, 1985, DIABETES, V34, P380, DOI 10.2337/diabetes.34.4.380; RYAN EA, 1995, DIABETES, V44, P506, DOI 10.2337/diabetes.44.5.506; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SPELLACY WN, 1963, NEW ENGL J MED, V268, P988, DOI 10.1056/NEJM196305022681805; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P221; 1979, DIABETES, V29, P1039	27	201	207	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					227	230		10.1016/S0140-6736(96)90405-5	http://dx.doi.org/10.1016/S0140-6736(96)90405-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551882				2022-12-28	WOS:A1996TT06900011
J	Sabin, CA; Phillips, AN; Lee, CA				Sabin, CA; Phillips, AN; Lee, CA			Arguments contradict the ''foreign protein-zidovudine'' hypothesis - Response	BRITISH MEDICAL JOURNAL			English	Editorial Material									ROYAL FREE HOSP,HAEMOPHILIA CTR,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,HAEMOSTASIS UNIT,DEPT HAEMATOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Sabin, CA (corresponding author), ROYAL FREE HOSP,SCH MED,HIV RES UNIT,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1996, BMJ, V312; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; MONTORO JB, 1995, BLOOD, V86, P2213, DOI 10.1182/blood.V86.6.2213.bloodjournal8662213; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; 1994, HIV AIDS SURVEILLANC, V6, P1	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					211	212						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563584				2022-12-28	WOS:A1996TT48600023
J	Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC				Siniossoglou, S; Wimmer, C; Rieger, M; Doye, V; Tekotte, H; Weise, C; Emig, S; Segref, A; Hurt, EC			A novel complex of nucleoporins, which includes Sec13p and a Sec13p homolog, is essential for normal nuclear pores	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; RECONSTITUTION; PROTEINS; INVITRO; MUTANT; NSP1	In a genetic screen for nucleoporin-interacting components, a novel nuclear pore protein Nup84p, which exhibits homology to mammalian Nup107p, was isolated. Nup84p forms a complex with five proteins, of which Nup120p, Nup85p, Sec13p, and a Sec13p homolog were identified. Upon isolation of Sec13p-ProtA, nucleoporins were still associated, but the major copurifying band was a 150 kDa protein, showing that Sec13p occurs in two complexes. Disruption of any of the genes encoding Nup84p, Nup85p, or Nup120p caused defects in nuclear membrane and nuclear pore complex organization, as well as in poly(A)(+) RNA transport. Thus, the Nup84p complex in conjunction with Sec13-type proteins is required for correct nuclear pore biogenesis.	EUROPEAN MOLEC BIOL LAB, D-69115 HEIDELBERG, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; INST CURIE, CNRS UMR 144, SECT RECH, F-75231 PARIS, FRANCE	European Molecular Biology Laboratory (EMBL); Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Segref, Alexandra/C-8325-2011; Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; Tekotte, Hille/0000-0003-2164-7412; Segref, Alexandra/0000-0001-8095-4469				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; JORDAN EG, 1977, EXP CELL RES, V104, P446, DOI 10.1016/0014-4827(77)90114-8; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; LI O, 1995, MOL BIOL CELL, V6, P401, DOI 10.1091/mbc.6.4.401; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1994, J BIOL CHEM, V269, P17600; RASMUSSEN SW, 1994, YEAST, V10, pS63, DOI 10.1002/yea.320100008; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMOS G, 1995, FEBS LETT, V369, P107, DOI 10.1016/0014-5793(95)00674-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083	33	267	277	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					265	275		10.1016/S0092-8674(00)80981-2	http://dx.doi.org/10.1016/S0092-8674(00)80981-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565072	Bronze			2022-12-28	WOS:A1996TR59500013
J	Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L				Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L			Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein	NATURE			English	Article							T-CELL RECEPTOR; TUMOR NECROSIS FACTOR; MULTIPLE-SCLEROSIS	FOLLOWING induction of experimental encephalomyelitis with a T-cell clone, L10C1, that is specific for the myelin basic protein epitope p87-99, the inflammatory infiltrate in the central nervous system contains a diverse collection of T cells with heterogeneous receptors. We show here that when clone L10C1 is tolerized in vivo with an analogue of p87-99, established paralysis is reversed, inflammatory infiltrates regress, and the heterogeneous T-cell infiltrate disappears from the brain, with only the T-cell clones that incited disease remaining in the original lesions. We found that antibody raised against interleukin-4 reversed the tolerance induced by the altered peptide ligand. Treatment,vith this altered peptide ligand selectively silences pathogenic T cells and actively signals for the efflux of other T cells recruited to the site of disease as a result of the production of interleukin-4 and the reduction of tumour-necrosis factor-alpha in the lesion.	STANFORD UNIV,MED CTR,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; NEUROCRINE BIOSCI,LA JOLLA,CA 92121; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB1 1QP,ENGLAND; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94305	Stanford University; Stanford University; Stanford University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Weizmann Institute of Science; Neurocrine Biosciences; University of Cambridge; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Wraith, David/0000-0003-2147-5614; O'Garra, Anne/0000-0001-9845-6134; Steinman, Lawrence/0000-0002-2437-2250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GOLD DP, 1992, J IMMUNOL, V148, P1712; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; SELMAJ KW, 1990, J IMMUNOL, V144, P129; STEINMAN L, 1994, BEHRING I MITT, V94, P148; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGT AB, 1994, J IMMUNOL, V153, P1665; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	21	361	379	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					343	346		10.1038/379343a0	http://dx.doi.org/10.1038/379343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552189				2022-12-28	WOS:A1996TR32300058
J	Andreone, P; Cursaro, C; Gramenzi, A; Trevisani, F; Gasbarrini, G; Bernardi, M				Andreone, P; Cursaro, C; Gramenzi, A; Trevisani, F; Gasbarrini, G; Bernardi, M			Interferon and hepatocellular carcinoma	LANCET			English	Letter									CATHOLIC UNIV,ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Andreone, P (corresponding author), UNIV BOLOGNA,I-40138 BOLOGNA,ITALY.		Andreone, Pietro/K-8050-2016	Andreone, Pietro/0000-0002-4794-9809; Cursaro, Carmela/0000-0002-5644-2508				COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; COTTONE M, 1994, J HEPATOL, V21, P1029, DOI 10.1016/S0168-8278(05)80613-0; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; TREVISANI F, 1995, CANCER-AM CANCER SOC, V75, P2220, DOI 10.1002/1097-0142(19950501)75:9<2220::AID-CNCR2820750906>3.0.CO;2-4	5	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					195	195						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544566				2022-12-28	WOS:A1996TQ24400050
J	Moulin, DE; Iezzi, A; Amireh, R; Sharpe, WKJ; Boyd, D; Merskey, H				Moulin, DE; Iezzi, A; Amireh, R; Sharpe, WKJ; Boyd, D; Merskey, H			Randomised trial of oral morphine for chronic non-cancer pain	LANCET			English	Article							ANALGESICS; DEPENDENCY	Background The use of opioid analgesics for chronic noncancer pain is controversial. Some surveys report good pain relief and improvement in performance while others suggest a poor outcome with a propensity to psychological dependence or addiction. Methods We undertook a randomised double-blind crossover study to test the hypothesis that oral morphine relieves pain and improves the quality of life in patients with chronic regional pain of soft tissue or musculoskeletal origin who have not responded to codeine, antiinflammatory agents, and antidepressants. Morphine was administered as a sustained-release preparation in doses up to 60 mg twice daily and compared with benztropine (active placebo) in doses up to 1 mg twice daily over three-week titration, six-week evaluation, and two-week washout phases. Pain intensity, pain relief, and drug liking were rated weekly and psychological features, functional status, and cognition were assessed at baseline and at the end of each evaluation phase. Findings After dose titration in the 46 patients who completed the study, the mean daily doses of drugs were morphine 83.5 mg and benztropine 1 7 mg, On visual analogue scales, the morphine group showed a reduction in pain intensity relative to placebo in period I (p=0 01) and this group also fared better in a crossover analysis of the sum of pain intensity differences from baseline (p=0.02). No other significant differences were detected. Interpretation In patients with treatment-resistant chronic regional pain of soft-tissue or musculoskeletal origin, nine weeks of oral morphine in doses up to 120 mg daily may confer analgesic benefit with a low risk of addiction but is unlikely to yield psychological or functional improvement.	VICTORIA HOSP,LONDON,ON N6A 4G5,CANADA; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT PSYCHIAT,LONDON,ON,CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)								BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOTNEY M, 1983, ANN NEUROL, V13, P160, DOI 10.1002/ana.410130209; BOUKOMAS AJ, 1992, ANN CLIN PSYCHAITRY, V4, P185; CHERNY NI, 1994, TXB PAIN, P1437; Derogatis L. R., 1975, SCL 90 R INVENTAIRE; FAUST D, 1989, J NERV MENT DIS, V177, P25, DOI 10.1097/00005053-198901000-00004; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; JASINSKI DR, 1977, HDB EXPT PHARMACOLOG, V45, P197; JONES B, 1989, DESIGN ANAL CROSSOVE; JORANSON DE, 1994, MCNEIL NATIONAL PAIN; Kolb L, 1925, MENT HYG, V9, P300; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MARUTA T, 1979, MAYO CLIN PROC, V54, P241; MARUTA T, 1981, PAIN, V11, P389, DOI 10.1016/0304-3959(81)90638-2; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; McNair D. M., 1982, PROFILE MOOD STATES; MCNAIRY SL, 1984, PAIN, V18, P169, DOI 10.1016/0304-3959(84)90884-4; MEDINA JL, 1977, HEADACHE, V17, P12, DOI 10.1111/j.1526-4610.1977.hed1701012.x; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; PORTER J, 1980, NEW ENGL J MED, V302, P123; RAYPORT M, 1954, JAMA-J AM MED ASSOC, V156, P684, DOI 10.1001/jama.1954.02950070012004; REIDENBERG MM, 1994, CLIN PHARMACOL THER, V55, P367, DOI 10.1038/clpt.1994.43; TAIT RC, 1987, ARCH PHYS MED REHAB, V68, P438; Taub A., 1982, NARCOTIC ANALGESICS, P199; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; TURK DC, 1994, TXB PAIN, P1337; TURNER JA, 1982, PAIN, V12, P357, DOI 10.1016/0304-3959(82)90180-4; VONKORFF M, 1992, HDB PAIN ASSESSMENT, P391; WARD SE, 1994, PAIN, V56, P299, DOI 10.1016/0304-3959(94)90168-6; WATSON CPN, 1994, J PAIN SYMPTOM MANAG, V9, P392; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y	35	314	319	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					143	147		10.1016/S0140-6736(96)90339-6	http://dx.doi.org/10.1016/S0140-6736(96)90339-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544547				2022-12-28	WOS:A1996TQ24400008
J	Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA				Desenclos, JC; Bouvet, P; BenzLemoine, E; Grimont, F; Desqueyroux, H; Rebiere, I; Grimont, PA			Large outbreak of Salmonella enterica serotype paratyphi B infection caused by a goats' milk cheese, France, 1993: A case finding and epidemiological study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER ENTERITIS	Objective-To assess the magnitude of a nationwide outbreak of infection with Salmonella enterica serotype paratyphi B and identify the vehicle and source of infection. Design - A case finding study of S paratyphi B infection between 15 August and 30 November 1993; a pair matched case-control study; an environmental investigation at a processing plant that produced a raw goats' milk cheese incriminated in the outbreak; phage typing and genotyping of food and human Sparatyphi B isolates. Setting - France, 15 August to 30 November 1993. Subjects - 273 patients with S paratyphi B infection; 59 pairs of cases and controls matched for age, sex, and city of residence. Main outcome measures - Numbers of cases and incidence rates by region of residence and age; matched odds ratios for dairy food preferences. Results - Among the 273 cases there was one death; 203 (78%) strains belonged to phage type 1 var 3. The incidence of infection was greatest in the region where goats) milk cheese is commonly produced. Comparison of cases and controls showed a 12-fold greater risk of illness (95% confidence interval 1.6 to 92.3) from eating brand A unpasteurised goats' milk cheese. Sparatyphi B isolates of phage type 1 var 3 were recovered from cheese A, goats' milk at the plant processing cheese A, and goats' milk supplied to the plant by a single farm. Genotypic IS 200 typing of food and human 1 var 3 phage type isolates showed a common IS 200 pattern. Conclusion - This outbreak emphasises the potential health hazards of widely distributed unpasteurised milk products in France and the need for their close bacterial monitoring.	INST PASTEUR, CTR NATL REFERENCE SALMONELLA SHIGELLA, PARIS, FRANCE; DIRECT DEPT AFFAIRES SANIT & SOCIALES DEUX SEVRES, NIORT, FRANCE; INST PASTEUR, CTR NATL REFERENCE TYPAGE MOLEC ENTER, PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Desenclos, JC (corresponding author), RESEAU NATL SANTE PUBL, F-94415 ST MAURICE, FRANCE.							Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BILLE J, 1990, T IND MICR, P71; CAZENAVE DJC, 1993, B EPIDEMIOLOGIQUE HE, V48, P222; CHAUVIN P, 1993, B EPIDEMIOLOGIQUE HE, V21, P93; EZQUERRA E, 1993, J GEN MICROBIOL, V139, P2409, DOI 10.1099/00221287-139-10-2409; FELIX A, 1951, LANCET, V2, P10; GRIMONT PAD, 1991, B EPIDEMIOLOGIQUE HE, V25, P102; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; POTELON JL, 1989, B EPIDEMIOLOGIQUE HE, V24, P98; ROBINSON DA, 1981, BRIT MED J, V282, P1374, DOI 10.1136/bmj.282.6273.1374; ROBINSON DA, 1979, BRIT MED J, V1, P1171, DOI 10.1136/bmj.1.6172.1171; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Talbot J C, 1967, Public Health, V81, P191, DOI 10.1016/S0033-3506(67)80185-9; WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P227, DOI 10.1017/S002217240006023X; 1993, GUIDELINES APPLICATI; 1991, RECENSEMENT GENERRAL	16	57	59	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					91	94						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555937	Green Published			2022-12-28	WOS:A1996TQ16800024
J	Klein, R; Klein, BEK; Moss, SE				Klein, R; Klein, BEK; Moss, SE			Relation of glycemic control to diabetic microvascular complications in diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			STAGE RENAL-DISEASE; GROSS PROTEINURIA; METABOLIC CONTROL; 4-YEAR INCIDENCE; PLASMA-GLUCOSE; BLOOD-PRESSURE; PIMA-INDIANS; RETINOPATHY; NEPHROPATHY; POPULATION	Objective: To describe the relation between glycated hemoglobin and the incidence or progression, or both, of diabetic microvascular complications in persons with insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). Design: Population-based cohort study. Setting: An 11-county area in southern Wisconsin. Patients: All persons with IDDM diagnosed before age 30 and taking insulin (n = 996) and a probability sample (based on duration of disease) of persons diagnosed with diabetes at age 30 or older who were either taking insulin (n = 674) or not taking insulin (n = 696) and who participated in a baseline examination from 1980 to 1982. Survivors of the cohort were re-examined again in 1984 to 1986 and 1990 to 1992. Measurements: The incidence and progression of diabetic retinopathy was determined by masked grading of stereoscopic color fundus photographs using the modified Early Treatment Diabetic Retinopathy Study severity scale. Gross proteinuria was determined using a dipstick. Ten-year incidence of renal dialysis or transplantation or loss of tactile sensation or of temperature sensitivity was based on self-reported history. Results: The glycated hemoglobin level at baseline was strongly related to the incidence or progression, or both, of diabetic retinopathy, the incidence of gross proteinuria, and the incidence of loss of tactile sensation or temperature sensitivity in persons with either IDDM or NIDDM. Conclusions: These prospective epidemiologic data suggest that glycemic control is similarly related to the incidence and progression of diabetic microvascular complications in both IDDM and NIDDM. However, further evidence from clinical trials in persons with NIDDM is necessary to assess the risks and benefits of such treatment in preventing these complications.			Klein, R (corresponding author), UNIV WISCONSIN, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 610 N WALNUT ST, 460 WARF, MADISON, WI 53705 USA.				NEI NIH HHS [EYO-3083] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DYCK PJ, 1985, ADV EXP MED BIOL, V189, P305; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290; HASSLACHER C, 1985, DIABETOLOGIA, V28, P6, DOI 10.1007/BF00276992; HASSLACHER C, 1989, NEPHROL DIAL TRANSPL, V4, P859, DOI 10.1093/ndt/4.10.859; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KLEIN R, 1993, DIABETES, V42, P381, DOI 10.2337/diabetes.42.3.381; KLEIN R, 1987, DIABETES CARE, V10, P633, DOI 10.2337/diacare.10.5.633; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1985, ADV EXP MED BIOL, V189, P321; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; KOHNER EM, 1987, PRACT CARDIOL, V13, P70; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LEE ET, 1992, DIABETES CARE, V15, P1620, DOI 10.2337/diacare.15.11.1620; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAUER SM, 1985, ADV EXP MED BIOL, V189, P299; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; ORCHARD TJ, 1994, DIABETES CARE, V17, P326, DOI 10.2337/diacare.17.4.326; PETTITT DJ, 1980, LANCET, V2, P1050; PUGH JA, 1993, DIABETOLOGIA, V36, P1094, DOI 10.1007/BF02374504; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; WU MS, 1990, DIABETES CARE, V13, P1, DOI 10.2337/diacare.13.1.1; YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697; 1976, PREV MED, V5, P207; 1981, INVEST OPHTH VIS SCI, V21, P210; 1981, FAST HEMOGLOBIN TEST, P1; PB85223006AS	43	197	211	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				90	96		10.7326/0003-4819-124-1_Part_2-199601011-00003	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554220				2022-12-28	WOS:A1996TL94400003
J	Kiberd, BA; Jindal, KK				Kiberd, BA; Jindal, KK			Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; NEPHROPATHY; MICROALBUMINURIA; MELLITUS; PREDICTOR	Objective-To examine the conditions necessary to make screening for microalbuminuria in patients with insulin dependent diabetes mellitus cost effective. Design-This economic evaluation compared two strategies designed to prevent the development of end stage renal disease in patients with insulin dependent diabetes with disease for five years. Strategy A, screening for microalbuminuria as currently recommended, was compared with strategy B, a protocol in which patients were screened for hypertension and macroproteinuria. Intervention-Patients identified in both strategies were treated with an angiotensin converting enzyme inhibitor. Setting-Computer simulation. Main outcome measures-Strategy costs and quality adjusted life years (QALYs). Results-The model predicted that strategy A would produce an additional 0 . 00967 QALYs at a present value cost of $261.53 (1990 US$) per patient (or an incremental cost/QALY of $27041.69) over strategy B. The incremental cost/QALY for strategy A over B was sensitive to several variables. If the positive predictive value of screening for microalbuminuria (impact of false label and unnecessary treatment) is <0 . 72, the effect of treatment to delay progression from microalbuminuria to macroproteinuria is <1 . 6 years, the cumulative incidence of diabetic nephropathy falls to < 20%, or > 64% of patients demonstrate hypertension at the onset of microalbuminuria, then the incremental costs/QALY will exceed $75 000. Conclusions-Whether microalbuminuria surveillance in this population is cost effective requires more information. Being aware of the costs, recommendation pitfalls, and gaps in our knowledge should help focus our efforts to provide cost effective care to this population.	DALHOUSIE UNIV,DEPT MED,HALIFAX,NS,CANADA	Dalhousie University								BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; COHEN DL, 1987, DIABETIC MED, V4, P437, DOI 10.1111/j.1464-5491.1987.tb00905.x; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P42; FORSBLOM CM, 1992, BRIT MED J, V305, P1051, DOI 10.1136/bmj.305.6861.1051; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; GLEESON RE, 1990, MED RISKS TRENDS, V2, P11; HOWEY JEA, 1988, KIDNEY HYPERTENSION, P41; JOHNSTON J, 1993, BRIT MED J, V306, P493, DOI 10.1136/bmj.306.6876.493-a; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANGILI R, 1994, DIABETOLOGIA, V37, P1015, DOI 10.1007/s001250050212; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; Mogensen C E, 1991, Adv Nephrol Necker Hosp, V20, P191; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1995, DIABETES CARE, V18, P572, DOI 10.2337/diacare.18.4.572; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; NEASE RF, 1994, MED DECIS MAKING, V14, P382, DOI 10.1177/0272989X9401400409; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; Torrance GW, 1987, METHODS EC EVALUATIO; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; 1994, WHO TECH REP SER, V844, P55; 1993, AM J KIDNEY S2, V22, P21; 1994, 1992 CAN I HLTH INF; 1992, AM J KIDNEY DIS S2, V20, P55; 1991, 3 NEW ACE INHIBITORS, V33, P83; 1994, AM J KIDNEY DIS, V24, P48	38	91	91	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1595	1599		10.1136/bmj.311.7020.1595	http://dx.doi.org/10.1136/bmj.311.7020.1595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555801	Green Published			2022-12-28	WOS:A1995TL42200017
J							Diabet Control Complications Trial Res Grp	Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, insulin-dependent; insulin; neuropsychological tests; hypoglycemia	RECURRENT SEVERE HYPOGLYCEMIA; COGNITIVE FUNCTION; INSULIN-TREATMENT; BRAIN-DAMAGE; IMPAIRMENT; MELLITUS; EPISODES; DEFICITS	Objective: To examine the effect of intensive therapy on neuropsychological performance in patients who participated in the Diabetes Control and Complications Trial (DCCT). Design: Multicenter, randomized, controlled clinical trial. Setting: 29 DCCT clinical centers. Patients: 1441 patients with insulin-dependent diabetes mellitus (IDDM) between 13 and 39 years of age who had had IDDM for 1 to 15 years and had no or minimal retinopathy or nephropathy at baseline. Volunteers were ex eluded if they had a history of substance abuse, psychological disturbance, or recurrent hypoglycemia with coma or seizure. Intervention: Intensive therapy with 3 or more daily insulin injections or continuous subcutaneous insulin infusion, guided by 4 or more glucose tests per day, compared with conventional therapy with 1 or 2 daily insulin injections. Outcome Measures: Neuropsychological assessments were done at baseline; years 2, 5, and 7; and the end of the study. Eight cognitive domain scores were developed from the test results and were used to identify patients whose neuropsychological performance had clinically worsened. Results: Intensive therapy did not affect neuropsychological performance. In addition, patients who had repeated episodes of hypoglycemia did not perform differently than patients who did not have repeated episodes. Conclusion: Intensive therapy and the attendant risk for hypoglycemia were not associated with neuropsychological impairment in the DCCT.					Zinman, Bernard/E-7266-2013; Hramiak, Irene/G-3305-2011					Arnold M. B., 1984, MEMORY BRAIN; AUER RN, 1986, STROKE, V17, P699, DOI 10.1161/01.STR.17.4.699; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; CHALMERS J, 1991, DIABETES CARE, V14, P922, DOI 10.2337/diacare.14.10.922; Cochran W.G, 1957, STAT METHODS, V6th ed; COX DJ, 1993, DIABETES, V42, P239, DOI 10.2337/diabetes.42.2.239; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DEARY IJ, 1993, DIABETES, V42, P341, DOI 10.2337/diabetes.42.2.341; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; GOLD AE, 1993, DIABETIC MED, V10, P503, DOI 10.1111/j.1464-5491.1993.tb00110.x; HOFFMAN RG, 1989, DIABETES CARE, V12, P193, DOI 10.2337/diacare.12.3.193; JASTAK JJ, 1978, MANUAL WIDE RANGE AC; KALIMO H, 1980, ACTA NEUROL SCAND, V62, P345; LANGAN SJ, 1991, DIABETOLOGIA, V34, P337, DOI 10.1007/BF00405006; Lewis RF, 1979, MANUAL REPEATABLE CO; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P194; MEYERS RE, 1971, BRAIN HYPOXIA, P195; PATRICK AW, 1990, DIABETIC MED, V7, P349, DOI 10.1111/j.1464-5491.1990.tb01403.x; REICHARD P, 1994, DIABETES, V43, P313, DOI 10.2337/diabetes.43.2.313; REICHARD P, 1991, BRIT MED J, V303, P1439, DOI 10.1136/bmj.303.6815.1439; REICHARD P, 1991, J INTERN MED, V229, P9, DOI 10.1111/j.1365-2796.1991.tb00299.x; Reitan RM, 1985, HALSTEAD REITAN NEUR; ROURKE BP, 1973, J CONSULT CLIN PSYCH, V41, P128, DOI 10.1037/h0035613; ROVET JF, 1988, CHILD DEV, V59, P226; RYAN C, 1985, PEDIATRICS, V75, P921; RYAN C, 1980, ALCOHOL CLIN EXP RES, V4, P288, DOI 10.1111/j.1530-0277.1980.tb04816.x; RYAN C, 1991, HDB CLIN TRIALS NEUR, P217; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wechsler DW., 1999, INTELLIGENCE SCALE C; WREDLING R, 1990, DIABETOLOGIA, V33, P152, DOI 10.1007/BF00404042; [No title captured]; 1994, J CLIN EXP NEUROPSYC, V16, P303	36	146	146	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					379	+		10.7326/0003-4819-124-4-199602150-00001	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554246				2022-12-28	WOS:A1996TV22000001
J	Schmied, H; Kurz, A; Sessler, DI; Kozek, S; Reiter, A				Schmied, H; Kurz, A; Sessler, DI; Kozek, S; Reiter, A			Mild hypothermia increases blood loss and transfusion requirements during total hip arthroplasty	LANCET			English	Article							BLEEDING-TIME; TEMPERATURE; ANESTHESIA; BYPASS	Background In-vitro studies indicate that platelet function and the coagulation cascade are impaired by hypothermia. However, the extent to which perioperative hypothermia influences bleeding during surgery remains unknown. Accordingly, we tested the hypothesis that mild hypothermia increases blood loss and allogeneic transfusion requirements during hip arthroplasty. Methods Blood loss and transfusion requirements were evaluated in 60 patients undergoing primary, unilateral total hip arthroplasties who were randomly assigned to normothermia (final intraoperative core temperature 36.6 [0.4]degrees C) or mild hypothermia (35.0 [0.5]degrees C). Crystalloid, colloid, scavenged red cells, and allogeneic blood were administered by strict protocol. Findings Intra- and postoperative blood loss was significantly greater in the hypothermic patients: 2.2 (0.5) L vs 1.7 (0.3) L, p<0.001). Eight units of allogeneic packed red cells were required in seven of the 30 hypothermic patients, whereas only one normothermic patient required a unit of allogeneic blood (p<0.05 for administered volume). A typical decrease in core temperature in patients undergoing hip arthroplasty will thus augment blood loss by approximately 500 mL. Interpretation The maintenance of intraoperative normothermia reduces blood loss and allogeneic blood requirements in patients undergoing total hip arthroplasty.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,THERMOREGULAT RES LAB,SAN FRANCISCO,CA 94143; HOSP AMSTETTEN,DEPT ANAESTHESIA & INTENS CARE MED,AMSTETTEN,AUSTRIA; UNIV VIENNA,DEPT ANAESTHESIA & INTENS CARE MED,VIENNA,AUSTRIA	University of California System; University of California San Francisco; University of Vienna			Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Kurz, Andrea/0000-0001-5887-3099	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049670] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49670] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNKER JP, 1958, P SOC EXP BIOL MED, V97, P199; CSETE M, IN PRESS CRIT CARE M; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; GOTO H, 1985, ANESTHESIOLOGY, V63, P107; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; KHURI SF, 1992, J THORAC CARDIOV SUR, V104, P94; KURZ A, 1995, J CLIN ANESTH, V7, P359, DOI 10.1016/0952-8180(95)00028-G; KURZ A, 1993, ANESTH ANALG, V77, P89; KURZ A, 1955, ANESTHESIOLOGY, V83, pA227; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; LUBARSKY DA, 1994, ANESTH ANALG, V79, P629; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; Meinert CL., 1986, CLIN TRIALS DESIGN C; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; RODGERS RPC, 1990, SEMIN THROMB HEMOST, V16, P1, DOI 10.1055/s-2007-1002658; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; VALERI CR, 1992, J THORAC CARDIOV SUR, V104, P108	20	621	649	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					289	292		10.1016/S0140-6736(96)90466-3	http://dx.doi.org/10.1016/S0140-6736(96)90466-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569362	Bronze			2022-12-28	WOS:A1996TT48500009
J	Hurtley, SM				Hurtley, SM			Lysosomal degradation of ubiquitin-tagged receptors	SCIENCE			English	Editorial Material																		GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	4	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					617	617		10.1126/science.271.5249.617	http://dx.doi.org/10.1126/science.271.5249.617			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571124				2022-12-28	WOS:A1996TT87000035
J	Mao, L; Schoenberg, MP; Scicchitano, M; Erozan, YS; Merlo, A; Schwab, D; Sidransky, D				Mao, L; Schoenberg, MP; Scicchitano, M; Erozan, YS; Merlo, A; Schwab, D; Sidransky, D			Molecular detection of primary bladder cancer by microsatellite analysis	SCIENCE			English	Article							URINARY CYTOLOGY; IDENTIFICATION; CHROMOSOME-11; MUTATIONS; LOSSES; GENES; CELLS	Microsatellite DNA markers have been widely used as a tool for the detection of loss of heterozygosity and genomic instability in primary tumors. In a blinded study, urine samples from 25 patients with suspicious bladder lesions that had been identified cystoscopically were analyzed by this molecular method and by conventional cytology. Microsatellite changes matching those in the tumor were detected in the urine sediment of 19 of the 20 patients (95 percent) who were diagnosed with bladder cancer, whereas urine cytology detected cancer cells in 9 of 18 (50 percent) of the samples. These results suggest that microsatellite analysis, which in principle can be performed at about one-third the cost of cytology, may be a useful addition to current screening methods for detecting bladder cancer.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT UROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BORING CC, 1995, CA CANC J CLIN, V45, P8; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHANG WYH, 1995, CANCER RES, V55, P3246; ELBOLKAINY MN, 1980, J UROLOGY, V124, P20, DOI 10.1016/S0022-5347(17)55271-4; FARROW GM, 1976, CANCER RES, V36, P2495; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HOPKINS SC, 1983, J UROLOGY, V130, P61, DOI 10.1016/S0022-5347(17)50953-2; HRUBAN RH, 1994, NEW ENGL J MED, V330, P1276, DOI 10.1056/NEJM199405053301805; KNOWLES MA, 1994, CANCER RES, V54, P531; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; MOORE LE, 1993, ENVIRON MOL MUTAGEN, V22, P130, DOI 10.1002/em.2850220304; MURPHY WM, 1984, CANCER, V53, P1555, DOI 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G; PAPANICOLAOU GN, 1945, SCIENCE, V101, P519, DOI 10.1126/science.101.2629.519; ROSIN MP, 1995, CANCER RES, V55, P5213; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P163, DOI 10.1016/0165-4608(86)90384-5; SARNACKI CT, 1971, J UROLOGY, V106, P761, DOI 10.1016/S0022-5347(17)61391-0; SIDRANSKY D, 1992, UROL CLIN N AM, V19, P629; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; TSAI YC, 1990, CANCER RES, V50, P44; WENZ HM, 1994, NUCLEIC ACIDS RES, V22, P4002, DOI 10.1093/nar/22.19.4002; WHEELESS LL, 1994, CYTOMETRY, V17, P319, DOI 10.1002/cyto.990170407; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU SQ, 1991, CANCER RES, V51, P3323	30	345	392	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					659	662		10.1126/science.271.5249.659	http://dx.doi.org/10.1126/science.271.5249.659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571131				2022-12-28	WOS:A1996TT87000050
J	Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC				Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC			Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; EXPERIENCE; PREGNANCY; TOXICITY	Background Crohn's ulcerative gastrointestinal disease is presently managed through a variety of medical interventions, including-according to severity of illness-anti-inflammatory, immunosuppressive, and corticosteroid agents; and with remedial surgery to correct anatomical abnormalities caused by disease processes. The immunosuppressant azathioprine (or its metabolite, 6-mercaptopurine) is considered an efficient maintenance therapy for Crohn's, but there is always concern about bone-marrow suppression, liver damage, and other adverse effects. For how long persons with this disease should be given these drugs has not been determined. Methods Patients who were treated with azathioprine or 6-mercaptopurine for more than 6 months, and who were in prolonged clinical remission (>6 months without steroids) were followed. The time-to-relapse was analysed in those on treatment, in those who stopped treatment for reasons other than a relapse, and in the whole sample, taking into account that they could be treated with the drugs or not, as a function of time. The influence of concomitant variables on time-to-relapse rate was examined using the Cox proportional hazard model. Findings In the 157 patients who continued to take the therapy, cumulative probabilities of relapse al 1 and 5 years were 11% and 32% respectively. Female gender, younger age, and a time for achieving remission more than 6 months were associated with a higher risk of relapse. In 42 patients who stopped therapy, probabilities of relapse at 1 and 5 years were 38% and 75%, respectively. Male gender, younger age and duration of remisson less than 4 years were associated with a higher risk of relapse. After 4 years of remission on these drugs, the risk of relapse appeared to be similar, whether the therapy was maintained or stopped. Interpretation Taking into account the potential risks of long-term immunosuppressive therapy, the usefulness of maintaining azathioprine or 6-mercaptopurine in patients who have been in remission for more than 4 years is questionable.	HOP ST LOUIS,SERV GASTROENTEROL,F-75010 PARIS,FRANCE; HOP ST LAZARE,SERV GASTROENTEROL,F-75475 PARIS,FRANCE; UNIV PARIS 07,INSERM,U263,CTR BIOINFORMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; ALTMAN DG, 1994, STAT MED, V13, P201; BYAR DP, 1988, CANCER CLIN TRIALS, P382; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; COTTONE M, 1994, GASTROENTEROLOGY, V106, P643, DOI 10.1016/0016-5085(94)90697-1; EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GAUDIER FL, 1988, SURG GYNECOL OBSTET, V167, P533; HARVEY RF, 1980, LANCET, V1, P514; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KORELITZ BI, 1993, AM J GASTROENTEROL, V88, P1198; LARVOL L, 1994, NEW ENGL J MED, V331, P883, DOI 10.1056/NEJM199409293311321; LEB DE, 1971, ARCH INTERN MED, V128, P441, DOI 10.1001/archinte.128.3.441; LEMANN M, 1990, GASTROEN CLIN BIOL, V14, P548; LENNARDJONES JE, 1981, DIGEST DIS SCI, V77, P364; LILLEYMAN JS, 1994, LANCET, V343, P1188, DOI 10.1016/S0140-6736(94)92400-7; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; NYMAN M, 1985, SCAND J GASTROENTERO, V20, P1197, DOI 10.3109/00365528509089276; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; ODONOGHUE DP, 1978, LANCET, V2, P944; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; REIMERS TJ, 1978, SCIENCE, V201, P65, DOI 10.1126/science.663638; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; TUCHMANNDUPLESS.H, 1966, CR SOC BIOL, V166, P501	27	405	412	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					215	219		10.1016/S0140-6736(96)90402-X	http://dx.doi.org/10.1016/S0140-6736(96)90402-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551879				2022-12-28	WOS:A1996TT06900008
J	Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB				Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB			The 2.0 angstrom crystal structure of a heterotrimeric G protein	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; BETA-GAMMA; SIGNAL TRANSDUCTION; LIPID MODIFICATIONS; AMINO TERMINUS; GTP-BINDING; PHOSPHODIESTERASE; IDENTIFICATION	The structure of a heterotrimeric G protein reveals the mechanism of the nucleotide-dependent engagement of the alpha and beta gamma subunits that regulates their interaction with receptor and effector molecules. The interaction involves two distinct interfaces and dramatically alters the conformation of the alpha but not of the beta gamma subunits. The location of the known sites for post-translational modification and receptor coupling suggest a plausible orientation with respect to the membrane surface and an activated heptahelical receptor.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BRUNGER A, 1993, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	56	1006	1028	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					311	319		10.1038/379311a0	http://dx.doi.org/10.1038/379311a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552184				2022-12-28	WOS:A1996TR32300049
J	Hayden, FG; Treanor, JJ; Betts, RF; Lobo, M; Esinhart, JD; Hussey, EK				Hayden, FG; Treanor, JJ; Betts, RF; Lobo, M; Esinhart, JD; Hussey, EK			Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS NEURAMINIDASE; ACID; AMANTADINE; PROPHYLAXIS; ADULTS	Objective. - The current study evaluated whether intranasal administration of the sialic acid analog 4-guanidino-Neu5Ac2en (GG167), an inhibitor of influenza virus neuraminidase, was effective and safe in either preventing or treating experimental human influenza. Methods. - Four randomized, double-blind, placebo-controlled trials involving three prophylaxis limbs, two early treatment limbs, and one delayed treatment limb were conducted. Setting. - Isolation in individual rooms. Participants. - Susceptible (serum hemagglutination-inhibition antibody titer less than or equal to 1:8) adult volunteers (n=166) were inoculated intranasally with 10(5) TCID50 influenza A/Texas/91 (H1N1) virus. Intervention. - GG167, 3.6 to 16 mg, was administered intranasally two or six times daily beginning 4 hours before inoculation (prophylaxis) or 1 or 2 days afterward (early or delayed treatment). Main Outcomes. - Virological measures were frequency of infection based on viral shedding and/or seroconversion (prophylaxis) or quantitative viral shedding based on titers and duration of virus recovery (treatment). Clinical measures were the frequency of febrile illness and symptom severity scores. Results. - Intranasal GG167 was well tolerated for both prophylaxis and therapy, For all dose groups combined, GG167 prophylaxis was 82% effective in preventing laboratory evidence of infection and 95% effective in preventing febrile illness (P<.01 vs placebo). Early treatment with GG167 reduced peak viral titers by 2.0 log(10), the median duration of viral shedding by 3 days, and the frequency of febrile illness by 85% (P<.05 for each comparison). Other measures of illness were reduced by approximately 50% to 70% in the GG167 dosing groups. Twice daily dosing was as effective as six times daily. Conclusions. - Direct respiratory administration of the selective neuraminidase inhibitor GG167 appears safe and effective for both prevention and early treatment of experimental influenza. Influenza virus neuraminidase is important for viral replication in humans.	UNIV ROCHESTER,SCH MED,ROCHESTER,NY; GLAXO RES INST,RES TRIANGLE PK,NC	University of Rochester; GlaxoSmithKline	Hayden, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,BOX 473,CHARLOTTESVILLE,VA 22908, USA.							[Anonymous], ANTIMICROB AGENTS CH; AOKI FY, 1976, BRIT J CLIN PHARMACO, V3, P869, DOI 10.1111/j.1365-2125.1976.tb00640.x; BEUTNER KR, 1979, J INFECT DIS, V140, P844, DOI 10.1093/infdis/140.6.844; BURNET FM, 1948, AUST J EXP BIOL MED, V26, P381, DOI 10.1038/icb.1948.39; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; COUCH RB, 1974, J INFECT DIS, V129, P411, DOI 10.1093/infdis/129.4.411; DAWKINS AT, 1968, J AMER MED ASSOC, V203, P1095, DOI 10.1001/jama.203.13.1095; DOUGLAS RG, 1990, NEW ENGL J MED, V322, P443, DOI 10.1056/NEJM199002153220706; EFTHYMIOPOULOS C, 1994, 34TH INT C ANT AG CH; HARDY JG, 1985, J PHARM PHARMACOL, V37, P294, DOI 10.1111/j.2042-7158.1985.tb05069.x; HAYDEN FG, 1994, ANTIMICROB AGENTS CH, V38, P1178, DOI 10.1128/AAC.38.5.1178; HAYDEN FG, 1994, ANTIVIR RES, V25, P123, DOI 10.1016/0166-3542(94)90101-5; HAYDEN FG, 1994, TXB RESP MED, V1, P977; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; LIU CG, 1993, VIROLOGY, V194, P403, DOI 10.1006/viro.1993.1276; LIU CG, 1995, J VIROL, V69, P1099, DOI 10.1128/JVI.69.2.1099-1106.1995; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; MONTO AS, 1973, LANCET, V1, P623, DOI 10.1016/S0140-6736(73)92196-X; MURPHY BR, 1972, NEW ENGL J MED, V286, P1329, DOI 10.1056/NEJM197206222862502; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; PALESE P, 1976, J GEN VIROL, V33, P159, DOI 10.1099/0022-1317-33-1-159; PALESE P, 1974, VIROLOGY, V59, P490, DOI 10.1016/0042-6822(74)90458-9; PALESE P, 1977, CHEMOPROPHYLAXIS VIR, P189; REUMAN PD, 1989, ANTIVIR RES, V11, P27, DOI 10.1016/0166-3542(89)90018-1; RYAN DM, 1994, ANTIMICROB AGENTS CH, V38, P2270, DOI 10.1128/AAC.38.10.2270; SCHULMAN JL, 1968, J VIROL, V2, P778, DOI 10.1128/JVI.2.8.778-786.1968; SEARS SD, 1987, ANTIMICROB AGENTS CH, V31, P1470, DOI 10.1128/AAC.31.10.1470; SETO JT, 1966, VIROLOGY, V30, P731, DOI 10.1016/0042-6822(66)90178-4; SHENGQIANG LI, 1993, J VIROL, V67, P6667; SMORODINTSEV AA, 1970, J AMER MED ASSOC, V213, P1448, DOI 10.1001/jama.213.9.1448; SPERBER SJ, 1988, J INFECT DIS, V158, P166, DOI 10.1093/infdis/158.1.166; THOMAS GP, 1994, ANTIVIR RES, V24, P351, DOI 10.1016/0166-3542(94)90081-7; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WEBSTER RG, 1988, VIROLOGY, V164, P230, DOI 10.1016/0042-6822(88)90640-X; WOODS JM, 1993, ANTIMICROB AGENTS CH, V37, P1473, DOI 10.1128/AAC.37.7.1473	38	240	250	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					295	299		10.1001/jama.275.4.295	http://dx.doi.org/10.1001/jama.275.4.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544269				2022-12-28	WOS:A1996TP96500025
J	Price, D				Price, D			Lessons for health care rationing from the case of child B	BRITISH MEDICAL JOURNAL			English	Article								More details have emerged about the child B leukaemia case with the publication of the All England Law Report on the Appeal Court decision. At the time the view was widely held that the controversy might have been avoided if the responsible health authority had consulted the public. The law report reveals, however, that the courts adopted a moral language widely at variance with that of the patient's doctor. The courts were concerned to support a utilitarian decision procedure based on calculations of the greatest overall good; the doctor was concerned with the best interests of a sick child. The doctor-patient relationship may be damaged when public consideration transforms the issue in this way. Also, the Appeal Court supported a decision which claimed to have ''weighed'' opposing evaluations, but it excused the health authority from describing how that weighing took place. One of the main criticisms of the utilitarian approach, however, is that weighing of this type is extremely difficult to justify. By its ruling the court has made legal challenge on the grounds of inadequate consultation virtually impossible to substantiate.			Price, D (corresponding author), NORTHUMBRIA UNIV,SOCIAL WELFARE RES UNIT,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND.		Price, Donald D./A-3094-2008	Price, Donald D./0000-0002-8971-7184				HALL C, 1995, INDEPENDENT     0311, P1; SMITH R, 1995, BRIT MED J, V310, P686, DOI 10.1136/bmj.310.6981.686	2	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					167	169						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563539				2022-12-28	WOS:A1996TR32500027
J	Theriot, JA				Theriot, JA			Worm sperm and advances in cell locomotion	CELL			English	Review							AMEBOID SPERM; ASCARIS-SUUM; CAENORHABDITIS-ELEGANS; PROTEIN MSP; NEMATODE; ACTIN; CYTOSKELETON				Theriot, JA (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535				CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Foor W. E., 1970, Biol Reprod, V2, P177, DOI 10.1095/biolreprod2.Supplement_2.177; HEATH J P, 1992, Current Biology, V2, P301, DOI 10.1016/0960-9822(92)90877-D; Italiano JE, 1996, CELL, V84, P105, DOI 10.1016/S0092-8674(00)80997-6; KING KL, 1994, J CELL SCI, V107, P2941; KING KL, 1994, CELL MOTIL CYTOSKEL, V27, P193, DOI 10.1002/cm.970270302; KING KL, 1992, J CELL SCI, V101, P847; KLASS MR, 1981, DEV BIOL, V84, P299, DOI 10.1016/0012-1606(81)90398-5; LHEMAULT SW, 1996, IN PRESS NEMATODE C, V2; NELSON GA, 1982, J CELL BIOL, V92, P121, DOI 10.1083/jcb.92.1.121; NELSON GA, 1981, EXP CELL RES, V131, P149, DOI 10.1016/0014-4827(81)90415-8; ROBERTS TM, 1995, CURR OPIN CELL BIOL, V7, P13, DOI 10.1016/0955-0674(95)80039-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; SCOTT AL, 1989, PARASITOLOGY, V98, P471, DOI 10.1017/S0031182000061564; SEPSENWOL S, 1989, J CELL BIOL, V108, P55, DOI 10.1083/jcb.108.1.55; STEWART M, 1994, J MOL BIOL, V242, P60; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2	18	42	44	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					1	4		10.1016/S0092-8674(00)80068-9	http://dx.doi.org/10.1016/S0092-8674(00)80068-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548813	Bronze			2022-12-28	WOS:A1996TQ17000001
J	Vescovi, EG; Soncini, FC; Groisman, EA				Vescovi, EG; Soncini, FC; Groisman, EA			Mg2+ as an extracellular signal: Environmental regulation of Salmonella virulence	CELL			English	Article							ESCHERICHIA-COLI; MAGNESIUM-METABOLISM; EPITHELIAL-CELLS; TYPHIMURIUM; EXPRESSION; TRANSPORT; PROTEINS; BACTERIA; GENE; MACROPHAGES	Ions are not traditionally thought to act as first messengers in signal transduction cascades. However, while searching for genes regulated by the PhoP/PhoQ virulence regulatory system of Salmonella typhimurium, we recovered two loci whose expression is controlled by the concentration of Mg2+. To determine whether Mg2+ is the signal modulating the whole PhoP/ phoQ system, we evaluated the gene expression pattern of six PhoP-activated genes. Growth in physiological concentrations of divalent cations repressed transcription of PhoP-activated genes and rendered wild-type Salmonella phenotypically PhoP(-). Mg2+ changed the conformation of the periplasmic domain of phoQ, identifying this protein as a Mg2+ sensor. A mutation in the sensing domain of phoQ altered the set point for Mg2+ and rendered Salmonella avirulent.			Vescovi, EG (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.			Soncini, Fernando/0000-0002-8925-7763; Garcia Vescovi, Eleonora/0000-0002-4431-8606	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029554] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; Brown Edward M., 1994, P15; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Davis R., 1980, ADV BACTERIAL GENETI; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FOSTER JW, 1990, J BACTERIOL, V172, P771, DOI 10.1128/jb.172.2.771-778.1990; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; GROISMAN EA, 1992, J BACTERIOL, V174, P486, DOI 10.1128/jb.174.2.486-491.1992; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; HEBERT SC, 1995, CURR OPIN CELL BIOL, V7, P484, DOI 10.1016/0955-0674(95)80004-2; KIER LD, 1979, J BACTERIOL, V138, P155, DOI 10.1128/JB.138.1.155-161.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller J. H, 1972, EXPT MOL GENETICS; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; NORRIS V, 1991, MOL MICROBIOL, V5, P775, DOI 10.1111/j.1365-2958.1991.tb00748.x; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; RATHMAN M, 1995, 95TH GEN M WASH; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; ROOF SK, 1994, J AM COLL NUTR, V13, P424; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SILVER S, 1971, J BIOL CHEM, V246, P569; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VESCOVI EG, 1994, RES MICROBIOL, V145, P473, DOI 10.1016/0923-2508(94)90096-5; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x	47	628	641	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					165	174		10.1016/S0092-8674(00)81003-X	http://dx.doi.org/10.1016/S0092-8674(00)81003-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548821	Bronze			2022-12-28	WOS:A1996TQ17000019
J	Sharpe, M; Hawton, K; Simkin, S; Surawy, C; Hackmann, A; Klimes, I; Peto, T; Warrell, D; Seagroatt, V				Sharpe, M; Hawton, K; Simkin, S; Surawy, C; Hackmann, A; Klimes, I; Peto, T; Warrell, D; Seagroatt, V			Cognitive behaviour therapy for the chronic fatigue syndrome: A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; PAIN	Objective-To evaluate the acceptability and efficacy of adding cognitive behaviour therapy to the medical care of patients presenting with the chronic fatigue syndrome. Design-Randomised controlled trial with final assessment at 12 months. Setting-An infectious diseases outpatient clinic. Subjects-60 consecutively referred patients meeting consensus criteria for the chronic fatigue syndrome. Interventions-Medical care comprised assessment, advice, and follow up in general practice. Patients who received cognitive behaviour therapy were offered 16 individual weekly sessions in addition to their medical care. Main outcome measures-The proportions of patients (a) who achieved normal daily functioning (Karnofsky score 80 or more) and (b) who achieved a clinically significant improvement in functioning (change in Karnofsky score 10 points or more) by 12 months after randomisation. Results-Only two eligible patients refused to participate. All randomised patients completed treatment. An intention to treat analysis showed that 73% (22/30) of recipients of cognitive behaviour therapy achieved a satisfactory outcome as compared with 27% (8/30) of patients who were given only medical care (difference 47 percentage points; 95% confidence interval 24 to 69). Similar differences were observed in subsidiary outcome measures. The improvement in disability among patients given cognitive behaviour therapy continued after completion of therapy. illness beliefs and coping behaviour previously associated with a poor outcome changed more with cognitive behaviour therapy than with medical care alone. Conclusion-Adding cognitive behaviour therapy to the medical care of patients with the chronic fatigue syndrome is acceptable to patients and leads to a sustained reduction in functional impairment.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,UNIT HLTH CARE EPIDEMIOL,OXFORD OX3 7JX,ENGLAND	University of Oxford; University of Oxford	Sharpe, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.			sharpe, michael/0000-0002-6474-9980	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECK AT, 1979, COGNITIVE THERAPY DE; BONNER D, 1994, J NEUROL NEUROSUR PS, V57, P617, DOI 10.1136/jnnp.57.5.617; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; FRIEDBERG F, 1994, CLIN INFECT DIS   S1, V18, P105; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GRIECO A, 1984, HEALTH PSYCHOL, V3, P129, DOI 10.1037/0278-6133.3.2.129; HOLLON SD, 1991, J CONSULT CLIN PSYCH, V59, P88, DOI 10.1037/0022-006X.59.1.88; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; LLOYD AR, 1988, LANCET, V1, P1286; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SHARPE MC, IN PRESS PSYCHIATR C; SHARPE MC, 1995, J MUSCULOSKELET PAIN, V3, P141; SPITZER RL, 1986, INSTRUCTION MANUAL S; STREINER DL, 1995, CAN J PSYCHIAT, V40, P60; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; TAIT RC, 1987, ARCH PHYS MED REHAB, V68, P438; THOMAS PK, 1993, BMJ-BRIT MED J, V306, P1557, DOI 10.1136/bmj.306.6892.1557; TURNER JA, 1988, J CONSULT CLIN PSYCH, V56, P261, DOI 10.1037/0022-006X.56.2.261; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1989, J ROY COLL GEN PRACT, V39, P26; WILSON A, 1994, AM J MED, V96, P544, DOI 10.1016/0002-9343(94)90095-7; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1987, DIAGNOSTIC STATISTIC	30	342	344	0	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					22	26		10.1136/bmj.312.7022.22	http://dx.doi.org/10.1136/bmj.312.7022.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP209	8555852	Green Published			2022-12-28	WOS:A1996TP20900018
J	Hiss, RG; Greenfield, S				Hiss, RG; Greenfield, S			Forum three: Changes in the US health care system that would facilitate improved care for non-insulin-dependent diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				At the conclusion of the conference detailed in this supplement, conference attendees participated in one of three fora to discuss an assigned topic and incorporate conference presentations into the discussion. Forum Three, the results of which are reported here, addressed the challenging question of what changes in the U.S. health care system would facilitate improved care for patients with non-insulin-dependent diabetes mellitus (NIDDM). Using the nominal group process-a discussion technique designed to obtain a rank-ordered list of responses to the challenge question from a group of informed persons-forum Three made the following priority recommendations: 1) Establish universal access to the comprehensive preventive services necessary to optimally manage the estimated 16 million Americans with NIDDM; 2) create a system of co-management between primary and specialty care services; and 3) modify the current health care system to include a program for increased patient and public awareness of the seriousness of NIDDM, special training for primary care residents and practicing physicians in this area, development of standards of care, creation of a central coordinating agency for all aspects of diabetes care, and development of outcome-based goals for patients and providers.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI USA	Tufts Medical Center; University of Michigan System; University of Michigan				Greenfield, Sheldon/0000-0003-4628-1998				BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; DELBECQ AL, 1971, J APPL BEHAV SCI, V7, P466, DOI 10.1177/002188637100700404; FISHER EB, 1994, NIH943773 NAT I DIAB, P101; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, IN PRESS JAMA; HISS RG, 1994, DIABETES REV, V2, P310; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; 1989, NIH892925 US DEP HLT; 1976, DHEW781086 NAT HEART; 1976, DHEW761018 US DEP HL; 1995, DIABETES CARE S1, V18, P1	11	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				180	183		10.7326/0003-4819-124-1_Part_2-199601011-00021	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554216				2022-12-28	WOS:A1996TL94400021
J	Thanos, D; Maniatis, T				Thanos, D; Maniatis, T			Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome	CELL			English	Article							FACTOR-BINDING-SITES; NF-KAPPA-B; REGULATORY ELEMENTS; INTERFERON GENE; ACTIVATION; PROMOTER; IRF-1; TRANSCRIPTION; DOMAINS; CELLS	We present evidence that transcriptional activation of the human interferon-beta (IFN beta) gene requires the assembly of a higher order transcription enhancer complex (enhanceosome). This multicomponent complex includes at least three distinct transcription factors and the high mobility group protein HMG I(Y). Both the in vitro assembly and in vivo transcriptional activity of this complex require a precise helical relationship between individual transcription factor-binding sites. In addition, HMG I(Y), which binds specifically to three sites within the enhancer, promotes cooperative binding of transcription factors in vitro and is required for transcriptional synergy between these factors in vivo. Thus, HMG I(Y) plays an essential role in the assembly and function of the IFN beta gene enhanceosome.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Li, Yapeng/N-1042-2017; Thanos, Dimitris/AAE-5720-2019	Li, Yapeng/0000-0002-5042-6881; 	NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CORBIN V, 1990, GENETICS, V124, P637; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GONZALEZCRESPO S, 1994, SCIENCE, V264, P255, DOI 10.1126/science.8146656; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKINIGHT SL, 1982, TRANSCRIPTIONAL REGU; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MEACOCK S, 1994, J BIOL CHEM, V269, P31756; Miller J.H., 1972, EXPT MOL GENETICS; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; ONDEK B, 1988, NATURE, V333, P42; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PTASHNE M, 1992, GENETIC SWITCH GENE; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SZYMANSKI K, 1995, EMBO J, V10, P2229; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THANOS D, 1993, COLD SPRING HARB SYM, V58, P733; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266	53	846	853	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1091	1100		10.1016/0092-8674(95)90136-1	http://dx.doi.org/10.1016/0092-8674(95)90136-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548797	Bronze			2022-12-28	WOS:A1995TM76200006
J	Haslam, F				Haslam, F			Views from the gallery	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1712	1713		10.1136/bmj.311.7021.1712	http://dx.doi.org/10.1136/bmj.311.7021.1712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541771	Green Published			2022-12-28	WOS:A1995TL94200033
J	Levine, M; Gent, M; Hirsh, J; Leclerc, J; Anderson, D; Weitz, J; Ginsberg, J; Turpie, AG; Demers, C; Kovacs, M; Geerts, W; Kassis, J; Desjardins, L; Cusson, J; Cruickshank, M; Powers, P; Brien, W; Haley, S; Willan, A				Levine, M; Gent, M; Hirsh, J; Leclerc, J; Anderson, D; Weitz, J; Ginsberg, J; Turpie, AG; Demers, C; Kovacs, M; Geerts, W; Kassis, J; Desjardins, L; Cusson, J; Cruickshank, M; Powers, P; Brien, W; Haley, S; Willan, A			A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS STANDARD HEPARIN; VENOUS THROMBOSIS; PULMONARY-EMBOLISM	Background Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use. We compared these two approaches. Methods. Patients with acute proximal deep-vein thrombosis were randomly assigned to receive either intravenous standard heparin in the hospital (253 patients) or low-molecular-weight heparin (1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily) administered primarily at home (247 patients). The study design allowed outpatients taking low-molecular-weight heparin to go home immediately and hospitalized patients taking low-molecular-weight heparin to be discharged early. All the patients received warfarin starting on the second day. Thirteen of the 247 patients receiving low-molecular-weight heparin (5.3 percent) had recurrent thromboembolism, as compared with 17 of the 253 patients receiving standard heparin (6.7 percent; P=0.57; absolute difference, 1.4 percentage points; 95 percent confidence interval, -3.0 to 5.7). Five patients receiving low-molecular-weight heparin had major bleeding, as compared with three patients receiving standard heparin. After randomization, the patients who received low-molecular-weight heparin spent a mean of 1.1 days in the hospital, as compared with 6.5 days for the standard-heparin group; 120 patients in the low-molecular-weight-heparin group did not need to be hospitalized at all. Conclusions. Low-molecular-weight heparin can be used safely and effectively to treat patients with proximal deep-vein thrombosis at home.	MCMASTER UNIV,HAMILTON,ON,CANADA; HAMILTON CIV HOSP,RES CTR,HAMILTON,ON,CANADA; MCGILL UNIV,MONTREAL,PQ,CANADA; DALHOUSIE UNIV,HALIFAX,NS,CANADA; UNIV LAVAL,QUEBEC CITY,PQ,CANADA; UNIV WESTERN ONTARIO,LONDON,ON,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; UNIV MONTREAL,MONTREAL,PQ,CANADA	McMaster University; McMaster University; McGill University; Dalhousie University; Laval University; Western University (University of Western Ontario); University of Toronto; Universite de Montreal	Levine, M (corresponding author), ONTARIO CANC TREATMENT & RES FDN,HAMILTON REG CANC CTR,699 CONCESS ST,HAMILTON,ON L8V 5C2,CANADA.		Weitz, Jeffrey/AAD-1929-2019; Kovacs, Michael/G-3315-2011; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; BONEU B, 1988, SEMIN THROMB HEMOST, V14, P8; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; HIRSH J, 1976, CIRCULATION, V53, P691, DOI 10.1161/01.CIR.53.4.691; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HOLM HA, 1986, HAEMOSTASIS, V16, P30; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; LAGERSTEDT CI, 1985, LANCET, V2, P515; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; PINI M, 1994, THROMB HAEMOSTASIS, V72, P191; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639	22	979	1014	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					677	681		10.1056/NEJM199603143341101	http://dx.doi.org/10.1056/NEJM199603143341101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594425				2022-12-28	WOS:A1996TZ52800001
J	Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C				Ramachandran, VS; Tyler, CW; Gregory, RL; RogersRamachandran, D; Duensing, S; Pillsbury, C; Ramachandran, C			Rapid adaptive camouflage in tropical flounders	NATURE			English	Article								Despite the commonly held view that flatfish can change their surface markings to match their background pattern(1), there have been few systematic studies(2,3) and it has recently been claimed(4) that their capacity for such adaptive changes is minimal. Here we show that the tropical flatfish Bothus ocellatus can achieve pattern-matching with surprising fidelity. By adjusting the contrast of different sets of 'splotches' of different grain size (or spatial frequency) on the skin, the fish can blend into a wide range of background textures in just 2-8 seconds.			Ramachandran, VS (corresponding author), UNIV CALIF SAN DIEGO,BRAIN & PERCEPT LAB,0109,,LA JOLLA,CA 92093, USA.							BOMFORD L, 1992, CAMOUFLAGE COLOR; Mast S. O., 1916, Bulletin of the Bureau of Fisheries Washington, V34; PACKARD A, 1995, CEPHALOPOD NEUROBIOL, P231; SAIDEL WM, 1988, SENSORY BIOL AQUATIC; SAIDEL WM, 1977, THESIS MIT CAMBRIDGE; Sumner F. B., 1911, Journal of Experimental Zoology Philadelphia, V10, DOI 10.1002/jez.1400100405	6	89	98	3	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					815	818		10.1038/379815a0	http://dx.doi.org/10.1038/379815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587602				2022-12-28	WOS:A1996TX50100055
J	Baukrowitz, T; Yellen, G				Baukrowitz, T; Yellen, G			Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel	SCIENCE			English	Article							POTASSIUM CHANNELS; MOLECULAR MECHANISMS; LOCAL-ANESTHETICS; CALCIUM CHANNELS; INACTIVATION	Quaternary ammonium blockers inhibit many voltage-activated potassium (K+) channels from the intracellular side. When applied to Drosophila Shaker potassium channels expressed in mammalian cells, these rapidly reversible blockers produced use-dependent inhibition through an unusual mechanism-they promoted an intrinsic conformational change known as C-type inactivation, from which recovery is slow. The blockers did so by cutting off potassium ion flow to a site in the pore, which then emptied at a rate of 10(5) ions per second. This slow rate probably reflected the departure of the last ion from the multi-ion pore: Permeation of ions (at 10(7) per second) occurs rapidly because of ion-ion repulsion, but the last ion to leave would experience no such repulsion.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School				Baukrowitz, Thomas/0000-0003-4562-0505; Yellen, Gary/0000-0003-4228-7866	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029693] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS029693, NS29693] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; BAUKROWITZ T, UNPUB; BIGGER JT, 1985, PHARM BASIS THERAPEU, pCH31; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLATSKY TJ, 1990, CIRCULATION, V82, P2235, DOI 10.1161/01.CIR.82.6.2235; Crank J., 1975, MATH DIFFUSION; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HILLE B, 1992, IONIC CHANNELS EXCIT, pCH11; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; LABARCA P, 1992, Biophysical Journal, V61, pA378; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MACDONALD RL, 1989, EPILEPSIA, V30, pS19, DOI 10.1111/j.1528-1157.1989.tb05810.x; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; YELLEN G, 1984, J GEN PHYSIOL, V84, P187, DOI 10.1085/jgp.84.2.187; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	28	194	195	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					653	656		10.1126/science.271.5249.653	http://dx.doi.org/10.1126/science.271.5249.653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571129				2022-12-28	WOS:A1996TT87000048
J	Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM				Hotamisligil, GS; Peraldi, P; Budavari, A; Ellis, R; White, MF; Spiegelman, BM			IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELLS; IRS-1	Tumor necrosis factor-alpha (TNF-alpha) is an important mediator of insulin resistance in obesity and diabetes through its ability to decrease the tyrosine kinase activity of the insulin receptor (IR). Treatment of cultured murine adipocytes with TNF-alpha was shown to induce serine phosphorylation of insulin receptor substrate 1 (IRS-1) and convert IRS-1 into an inhibitor of the IR tyrosine kinase activity in vitro. Myeloid 32D cells, which lack endogenous IRS-1, were resistant to TNF-alpha-mediated inhibition of IR signaling, whereas transfected 32D cells that express IRS-1 were very sensitive to this effect of TNF-alpha. An inhibitory form of IRS-1 was observed in muscle and fat tissues from obese rats. These results indicate that TNF-alpha induces insulin resistance through an unexpected action of IRS-1 to attenuate insulin receptor signaling.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Robles-Sardin, Alma E/M-7714-2015; Peraldi, Pascal/O-4592-2016	Robles-Sardin, Alma E/0000-0003-2044-7793; Peraldi, Pascal/0000-0003-0205-9252	NIDDK NIH HHS [DK 42539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEGUM N, 1995, DIABETES, V44, pA140; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOUGLAS RG, 1991, AM J PHYSIOL, V261, pE606, DOI 10.1152/ajpendo.1991.261.5.E606; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, UNPUB; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRODER G, 1995, DIABETES, V44, pA264; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Moller DE, 1993, INSULIN RESISTANCE; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1	27	2023	2109	6	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					665	668		10.1126/science.271.5249.665	http://dx.doi.org/10.1126/science.271.5249.665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571133				2022-12-28	WOS:A1996TT87000052
J	Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF				Klein, MG; Cheng, H; Santana, LF; Jiang, YH; Lederer, WJ; Schneider, MF			Two mechanisms of quantized calcium release in skeletal muscle	NATURE			English	Article							FROG TWITCH FIBERS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; ANTIPYRYLAZO-III; CHARGE MOVEMENT; CHANNEL; PURIFICATION; SIGNALS	SKELETAL muscle uses voltage sensors in the transverse tubular membrane(1-3) that are linked by protein-protein interactions(4-6) to intracellular ryanodine receptors(7-10), which gate the release of calcium from the sarcoplasmic reticulum. Here we show, by using voltage-clamped single fibres and confocal imaging, that sto chastic calcium-release events, visualized as Ca2+ sparks, occur in skeletal muscle and originate at the tried. Unitary triadic Ca2+-release events are initiated by the voltage sensor in a steeply voltage-dependent manner, or occur spontaneously by a mechanism independent of the voltage sensor. Large amplitude events also occur during depolarization and consist of two or more unitary events. We propose a 'dual-control' model for discrete Ca2+ release events from the sacroplasmic reticulum that unifies diverse observations about Ca2+-signalling in frog skeletal muscle, and that may be applicable to other excitable cells.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Santana, Luis/AAF-9298-2019; Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010	Santana, Luis/0000-0002-4297-8029; Heping, Cheng/0000-0002-9604-6702; 				BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; ENDO M, 1966, J PHYSIOL-LONDON, V185, P224, DOI 10.1113/jphysiol.1966.sp007983; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIAMSTRON.C, 1994, REV PHYSL, V56, P509; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; IRVING M, 1987, J GEN PHYSIOL, V89, P1, DOI 10.1085/jgp.89.1.1; KLEIN MG, 1990, J PHYSIOL-LONDON, V425, P599, DOI 10.1113/jphysiol.1990.sp018120; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MAYLIE J, 1987, J GEN PHYSIOL, V89, P83, DOI 10.1085/jgp.89.1.83; MAYLIE J, 1991, J PHYSIOL-LONDON, V442, P551, DOI 10.1113/jphysiol.1991.sp018808; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MINTA A, 1989, J BIOL CHEM, V264, P8171; PIZARRO G, 1991, J GEN PHYSIOL, V97, P913, DOI 10.1085/jgp.97.5.913; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P747; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; STEM MD, 1992, BIOPHYS J, V63, P497; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901	31	273	282	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					455	458		10.1038/379455a0	http://dx.doi.org/10.1038/379455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559251				2022-12-28	WOS:A1996TT30400061
J	Mirenowicz, J; Schultz, W				Mirenowicz, J; Schultz, W			Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli	NATURE			English	Article							NUCLEUS-ACCUMBENS; VENTRAL STRIATUM; MONKEY; RESPONSES; REWARD; INVIVO; MICRODIALYSIS; AMYGDALA; PRIMATE; COMPLEX	MIDBRAIN dopamine systems are crucially involved in motivational processes underlying the learning and execution of goal-directed behaviour(1-5). Dopamine neurons in monkeys are uniformly activated by unpredicted appetitive stimuli such as food and liquid rewards and conditioned, reward-predicting stimuli. By contrast, fully predicted stimuli are ineffective(6-8), and the omission of predicted reward depresses their activity(9). These characteristics follow associative-learning rules(10,11), suggesting that dopamine responses report an error in reward prediction(12). Accordingly, neural network models are efficiently trained using a dopamine-like reinforcement signal(13,14). However, it is unknown whether the responses to environmental stimuli concern specific motivational attributes or reflect more general stimulus salience(4,15). To resolve this, we have compared dopamine impulse responses to motivationally opposing appetitive and aversive stimuli. In contrast to appetitive events, primary and conditioned non-noxious aversive stimuli either failed to activate dopamine neurons or, in cases of close resemblance with appetitive stimuli, induced weaker responses than appetitive stimuli. Thus, dopamine neurons preferentially report environmental stimuli with appetitive rather than aversive motivational value.	UNIV FRIBOURG,INST PHYSIOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								ABERCROMBIE ED, 1989, J NEUROCHEM, V52, P1655, DOI 10.1111/j.1471-4159.1989.tb09224.x; [Anonymous], 1992, SEMIN NEUROSCI; BENINGER RJ, 1983, SCIENCE, V220, P1304, DOI 10.1126/science.6857251; CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0; CHERGUI K, 1994, NEUROSCIENCE, V62, P641, DOI 10.1016/0306-4522(94)90465-0; CHURCH WH, 1987, BRAIN RES, V412, P397, DOI 10.1016/0006-8993(87)91150-4; DELONG MR, 1983, J NEUROSCI, V3, P1599; Dickinson A., 1980, CONT ANIMAL LEARNING; FREUND TF, 1984, NEUROSCIENCE, V13, P1189, DOI 10.1016/0306-4522(84)90294-X; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GAFFAN D, 1987, J NEUROSCI, V7, P2285; GARRIS PA, 1994, NEUROSCIENCE, V59, P417, DOI 10.1016/0306-4522(94)90606-8; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOUILOT A, 1986, BRAIN RES, V397, P395, DOI 10.1016/0006-8993(86)90646-3; MIRENOWICZ J, 1994, J NEUROPHYSIOL, V72, P1024, DOI 10.1152/jn.1994.72.2.1024; NISHIJO H, 1988, J NEUROSCI, V8, P3570; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SCHULTZ W, 1987, J NEUROPHYSIOL, V57, P201, DOI 10.1152/jn.1987.57.1.201; SCHULTZ W, 1983, EXP BRAIN RES S, V7, P171; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; YOUNG AMJ, 1992, NEUROSCIENCE, V48, P871, DOI 10.1016/0306-4522(92)90275-7; YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E; [No title captured]; [No title captured]	30	620	630	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					449	451		10.1038/379449a0	http://dx.doi.org/10.1038/379449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559249				2022-12-28	WOS:A1996TT30400059
J	Struhl, K				Struhl, K			Chromatin structure and RNA polymerase II connection: Implications for transcription	CELL			English	Review											Struhl, K (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2	15	149	151	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					179	182		10.1016/S0092-8674(00)80970-8	http://dx.doi.org/10.1016/S0092-8674(00)80970-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565061	Bronze			2022-12-28	WOS:A1996TR59500002
J	GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB				GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB			E-coli SSB activates N4 virion RNA polymerase promoters by stabilizing a DNA hairpin required for promoter recognition	CELL			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; PURIFICATION; REPLICATION; INITIATION	Bacteriophage N4 virion RNA polymerase transcription of double-stranded promoter-containing DNAs requires supercoiled template and E. coli single-stranded DNA-binding protein (EcoSSB); other single-stranded DNA-binding proteins cannot substitute. The DNA determinants of virion RNA polymerase binding at the promoter comprise a small template-strand hairpin. The requirement for EcoSSB is surprising, since single-stranded DNA-binding proteins destabilize hairpin structures. DNA footprinting of EcoSSB on wild-type and mutant promoters indicates that EcoSSB stabilizes the template-strand hairpin owing to the hairpin-loop sequences. Other single-stranded DNA-binding proteins destabilize the promoter hairpin, explaining the specificity of EcoSSB activation. We conclude that EcoSSB activates transcription by providing the appropriate DNA structure for polymerase binding. The existence of small hairpins stable to single-stranded protein binding suggests a novel mechanism that provides structural determinants for specific recognition in single-stranded DNA transactions by an otherwise nonspecific DNA-binding protein.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago	GlucksmannKuis, MA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007099, R01AI012575] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI12575, 5T32 AI 07099] Funding Source: Medline; NIGMS NIH HHS [GM08369] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1995, NATURE, V374, P371; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BENZ EW, 1983, MECHANISTIC STUDIES, P279; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P130; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P320; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIRAO I, 1994, NUCLEIC ACIDS RES, V22, P576, DOI 10.1093/nar/22.4.576; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KIM YT, 1992, J BIOL CHEM, V267, P15022; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LONBERG N, 1981, J MOL BIOL, V145, P122; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; Maxam A M, 1980, Methods Enzymol, V65, P499; POOM R, 1977, BIOCHEMISTRY-US, V16, P486; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SUN W, 1994, J BIOL CHEM, V268, P8026; VOLOGODSKII A, 1992, TOPOLOGY PHYSICS CIR, P105; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	32	57	59	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					147	154		10.1016/S0092-8674(00)81001-6	http://dx.doi.org/10.1016/S0092-8674(00)81001-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548819	Bronze			2022-12-28	WOS:A1996TQ17000017
J	Koelle, MR; Horvitz, HR				Koelle, MR; Horvitz, HR			EGL-10 regulates G protein signaling in the C-elegans nervous system and shares a conserved domain with many mammalian proteins	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; MOTOR NEURONS; A-FACTOR; MUTANTS; RECEPTOR; TRANSDUCIN; PHOSDUCIN	The frequencies of certain periodic behaviors of the nematode C. elegans are regulated in a dose-dependent manner by the activity of the gene egl-10. These behaviors are modulated oppositely by the activity of the G protein alpha subunit gene goa-1, suggesting that egl-10 may regulate a G protein signaling pathway in a dose-dependent fashion. egl-10 encodes a protein similar to Sst2p, a negative regulator of G protein signaling in yeast. EGL-10 protein is localized in neural processes, where it may function in neurotransmitter signaling. Two previously known and 13 newly identified mammalian genes have similarity to egl-10 and SST2, and we propose that members of this family regulate many G protein signaling pathways.			Koelle, MR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BAILEY CH, 1994, ADV SEC MESS PHOSPH, V29, P529; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; BRENNER S, 1974, GENETICS, V77, P71; Catty D., 1988, ANTIBODIES PRACTICAL; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CROLL NA, 1975, J ZOOL, V176, P159, DOI 10.1111/j.1469-7998.1975.tb03191.x; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; Hille B., 1992, IONIC CHANNELS EXCIT; HONG JX, 1993, J IMMUNOL, V150, P3895; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KURJAN J, 1993, ANNU REV GENET, V27, P147; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sambrook J, 1989, MOL CLONING LABORATO; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; THOMAS JH, 1990, GENETICS, V124, P855; TRENT C, 1983, GENETICS, V104, P619; Trent C, 1983, THESIS MIT; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB, 1988, NEMATODE CAENORHABDI	47	492	510	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					115	125		10.1016/S0092-8674(00)80998-8	http://dx.doi.org/10.1016/S0092-8674(00)80998-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548815	Bronze			2022-12-28	WOS:A1996TQ17000014
J	Gohdes, D; RithNajarian, S; Acton, K; Shields, R				Gohdes, D; RithNajarian, S; Acton, K; Shields, R			Improving diabetes care in the primary health setting - The Indian Health Service experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			AMERICAN-INDIANS; COMPLICATIONS; PREVALENCE; MELLITUS; TRIAL	Purpose: To identify key systems issues from the Indian Health Service (IHS) experience that must be addressed to improve metabolic control among patients with noninsulin-dependent diabetes mellitus (NIDDM) who were followed in primary care settings. Data Sources: Records of diabetic patients seen in IHS facilities in specific geographic regions from 1987 to 1994. Study Selection: A representative-sample of charts from each facility was reviewed yearly to measure key variables. The sampling frame was the number of diabetic patients currently active on the registry and the sample size calculated to measure a 10% change in selected practices at each facility. Extraction: Regional diabetes coordinators reviewed charts or trained local providers to sample and extract data in a standard format. Results: Regional data were examined to show trends in the performance of immunizations and foot examinations and in other variables such as hypertension and metabolic control. The percentage of diabetic patients who received a single dose of pneumococcal vaccine improved from 24% in 1987 to 1988 to 57% in 1994 (P < 0.01 for trend) among diabetic patients in Minnesota, Wisconsin, and Michigan. Rates of yearly comprehensive foot examination increased from 36% to 58% (P < 0.01 for trend) over the same period. In Montana and Wyoming, the percentage of diabetic patients with uncontrolled hypertension (defined as the mean of three systolic blood pressure measurements of greater than or equal to 140 mm Hg or diastolic pressure measurements greater than or equal to 90 mm Hg, or both, during the previous year) decreased from 36% in 1992 to 25% in 1993 after the regional diabetes coordinator emphasized hypertension control. In 1994, when less emphasis was placed on hypertension, 33% of the diabetic patients had uncontrolled hypertension. Estimates of metabolic control from records of diabetic patients in Washington, Oregon, and Idaho in 1994 showed that 29% of patients had excellent metabolic control (a hemoglobin A(1c) [HbA(1c)] level less than or equal to 7.5% or mean blood glucose level less than or equal to 9.2 mmol/L) within the past year; only 9% experienced poor control (a HbA(1c) level > 12% or mean blood glucose level > 18.9 mmol/L). Conclusions: The IHS experience shows that standard, ongoing monitoring of key variables allows facilities to improve diabetes care. Simple, reliable methods of defining metabolic control combined with a feedback system in the primary care setting are needed to improve metabolic control in patients with NIDDM.	BEMIDJI AREA INDIAN HLTH SERV, BEMIDJI, MN 56601 USA; TRIBAL HLTH & HUMAN SERV, BILLINGS AREA DIABET PROGRAM, ST IGNATIUS, MT 59865 USA; PORTLAND AREA DIABET PROGRAM, BELLINGHAM, WA 98225 USA		Gohdes, D (corresponding author), INDIAN HLTH SERV, DIABET PROGRAM, 5300 HOMESTEAD RD NE, ALBUQUERQUE, NM 87110 USA.							ACTON K, 1993, DIABETES CARE, V16, P372, DOI 10.2337/diacare.16.1.372; BIRKE JA, 1986, LEPROSY REV, V57, P261; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; DUMAS J, 1994, DIABETES CARE, V17, P1227, DOI 10.2337/diacare.17.10.1227; FIELD M, 1992, I MED GUIDELINES CLI; GOHDES D, 1995, NEW ENGL J MED, V332, P269; GOHDES DM, 1986, DIABETES CARE, V9, P609, DOI 10.2337/diacare.9.6.609; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; LITTLE RR, 1992, CLIN CHEM, V38, P2472; LITTLE RR, 1991, CLIN CHEM, V37, P1725; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MAYFIELD JA, 1994, DIABETES CARE, V17, P918, DOI 10.2337/diacare.17.8.918; NAGAFUCHI S, 1993, DIABETES CARE, V16, P1408, DOI 10.2337/diacare.16.10.1408; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NATHAN DM, 1994, DIABETES CARE, V17, P1228, DOI 10.2337/diacare.17.10.1228; RITHNAJARIAN SJ, 1992, DIABETES CARE, V15, P1386, DOI 10.2337/diacare.15.10.1386; SANTIAGO JV, 1993, DIABETES, V42, P1549, DOI 10.2337/diab.42.11.1549; SANTIAGO JV, 1994, DIABETES CARE, V17, P1229, DOI 10.2337/diacare.17.10.1229; SCHRAER C, 1995, DIABETES, V44, pA121; SCHRAER CD, 1993, DIABETES CARE, V16, P257, DOI 10.2337/diacare.16.1.257; 1989, MMWR-MORBID MORTAL W, V38, P73; 1994, NIH943530 US DEP HLT; 1994, GUIDE ADULT IMMUNIZA, P107; 1994, TRENDS INDIAN HLTH 1	27	23	23	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				149	152		10.7326/0003-4819-124-1_Part_2-199601011-00013	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554208				2022-12-28	WOS:A1996TL94400013
J	Keen, H				Keen, H			Management of non-insulin-dependent diabetes mellitus - The United Kingdom experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				Care of persons with non-insulin-dependent diabetes mellitus (NIDDM) in the United Kingdom resembles that in the United States. However, health care practice in Europe is being influenced by the Saint Vincent Declaration, the joint European World Health Organization-International Diabetes Federation initiative, which emphasizes prevention of diabetic complications. In recent years, the responsibility for care for NIDDM has shifted in the United Kingdom to general practice teams. The effect of this shift on the quality of care and the coordinating and educational role of local diabetes specialist teams is discussed, as is the importance of an individualized ''menu'' of care for each patient. This menu aims for optimum blood glucose level control as well as detection and correction of risk factors for diabetic complications. The pervasive and dangerous notion of NIDDM as a ''mild'' disease must be corrected. The importance of systematic auditing of process and outcomes in diabetes care is emphasized, as is the need for regular data acquisition, aggregation, and analysis to achieve continuous improvement in the quality of care. Although patient-health professional encounters are the core of good diabetes care, the need for larger-scale appraisal on a local, regional, and national basis is now apparent.	BRITISH DIABET ASSOC, LONDON, ENGLAND		Keen, H (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, METAB MED UNIT, HUNTS HOUSE, LONDON SE1 9RT, ENGLAND.							Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; GOLDNER MG, 1971, J AMER MED ASSOC, V218, P1400, DOI 10.1001/jama.218.9.1400; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; KRANS HM, 1992, WHO EURIGPOR0553 REG; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WILSON AE, 1993, DIABETIC MED, V10, P378, DOI 10.1111/j.1464-5491.1993.tb00084.x; 1995, REPORT ST VINCENT JO; 1995, UNPUB LOCAL DIABETES; 1980, WHO TECHNICAL REPORT, V646; 1994, WHO TECHNICAL REPORT, V844	10	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				156	159		10.7326/0003-4819-124-1_Part_2-199601011-00015	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00015			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554210				2022-12-28	WOS:A1996TL94400015
J	Quickel, KE				Quickel, KE			Diabetes in a managed care system	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			SERVICE; OUTCOMES; SETTINGS; PROGRAM; FEE	Health care expenditures account for over 14% of the gross domestic product in the United States. Managed care has evolved to control these costs. Because diabetes accounts for nearly 15% of health care expenditures, the strategies used by managed care organizations are expected to have a particular effect on diabetes. Managed care organizations have two primary goals: to control costs and to provide care of sufficient quality to attract and satisfy enrollees. Managed care organizations have designed strategies to meet these goals. Four primary managed care strategies and their effects on diabetes care are discussed: 1) payment incentives rewarding desired provider practice patterns; 2) designation of providers who possess desirable practice behaviors; 3) coverage policies that control the services paid for; and 4) traditional insurance strategies that determine who is eligible for insurance and what premiums are to be paid. The few direct studies of the effects of each strategy on the care of diabetic persons are discussed. The conclusion is that although managed care organizations have the potential to provide excellent care for diabetic persons, little evidence exists that they have improved either the quality or the cost-effectiveness of diabetes care. Recommendations to guide the development of cost-effective care for diabetic persons are presented.			Quickel, KE (corresponding author), JOSLIN DIABET CTR, 1 JOSLIN PL, BOSTON, MA 02215 USA.							CARTLAND JDC, 1992, PEDIATRICS, V89, P183; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; GEFFNER DL, 1992, DIABETES CARE, V15, P44, DOI 10.2337/diacare.15.1.S44; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KERTESZ L, 1995, MODERN HEALTHCA 0417, P17; LANGWELL K, 1992, CBO STAFF MEMORANDUM; LEVETAN CS, 1995, AM J MED, V99, P22, DOI 10.1016/S0002-9343(99)80100-4; LYTTLE C, 1989, ANN INTERN MED, V111, P604, DOI 10.7326/0003-4819-111-7-604; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MUHLHAUSER I, 1983, DIABETOLOGIA, V25, P470; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; PRASHKER MJ, 1991, ANN INTERN MED, V115, P715, DOI 10.7326/0003-4819-115-9-715; REDHEAD J, 1993, DIABETIC MED, V10, P672, DOI 10.1111/j.1464-5491.1993.tb00143.x; RETCHIN SM, 1991, ARCH INTERN MED, V151, P2244, DOI 10.1001/archinte.151.11.2244; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINNOCK P, 1986, J INSURANCE MED, V18, P24; SLEE VN, 1991, HLTH CARE TERMS; STARFIELD B, 1994, DIABETES CARE, V17, P12; STARR B, 1995, BUSINESS HLTH MAG SC, V13, P56; TAYLOR AK, 1987, DIABETES CARE, V10, P87, DOI 10.2337/diacare.10.1.87; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; VAUGHAN NJA, 1994, DIABETIC MED, V11, P418; WEINBERGER M, 1988, MED CARE, V26, P77, DOI 10.1097/00005650-198801000-00008; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; 1987, 3RD PARTY REIMBURSEM, V6, P1; 1992, CBO STUDY PROJECTION; 1994, DIABETES CARE S1, V2, P1555; 1993, DIRECT INDIRECT COST	34	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				160	163		10.7326/0003-4819-124-1_Part_2-199601011-00016	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554211				2022-12-28	WOS:A1996TL94400016
J	HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW				HELZLSOUER, KJ; ALBERG, AJ; GORDON, GB; LONGCOPE, C; BUSH, TL; HOFFMAN, SC; COMSTOCK, GW			SERUM GONADOTROPINS AND STEROID-HORMONES AND THE DEVELOPMENT OF OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROEPIANDROSTERONE SULFATE; POSTMENOPAUSAL WOMEN; BREAST-CANCER; ANDROGEN; GROWTH; RISK; DIETARY	Objective.-To prospectively examine the association between endogenous hormones and development of ovarian cancer. Design.-Nested case-control study. Setting.-A population-based serum bank in Washington County, Maryland. Participants.-Serum samples were collected in 1974 from 20 305 county residents and stored at - 70 degrees C. From 1975 through 1989, a total of 31 cases of ovarian cancer were identified in women who were not taking hormones at the time of blood collection. These cases were matched to 62 controls on age, menopausal status, and, for premenopausal women, number of days from the beginning of the last menstrual period. Main Outcome Measure.-Prediagnostic endogenous hormone levels of cases and controls were compared. Results.-Mean follicle-stimulating hormone levels were lower among cases (43.3 IU/L) compared with controls (54.4 IU/L) (P=.04), and increasing levels were associated with significantly lower risk (P for trend=.01), particularly among postmenopausal women. Luteinizing hormone levels were 9% lower among cases than controls, but the difference was not statistically significant (P=.39). Compared with controls, cases had higher androstenedione levels (4.5 nmol/L vs 3.3 nmol; P=.03) and higher dehydroepiandrosterone (DHEA) levels (15.9 nmol/L vs 9.7 nmol/L; P=.02). The risk of ovarian cancer increased with higher levels of androstenedione and DHEA sulfate (P for trend=.008 and .11, respectively). These associations were not materially different between premenopausal and postmenopausal women. Conclusion.-The results suggest that women with low serum gonadotropin levels or high androgen levels have an increased risk of ovarian cancer. These findings do not support the hypothesis that pituitary gonadotropins increase the risk of ovarian cancer. Replication of the study in other populations is highly desirable.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; UNIV MASSACHUSETTS, MED CTR, DEPT OBSTET & GYNECOL, WORCESTER, MA USA	Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	HELZLSOUER, KJ (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.				NCI NIH HHS [CA01522, CA36390, CA47503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA036390, R01CA047503, R01CA036390] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breslow N, 1980, STAT METHODS CANC RE, P248; BYERS T, 1983, JNCI-J NATL CANCER I, V71, P681; CARLSTROM K, 1985, ACTA OBSTET GYN SCAN, V64, P267, DOI 10.3109/00016348509155126; CRAMER DW, 1984, OBSTET GYNECOL, V63, P833; CUZICK J, 1983, INT J CANCER, V32, P723, DOI 10.1002/ijc.2910320611; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; GARDNER WU, 1961, J NATL CANCER I, V26, P829; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; HEINONEN PK, 1986, GYNECOL ONCOL, V25, P1, DOI 10.1016/0090-8258(86)90058-2; HELZLSOUER KJ, 1992, CANCER RES, V52, P1; HSING AW, 1989, CLIN CHEM, V35, P2145; LONGCOPE C, 1986, MATURITAS, V8, P189, DOI 10.1016/0378-5122(86)90025-3; LUCISANO A, 1986, MATURITAS, V8, P57, DOI 10.1016/0378-5122(86)90008-3; MAHLCK CG, 1986, ACTA OBSTET GYN SCAN, P1; MANGO D, 1985, J ENDOCRINOL INVEST, V8, P359, DOI 10.1007/BF03348514; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SAWADA M, 1990, INT J CANCER, V45, P359, DOI 10.1002/ijc.2910450225; SIMON WE, 1983, J NATL CANCER I, V70, P839; SLOTMAN BJ, 1989, CANCER LETT, V45, P213, DOI 10.1016/0304-3835(89)90080-3; SPICER DV, 1993, CONTRACEPTION, V47, P427, DOI 10.1016/0010-7824(93)90095-O; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; 1988, NCI NIH882789 PUBL H	26	211	226	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1926	1930		10.1001/jama.274.24.1926	http://dx.doi.org/10.1001/jama.274.24.1926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568986				2022-12-28	WOS:A1995TL16900034
J	Watura, R; Lloyd, DCF; Chawda, S				Watura, R; Lloyd, DCF; Chawda, S			Magnetic resonance imaging of the knee: Direct access for general practitioners	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT RADIOL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								BOEREE NR, 1991, INJURY, V22, P291, DOI 10.1016/0020-1383(91)90008-3; MAIR WJ, 1974, BMJ-BRIT MED J, V3, P732, DOI 10.1136/bmj.3.5933.732; POLLY DW, 1988, J BONE JOINT SURG AM, V70A, P192, DOI 10.2106/00004623-198870020-00005; Smith G L, 1979, J R Coll Gen Pract, V29, P539; WRIGHT HJ, 1979, J ROY SOC MED, V72, P88	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1614	1614		10.1136/bmj.311.7020.1614	http://dx.doi.org/10.1136/bmj.311.7020.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555806	Green Published			2022-12-28	WOS:A1995TL42200025
J	Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF				Tappero, JW; Khan, AS; Pinner, RW; Wenger, JD; Graber, JM; Armstrong, LR; Holman, RC; Ksiazek, TG; Khabbaz, RF			Utility of emergency, telephone-based national surveillance for Hantavirus pulmonary syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On May 27, 1993, in response to the outbreak investigation of newly recognized Hantavirus pulmonary syndrome (HPS) in the Four Corners states (New Mexico, Arizona, Utah, and Colorado), the Centers for Disease Control and Prevention established a national surveillance case definition for severe, unexplained respiratory disease to determine the extent of HPS throughout the United States, A toll-free telephone hotline number was instituted to provide updated information about unexplained respiratory illness and to serve as a passive mechanism for reporting suspected cases. Clinical information was obtained from callers reporting suspected cases, and diagnostic specimens and medical record reviews were requested from health care providers, From June 3 through December 31, 1993, the hotline received 21 443 telephone inquiries; callers identified 280 suspected cases living outside the Four Comers states with at least one specimen available for diagnostic testing. By December 31, 1993, 21 confirmed cases (age range, 14 to 58 years) residing in 11 states outside the Four Corners region had been identified, This passive surveillance system was successful in rapidly identifying the widespread sporadic geographic distribution for HPS cases throughout the United States and could serve as a model for similar emergencies, Expanding and coordinating surveillance systems for the early detection, tracking, and evaluation of emerging infections is a critical component of disease prevention.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,BIOMETR ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Berkelman RL, 1996, JAMA-J AM MED ASSOC, V275, P315, DOI 10.1001/jama.275.4.315; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; Carleton M.D., 1989, P7; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAPMAN LE, 1994, INFECT AGENT DIS, V3, P234; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; ELLIOTT LH, 1994, AM J TROP MED HYG, V51, P102, DOI 10.4269/ajtmh.1994.51.102; FELDMANN H, 1993, VIRUS RES, V30, P351, DOI 10.1016/0168-1702(93)90101-R; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KHAN AS, IN PRESS J INFECT DI; KSAIZEK TG, 1995, AM J TROP MED HYG, V52, P117; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; ROLLIN PE, 1995, J MED VIROL, V46, P35, DOI 10.1002/jmv.1890460108; SHEFER AM, 1994, CLIN INFECT DIS, V19, P1105, DOI 10.1093/clinids/19.6.1105; SPIROPOULOU CF, 1994, VIROLOGY, V200, P715, DOI 10.1006/viro.1994.1235; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; THACKER SB, 1983, JAMA-J AM MED ASSOC, V249, P1181; ZAKI SR, 1995, AM J PATHOL, V146, P552; ZAKI SR, IN PRESS ARCH PATHOL; ZEITZ PS, 1995, J INFECT DIS, V171, P864, DOI 10.1093/infdis/171.4.864; 1993, MMWR-MORBID MORTAL W, V42, P612; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P99; 1993, MMWR-MORBID MORTAL W, V42, P441; 1993, MMWR-MORBID MORTAL W, V42, P421; 1994, MMWR-MORBID MORTAL W, V43, P105; 1993, MMWR-MORBID MORTAL W, V42, P816; 1994, MMWR-MORBID MORTAL W, V43, P45	32	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					398	400		10.1001/jama.275.5.398	http://dx.doi.org/10.1001/jama.275.5.398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569020				2022-12-28	WOS:A1996TT30300034
J	Zahn, R; Perrett, S; Stenberg, G; Fersht, AR				Zahn, R; Perrett, S; Stenberg, G; Fersht, AR			Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB	SCIENCE			English	Article							HYDROGEN-EXCHANGE; ESCHERICHIA-COLI; PROTEIN; BARNASE; STABILITY; BINDING; SURFACE; PATHWAY	Hydrogen-deuterium exchange of 39 amide protons of Bacillus amyloliquefaciens ribonuclease (barnase) was analyzed by two-dimensional nuclear magnetic resonance in the presence of micromolar concentrations of the molecular chaperones GroEL and SecB. Both chaperones bound to native barnase under physiological conditions and catalyzed exchange of deeply buried amide protons with solvent. Such exchange required complete unfolding of barnase, which occurred in the complex with the chaperones. Subsequent collapse of unfolded barnase to the exchange-protected folding intermediate was markedly slowed in the presence of GroEL or SecB. Thus, both chaperones have the potential to correct misfolding in proteins by annealing.	UNIV CAMBRIDGE,MRC,UNIT PROT FUNCT & DESIGN,DEPT CHEM,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge			Perrett, Sarah/AAS-9483-2020; Fersht, Alan R/B-2189-2008	Perrett, Sarah/0000-0003-0137-0997; 				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CORRALES F, UNPUB; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PERRETT S, 1995, BIOCHEMISTRY-US, V34, P9288, DOI 10.1021/bi00029a003; PERRETT S, UNPUB; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; RODER H, 1985, BIOCHEMISTRY-US, V24, P7396, DOI 10.1021/bi00346a055; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STENBERG G, UNPUB; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOPPING TB, 1994, PROTEIN SCI, V3, P760; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZAHN R, 1994, THESIS U MUNICH	46	134	135	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					642	645		10.1126/science.271.5249.642	http://dx.doi.org/10.1126/science.271.5249.642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571125				2022-12-28	WOS:A1996TT87000044
J	Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP				Michallet, M; Archimbaud, E; Bandini, G; Rowlings, PA; Deeg, HJ; Gahrton, G; Montserrat, E; Rozman, C; Gratwohl, A; Gale, RP			HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIVARIATE SURVIVAL ANALYSIS; PROGNOSIS; FLUDARABINE; ADULTS	Objective: To characterize in detail the outcomes of HLA-identical sibling bone marrow transplantation for chronic lymphocytic leukemia (CLL) in patients Lounger than 60 years of age. Design: Retrospective cohort study. Setting: 30 centers for bone marrow transplantation worldwide, which reported data on outcome of HLA-identical sibling bone marrow transplantation for CLL to the European Group for Blood and Marrow Transplantation or the International Bone Marrow Transplant Registry between 1984 and 1992. Patients: 54 patients diagnosed with CLL (median age, 41 years; range, 21 to 58 years). The median interval from diagnosis to transplantation was 37 months (range, 5 to 130 months). At the time of transplantation, 3 patients were at Rai stage 0; 10 were at stage 1; 10 were at stage 2; 7 were at stage 3; and 22 were at stage 4. Intervention: Transplant regimens varied. Most patients received high-dose cyclophosphamide and total body irradiation, followed by infusion of bone marrow from an HLA-identical sibling. After transplantation, immune suppression with cyclosporine or methotrexate or both was generally used to prevent graft-versus-host disease. Measurements: The primary outcome was survival. We also studied hematologic remission, defined as normalization of the leukocyte count, hemoglobin level, and platelet count, and absence of lymphadenopathy and splenomegaly. Results: 38 patients (70%) achieved hematologic remission. Twenty-four (44%) remain alive a median of 27 months (range, 5 to 80 months) after transplantation. Three-year survival probability was 46% (95% CI, 32% to 60%). Three patients who received transplants at Rai stage 0 remain alive 21, 32, and 45 months after transplantation. Three-year survival probabilities were as follows: 68% (CI, 38% to 98%) in 10 patients who received transplants at Rai stage 1, 30% (CI, 2% to 58%) in 10 patients who received transplants at Rai stage 2, 57% (CI, 21% to 93%) in 7 patients who received transplants at Rai stage 3, and 34% (CI, 12% to 56%) in 22 patients who received transplants at Rai stage 4 CLL. Five patients (9%) died of progressive leukemia and 25 (46%) of treatment-related complications. Conclusions: Bone marrow transplants from HLA-identical siblings can result in hematologic remission and survival in persons with CLL, but it is uncertain how these results compare with those of conventional therapies.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, HLTH POLICY INST, MILWAUKEE, WI 53226 USA; SAN ORSOLA HOSP, BOLOGNA, ITALY; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; KAROLINSKA INST, HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, HUDDINGE, SWEDEN; SALICK HLTH CARE INC, LOS ANGELES, CA USA; HOP EDOUARD HERRIOT, HOP LYON, F-69437 LYON 03, FRANCE; HOP EDOUARD HERRIOT, SERV HEMATOL, F-69437 LYON 03, FRANCE; HUDDINGE HOSP, KAROLINSKA INST, DEPT MED, S-14186 HUDDINGE, SWEDEN; ST VINCENTS HOSP, DEPT HEMATOL, SYDNEY, NSW, AUSTRALIA; ROYAL POSTGRAD MED SCH, DEPT HEMATOL, LONDON, ENGLAND; CLAUDE HURIEZ HOSP, DEPT HEMATOL, LILLE, FRANCE; LONG ISL JEWISH MED CTR, NEW HYDE PK, NY 11042 USA; UNIV HOSP, DIV HEMATOL, DEPT INTERNAL MED, BASEL, SWITZERLAND; HOSP CLIN BARCELONA, BARCELONA, SPAIN	Medical College of Wisconsin; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Fred Hutchinson Cancer Center; Karolinska Institutet; Karolinska Institutet; CHU Lyon; CHU Lyon; Karolinska Institutet; St Vincents Hospital Sydney; Imperial College London; Universite de Lille - ISITE; CHU Lille; Northwell Health; University of Barcelona; Hospital Clinic de Barcelona					NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDINI G, 1991, BONE MARROW TRANSPL, V7, P251; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; GAJEWSKI JL, 1996, IN PRESS J CLIN ONCO; GALE RP, 1993, BAILLIERE CLIN HAEM, V6, P879, DOI 10.1016/S0950-3536(05)80181-7; GALE RP, 1996, IN PRESS LEUKEMIA; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; JULIUSSON G, 1993, CHRONIC LYMPHOCYTIC, P83; KEATING MJ, 1993, BLOOD, V81, P2878; KHOURI IF, 1994, J CLIN ONCOL, V12, P748, DOI 10.1200/JCO.1994.12.4.748; LEE JS, 1987, BLOOD, V69, P929; MICHALLET M, 1991, BONE MARROW TRANSPL, V7, P275; MONTSERRAT E, 1989, ANN INTERN MED, V110, P236; MONTSERRAT E, 1991, BLOOD, V78, P1545; MONTSERRAT E, 1986, BRIT J HAEMATOL, V62, P567, DOI 10.1111/j.1365-2141.1986.tb02969.x; RABINOWE SN, 1993, BLOOD, V82, P1366; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROZMAN C, 1984, BLOOD, V64, P642	20	204	207	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					311	315		10.7326/0003-4819-124-3-199602010-00005	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554226				2022-12-28	WOS:A1996TR59600005
J	Shaper, AG				Shaper, AG			Reflections on the seven countries study	LANCET			English	Editorial Material											Shaper, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							BLACKBURN H, 1995, TRAIL HEART ATTACKS, P148; Kromhout D., 1994, 7 COUNTRIES STUDY SC, P219; TOSHIMA H, 1994, LESSONS SCI 7 COUNTR, P243	3	7	7	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					208	208		10.1016/S0140-6736(96)90396-7	http://dx.doi.org/10.1016/S0140-6736(96)90396-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551873				2022-12-28	WOS:A1996TT06900002
J	Savage, B; Saldivar, E; Ruggeri, ZM				Savage, B; Saldivar, E; Ruggeri, ZM			Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor	CELL			English	Article							VONWILLEBRAND-FACTOR-BINDING; CORONARY-ARTERY THROMBOSIS; MEMBRANE GLYCOPROTEIN-IB; IIB-IIIA COMPLEX; SHEAR-STRESS; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; DOMAIN; AGGREGATION; DISEASE	We have identified two distinct mechanisms initiating the adhesion of flowing platelets to thrombogenic surfaces. The integrin alpha(IIb)beta(3) promotes immediate arrest onto fibrinogen but is fully efficient only at wall shear rates below 600-900 s(-1), perhaps because of a relatively slow rate of bond formation or low resistance to tensile stress. In contrast, glycoprotein Ib alpha binding to immobilized von Willebrand factor (vWF) appears to have fast association and dissociation rates as well as high resistance to tensile stress, supporting slow movement of platelets in continuous contact with the surface even at shear rates in excess of 6000 s(-1). This eventually allows activated alpha(IIb)beta(3) to arrest platelets onto vWF under conditions not permissive of direct binding to fibrinogen. The coupling of these different functions may be crucial for thrombogenesis.	SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Savage, B (corresponding author), SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.		Pieper, Maja/AAN-8539-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL048728, R37HL042846, R01HL042846] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; COLLER BS, 1980, BLOOD, V55, P169; DISE CA, 1982, J BIOL CHEM, V257, P4701; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FUJIMURA Y, 1991, BLOOD, V77, P113; Fung YC., 1981, BIOMECHANICS; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BLOOD, V60, P663; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; HANDA M, 1986, J BIOL CHEM, V261, P2579; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MOAKE JL, 1988, BLOOD, V71, P1366; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MUSTARD JF, 1978, BLOOD, V52, P453; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NICHOLS TC, 1991, CIRCULATION, V83, P56; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; STRONY J, 1990, CIRCULATION, V81, P1106, DOI 10.1161/01.CIR.81.3.1106; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1971, NEW ENGL J MED, V285, P369, DOI 10.1056/NEJM197108122850703; WEISS HJ, 1993, J LAB CLIN MED, V122, P324; Whitmore R.L., 1968, RHEOLOGY CIRCULATION	57	945	975	3	65	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					289	297		10.1016/S0092-8674(00)80983-6	http://dx.doi.org/10.1016/S0092-8674(00)80983-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565074	Bronze			2022-12-28	WOS:A1996TR59500015
J	Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA				Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA			Calcium oscillations in mammalian eggs triggered by a soluble sperm protein	NATURE			English	Article							SEA-URCHIN EGGS; FERTILIZATION; ACTIVATION; OOCYTES; FUSION	AT fertilization in mammals, the sperm induces a characteristic series of Ca2+ oscillations in the egg which serve as the essential trigger for egg activation and early development of the embryo(1-3). It is not known how the sperm initiates this fundamental process, however(4-6), nor has any pathway linking sperm-egg membrane-receptor binding with intracellular Ca2+ release been demonstrated(7-11). Microinjection of sperm extracts into mammalian eggs elicits Ca2+ oscillations identical to those occurring at fertilization(12-14), which suggests that sperm may introduce a Ca2+ oscillation-inducing factor into the egg on gamete membrane fusion(12,15-18). Here we identify a soluble sperm protein that exhibits Ca2+ oscillation-inducing ('oscillogen') activity in eggs, Sperm oscillogen exists as an oligomer with a subunit of M(r) 33K and a specific intracellular localization at the equatorial segment of the sperm head. Cloning of the 33K oscillogen complementary DNA indicates similarity with a hexose phosphate isomerase found in prokaryotes. This sperm-derived oscillogen, termed oscillin, may represent the physiological trigger for development in mammals.	NATL INST MED RES, MRC, LONDON NW7 1AA, ENGLAND; ST GEORGE HOSP, SCH MED, MRC, EXPTL EMBRYOL & TERATOL UNIT, LONDON SW17 0RE, ENGLAND; UCL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND	MRC National Institute for Medical Research; St Georges University London; University of London; University College London			Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Lai, Tony/0000-0003-2852-8547; Swann, Karl/0000-0002-4355-1449				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berrie CP, 1996, BIOCHEM J, V313, P369, DOI 10.1042/bj3130369; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DALE B, 1985, EXPERIENTIA, V41, P1068, DOI 10.1007/BF01952148; DOZORTSEV D, 1995, HUM REPROD, V10, P403, DOI 10.1093/oxfordjournals.humrep.a135952; Foltz KR, 1993, ZYGOTE, V1, P276, DOI 10.1017/S0967199400001593; HARLOW E, 1988, ANTIBODIES LABORATOR; HOMA ST, 1994, HUM REPROD, V9, P2356, DOI 10.1093/oxfordjournals.humrep.a138452; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; NUCCITELLI R, 1991, CURR TOP DEV BIOL, V25, P1; OHLENDIECK K, 1995, TRENDS BIOCHEM SCI, V20, P29, DOI 10.1016/S0968-0004(00)88947-1; Shen SS, 1992, CURR OPIN GENET DEV, V2, P642, DOI 10.1016/S0959-437X(05)80185-6; STICE SL, 1990, MOL REPROD DEV, V25, P272, DOI 10.1002/mrd.1080250309; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; Swann K, 1993, ZYGOTE, V1, P273, DOI 10.1017/S0967199400001581; TESARIK J, 1994, HUM REPROD, V9, P511, DOI 10.1093/oxfordjournals.humrep.a138537; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Yanagimachi R., 1988, P135	26	339	346	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					364	368		10.1038/379364a0	http://dx.doi.org/10.1038/379364a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552195				2022-12-28	WOS:A1996TR32300064
J	LeDuc, JW				LeDuc, JW			World Health Organization strategy for emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LeDuc, JW (corresponding author), WHO,DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], 1995, WKLY EPIDEMIOL REC, V5, P35; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Lederberg J., 1992, EMERGING INFECTIONS; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OBRIEN TF, 1995, EMERG INFECT DIS, V1, P66, DOI 10.3201/eid0102.950209; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; 1994, B WORLD HEALTH ORGAN, V72, P845; 1995, WHOCDSBVI952 PUBL; 1995, REPORT NATIONAL SCI	12	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					318	320		10.1001/jama.275.4.318	http://dx.doi.org/10.1001/jama.275.4.318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544274				2022-12-28	WOS:A1996TP96500030
J	AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN				AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN			Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease	LANCET			English	Article							SPORADIC ALZHEIMERS-DISEASE	Background Variants of the apolipoprotein E (APOE) gene influence the age of onset of Alzheimer's disease. APOE may influence the presentation of other neurological diseases. We investigated the relationship between the allelic variants of apolipoprotein E and clinical presentation in motor neuron disease. Methods 123 patients with motor neuron disease and 121 controls were studied. Diagnosis, location of onset and date of onset were recorded prospectively. Genotyping was performed blind to clinical information. Findings Possession of at least one epsilon 4 allele was significantly more common in patients with bulbar onset motor neuron disease (14/33, 42%) than in limb onset patients (20/90, 22%) and controls (26/121, 21%) (chi(2)=4.93, p=0.026 and chi(2)=5.91, p=0.015, respectively). Interpretation These results suggest that the apolipoprotein E epsilon 4 allele may influence the pattern of motor neuron loss in motor neuron disease and that it may affect neuronal function in ways unrelated to the deposition of beta-amyloid or accumulation of neurofibrillary tangles.	INST PSYCHIAT,DEPT CLIN NEUROSCI,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,KINGS MND CARE & RES CTR,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHOL,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London			Powell, John F/G-4412-2011; Al-Chalabi, Ammar/E-5361-2010; Leigh, Peter/AAD-5638-2019	Powell, John F/0000-0001-6124-439X; Al-Chalabi, Ammar/0000-0002-4924-7712; 				ABRAHAMS S, 1995, J NEUROL SCI, V129, P54, DOI 10.1016/0022-510X(95)00063-8; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T; REBECK GW, 1993, NEURON, V11, P575; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHNEIDER JA, 1995, ANN NEUROL, V38, P131, DOI 10.1002/ana.410380122; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WHENHAM PR, 1991, LANCET, V337, P1158	10	83	84	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					159	160		10.1016/S0140-6736(96)90343-8	http://dx.doi.org/10.1016/S0140-6736(96)90343-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544551				2022-12-28	WOS:A1996TQ24400012
J	Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L				Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L			COPI- and COPII-coated vesicles bud directly from the endoplasmic reticulum in yeast	CELL			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; TRANSPORT VESICLES; GOLGI-COMPLEX; GUANINE-NUCLEOTIDE; PROTEIN-TRANSPORT; BETA-COP; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; MEMBRANE-PROTEIN	The cytosolic yeast proteins Sec13p-Sec31p, Sec23p-Sec24p, and the small GTP-binding protein Sar1p generate protein transport vesicles by forming the membrane coat termed COPII. We demonstrate by thin section and immunoelectron microscopy that purified COPII components form transport vesicles directly from the outer membrane of isolated yeast nuclei. Another set of yeast cytosolic proteins, coatomer and Arf1p (COPI), also form coated buds and vesicles from the nuclear envelope. Formation of COPI-coated, but not COPII-coated, buds and vesicles on the nuclear envelope is inhibited by the fungal metabolite brefeldin A. The two vesicle populations are distinct. However, both vesicle types are devoid of endoplasmic reticulum (ER) resident proteins, and each contains targeting proteins necessary for docking at the Golgi complex. Our data suggest that COPI and COPII mediate separate vesicular transport pathways from the ER.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	Bednarek, SY (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DOERING TL, 1996, IN PRESS EMBO J; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; OPRINS A, 1994, J CELL BIOL, V124, P725; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SEGAARD M, 1994, CELL, V8, P937; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	60	234	242	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1183	1196		10.1016/0092-8674(95)90144-2	http://dx.doi.org/10.1016/0092-8674(95)90144-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548805	Bronze			2022-12-28	WOS:A1995TM76200014
J	Watemberg, N; Morton, LD				Watemberg, N; Morton, LD			Periodic lateralized epileptiform discharges	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Watemberg, N (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					634	634		10.1056/NEJM199603073341005	http://dx.doi.org/10.1056/NEJM199603073341005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592527	Green Published			2022-12-28	WOS:A1996TX69300005
J	Keiler, KC; Waller, PRH; Sauer, RT				Keiler, KC; Waller, PRH; Sauer, RT			Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA	SCIENCE			English	Article							N-END RULE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; STABLE RNA; CLONING	Variants of lambda repressor and cytochrome b(562) translated from messenger RNAs without stop codons were modified by carboxyl terminal addition of an ssrA-encoded peptide tag and subsequently degraded by carboxyl terminal-specific proteases present in both the cytoplasm and periplasm of Escherichia coli, The tag appears to be added to the carboxyl terminus of the nascent polypeptide chain by cotranslational switching of the ribosome from the damaged messenger RNA to ssrA RNA.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Sauer, Robert/0000-0002-1719-5399; Keiler, Kenneth/0000-0001-8753-335X	NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892, R01AI015706, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONOV VK, 1993, CHEM PROTEOLYSIS, P36; BALZI E, 1990, J BIOL CHEM, V265, P7464; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Clechanover A., 1994, CELL, V79, P13; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HERSHEY JWB, 1987, CELLULAR MOL BIOL, P613; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; KELLER KC, 1996, J BIOL CHEM, V281, P2589; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; RAY BK, 1979, MOL GEN GENET, V174, P25, DOI 10.1007/BF00433301; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392	30	858	896	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					990	993		10.1126/science.271.5251.990	http://dx.doi.org/10.1126/science.271.5251.990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584937				2022-12-28	WOS:A1996TV70400050
J	Tycowski, KT; Shu, MD; Steitz, JA				Tycowski, KT; Shu, MD; Steitz, JA			A mammalian gene with introns instead of exons generating stable RNA products	NATURE			English	Article							SMALL NUCLEOLAR RNAS	THE nucleoli of eukaryotic cells are the sites of ribosomal RNA transcription and processing and of ribosomal subunit assembly. They contain multiple small nucleolar RNAs (snoRNAs), several of which are essential for rRNA maturation(1). The U3, U8 and U13 snoRNA genes are transcribed independently, whereas U14-U24, as well as E3, are located within introns of protein-coding genes, most of whose functions are linked to translation. These snoRNAs are co-transcribed with their host pre-mRNAs and released by processing from excised introns(1,2). Here we show that, in addition to U22, seven novel fibrillarin-associated snoRNAs, named U25-U31, are encoded within different introns of the unusually compact mammalian U22 host gene (UHG). All seven RNAs exhibit extensive (12-15 nucleotides) complementarity to different segments of the mature rRNAs, followed by a C/AUGA ('U-turn') sequence. The spliced UHG RNA, although it is associated with polysomes, has little potential for protein coding, is short-lived, and is poorly conserved between human and mouse. Thus, the introns rather than the exons specify the functional products of UHG.			Tycowski, KT (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MAQUAT LE, 1995, RNA, V1, P453; MATTICK JS, 1994, CURR OPIN GENET DEV, V4, P823, DOI 10.1016/0959-437X(94)90066-3; MAXWELL ES, 1995, A REV BIOCH, V35, P899; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; PELLIZZONI L, 1994, NUCLEIC ACIDS RES, V22, P4607, DOI 10.1093/nar/22.22.4607; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025	16	247	258	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					464	466		10.1038/379464a0	http://dx.doi.org/10.1038/379464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559254				2022-12-28	WOS:A1996TT30400064
J	Berkelman, RL; Pinner, RW; Hughes, JM				Berkelman, RL; Pinner, RW; Hughes, JM			Addressing emerging microbial threats in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Berkelman, RL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,1600 CLIFTON RD NE,MAILSTOP C12,ATLANTA,GA 30333, USA.							BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Cassel GH, 1994, ASM NEWS, V60, P251; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; DOWDLE WR, 1993, ANNU REV PUBL HEALTH, V14, P649; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; GAYNES RP, 1991, AM J MED, V91, P1165; KAPLAN JE, 1995, CLIN INFECT DIS   S1, V21, P12; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEDERBERG J, 1993, ASM NEWS, V59, P162; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Morse Stephen S., 1993, EMERGING VIRUSES; STACHE RD, 1995, EMERGING INFECT DIS, V1, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1995, EMERGING INFECT J, V1, P105; 1995, REPORT NSTC COMMITTE; 1994, MMWR-MORBID MORTAL W, V43, P740; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P421; 1991, ADDRESSING EMERGING; 1995, MMWR-MORBID MORTAL W, V44, P121; 1994, CAN COMMUN DIS REP, V20, P1; 1995, MMWR-MORBID MORTAL W, V44, P535	24	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					315	317		10.1001/jama.275.4.315	http://dx.doi.org/10.1001/jama.275.4.315			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544273				2022-12-28	WOS:A1996TP96500029
J	Hall, JC; Tarala, RA; Tapper, J; Hall, JL				Hall, JC; Tarala, RA; Tapper, J; Hall, JL			Prevention of respiratory complications after abdominal surgery: A randomised clinical trial	BRITISH MEDICAL JOURNAL			English	Article							INCENTIVE SPIROMETRY; PULMONARY COMPLICATIONS; CHEST PHYSIOTHERAPY; DIAPHRAGMATIC FUNCTION; RISK; CHOLECYSTECTOMY; ATELECTASIS; ANESTHESIA	Objective-To evaluate the prevention of respiratory complications after abdominal surgery by a comparison of a global policy of incentive spirometry with a regimen consisting of deep breathing exercises for low risk patients and incentive spirometry plus physiotherapy for high risk patients. Design-Stratified randomised trial. Setting-General surgical service of an urban teaching hospital. Patients-456 patients undergoing abdominal surgery. Patients less than 60 years of age with an American Society of Anesthesia classification of 1 were considered to be at low risk. Outcome measures-Respiratory complications were defined as clinical features consistent with collapse or consolidation, a temperature above 38 degrees C, plus either confirmatory chest radiology or positive results on sputum microbiology. We also recorded the time that staff devoted to prophylactic respiratory therapy. Results-There was good baseline equivalence between the groups. The incidence of respiratory complications was 15% (35/231) for patients in the incentive spirometry group and 12% (28/225) for patients in the mixed therapy group (P=0.40; 95% confidence interval -3.6% to 9.0%). It required similar amounts of staff time to provide incentive spirometry and deep breathing exercises for low risk patients. The inclusion of physiotherapy for high risk patients, however, resulted in the utilisation of an extra 30 minutes of staff time per patient. Conclusions-When the use of resources is taken into account, the most efficient regimen of prophylaxis against respiratory complications after abdominal surgery is deep breathing exercises for low risk patients and incentive spirometry for high risk patients.			Hall, JC (corresponding author), UNIV WESTERN AUSTRALIA,ROYAL PERTH HOSP,DEPT SURG,PERTH,WA 6000,AUSTRALIA.							BAKER WL, 1990, AM REV RESPIR DIS, V141, P343, DOI 10.1164/ajrccm/141.2.343; CELLI BR, 1984, AM REV RESPIR DIS, V130, P12; CHUTER TAM, 1989, SURGERY, V105, P488; CHUTER TAM, 1990, CHEST, V97, P1110, DOI 10.1378/chest.97.5.1110; DUREUIL B, 1987, BRIT J ANAESTH, V59, P1230, DOI 10.1093/bja/59.10.1230; FLEISS JL, 1981, STATISTICAL METHODS, P178; FORD GT, 1993, CLIN CHEST MED, V14, P237; HALL JC, 1991, LANCET, V337, P953, DOI 10.1016/0140-6736(91)91580-N; HALL JC, 1993, AUST NZ J SURG, V63, P356, DOI 10.1111/j.1445-2197.1993.tb00402.x; HALL JC, 1991, CHEST, V99, P923, DOI 10.1378/chest.99.4.923; HALL JC, 1991, ARCH SURG-CHICAGO, V126, P512; JACKSON CV, 1988, ARCH INTERN MED, V148, P2120, DOI 10.1001/archinte.148.10.2120; JONES JG, 1987, BRIT J ANAESTH, V59, P949, DOI 10.1093/bja/59.8.949; Levy P A, 1979, Respir Care, V24, P701; ROUKEMA JA, 1988, ARCH SURG-CHICAGO, V123, P30; SCHWIEGER I, 1986, CHEST, V89, P652, DOI 10.1378/chest.89.5.652; SELSBY DS, 1989, BMJ-BRIT MED J, V298, P541, DOI 10.1136/bmj.298.6673.541; STILLER KR, 1992, BRIT J SURG, V79, P745, DOI 10.1002/bjs.1800790807; STRANDBERG A, 1987, ACTA ANAESTH SCAND, V31, P21, DOI 10.1111/j.1399-6576.1987.tb02513.x; TORRINGTON KG, 1988, CHEST, V93, P946, DOI 10.1378/chest.93.5.946; VACANTI CJ, 1970, ANESTH ANAL CURR RES, V49, P564; 1989, PRINCIPLES ANALGESIC, P10; 1965, LANCET, V2, P775	23	79	83	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					148	152						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563533				2022-12-28	WOS:A1996TR32500020
J	Kubba, AK; Young, M				Kubba, AK; Young, M			Ludwig van Beethoven: A medical biography	LANCET			English	Biographical-Item									UNIV GLASGOW LIB, GLASGOW, LANARK, SCOTLAND	University of Glasgow	Kubba, AK (corresponding author), WESTERN GEN HOSP, GASTROINTESTINAL UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							Jacobsohn L, 1927, DEUT MED WOCHENSCHR, V53, P1610; Larkin E, 1970, BEETHOVEN LAST DECAD, P448; LONDON SJ, 1964, ARCH INTERN MED, V113, P442, DOI 10.1001/archinte.1964.00280090128021; McCABE B F, 1958, Ann Otol Rhinol Laryngol, V67, P192; NAIKEN VS, 1971, ANN INTERN MED, V74, P995, DOI 10.7326/0003-4819-74-6-995; O'Shea John, 1993, MUSIC MED; ORGA A, 1978, BEETHOVEN HIS LIFE T; PALFERMAN TG, 1990, J ROY SOC MED, V83, P640, DOI 10.1177/014107689008301015; SCHWEISHEIMER W, 1944, MUSICAL Q, V30, P289; SHARMA OP, 1994, J ROY SOC MED, V87, P283; SORSBY M, 1974, TENEMENTS CLAY, P181; STEVENS K M, 1970, Journal of the American Medical Association, V213, P434, DOI 10.1001/jama.213.3.434; Thayer C. Alexander Wheelock, 1970, THAYERS LIFE BEETHOV, p1061ff; Tremble E, 1932, CAN MED ASS J, V27, P546; von Frimmel T, 1926, BEETHOVEN HDB, V1, P38; WALLACE, 1867, BEETHOVENS LETT, V1, P16	16	30	32	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					167	170		10.1016/S0140-6736(96)90346-3	http://dx.doi.org/10.1016/S0140-6736(96)90346-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544554	Bronze			2022-12-28	WOS:A1996TQ24400015
J	Shears, P				Shears, P			Pseudo-outbreaks	LANCET			English	Editorial Material											Shears, P (corresponding author), UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							Casemore D P, 1992, Commun Dis Rep CDR Rev, V2, pR66; HALL SM, 1985, J HOSP INFECT, V6, P312, DOI 10.1016/0195-6701(85)90036-2; JOCE RE, 1995, EPIDEMIOL INFECT, V115, P31, DOI 10.1017/S095026880005809X; JUMAA PA, 1994, J HOSP INFECT, V27, P167, DOI 10.1016/0195-6701(94)90124-4; LAUSSUCQ S, 1988, J CLIN MICROBIOL, V26, P1442, DOI 10.1128/JCM.26.8.1442-1444.1988; Shears P, 1994, Commun Dis Rep CDR Rev, V4, pR9; WEINSTEIN RA, 1977, LANCET, V2, P862	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					138	138		10.1016/S0140-6736(96)90337-2	http://dx.doi.org/10.1016/S0140-6736(96)90337-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544545				2022-12-28	WOS:A1996TQ24400006
J	Sorrell, VL; Davis, MJ; Bove, AA				Sorrell, VL; Davis, MJ; Bove, AA			Origins of coronary artery ectasia	LANCET			English	Editorial Material									UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; TEMPLE UNIV HOSP & MED SCH, PHILADELPHIA, PA 19140 USA	University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sorrell, VL (corresponding author), E CAROLINA UNIV, SCH MED, 4S-22 BRODY, GREENVILLE, NC 27834 USA.							CARMICHAEL P, 1963, ARCH ENVIRON HEALTH, V7, P424, DOI 10.1080/00039896.1963.10663561; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P113; England JF., 1981, MED J AUSTRALIA, V68, P260; ENGLAND JF, 1981, MED J AUSTRALIA, V2, P140; HARTNELL GG, 1985, BRIT HEART J, V54, P392; LANGE RL, 1972, CIRCULATION, V46, P666, DOI 10.1161/01.CIR.46.4.666; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658	10	37	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					136	137		10.1016/S0140-6736(96)90335-9	http://dx.doi.org/10.1016/S0140-6736(96)90335-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544543				2022-12-28	WOS:A1996TQ24400004
J	Laakso, M				Laakso, M			Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus - The Finnish studies	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			GLUCOSE	Purpose: To review population-based studies that investigated the association and nature of association between glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus (NIDDM). Data Sources: Study 1 included 133 newly diagnosed patients with NIDDM from eastern Finland, who were 45 to 64 years of age at baseline. These patients were followed up to 10 years for cardiovascular mortality. Study 2 included 229 newly or previously diagnosed patients with NIDDM from eastern Finland, aged 65 to 74 years at baseline. These patients were followed up to 3.5 years for coronary heart disease mortality and all coronary heart disease events (mortality or nonfatal myocardial infarction). Study Selection: Prospective, population-based studies that included indicators of glycemic control and the evaluation of coronary heart disease and cardiovascular risk. Results: Study 1 : 10-year cardiovascular mortality was significantly and linearly associated with glycemic control (fasting blood glucose and glycated hemoglobin A(1) levels) independently of the mode of treatment. A high fasting blood glucose level significantly predicted cardiovascular mortality in multiple logistic regression analysis independently of other risk factors. Study 2: Glycated hemoglobin A(1c) was the most important single risk factor associated with coronary heart disease death or all coronary heart disease events. In multiple logistic regression analysis, glycated hemoglobin A(1c) was significantly associated with coronary heart disease death after adjustment for other cardiovascular risk factors. Conclusions: Two prospective, population-based studies from Finland give evidence for the linear association of glycemic control with the risk for coronary heart disease in middle-aged and elderly patients with NIDDM.			Laakso, M (corresponding author), KUOPIO UNIV, DEPT MED, SF-70210 KUOPIO, FINLAND.							BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LYONS TJ, 1992, DIABETES, V41, P67, DOI 10.2337/diab.41.2.S67; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TURNER RC, 1985, DIABETES, V34, P793; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; 1985, TECHNICAL REPORT SER, V727; 1990, MONICA MANUAL	12	124	129	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				127	130		10.7326/0003-4819-124-1_Part_2-199601011-00009	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554204				2022-12-28	WOS:A1996TL94400009
J	Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W				Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W			SecA membrane cycling at SecYEG is driven by distinct ATP binding and hydrolysis events and is regulated by SecD and SecF	CELL			English	Article							COLI PLASMA-MEMBRANE; PROTON MOTIVE FORCE; PRECURSOR PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; TRIGGER FACTOR; PREPROTEIN TRANSLOCASE; PRESECRETORY PROTEINS; SECRETORY PROTEINS	The SecA subunit of E. coli preprotein translocase promotes protein secretion during cycles of membrane insertion and deinsertion at SecYEG. This process is regulated both by nucleotide binding and hydrolysis and by the SecD and SecF proteins. In the presence of associated preprotein, the energy of ATP binding at nucleotide-binding domain 1 (NBD1) drives membrane insertion of a 30 kDa domain of SecA, while deinsertion of SecA requires the hydrolysis of this ATP. SecD and SecF stabilize the inserted state of SecA. ATP binding at NBD2, though needed for preprotein translocation, is not needed for SecA insertion or deinsertion.	UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	University of Crete; Harvard University; Harvard Medical School; Wesleyan University	Economou, A (corresponding author), DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P4205, DOI 10.1002/j.1460-2075.1990.tb07645.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRUNDERSON KL, 1995, CELL, V82, P231; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RENSING SA, 1994, MOL PHYLOGENET EVOL, V3, P187, DOI 10.1006/mpev.1994.1021; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; TANI K, 1989, J BIOL CHEM, V264, P18582; UEGUCHI C, 1990, J BACTERIOL, V172, P5643, DOI 10.1128/jb.172.10.5643-5649.1990; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P18577	56	271	274	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1171	1181		10.1016/0092-8674(95)90143-4	http://dx.doi.org/10.1016/0092-8674(95)90143-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548804	hybrid			2022-12-28	WOS:A1995TM76200013
J	BARSKY, AJ; BORUS, JF				BARSKY, AJ; BORUS, JF			SOMATIZATION AND MEDICALIZATION IN THE ERA OF MANAGED CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERSISTENT SOMATIZING PATIENTS; PSYCHIATRIC-CONSULTATION; COMMON SYMPTOMS; FAMILY-PRACTICE; DISORDER; HEALTH; PREVALENCE; COMMUNITY; PHYSICIANS; UTILIZERS	Somatization, the reporting of somatic symptoms that have no pathophysiological explanation, appears to be increasing as sociocultural currents reduce the public's tolerance of mild symptoms and benign infirmities and lower the threshold for seeking medical attention for such complaints. These trends coincide with a progressive medicalization of physical distress in which uncomfortable bodily states and isolated symptoms are reclassified as diseases fdr which medical treatment is sought. Somatization and medicalization are likely to become more problematic in the era of managed care. Under capitation, providers will have greater incentives to reduce utilization, and somatizing patients may feel forced to express their ''dis-ease'' in more urgent and exaggerated terms in order to gain access to the physician. in addition, prepaid subscribers will suffer little financial disincentive to seek medical attention for relatively minor complaints; therefore, they are likely to increase the demand for physician consultation. This situation suggests an urgent need to improve the management of somatizing patients. Innovative consultative, behavioral, and educational interventions are now available. In addition, medical professionals should greet the process of medicalization with considerable caution and educate the public more about the normative presence of symptoms and bodily distress in healthy people. Additional research is needed into somatization and its relationship to the demand for medical care. In an era of managed care, increased attention should be devoted to understanding and controlling the demand for care, a large portion of which is symptom driven.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR STUDY ILLNESS EXPERIENCE,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	BARSKY, AJ (corresponding author), BRIGHAM & WOMENS HOSP,DIV PSYCHIAT,75 FRANCIS ST,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL-43216] Funding Source: Medline; NIMH NIH HHS [MH-40487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALONZO AA, 1979, SOC SCI MED-MED SOC, V13, P397, DOI 10.1016/0271-7123(79)90074-9; BACKETT EM, 1954, BRIT MED J, V1, P109, DOI 10.1136/bmj.1.4854.109; BANKS MH, 1975, INT J EPIDEMIOL, V4, P189, DOI 10.1093/ije/4.3.189; BARKER LR, 1982, PRINCIPLES AMBULATOR, P1; BARR JK, 1983, J HEALTH SOC BEHAV, V24, P244, DOI 10.2307/2136574; BARSKY AJ, 1991, J GEN INTERN MED, V6, P413, DOI 10.1007/BF02598162; BARSKY AJ, IN PRESS PSYCHOSOMAT; BARSKY AJ, 1988, WORRIED SICK OUR TRO; BASS C, 1991, BRIT J CLIN PRACT, V45, P237; BASS C, 1990, SOMATIZATION PHYSICA; BEABER RJ, 1984, PSYCHOSOMATICS, V25, P39, DOI 10.1016/S0033-3182(84)73095-7; BENJAMIN S, 1994, LIAISON PSYCHIATRY D; BORUS JF, 1988, GEN HOSP PSYCHIAT, V10, P317, DOI 10.1016/0163-8343(88)90002-3; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CONRAD P, 1992, ANNU REV SOCIOL, V18, P209, DOI 10.1146/annurev.so.18.080192.001233; CRAIG TKJ, 1993, BRIT J PSYCHIAT, V163, P579, DOI 10.1192/bjp.163.5.579; Cummings N A, 1981, Health Policy Q, V1, P159; DEGRUY F, 1987, J FAM PRACTICE, V25, P45; DEMERS RY, 1980, J FAM PRACTICE, V11, P1085; DEVRIES NW, 1982, USE ABUSE MED; DUNNELL K, 1972, MED TAKERS PRESCRIBE, P8; EGAN KJ, 1987, J PSYCHOSOM RES, V31, P11, DOI 10.1016/0022-3999(87)90093-6; ESCOBAR JI, 1987, AM J PUBLIC HEALTH, V77, P837, DOI 10.2105/AJPH.77.7.837; ESCOBAR JI, 1987, ARCH GEN PSYCHIAT, V44, P713; FELDMAN R, 1992, PAYING PHYSICIANS OP; FINK P, 1992, PSYCHOL MED, V22, P173, DOI 10.1017/S0033291700032827; FINK P, 1992, J PSYCHOSOM RES, V36, P439, DOI 10.1016/0022-3999(92)90004-L; FOLLETTE WT, 1968, MED CARE, V6, P31; GARFIELD SR, 1976, NEW ENGL J MED, V294, P426, DOI 10.1056/NEJM197602192940806; GOLDBERG D, 1979, INT J MENT HEALTH, V8, P30, DOI 10.1080/00207411.1979.11448831; GOUGH HG, 1977, MED EDUC, V11, P380, DOI 10.1111/j.1365-2923.1977.tb00636.x; HANNEY DR, 1979, SYMPTOM ICEBERG STUD, P31; HARRIS L, 1989, INSIDE AM; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HILKEVITCH A, 1965, INT J NEUROPSYCH, V1, P371; Illich I., 1976, MED NEMESIS; KASHNER TM, 1992, MED CARE, V30, P811, DOI 10.1097/00005650-199209000-00005; KATON W, 1984, COMPR PSYCHIAT, V25, P208, DOI 10.1016/0010-440X(84)90009-9; KATON W, 1990, GEN HOSP PSYCHIAT, V12, P355, DOI 10.1016/0163-8343(90)90002-T; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KIRMAYER LJ, 1991, J NERV MENT DIS, V179, P647, DOI 10.1097/00005053-199111000-00001; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LIN EHB, 1991, J GEN INTERN MED, V6, P241, DOI 10.1007/BF02598969; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; LIPOWSKI ZJ, 1986, CAN MED ASSOC J, V135, P609; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MCFARLAND BH, 1985, MED CARE, V23, P1211; Mechanic D, 1974, POLITICS MED SOCIAL; Mishler ElliotG., 1981, SOCIAL CONTEXTS HLTH; NOYES R, 1993, ARCH GEN PSYCHIAT, V50, P961; OGRADY KF, 1985, NEW ENGL J MED, V313, P384; PILOWSKY I, 1987, J PSYCHOSOM RES, V31, P177, DOI 10.1016/0022-3999(87)90074-2; QUILL TE, 1988, J GEN INTERN MED, V3, P267, DOI 10.1007/BF02596343; REGIER DA, 1993, ARCH GEN PSYCHIAT, V550, P85; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; ROGHMANN KJ, 1973, PEDIATR RES, V7, P520, DOI 10.1203/00006450-197305000-00005; SALKOVSKIS PM, 1989, COGNITIVE BEHAV THER, P235; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; Shorter E., 1985, BEDSIDE MANNERS; Shorter E., 1992, PARALYSIS FATIGUE HI; SIMON G, 1995, AM J PSYCHIAT, V152, P352; SMITH GR, 1986, NEW ENGL J MED, V314, P1407, DOI 10.1056/NEJM198605293142203; SMITH GR, 1986, ARCH INTERN MED, V146, P69, DOI 10.1001/archinte.146.1.69; SMITH GR, 1995, ARCH GEN PSYCHIAT, V52, P238; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; STEWART DE, 1990, PSYCHOSOMATICS, V31, P153, DOI 10.1016/S0033-3182(90)72188-3; STRAIN JJ, 1994, PSYCHOSOMATICS, V35, P253, DOI 10.1016/S0033-3182(94)71773-4; SWARTZ M, 1986, AM J PSYCHIAT, V143, P1403; VANDERGAGG J, 1978, MED CARE, V26, P299; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; VERBRUGGE LM, 1987, MED CARE, V25, P539, DOI 10.1097/00005650-198706000-00008; Veroff J., 1981, INNER AM; WADSWORTH MEJ, 1971, HLTH SICKNESS CHOICE; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; ZOCCOLILLO MS, 1986, SOUTHERN MED J, V79, P532, DOI 10.1097/00007611-198605000-00004	80	244	247	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1931	1934		10.1001/jama.274.24.1931	http://dx.doi.org/10.1001/jama.274.24.1931			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TL169	8568987				2022-12-28	WOS:A1995TL16900035
J	NIGHTINGALE, S				NIGHTINGALE, S			NEW INFORMATION SHEETS FOR IRBS AND CLINICAL INVESTIGATORS AVAILABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, S (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V272, P582	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-28	WOS:A1995TL16900009
J	Cairns, JA				Cairns, JA			Medical management of unstable angina	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIALS; ACUTE CORONARY SYNDROMES; ARTERY DISEASE; HEART-DISEASE; DOUBLE-BLIND; ASPIRIN; NIFEDIPINE; DILTIAZEM; PATHOGENESIS				Cairns, JA (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA.		Cairns, John/AAI-8744-2021					ANDREFOUET X, 1983, EUR HEART J, V4, P691, DOI 10.1093/oxfordjournals.eurheartj.a061380; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; FANG ZY, 1991, AM J CARDIOL, V68, pC42; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GERSTENBLITH G, 1982, NEW ENGL J MED, V306, P885, DOI 10.1056/NEJM198204153061501; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P121; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LUBSEN J, 1987, AM J CARDIOL, V60, pA18; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1990, LANCET, V336, P827; 1994, CIRCULATION, V89, P1545	18	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1644	1645		10.1016/S0140-6736(95)92834-0	http://dx.doi.org/10.1016/S0140-6736(95)92834-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551818				2022-12-28	WOS:A1995TL42300004
J	Maynard, A; Bloor, K				Maynard, A; Bloor, K			Introducing a market to the United Kingdom's National Health Service	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COSTS				Maynard, A (corresponding author), UNIV YORK, YORK YO1 5DD, N YORKSHIRE, ENGLAND.			Bloor, Karen/0000-0003-4852-9854				Benzeval M, 1995, TACKLING INEQUALITIE; BLOOR K, 1993, 113 U YORK CTR HLTH; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; Dawson D, 1995, 131 U YORK CTR HLTH; DAWSON D, 1994, 115 U YORK CTR HLTHE; DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; ENTHOVEN AC, 1985, NPHT OCCASIONAL PAPE, V5; Enthoven AC, 1980, HLTH PLAN ONLY PRACT; FREEMANTLE N, 1993, PUBLIC ADMIN, V71, P535, DOI 10.1111/j.1467-9299.1993.tb00990.x; FREEMANTLE N, 1992, EFFECTIVE HLTH CARE, V4; FRY J, 1993, GEN PRACTICE FACTS; GRIFFITHS R, 1983, NHS MANAGEMENT ENQUI; HOFFENBERG R, 1987, BRIT MED J, V295, P1505, DOI 10.1136/bmj.295.6612.1505; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LAING W, 1994, LAINGS REV PRIVATE H; MARINKER M, 1984, NEW NHS ACT 1996, P17; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MAYNARD A, 1986, BRIT MED J, V292, P1438, DOI 10.1136/bmj.292.6533.1438; MAYNARD A, 1994, SOC SCI MED, V39, P1433, DOI 10.1016/0277-9536(94)90238-0; MAYNARD A, 1993, HEALTH POLICY, V23, P193, DOI 10.1016/0168-8510(93)90057-V; MAYNARD AK, 1986, HLTH ED GEN PRACTICE, P22; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; PETCHEY R, 1993, BRIT MED J, V306, P699, DOI 10.1136/bmj.306.6879.699; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SMITH T, 1988, BRIT MED J, V296, P1, DOI 10.1136/bmj.296.6614.1; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; WHITTY P, 1992, BRIT MED J, V304, P1039, DOI 10.1136/bmj.304.6833.1039; 1994, OPERATION INTERNAL M; 1994, HLTH PERSONAL SOCIAL; 1995, RENEWING NHS LABOURS; 1995, 24 REP; [No title captured]; 1994, EL9474 DEP HLTH; 1993, COCHRANE PREGNANCY C; 1994, OECD EC SURVEYS; 1989, CMND555; 1995, PRICE THEIR HEADS ME; 1995, OHE COMPENDIUM 1995; 1995, BRIT MED J, V310, P1045	43	30	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					604	608		10.1056/NEJM199602293340918	http://dx.doi.org/10.1056/NEJM199602293340918			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569843				2022-12-28	WOS:A1996TW69600027
J	Dickover, RE; Garratty, EM; Herman, SA; Sim, MS; Plaeger, S; Boyer, PJ; Keller, M; Deveikis, A; Stiehm, ER; Bryson, YJ				Dickover, RE; Garratty, EM; Herman, SA; Sim, MS; Plaeger, S; Boyer, PJ; Keller, M; Deveikis, A; Stiehm, ER; Bryson, YJ			Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission - Effect of maternal zidovudine treatment on viral load	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; P24 ANTIGEN; INFECTION; INUTERO; WOMEN	Objective. - To determine if there are levels of human immunodeficiency virus type 1 (HIV-1) associated with a high or low risk of perinatal transmission and to ascertain the mechanism by which zidovudine treatment reduces perinatal transmission. Design. - A nonrandomized prospective cohort study, Setting. - University medical center and two general hospital affiliates from May 1989 to September 1994. Patients. - Ninety-two HIV-1-seropositive women (95 pregnancies) and their 97 infants. Intervention. - forty-two mothers (43 pregnancies) received zidovudine therapy during pregnancy and/or during labor and delivery. Eleven infants received prophylactic zidovudine for the first 6 weeks after delivery. Main Outcome Measure. - HIV-1 infection status of the infant. Results. - Twenty of the 97 infants were perinatally infected with HIV-1. Transmitting mothers were more likely to have plasma HIV-1 RNA levels higher than 50 000 copies per milliliter at delivery than nontransmitting mothers (15 [75.0%] of 20 transmitters vs four [5.3%] of 75 nontransmitters; P<.001). None of the 63 women with less than 20 000 HIV-1 RNA copies per milliliter transmitted. Twenty-two women treated with open-label oral zidovudine during gestation showed an eightfold median decrease in plasma RNA levels (median [25th and 75th percentile], 43 043 [5699 and 63 053] copies per milliliter before zidovudine vs 4238 [603 and 5116] HIV-1 RNA copies per milliliter at delivery; P<.001), and none transmitted. Four zidovudine-treated women with high HIV-1 levels transmitted despite the presence of zidovudine-sensitive virus in vitro in both the mothers and their infants. Conclusions. - Maternal HIV-1 RNA levels were highly predictive of perinatal transmission risk and suggest that certain levels of virus late in gestation and/or during labor and delivery are associated with both a high risk and a low risk of transmission, Our results also suggest that zidovudine exerts a major protective effect by reducing maternal HIV-1 RNA levels prior to delivery and that further strategies are needed to prevent perinatal transmission in women with high or increasing virus levels and/or zidovudine-resistant virus.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; ROCHE MOL SYST,SOMERVILLE,NJ; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90024; LONG BEACH MEM MED CTR,DEPT PEDIAT,LOS ANGELES,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030629, R01HD026621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27550] Funding Source: Medline; NICHD NIH HHS [HD26621, HD30629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BORKOWSKY W, 1994, J PEDIATR-US, V125, P345, DOI 10.1016/S0022-3476(05)83274-3; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DICKOVER RE, 1994, J INFECT DIS, V170, P1279, DOI 10.1093/infdis/170.5.1279; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HAUSNER MA, 1993, J IMMUNOL METHODS, V157, P181, DOI 10.1016/0022-1759(93)90085-L; JACKSON JB, 1993, AIDS, V7, P1475, DOI 10.1097/00002030-199311000-00011; KLIKS SC, 1994, JAMA-J AM MED ASSOC, V272, P467, DOI 10.1001/jama.272.6.467; LANDESMAN SH, 1994, INT C ANT AG CHEM OC; MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; ROQUES P, 1993, AIDS, V7, pS39, DOI 10.1097/00002030-199311002-00009; ROUZIOUX C, 1993, AIDS, V7, pS49, DOI 10.1097/00002030-199311002-00011; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCARLATTI G, 1993, AIDS, V7, pS45, DOI 10.1097/00002030-199311002-00010; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8031; ZWEIG MH, 1993, CLIN CHEM, V39, P561; 1994, ACTG VIROLOGY MANUAL; 1992, LANCET, V339, P1007; 1992, MMWR-MORBID MORTAL W, V41, P1	29	260	266	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					599	605		10.1001/jama.275.8.599	http://dx.doi.org/10.1001/jama.275.8.599			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594240				2022-12-28	WOS:A1996TW62700019
J	Weston, B; Lauria, M				Weston, B; Lauria, M			Patient advocacy in the 1990s	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEUKEMIA				Weston, B (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.		/L-2667-2019					EMMINGER W, 1992, BONE MARROW TRANSPL, V9, P313; HOROWITZ MM, 1992, BLOOD, V79, P2771; IGLEHART JK, 1995, NEW ENGL J MED, V333, P1019, DOI 10.1056/NEJM199510123331525; THUROW LC, 1985, NEW ENGL J MED, V313, P611, DOI 10.1056/NEJM198509053131005; 1987, NEW ENGL J MED, V316, P333	5	14	14	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					543	544		10.1056/NEJM199602223340818	http://dx.doi.org/10.1056/NEJM199602223340818			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559225				2022-12-28	WOS:A1996TV68600030
J	Strom, BL; Berlin, JA; Kinman, JL; Spitz, PW; Hennessy, S; Feldman, H; Kimmel, S; Carson, JL				Strom, BL; Berlin, JA; Kinman, JL; Spitz, PW; Hennessy, S; Feldman, H; Kimmel, S; Carson, JL			Parenteral ketorolac and risk of gastrointestinal and operative site bleeding - A postmarketing surveillance study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the risk of gastrointestinal and operative site bleeding associated with the use of parenteral ketorolac tromethamine. Design.-Postmarketing surveillance inception cohort study. Setting.-A total of 35 hospitals throughout the Philadelphia, Pa, region, 1991 to 1993. Patients.-Patients administered In 272 courses of parenteral ketorolac therapy were compared with patients administered 10 247 courses of a parenteral opiate who were matched to the ketorolac patients by hospital, admitting service, and date of initiation of study drug. Main Outcome Measures.-Rnedical records were reviewed for demographics, medical history, doses and duration of study drug, various aspects of the hospital course including surgery and concomitant medications, and adverse events. Results.-The multivariate adjusted odds ratio (OR) comparing ketorolac with opiates for gastrointestinal bleeding was 1.30 (95% confidence interval [Cl], 1.11 to 1.52); for operative site bleeding, the OR was 1.02 195% Cl, 0.95 to 1.10). The OR was elevated further in subjects 75 years of age or older for both gastrointestinal bleeding (OR=1.66; 95% Cl, 1.23 to 2.25) and operative site bleeding (OR=1.12; 95% Cl, 0.94 to 1.35). A dose-response relationship was evident between average daily ketorolac dose and both gastrointestinal bleeding and operative site bleeding (trend test P<.001 for both). When analgesic therapy lasted 5 or fewer days, ketorolac was associated with only a small increased risk of gastrointestinal bleeding (OR=1.17; 95% Cl, 0.99 to 1.30); when therapy was prolonged beyond 5 days, the OR was 2.20 (95% Cl, 1.36 to 3.57). The association of ketorolac with operative site bleeding was not affected by duration of therapy. Conclusions.-The overall associations between ketorolac use and both gastrointestinal bleeding and operative site bleeding are small. However, the risk associated with the drug is larger and clinically important when ketorolac is used in higher doses, in older subjects, and for more than 5 days. Improving physicians' prescribing practices by limiting the dose and duration of ketorolac use, especially in the elderly, should enhance its overall risk-benefit balance.	UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOSTAT & EPIDEMIOL,PHILADELPHIA,PA 19104; SYNTEX INC,SYNTEX DEV RES,WORLD SAFETY SURVEILLANCE & REPORTING,PALO ALTO,CA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,DIV GEN INTERNAL MED,NEW BRUNSWICK,NJ 08903	University of Pennsylvania; University of Pennsylvania; Syntex Corporation; Rutgers State University New Brunswick; Rutgers State University Medical Center	Strom, BL (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,824 BLOCKLEY HALL,PHILADELPHIA,PA 19104, USA.							BROWN CR, 1990, PHARMACOTHERAPY, V10, pS59; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; CHOO V, 1993, LANCET, V342, P109, DOI 10.1016/0140-6736(93)91304-5; Fleiss JL, 1981, STATISTICAL METHODS, P61; FOLSLAND B, 1990, J INT MED RES, V18, P305, DOI 10.1177/030006059001800407; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; LEWIS S, 1994, LANCET, V343, P784, DOI 10.1016/S0140-6736(94)91850-3; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; REMINGTON RD, 1985, STATISTICS APPLICATI, P187; STOUTEN EM, 1992, ACTA ANAESTH SCAND, V36, P716, DOI 10.1111/j.1399-6576.1992.tb03551.x; 1992, WHO ADVERSE EVENT DI	11	249	262	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					376	382		10.1001/jama.275.5.376	http://dx.doi.org/10.1001/jama.275.5.376			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569017				2022-12-28	WOS:A1996TT30300031
J	Kelner, KL				Kelner, KL			Ion channels: Opening the gate	SCIENCE			English	Editorial Material							SODIUM											ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; LARSSON HP, IN PRESS NEURON; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	5	2	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					615	615		10.1126/science.271.5249.615	http://dx.doi.org/10.1126/science.271.5249.615			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571122				2022-12-28	WOS:A1996TT87000033
J	OBrien, CP; McLellan, AT				OBrien, CP; McLellan, AT			Myths about the treatment of addiction	LANCET			English	Article							ALCOHOL DEPENDENCE; HYPERTENSION; NALTREXONE				OBrien, CP (corresponding author), UNIV PENN,VA MED CTR,DEPT PSYCHIAT,3900 CHESTNUT ST,PHILADELPHIA,PA 19104, USA.				NIDA NIH HHS [P50-DA-05186] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005186] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALTERMAN AI, 1991, J NERV MENT DIS, V179, P401, DOI 10.1097/00005053-199107000-00003; Armor D. J., 1976, ALCOHOLISM TREATMENT; Ball J.C., 2012, EFFECTIVENESS METHAD; CLARK LT, 1991, AM HEART J, V121, P664, DOI 10.1016/0002-8703(91)90443-L; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DELEON G, 1994, 841286 NAT I DRUG AB; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; GERSTEIN DR, 1979, AM J DRUG ALCOHOL AB, V6, P1, DOI 10.3109/00952997909007029; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GERSTEIN DR, 1994, ADP94628 CAL DEP ALC; GORLIN R, 1991, AM HEART J, V121, P658, DOI 10.1016/0002-8703(91)90442-K; GRABER AL, 1992, DIABETES CARE, V15, P1477, DOI 10.2337/diacare.15.11.1477; Harrison W. H., 1993, INTERNAL MED; HAVASSY BE, 1995, ADDICTION, V90, P699, DOI 10.1046/j.1360-0443.1995.90569911.x; Herman W. H., 1985, DIABETIC RENAL DISOR; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HOROWITZ RI, 1990, LANCET, V336, P542; Hubbard RL, 1989, DRUG ABUSE TREATMENT; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MCLELLAN AT, 1980, DRUG ALCOHOL DEPEN, V5, P189, DOI 10.1016/0376-8716(80)90179-9; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller WR, 1986, TREATING ADDICTIVE B; Moos R, 1990, ALCOHOLISM TREATMENT; OBRIEN CP, 1986, PHILADELPHIA MED, V82, P442; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; SCHAUB AF, 1993, CLIN EXP HYPERTENS, V15, P1121, DOI 10.3109/10641969309037099; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SIMPSON DD, 1980, ARCH GEN PSYCHIAT, V37, P896; SINNOCK P, 1955, HOSPITALIZATION DIAB; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1989, PUBLIC USE DATATAPE; 1989, PREVENTION TREATMENT	34	343	349	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					237	240		10.1016/S0140-6736(96)90409-2	http://dx.doi.org/10.1016/S0140-6736(96)90409-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551886	hybrid			2022-12-28	WOS:A1996TT06900015
J	Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A				Chandrasekharan, UM; Sanker, S; Glynias, MJ; Karnik, SS; Husain, A			Angiotensin II-forming activity in a reconstructed ancestral chymase	SCIENCE			English	Article							SUBSTRATE-SPECIFICITY; SUBSTANCE-P; HUMAN HEART; MAST-CELLS; PEPTIDE; ENZYME; GENE; RAT	The current model of serine protease diversity theorizes that the earliest protease molecules were simple digestive enzymes that gained complex regulatory functions and restricted substrate specificities through evolution. Among the chymase group of serine proteases are enzymes that convert angiotensin I to angiotensin II, as well as others that simply degrade angiotensins. An ancestral chymase reconstructed with the use of phylogenetic inference, total gene synthesis, and protein expression had efficient and specific angiotensin II-forming activity (turnover number, about 700 per second). Thus, angiotensin II-forming activity is the more primitive state for chymases, and the loss of such activity occurred later in the evolution of some of these serine proteases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012; Karnik, Sadashiva/Y-2477-2019	Husain, Ahsan/0000-0003-3426-3469; Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL44201, R01 HL057470, HL33713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713, R01HL044201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; ERDOS EG, 1985, BIOCHEM SOC T, V13, P42, DOI 10.1042/bst0130042; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HAKANSON R, 1986, HISTOCHEMISTRY, V86, P5, DOI 10.1007/BF00492340; HENDERSON IW, 1981, ADV ANIMAL COMP PHYS, P355; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; HOIT BD, 1995, J CLIN INVEST, V95, P1519, DOI 10.1172/JCI117824; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; PASTOR LM, 1988, J SUBMICR CYTOL PATH, V20, P25; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REMMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097; SWOFFORD DL, 1992, PAUP PHYLOGENETIC AN; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	20	166	170	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					502	505		10.1126/science.271.5248.502	http://dx.doi.org/10.1126/science.271.5248.502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560264				2022-12-28	WOS:A1996TR32200041
J	Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD				Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD			Transmission of tuberculosis among the urban homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; COMPLEX; ELEMENT; IS6110; TOOL	Objective. - To determine the relative frequencies of primary and reactivation tuberculosis in the urban homeless. Design. - Prospective evaluation of homeless tuberculosis patients. Setting. - Central Los Angeles, Calif. Patients. - Thirty-four homeless patients with culture-proven tuberculosis. Interventions. - IS61 10-based restriction fragment length polymorphism (RFLP) analysis was performed on Mycobacterium tuberculosis isolates. If results were inconclusive, pTBN12-based RFLP analysis was performed. Main Outcome Measure. - Clustering of M tuberculosis isolates. A cluster consisted of two or more isolates with indistinguishable RFLP patterns. Results. - Twenty-four of 34 homeless patients had clustered isolates in six clusters. Conclusions. - The minimum percentage of cases due to primary tuberculosis in the homeless was estimated to be 53%, compared with the traditional estimate of 10% in the general population. The results suggest that primary tuberculosis caused the majority of tuberculosis cases in this population of the urban homeless in central Los Angeles.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV ARKANSAS MED SCI HOSP,DEPT PATHOL,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT ANAT,LITTLE ROCK,AR 72205; MCLELLAN MEM VET HOSP,MED RES SERV,LITTLE ROCK,AR; STATOLOGY,TAHOE PARADISE,CA	University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Barnes, PF (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED,DIV INFECT DIS,HMR 904,2025 ZONAL AVE,LOS ANGELES,CA 90033, USA.				NIAID NIH HHS [AI35265, AI35222] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035265, R01AI035222] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BERMUDEZ LE, 1991, J INFECT DIS, V163, P1286, DOI 10.1093/infdis/163.6.1286; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; COUSINS DV, 1993, VET MICROBIOL, V37, P1, DOI 10.1016/0378-1135(93)90178-A; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; MCMURRAY DN, 1992, J NUTR, V122, P738, DOI 10.1093/jn/122.suppl_3.738; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P9	17	120	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					305	307		10.1001/jama.275.4.305	http://dx.doi.org/10.1001/jama.275.4.305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544271				2022-12-28	WOS:A1996TP96500027
J	Tenover, FC; Hughes, JM				Tenover, FC; Hughes, JM			The challenges of emerging infectious diseases - Development and spread of multiply-resistant bacterial pathogens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECTRUM BETA-LACTAMASES; ANTIMICROBIAL RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; ENTEROCOCCUS-FAECALIS; PENICILLIN-RESISTANT; NOSOCOMIAL OUTBREAK; CEPHALOSPORINS; MECHANISMS; GENES				Tenover, FC (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,NOSOCOMIAL PATHOGENS LAB BRANCH G08,ATLANTA,GA 30333, USA.							Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; AKIBA T, 1960, Jpn J Microbiol, V4, P219; [Anonymous], 1993, METHODS DILUTION ANT; [Anonymous], 1995, IMPACTS ANTIBIOTIC R; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BURWEN DR, 1994, J INFECT DIS, V170, P1622, DOI 10.1093/infdis/170.6.1622; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CLEWELL DB, 1986, ANNU REV MICROBIOL, V40, P635, DOI 10.1146/annurev.mi.40.100186.003223; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DeFlaun M.F., 1991, GENE TRANSFER ENV, P1; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; ELWELL LP, 1975, INFECT IMMUN, V12, P404, DOI 10.1128/IAI.12.2.404-410.1975; GARDNER P, 1968, LANCET, V2, P407; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; GOOTZ TD, 1990, CLIN MICROBIOL REV, V3, P13, DOI 10.1128/CMR.3.1.13-31.1990; HACKBARTH CJ, 1989, ANTIMICROB AGENTS CH, V33, P991, DOI 10.1128/AAC.33.7.991; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HOFFMAN J, 1995, NEW ENGL J MED, V333, P481; INFANTERIVARD C, 1993, EPIDEMIOL REV, V15, P444, DOI 10.1093/oxfordjournals.epirev.a036129; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; KATSANIS GP, 1994, J CLIN MICROBIOL, V32, P691, DOI 10.1128/JCM.32.3.691-696.1994; KAUFHOLD A, 1992, ANTIMICROB AGENTS CH, V36, P1215, DOI 10.1128/AAC.36.6.1215; Kirby WMM, 1944, SCIENCE, V99, P452, DOI 10.1126/science.99.2579.452; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; Lederberg J., 1992, EMERGING INFECTIONS; LYYTIKAINEN O, 1995, J HOSP INFECT, V31, P41, DOI 10.1016/0195-6701(95)90082-9; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGOWAN JE, 1989, ANTIMICROB AGENTS CH, V33, P1855, DOI 10.1128/AAC.33.11.1855; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; MOSSINGHOFF GJ, 1995, NEW DRUG APPROVALS 1, P1; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; MURRAY BE, 1986, J CLIN INVEST, V77, P289, DOI 10.1172/JCI112289; NAVARRO F, 1994, ANTIMICROB AGENTS CH, V38, P1788, DOI 10.1128/AAC.38.8.1788; NEU HC, 1990, DIAGN MICR INFEC DIS, V13, P195, DOI 10.1016/0732-8893(90)90109-9; NEU HC, 1982, ANN INTERN MED, V97, P408, DOI 10.7326/0003-4819-97-3-408; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; OUNISSI H, 1990, ANTIMICROB AGENTS CH, V34, P2164, DOI 10.1128/AAC.34.11.2164; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; PHILLIPS I, 1976, LANCET, V2, P656; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; ROY C, 1985, EUR J CLIN MICROBIOL, V4, P146, DOI 10.1007/BF02013586; SIMPSON IN, 1994, J ANTIMICROB CHEMOTH, V34, P353, DOI 10.1093/jac/34.3.353; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; SOUGAKOFF W, 1988, REV INFECT DIS, V10, P879; SWENSON JM, 1994, J CLIN MICROBIOL, V32, P1700, DOI 10.1128/JCM.32.7.1700-1704.1994; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P1524, DOI 10.1128/JCM.33.6.1524-1527.1995; TENOVER FC, 1991, AM J MED, V91, pS76, DOI 10.1016/0002-9343(91)90347-Z; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; TRIEUCUOT P, 1985, EMBO J, V4, P3583, DOI 10.1002/j.1460-2075.1985.tb04120.x; 1995, INFECT CONT HOSP EP, V16, P105; 1993, MMWR-MORBID MORTAL W, V42, P597; 1995, REPORT ASM TASK FORC; 1994, ANTIMICROB AGENTS CH, V38, P908	63	210	224	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					300	304		10.1001/jama.275.4.300	http://dx.doi.org/10.1001/jama.275.4.300			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544270				2022-12-28	WOS:A1996TP96500026
J	Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG				Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG			Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization	SCIENCE			English	Article							ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; RHODOPSIN; KINASE; MECHANISM; PATHWAYS; BINDING	beta-Arrestins are proteins that bind phosphorylated heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) and contribute to the desensitization of GPCRs by uncoupling the signal transduction process. Resensitization of GPCR responsiveness involves agonist-mediated receptor sequestration. Overexpression of beta-arrestins in human embryonic kidney cells rescued the sequestration of beta(2)-adrenergic receptor (beta(2)AR) mutants defective in their ability to sequester, an effect enhanced by simultaneous overexpression of beta-adrenergic receptor kinase 1, Wild-type beta(2)AR sequestration was inhibited by the overexpression of two beta-arrestin mutants. These findings suggest that beta-arrestins play an integral role in GPCR internalization and thus serve a dual role in the regulation of GPCR function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337	28	799	815	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					363	366		10.1126/science.271.5247.363	http://dx.doi.org/10.1126/science.271.5247.363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553074				2022-12-28	WOS:A1996TQ52800045
J	Yeh, SR; Fricke, RA; Edwards, DH				Yeh, SR; Fricke, RA; Edwards, DH			The effect of social experience on serotonergic modulation of the escape circuit of crayfish	SCIENCE			English	Article							BEHAVIOR; RECEPTORS; AGGRESSION; OCTOPAMINE; LOBSTERS	The neuromodulator serotonin has widespread effects in the nervous systems of many animals, often influencing aggression;and dominance status. In crayfish, the effect of serotonin on the neural circuit for tailflip escape behavior was found to depend on the animal's social experience. Serotonin reversibly enhanced the response to sensory stimuli of the lateral giant (LG) tailflip command neuron in socially dominant crayfish, reversibly inhibited it in subordinate animals, and persistently enhanced it in socially isolated crayfish, Serotonin receptor agonists had opposing effects: A vertebrate serotonin type 1 receptor agonist inhibited the LG neurons in dominant and subordinate crayfish and had no effect in isolates, whereas a vertebrate serotonin type 2 receptor agonist enhanced the LG neurons' responses in all three types of crayfish. The LG neurons appear to have at ]east two populations of serotonin receptors that differ in efficacy in dominant, subordinate, and socially isolate crayfish.	GEORGIA STATE UNIV,DEPT BIOL,ATLANTA,GA 30302; EMORY UNIV,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322	University System of Georgia; Georgia State University; Emory University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026457] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS26457] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOVBJERG RV, 1953, PHYSIOL ZOOL, V26, P173, DOI 10.1086/physzool.26.2.30154514; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; COCCARO EF, 1992, INT CLIN PSYCHOPHARM, V7, P3, DOI 10.1097/00004850-199200710-00001; EDWARDS DH, 1991, J NEUROSCI, V11, P2117; GLANZMAN DL, 1983, J NEUROSCI, V3, P2263; GLENNON RA, 1987, J MED CHEM, V30, P1, DOI 10.1021/jm00384a001; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; LEONARD BE, 1992, INT CLIN PSYCHOPHARM, V7, P13, DOI 10.1097/00004850-199200710-00002; LINNOILA VMI, 1992, J CLIN PSYCHIAT, V53, P46; LIVINGSTONE MS, 1980, SCIENCE, V208, P76, DOI 10.1126/science.208.4439.76; REAL D, 1990, BRAIN RES, V521, P203, DOI 10.1016/0006-8993(90)91544-Q; STEKLIS HD, 1986, AM J PRIMATOL, V11, P133, DOI 10.1002/ajp.1350110206; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; VU ET, 1993, J NEUROSCI, V13, P4379; WINBERG S, 1992, J COMP PHYSIOL A, V170, P93; Wine J.J., 1982, P241; YEH SC, UNPUB; ZHANG B, 1994, J EXP BIOL, V190, P55; ZUCKER RS, 1972, J NEUROPHYSIOL, V35, P599, DOI 10.1152/jn.1972.35.5.599	21	217	218	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					366	369		10.1126/science.271.5247.366	http://dx.doi.org/10.1126/science.271.5247.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553075	Green Submitted			2022-12-28	WOS:A1996TQ52800046
J	Norton, B; HomerWard, M; Donnelly, MT; Long, RG; Holmes, GKT				Norton, B; HomerWard, M; Donnelly, MT; Long, RG; Holmes, GKT			A randomised prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS	Objective-To compare percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. Design-Randomised prospective study of inpatients with acute stroke requiring enteral nutrition. Setting-One university hospital (Nottingham) and one district general hospital (Derby). Subjects-30 patients with persisting dysphagia at 14 days after acute stroke: 16 patients were randomised to gastrostomy tube feeding and 14 to nasogastric tube feeding. Main outcome measures-Six week mortality; amount of feed administered; change in nutritional state; treatment failure; and length of hospital stay. Results-Mortality at 6 weeks was significantly lower in the gastrostomy group with two deaths (12%) compared with eight deaths (57%) in the nasogastric group (P<0.05). All gastrostomy fed patients (16) received the total prescribed feed whereas 10/14 (71%) of nasogastric patients lost at least one day's feed. Nasogastric patients received a significantly (P<0.001) smaller proportion of their prescribed feed (78%; 95% confidence interval 63% to 94%) compared with the gastrostomy group (100%). Patients fed via a gastrostomy tube showed greater improvement in nutritional state, according to several different criteria at six weeks compared with the nasogastric group. In the gastrostomy group the mean albumin concentration increased from 27.1 g/l (24.5 g/l to 29.7 g/l to 30.1 g/l (28.3 g/l to 31.9 g/l. In contrast, among the nasogastric group there was a reduction from 31.4 g/l (28.6 g/l to 34.2 g/l) to 22.3 g/l (20.7 g/l to 23.9 g/l) (P<0.003). In addition, there were fewer treatment failures in the gastrostomy group (0/16 versus 3/14). Six patients from the gastrostomy group were discharged from hospital within six weeks of the procedure compared with none from the nasogastric group (P<0.05). Conclusion-This study indicates that early gastrostomy tube feeding is greatly superior to nasogastric tube feeding and should be the nutritional treatment of choice for patients with acute dysphagic stroke.	CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Norton, B (corresponding author), DERBYSHIRE ROYAL INFIRM,DERBY DE1 2QY,ENGLAND.							ABERNATHY GB, 1989, JPEN-PARENTER ENTER, V13, P387, DOI 10.1177/0148607189013004387; BARER DH, 1984, BRIT MED J, V289, P1622, DOI 10.1136/bmj.289.6458.1622; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; GRANT JP, 1988, ANN SURG, V207, P598, DOI 10.1097/00000658-198805000-00014; JONES M, 1990, JPEN-PARENTER ENTER, V14, P533, DOI 10.1177/0148607190014005533; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; MAHONEY F I, 1965, Md State Med J, V14, P61; PARK RHR, 1992, BRIT MED J, V304, P1406, DOI 10.1136/bmj.304.6839.1406; PETERS RA, 1994, BR J INT CARE, V4, P88; PONSKY JL, 1981, GASTROINTEST ENDOSC, V27, P9, DOI 10.1016/S0016-5107(81)73133-X; RAHA SK, 1994, AGE AGEING, V23, P162, DOI 10.1093/ageing/23.2.162; REES RGP, 1988, JPEN-PARENTER ENTER, V12, P469, DOI 10.1177/0148607188012005469; STONE SP, 1994, J ROY COLL PHYS LOND, V28, P52; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372; WALTON JN, 1993, BRAINS DISEASES NERV; WICKS C, 1992, GUT, V33, P613, DOI 10.1136/gut.33.5.613; WOLFSEN H, 1993, GASTROENTEROL CLIN N, V2, P259; 1992, POSITIVE APPROACH NU	19	298	309	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					13	16		10.1136/bmj.312.7022.13	http://dx.doi.org/10.1136/bmj.312.7022.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555849	Green Published			2022-12-28	WOS:A1996TP20900016
J	BERO, L; RENNIE, D				BERO, L; RENNIE, D			THE COCHRANE COLLABORATION - PREPARING, MAINTAINING, AND DISSEMINATING SYSTEMATIC REVIEWS OF THE EFFECTS OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIALS		UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; BAILAR JC, 1995, J CLIN EPIDEMIOL, V48, P149, DOI 10.1016/0895-4356(94)00149-K; CHALMERS I, 1993, DOING MORE GOOD HARM, P153; DONALD A, 1995, COCHRANE DATABASE SY; FEINSTEIN AR, 1995, J CLIN EPIDEMIOL, V48, P71, DOI 10.1016/0895-4356(94)00110-C; LIBERATI A, 1995, J CLIN EPIDEMIOL, V48, P81, DOI 10.1016/0895-4356(94)00115-7; Lock Stephen P., 1991, FUTURE MED J, P127; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SPITZER WO, 1995, J CLIN EPIDEMIOL, V48, P1, DOI 10.1016/0895-4356(94)00109-4; 1994, COCHRANE COLLABORATI; 1995, JAMA-J AM MED ASSOC, V273, P776; 1994, JAMA-J AM MED ASSOC, V272, P1926	16	337	344	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1935	1938		10.1001/jama.274.24.1935	http://dx.doi.org/10.1001/jama.274.24.1935			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568988				2022-12-28	WOS:A1995TL16900036
J	Davidson, AJ				Davidson, AJ			Gone to the devil: The murals of Ile Royale hospital	BRITISH MEDICAL JOURNAL			English	Article											Davidson, AJ (corresponding author), MATRA MARCONI SPACE,STEVENAGE SG1 2EX,HERTS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1713	1714		10.1136/bmj.311.7021.1713	http://dx.doi.org/10.1136/bmj.311.7021.1713			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541772	Green Published			2022-12-28	WOS:A1995TL94200034
J	Schreiber, S; Howaldt, S; Schnoor, M; Nikolaus, S; Bauditz, J; Gasche, C; Lochs, H; Raedler, A				Schreiber, S; Howaldt, S; Schnoor, M; Nikolaus, S; Bauditz, J; Gasche, C; Lochs, H; Raedler, A			Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE ULCERATIVE-COLITIS; NECROSIS-FACTOR-ALPHA; CROHNS-DISEASE; ENHANCED PRODUCTION; MONONUCLEAR-CELLS; ACTIVITY INDEX; INTERLEUKIN-1; INTERFERON	Background. Some patients with inflammatory bowel disease have anemia that is refractory to treatment with iron and vitamins. We examined whether administering iron and recombinant erythropoietin could raise hemoglobin levels in such patients. Methods. Thirty-four patients with inflammatory bowel disease (15 with ulcerative colitis and 19 with Crohn's disease) and anemia refractory to iron therapy (hemoglobin concentrations below 10.0 g per deciliter [6.2 mmol per liter]) were randomly assigned in a prospective, double-blind, 12-week trial to receive either oral iron (100 mg per day) and subcutaneous erythropoietin (150 U per kilogram of body weight twice per week) (n=17) or oral iron and placebo (n=17). The primary measure of efficacy was an increase in hemoglobin levels of more than 1.0 g per deciliter (0.62 mmol per liter). Additional analyses were performed with other patients with inflammatory bowel disease. Results. The severity of anemia was related to clinical disease activity as well as to in vitro monocyte secretion of interleukin-1 beta, a proinflammatory cytokine. Serum erythropoietin concentrations were increased in 52 randomly selected outpatients with inflammatory bower disease and anemia, but the concentrations were inadequate in relation to the degree of anemia. Twelve weeks of therapy with recombinant erythropoietin and oral iron increased mean (+/-SE) hemoglobin concentrations from 8.81+/-0.27 g per deciliter (5.47+/-0.17 mmol per liter) to 10.52+/-0.41 g per deciliter (6.5+/-0.25 mmol per liter),whereas hemoglobin concentrations in the placebo group decreased from 8.69+/-0.11 g per deciliter (5.4+/-0.068 mmol per liter) to 7.84+/-0.33 g per deciliter (4.9+/-0.2 mmol per liter) (P<0.001), After 12 weeks, hemoglobin levels had increased by more than 1.0 g per deciliter in 82 percent of the patients in the erythropoietin group, as compared with 24 percent of those in the placebo group (P=0.002). There were five treatment failures in the placebo group and two in the erythropoietin group (P=0.18); treatment failure was defined as a decrease in hemoglobin levels of more than 2.0 g per deciliter (1.24 mmol per liter) to a value below 8.0 g per deciliter (4.96 mmol per liter) or any decrease to less than 6.5 g per deciliter (4.03 mmol per liter). Conclusions. In patients with inflammatory bowel disease and anemia refractory to treatment with iron and vitamins, treatment with oral iron and recombinant erythropoietin can raise hemoglobin levels. (C) 1996, Massachusetts Medical Society.	UNIV HAMBURG, DEPT MED, HAMBURG, GERMANY; HUMBOLDT UNIV BERLIN, CHARITE HOSP, DEPT MED 4, D-10117 BERLIN, GERMANY; UNIV VIENNA, DEPT MED 4, VIENNA, AUSTRIA	University of Hamburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Vienna			Gasche, Christoph W/A-5139-2013	Gasche, Christoph/0000-0002-3752-6685				BEST WR, 1979, GASTROENTEROLOGY, V77, P843; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAZZOLA M, 1992, BRIT J HAEMATOL, V80, P278, DOI 10.1111/j.1365-2141.1992.tb08133.x; COTES PM, 1982, BRIT J HAEMATOL, V50, P427, DOI 10.1111/j.1365-2141.1982.tb01938.x; ERSLEV AJ, 1980, ANN CLIN LAB SCI, V10, P250; ESCHBACH JW, 1989, AM J KIDNEY DIS, V14, P2; FAQUIN WC, 1992, BLOOD, V79, P1987; FUCHS D, 1991, EUR J HAEMATOL, V46, P65; HENRY DH, 1992, SEMIN ONCOL, V19, P3; HORINA JH, 1993, GASTROENTEROLOGY, V104, P1828, DOI 10.1016/0016-5085(93)90666-Z; JOHANNSEN H, 1989, EUR J HAEMATOL, V43, P201; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MACDOUGALL IC, 1989, LANCET, V1, P425; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MEANS RT, 1991, BLOOD, V78, P2564; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Sachs L., 1992, ANGEW STAT, V7th, P361; SCHLAGETER MH, 1990, CLIN CHEM, V36, P1731; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; SHAPIRO SS, 1968, J AM STAT ASSOC, V63, P1343, DOI 10.2307/2285889; SMITH MA, 1992, ANN RHEUM DIS, V51, P753, DOI 10.1136/ard.51.6.753	24	164	174	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					619	623		10.1056/NEJM199603073341002	http://dx.doi.org/10.1056/NEJM199603073341002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592524				2022-12-28	WOS:A1996TX69300002
J	Williams, RM				Williams, RM			The costs of visits to emergency departments	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-CARE; PHYSICIANS; ADMISSIONS; SEVERITY	Background. Many visits to emergency departments are for minor medical problems, and these visits are criticized as being expensive and economically inefficient. This study examines the marginal costs (the extra costs for an additional visit) of emergency department visits. Methods. Monthly data on the costs of hospital and physicians' services from 1991 through 1993 were obtained from a sample of six community hospitals in Michigan. The data were analyzed with ordinary least-squares regression techniques to determine the ratio of marginal to average costs. Average and marginal costs were then determined for 24,010 visits during 12 randomly selected weeks in 1993. A visit by an individual patient was the unit of analysis, and visits were classified as nonurgent, semiurgent, or urgent according to explicit criteria. Costs and charges were determined for all visits and were classified according to the degree of urgency. Results. For all emergency department visits, the average charge was $383, the average cost was $209, and the marginal cost was $88 (42 percent of the average cost). Thirty-two percent of the visits were classified as nonurgent, 26 percent as semiurgent, and 42 percent as urgent. For nonurgent visits, the average charge was $124, the average cost was $62, and the marginal cost was only $24, For semiurgent visits, the average charge was $312, the average cost was $159, and the marginal cost was $67, For urgent visits, the average charge was $621, the average cost was $351, and the marginal cost was $148. Conclusions. The true costs of nonurgent care in the emergency department are relatively low. The potential savings from a diversion of nonurgent visits to private physicians' offices may therefore be much less than is widely believed. (C)1996, Massachusetts Medical Society.			Williams, RM (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH M3224,DEPT HLTH POLICY & MANAGEMENT,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.							ALTMAN SH, 1981, ANNU REV PUBL HEALTH, V2, P117, DOI 10.1146/annurev.pu.02.050181.001001; *AM MED ASS, 1994, PHYS CURR PROC TERM; BAKER LC, 1994, HEALTH AFFAIR, V13, P162, DOI 10.1377/hlthaff.13.5.162; BARAFF LJ, 1991, ANN EMERG MED, V20, P1, DOI 10.1016/S0196-0644(05)81108-4; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; CLINTON WJ, 1993, JOINT SESS C NAT SEP; *DEP HLTH HUM SERV, 1983, NON US HOSP EM DEP M; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; *GEN ACC OFF, 1993, PUBL; GRANNEMANN TW, 1986, J HEALTH ECON, V5, P107, DOI 10.1016/0167-6296(86)90001-9; GUTERMAN JJ, 1985, ANN EMERG MED, V14, P1191, DOI 10.1016/S0196-0644(85)81028-3; HADDY RI, 1987, J FAM PRACTICE, V24, P389; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2361, DOI 10.1001/jama.260.16.2361; Huntley H C, 1977, JACEP, V6, P296; KLEM SA, 1990, J PEDIATR-US, V116, P231, DOI 10.1016/S0022-3476(05)82879-3; KRONENFELD JJ, 1978, J HEALTH SOC BEHAV, V19, P68, DOI 10.2307/2136323; LAVE JR, 1970, AM ECON REV, V60, P379; MARGOLIS J, 1994, MED GROUP PRACT UPDA, V33, P1; MCCAIG LF, 1994, ADV DATA VITAL HLTH, V245; Melnick G A, 1989, Health Care Financ Rev, V10, P29; Miller M E, 1992, Health Care Financ Rev, V14, P135; MITCHELL TA, 1992, ANN EMERG MED, V21, P1208, DOI 10.1016/S0196-0644(05)81748-2; MUNOZ E, 1985, JAMA-J AM MED ASSOC, V254, P1763, DOI 10.1001/jama.254.13.1763; MUNOZ E, 1988, AM J OBSTET GYNECOL, V158, P1176, DOI 10.1016/0002-9378(88)90249-9; NICHOLSON W, 1987, INTERMEDIATE MICROEC, P191; *PRACT MAN INF COR, 1994, PHYS FEES COMP GUID; *SAS I, 1990, SAS US GUID; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SAYWELL RM, 1992, AM J EMERG MED, V10, P8, DOI 10.1016/0735-6757(92)90116-F; STRATMANN WC, 1975, MED CARE, V13, P1033, DOI 10.1097/00005650-197512000-00005; WILLIAMS RM, 1995, THESIS U MICHIGAN; World Health Organization, 1980, INT CLASSIFICATION D; 1994, NEW ENGL J MED, V330, P1426	33	257	259	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					642	646		10.1056/NEJM199603073341007	http://dx.doi.org/10.1056/NEJM199603073341007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592529				2022-12-28	WOS:A1996TX69300007
J	BennettGuerrero, E; Jimenez, JL; White, WD; DAmico, EB; Baldwin, BI; Schwinn, DA				BennettGuerrero, E; Jimenez, JL; White, WD; DAmico, EB; Baldwin, BI; Schwinn, DA			Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery - A randomized, double-blind, placebo-controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPEN-HEART-SURGERY; THYROID-HORMONE INDEXES; CARDIOPULMONARY BYPASS; NONTHYROIDAL ILLNESSES; VENTRICULAR-FUNCTION; MYOCARDIAL ISCHEMIA; STUNNED MYOCARDIUM; BLOOD-FLOW; DOBUTAMINE; RECOVERY	Objective.-To test the hypothesis that triiodothyronine (T-3) administration improves hemodynamic variables and decreases inotropic drug requirements in cardiac surgery patients. Design.-Prospective, randomized, double-blind, placebo-controlled trial. Setting.-Tertiary care medical center. Patients.-A total of 211 patients undergoing coronary artery surgery at high risk for requiring inotropic drug support. Intervention.-At release of aortic cross-clamp, patients were randomized to an intravenous infusion of T-3 (0.8 mu g/kg followed by 0.12 mu g . kg(-1). h(-1) for 6 hours), dopamine (positive control, 5 mu g . kg(-1). min(-1) for 6 hours), or placebo. Main Outcome Measures.-Perioperative hemodynamic variables, inotropic support requirements, and serum T-3 concentrations. Results.-Mean+/-SEM free T-3 serum concentrations decreased significantly during cardiopulmonary bypass in all groups (from 0.0035+/-0.0001 nmol/L [0.23+/-0.01 ng/dl] to 0.001+/-0.0001 nmol/L. [0.07+/-0.00 ng/dl]; P=.001) and increased to 0.0133+/-0.0004 nmol/L [0.87+/-0.03 ng/dL] (twice normal range; P<.001) following initiation of intravenous T-3. Intravenous T-3 did not change hemodynamic variables or inotropic drug requirements; however, heart rate increased (P<.001), and a trend toward decreased use of inotropic agents was demonstrated in the dopamine group. Conclusions.-Triiodothyronine administration prevents decreases in serum thyroid hormone concentrations associated with cardiopulmonary bypass. Intravenous T-3 does not have dramatic effects on hemodynamic variables in this setting as has been previously suggested. Although mild effects on myocardial performance may exist, we cannot recommend at this time the routine use of intravenous T-3 as an inotropic agent in patients undergoing coronary artery bypass graft surgery.	DUKE UNIV, MED CTR, DEPT SURG, DUKE HEART CTR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DUKE HEART CTR, DURHAM, NC 27710 USA	Duke University; Duke University	BennettGuerrero, E (corresponding author), DUKE UNIV, MED CTR, DEPT ANESTHESIOL, DUKE HEART CTR, BOX 3094, DURHAM, NC 27710 USA.			Schwinn, Debra/0000-0002-9696-5231				ANSELL J, 1984, ARCH INTERN MED, V144, P949, DOI 10.1001/archinte.144.5.949; BREISBLATT WM, 1990, J AM COLL CARDIOL, V15, P1261, DOI 10.1016/S0735-1097(10)80011-7; BREMNER WF, 1978, J THORAC CARDIOV SUR, V75, P392; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; CHOPRA IJ, 1983, ANN INTERN MED, V98, P946, DOI 10.7326/0003-4819-98-6-946; CHRISTAKIS GT, 1992, J THORAC CARDIOV SUR, V103, P1083; CHU SH, 1991, ANN THORAC SURG, V52, P791, DOI 10.1016/0003-4975(91)91213-F; DiSesa V J, 1987, J Card Surg, V2, P385, DOI 10.1111/j.1540-8191.1987.tb00197.x; DISESA VJ, 1986, CLIN CARDIOL, V9, P253, DOI 10.1002/clc.4960090604; DISESA VJ, 1982, J THORAC CARDIOV SUR, V83, P256; DUKE GJ, 1994, CRIT CARE MED, V22, P1919; DYKE CM, 1991, ANN THORAC SURG, V52, P14, DOI 10.1016/0003-4975(91)91410-W; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOENEN M, 1992, CHEST, V5, P804; GOETZSCHE BH, 1992, J THORAC CARDIOVASC, V104, P273; HAMBLIN PS, 1986, J CLIN ENDOCR METAB, V62, P717, DOI 10.1210/jcem-62-4-717; HAMILTON MA, 1990, J AM COLL CARDIOL, V16, P91, DOI 10.1016/0735-1097(90)90462-X; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HOLLAND FW, 1992, ANN THORAC SURG, V54, P301, DOI 10.1016/0003-4975(92)91389-Q; HOLLAND FW, 1991, ANN THORAC SURG, V52, P46, DOI 10.1016/0003-4975(91)91416-S; KAPTEIN EM, 1982, CLIN ENDOCRINOL, V16, P565, DOI 10.1111/j.1365-2265.1982.tb03173.x; KHURI SF, 1993, THROMBOSIS HEMORRHAG, P1051; KLEMPERER JD, 1995, J THORAC CARDIOV SUR, V109, P457, DOI 10.1016/S0022-5223(95)70276-8; KLEMPERER JD, 1995, NEW ENGL J MED, V333, P1522, DOI 10.1056/NEJM199512073332302; KUAN P, 1984, J AM COLL CARDIOL, V3, P1391, DOI 10.1016/S0735-1097(84)80276-4; LANZA F, 1988, AM J PHYSIOL, V255, pH1276, DOI 10.1152/ajpheart.1988.255.6.H1276; Levy JH, 1990, J CARDIOTHORAC AN S5, V4, P7; LOPRESTI JS, 1989, ANN INTERN MED, V110, P970, DOI 10.7326/0003-4819-110-12-970; MANGANO DT, 1985, ANESTHESIOLOGY, V62, P571, DOI 10.1097/00000542-198505000-00005; MITCHELL IM, 1992, J THORAC CARDIOV SUR, V103, P800; NOVITZKY D, 1988, ANN THORAC SURG, V45, P50, DOI 10.1016/S0003-4975(10)62396-X; NOVITZKY D, 1989, J THORAC CARDIOV SUR, V98, P972; Novitzky D, 1989, Eur J Cardiothorac Surg, V3, P140, DOI 10.1016/1010-7940(89)90092-4; NOVITZKY D, 1991, ANN THORAC SURG, V51, P10, DOI 10.1016/0003-4975(91)90438-V; PALAZZO MG, 1991, INTENS CARE MED, V17, P325, DOI 10.1007/BF01716190; RIRIE DG, 1995, ANESTHESIOLOGY, V82, P1004, DOI 10.1097/00000542-199504000-00025; ROBUSCHI G, 1986, HORM RES, V23, P151, DOI 10.1159/000180311; Royster R L, 1993, J Cardiothorac Vasc Anesth, V7, P19; ROYSTER RL, 1991, ANESTH ANALG, V72, P729; SALATI M, 1990, J THORAC CARDIOV SUR, V100, P464; SALOMON NW, 1982, ANN THORAC SURG, V33, P48, DOI 10.1016/S0003-4975(10)63198-0; SATO Y, 1982, JPN CIRC J, V46, P1059, DOI 10.1253/jcj.46.1059; SCHWINN DA, 1991, CIRCULATION, V84, P2559, DOI 10.1161/01.CIR.84.6.2559; SEGAL J, 1989, ENDOCR RES, V15, P619, DOI 10.3109/07435808909036355; SLAG MF, 1981, JAMA-J AM MED ASSOC, V245, P43, DOI 10.1001/jama.245.1.43; SNOW TR, 1992, CARDIOLOGY, V80, P112, DOI 10.1159/000174988; STERLING K, 1986, ENDOCRINOLOGY, V119, P292, DOI 10.1210/endo-119-1-292; TEIGER E, 1993, EUR HEART J, V14, P629, DOI 10.1093/eurheartj/14.5.629; TEOH KH, 1987, J THORAC CARDIOV SUR, V93, P291; VATNER SF, 1979, CIRC RES, V45, P793, DOI 10.1161/01.RES.45.6.793; WALKER JD, 1995, J THORAC CARDIOV SUR, V110, P315, DOI 10.1016/S0022-5223(95)70227-X; WECHSLER AS, 1993, J CARDIAC SURG, V8, P338; 1995, HEART STROKE FACTS 1, P1	55	112	115	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1996	275	9					687	692		10.1001/jama.275.9.687	http://dx.doi.org/10.1001/jama.275.9.687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX174	8594265				2022-12-28	WOS:A1996TX17400023
J	Keilson, LM; Vary, CPH; Sprecher, DL; Renfrew, R				Keilson, LM; Vary, CPH; Sprecher, DL; Renfrew, R			Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene	ANNALS OF INTERNAL MEDICINE			English	Article							METABOLISM; HYPERTRIGLYCERIDEMIA; DEFICIENCY	Objective: To explore genetic mechanisms for pregnancy-associated pancreatitis and hyperlipidemia in two sisters. Design: Case history. Setting: Tertiary care facility with outpatient follow-up. Patients: Two sisters with acute pancreatitis and the acute respiratory distress syndrome were admitted (patient 1) or transferred (patient 2) to an intensive care setting with severely elevated triglyceride levels. Patient 1 was in the last trimester of pregnancy; patient 2 was 1 month post partum. Both patients were of French Canadian ancestry. Intervention: Acute treatment was directed at stabilizing both patients medically (with fat restriction) and one patient surgically (patient 2). Treatment with fat restriction, weight loss, and gemfibrozil was continued after hospitalization. R Results: Through DNA sequencing, we detected a mutation at amino acid residue 188 of lipoprotein lipase (LPL), reflecting product from one allele of the LPL gene in which a glutamine residue was substituted for a glycine (gly 188-->glu). Conclusion: LPL plays a key role in regulating triglyceride levels in pregnancy. Mutations of LPL may place the patient at risk for pancreatitis. This heterozygous LPL mutation, gly188-->glu, is prevalent in certain ethnic groups and may be a common cause of pancreatitis associated with pregnancy.	MAINE MED CTR, RES INST, PORTLAND, ME 04102 USA; UNIV CINCINNATI, LIPID RES DIV, CINCINNATI, OH USA; REDDINGTON FAIRVIEW HOSP, SKOWHEGAN, ME USA	Maine Medical Center; University of Cincinnati	Keilson, LM (corresponding author), MAINE MED CTR, CTR LIPIDS & CARDIOVASC HLTH, 48 GILMAN ST, PORTLAND, ME 04102 USA.							BERGERON J, 1992, CLIN GENET, V41, P206; DAVIDOFF F, 1973, NEW ENGL J MED, V289, P552, DOI 10.1056/NEJM197309132891103; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; GILLETT MPT, 1979, ATHEROSCLEROSIS, V33, P495, DOI 10.1016/0021-9150(79)90040-6; GLUECK CJ, 1980, AM J OBSTET GYNECOL, V136, P755, DOI 10.1016/0002-9378(80)90452-4; HERRERA E, 1988, AM J OBSTET GYNECOL, V158, P1575, DOI 10.1016/0002-9378(88)90193-7; HUNNINGHAKE DB, 1991, DRUG TREATMENT HYPER, P92; IVERIUS PH, 1988, J CLIN INVEST, V82, P1106, DOI 10.1172/JCI113667; KINNUNEN PKJ, 1980, EUR J CLIN INVEST, V10, P469, DOI 10.1111/j.1365-2362.1980.tb02087.x; KNOPP RH, 1973, J REPROD MED, V10, P95; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; MA YH, 1994, J LIPID RES, V35, P1066; MA YH, 1993, J CLIN INVEST, V91, P1953, DOI 10.1172/JCI116414; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; NIES BM, 1990, AM J PERINAT, V7, P166, DOI 10.1055/s-2007-999472; SANDERSON SL, 1991, JAMA-J AM MED ASSOC, V265, P1858, DOI 10.1001/jama.265.14.1858; SPENCE JD, 1995, ANN INTERN MED, V123, P493, DOI 10.7326/0003-4819-123-7-199510010-00003; SPRECHER DL, 1992, J LIPID RES, V33, P859; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WATTS GF, 1992, BRIT J OBSTET GYNAEC, V99, P163, DOI 10.1111/j.1471-0528.1992.tb14481.x	21	35	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					425	428		10.7326/0003-4819-124-4-199602150-00007	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554252				2022-12-28	WOS:A1996TV22000007
J	Pisetsky, DS				Pisetsky, DS			The breakthrough	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Pisetsky, DS (corresponding author), DUKE UNIV, MED CTR,VET AFFAIRS MED CTR,BOX 151G,ROOM E-1008, 508 FULTON ST, DURHAM, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					345	347		10.7326/0003-4819-124-3-199602010-00013	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554234				2022-12-28	WOS:A1996TR59600013
J	Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R				Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R			Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease	LANCET			English	Article							PROTEINURIA	Background Primary and secondary forms of focal segmental glomerulosclerosis (FSGS) are common causes of glomerular proteinuria. Secondary forms of FSGS seem to be the result of adaptive changes that follow a reduction in renal mass. We saw an elderly patient with severe bilateral renal vascular disease (RVD) who had FSGS on percutaneous biopsy. To find out whether elderly patients with atherosclerotic RVD are predisposed to the development of FSGS, we reviewed all cases of FSGS at our institution between 1990 and 1995. Methods We identified 59 cases of biopsy-proven FSGS and examined clinical, histological, and radiographic records. Findings Of the 59 patients, 24 were older than 50 years; eight of these had RVD. No patient under the age of 50 had RVD. Seven of the eight patients with RVD and FSGS had substantial proteinuria at presentation. All had typical glomerular lesions with focal segmental tuft collapse and synechiae; other glomeruli were hypertrophic. All patients showed further decline in renal function on follow-up. Interpretation The association of FSGS and RVD may represent an under-recognised aetiology of significant proteinuria in elderly patients.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital				Pascual, Manuel A./0000-0001-7747-1693				ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; DAGATI V, 1994, KIDNEY INT, V46, P1223, DOI 10.1038/ki.1994.388; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; FREEDMAN BI, 1995, AM J KIDNEY DIS, V25, P207, DOI 10.1016/0272-6386(95)90001-2; GEPHARDT GN, 1984, CLEVELAND CLIN Q, V51, P371, DOI 10.3949/ccjm.51.2.371; HARVEY JM, 1992, LANCET, V340, P1435, DOI 10.1016/0140-6736(92)92624-O; KUMAR A, 1980, ARCH INTERN MED, V140, P1631, DOI 10.1001/archinte.140.12.1631; MCLACHLAN M, 1981, BRIT J RADIOL, V54, P488, DOI 10.1259/0007-1285-54-642-488; PICKERING TG, 1993, DISEASES KIDNEY, P1451; RENNKE HG, 1989, AM J KIDNEY DIS, V13, P443, DOI 10.1016/S0272-6386(89)80001-0	10	61	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					231	233		10.1016/S0140-6736(96)90406-7	http://dx.doi.org/10.1016/S0140-6736(96)90406-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551883				2022-12-28	WOS:A1996TT06900012
J	Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M				Acton, S; Rigotti, A; Landschulz, KT; Xu, SZ; Hobbs, HH; Krieger, M			Identification of scavenger receptor SR-BI as a high density lipoprotein receptor	SCIENCE			English	Article							CHOLESTERYL LINOLEYL ETHER; APOPROTEIN-A-I; SELECTIVE UPTAKE; MEDIATED ENDOCYTOSIS; HEPATOMA-CELLS; ADRENAL-GLAND; RAT; ESTERS; METABOLISM; HEPATOCYTES	High density lipoprotein (HDL) and low density lipoprotein (LDL) are cholesterol transport particles whose plasma concentrations are directly (LDL) and inversely (HDL) correlated with risk for atherosclerosis. LDL catabolism involves cellular uptake and degradation of the entire particle by a well-characterized receptor. HDL, in contrast, selectively delivers its cholesterol, but not protein, to cells by unknown receptors. Here it is shown that the class B scavenger receptor SR-BI is an HDL receptor. SR-BI binds HDL with high affinity, is expressed primarily in liver and nonplacental steroidogenic tissues, and mediates selective cholesterol uptake by a mechanism distinct from the classic LDL receptor pathway.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Eckhardt, Erik/G-1567-2010; Girelli, Domenico/B-1183-2008	Girelli, Domenico/0000-0001-9684-1899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009047, P01HL041484, R01HL052212] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL41484, HL09047] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1981, J BIOL CHEM, V256, P7362; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; ASSRNAN G, 1995, METABOLIC MOL BASES, P2053; BABITT J, UNPUB; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; Brown M S, 1979, Recent Prog Horm Res, V35, P215; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Converse CA, 1992, LIPOPROTEIN ANAL PRA; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; MACKINNON M, 1986, J BIOL CHEM, V261, P2548; MURPHY BD, 1985, ENDOCRINOLOGY, V116, P1587, DOI 10.1210/endo-116-4-1587; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P375, DOI 10.1016/0005-2760(90)90083-A	43	1933	2048	1	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					518	520		10.1126/science.271.5248.518	http://dx.doi.org/10.1126/science.271.5248.518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560269				2022-12-28	WOS:A1996TR32200046
J	Cossart, P; Boquet, P; Normark, S; Rappuoli, R				Cossart, P; Boquet, P; Normark, S; Rappuoli, R			Cellular microbiology emerging	SCIENCE			English	Editorial Material									FAC MED NICE,INSERM,U452,F-06107 NICE,FRANCE; KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN; IST RIC IMMUNOBIOL,I-53100 SIENA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet	Cossart, P (corresponding author), INST PASTEUR,UNITE INTERACT BACTERIES CELLULES,PARIS,FRANCE.							ADAM T, 1995, J CELL BIOL, V129, P367, DOI 10.1083/jcb.129.2.367; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COSSART P, 1995, CURR OPIN CELL BIOL, V7, P94, DOI 10.1016/0955-0674(95)80050-6; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WICK MJ, 1991, CELL, V67, P651; 1995, INSERM P LAUDAT C AI; 1989, INSERM P LAUDAT C BI; 1991, ASCB EMBO C AROLLA	24	120	123	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					315	316		10.1126/science.271.5247.315	http://dx.doi.org/10.1126/science.271.5247.315			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553065				2022-12-28	WOS:A1996TQ52800030
J	Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT				Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT			C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity	SCIENCE			English	Article							RAPID PURIFICATION; MOUSE COMPLEMENT; LYMPHOCYTES-B; RECEPTOR; SYSTEM; ANTIBODY; PROTEINS; INVIVO; SELF	An optimal immune response should differentiate between harmful and innocuous antigens. Primitive systems of innate immunity, such as the complement system, may play a role in this distinction. When activated, the C3 component of complement attaches to potential antigens on microorganisms. To determine whether this alters acquired immune recognition, mice were immunized with a recombinant model antigen, hen egg lysozyme (HEL), fused to murine C3d. HEL bearing two and three copies of C3d was 1000- and 10,000-fold more immunogenic, respectively, than HEL alone. Thus, C3d is a molecular adjuvant of innate immunity that profoundly influences an acquired immune response.	UNIV CAMBRIDGE,SCH MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of Cambridge; Stanford University; Howard Hughes Medical Institute; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Allison, Michael/0000-0003-3677-3294	NIAID NIH HHS [AI07247, AI19512] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KROP I, IN PRESS EUR J IMMUN; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; TAYLOR ME, 1991, BIOCHEM J, V274, P575, DOI 10.1042/bj2740575; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WENG WK, 1994, J BIOL CHEM, V269, P32514	21	944	1043	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					348	350		10.1126/science.271.5247.348	http://dx.doi.org/10.1126/science.271.5247.348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553069				2022-12-28	WOS:A1996TQ52800040
J	Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE				Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE			DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1	SCIENCE			English	Article							CANCER; CARCINOMAS; PANCREAS	About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel of pancreatic carcinomas were analyzed for convergent sites of homboygous deletion. Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway. Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,GRAD PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741	NCI NIH HHS [CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CONE D, 1993, NATURE, V366, P698; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRANCKE U, 1994, CYTOGENET CELL GENET, V66, P196, DOI 10.1159/000133697; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HAHN S, UNPUB; HAHN SA, 1995, CANCER RES, V55, P4670; HAHN SA, IN PRESS CANCER RES; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HURSH DA, 1993, DEVELOPMENT, V117, P1211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1985, CANCER RES, V45, P1437; Leach Francis, COMMUNICATION; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; REDSTON MS, 1994, CANCER RES, V54, P3025; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SILVERMAN GA, 1993, PCR METH APPL, V3, P141; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	27	2055	2166	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					350	353		10.1126/science.271.5247.350	http://dx.doi.org/10.1126/science.271.5247.350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553070				2022-12-28	WOS:A1996TQ52800041
J	Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P				Mortier, E; Pouchot, J; Girard, L; Boussougant, Y; Vinceneux, P			Assessment of urine analysis for the diagnosis of tuberculosis	BRITISH MEDICAL JOURNAL			English	Article									UNIV PARIS 07,HOP LOUIS MOURIER,DEPT MICROBIOL,F-92700 COLOMBES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite	Mortier, E (corresponding author), UNIV PARIS 07,HOP LOUIS MOURIER,DEPT INTERNAL MED,F-92700 COLOMBES,FRANCE.							BARBEZAT C, 1981, SCHWEIZ RUNDSCH MED, V70, P241; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BENTZ RR, 1975, AM REV RESPIR DIS, V111, P647; FAVEZ G, 1972, SCHWEIZ MED WSCHR, V102, P877; GARCIARODRIGUEZ JA, 1994, CLIN INFECT DIS, V18, P557, DOI 10.1093/clinids/18.4.557	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					27	28		10.1136/bmj.312.7022.27	http://dx.doi.org/10.1136/bmj.312.7022.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555854	Green Published			2022-12-28	WOS:A1996TP20900020
J	Torgerson, DJ; Spencer, A				Torgerson, DJ; Spencer, A			Marginal costs and benefits	BRITISH MEDICAL JOURNAL			English	Article								Decision makers are interested in measuring the costs and benefits of various interventions, and sometimes they are presented with the average costs and benefits of alternative interventions and asked to compare these. Usually a newer intervention is being compared with an existing one, and the most appropriate comparison is not of average costs (and benefits) but of the extra-or marginal-costs (and benefits) of the new intervention. Reanalysis of the cost effectiveness ratio of biochemical screening of all women for Down's syndrome compared with age based screening shows that the marginal cost effectiveness of biochemical screening is pound 47 786, compared with an average cost effectiveness of pound 37 591. It may sometimes be difficult or costly to calculate marginal costs and benefits, but this should be done whenever possible.	UNIV YORK,DEPT ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Torgerson, DJ (corresponding author), UNIV YORK,CTR HLTH ECON,NATL PRIMARY CARE RES & DEV,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Spencer, Anne/0000-0002-8163-3103				HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; MCGHEE SM, 1994, BRIT J GEN PRACT, V44, P441; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; Piggott M, 1994, J Med Screen, V1, P45; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WHYNES DK, 1995, HEALTH ECON, V4, P31, DOI 10.1002/hec.4730040104; WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211	7	37	37	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					35	36		10.1136/bmj.312.7022.35	http://dx.doi.org/10.1136/bmj.312.7022.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555859	Green Published			2022-12-28	WOS:A1996TP20900025
J	ASSENDELFT, WJJ; KOES, BW; KNIPSCHILD, PG; BOUTER, LM				ASSENDELFT, WJJ; KOES, BW; KNIPSCHILD, PG; BOUTER, LM			THE RELATIONSHIP BETWEEN METHODOLOGICAL QUALITY AND CONCLUSIONS IN REVIEWS OF SPINAL MANIPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; RANDOMIZED CLINICAL-TRIALS; MANUAL THERAPY; MANAGEMENT; ARTICLES; EFFICACY; METAANALYSIS; MOBILIZATION; SCIENCE; STATE	Objective.-To study the relationship between the methodological quality and other characteristics of reviews of spinal manipulation for low back pain on the one hand and the reviewers' conclusions on the effectiveness of manipulation on the other hand. Data Sources.-Reviews identified by MEDLINE search, citation tracking, library search, and correspondence with experts. Study Selection.-English- or Dutch-language reviews published up to 1993 dealing with spinal manipulation for low back pain that include at least two randomized clinical trials (RCTs). Data Extraction.-Methodological quality was assessed using a standardized criteria list applied independently by two assessors (range, 0% to 100%). Other extracted characteristics were the comprehensiveness of the search, selective citation of studies, language, inclusion of non-RCTs, type of publication, reviewers' professional backgrounds, and publication in a spinal manipulation journal or book. The reviewers' conclusions were classified as negative, neutral, or positive. Data Synthesis.-A total of 51 reviews were assessed, 17 of which were neutral and 34 positive. The methodological quality was low, with a median score of 23%. Nine of the 10 methodologically best reviews were positive. Other factors associated with a positive reviewers' conclusion were review of spinal manipulation only, inclusion of a spinal manipulator in the review team, and a comprehensive literature search. Conclusions.-The majority of the reviews concluded that spinal manipulation is an effective treatment for low back pain. Although, in particular, the reviews with a relatively high methodological quality had a positive conclusion, strong conclusions were precluded by the overall low quality of the reviews. More empirical research on the review methods applied to other therapies in other professional fields is needed to further explore our findings about the factors related to a positive reviewers' conclusion.	UNIV LIMBURG,DEPT EPIDEMIOL,MAASTRICHT,NETHERLANDS; FREE UNIV AMSTERDAM,DEPT BIOSTAT & EPIDEMIOL,AMSTERDAM,NETHERLANDS	Hasselt University; Vrije Universiteit Amsterdam	ASSENDELFT, WJJ (corresponding author), FREE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,VAN DER BOECHORSTSTRAAT 7,1081 BT AMSTERDAM,NETHERLANDS.		assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014; Koes, Bart w/K-4614-2016	assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778; Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482				ABENHAIM L, 1992, CLIN INVEST MED, V15, P527; ANDERSON R, 1992, J MANIP PHYSIOL THER, V15, P181; ASSENDELFT WJJ, 1992, J MANIP PHYSIOL THER, V15, P487; AUFDEMKAMPE G, 1991, ORTHOPEDISCHE GENEES, P115; BLOCH R, 1987, SPINE, V12, P430, DOI 10.1097/00007632-198706000-00002; BOUTER LM, 1990, 3RD P INT PHYS C SYD, P438; BOUTER LM, 1985, MED CONTACT, V40, P357; BRANSON MH, 1984, CONCEPTS MECHANISMS, P90; Bronfort G, 1992, PRINCIPLES PRACTICE, P415; BRUNARSKI DJ, 1984, J MANIP PHYSIOL THER, V7, P243; CHAPMANSMITH D, 1989, J MANIP PHYSIOL THER, V12, P142; CONLON J, 1992, CHIROPRACTIC TREATME; COULEHAN JL, 1985, CULT MED PSYCHIAT, V9, P353; CURTIS P, 1988, OCCUP MED, V3, P31; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DEYO RA, 1991, CONT CONSERVATIVE CA, P169; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; DICKERSIN K, 1994, BRIT MED J, V309, P286; DIFABIO RP, 1992, PHYS THER, V72, P853, DOI 10.1093/ptj/72.12.853; DIFABIO RP, 1986, PHYS THER, V66, P51, DOI 10.1093/ptj/66.1.51; EVANS DP, 1985, EMPIRICAL APPROACHES, P228; FLOR H, 1984, PAIN, V19, P105, DOI 10.1016/0304-3959(84)90831-5; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GATTERMAN MI, 1990, CHIROPRACTIC MANAGEM, P397; GEIRINGER SR, 1993, REHABILITATION MED P, P451; GILBERT JR, 1986, CAN FAM PHYSICIAN, V32, P1855; GOLDSCHMIDT PG, 1986, HEALTH SERV RES, V21, P215; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GRAHAME R, 1980, CLIN RHEUM DIS, V6, P143; GREENLAND S, 1980, J OCCUP ENVIRON MED, V22, P670, DOI 10.1097/00043764-198010000-00014; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; HALDEMAN S, 1986, CLIN SPORT MED, V5, P277; HALDEMAN S, 1991, ADULT SPINE PRINCIPL, P1581; HALDEMAN S, 1980, LOW BACK PAIN, P245; HALDEMAN S, 1983, CLIN ORTHOP RELAT R, V179, P62; HAYNES RB, 1992, BRIT MED J, V304, P330, DOI 10.1136/bmj.304.6823.330; HOFFMAN RM, 1994, SPINE, V19, pS2068; INGLIS BD, 1979, CHIROPRACTIC NZ REPO, P200; Jacobs J W, 1991, Ned Tijdschr Geneeskd, V135, P317; JAYSON MIV, 1986, BRIT MED J, V293, P1454, DOI 10.1136/bmj.293.6560.1454; JULL GA, 1986, MODERN MANUAL THERAP, P740; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KUKURIN GW, 1985, AM CHIROPR ASS J, V19, P41; LABAN MM, 1992, ORTHOP CLIN N AM, V23, P451; Lankhorst G J, 1987, Ned Tijdschr Geneeskd, V131, P898; LAWRENCE VA, 1992, J CLIN EPIDEMIOL, V45, P301, DOI 10.1016/0895-4356(92)90091-Z; LEBOEUF C, 1990, J MANIP PHYSIOL THER, V13, P89; LEE CK, 1988, ORTHOP CLIN N AM, V19, P797; Light R., 1984, SUMING UP SCI REV RE, P160; LYNOU N, 1987, LEGITIMATION REGISTR, P135; MACDONALD MJ, 1988, J CHIROPRACTIC R AUT, P2; MANGA P, 1993, EFFECTIVENESS COST E, P35; MILNE R, 1993, J EPIDEMIOL COMMUN H, V47, P169, DOI 10.1136/jech.47.3.169; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MORITZ U, 1979, SCAND J REHABIL MED, V11, P173; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NACHEMSON A, 1985, INT ORTHOP, V9, P1, DOI 10.1007/BF00267031; NACHEMSON A, 1969, Scandinavian Journal of Rehabilitation Medicine, V1, P85; NACHEMSON A, 1969, SCAND J REHABIL MED, P85; NACHEMSON A, 1977, APROACHES VALIDATION, P42; NACHEMSON A, 1980, LUMBAR SPINE BACK PA, P453; NACHEMSON AL, 1992, CLIN ORTHOP RELAT R, V279, P8; NACHEMSON AL, 1985, CLIN ORTHOPAEDICS, V200, P266; ODONOGHUE CE, 1986, MODERN MANUAL THERAP, P849; OROURKE K, 1989, J CLIN EPIDEMIOL, V42, P1021, DOI 10.1016/0895-4356(89)90168-6; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; OXMAN A, 1994, PREPARING MAINTAININ; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PARIS SV, 1983, CLIN ORTHOPAEDICS, V179, P55; Pedersen P, 1990, EUR J CHIROPRACTIC, V38, P41; QUINET RJ, 1979, SEMIN ARTHRITIS RHEU, V8, P261, DOI 10.1016/0049-0172(79)90005-2; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P359; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHEKELLE PG, 1991, APPROPRIIATENESS SPI; SILAGY CA, 1993, FAM PRACT, V10, P337, DOI 10.1093/fampra/10.3.337; TAN JC, 1992, BAILLIERE CLIN RHEUM, V6, P629, DOI 10.1016/S0950-3579(05)80131-1; WARDWELL W, 1992, CHIROPRACTIC HIST EV; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; WINER CER, 1985, ASPECTS MANIPULATIVE, P97; YATES AAH, 1980, LUMBAR SPINE BACK PA, P437; ZINN WM, 1981, THER UMSCH, V38, P642; 1987, SPINE S, V12, P9; 1994, JAMA-J AM MED ASSOC, V272, P1926	87	89	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1942	1948		10.1001/jama.274.24.1942	http://dx.doi.org/10.1001/jama.274.24.1942			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568990	Green Submitted			2022-12-28	WOS:A1995TL16900038
J	Espinel, CH				Espinel, CH			Masaccio's cripple: A neurological syndrome. Its art, medicine, and values	LANCET			English	Editorial Material									GEORGETOWN UNIV,SCH MED,ARLINGTON,VA 22205	Georgetown University	Espinel, CH (corresponding author), BLOOD PRESSURE CTR,1715 N GEORGE MASON DR,SUITE 401,ARLINGTON,VA 22205, USA.							BALDINI U, 1992, BRANCACCI CHAPEL, P170; BERTI L, 1968, OPERA COMPLETA MASAC; CASTIGLIONI A, 1934, RENAISSANCE MED ITAL, P1; ESPINEL CH, 1994, LANCET, V344, P1750, DOI 10.1016/S0140-6736(94)92891-6; Haerer A, 1992, DEJONGS NEUROLOGIC E DEJONGS NEUROLOGIC E; Kemp Martin, 1990, SCI ART, P9; PAUL JR, 1971, HIST POLIOMYELITIS, P10; PELLEGRINO E, 1979, HUMANISM PHYSICIAN, P155; POPEHENNESSY J, 1993, DONATELLOS SCULPTURE, P11; ROWLAND LP, 1995, MERRITTS TXB NEUROLO, P47; Vasari G, 1965, LIVES ARTISTS, P125; WALTON J, 1985, BRAINS DISEASES NERV, P280; WECHSLER IS, 1963, CLIN NEUROLOGY, P639	13	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1684	1686		10.1016/S0140-6736(95)92846-4	http://dx.doi.org/10.1016/S0140-6736(95)92846-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551830	hybrid			2022-12-28	WOS:A1995TL42300016
J	Last, J				Last, J			Redefining the unacceptable	LANCET			English	Editorial Material											Last, J (corresponding author), UNIV OTTAWA,FAC MED,OTTAWA,ON,CANADA.							Hertzman C, 1995, ENV HLTH CENTRAL E E; HOMERDIXON TF, 1991, INT SECURITY, V16, P76, DOI 10.2307/2539061; HOMERDIXON TF, 1994, INT SECURITY, V19, P5, DOI 10.2307/2539147; KAIN KC, 1995, ANN R COLL PHYSICIAN, V28, P141; LAST JM, 1995, IMPLICATIONS GLOBAL; McMichael A J, 1993, PLANETARY OVERLOAD G; Percival Valerie, 1995, ENV SCARCITY VIOLENT; ROSENAU M, 1913, PREVENTIVE MED HYGIE, P684; VICKERS G, 1958, LANCET, V1, P599; 1993, WORLDWATCH I STATE W; 1989, ALMA ATA YEAR 2000 R, P31; 1995, 1995 WHO WORLD HLTH; 1995, 1995 WMO UNEP WHO RE; 1995, STATE WORLDS FISHERI	14	6	6	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1642	1643		10.1016/S0140-6736(95)92832-4	http://dx.doi.org/10.1016/S0140-6736(95)92832-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551816				2022-12-28	WOS:A1995TL42300002
J	Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK				Nordlee, JA; Taylor, SL; Townsend, JA; Thomas, LA; Bush, RK			Identification of a Brazil-nut allergen in transgenic soybeans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BERTHOLLETIA-EXCELSA; RICH PROTEIN; METHIONINE; EXPRESSION; ALBUMIN	Background The nutritional qulaity of soybeans (Glycine maul is compromised by a relative deficiency of methionine in the protein fraction of the seeds. To improve the nutritional quality, methionine-rich 2S albumin from the Brazil nut (Bertholletia excelsa) has been introduced into transgenic soybeans. Since the Brazil nut is a known allergenic food, we assessed the allergenicity of the 2S albumin. Methods. The ability of proteins in transgenic and nontransgenic soybeans, Brazil nuts, and purified 25 albumin to bind to IgE in serum from subjects allergic to Brazil nuts was determined by radioallergosorbent tests (four subjects) and sodium dodecyl sulfate-polyacrylamide-gel electrophoresis (nine subjects) with immunoblotting and autoradiography. Three subjects also underwent skin-prick testing with extracts of soybean, transgenic soybean, and Brazil nut. Results On radioallergosorbent testing of pooled serum from four subjects allergic to Brazil nuts, protein extracts of transgenic soybean inhibited binding of IgE to Brazil-nut proteins. On immunoblotting, serum IgE from eight of nine subjects bound to purified 2S albumin from the Brazil nut and to proteins of similar molecular weight in the Brazil nut and the transgenic soybean. On skin-prick testing, three subjects had positive reactions to extracts of Brazil nut and transgenic soybean and negative reactions to soybean extract. Conclusions. The 2S albumin is probably a major Brazil-nut allergen, and the transgenic soybeans analyzed in this study contain this protein. Our study shows that an allergen from a food known to be allergenic can be transferred into another food by genetic engineering.	PIONEER HI BRED INT INC,RES & PROD DEV,JOHNSTON,IA; UNIV WISCONSIN,DEPT MED,MADISON,WI; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET AFFAIRS HOSP,MADISON,WI	DuPont; Pioneer Hi-Bred International, Inc.; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nordlee, JA (corresponding author), UNIV NEBRASKA,DEPT FOOD SCI & TECHNOL,LINCOLN,NE 68583, USA.		Taylor, Steve L./V-1341-2019					ALDOPHSON CR, 1986, MANUAL CLIN LAB IMMU, P652; ALTENBACH SB, 1987, PLANT MOL BIOL, V8, P239, DOI 10.1007/BF00015032; ALTENBACH SB, 1989, PLANT MOL BIOL, V13, P513, DOI 10.1007/BF00027311; ALTENBACH SB, 1992, PLANT MOL BIOL, V18, P235, DOI 10.1007/BF00034952; ARAGAO FJL, 1992, PLANT MOL BIOL, V20, P357, DOI 10.1007/BF00014508; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P253, DOI 10.1159/000232110; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; CAREY B, 1993, HEALTH, V7, P24; FOX JL, 1994, BIO-TECHNOL, V12, P568; GUERCHE P, 1990, MOL GEN GENET, V221, P306, DOI 10.1007/BF00259393; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melo Vania Maria Maciel, 1994, Food and Agricultural Immunology, V6, P185, DOI 10.1080/09540109409354829; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Norman P, 1986, MANUAL CLIN LABORATO, P660; SAALBACH I, 1994, MOL GEN GENET, V242, P226, DOI 10.1007/BF00391017; SNYDER J, 1992, LONGEVITY, V4, P52; SUN SSM, 1987, J AGR FOOD CHEM, V35, P232, DOI 10.1021/jf00074a016; TAYLOR SL, 1992, FOOD TECHNOL-CHICAGO, V46, P146; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND JA, 1994, J CELL BIOCH SA, V18, P78; Utsumi S, 1992, Adv Food Nutr Res, V36, P89, DOI 10.1016/S1043-4526(08)60105-9; 1992, FED REGISTER, V57, P22984	27	438	494	4	135	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					688	692		10.1056/NEJM199603143341103	http://dx.doi.org/10.1056/NEJM199603143341103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594427	Green Published			2022-12-28	WOS:A1996TZ52800003
J	Casadevall, N; Dupuy, E; MolhoSabatier, P; Tobelem, G; Varet, B; Mayeux, P				Casadevall, N; Dupuy, E; MolhoSabatier, P; Tobelem, G; Varet, B; Mayeux, P			Brief report: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ERYTHROBLAST CYTOTOXICITY; INVITRO; PLASMA; INHIBITOR; RECEPTOR; LINE		HOP NECKER ENFANTS MALAD,DEPT HEMATOL,PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U363,VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Casadevall, N (corresponding author), HOP R POINCARE,DEPT HEMATOL,104 BLVD RAYMOND POINCARE,F-92380 GARCHES,FRANCE.							BARNES RD, 1966, LANCET, V2, P1464; DESSYPRIS EN, 1991, SEMIN HEMATOL, V28, P275; DESSYPRIS EN, 1982, BLOOD, V59, P114; DiGiacomo J, 1966, J Mt Sinai Hosp N Y, V33, P382; DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293, DOI 10.1210/endo-116-6-2293; EISEMANN G, 1954, NEW ENGL J MED, V251, P1044, DOI 10.1056/NEJM195412232512603; FRANCIS DA, 1982, BRIT MED J, V284, P85, DOI 10.1136/bmj.284.6309.85; HERMINE O, 1992, BLOOD, V80, P3060; HOFFMAN R, 1978, BLOOD, V52, P255; JEPSON JH, 1968, CAN MED ASSOC J, V99, P99; KHELIF A, 1985, SCAND J HAEMATOL, V34, P13; KOMATSU N, 1991, CANCER RES, V51, P341; KRANTZ SB, 1974, NEW ENGL J MED, V291, P345; KRANTZ SB, 1972, BLOOD-J HEMATOL, V39, P347, DOI 10.1182/blood.V39.3.347.347; KRANTZ SB, 1973, J CLIN INVEST, V52, P324, DOI 10.1172/JCI107188; KRANTZ SB, 1967, P NATL ACAD SCI USA, V58, P493, DOI 10.1073/pnas.58.2.493; KRANTZ SB, 1969, BLOOD-J HEMATOL, V34, P1; LACOMBE C, 1984, BLOOD, V64, P71; MANGAN KF, 1986, AM J HEMATOL, V23, P167, DOI 10.1002/ajh.2830230211; MANGAN KF, 1985, BLOOD, V66, P533; MARMONT A, 1975, BLOOD, V45, P247; MAUNG ZT, 1994, BRIT J HAEMATOL, V87, P189, DOI 10.1111/j.1365-2141.1994.tb04890.x; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1990, FEBS LETT, V269, P167, DOI 10.1016/0014-5793(90)81145-E; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; MESSNER HA, 1981, NEW ENGL J MED, V304, P1334, DOI 10.1056/NEJM198105283042205; NAGASAWA T, 1981, BLOOD, V57, P1025; PESCHLE C, 1975, BRIT J HAEMATOL, V30, P411, DOI 10.1111/j.1365-2141.1975.tb01855.x; ZAENTZ SD, 1976, BRIT J HAEMATOL, V32, P47, DOI 10.1111/j.1365-2141.1976.tb01874.x; ZAENTZ SD, 1973, J LAB CLIN MED, V82, P31	30	172	175	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					630	633		10.1056/NEJM199603073341004	http://dx.doi.org/10.1056/NEJM199603073341004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592526				2022-12-28	WOS:A1996TX69300004
J	Eddy, DM				Eddy, DM			Benefit language - Criteria that will improve quality while reducing costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KAISER PERMANENTE SO CALIF,PASADENA,CA	Kaiser Permanente								EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P817, DOI 10.1001/jama.272.10.817; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; HALL M, 1992, HLTH INSURERS ASSESS	3	54	54	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					650	657		10.1001/jama.275.8.650	http://dx.doi.org/10.1001/jama.275.8.650			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594249				2022-12-28	WOS:A1996TW62700029
J	Levinsky, NG				Levinsky, NG			Social, institutional, and economic barriers to the exercise of patients' rights	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Levinsky, NG (corresponding author), BOSTON UNIV,MED CTR,BOSTON,MA 02118, USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; Friedman B, 1995, Health Care Financ Rev, V16, P201; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Rothman D., 1991, STRANGERS BEDSIDE HI, DOI DOI 10.4324/9781315130286; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Slovenko R, 1994, Med Law, V13, P467; SULMASY DP, 1994, J CLIN ETHIC, V5, P189; Weston B, 1996, NEW ENGL J MED, V334, P543, DOI 10.1056/NEJM199602223340818; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1975, PATIENTS BILL RIGHTS	13	13	13	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					532	534		10.1056/NEJM199602223340812	http://dx.doi.org/10.1056/NEJM199602223340812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV686	8559211				2022-12-28	WOS:A1996TV68600012
J	Sgarbossa, EB; Pinski, SL; Barbagelata, A; Underwood, DA; Gates, KB; Topol, EJ; Califf, RM; Wagner, GS				Sgarbossa, EB; Pinski, SL; Barbagelata, A; Underwood, DA; Gates, KB; Topol, EJ; Califf, RM; Wagner, GS			Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENTRICULAR-CONDUCTION DISTURBANCES; EMERGENCY ROOM PATIENTS; ST-SEGMENT CHANGES; THROMBOLYTIC THERAPY; FOLLOW-UP; MULTICENTER; CRITERIA; DISEASE; SIZE	Background. The presence of left bundle-branch block on the electrocardiogram may conceal the changes of acute myocardial infarction, which can delay both its recognition and treatment, We tested electrocardiographic criteria for the diagnosis of acute infarction in the presence of left bundle-branch block. Methods. The base-line electrocardiograms of patients enrolled in the GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) trial who had left bundle-branch block and acute myocardial infarction confirmed by enzyme studies were blindly compared with the electrocardiograms of control patients who had chronic coronary artery disease and left bundle-branch block. The electrocardiographic criteria for the diagnosis of infarction were then tested in an independent sample of patients presenting with acute chest pain and left bundle-branch block. Results. Of 26,003 North American patients, 131 (0.5 percent) with acute myocardial infarction had left bundle-branch block, The three electrocardiographic criteria with independent value in the diagnosis of acute infarction in these patients were ST-segment elevation of 1 mm or more that was concordant with (in the same direction as) the QRS complex; ST-segment depression of 1 mm or more in lead V-1, V-2, or V-3; and ST-segment elevation of 5 mm or more that was discordant with (in the opposite direction from) the QRS complex, We used these three criteria to develop a scoring system (0 to 5), which allowed a highly specific diagnosis of acute myocardial infarction to be made. Conclusions. We developed and validated a clinical prediction rule based on a set of electrocardiographic criteria for the diagnosis of acute myocardial infarction in patients with chest pain and left bundle-branch block, The use of these criteria, which are based on simple ST-segment changes, may help identify patients with acute myocardial infarction, who can then receive appropriate treatment. (C) 1996, Massachusetts Medical Society.	FDN FAVALORO, BUENOS AIRES, DF, ARGENTINA; DUKE UNIV, MED CTR, DURHAM, NC USA	Duke University	Sgarbossa, EB (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, DESK M-24, CLEVELAND, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BESOAINSANTANDER M, 1960, AM HEART J, V60, P886, DOI 10.1016/0002-8703(60)90120-4; BODEN WE, 1987, AM J CARDIOL, V59, P782, DOI 10.1016/0002-9149(87)91091-5; BREN GB, 1987, CIRCULATION, V76, P18; CABRERA E, 1953, Arch Inst Cardiol Mex, V23, P441; CALIFF RM, 1992, CHEST, V101, pS106, DOI 10.1378/chest.101.4_Supplement.106S; CANNON A, 1989, AM J CARDIOL, V64, P1216, DOI 10.1016/0002-9149(89)90886-2; CHAPMAN MG, 1957, CIRCULATION, V16, P558, DOI 10.1161/01.CIR.16.4.558; COOK RW, 1958, CIRCULATION, V18, P603, DOI 10.1161/01.CIR.18.4.603; DOUCET P, 1966, AM J CARDIOL, V17, P171, DOI 10.1016/0002-9149(66)90349-3; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FLOWERS NC, 1987, J AM COLL CARDIOL, V9, P684, DOI 10.1016/S0735-1097(87)80065-7; FREEDMAN RA, 1987, J AM COLL CARDIOL, V10, P73, DOI 10.1016/S0735-1097(87)80162-6; GUSTAFSON T, 1994, EPISTAT REFERENCE MA; HAMBY RI, 1983, AM HEART J, V106, P471, DOI 10.1016/0002-8703(83)90688-9; HANDS ME, 1988, AM HEART J, V116, P23, DOI 10.1016/0002-8703(88)90245-1; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; KENNAMER R, 1956, AM HEART J, V51, P78, DOI 10.1016/0002-8703(56)90177-6; KLEIMAN NS, 1994, CIRCULATION, V90, P2658, DOI 10.1161/01.CIR.90.6.2658; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; MCANULTY JH, 1984, PROG CARDIOVASC DIS, V26, P333, DOI 10.1016/0033-0620(84)90009-4; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; Moia B., 1945, REV ARGENTINA CARDIOL, V11, P341; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OHMAN EM, 1990, CIRCULATION, V82, P1073, DOI 10.1161/01.CIR.82.3.1073; OPOLSKI G, 1986, INT J CARDIOL, V10, P141, DOI 10.1016/0167-5273(86)90222-6; PANTRIDGE JF, 1951, CIRCULATION, V3, P589, DOI 10.1161/01.CIR.3.4.589; Pelberg A L, 1989, Qual Assur Util Rev, V4, P39; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; SABIA P, 1991, CIRCULATION, V84, pI85; SCHAMROTH L, 1989, 12 LEAD ELECTROCARDI, P193; SCHOR S, 1976, JAMA-J AM MED ASSOC, V236, P941; SCHWEITZER P, 1990, AM HEART J, V119, P642, DOI 10.1016/S0002-8703(05)80288-1; SCLAROVSKY S, 1988, CLIN CARDIOL, V11, P757, DOI 10.1002/clc.4960111107; STARK KS, 1991, AM J CARDIOL, V67, P1219, DOI 10.1016/0002-9149(91)90930-J; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wackers F J, 1987, Cardiol Clin, V5, P393; WACKERS FJ, 1983, INT J CARDIOL, V2, P521, DOI 10.1016/0167-5273(83)90157-2; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEINER R, 1983, J AM OSTEOPATH ASSOC, V83, P119; WILLEMS JL, 1985, J AM COLL CARDIOL, V5, P1261, DOI 10.1016/S0735-1097(85)80335-1; 1990, EGRET REFERENCE MANU	53	394	413	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					481	487		10.1056/NEJM199602223340801	http://dx.doi.org/10.1056/NEJM199602223340801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559200				2022-12-28	WOS:A1996TV68600001
J	Friedmann, PD; Brett, AS; MayoSmith, MF				Friedmann, PD; Brett, AS; MayoSmith, MF			Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						cardiology; physicians, family; outcome and process; assessment (health care); risk; health promotion	CORONARY-ARTERY DISEASE; DECISION-MAKING; PHYSICIANS; PROBABILITY; SURVIVAL; JUDGMENT; SURGERY; TRIAL; CARE	Objective: To compare generalists' and cardiologists' estimates of baseline cardiovascular risk and the outcomes of preventive therapy. Design: Cross-sectional mail survey using written case simulations of typical patients from primary prevention trials for hypercholesterolemia and isolated systolic hypertension, and tertiary prevention studies of coronary artery bypass surgery for chronic stable angina with left main coronary stenosis, Participants: Nationally representative sample of 599 practicing family physicians, general internists, and cardiologists selected from the American Medical Association masterfile. Among eligible physicians, 84 (44%) of 191 family physicians, 77 (40%) of 194 general internists, and 66 (34%) of 194 cardiologists responded. Measurements: Estimates of risk at baseline and after therapy, and whether therapy generally would be recommended. Results: For both primary prevention case simulations (scenarios), cardiologists provided lower, more accurate estimates of baseline cardiovascular risk and of absolute therapeutic benefit than either family physicians or general internists. The range of the generalists' estimates was extremely wide. Perceptions of relative risk reduction and treatment recommendations for the primary prevention scenarios did not differ among specialties. Overall, generalists who would not recommend primary preventive therapy in these scenarios appeared to give more accurate estimates than did generalists who would recommend such therapy. Conclusions: Many generalists have inflated perceptions of cardiovascular risk without treatment and of the benefit of risk-modifying medical treatment. Further study should assess the reasons for these misperceptions and their effect on counseling about primary preventive therapy.	DEACONESS HOSP, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; VET AFFAIRS MED CTR, MANCHESTER, NH USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)								[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1991, MINITAB REFERENCE MA; ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; AYANIAN JZ, 1991, MED DECIS MAKING, V11, P154, DOI 10.1177/0272989X9101100302; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BERWICK DM, 1981, AM J MED, V71, P991, DOI 10.1016/0002-9343(81)90325-9; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Bursztajn HJ, 1981, MED CHOICES MED CHAN; CHAITMAN BR, 1981, AM J CARDIOL, V48, P765, DOI 10.1016/0002-9149(81)90156-9; CHRISTENSENSZALANSKI JJJ, 1981, J EXP PSYCHOL HUMAN, V7, P928, DOI 10.1037/0096-1523.7.4.928; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; DOLAN JG, 1986, MED DECIS MAKING, V6, P216, DOI 10.1177/0272989X8600600406; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; FREIDSON E, 1975, PROFESSION MED; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1995, J GEN INTERN MED, V10, P147, DOI 10.1007/BF02599671; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRELBE J, 1977, BRIT MED J, V2, P1572; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; MANU P, 1984, MED CARE, V22, P366, DOI 10.1097/00005650-198404000-00008; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARTIN BC, 1974, DONT SURVEY PHYSICIA; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PICKERING TG, 1983, JAMA-J AM MED ASSOC, V249, P399, DOI 10.1001/jama.249.3.399; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; REDELMEIER DA, 1991, MED DECIS MAKING, V11, P169, DOI 10.1177/0272989X9101100304; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; REED WW, 1993, J GEN INTERN MED, V8, P591, DOI 10.1007/BF02599710; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Roback G, 1994, PHYSICIAN CHARACTERI; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCHWARTZ S, 1986, MED THINKING PSYCHOL, P162; TAKARO T, 1982, CIRCULATION, V66, P14, DOI 10.1161/01.CIR.66.1.14; TAMBOR ES, 1993, AM J PUBLIC HEALTH, V83, P1599, DOI 10.2105/AJPH.83.11.1599; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WARD MM, 1993, ARCH INTERN MED, V153, P2229, DOI 10.1001/archinte.153.19.2229; 1990, SAS STAT USERS GUIDE; 1989, GUIDE CLIN PREVENTIV, pR28	51	107	107	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					414	+		10.7326/0003-4819-124-4-199602150-00005	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554250				2022-12-28	WOS:A1996TV22000005
J	Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S				Watanabe, G; Saito, Y; Madaule, P; Ishizaki, T; Fujisawa, K; Morii, N; Mukai, H; Ono, Y; Kakizuka, A; Narumiya, S			Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho	SCIENCE			English	Article							BOTULINUM C3 EXOENZYME; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; REQUIRES; P21	The Rho guanosine 5'-triphosphatase (GTPase) cycles between the active guanosine triphosphate (GTP)-bound form and the inactive guanosine diphosphate-bound form and regulates cell adhesion and cytokinesis, but how it exerts these actions is unknown. The yeast two-hybrid system was used to clone a complementary DNA for a protein (designated Rhophilin) that specifically bound to GTP-Rho. The Rho-binding domain of this protein has 40 percent identity with a putative regulatory domain of a protein kinase, PKN. PKN itself bound to GTP-Rho and was activated by this binding both in vitro and in vivo. This study indicates that a serine-threonine protein kinase is a Rho effector and presents an amino acid sequence motif for binding to GTP-Rho that may be shared by a family of Rho target proteins.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN	Kyoto University; Kobe University				Mukai, Hideyuki/0000-0002-0167-8695				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIZAKI T, IN PRESS EMBO J; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABE G, UNPUB, P55215; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	33	352	375	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					645	648		10.1126/science.271.5249.645	http://dx.doi.org/10.1126/science.271.5249.645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571126				2022-12-28	WOS:A1996TT87000045
J	Fata, FT; Herzlich, BC; Schiffman, G; Ast, AL				Fata, FT; Herzlich, BC; Schiffman, G; Ast, AL			Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B-12 levels	ANNALS OF INTERNAL MEDICINE			English	Article						pneumococcal vaccine; antibody formation; vitamin B-12 deficiency; vitamin B-12; Streptococcus pneumoniae	COBALAMIN MALABSORPTION; HOLOTRANSCOBALAMIN-II; MEGALOBLASTIC-ANEMIA; TRANSCOBALAMIN-II; DEFICIENCY; VACCINE; EFFICACY	Objective: To determine whether immunocompetent elderly patients with low serum vitamin B-12 levels have impaired serum antibody responses to the 23-polyvalent pneumococcal polysaccharide vaccine. Design: Controlled, prospective cohort study. Measurements: 15 patients with low serum vitamin B-12 levels and 15 age- and diagnosis-matched patients with normal levels were vaccinated. Serum antibody titers to 12 pneumococcal serotypes were measured by radioimmunoassay before and 4 weeks after vaccination. Results: The difference between the geometric mean of the vaccine anti body titers before a nd after vaccination for all 12 serotypes was lower (P = 0.005) in the patients with low vitamin B-12 levels than in the patients with normal levels. When mean corpuscular volume and age were controlled for, vitamin B-12 remained an independent predictor of antibody response (P = 0.005). Erythrocyte mean corpuscular volume was also an independent predictor of the increase in titer (P = 0.03). Conclusions: Patients with low vitamin B-12 levels had impaired antibody responses to pneumococcal vaccine. Further study is necessary to determine whether treatment with vitamin B-12 can enhance specific immunoglobulin synthesis and improve the clinical efficacy of the pneumococcal vaccine in patients with low vitamin B-12 levels.	MAIMONIDES HOSP, DEPT MED, BROOKLYN, NY 11219 USA; SUNY HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA	Maimonides Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								AMMANN AJ, 1980, P SOC EXP BIOL MED, V164, P312; BOLAN G, 1986, ANN INTERN MED, V104, P1, DOI 10.7326/0003-4819-104-1-1; CARMEL R, 1994, DIGEST DIS SCI, V39, P2516, DOI 10.1007/BF02087684; CARMEL R, 1987, J LAB CLIN MED, V109, P454; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; DOSCHERHOLMEN A, 1976, BRIT J HAEMATOL, V33, P261, DOI 10.1111/j.1365-2141.1976.tb03537.x; Fedson DS, 1994, VACCINES, P517; GOH YT, 1991, BLOOD S, V78, pA100; Hall C. A., 1981, Nutrition Research, V1, P349, DOI 10.1016/S0271-5317(81)80036-X; HERBERT V, 1994, AM J CLIN NUTR, V59, p1213S, DOI 10.1093/ajcn/59.5.1213S; HERBERT V, 1962, J CLIN INVEST, V41, P1263, DOI 10.1172/JCI104589; HERBERT V, 1988, ARCH INTERN MED, V148, P1705, DOI 10.1001/archinte.148.8.1705; HERBERT V, 1985, BLOOD S, V66, pA45; HERZLICH B, 1988, LAB INVEST, V58, P332; HITZIG WH, 1975, CLIN EXP IMMUNOL, V20, P105; HITZIG WH, 1974, J PEDIATR-US, V85, P622, DOI 10.1016/S0022-3476(74)80503-2; KAFETZ K, 1985, POSTGRAD MED J, V61, P1065, DOI 10.1136/pgmj.61.722.1065; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; MARCUS DL, 1987, J AM GERIATR SOC, V35, P635, DOI 10.1111/j.1532-5415.1987.tb04339.x; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; SCHIFFMAN G, 1971, J EXP MED, V134, P600, DOI 10.1084/jem.134.3.600; SCHIFFMAN G, 1983, P SOC EXP BIOL MED, V174, P309; SCHIFFMAN G, 1980, J IMMUNOL METHODS, V33, P133, DOI 10.1016/S0022-1759(80)80004-4; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; TEFFERI A, 1994, MAYO CLIN PROC, V69, P181, DOI 10.1016/S0025-6196(12)61046-5; VANDOMMELEN CKV, 1963, ACTA MED SCAND, V174, P193; VU T, 1993, AM J HEMATOL, V42, P202, DOI 10.1002/ajh.2830420212; WICKRAMASINGHE SN, 1993, J CLIN PATHOL, V46, P537, DOI 10.1136/jcp.46.6.537	30	44	46	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					299	+		10.7326/0003-4819-124-3-199602010-00003	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR596	8554224				2022-12-28	WOS:A1996TR59600003
J	Delany, L				Delany, L			Altruism by proxy: Volunteering children for bone marrow donation - Protecting children from forced altruism: The legal approach	BRITISH MEDICAL JOURNAL			English	Article									KAISER PERMANENTE MED CTR,DIV PAED HAEMATOL & ONCOL,OAKLAND,CA 94611	Kaiser Permanente	Delany, L (corresponding author), MANCHESTER METROPOLITAN UNIV,SCH LAW,MANCHESTER M13 0JA,LANCS,ENGLAND.							MCBRIDE G, 1990, BRIT MED J, V300, P1224; SKEGG PDG, MLR, V36, P381; 1995, MENTAL INCAPACITY	3	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					240	240						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT486	8563594				2022-12-28	WOS:A1996TT48600036
J	Duesberg, P				Duesberg, P			Non-HIV hypotheses must be studied more carefully	BRITISH MEDICAL JOURNAL			English	Editorial Material							HIGH-PURITY; HEMOPHILIACS				Duesberg, P (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.							CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; COHEN J, 1995, SCIENCE, V269, P1044, DOI 10.1126/science.7652551; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DEBIASI R, 1991, BLOOD, V78, P1919; DUESBERG P, 1955, LANCET, V346, P1371; DUESBERG PH, 1995, GENETICA, V95, P51, DOI 10.1007/BF01435001; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; HO DD, 1990, NEW ENGL J MED, V322, P1467; KREISS JK, 1984, JAMA-J AM MED ASSOC, V251, P1450, DOI 10.1001/jama.251.11.1450; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; STEDMAN TL, 1982, STEDMANS MED DICT, P1049; 1994, PHYSICIANS DESK REFE, P742; 1994, HIV AICS SURVEILLANC, V6, P1	14	4	4	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					210	211						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563583				2022-12-28	WOS:A1996TT48600022
J	Jamieson, DRS; Teasdale, E; Willison, HJ				Jamieson, DRS; Teasdale, E; Willison, HJ			Lesson of the week - False localising signs in the spinal cord	BRITISH MEDICAL JOURNAL			English	Article											Jamieson, DRS (corresponding author), SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND.		willison, hugh/HCI-7819-2022					EPSTEIN JA, 1963, ARCH NEUROL-CHICAGO, V8, P307, DOI 10.1001/archneur.1963.00460030091009; LANGFITT TW, 1967, J AMER MED ASSOC, V200, P382, DOI 10.1001/jama.200.5.382; LOURIE H, 1973, JAMA-J AM MED ASSOC, V226, P302, DOI 10.1001/jama.226.3.302; MAIR WGP, 1953, BRAIN, V76, P70, DOI 10.1093/brain/76.1.70; ONO K, 1977, Spine, V2, P109, DOI 10.1097/00007632-197706000-00004; SIMMONS Z, 1986, SPINE, V11, P869, DOI 10.1097/00007632-198611000-00004; STARK RJ, 1981, ANN NEUROL, V9, P58, DOI 10.1002/ana.410090111; Stookey B, 1928, ARCH NEURO PSYCHIATR, V20, P275, DOI 10.1001/archneurpsyc.1928.02210140043003; TAYLOR AR, 1974, BRAIN, V97, P473, DOI 10.1093/brain/97.1.473; YASUOKA S, 1978, J NEUROSURG, V49, P828, DOI 10.3171/jns.1978.49.6.0828	10	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					243	244						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563595				2022-12-28	WOS:A1996TT48600040
J	Neer, EJ; Smith, TF				Neer, EJ; Smith, TF			G protein heterodimers: New structures propel new questions	CELL			English	Review							DEHYDROGENASE; RESOLUTION		HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,DEPT PHARMACOL,BOSTON,MA 02215; BOSTON UNIV,BIOMOLEC ENGN RES CTR,BOSTON,MA 02215	Harvard University; Harvard Medical School; Boston University; Boston University	Neer, EJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115, USA.							BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BOURNE HR, 1995, SCIENCE, V270, P933, DOI 10.1126/science.270.5238.933; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; GARCIAHIGUERA I, 1996, IN PRESS J BIOL CHEM; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; XIA ZX, 1992, J BIOL CHEM, V267, P22289	15	191	193	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					175	178		10.1016/S0092-8674(00)80969-1	http://dx.doi.org/10.1016/S0092-8674(00)80969-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565060	hybrid			2022-12-28	WOS:A1996TR59500001
J	Vito, P; Lacana, E; DAdamio, L				Vito, P; Lacana, E; DAdamio, L			Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; T-CELL HYBRIDOMAS; DNA FRAGMENTATION; ENDONUCLEASE ACTIVATION; THYMOCYTE APOPTOSIS; IMMATURE THYMOCYTES; SUICIDE PROCESS; MESSENGER-RNA; DEATH; INITIATION	Two apoptosis-linked genes, named ALG-2 and ALG-3, were identified by means of a functional selection strategy. ALG-2 codes for a Ca2+-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-3, a partial complementary DNA that is homologous to the familial Alzheimer's disease gene STM2, rescues a T cell hybridoma from T cell receptor- and Fas-induced apoptosis. These findings suggest that ALG-2 may mediate Ca2+-regulated signals along the death pathway and that cell death may play a role in Alzheimer's disease.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,T CELL MOLEC BIOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			vito, pasquale/ABF-5505-2020	D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; vito, pasquale/0000-0002-5721-7716				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BROWN KS, UNPUB; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CIFONE MG, 1993, J EXP MED, V177, P1547; COHEN JJ, 1984, J IMMUNOL, V132, P38; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGEYAMA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P255, DOI 10.1016/0167-4781(80)90018-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LACANA E, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHIMI Y, 1995, J IMMUNOL, V154, P599; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SARIN A, 1995, J IMMUNOL, V154, P5806; SHI YF, 1990, J IMMUNOL, V144, P3326; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; VITO P, UNPUB; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	55	459	477	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					521	525		10.1126/science.271.5248.521	http://dx.doi.org/10.1126/science.271.5248.521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560270	Green Submitted			2022-12-28	WOS:A1996TR32200047
J	Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA				Wilson, CJ; Chao, DM; Imbalzano, AN; Schnitzler, GR; Kingston, RE; Young, RA			RNA polymerase II holoenzyme contains SWI/SNF regulators involved in chromatin remodeling	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATORS; NEGATIVE REGULATOR; SNF6 PROTEINS; YEAST; GENES; EXPRESSION; SNF2/SWI2; DNA	The RNA polymerase II holoenzyme contains RNA polymerase II, a subset of general transcription factors and SRB regulatory proteins. We report here that SWI and SNF gene products, previously identified as global gene regulators whose functions include remodeling chromatin, are also integral components of the yeast RNA polymerase II holoenzyme. The SWI/SNF proteins are components of the SRB complex, also known as the mediator, which is tightly associated with the RNA polymerase II C-terminal repeat domain. The SWI/SNF components provide the holoenzyme with the capacity to disrupt nucleosomal DNA and thus facilitate stable binding of various components of the transcription initiation complex at promoters.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wilson, CJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Wilson, Christopher/0000-0002-9146-522X; Chao, David/0000-0001-9198-337X				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HAPPEL AM, 1991, GENETICS, V128, P69; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1996, IN PRESS METH ENZYMO; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, GENE DEV, V6, P2233; LAURENT BC, 1990, MOL CELL BIOL, V11, P5615; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SHELDON M, 1995, CURR BIOL, V5, P423; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREICH I, 1995, MOL CELL BIOL, V15, P4240; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	336	339	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					235	244		10.1016/S0092-8674(00)80978-2	http://dx.doi.org/10.1016/S0092-8674(00)80978-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565069	Bronze			2022-12-28	WOS:A1996TR59500010
J	Davis, CE				Davis, CE			Fresh vs preserved stool specimens for detection of parasites	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Davis, CE (corresponding author), UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103, USA.							BRONSDON MA, 1984, J CLIN MICROBIOL, V19, P952, DOI 10.1128/JCM.19.6.952-953.1984; DAVIS CE, 1994, HARRISONS PRINCIPLES, P872; Garcia Lynne S., 1995, P1145; SMITH JW, 1979, AM J CLIN PATHOL, V72, P371; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	327						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544277				2022-12-28	WOS:A1996TP96500034
J	Nightingale, SL				Nightingale, SL			First protease inhibitor approved for treatment of HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-28	WOS:A1996TP96500005
J	Meyer, RE				Meyer, RE			The disease called addiction: Emerging evidence in a 200-year debate	LANCET			English	Article							ALCOHOL DEPENDENCE SYNDROME; CROSS-FOSTERING ANALYSIS; INHERITANCE; ETHANOL; PSYCHOPATHOLOGY; INVOLVEMENT; CONSUMPTION; PREDICTORS; NALTREXONE; RESPONSES				Meyer, RE (corresponding author), ASSOC ACAD HLTH CTR, WASHINGTON, DC 20036 USA.							ARMOR DJ, 1976, R1739NIAAA RAND CORP; BABOR TF, 1987, BRIT J ADDICT, V82, P393; BABOR TF, 1992, ALCOHOLISM N AM EURO, P182; BEGLEITER H, 1984, SCIENCE, V225, P1493, DOI 10.1126/science.6474187; BEITNERJOHNSON D, 1992, ANN NY ACAD SCI, V654, P70, DOI 10.1111/j.1749-6632.1992.tb25957.x; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; CADOR M, 1989, NEUROSCIENCE, V30, P77, DOI 10.1016/0306-4522(89)90354-0; CADORET RJ, 1985, ARCH GEN PSYCHIAT, V42, P161, DOI 10.1001/archpsyc.1985.01790250055007; CAHALAN D, BIOL ALCOHOL, V5, P201; CHICK J, 1980, BRIT J ADDICT, V75, P265; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; DAVIES DL, 1962, Q J STUD ALCOHOL, V23, P94; EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; EDWARDS G, 1985, J STUD ALCOHOL, V46, P181, DOI 10.15288/jsa.1985.46.181; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GRANT KA, IN PRESS CLIN NEUROS; HEATH AC, 1991, J STUD ALCOHOL, V52, P345, DOI 10.15288/jsa.1991.52.345; HEATH AC, 1991, J STUD ALCOHOL, V52, P352; HEATHER N, 1983, BRIT J CLIN PSYCHOL, V22, P11, DOI 10.1111/j.2044-8260.1983.tb00574.x; HELZER JE, 1985, NEW ENGL J MED, V312, P1678, DOI 10.1056/NEJM198506273122605; HELZER JE, 1990, ARCH GEN PSYCHIAT, V47, P313; HESSELBROCK MN, 1985, ARCH GEN PSYCHIAT, V42, P1050; HODGSON R, 1979, BEHAV RES THER, V17, P379, DOI 10.1016/0005-7967(79)90009-3; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; HYMAN SE, 1993, CURR OPIN NEUROL NEU, V6, P608; JELLINEK EM, 1960, DISEASE CONCEPT ALCO; JESSON R, 1977, PROBLEM BEHAVIOR PSY; KANDEL D, 1975, SCIENCE, V190, P912, DOI 10.1126/science.1188374; Kandel D B, 1985, Adv Alcohol Subst Abuse, V4, P139; KAPLAN RF, 1983, BRIT J ADDICT, V78, P259; KENDLER KS, 1992, JAMA-J AM MED ASSOC, V268, P1877, DOI 10.1001/jama.268.14.1877; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KREEK MJ, 1992, RES P ARNMD, V70, P205; LABERG JC, 1986, BRIT J ADDICT, V81, P797; Lender Mark Edward, 1982, DRINKING AM HIST; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MARTIN WA, 1969, J PSYCHIATR RES, V7, P7; MCBRIDE WJ, IN PRESS ALCOHOL CLI; MELLO NK, 1971, RECENT ADV STUDIES A, P647; MERRY J, 1966, LANCET, V1, P1257, DOI 10.1016/S0140-6736(66)90261-3; MEYER RE, 1991, NEUROPHARMACOLOGY ET, P251; MORSE RM, 1992, JAMA-J AM MED ASSOC, V268, P1012, DOI 10.1001/jama.268.8.1012; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; Nutt DJ, 1996, LANCET, V347, P31, DOI 10.1016/S0140-6736(96)91561-5; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; ORFORD J, 1976, BEHAV RES THER, V14, P409, DOI 10.1016/0005-7967(76)90087-5; Peele S, 1989, DISEASING AM; PENDERY ML, 1982, SCIENCE, V217, P169, DOI 10.1126/science.7089552; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; POLICH AM, 1980, R2433NIAAA RAND CORP; Reid L D, 1984, Alcohol, V1, P33, DOI 10.1016/0741-8329(84)90033-8; ROUNSAVILLE BJ, 1987, ARCH GEN PSYCHIAT, V44, P505; SCHUCKIT MA, 1984, ARCH GEN PSYCHIAT, V41, P879; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037/0021-843X.91.3.199; SOBELL MB, 1976, BEHAV RES THER, V14, P195, DOI 10.1016/0005-7967(76)90013-9; STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251; Vaillant G.E., 1995, WISDOM EGO; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WALLER MB, 1983, PHARMACOL BIOCHEM BE, V19, P683, DOI 10.1016/0091-3057(83)90345-3; [No title captured]	61	38	40	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					162	166		10.1016/S0140-6736(96)90345-1	http://dx.doi.org/10.1016/S0140-6736(96)90345-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ244	8544553				2022-12-28	WOS:A1996TQ24400014
J	Naktinis, V; Turner, J; ODonnell, M				Naktinis, V; Turner, J; ODonnell, M			Molecular switch in a replication machine defined by an internal competition for protein rings	CELL			English	Article							POLYMERASE-III HOLOENZYME; CELL NUCLEAR ANTIGEN; PRIMER-TEMPLATE JUNCTION; ACCESSORY PROTEINS; ESCHERICHIA-COLI; FACTOR-C; DNA; COMPLEX; BACTERIOPHAGE-T4; SUBUNIT	Replication machines use ring-shaped clamps that encircle DNA to tether the polymerase to the chromosome. The clamp is assembled on DNA by a clamp loader. This report shows that the polymerase and clamp loader coordinate their actions with the clamp by competing for it through overlapping binding sites. The competition is modulated by DNA. In the absence of DNA, the clamp associates with the clamp loader. But after the clamp is placed on DNA, the polymerase develops a tight grip on the clamp and out-competes the clamp loader. After replication of the template, the polymerase looses affinity for the clamp. Now the clamp loader regains access to the clamp and removes it from DNA thus recycling it for future use.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute	Naktinis, V (corresponding author), CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021, USA.							BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SH, 1991, J BIOL CHEM, V266, P594; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TURNER J, 1994, METHOD ENZYMOL, V262, P442; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZHONG M, 1995, P NATL ACAD SCI USA, V92, P2111, DOI 10.1073/pnas.92.6.2111	41	128	131	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					137	145		10.1016/S0092-8674(00)81000-4	http://dx.doi.org/10.1016/S0092-8674(00)81000-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548818	hybrid			2022-12-28	WOS:A1996TQ17000016
J	Lip, GYH; Lowe, GDO				Lip, GYH; Lowe, GDO			ABC of atrital fibrillation - Antithrombotic treatment for atrial fibrillation	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,DEPT CARDIOL,CITY HOSP,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,LANARK,SCOTLAND; UNIV BIRMINGHAM,DEPT MED,CITY HOSP,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; Royal Infirmary of Edinburgh; University of Glasgow; University of Birmingham								ALBERS GW, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1995, CHEST S, V108, P352; LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X; 1990, J CLIN PATHOL, V43, P177	4	71	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					45	49		10.1136/bmj.312.7022.45	http://dx.doi.org/10.1136/bmj.312.7022.45			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555864	Green Published			2022-12-28	WOS:A1996TP20900031
J	Dangl, JL; Preuss, D; Schroeder, JI				Dangl, JL; Preuss, D; Schroeder, JI			Talking through walls: Signaling in plant development	CELL			English	Editorial Material							ARABIDOPSIS; MUTATION; POLLEN; GENE		UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of Chicago; University of California System; University of California San Diego	Dangl, JL (corresponding author), UNIV N CAROLINA,DEPT BIOL,CB 3280,CHAPEL HILL,NC 27599, USA.			Schroeder, Julian/0000-0002-3283-5972				ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BONAS U, 1994, BACTERIAL PATHOGENES, P79; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COLIMER A, 1994, BACTERIAL PAHTOGENES, P43; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DOUGHTY J, 1993, P NATL ACAD SCI USA, V90, P467, DOI 10.1073/pnas.90.2.467; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; LARENCE GJ, 1995, PLANT CELL, V7, P1195; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NASRALLAH JB, 1994, SCIENCE, V5, P1325; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; RITTER C, 1996, IN PRESS PLANT CELL; RUBIO F, 1995, IN PRESS SCIENCE; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9536; SMITH LG, 1992, DEVELOPMENT, V116, P21; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WU HM, 1995, CELL, V82, P395, DOI 10.1016/0092-8674(95)90428-X	35	30	32	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1071	1077		10.1016/0092-8674(95)90134-5	http://dx.doi.org/10.1016/0092-8674(95)90134-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548795	Bronze			2022-12-28	WOS:A1995TM76200004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CHLORZOXAZONE WARNING ON HEPATOTOXICITY IS STRENGTHENED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-28	WOS:A1995TL16900012
J	Bowen, EF; Wilson, P; Atkins, M; Madge, S; Griffiths, PD; Johnson, MA; Emery, VC				Bowen, EF; Wilson, P; Atkins, M; Madge, S; Griffiths, PD; Johnson, MA; Emery, VC			Natural history of untreated cytomegalovirus retinitis	LANCET			English	Note							POLYMERASE CHAIN-REACTION; RETINOPATHY; DISEASE	Cytomegalovirus infection is common in patients with AIDS, and often causes retinitis. Treatment is rarely curative, but the progression of retinitis is delayed. The untreated course of cytomegalovirus retinitis in AIDS is unknown. We report a 35-year-old man with retinitis who refused treatment. Retinitis resulted in blindness within 6 months. Measurement of cytomegalovirus genomes showed an increasing viral load in blood and urine.	ROYAL FREE HOSP,SCH MED,DEPT THORAC MED & HIV MED,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT OPHTHALMOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Bowen, EF (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT VIROL,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.		Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				FOX JC, 1992, J GEN VIROL, V73, P2405, DOI 10.1099/0022-1317-73-9-2405; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; HEINEMANN MH, 1992, AM J MED, V92; HOLLAND GN, 1992, ARCH OPHTHALMOL-CHIC, V110, P1435, DOI 10.1001/archopht.1992.01080220097029; HOLLAND GN, 1989, ARCH OPHTHALMOL-CHIC, V107, P1759, DOI 10.1001/archopht.1989.01070020841024; HOOVER D, 1993, NEW ENGL J MED, V26, P1922; KIDD IM, 1993, TRANSPLANTATION, V56, P867, DOI 10.1097/00007890-199310000-00018; 1992, NEW ENGL J MED, V326, P213	8	44	46	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1671	1673		10.1016/S0140-6736(95)92842-1	http://dx.doi.org/10.1016/S0140-6736(95)92842-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551826				2022-12-28	WOS:A1995TL42300012
J	Pembrey, S				Pembrey, S			Of no fixed abode: Homeless house officers	BRITISH MEDICAL JOURNAL			English	Article									NATL INST NURSING,OXFORD,ENGLAND										0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1706	1707		10.1136/bmj.311.7021.1706	http://dx.doi.org/10.1136/bmj.311.7021.1706			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541769	Green Published			2022-12-28	WOS:A1995TL94200031
J	Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G				Lee, A; Thomas, P; Cupidore, L; Serjeant, B; Serjeant, G			Improved survival in homozygous sickle cell disease: Lessons from a cohort study	BRITISH MEDICAL JOURNAL			English	Article							BONE-MARROW TRANSPLANTATION; CHEST SYNDROME; ANEMIA; CHILDREN; TRANSFUSION; SEPTICEMIA	Objective-To examine whether simple interventions in a sickle cell clinic improve survival in sickle cell disease. Design-Survival curve analysis and hazard ratios in a cohort study followed from birth. Setting-MRC Laboratories (Jamaica) at the University of the West Indies, and Victoria Jubilee Hospital, Kingston, Jamaica. Subject-315 patients with homozygous sickle cell disease detected during the screening of 100 000 consecutive non-operative deliveries between June 1973 and December 1981 at the main government maternity hospital, Kingston, Jamaica. Interventions-Prophylactic penicillin to prevent pneumococcal septicaemia, parental education in early diagnosis of acute splenic sequestration, close monitoring in sickle cell clinic, Main outcome measures-Survival. Results-Survival appeared to improve, the log rank test for trend comparing the first, second, and last third of the study reaching borderline significance (P=0.05). Combined deaths from acute splenic sequestration and pneumococcal septicaemia-meningitis declined significantly (test for trend, P=0 . 02). Conclusion-Early diagnosis and simple prophylactic measures significantly reduce deaths associated with homozygous sickle cell disease.	UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA	University West Indies Mona Jamaica				Thomas, Peter/0000-0003-2478-4324				BEUTLER E, 1991, SEMIN HEMATOL, V28, P263; DAVIES SC, 1984, LANCET, V1, P36; EMOND AM, 1985, J PEDIATR-US, V107, P201, DOI 10.1016/S0022-3476(85)80125-6; FERSTER A, 1992, BRIT J HAEMATOL, V80, P102, DOI 10.1111/j.1365-2141.1992.tb06407.x; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MALLOUH AA, 1988, AM J DIS CHILD, V142, P178, DOI 10.1001/archpedi.1988.02150020080034; MENTZER WC, 1994, AM J PEDIAT HEMATOL, V16, P27; POWARS D, 1983, PEDIATRICS, V71, P927; POWARS D, 1981, JAMA-J AM MED ASSOC, V245, P1839, DOI 10.1001/jama.245.18.1839; RUSSELL MO, 1984, BLOOD, V63, P162; SERJEANT BE, 1974, CLIN CHEM, V20, P666; SERJEANT GR, 1981, LANCET, V2, P595; STEVENS MCG, 1986, PEDIATRICS, V78, P124; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195	16	131	133	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1600	1602		10.1136/bmj.311.7020.1600	http://dx.doi.org/10.1136/bmj.311.7020.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555802	Green Published			2022-12-28	WOS:A1995TL42200019
J	Iams, JD; Goldenberg, RL; Meis, PJ; Mercer, BM; Moawad, A; Das, A; Thom, E; McNellis, D; Copper, RL; Johnson, F; Roberts, JM; Hauth, JC; Northern, A; Neely, C; MuellerHeubach, E; Swain, M; Frye, A; Lindheimer, M; Jones, P; Brown, MEL; Siddiqi, TA; Elder, N; Coombs, T; VanHorn, J; Bain, R; Leuchtenburg, L; Fischer, M; Harger, JH; Cotroneo, M; Stallings, C; Yaffe, S; Catz, C; Klebanoff, M; Landon, MB; Schneider, J; Mueller, C; Carey, JC; Meier, A; Liles, E; Newman, RB; Collins, BA; Metcalf, T; Odell, V; Sibai, B; Ramsey, R; Fricke, JL; Treadwell, M; Norman, GS				Iams, JD; Goldenberg, RL; Meis, PJ; Mercer, BM; Moawad, A; Das, A; Thom, E; McNellis, D; Copper, RL; Johnson, F; Roberts, JM; Hauth, JC; Northern, A; Neely, C; MuellerHeubach, E; Swain, M; Frye, A; Lindheimer, M; Jones, P; Brown, MEL; Siddiqi, TA; Elder, N; Coombs, T; VanHorn, J; Bain, R; Leuchtenburg, L; Fischer, M; Harger, JH; Cotroneo, M; Stallings, C; Yaffe, S; Catz, C; Klebanoff, M; Landon, MB; Schneider, J; Mueller, C; Carey, JC; Meier, A; Liles, E; Newman, RB; Collins, BA; Metcalf, T; Odell, V; Sibai, B; Ramsey, R; Fricke, JL; Treadwell, M; Norman, GS			The length of the cervix and the risk of spontaneous premature delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRETERM DELIVERY; CONTROLLED TRIAL; ULTRASONOGRAPHY; PREDICTION; PREGNANCY; CERCLAGE; WOMEN	Background. The role of the cervix in the pathogenesis of premature delivery is controversial. In a prospective, multicenter study of pregnant women, we used vaginal ultrasonography to measure the length of the cervix; we also documented the incidence of spontaneous delivery before 35 weeks' gestation. Methods. At 10 university-affiliated prenatal clinics, we performed vaginal ultrasonography at approximately 24 and 28 weeks of gestation in women with singleton pregnancies. We then assessed the relation between the length of the cervix and the risk of spontaneous preterm delivery. Results. We examined 2915 women at approximately 24 weeks of gestation and 2531 of these women again at approximately 28 weeks. Spontaneous preterm delivery (at less than 35 weeks) occurred in 126 of the women (4.3 percent) examined at 24 weeks. The length of the cervix was normally distributed at 24 and 28 weeks (mean [+/-SD], 35.2+/-8.3 mm and 33.7+/-8.5 mm, respectively). The relative risk of preterm delivery increased as the length of the cervix decreased. When women with shorter cervixes at 24 weeks were compared with women with values above the 75th percentile, the relative risks of preterm delivery among the women with shorter cervixes were as follows: 1.98 for cervical lengths at or below the 75th percentile (40 mm), 2.35 for lengths at or below the 50th percentile (35 mm), 3.79 for lengths at or below the 25th percentile (30 mm), 6.19 for lengths at or below the 10th percentile (26 mm), 9.49 for lengths at or below the 5th percentile (22 mm), and 13.99 for lengths at or below the Ist percentile (13 mm) (P<0.001 for values at or below the 50th percentile; P=0.008 for values at or below the 75th percentile). For the lengths measured at 28 weeks, the corresponding relative risks were 2.80, 3.52, 5.39, 9.57, 13.88, and 24.94 (P<0.001 for values at or below the 50th percentile; P=0.003 for values at the 75th percentile). Conclusions. The risk of spontaneous preterm delivery is increased in women who are found to have a short cervix by vaginal ultrasonography during pregnancy.	UNIV ALABAMA,DEPT OBSTET & GYNECOL,BIRMINGHAM,AL 35294; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT OBSTET & GYNECOL,WINSTON SALEM,NC 27103; UNIV TENNESSEE,DEPT OBSTET & GYNECOL,MEMPHIS,TN 38103; UNIV CHICAGO,DEPT OBSTET & GYNECOL,CHICAGO,IL 60637; GEORGE WASHINGTON UNIV,CTR BIOSTAT,DEPT OBSTET & GYNECOL,WASHINGTON,DC; NICHHD,DEPT OBSTET & GYNECOL,BETHESDA,MD 20892; UNIV PITTSBURGH,DEPT OBSTET & GYNECOL,PITTSBURGH,PA; UNIV CINCINNATI,CINCINNATI,OH; MED UNIV S CAROLINA,CHARLESTON,SC 29425; UNIV OKLAHOMA,OKLAHOMA CITY,OK; WAYNE STATE UNIV,DETROIT,MI; MAGEE WOMENS HOSP,PITTSBURGH,PA 15213	University of Alabama System; University of Alabama Birmingham; Wake Forest University; Wake Forest Baptist Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Chicago; George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati; Medical University of South Carolina; University of Oklahoma System; University of Oklahoma Health Sciences Center; Wayne State University	Iams, JD (corresponding author), OHIO STATE UNIV,DEPT OBSTET & GYNECOL,1654 UPHAM DR,COLUMBUS,OH 43210, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027917, U10HD027915, U10HD021410] Funding Source: NIH RePORTER; NICHD NIH HHS [U10-HD-21410, U10-HD-27915, U10-HD-27917] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN HF, 1990, AM J OBSTET GYNECOL, V163, P859, DOI 10.1016/0002-9378(90)91084-P; ANDERSEN HF, 1991, J CLIN ULTRASOUND, V19, P77, DOI 10.1002/jcu.1870190204; BISHOP EH, 1964, OBSTET GYNECOL, V24, P266; Cunningham FG, 1993, WILLIAMS OBSTETRICS, P673; HOLCOMB WL, 1991, OBSTET GYNECOL, V78, P43; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P120; IAMS JD, 1995, AM J OBSTET GYNECOL, V172, P1097, DOI 10.1016/0002-9378(95)91469-2; LAZAR P, 1984, BRIT J OBSTET GYNAEC, V91, P731, DOI 10.1111/j.1471-0528.1984.tb04841.x; MOORE TR, 1994, OBSTET GYNECOL, V83, P517, DOI 10.1097/00006250-199404000-00006; OKITSU O, 1992, ULTRASOUND OBST GYN, V2, P402, DOI 10.1046/j.1469-0705.1992.02060402.x; PARIKH MN, 1961, J OBSTET GYN BR COMM, V68, P818; RUSH RW, 1984, BRIT J OBSTET GYNAEC, V91, P724, DOI 10.1111/j.1471-0528.1984.tb04840.x; Rush RW, 1993, BRIT J OBSTET GYNAEC, V100, P516; SONEK JD, 1990, OBSTET GYNECOL, V76, P172	14	1295	1352	1	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					567	572		10.1056/NEJM199602293340904	http://dx.doi.org/10.1056/NEJM199602293340904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569824				2022-12-28	WOS:A1996TW69600004
J	Berendsen, HJC				Berendsen, HJC			Bio-molecular dynamics comes of age	SCIENCE			English	Editorial Material									UNIV GRONINGEN,BIOSON RES INST,GRONINGEN,NETHERLANDS	University of Groningen	Berendsen, HJC (corresponding author), UNIV GRONINGEN,DEPT BIOPHYS CHEM,GRONINGEN,NETHERLANDS.							AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; AMADEI A, IN PRESS J BIOMOL ST; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAAIJE JGEM, 1993, J CHEM PHYS, V99, P9202, DOI 10.1063/1.465536; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; MARRINK SJ, 1994, J PHYS CHEM-US, V98, P4155, DOI 10.1021/j100066a040; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; 1995, COMPUT PHYS COMMUN, V91	9	49	50	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 16	1996	271	5251					954	955		10.1126/science.271.5251.954	http://dx.doi.org/10.1126/science.271.5251.954			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584930				2022-12-28	WOS:A1996TV70400037
J	Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM				Guler, ML; Gorham, JD; Hsieh, CS; Mackey, AJ; Steen, RG; Dietrich, WF; Murphy, KM			Genetic susceptibility to Leishmania: IL-12 responsiveness in T(H)1 cell development	SCIENCE			English	Article							CD4+ T-CELLS; CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA; IFN-GAMMA; IMMUNOLOGICAL REGULATION; MURINE LEISHMANIASIS; MICE; INTERLEUKIN-4; INVITRO; RESISTANCE	The genetic background of T lymphocytes influences development of the T helper (T-H) phenotype, resulting in either resistance or susceptibility of certain mouse strains to pathogens such as Leishmania major. With an in vitro model system, a difference in maintenance of responsiveness of T cells to interleukin-12 (IL-12) was detected between BALB/c and B10.D2 mice, Although naive T cells from both strains initially responded to IL-12, BALB/c T cells lost IL-12 responsiveness after stimulation with antigen in vitro, even when cocultured with B10.D2 T cells, Thus, susceptibility of BALB/c mice to infection with L. major may derive from the loss of the ability to generate IL-12-induced T(H)1 responses rather than from an IL-4-induced T(H)2 response.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA	Washington University (WUSTL); Massachusetts Institute of Technology (MIT); Whitehead Institute					NIAID NIH HHS [AI31238, AI34580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031238, U19AI034580, U01AI034580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; GORHAM J, UNPUB; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x; SADICK MD, 1986, J IMMUNOL, V136, P655; SADICK MD, 1987, J IMMUNOL, V139, P1303; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, J IMMUNOL, V135, P2108; YANAGIDA T, 1994, J IMMUNOL, V152, P4919	33	331	334	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					984	987						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584935				2022-12-28	WOS:A1996TV70400048
J	Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C				Clemens, J; Brenner, R; Rao, M; Tafari, N; Lowe, C			Evaluating new vaccines for developing countries - Efficacy or effectiveness?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VI-CAPSULAR POLYSACCHARIDE; BOVINE ROTAVIRUS VACCINE; ENTERIC-COATED CAPSULES; TITER MEASLES-VACCINES; CONTROLLED FIELD TRIAL; ORAL CHOLERA VACCINES; CHILDHOOD TUBERCULOSIS; CONJUGATE VACCINE; TYPHOID VACCINE; ANTIBODY-RESPONSE	Despite the profusion of promising new vaccines against illnesses prevalent in developing countries, uncertainties about the balance between costs and benefits of new vaccines have retarded their use in public health practice. Conventional prelicensure trials of vaccine protection exacerbate these uncertainties by focusing on measurement of vaccine efficacy-the performance of a vaccine under idealized conditions. Vaccine effectiveness trials provide a more pragmatic perspective by addressing the performance of a vaccine under the ordinary conditions of a public health program, by capturing direct as well as indirect effects of vaccination, and by comprehensively addressing outcomes of public health concern. The use of effectiveness trials should enable more rational triaging of new vaccines for developing countries and may accelerate the introduction of new vaccines into public health practice by resolving speculative debates about practical costs and benefits.	NICHHD, DIV EPIDEMIOL STAT & PREVENT RES, BETHESDA, MD 20892 USA; NICHHD, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1988, LANCET, V2, P809; ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; [Anonymous], 1981, Int J Epidemiol, V10, P73; [Anonymous], 1993, WORLD DEV REPORT INV; [Anonymous], 1992, WKLY EPIDEMIOL REC, V67, P357; BASCH PF, 1994, VACCINES WORLD HLTH, P95; BEGG N, 1990, VACCINE, V8, P180, DOI 10.1016/0264-410X(90)90042-K; BINKIN N, 1982, LANCET, V2, P315; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLOK L, 1994, LANCET, V344, P1022; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; CLEMENS J, 1990, PROSPECTS PUBLIC HLT, P131; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; CLEMENS JD, 1988, LANCET, V1, P1375; CLEMENS JD, 1990, NEW GENERATION VACCI, P51; Clemens John, 1994, P425; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; COMSTOCK GW, 1994, EPIDEMIOL REV, V16, P77, DOI 10.1093/oxfordjournals.epirev.a036147; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEMOL P, 1986, LANCET, V2, P108; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EGAN W, 1995, JAMA-J AM MED ASSOC, V273, P888; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FEDSON DS, 1990, PROSPECTS PUBLIC HLT, P131; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; GARENNE M, 1993, AM J EPIDEMIOL, V138, P182, DOI 10.1093/oxfordjournals.aje.a116844; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Greenwood M, 1915, Proc R Soc Med, V8, P113; HALL AJ, 1989, LANCET, V1, P1057; HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HANLON P, 1987, LANCET, V1, P1342; HARRINGTON D, 1990, NEW GENERATION VACCI, P43; HENDRICKSE RG, 1975, T ROY SOC TROP MED H, V69, P31, DOI 10.1016/0035-9203(75)90007-3; HLADY WG, 1992, AM J PUBLIC HEALTH, V82, P1365, DOI 10.2105/AJPH.82.10.1365; HULL HF, 1983, LANCET, V1, P972; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KLUGMAN KP, 1987, LANCET, V2, P1165; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; LAGOS R, IN PRESS PEDIATR INF; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; LEE JW, 1994, SCIENCE, V266, P527, DOI 10.1126/science.7939695; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1990, LANCET, V336, P891; Markowitz LE, 1994, VACCINES, P229; MCINTYRE RC, 1982, B WORLD HEALTH ORGAN, V60, P767; MELNICK JL, 1994, VACCINES, P155; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PADUNGCHAN S, 1986, B WORLD HEALTH ORGAN, V64, P247; PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PICHICHERO ME, 1990, J INFECT DIS, V162, P753, DOI 10.1093/infdis/162.3.753; PIERCE NF, 1994, LANCET, V344, P1022, DOI 10.1016/S0140-6736(94)91682-9; REINGOLD AL, 1985, LANCET, V2, P114; ROBBINS A, 1993, PEDIATR INFECT DIS J, V12, P523, DOI 10.1097/00006454-199306000-00012; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SACKETT DL, 1983, CLIN TRIALS, P65; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHWARTZ D, 1980, CLIN TRIALS; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1982, TUBERCLE, V63, P23, DOI 10.1016/S0041-3879(82)80006-8; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STANFORD JL, 1987, TUBERCLE, V68, P169, DOI 10.1016/0041-3879(87)90052-3; SWERDLOW DL, 1994, LANCET, V344, P1302, DOI 10.1016/S0140-6736(94)90793-5; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; VADHEIM CM, 1994, ARCH PEDIAT ADOL MED, V148, P51, DOI 10.1001/archpedi.1994.02170010053011; VESIKARI T, 1984, LANCET, V1, P977; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; Weinstein M. C., 1980, CLIN DECISION ANAL, P228; WHITTLE H, 1988, LANCET, V2, P811; 1985, EXPANDED PROGRAMME I, V7, P1; 1991, WKLY EPIDEMIOL REC, V66, P259; 1994, MMWR-MORBID MORTAL W, V43, P144; 1990, WIKLY EPIDEMIOL REC, V65, P2	87	135	139	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					390	397		10.1001/jama.275.5.390	http://dx.doi.org/10.1001/jama.275.5.390			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569019				2022-12-28	WOS:A1996TT30300033
J	Kizer, KW				Kizer, KW			Nasopharyngeal radium treatment of veterans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), DEPT VET AFFAIRS,OFF PUBL HLTH & ENVIRONM HAZARDS,810 VERMONT AVE NW,WASHINGTON,DC 20420, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569001				2022-12-28	WOS:A1996TT30300007
J	Jensen, BV; Nielsen, SL; Skovsgaard, T				Jensen, BV; Nielsen, SL; Skovsgaard, T			Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy	LANCET			English	Article							CONGESTIVE HEART-FAILURE; RISK-FACTORS; CARDIOTOXICITY; DOXORUBICIN; ADRIAMYCIN	Background Anthracycline chemotherapy in cancer can cause severe, frequently fatal congestive heart failure (CHF), the first-line treatment for which is diuretics and digoxin. We have studied the use of an angiotensin-converting-enzyme (ACE) inhibitor added as a third agent. Methods In an observational study in hospital and as outpatients, 92 patients with advanced breast cancer were treated with epirubicin at a cumulative dose of 360 to 1000 mg/m(2) (median 1000). Of 85 evaluable, nine developed life-threatening CHF at 1.5 to 13 months after ending epirubicin. Left ventricular ejection fraction (LVEF) decreased from normal to 18 to 35%. All received frusemide and digoxin, and then, after transient clinical relief, enalapril or ramipril (initially 1.25 mg orally daily, increasing to 10-15 mg after 4-6 weeks). Findings Eight of the nine patients deteriorated while on digoxin/diuretic. Within 3 months of starting the ACE inhibitor in these patients, LVEF had increased to normal or near normal. Only one patient died in heart failure. Followup ranged from 11 to 42 months (median 26). The ACE inhibitor was well-tolerated, with no first-dose hypotension, except for one patient who discontinued treatment after 6 months months because of persistent cough. Two others discontinued treatment with their ACE inhibitor after 22 and 28 months because they felt well. Survival in the nine patients was similar to that of those who did not develop CHF. Interpretation Our experience suggests that treatment of anthracycline-induced CHF with an ACE inhibitor should start soon after clinical improvement on digoxin/diuretic regardless of the severity of symptoms rather than waiting for clinical deterioration.	UNIV COPENHAGEN,HERLEV HOSP,DEPT CLIN PHYSIOL & NUCL MED,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	Jensen, BV (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT ONCOL,DK-2730 HERLEV,DENMARK.							BRYNJOLF I, 1984, EUR HEART J, V5, P756, DOI 10.1093/oxfordjournals.eurheartj.a061738; CAULFIELD JB, 1988, AM J PATHOL, V133, P298; HAQ MM, 1985, CANCER-AM CANCER SOC, V56, P1361, DOI 10.1002/1097-0142(19850915)56:6<1361::AID-CNCR2820560624>3.0.CO;2-S; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; MINOW RA, 1977, CANCER, V39, P1397, DOI 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U; MORTENSEN SA, 1986, INT J CLIN PHARM RES, V6, P137; NIELSEN D, 1990, J CLIN ONCOL, V8, P1806, DOI 10.1200/JCO.1990.8.11.1806; PRAGA C, 1979, CANCER TREAT REP, V63, P1827; TORTI FM, 1986, CANCER RES, V46, P3722; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; 1987, NEW ENGL J MED, V316, P1429	12	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					297	299		10.1016/S0140-6736(96)90469-9	http://dx.doi.org/10.1016/S0140-6736(96)90469-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569365				2022-12-28	WOS:A1996TT48500012
J	Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA				Dewsnup, DH; Galgiani, JN; Graybill, JR; Diaz, M; Rendon, A; Cloud, GA; Stevens, DA			Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?	ANNALS OF INTERNAL MEDICINE			English	Article						coccidioidomycosis; meningitis, fungal; azoles; triazoles; recurrence	ITRACONAZOLE THERAPY; FLUCONAZOLE THERAPY; KETOCONAZOLE; ANTIFUNGAL; MYCOSES	Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral atole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to atole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom atole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular atole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving atole therapy and 2) that discontinuing atole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even longterm triazole therapy.	SANTA CLARA VALLEY MED CTR, DEPT MED, DIV INFECT DIS, SAN JOSE, CA 95128 USA; VET AFFAIRS MED CTR, DEPT MED, DIV INFECT DIS, TUCSON, AZ 85723 USA; UNIV TEXAS, HLTH SCI CTR, DEPT INFECT DIS, AUDIE MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX 78284 USA; UNIV ALABAMA, MED CTR, TUMOR INST, BIRMINGHAM, AL 35294 USA; CALIF INST MED RES, SAN JOSE, CA 95128 USA; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA; NIAID, MYCOSES STUDY GRP, BETHESDA, MD USA; UNIV ARIZONA, TUCSON, AZ USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; UNIV AUTONOMA NUEVO LEON, MONTERREY, MEXICO; UNIV HOSP, MONTERREY, MEXICO	Santa Clara Valley Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Texas System; University of Texas Health San Antonio; University of Alabama System; University of Alabama Birmingham; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon			Rendon, Adrian/S-1531-2017; Galgiani, John/GLT-7012-2022; A., Rendon/AAE-5931-2021	Rendon, Adrian/0000-0001-8973-4024; A., Rendon/0000-0001-8973-4024	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT J, 1990, FLUCONAZOLE OVERVIEW, P1; BORELLI D, 1979, POSTGRAD MED J, V55, P657, DOI 10.1136/pgmj.55.647.657; CAUWENBERGH G, 1990, J AM ACAD DERMATOL, V23, P549; DENNING DW, 1990, MYCOSES IN AIDS PATIENTS, P305; DEWSNUP DH, 1991, 31ST INT C ANT AG CH, P1156; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DUPONT B, 1988, 10TH P C INT SOC HUM, P197; EINSTEIN HE, 1961, CALIF MED, V94, P339; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Graybill J R, 1988, Ann N Y Acad Sci, V544, P488, DOI 10.1111/j.1749-6632.1988.tb40446.x; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; Kelly P.C., 1980, COCCIDIOIDOMYCOSIS T, P163, DOI [10.1007/978-1-4757-1712-9_11, DOI 10.1007/978-1-4757-1712-9_11]; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; RESTREPO A, 1980, REV INFECT DIS, V2, P519; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; STEVENS DA, 1983, DRUGS, V26, P347, DOI 10.2165/00003495-198326040-00004; STEVENS DA, 1986, INFECTIOUS DISEASES; TUCKER RM, 1990, J AM ACAD DERMATOL, V23, P593, DOI 10.1016/0190-9622(90)70261-F; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; 1993, MMWR-MORBID MORTAL W, V42, P21	23	130	135	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					305	+		10.7326/0003-4819-124-3-199602010-00004	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554225				2022-12-28	WOS:A1996TR59600004
J	Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE				Steegmans, PHA; Fekkes, D; Hoes, AW; Bak, AAA; vanderDoes, E; Grobbee, DE			Low serum cholesterol concentration and serotonin metabolism in men	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,SECT PATHOPHYSIOL BEHAV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; KAPLAN JR, 1994, PSYCHOSOM MED, V56, P479, DOI 10.1097/00006842-199411000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; SALTER M, 1992, LANCET, V339, P1169	5	109	111	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					221	221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563588	Green Published			2022-12-28	WOS:A1996TT48600028
J	WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE				WiedauPazos, M; Goto, JJ; Rabizadeh, S; Gralla, EB; Roe, JA; Lee, MK; Valentine, JS; Bredesen, DE			Altered reactivity of superoxide dismutase in farmilial amyotrophic lateral sclerosis	SCIENCE			English	Article							HYDROGEN-PEROXIDE; COPPER; ENZYME	A subset of individuals with familiar amyotrophic lateral sclerosis (FALS) possesses dominantly inherited mutations in the gene that encodes copper-zinc superoxide dismutase (CuZnSOD). A4V and G93A, two of the mutant enzymes associated with FALS, were shown to catalyze the oxidation of a model substrate (spin trap 5,5'-dimethyl-1-pyrroline N-oxide) by hydrogen peroxide at a higher rate than that seen with the wild-type enzyme. Catalysis of this reaction by A4V and G93A was more sensitive to inhibition by the copper chelators diethyldithiocarbamate and penicillamine than was catalysis by wild-type CuZnSOD. The same two chelators reversed the apoptosis-inducing effect of mutant enzymes expressed in a neural cell line. These results suggest that oxidative reactions catalyzed by mutant CuZnSOD enzymes initiate the neuropathologic changes in FALS.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INTERDEPARTMENTAL PROGRAM NEUROSCI, LOS ANGELES, CA 90095 USA; LA JOLLA CANC RES FDN, PROGRAM AGING, LA JOLLA, CA 92037 USA; LOYOLA MARYMOUNT UNIV, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90045 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21218 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Sanford Burnham Prebys Medical Discovery Institute; Loyola Marymount University; Johns Hopkins University			Lee, Michael K/D-9491-2013; Valentine, Joan S/B-6665-2008	Lee, Michael K/0000-0001-5865-9682; Valentine, Joan S/0000-0002-7174-925X	NIA NIH HHS [AG12282] Funding Source: Medline; NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN RH, CELL, V687, P95; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; DAMANI LA, 1989, SULPHUR CONTAINING D, V3; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DURAND M M, 1990, Society for Neuroscience Abstracts, V16, P40; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GANDARA DR, 1995, J CLIN ONCOL, V13, P490, DOI 10.1200/JCO.1995.13.2.490; GOTO JJ, UNPUB; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JOYCE DA, 1993, AGENT ACTION SUPPL, V44, P203; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1979, J BIOL CHEM, V254, P1623; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; REINKE LA, 1994, FREE RADICAL RES, V21, P213, DOI 10.3109/10715769409056573; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	28	639	650	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					515	518		10.1126/science.271.5248.515	http://dx.doi.org/10.1126/science.271.5248.515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560268				2022-12-28	WOS:A1996TR32200045
J	Brock, DJH				Brock, DJH			Prenatal screening for cystic fibrosis: 5 years' experience reviewed	LANCET			English	Article							CARRIERS; CARE	Background Although several programmes of prenatal screening for cystic fibrosis have been completed and reported, there are still uncertainties about rates of take up and also about the action of parents identified as having a one-in-four risk of an affected child. I report 5 years' experience with the two-step and couple models of prenatal screening of cystic fibrosis. Methods Screening has been available at two antenatal clinics in Edinburgh, UK, since January, 1992, first on a research basis and then routinely. 25 000 couples have been screened. Findings Take-up rates for the two-step and couple models of delivery are very similar at about 70%. Take-up rates did not change when screening moved from a research to a routine service. Of 22 high-risk couples identified entirely through screening, 20 (91%) opted for prenatal diagnosis. Four couples returned for second and two for third monitored pregnancies. In all eight cases where affected fetuses were identified, pregnancy was terminated. Interpretation These data remove one of the few remaining obstacles to a general implementation of prenatal screening for cystic fibrosis.			Brock, DJH (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BOWMAN JE, 1991, AM J HUM GENET, V48, P433; BROCK D, 1990, AM J HUM GENET, V47, P164; DOHERTY RA, 1994, LANCET, V343, P172, DOI 10.1016/S0140-6736(94)90961-X; KABACK MM, 1977, TAY SACHS DISEASE SC, P13; LIVINGSTONE J, 1993, CLIN GENET, V43, P57, DOI 10.1111/j.1399-0004.1993.tb04427.x; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; MODELL B, 1984, CLIN APPROACH THALAS, P354; Morris J K, 1995, J Med Screen, V2, P22; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1988, BRIT MED J, V297, P1599	16	55	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					148	150		10.1016/S0140-6736(96)90340-2	http://dx.doi.org/10.1016/S0140-6736(96)90340-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544548				2022-12-28	WOS:A1996TQ24400009
J	Katchan, B; Karaplis, AC; Begin, LR; Trifiro, M				Katchan, B; Karaplis, AC; Begin, LR; Trifiro, M			Hypercalcaemia with lymphoedema	LANCET			English	Article							AUTOANTIBODIES		MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH HOSP,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH HOSP,DEPT PATHOL,MONTREAL,PQ H3T 1E2,CANADA; LADY DAVIS RES INST,MONTREAL,PQ H3T 1E2,CANADA	McGill University; McGill University; McGill University								BRAUDE S, 1991, LANCET, V337, P140, DOI 10.1016/0140-6736(91)90802-V; MARTIN TJ, 1995, CLIN ENDOCRINOL, V42, P535, DOI 10.1111/j.1365-2265.1995.tb02674.x; MOLLER DE, 1988, AM J MED, V84, P334, DOI 10.1016/0002-9343(88)90436-6; SALVI M, 1988, ENDOCR REV, V9, P450, DOI 10.1210/edrv-9-4-450	4	7	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					161	161		10.1016/S0140-6736(96)90344-X	http://dx.doi.org/10.1016/S0140-6736(96)90344-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544552				2022-12-28	WOS:A1996TQ24400013
J	Davies, T				Davies, T			Physical illness in psychiatric patients may be managed poorly - Commentary	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				Davies, T (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.							AMADDEO F, 1995, BRIT J PSYCHIAT, V166, P783, DOI 10.1192/bjp.166.6.783; JUSIC N, 1994, BRIT J PSYCHIAT, V165, P787, DOI 10.1192/bjp.165.6.787; MORTENSEN PB, 1993, BRIT J PSYCHIAT, V163, P183, DOI 10.1192/bjp.163.2.183; SIMS A, 1987, BRIT MED J, V294, P986, DOI 10.1136/bmj.294.6578.986; STRATHDEE G, 1993, DIMENSIONS COMMUNITY, P62	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					82	82						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ168	8555933				2022-12-28	WOS:A1996TQ16800020
J	Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J				Gravholt, CH; Juul, S; Naeraa, RW; Hansen, J			Prenatal and postnatal prevalence of Turner's syndrome: A registry study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHROMOSOMAL MOSAICISM; 45,X/46,XY MOSAICISM; MATERNAL AGE; MONOSOMY-X; ABNORMALITIES; AMNIOCENTESIS; DIAGNOSIS; PREGNANCY; CHILDREN; ORIGIN	Objective-To study prevalence of Turner's syndrome in Denmark and to assess validity of prenatal diagnosis. Design-Study of data on prenatal and postnatal Turner's syndrome in Danish Cytogenetic Central Register. Subjects-All registered Turner's syndrome karyotypes (100 prenatal cases and 215 postnatal cases) during 1970-93. Main outcome measures-Prevalence of Turner's syndrome karyotypes among prenatally tested fetuses and Turner's syndrome among liveborn infants. Results-Among infant girls, prevalence of Turner's syndrome was 32/100000. Among female fetuses tested by amniocentesis, prevalence of Turner's syndrome karyotypes was 176/100000 (relative risk of syndrome, 6.74 compared with prevalence among untested pregnancies). Among female fetuses tested by chorion villus sampling, prevalence of syndrome karyotypes was 392/100000 (relative risk, 16.8). We excluded prenatal tests referred because of results of ultrasound scanning: among fetuses tested by amniocentesis revised relative risk was 5.68, while revised relative risk among fetuses tested by chorion villus sampling was 13.3. For 29 fetuses with prenatal diagnosis of possible Turner's syndrome, pregnancy was allowed to continue and 24 children were live born. Thirteen of these children were karyotyped postnatally, and diagnosis of Turner's syndrome had to be revised for eight, seven being normal girls and one boy, This gives tentative predictive value of amniocentesis in diagnosing Turner's syndrome of betmeen 21% and 67%. There was no significant relation between mother's age and risk of Turner's syndrome. Conclusions-Discrepancy between prenatal and postnatal prevalence of Turner's syndrome challenges specificity of prenatal examination in diagnosing Turner's syndrome.	AARHUS UNIV, DEPT EPIDEMIOL & SOCIAL MED, AARHUS, DENMARK; AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, PAEDIAT DEPT A, DK-8000 AARHUS C, DENMARK; AARHUS UNIV HOSP, AARHUS PSYCHIAT HOSP, DANISH CYTOGENET CENT REGISTER, DK-8000 AARHUS C, DENMARK	Aarhus University; Aarhus University; Aarhus University	Gravholt, CH (corresponding author), AARHUS UNIV HOSP, AARHUS KOMMUNEHOSP, MED DEPT M ENDOCRINOL & DIABET, DK-8000 AARHUS C, DENMARK.		Gravholt, Claus H./Z-1435-2018	Gravholt, Claus H./0000-0001-5924-1720				BERNASCONI S, 1994, ACTA PAEDIATR, V83, P292, DOI 10.1111/j.1651-2227.1994.tb18097.x; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CAROTHERS AD, 1980, ANN HUM GENET, V43, P355, DOI 10.1111/j.1469-1809.1980.tb01570.x; CHANG HJ, 1990, AM J HUM GENET, V46, P156; CONNOR JM, 1989, ACTA PAEDIATR SCAND, P77; GRAVHOLT CH, 1991, HUM GENET, V88, P49, DOI 10.1007/BF00204928; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; HOOK EB, 1989, AM J HUM GENET, V45, P855; IMAIZUMI K, 1993, INT CONGR SER, V1014, P3; JACOBS PA, 1974, ANN HUM GENET, V37, P359, DOI 10.1111/j.1469-1809.1974.tb01843.x; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; KAJII T, 1979, HUM GENET, V51, P147, DOI 10.1007/BF00287168; KEIDING N, 1994, BRIT MED J, V309, P131, DOI 10.1136/bmj.309.6947.131b; KULKARNI R, 1989, PRENATAL DIAG, V9, P439, DOI 10.1002/pd.1970090610; LARSEN T, 1995, CLIN GENET, V48, P6; LIPPE B, 1991, ENDOCRIN METAB CLIN, V20, P121, DOI 10.1016/S0889-8529(18)30284-6; LORDASANCHEZ I, 1992, AM J MED GENET, V42, P487, DOI 10.1002/ajmg.1320420414; LOUGHLIN SAR, 1991, J MED GENET, V28, P156, DOI 10.1136/jmg.28.3.156; MARTIN RH, 1987, AM J HUM GENET, V41, P484; MIKKELSEN M, 1992, PRAENATALE UNDERSOGE, P1; MINY P, 1991, PRENATAL DIAG, V11, P581, DOI 10.1002/pd.1970110815; NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097; NISANI R, 1989, PRENATAL DIAG, V9, P223, DOI 10.1002/pd.1970090402; ROLAND B, 1990, PRENATAL DIAG, V10, P333, DOI 10.1002/pd.1970100509; SCHWINGER E, 1989, PRENATAL DIAG, V9, P639, DOI 10.1002/pd.1970090907; THARAPEL AT, 1989, PRENATAL DIAG, V9, P467, DOI 10.1002/pd.1970090703; TOMKINS DJ, 1989, PRENATAL DIAG, V9, P139, DOI 10.1002/pd.1970090210; VILLAMAR M, 1990, ANN GENET-PARIS, V33, P29; WARBURTON D, 1980, LANCET, V1, P167; WHEELER M, 1988, AM J MED GENET, V29, P565, DOI 10.1002/ajmg.1320290314	32	120	129	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					16	21		10.1136/bmj.312.7022.16	http://dx.doi.org/10.1136/bmj.312.7022.16			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555850	Green Published			2022-12-28	WOS:A1996TP20900017
J	Molkentin, JD; Black, BL; Martin, JF; Olson, EN				Molkentin, JD; Black, BL; Martin, JF; Olson, EN			Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins	CELL			English	Article							HELIX-LOOP-HELIX; ENHANCER-BINDING-FACTOR; TRANSCRIPTION FACTORS; BASIC REGION; MYOD FAMILY; FACTOR-II; OLIGOMERIZATION; MYOBLASTS; COMPLEXES; PRODUCTS	Members of the myocyte enhancer factor-2 (MEF2) family of MADS domain transcription factors cannot induce myogenesis in transfected fibroblasts, but when coexpressed with the myogenic basic-helix-loop-helix (bHLH) proteins MyoD or myogenin they dramatically increase the extent of myogenic conversion above that seen with either myogenic bHLH factor alone. This cooperativity required direct interactions between the DNA-binding domains of MEF2 and the myogenic bHLH factors, but only one of the factors needed a transactivation domain, and only one of the factors needed to be bound to DNA. These interactions allow either factor to activate transcription through the other's binding site and reveal a novel mechanism for indirect activation of gene expression via protein-protein interactions between the DNA-binding domains of heterologous classes of transcription factors.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Molkentin, Jeffery/0000-0002-3558-6529; Black, Brian/0000-0002-6664-8913	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	56	684	707	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1125	1136		10.1016/0092-8674(95)90139-6	http://dx.doi.org/10.1016/0092-8674(95)90139-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548800	Bronze			2022-12-28	WOS:A1995TM76200009
J	Lees, AJ				Lees, AJ			Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease	BRITISH MEDICAL JOURNAL			English	Article							DEPRENYL	Objective-To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease. Design-Open, long term, prospective randomised trial. Setting-93 hospitals throughout United Kingdom. Subjects-520 patients with early Parkinson's disease who were not receiving dopaminergic treatment. Interventions-Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2), Main outcome measures-Assessments of serial disability, frequency and severity of adverse events, and deaths from all causes. Results-After average of 5 . 6 years' follow up, mortality ratio in arm 2 compared with arm 1 was 1 . 57 (95% confidence interval 1 . 09 to 2 . 30), and difference in survival between the two arms was significant (log rank test, P=0 . 015). Hazard ratio adjusted for age and sex was 1 . 49 (1 . 02 to 2 . 16), and sifter adjustment for other baseline factors it increased to 1 . 57 (1 . 07 to 2 . 31), Patients in arm 1 had slightly worse disability scores than those in arm 2, but differences were not significant, Functionally disabling peak dose dyskinesias and on/off fluctuations were more frequent in arm 2 than arm 1, During the trial the dose of levodopa required to produce optimum motor control steadily increased in arm 1 (median daily dose 375 mg at 1 year and 625 mg at 4 years), but median dose in arm 2 did not change (375 mg). Conclusions-Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease, Moreover, mortality was significantly higher with combination treatment, casting doubts on its chronic use in Parkinson's disease.			Lees, AJ (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, PARKINSONS DIS RES GRP UNITED KINGDOM, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Lees, Andrew J/A-6605-2009	Lees, Andrew J/0000-0002-2476-4385				BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; BRADFORDHILL A, 1971, LANCET; BRANNAN T, 1995, ANN NEUROL, V37, P95, DOI 10.1002/ana.410370117; CANTER GJ, 1961, J NERV MENT DIS, V133, P143, DOI 10.1097/00005053-196108000-00010; CLARKE CE, 1995, MOVEMENT DISORD, V10, P250, DOI 10.1002/mds.870100303; COHEN G, 1989, ANN NEUROL, V26, P689, DOI 10.1002/ana.410260518; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEES AJ, 1993, BRIT MED J, V307, P469; MARSDEN CD, 1976, LANCET, V1, P292, DOI 10.1016/S0140-6736(76)91416-1; MENA MA, 1992, MOVEMENT DISORD, V5, P62; MYLLYLA VV, 1993, MOV DISORD S1, V8, P541; POEWE WH, 1986, NEUROLOGY, V36, P1528, DOI 10.1212/WNL.36.11.1528; SHAW KM, 1980, Q J MED, V49, P283; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; TATTON WG, 1991, J NEUROSCI RES, V30, P666, DOI 10.1002/jnr.490300410; WARD CD, 1994, J NEUROL NEUROSUR PS, V57, P217, DOI 10.1136/jnnp.57.2.217; WEBSTER DD, 1968, MOD TREAT, V5, P257	20	302	307	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1602	1607		10.1136/bmj.311.7020.1602	http://dx.doi.org/10.1136/bmj.311.7020.1602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555803	Green Published			2022-12-28	WOS:A1995TL42200020
J	Lip, GYH; Watson, RDS; Singh, SP				Lip, GYH; Watson, RDS; Singh, SP			ABC of atrial fibrillation - Drugs for atrial fibrillation	BRITISH MEDICAL JOURNAL			English	Article							SINUS RHYTHM; MAINTENANCE; MANAGEMENT; QUINIDINE; THERAPY		UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; CHANNER KS, 1991, BRIT J CLIN PHARMACO, V32, P267, DOI 10.1111/j.1365-2125.1991.tb03898.x; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COWAN JC, 1993, BRIT HEART J, V70, P304; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; LIP GYH, 1993, Q J MED, V86, P467, DOI 10.1093/qjmed/86.8.467; REIFFEL JA, 1994, CLIN CARDIOL, V17, P103, DOI 10.1002/clc.4960170303; SINGH BN, 1970, S CARDIAC ARRHYTHMIA	9	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1631	1634		10.1136/bmj.311.7020.1631	http://dx.doi.org/10.1136/bmj.311.7020.1631			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555811	Green Published			2022-12-28	WOS:A1995TL42200035
J	Pallen, M				Pallen, M			Guide to the Internet - Logging in, fetching files, reading news	BRITISH MEDICAL JOURNAL			English	Article								Aside from email and the world wide web, there are several other systems for distributing information on the Internet. Telnet is a system that allows you to log on to a remote computer from anywhere on the Internet and affords access to many useful biomedical sites on the Internet, File transfer protocol (FTP) is a method of transferring files from one computer to another over the Internet. It can be used to download files, including software, from numerous publicly accessible ''anonymous FTP archives'' around the world. Such archives can be searched using a tool known as Archie. Network News is a system of electronic discussion groups covering almost every imaginable subject, including many areas of medicine and the biomedical sciences; MOOs are virtual environments that allow real time electronic conferencing and teaching over the Internet. It is difficult to predict the future of medicine on the Internet. However, the net opens up many possibilities not available through previous technologies, It is now up to medical practitioners to realise the Internet's full potential.			Pallen, M (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.		Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				Krol E, 1994, WHOLE INTERNET USERS; LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387; MCLAREN P, 1995, BRIT MED J, V310, P1390, DOI 10.1136/bmj.310.6991.1390; RHEINGOLD G, 1994, VIRTUAL COMMUNITY	4	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1626	1630		10.1136/bmj.311.7020.1626	http://dx.doi.org/10.1136/bmj.311.7020.1626			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555810	Green Published			2022-12-28	WOS:A1995TL42200034
J	Daoust, P; Schapiro, B				Daoust, P; Schapiro, B			Histoplasmosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Daoust, P (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1996	334	11					700	700		10.1056/NEJM199603143341105	http://dx.doi.org/10.1056/NEJM199603143341105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ528	8594429				2022-12-28	WOS:A1996TZ52800005
J	NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ				NostenBertrand, M; Errington, ML; Murphy, KPSJ; Tokugawa, Y; Barboni, E; Kozlova, E; Michalovich, D; Morris, RGM; Silver, J; Stewart, CL; Bliss, TVP; Morris, RJ			Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL GRANULE CELLS; DENTATE GYRUS INVITRO; II MUTANT MICE; MEMORY; MODULATION; LESIONS; RAT	The process of learning involves stable changes in synaptic efficacy for which long-term potentiation (LTP)(1) provides a widely adopted mammalian model. Synaptic modification induced by learning or LTP may involve the action of cell adhesion molecules(2-4). One such candidate is the ubiquitous neuronal glycoprotein Thy-1 (refs 5, 6). In mice in which the gene encoding Thy-1 has been inactivated, we find a regionally selective impairment of LTP in vivo in the hippocampal formation: LTP is normal in area CA1 but strongly inhibited in the dentate gyrus. Spatial learning by Thy-1-deficient mice, as assessed in the watermaze(7), is unimpaired. Thus LTP in the cortical input to the dentate gyrus seems not to be required for spatial learning.	NATL INST MED RES, DEPT NEUROBIOL, LONDON NW7 1AA, ENGLAND; NATL INST MED RES, DEPT NEUROPHYSIOL, LONDON NW7 1AA, ENGLAND; CORNELL UNIV, COLL MED, N SHORE UNIV HOSP, DIV MOLEC MED, NEW YORK, NY 11030 USA; UNIV ROMA LA SAPIENZA, DEPT HUMAN BIOPATHOL, I-00100 ROME, ITALY; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV EDINBURGH, CTR NEUROSCI, EDINBURGH EH8 9LE, MIDLOTHIAN, SCOTLAND; ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA; UNITED MED & DENT SCH, GUYS HOSP, DEPT EXPTL PATHOL, LONDON SE1 9RT, ENGLAND	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Cornell University; Northwell Health; North Shore University Hospital; Sapienza University Rome; Erasmus University Rotterdam; University of Edinburgh; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Murphy, Kerry/H-1934-2012; Morris, Richard G M/C-9982-2013	Michalovich, David/0000-0003-4452-5776; Kozlova, Elena/0000-0002-2234-0079				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CHO YH, 1995, NEUROBIOL LEARN MEM, V64, P285, DOI 10.1006/nlme.1995.0011; CONRAD CD, 1993, J NEUROSCI, V13, P2582, DOI 10.1523/JNEUROSCI.13-06-02582.1993; FAZELI MS, 1994, NEUROSCI LETT, V169, P77, DOI 10.1016/0304-3940(94)90360-3; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GORDON JA, 1994, SOC NEUR ABSTR, V20; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MORRIS R, 1992, BIOESSAYS, V14, P715, DOI 10.1002/bies.950141014; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; Naquet P, 1989, Immunol Ser, V45, P99; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1995, J NEUROSCI, V15, P811; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P59, DOI 10.1016/0166-4328(87)90036-2; WIGSTROM H, 1983, BRAIN RES, V275, P153, DOI 10.1016/0006-8993(83)90428-6	30	204	211	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					826	829		10.1038/379826a0	http://dx.doi.org/10.1038/379826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587606				2022-12-28	WOS:A1996TX50100059
J	Nathanielsz, PW				Nathanielsz, PW			Fetal and neonatal environment has influence on brain development	LANCET			English	News Item														Nathanielsz, Peter/0000-0001-8410-6280					0	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					314	314		10.1016/S0140-6736(96)90479-1	http://dx.doi.org/10.1016/S0140-6736(96)90479-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569370	Bronze			2022-12-28	WOS:A1996TT48500020
J	Sabin, CA; Pasi, KJ; Phillips, AN; Lilley, P; Bofill, M; Lee, CA				Sabin, CA; Pasi, KJ; Phillips, AN; Lilley, P; Bofill, M; Lee, CA			Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOPHILIC COHORT; VIRUS; PROGRESSION; INFECTION; DISEASE	Objective-To investigate the hypothesis that high usage of clotting factor concentrate, rather than HIV infection, is the cause of immunodeficiency and AIDS in men with haemophilia. Design-A comparison of AIDS defining conditions and CD4 counts in HIV positive and HIV negative patients with haemophilia matched for usage of clotting factor concentrate. Setting-A comprehensive care haemophilia centre. Subjects-17 HIV positive and 17 HIV negative male patients with haemophilia A (age range 12-60 at beginning of study period) who had received similar amounts of clotting factor concentrate yearly over the years 1980-90. Main outcome measures-Clinical events listed as AIDS defining in the Centers for Disease Control AIDS definition; CD4 lymphocyte counts; death. Results-Of 108 HIV positive male patients with haemophilia A, only 17 could be matched to an HIV negative patient. This was due to the much higher average usage of factor VIII in the HIV positive group. Between 1980 and 1990, 16 clinical events occurred in nine of the 17 HIV positive patients. No event occurred in the 17 HIV negative patients. In each pair the mean CD4 count during follow up was, on average, 0.5x10(9)/l lower in the HIV positive patient. Conclusion-These data reject the hypothesis that high usage of clotting factor concentrate, rather than HIV infection, is the cause of immunodeficiency and AIDS in men with haemophilia.	ROYAL FREE HOSP, SCH MED, HAEMOPHILIA CTR, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, SCH MED, HAEMOSTASIS UNIT, LONDON NW3 2PF, ENGLAND; UNIV LONDON SCH MED, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, DEPT CLIN IMMUNOL, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Sabin, CA (corresponding author), ROYAL FREE HOSP, SCH MED, HIV RES UNIT, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.		Sabin, Caroline/C-2464-2008; Phillips, Andrew N/B-4427-2008	Sabin, Caroline/0000-0001-5173-2760; Phillips, Andrew N/0000-0003-2384-4807				BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; DUESBERG P, 1993, LANCET, V341, P957, DOI 10.1016/0140-6736(93)91247-J; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1992, PHARMACOL THERAPEUT, V55, P201, DOI 10.1016/0163-7258(92)90052-2; DUESBERG PH, 1989, P NATL ACAD SCI USA, V86, P755, DOI 10.1073/pnas.86.3.755; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; MADHOK R, 1986, BRIT MED J, V293, P978, DOI 10.1136/bmj.293.6553.978; MAYNE E, 1992, BLOOD COAGUL FIBRIN, V3, P205; PHILLIPS AN, 1991, J ACQ IMMUN DEF SYND, V4, P970; SABIN C, 1994, THROMB HAEMOSTASIS, V72, P214; SCHULMAN S, 1991, ANN HEMATOL, V63, P145, DOI 10.1007/BF01703246; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R	14	8	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	1996	312	7025					207	210						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT486	8563582	Green Published			2022-12-28	WOS:A1996TT48600021
J	Sellal, F; Mohr, M; Collard, M				Sellal, F; Mohr, M; Collard, M			Dementia in a 58-year-old woman	LANCET			English	Article							ALZHEIMERS		HOP UNIV STRASBOURG,INST PATHOL ANAT,F-67091 STRASBOURG,FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sellal, F (corresponding author), HOP UNIV STRASBOURG,NEUROL CLIN,F-67091 STRASBOURG,FRANCE.							MARTIN A, 1986, J CLIN EXP NEUROPSYC, V8, P594, DOI 10.1080/01688638608405178; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; 1991, ANN NEUROL, V30, P597; 1987, ANN INTERN MED, V107, P78	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					236	236		10.1016/S0140-6736(96)90408-0	http://dx.doi.org/10.1016/S0140-6736(96)90408-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551885				2022-12-28	WOS:A1996TT06900014
J	Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H				Weber, GF; Ashkar, S; Glimcher, MJ; Cantor, H			Receptor-ligand interaction between CD44 and osteopontin (Eta-1)	SCIENCE			English	Article							T-CELL ACTIVATION; SECRETED PHOSPHOPROTEIN; OSTEO-SARCOMA; BONE; LINES; IMMUNOLOCALIZATION; ANTIBODIES; DEFINITION; EXPRESSION; PROTEIN	The CD44 family of surface receptors regulates adhesion, movement, and activation of normal and neoplastic cells. The cytokine osteopontin (Eta-1), which regulates similar cellular functions, was found to be a protein ligand of CD44. Osteopontin induces cellular chemotaxis but not homotypic aggregation, whereas the inverse is true for the interaction between CD44 and a carbohydrate ligand, hyaluronate. The different responses of cells after CD44 ligation by either osteopontin or hyaluronate may account for the independent effects of CD44 on cell migration and growth. This mechanism may also be exploited by tumor cells to promote metastasis formation.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPED RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School	Weber, GF (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,DANA FARBER CANC INST,DIV IMMUNOPATHOL,BOSTON,MA 02115, USA.		Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012184, R37AI012184, R01AI013600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13600, AI12184] Funding Source: Medline; NIAMS NIH HHS [P01 AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTHER UG, 1991, CELL, V65, P13; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARESU O, 1991, INVAS METAST, V11, P2; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; BEHREND EI, 1994, CANCER RES, V54, P832; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENNING SM, 1990, J IMMUNOL, V144, P7; HU MCT, 1992, COLD SPRING HARB SYM, V57, P291, DOI 10.1101/SQB.1992.057.01.034; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PATARCA R, 1993, CRIT REV IMMUNOL, V13, P225; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432-0436.1988.tb00090.x; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH RP, 1990, J EXP MED, V171, P1931, DOI 10.1084/jem.171.6.1931; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; WASS JA, 1981, J NATL CANCER I, V66, P927; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282	37	745	780	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					509	512		10.1126/science.271.5248.509	http://dx.doi.org/10.1126/science.271.5248.509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560266				2022-12-28	WOS:A1996TR32200043
J	Evens, RG				Evens, RG			Appropriateness of routine chest radiography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Evens, RG (corresponding author), WASHINGTON UNIV,DEPT RADIOL,ST LOUIS,MO 63130, USA.							FENGOLD AO, 1975, PUBLIC HLTH REP, V90, P544; RUCKER L, 1983, JAMA-J AM MED ASSOC, V250, P3209, DOI 10.1001/jama.250.23.3209; SAGEL SS, 1974, NEW ENGL J MED, V291, P1001, DOI 10.1056/NEJM197411072911904; 1993, ACR STANDARD ADULT C; 1983, HHS FDA838204 US DEP	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544276				2022-12-28	WOS:A1996TP96500033
J	Bickmore, WA; Oghene, K				Bickmore, WA; Oghene, K			Visualizing the spatial relationships between defined DNA sequences and the axial region of extracted metaphase chromosomes	CELL			English	Article							SCAFFOLD ATTACHMENT; NUCLEAR SCAFFOLD; REPLICATION; KINETOCHORE; LOOP; ORGANIZATION; GENOME; GENES; SITES; SIZE	Using fluorescence in situ hybridization to extracted metaphase chromosomes, we present visual evidence that specific human DNA sequences occupy distinctive positions with respect to the axial region of chromosomes and that the DNA is organized into loops emanating from this region. In a stretch of unique DNA on chromosome 11, large loops of DNA can be traced and one specific region associated with the axial region of the chromosome. Within rDNA, nontranscribed spacer sequences are more closely apposed to the chromosome axis than are rRNA genes. Heterochromatic and euchromatic DNAs appear to be organized into loops of similar size. We could not detect loops at centromeres; most alphoid DNA appears to remain close to the axial region.			Bickmore, WA (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Bickmore, Wendy A/C-7314-2013	Bickmore, Wendy A/0000-0001-6660-7735				AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BLUMENTHAL AB, 1979, J CELL BIOL, V81, P255, DOI 10.1083/jcb.81.1.255; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; CALLAN HG, 1982, PROC R SOC SER B-BIO, V214, P417, DOI 10.1098/rspb.1982.0020; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1993, J CELL BIOL, V120, P1083, DOI 10.1083/jcb.120.5.1083; COOKE H, 1976, NATURE, V262, P182, DOI 10.1038/262182a0; CREMISI F, 1988, CHROMOSOMA, V97, P204, DOI 10.1007/BF00292962; DIJKWEL PA, 1988, BIOESSAYS, V9, P147; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; GASSER SM, 1989, INT REV CYTOL, V119, P57; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JEPPESEN P, 1985, J CELL SCI, V73, P245; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOENS PB, 1990, CHROMOSOMA, V100, P8, DOI 10.1007/BF00337598; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SATYAPRAKASH KL, 1980, CHROMOSOMA, V81, P1, DOI 10.1007/BF00292418; TRASK BJ, 1991, AM J HUM GENET, V48, P1; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YOON Y, 1995, MOL CELL BIOL, V15, P2482	37	63	65	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					95	104		10.1016/S0092-8674(00)80996-4	http://dx.doi.org/10.1016/S0092-8674(00)80996-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548831	Bronze			2022-12-28	WOS:A1996TQ17000012
J	Pini, P				Pini, P			Media wars	LANCET			English	Review																		ALTMAN L, 1995, NY TIMES        0110; BARINAGA M, 1995, SCIENCE, V269, P475, DOI 10.1126/science.7624769; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; GUILLEBAUD J, 1995, BRIT MED J, V311, P1111, DOI 10.1136/bmj.311.7013.1111; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HORTON R, 1995, BRIT MED J, V310, P985, DOI 10.1136/bmj.310.6985.985; HORTON R, 1995, EUR SCI EDITING, P3; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; Nelkin D., 1995, DNA MYSTIQUE GENE CU; Nelkin D, 1995, SELLING SCI PRESS CO; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; REES M, 1994, SCI PUBLIC AFFAI AUT, P3; ROUSH W, 1995, SCIENCE, V269, P627, DOI 10.1126/science.7624787; VANTRIGT AM, 1994, SOC SCI MED, V18, P637; WILKIE T, 1995, MAY S BLIND SCI TEMP; WILKINSON J, 1994, SCI PUBLIC AFFAI AUT, P14; WISE J, 1995, DOCTOR          0525, P29; 1995, 1994 CAT C SER CHIC, P16; 1994, NEW ENGL J MED, V330, P1608; 1995, NATURE, V376, P2; 1995, 8TH INT C INT FED SC; 1995, LANCET, V346, P1569	23	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1681	1683		10.1016/S0140-6736(95)92845-6	http://dx.doi.org/10.1016/S0140-6736(95)92845-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551829				2022-12-28	WOS:A1995TL42300015
J	Roffe, D; Roffe, C				Roffe, D; Roffe, C			Madness and care in the community: A medieval perspective	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REAPPRAISAL	Care in the community for insane people today is more a matter of expert provision than communal support. In consequence, although they are no longer confined to hospital, mentally ill people largely remain marginalised in a society that does not have the resources, nor often the inclination, to take responsibility for their care. The experience of insane people in medieval England seems to have been of a different order, as shown by a particularly well documented case dating from 1383. From the late 13th century congenital idiots were protected by law. Care of lunatics, by contrast, was primarily the responsibility of the family. However, where the family could not or was unwilling to provide, provision was made by the crown. Through the instrument of the inquisition, the diagnosis and social circumstances of each case were determined by commissioners in consultation with a local jury and all interested parties, including the subject himself or herself. The best interests of the subject remained a prime concern, and the settlement that was ordained was tried and enforced in law. The process was confined to those with real or personal estate, but it encompassed poor as well as rich and proved, through the close identity of the local community with the process, to be a sophisticated and effective mechanism for maintaining and sustaining insane people. Unlike today, care in the community was a communal activity that ensured a truly public provision for those who could not look after themselves.	HOPE HOSP, DEPT GERIATR MED, SALFORD M6 8HD, LANCS, ENGLAND		Roffe, D (corresponding author), UNIV SHEFFIELD, DEPT HIST, SHEFFIELD HUNDRED ROLLS PROJECT, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND.		Roffe, Christine/AAT-5611-2020	Roffe, Christine/0000-0002-5259-6649				CLARKE B, 1975, MENTAL DISORDER ENGL; Downer L. J., 1972, LEGES HENRICI PRIMI; Foucault M., 2009, MADNESS CIVILISATION; HARRIS BE, 1980, VICTORIA HIST COUNTY, V2, P180; Holt J.C., 1981, ENGLISH PARLIAMENT M, P1; HUNT DG, 1954, HEYWOOD MASSEY COURT; Ingleby H., 1919, RED REGISTER KINGS L; KROLL J, 1973, ARCH GEN PSYCHIAT, V29, P276; LUDERS A, 1910, STATUTES REALM, V1, pA226; MAITLAND FW, 1891, ENGL HIST REV, V6, P366; MEECH SB, 1940, BOOK OF MARGERY KEMP; NEUGEBAUER R, 1978, J HIST BEHAV SCI, V14, P158, DOI 10.1002/1520-6696(197804)14:2<158::AID-JHBS2300140209>3.0.CO;2-C; NEUGEBAUER R, 1979, ARCH GEN PSYCHIAT, V36, P477; PAGE W, 1909, VICTORIA HIST LONDON, V1, P495; POLLOCK F, 1923, HIST ENGLISH LAW TIM, V1, P321; PORTER R, 1988, HIST TODAY       FEB, P39; RICHARDSON HG, 1955, FLETA, V1, P21; RICHARDSON HG, 1955, FLETA, V89; RICHARDSON HG, 1955, FLETA, V72; RICHARSON HG, 1955, FLETA, V99; ROFFE DR, IN PRESS HASKINS SOC; WOODBINE GE, 1977, BRACTON LEGIBUS CONS, V4, P308; Zilboorg Gregory, 1941, HIST MED PSYCHOL	23	11	11	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	1995	311	7021					1708	1712		10.1136/bmj.311.7021.1708	http://dx.doi.org/10.1136/bmj.311.7021.1708			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TL942	8541770	Green Published			2022-12-28	WOS:A1995TL94200032
J	Shepherd, J				Shepherd, J			Ethical debate - Should doctors be more proactive as advocates for victims of violence? Towards interagency procedures to protect victims and prevent violence	BRITISH MEDICAL JOURNAL			English	Editorial Material							PERSPECTIVE; EMERGENCY; ACCIDENT				Shepherd, J (corresponding author), UNIV WALES COLL MED,CARDIFF CF4 4XY,S GLAM,WALES.							BASTIAN LD, 1992, CRIMINAL VICTIMISATI; CLARKSON C, 1994, CRIM LAW REV, P4; FARRINGTON DP, 1992, JUSTICE Q, V0009; FARRINGTON DP, 1994, STUDIES CRIME CRIME, V3, P104; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; MAYHEW P, 1993, HOME OFFFICE RES STU, V132; SHEPHERD J, 1990, BRIT J CRIMINOL, V30, P289, DOI 10.1093/oxfordjournals.bjc.a048022; SHEPHERD J, 1989, MED SCI LAW, V29, P251, DOI 10.1177/002580248902900311; SHEPHERD J, 1994, ALCOHOL ALCOHOLISM, V29, P5	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 16	1995	311	7020					1617	1618		10.1136/bmj.311.7020.1617a	http://dx.doi.org/10.1136/bmj.311.7020.1617a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TL422	8555808	Green Published			2022-12-28	WOS:A1995TL42200027
J	Flier, J; Insel, PA				Flier, J; Insel, PA			Seminars in medicine of the Beth Israel Hospital, Boston - Adrenergic receptors - Evolving concepts and clinical implications	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAILING HUMAN HEART; PROTEIN; GENE; CLASSIFICATION; EXPRESSION; RHODOPSIN; BINDING; CELLS		UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Flier, jeffrey/AAG-6223-2019		NHLBI NIH HHS [HL53773] Funding Source: Medline; NIGMS NIH HHS [GM31987, GM40781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040781, R01GM031987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; ALOUSI AA, 1991, FASEB J, V5, P2300, DOI 10.1096/fasebj.5.9.1650314; ARIENS EJ, 1983, BIOCHEM PHARMACOL, V32, P1539, DOI 10.1016/0006-2952(83)90324-6; BERTHELSEN S, 1977, LIFE SCI, V21, P595, DOI 10.1016/0024-3205(77)90066-2; BERTIN B, 1993, CARDIOVASC RES, V27, P1606, DOI 10.1093/cvr/27.9.1606; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; ENOCKSSON S, 1995, J CLIN INVEST, V95, P2239, DOI 10.1172/JCI117914; FORD APDW, 1994, TRENDS PHARMACOL SCI, V15, P167, DOI 10.1016/0165-6147(94)90136-8; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P14368, DOI 10.1021/bi00251a600; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; HERSCHELER J, 1994, ANN NY ACAD SCI, V733, P306; INSEL PA, 1991, BETA ADRENERGIC RECE, P295; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LEFKOWITZ RJ, 1984, NEW ENGL J MED, V310, P1570; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; PERKINS JP, 1991, BETA ADRENERGIC RECE; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; YAMADA S, 1994, LIFE SCI, V54, P1845, DOI 10.1016/0024-3205(94)90141-4	48	150	151	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 29	1996	334	9					580	585		10.1056/NEJM199602293340907	http://dx.doi.org/10.1056/NEJM199602293340907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW696	8569827				2022-12-28	WOS:A1996TW69600007
J	Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R				Wang, YK; Schnegelsberg, PNJ; Dausman, J; Jaenisch, R			Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin	NATURE			English	Article							REGULATORY GENE; EXPRESSION; MYOD; INACTIVATION; LETHALITY	The myogenic basic helix-loop-helix transcription factors, Myf5, MyoD, myogenin and MRF4, play key roles in skeletal muscle development(1,2). All of them induce myogenic differentiation in cultured non-muscle cells, suggesting that they might be functionally redundant. But the genes are expressed at different times during embryogenesis(3-6) and mice carrying a mutation in any of the genes have different phenotypes(7-13). A rib cage defect was observed in Myf5-deficient mice, which die perinatally(7). We investigated whether the rib cage defect was due to the failure of the early activation of the gene or to the unique interactions of Myf5 with specific downstream targets. For this we inserted a myogenin complementary DNA into the Myf5 locus by homologous recombination ,which simultaneously disrupted Myf5 function. We report here that mice homozygous for this myogenin gene knock-in (ki) developed a normal rib cage and were viable, therefore demonstrating functional redundancy of Myf5 and myogenin for rib formation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	Wang, YK (corresponding author), MIT, WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.							BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	21	126	134	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 29	1996	379	6568					823	825		10.1038/379823a0	http://dx.doi.org/10.1038/379823a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587605				2022-12-28	WOS:A1996TX50100058
J	Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE				Hennekens, CH; Lee, IM; Cook, NR; Hebert, PR; Karlson, EW; LaMotte, F; Manson, JE; Buring, JE			Self-reported breast implants and connective-tissue diseases in female health professionals - A retrospective cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN	Objective. - To evaluate the association of breast implants with connective-tissue diseases. Design and Participants. - Retrospective cohort study of 395 543 female health professionals who completed mailed questionnaires for potential participation in the Women's Health Study. A total of 10 830 women reported breast implants and 11 805 reported connective-tissue diseases between 1962 and 1991. Cox proportional hazards regression models were used in analyses. Main Outcome Measure. - Self-reported connective-tissue diseases. Results. - Compared with women who did not report breast implants, the relative risk (RR) of the combined end point of any connective-tissue disease among those who reported breast implants was 1.24 (95% confidence interval, 1.08 to 1.41, P=.0015). With respect to the individual diseases, the finding for other connective-tissue diseases (including mixed) was statistically significant (P=.017), the findings for rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of borderline statistical significance (.05<P<.10), and the finding for systemic lupus erythematosus was not statistically significant (P=.44). There were no clear trends in RR with increasing duration of breast implants. Conclusion. - These self-reported data from female health professionals are compatible with prior reports from other cohort studies that exclude a large hazard, but do suggest small increased risks of connective-tissue diseases among women with breast implants. The very large sample size makes chance an unlikely explanation for the results, but bias due to differential overreporting of connective-tissue diseases or selective participation by affected women with breast implants remains a plausible alternative explanation. The major contribution of this and other observational analytic studies has been to exclude large risks of connective-tissue diseases following breast implants.	HARVARD UNIV,SCH MED,DIV PREVENT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV RHEUMATOL IMMUNOL,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Hennekens, CH (corresponding author), BRIGHAM & WOMENS HOSP,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; BARTON TJ, 1983, ORGANOMETALLICS, V2, P1, DOI 10.1021/om00073a001; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BUSCH H, 1994, SEMIN ARTHRITIS RHEU, V24, P11, DOI 10.1016/0049-0172(94)90104-X; CHOW HY, 1995, ARTHRITIS RHEUM, V38, P264; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; COOK RR, 1994, ARTHRITIS RHEUM, V37, P153, DOI 10.1002/art.1780370202; COX DR, 1972, J R STAT SOC B, V34, P187; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; DUGOWSON CE, 1992, ARTHRITIS RHEUM S192, V35, pS566; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; FISHER JC, 1992, NEW ENGL J MED, V326, P1696, DOI 10.1056/NEJM199206183262511; FOREMAN J, 1992, BOSTON GLOBE    0125, P1; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; Hennekens CH, 1987, EPIDEMIOLOGY MED, P101; Hochberg M. C., 1994, Arthritis and Rheumatism, V37, pS369; Hochberg MC, 1995, LUPUS, V4, P454, DOI 10.1177/096120339500400606; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; Kolata Gina, 1995, N Y Times Web, P6; KOSSOVSKY N, 1994, SEMIN ARTHRITIS RHEU, V24, P18, DOI 10.1016/0049-0172(94)90105-8; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; LITTLE R, 1987, STATISTICAL ANAL MIS; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430, DOI 10.7326/0003-4819-122-6-199503150-00005; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; STAR VL, 1993, ARTHRITIS RHEUM, V36, P510; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SWAN SH, 1995, LANCET, V345, P319, DOI 10.1016/S0140-6736(95)90307-0; VASSEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002	39	205	210	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					616	621		10.1001/jama.275.8.616	http://dx.doi.org/10.1001/jama.275.8.616			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594243				2022-12-28	WOS:A1996TW62700022
J	Masland, RH				Masland, RH			Unscrambling color vision	SCIENCE			English	Editorial Material							HORIZONTAL CELLS; RECEPTIVE-FIELDS; RETINA				Masland, RH (corresponding author), MASSACHUSETTS GEN HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02114 USA.							[Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; Dacey DM, 1996, SCIENCE, V271, P656, DOI 10.1126/science.271.5249.656; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; HENDRY SHC, 1994, SCIENCE, V264, P575, DOI 10.1126/science.8160015; HUBEL D, 1990, COLD SPRING HARB SYM, V55, P643; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; STERLING P, 1995, INVEST OPHTH VIS SCI, V36, pS3; TAUCHI M, 1985, J NEUROSCI, V5, P2494; TSO DY, 1988, J NEUROSCI, V8, P1712; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; YANG G, 1992, SCIENCE, V258, P1949, DOI 10.1126/science.1470920	14	21	21	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	1996	271	5249					616	617		10.1126/science.271.5249.616	http://dx.doi.org/10.1126/science.271.5249.616			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571123				2022-12-28	WOS:A1996TT87000034
J	Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF				Krumholz, HM; Radford, MJ; Ellerbeck, EF; Hennen, J; Meehan, TP; Petrillo, M; Wang, Y; Jencks, SF			Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						aspirin; myocardial infarction; age factors; patient care characteristics; patient care planning	AGE; TRIALS	Objectives: To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival. Design: Observational study. Setting: All 352 nongovernment, acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients: 5490 consecutive Medicare beneficiaries who survived an acute myocardial infarction, were hospitalized between June 1992 and February 1993, and did not have a contraindication to aspirin. Measurements: Medical charts were reviewed to obtain information on the prescription of aspirin at discharge, contraindications, patient demographic characteristics, and clinical factors. Results: 4149 patients (76%) were prescribed aspirin at hospital discharge. In a multivariable analysis, an increased prescribed use of aspirin at discharge was correlated with several indicators of better overall health status (better left ventricular ejection fraction, absence of diabetes, shorter length of hospital stay, higher albumin level, and discharge to the patient's home). The prescribed use of aspirin at discharge was also associated with several specific patterns of care, including the use of cardiac procedures, p-blocker therapy at discharge, and aspirin during the hospitalization. The prescribed use of aspirin at discharge was associated with a lower mortality rate 6 months after discharge compared with no prescribed aspirin (odds ratio, 0.77; 95% CI, 0.61 to 0.98), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Aspirin was not prescribed at discharge to 24% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to aspirin. Several patient characteristics were associated with a higher risk for not being prescribed aspirin. Increasing the prescription of aspirin for these patients may provide an excellent opportunity to improve their care.	UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; US HLTH CARE FINANCING ADM, BALTIMORE, MD 21207 USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT 06030 USA	University of Connecticut; University of Connecticut	Krumholz, HM (corresponding author), YALE UNIV, SCH MED, CARDIOVASC SECT, 333 CEDAR ST, POB 208107, NEW HAVEN, CT 06520 USA.		, Harlan/AAI-2875-2020; Ellerbeck, Edward/I-8438-2014	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AUDET AM, 1993, ANN INTERN MED, V119, P1209, DOI 10.7326/0003-4819-119-12-199312150-00008; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; MOORE JG, 1991, GASTROENTEROLOGY, V100, P1626, DOI 10.1016/0016-5085(91)90661-4; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SILAGY CA, 1993, CLIN PHARMACOL THER, V54, P84, DOI 10.1038/clpt.1993.115	16	169	176	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1996	124	3					292	+		10.7326/0003-4819-124-3-199602010-00002	http://dx.doi.org/10.7326/0003-4819-124-3-199602010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR596	8554223				2022-12-28	WOS:A1996TR59600002
J	Leatherwood, J; LopezGirona, A; Russell, P				Leatherwood, J; LopezGirona, A; Russell, P			Interaction of Cdc2 and Cdc18 with a fission yeast ORC2-like protein	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; CELL-CYCLE; MITOSIS; GENE; SYSTEM	IN fission yeast, Cdc2 kinase has both positive and negative roles in regulating DNA replication, being first necessary for the transition from G(1) to S phase and later required to prevent the re-initiation of DNA replication during G(2)(1-3). We report here that Cdc2 interacts with Orp2, a protein similar to the Orc2 replication factor subunit of Saccharomyces cerevisiae origin recognition complex (ORC). ORC binds chromosomal origins and is essential for chromosomal replication initiation(4-6). Fission yeast Orp2 is required for DNA replication and interacts with the rate-limiting replication activator Cdc18. Cells lacking Orp2 undergo aberrant mitosis, indicating that Orp2 is involved in generating a checkpoint signal, These findings suggest that ORC functions are conserved among eukaryotes and provide evidence that Cdc2 controls DNA replication initiation by acting directly at chromosomal origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MAUNDRELL K, 1985, NUCLEIC ACIDS RES, V13, P3711, DOI 10.1093/nar/13.10.3711; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ZHOU C, 1989, J BIOL CHEM, V264, P9022	28	109	114	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					360	363		10.1038/379360a0	http://dx.doi.org/10.1038/379360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552194				2022-12-28	WOS:A1996TR32300063
J	Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB				Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB			Crystal structure of a G(A) protein beta gamma dimer at 2.1 angstrom resolution	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SUBUNIT; PHEROMONE	MANY signalling cascades use seven-helical transmembrane receptors coupled to heterotrimeric G proteins (G(alpha beta gamma)) to convert extracellular signals into intracellular responses(1). Upon nucleotide exchange catalysed by activated receptors, heterotrimers dissociate into GTP-bound G(alpha) subunits and G(beta gamma) dimers, either of which can modulate many downstream effectors(2,3). Here we use multiwavelength anomalous diffraction data to solve the crystal structure of the beta gamma dimer of the G protein transducin. The beta-subunit is primarily a seven-bladed beta-propeller that is partially encircled by an extended gamma-subunit. The beta-propeller, which contains seven structurally similar WD repeats, defines the stereochemistry of the WD repeat and the probable architecture of all WD-repeat-containing domains. The structure details interactions between G protein beta- and gamma-subunits and highlights regions implicated in effector modulation for the conserved family of G protein beta gamma dimers.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAMISTEN A, 1993, P NATL ACAD SCI USA, V90, P7706; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; GRISHIN AV, 1994, GENETICS, V138, P1081; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERVOOM L, 1992, FEBS LETT, V30, P131; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223	32	688	705	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					369	374		10.1038/379369a0	http://dx.doi.org/10.1038/379369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552196				2022-12-28	WOS:A1996TR32300065
J	Livingston, G; Manela, M; Katona, C				Livingston, G; Manela, M; Katona, C			Depression and other psychiatric morbidity in carers of elderly people living at home	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE RATES; COMMUNITY; DEMENTIA; RELATIVES	Objective-To describe the mental health of a community sample of carers of elderly people with dementia, depression, or physical disability and to compare that with the mental health of other adults living in the household and of those living alone. Design-Assessment of psychiatric morbidity and physical disability with standardised questionnaire in randomly selected enumeration districts; subjects were interviewed at home. Setting-London Borough of Islington. Subjects-700 people aged greater than or equal to 65 and other co-residents. Main outcome measure-Depression measured with standardised interview. Results-The prevalence of depression was not significantly higher in carers overall (15%) than in coresidents (11%). Being a woman carer was a significant predictor of psychiatric illness. Depression was more common in the carers of people with a psychiatric disorder than in coresidents (24% v 11%, P < 0.05) and in those living alone (19%). Depression was most common (47%) in women carers of people with dementia. Conclusion-The increase in psychiatric morbidity reported in carers of people with psychiatric disorders may reflect the lack of a confiding relationship.			Livingston, G (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, MORTIMER ST, LONDON W1N 8AA, ENGLAND.		Livingston, G/C-7081-2008	Katona, Cornelius/0000-0001-7451-0167; Livingston, Gill/0000-0001-6741-5516				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BERGMANN K, 1983, ELDERLY PEOPLE COMMU; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COLLINS C, 1992, RECENT ADV PSYCHOGER, P153; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; Foulds G. A, 1976, HIERARCHICAL NATURE; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GURLAND B, 1984, J GERONTOL, V39, P166, DOI 10.1093/geronj/39.2.166; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KAY DWK, 1985, PSYCHOL MED, V15, P771, DOI 10.1017/S0033291700005006; LEVIN E, 1989, FAMILIES SERVICES CO; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LINDESAY J, 1989, BRIT J PSYCHIAT, V155, P317, DOI 10.1192/bjp.155.3.317; LIVINGSTON G, 1990, PSYCHOL MED, V20, P137, DOI 10.1017/S0033291700013313; MANELA M, IN PRESS INT J GERIA; Murray J., 1995, PREVENTION ANXIETY D; NORUSIS MJ, SPSSPC4; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; PARKER G, DHSS715 U YORK SOC P; WADE DT, 1986, BRIT MED J, V293, P418, DOI 10.1136/bmj.293.6544.418; WING JK, 1976, PSYCHOL MED, V6, P665; 1987, GENERAL HOUSEHOLD SU	24	111	111	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					153	156						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TR325	8563534				2022-12-28	WOS:A1996TR32500022
J	MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E				MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E			Common-source outbreak of acute infection due to the North American liver fluke Metorchis conjunctus	LANCET			English	Article								Background We investigated an outbreak of acute clinical illness among 19 people who ate raw fish (sashimi) prepared from the white sucker, Catostomus commersoni, caught in a river north of Montreal, Canada. Methods We collected epidemiological, clinical, laboratory, and serological data on 19 individuals who ate the sashimi and six who did not. Because of the suggestive clinical picture, we set out to recover helminth parasites from uneaten fish. Findings The illness consisted of persistent upper abdominal pain, low grade fever, high blood eosinophil concentrations, and raised liver enzymes. After 10 days, opisthorchiid-like eggs were found in stools. Symptoms persisted for 3 days to 4 weeks without treatment, but responded rapidly to praziquantel therapy. Necropsy of golden hamsters infected with metacercariae from uneaten fish revealed adult flukes identified as Metorchis conjunctus. Interpretation We describe an acute illness caused by the North American liver fluke M conjunctus. This is a new human disease and is the first report of a common-source outbreak of an acute illness caused by liver flukes of the family Opisthorchiidae.	FISHERIES & OCEANS CANADA, MAURICE LAMONTAGNE INST, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA; MCGILL UNIV, INST PARASITOL, MONTREAL, PQ, CANADA	Fisheries & Oceans Canada; McGill University; McGill University	MacLean, JD (corresponding author), MCGILL UNIV, MONTREAL GEN HOSP, CTR TROP DIS, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							ALLEN J. A., 1934, CANADIAN JOUR RES, V10, P404; BABERO BERT B., 1952, PROC HELMINTHOL SOC WASHINGTON, V19, P15; BRASSARD P, 1985, CAN J PUBLIC HEALTH, V76, P322; BRONSHTEIN AM, 1985, MED PARAZITOL MOSK, V5, P31; Burch J. B, 1982, FRESHWATER SNAILS MO; CAMERON T W M, 1945, Can J Comp Med Vet Sci, V9, P302; Cameron Thomas W. M., 1944, CANADIAN JOUR RES SECT D ZOOL SCI, V22, P6; CAMERON THOMAS W. M., 1940, CANADIAN JOUR RES SECT D ZOOL SCI, V18, P325; CARTWRIGHT GE, 1949, AM J MED, V6, P259, DOI 10.1016/0002-9343(49)90021-2; CLARKE A.H., 1981, FRESHWATER MOLLUSCS; Cobbold T. S., 1860, P LINNEAN SOC LONDON, V17, P1; DITRICH O, 1992, FOLIA PARASIT, V39, P123; EVANS WS, 1963, THESIS U MANITOBA WI; FREEMAN AE, 1937, T AM MICROSC SOC, V57, P113; HARKEMA R, 1964, J PARASITOL, V50, P60, DOI 10.2307/3276029; HASWELLELKINS MR, 1992, J GASTROEN HEPATOL, V7, P538, DOI 10.1111/j.1440-1746.1992.tb01035.x; KOENIGSTEIN RP, 1949, T ROY SOC TROP MED H, V42, P503, DOI 10.1016/0035-9203(49)90057-7; Lee DS, 1980, ATLAS N AM FRESHWATE; MEL'NIKOV V I, 1979, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V48, P12; Mongeau N, 1961, Can Vet J, V2, P33; Rim H.-J., 1986, Korean Journal of Parasitology, V24, P1; Scott W. B., 1973, FISHERIES RES BOARD, V184; SKRJABIN K.I., 1950, TREMATODES ANIMALS M, V4; SMITH JW, 1975, INT J PARASITOL, V5, P133, DOI 10.1016/0020-7519(75)90019-3; WATSON TG, 1979, CAN J PUBLIC HEALTH, V70, P179; WATSON TG, 1979, THESIS MCGILL U MONT; WOBESER G, 1983, J WILDLIFE DIS, V19, P353; XU Z, 1979, CHIN MED J, V93, P423; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1995, WHO TECH REP SER, P849	30	32	38	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					154	158		10.1016/S0140-6736(96)90342-6	http://dx.doi.org/10.1016/S0140-6736(96)90342-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544550				2022-12-28	WOS:A1996TQ24400011
J	Haynes, BF; Pantaleo, G; Fauci, AS				Haynes, BF; Pantaleo, G; Fauci, AS			Toward an understanding of the correlates of protective immunity to HIV infection	SCIENCE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; PERSISTENT GENERALIZED LYMPHADENOPATHY; FOLLICULAR DENDRITIC CELLS; LYMPH-NODES; DEFICIENCY-SYNDROME; PROGNOSTIC VALUE; KAPOSIS SARCOMA; HOMOSEXUAL MEN; T-CELLS; HLA-DR	Considerable progress has been made recently in understanding the genetic, immunologic, and virologic factors in human immunodeficiency virus (HIV)-infected individuals who either rapidly progress or do not progress to acquired immunodeficiency syndrome (AIDS). In addition, detection of HIV-specific immune responses in HIV-negative individuals who have been exposed to the virus multiple times suggests that natural immune responses to HIV may be protective in rare individuals. Understanding the correlates of protective immunity to HIV infection is critical to efforts to develop preventive HIV vaccines as well as to determine the feasibility of treating HIV infection by boosting immunity to HIV.	DUKE UNIV, MED CTR,DEPT MED,DIV RHEUMATOL ALLERGY & IMMUNOL, DUKE CTR AIDS RES, DURHAM, NC 27710 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Pantaleo, Giuseppe/K-6163-2016		NCI NIH HHS [CA-28936, CA-43447] Funding Source: Medline; NIAID NIH HHS [AI-28662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028936, P01CA043447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ARENS M, 1993, AIDS RES HUM RETROV, V9, P1257, DOI 10.1089/aid.1993.9.1257; ARMSTRONG JA, 1984, LANCET, V2, P370; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; ASCHER M, 1990, 6TH INT C AIDS SAN F, V6, P153; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; ASJO B, 1990, AIDS RES HUM RETROV, V6, P1177, DOI 10.1089/aid.1990.6.1177; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BARONI CD, 1986, HISTOPATHOLOGY, V10, P5, DOI 10.1111/j.1365-2559.1986.tb02456.x; BEARDSLEY T, 1994, SCI AM, V270, P20; BENVENISTE R, 1994, AIDS RES HUM RETROV, V10, pS85; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BRUTKIEWICZ RR, 1995, J VIROL, V69, P3967, DOI 10.1128/JVI.69.7.3967-3971.1995; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHBINDER S, 1990, 30TH INT C ANT AG CH; BUCHBINDER S, 1993, 9TH INT C AIDS BERL, V9, P41; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CAVACINI LA, 1993, J ACQ IMMUN DEF SYND, V6, P1093; CHARGELEGUE D, 1993, CLIN EXP IMMUNOL, V93, P331, DOI 10.1111/j.1365-2249.1993.tb08181.x; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; CICHUTEK K, 1992, P NATL ACAD SCI USA, V89, P7365, DOI 10.1073/pnas.89.16.7365; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONTU L, 1984, TISSUE ANTIGENS, V23, P240, DOI 10.1111/j.1399-0039.1984.tb00038.x; CRUSE JM, 1991, PATHOBIOLOGY, V59, P324, DOI 10.1159/000163671; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DEMARTINO M, 1994, LANCET, V343, P191; DEPAOLI P, 1986, TISSUE ANTIGENS, V27, P116, DOI 10.1111/j.1399-0039.1986.tb01509.x; DETELS R, 1994, 10TH INT C AIDS YOK, V10, pA163; DEVERGNE O, 1991, AIDS, V5, P1071, DOI 10.1097/00002030-199109000-00002; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FABIO G, 1990, BRIT J HAEMATOL, V75, P531, DOI 10.1111/j.1365-2141.1990.tb07794.x; FARZADEGAN H, 1992, J INFECT DIS, V166, P1217, DOI 10.1093/infdis/166.6.1217; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FAUCI AS, 1994, 10TH INT C AIDS YOK, V10, P4; FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329; FOWKE K, 1994, 4TH ANN CAN C HIV AI; FOWKE K, 1992, 8TH INT C AIDS AMST, V8, pC249; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; FUST G, 1995, IMMUNOL TODAY, V16, P167, DOI 10.1016/0167-5699(95)80114-6; GEGERFELT A, 1991, VIROLOGY, V185, P162; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GIRARD M, 1992, 7TH P C CENT GARD PA, P75; Girard M, 1993, 8TH C CENT GARD PAR, P139; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; GREENOUGH TC, 1994, CLIN RES, V42, pA155; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HARDY AM, 1991, J ACQ IMMUN DEF SYND, V4, P386; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HARRER E, 1994, AIDS RES HUM RETROV, V10, pS77; HARRER E, ROA220484; HAYNES BF, 1995, AIDS RES HUM RETROV, V11, P211, DOI 10.1089/aid.1995.11.211; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HELBERT MR, 1993, IMMUNOL TODAY, V14, P340, DOI 10.1016/0167-5699(93)90232-A; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HO HN, 1993, J IMMUNOL, V150, P3070; HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37; ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11472, DOI 10.1073/pnas.91.24.11472; ITESCU S, 1992, RHEUM DIS CLIN N AM, V18, P683; JANVIER B, 1993, J ACQ IMMUN DEF SYND, V6, P898; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Just JJ, 1995, HUM IMMUNOL, V44, P156, DOI 10.1016/0198-8859(95)00034-8; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KAPLAN C, 1990, HUM HERED, V40, P290, DOI 10.1159/000153947; KASLOW R, 1994, MAR NAT I ALL INF DI; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KASLOW RA, 1994, J INFECT DIS, V169, P1332, DOI 10.1093/infdis/169.6.1332; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KIPROV DD, 1994, SCIENCE, V263, P737, DOI 10.1126/science.8303282; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN M, 1993, 9TH INT C AIDS BERL, V9, P46; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOHLER H, 1992, J ACQ IMMUN DEF SYND, V5, P1158; KOHLER H, 1995, IMMUNOLOGIST, V3, P32; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANDAY AL, 1993, CLIN IMMUNOL IMMUNOP, V69, P106, DOI 10.1006/clin.1993.1157; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LETVIN N, COMMUNICATION; LEVY JA, 1993, PEDIATR RES, V33, pS63; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; LEVY JA, 1993, 9TH INT C AIDS BERL, V9, P11; LEVY JA, 1993, DEC NAT AC SCI I MED; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; LOUIE LG, 1991, J ACQ IMMUN DEF SYND, V4, P814; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; LUZURIAGA K, 1995, J IMMUNOL, V154, P433; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MAKINO M, 1994, J IMMUNOL, V152, P4157; MALWE AC, 1993, 9TH INT C AIDS BERL, V9, P46; MANN D, 1993, 9TH INT C AIDS BERL, V9, P46; MANN DL, 1988, J ACQ IMMUN DEF SYND, V1, P13; MANN DL, 1992, AIDS RES HUM RETROV, V8, P1345, DOI 10.1089/aid.1992.8.1345; MANN DL, 1990, J ACQ IMMUN DEF SYND, V3, pS51; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MEYAARD L, 1993, IMMUNOL TODAY, V14, P161, DOI 10.1016/0167-5699(93)90279-T; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MONTEFIORI DC, 1991, AIDS, V5, P513, DOI 10.1097/00002030-199105000-00006; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; NEURATH AR, 1990, AIDS RES HUM RETROV, V6, P1183, DOI 10.1089/aid.1990.6.1183; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAPASTERIADES C, 1984, TISSUE ANTIGENS, V24, P313, DOI 10.1111/j.1399-0039.1984.tb02143.x; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; PAUZA D, UNPUB; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PHAIR JP, 1994, AIDS RES HUM RETROV, V10, P883, DOI 10.1089/aid.1994.10.883; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PINCUS SH, 1994, J CLIN INVEST, V93, P2505, DOI 10.1172/JCI117260; PLUMMER FA, 1993, INT C AIDS, V9, P23; POLLACK MS, 1984, HUM IMMUNOL, V11, P99, DOI 10.1016/0198-8859(84)90048-X; POLLACK MS, 1983, DIS MARKERS, V1, P135; POMERANTZ RJ, 1992, CURR OPIN IMMUNOL, V4, P475, DOI 10.1016/S0952-7915(06)80042-7; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; PRINCE HE, 1984, J CLIN IMMUNOL, V4, P242, DOI 10.1007/BF00914972; RACZ P, 1986, PROG ALLERGY, V37, P81; RAFFOUX C, 1987, TISSUE ANTIGENS, V29, P60, DOI 10.1111/j.1399-0039.1987.tb01550.x; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINGLER DJ, 1989, AM J PATHOL, V134, P373; ROBERTGUROFF M, 1993, J INFECT DIS, V167, P538, DOI 10.1093/infdis/167.3.538; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, pR3, DOI 10.1089/aid.1994.10.iii; ROSENBERG YJ, 1994, AIDS RES HUM RETROV, V10, P863, DOI 10.1089/aid.1994.10.863; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SAAG MS, 1994, AIDS RES HUM RETROV, V10, P887, DOI 10.1089/aid.1994.10.887; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHMITZ J, 1994, J IMMUNOL, V153, P1352; SCHNITTMAN SM, 1991, J IMMUNOL, V147, P2553; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P704; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SHEPPARD HW, 1992, ANNU REV MICROBIOL, V46, P533, DOI 10.1146/annurev.mi.46.100192.002533; SHEPPARD HW, COMMUNICATION; SHEPPARD HW, 1993, 9 INT C AIDS BERL JU, V9, P46; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SMERALDI RS, 1988, HUM IMMUNOL, V22, P73, DOI 10.1016/0198-8859(88)90038-9; SMERALDI RS, 1986, LANCET, V2, P1187; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STEEL CM, 1988, LANCET, V1, P1185; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; TENNERRACZ K, 1993, AM J PATHOL, V142, P1750; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TRAUGER RJ, 1993, IMMUNOLOGY, V78, P611; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; VITTECOQ D, 1995, P NATL ACAD SCI USA, V92, P1195, DOI 10.1073/pnas.92.4.1195; Wain-Hobson Simon, 1994, P185; WALKER BD, 1990, AIDS, V4, P177, DOI 10.1097/00002030-199003000-00001; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; WOLINSKY SM, COMMUNICATION; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993; YU X, 1994, 10TH INT C AIDS YOK, V10, P9; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	194	353	379	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					324	328		10.1126/science.271.5247.324	http://dx.doi.org/10.1126/science.271.5247.324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553066				2022-12-28	WOS:A1996TQ52800032
J	Anderson, R				Anderson, R			Clinical system security: Interim guidelines	BRITISH MEDICAL JOURNAL			English	Article											Anderson, R (corresponding author), UNIV CAMBRIDGE,COMP LAB,PEMBROKE ST,CAMBRIDGE CB2 3QG,ENGLAND.							ANDERSON R, 1996, E COMMUNICATION; Anderson R. J., 1995, BRIT MED J, V310, P5; CHESWICK WR, 1994, FIREWALLS INTERNET S; HAWKER A, 1995, J INFORMATICS P 0316, P19; LUCK N, 1994, DAILY EXPRESS   0216, P32; PITCHFORD RA, 1995, J INFORMATICS P 0906, P12; Rogers L, 1995, SUNDAY TIMES    1126, P1; SOMMERVILLE A, 1993, MED ETHICS TODAY ITS; WINKLER B, 9TH P US SEC S; WOODWARD B, 1995, NEW ENGL J MED, V21, P141; 1995, SETTING RECORDS STRA; 1995, HDB INFORMATION SECU; 1995, YOUR INFORMATION STU	13	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					109	111						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555896				2022-12-28	WOS:A1996TQ16800035
J	Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA				Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA			Reconstitution in vitro of the motile apparatus from the amoeboid sperm of Ascaris shows that filament assembly and bundling move membranes	CELL			English	Article							HEAVY-CHAIN GENE; AMEBOID SPERM; PROTEIN MSP; DICTYOSTELIUM-DISCOIDEUM; CELL LOCOMOTION; ACTIN; NEMATODE; SUUM; CYTOSKELETON; PONTICULIN	We have developed an in vitro motility system from Ascaris sperm, unique amoeboid cells that use filament arrays composed of major sperm protein (MSP) instead of an actin-based apparatus for locomotion. Addition of ATP to sperm extracts induces formation of fibers similar to 2 mu m in diameter. These fibers display the key features of the MSP cytoskeleton in vivo. Each fiber consists of a meshwork of MSP filaments and has at one end a vesicle derived from the plasma membrane at the leading edge of the cell. Fiber growth is due to filament assembly at the vesicle; thus, fiber elongation results in vesicle translocation, This in vitro system demonstrates directly that localized polymerization and bundling of filaments can move membranes acid provides a powerful assay for evaluating the molecular mechanism of amoeboid cell motility.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	Italiano, JE (corresponding author), FLORIDA STATE UNIV,DEPT BIOL SCI,B-157,TALLAHASSEE,FL 32306, USA.				NIGMS NIH HHS [GM-29994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029994, R01GM029994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHIA CP, 1993, J CELL BIOL, V120, P909, DOI 10.1083/jcb.120.4.909; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1991, ANN REV PHYSL, V53, P584; COSSART P, 1994, MOL MICROBIOL, V13, P395, DOI 10.1111/j.1365-2958.1994.tb00434.x; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HITT AL, 1994, J CELL BIOL, V126, P1433, DOI 10.1083/jcb.126.6.1433; Inoue S, 1986, VIDEO MICROSCOPY; KING KL, 1994, J CELL SCI, V107, P2941; KING KL, 1994, CELL MOTIL CYTOSKEL, V27, P193, DOI 10.1002/cm.970270302; KING KL, 1992, J CELL SCI, V101, P847; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; ROBERTS TM, 1995, CURR OPIN CELL BIOL, V7, P13, DOI 10.1016/0955-0674(95)80039-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; ROYAL D, 1995, CELL MOTIL CYTOSKEL, V31, P241, DOI 10.1002/cm.970310307; SEPSENWOL S, 1986, J PARASITOL, V72, P962, DOI 10.2307/3281855; SEPSENWOL S, 1989, J CELL BIOL, V108, P55, DOI 10.1083/jcb.108.1.55; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; SOUTHWICK FS, 1994, BIOESSAYS, V16, P885, DOI 10.1002/bies.950161206; STEWART M, 1993, J MOL BIOL, V232, P298, DOI 10.1006/jmbi.1993.1383; STEWART M, 1994, J MOL BIOL, V242, P60; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	43	96	98	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					105	114		10.1016/S0092-8674(00)80997-6	http://dx.doi.org/10.1016/S0092-8674(00)80997-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548814	Bronze			2022-12-28	WOS:A1996TQ17000013
J	Hiss, RG				Hiss, RG			Barriers to care in non-insulin-dependent diabetes mellitus - The Michigan experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				Objective: To determine the barriers to optimal care at the community level for patients with non-insulin-dependent diabetes mellitus (NIDDM). Design: Comprehensive evaluation of the clinical, psychosocial, and educational status of community-based patients with NIDDM, with subsequent review by local diabetes advisory councils of this status and the care those patients have received. The frequency with which patients visited their physician for diabetes management, received patient education, received diet counseling, and were examined by an ophthalmologist-four services universally recognized to be components of optimal diabetes care-was determined for all patients. Setting: Eight Michigan communities, four large and four small. Patients: From 1988 to 1994, 1056 patients with NIDDM (defined by stimulated C-peptide criteria) were studied. Results: The frequency with which all patients with NIDDM visited their community primary care physician in 1994 was 3.7 times per year (4.6 times for patients taking insulin and 3.2 times for those not taking insulin). Thirty-three percent of all patients with NIDDM (48% of those taking insulin and 24% of those not taking insulin) had received all three other essential services, whereas 15% (6% taking insulin and 20% not taking insulin) had never received any of these services. Factors contributing to this level of care and barriers preventing more intensive management of community-based patients with NIDDM were identified by the diabetes advisory councils as they analyzed data from their own communities. The councils determined that the main barriers to optimal care of community-based patients with NIDDM are that 1) NIDDM is not considered or managed as a serious problem by most physicians and their patients; 2) the genetic basis for and refractory nature of obesity are not generally appreciated; and 3) as a complex, multisystemic chronic illness, diabetes fits poorly in a health care delivery system designed to deal with acute and episodic illnesses. Conclusion: Most community-based patients with NIDDM are not aggressively managed because of attitudinal, educational, and systemic factors that act as barriers to optimal health care delivery.			Hiss, RG (corresponding author), UNIV MICHIGAN, SCH MED, CTR DIABET RES & TRAINING, G1103 TOWSLEY CTR, BOX 0201, ANN ARBOR, MI 48109 USA.				NIADDK NIH HHS [P60-AM-20572] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, DIABETES CARE, V17, P519; [Anonymous], 1994, Diabetes Care, V17, P616; DCCT Res Grp, 1986, DIABETES, V35, P530; HISS RG, 1994, DIABETES CARE, V17, P1124, DOI 10.2337/diacare.17.10.1124; HISS RG, 1992, DIABETES COMMUNITIES, V2; HORTON ES, 1990, DIABETES MELLITUS TH, P457; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; Logsdon D N, 1984, J Ambul Care Manage, V7, P46; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MARX J, 1994, SCIENCE, V266, P1477, DOI 10.1126/science.7985012; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1989, GUIDE CLIN PREVENTIV, pR19; 1995, DIABETES CARE S1, V18, P1	13	76	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				146	148		10.7326/0003-4819-124-1_Part_2-199601011-00012	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554207				2022-12-28	WOS:A1996TL94400012
J	Nathan, DM				Nathan, DM			The pathophysiology of diabetic complications: How much does the glucose hypothesis explain?	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			ALDOSE REDUCTASE INHIBITOR; SORBITOL PATHWAY; BLOOD-PRESSURE; RETINOPATHY; PATHOGENESIS; MELLITUS; NEUROPATHY; ASSOCIATION; PROGRESSION; NEPHROPATHY	Objective: To examine the putative pathogenetic mechanisms of the long-term, specific complications of diabetes mellitus. Data Sources: Literature review relevant to long-term diabetic complications and their pathogenesis. Study Selection: Studies of animal models of diabetes, epidemiologic investigations of diabetes and its long-term complications, and interventional studies examining intensive treatment of diabetes and its effect on the development and progression of complications. Data Synthesis: Diabetic retinopathy, nephropathy, and neuropathy occur in all clinical forms of diabetes mellitus, regardless of the cause of the diabetes. Hyperglycemia appears to be the major variable shared among these different clinical forms; and epidemiologic data, studies in animal models of diabetes, and the results of recent interventional studies such as the Diabetes Control and Complications Trial, all support an important and perhaps dominant role of hyperglycemia in the pathogenesis of complications. However, the diverse complications may not share the same pathogenesis. Different pathogenetic mechanisms may operate in different types of diabetic complications or at different stages of specific complications, or both. Conclusions: The level of chronic glycemia is the best established concomitant factor associated with diabetic complications. The mechanism by which hyperglycemia might cause complications remains unknown, and evidence for a uniform pathogenetic mechanism is far from established.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	Nathan, DM (corresponding author), MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02114 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK030643] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01066-18] Funding Source: Medline; NIDDK NIH HHS [UO1 DK30643-13] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ASBURY AK, 1970, BRAIN, V93, P555, DOI 10.1093/brain/93.3.555; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BETZ AL, 1983, EXP EYE RES, V36, P269, DOI 10.1016/0014-4835(83)90011-8; BEYERMEARS A, 1985, DIABETES, V34, P15, DOI 10.2337/diabetes.34.1.15; BLOODWORTH JMB, 1962, DIABETES, V11, P1; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUNN HF, 1975, BIOCHEM BIOPH RES CO, V67, P103, DOI 10.1016/0006-291X(75)90289-2; CALVER A, 1992, J CLIN INVEST, V90, P2548, DOI 10.1172/JCI116149; CERAMI A, 1988, DIABETES CARE, V11, P73; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; COHEN AJ, 1987, DIABETES, V36, P944, DOI 10.2337/diabetes.36.8.944; CORDER CN, 1979, FOL HISTOCH CYTOCHEM, V17, P137; CRAVEN PA, 1987, METABOLISM, V36, P95, DOI 10.1016/0026-0495(87)90070-9; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; ENGERMAN RL, 1994, DIABETOLOGIA, V37, P141, DOI 10.1007/s001250050084; FAGIUS J, 1985, DIABETOLOGIA, V28, P323; FRANK RN, 1994, DIABETES, V43, P169, DOI 10.2337/diab.43.2.169; GABBAY KH, 1966, SCIENCE, V151, P209, DOI 10.1126/science.151.3707.209; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GREENE DA, 1988, DIABETES, V37, P688, DOI 10.2337/diabetes.37.6.688; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HARRIS M, 1979, DIABETES, V28, P1039; HILL MA, 1993, DIABETES, V42, P1226, DOI 10.2337/diabetes.42.9.1226; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; KAPOOR A, 1989, SEMIN ARTHRITIS RHEU, V18, P168, DOI 10.1016/0049-0172(89)90059-0; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KNOWLES H C Jr, 1964, Trans Am Clin Climatol Assoc, V76, P142; KRENTZ AJ, 1992, DIABETIC MED, V9, P463, DOI 10.1111/j.1464-5491.1992.tb01818.x; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NATHAN DM, 1986, DIABETES, V35, P797, DOI 10.2337/diabetes.35.7.797; OSTERBY R, 1985, ACTA MED SCAND, V574, P3; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; RAFF MC, 1968, ARCH NEUROL-CHICAGO, V18, P487, DOI 10.1001/archneur.1968.00470350045004; RAHBAR S, 1969, BIOCHEM BIOPH RES CO, V36, P838, DOI 10.1016/0006-291X(69)90685-8; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMA AAF, 1993, DIABETIC MED, V10, P115, DOI 10.1111/j.1464-5491.1993.tb00027.x; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SMITS P, 1993, DIABETES, V42, P148, DOI 10.2337/diabetes.42.1.148; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; ZATZ R, 1986, AM J MED, V80, P443, DOI 10.1016/0002-9343(86)90719-9; 1979, J CHRON DIS, V32, P829	52	87	89	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				86	89		10.7326/0003-4819-124-1_Part_2-199601011-00002	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554219				2022-12-28	WOS:A1996TL94400002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC WORKSHOP ON PRESCRIPTION DRUG INFORMATION FOR PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0824, V60, P44182; 1995, JAMA-J AM MED ASSOC, V274, P1109	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	1995	274	24					1903	1903						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL169	8568972				2022-12-28	WOS:A1995TL16900010
J	Gordon, PM; Keohane, SG; Herd, RM				Gordon, PM; Keohane, SG; Herd, RM			White coat effects	BRITISH MEDICAL JOURNAL			English	Article											Gordon, PM (corresponding author), UNIV EDINBURGH,ROYAL INFIRM,DEPT DERMATOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							Dover S, 1991, Health Bull (Edinb), V49, P293; SYME D, 1991, BRIT J GEN PRACT, V41, P436	2	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1704	1704		10.1136/bmj.311.7021.1704	http://dx.doi.org/10.1136/bmj.311.7021.1704			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541767	Green Published			2022-12-28	WOS:A1995TL94200029
J	Murphy, K; Brunberg, JA				Murphy, K; Brunberg, JA			Miliary tuberculosis involving the central nervous system	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Murphy, K (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.								0	5	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					769	769		10.1056/NEJM199603213341205	http://dx.doi.org/10.1056/NEJM199603213341205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592551				2022-12-28	WOS:A1996TZ97900005
J	Scherrer, U; Vollenweider, L; Delabays, A; Savcic, M; Eichenberger, U; Kleger, GR; Fikrle, A; Ballmer, PE; Nicod, P; Bartsch, P				Scherrer, U; Vollenweider, L; Delabays, A; Savcic, M; Eichenberger, U; Kleger, GR; Fikrle, A; Ballmer, PE; Nicod, P; Bartsch, P			Inhaled nitric oxide for high-altitude pulmonary edema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAXING FACTOR; VASOCONSTRICTION; LUNG; NIFEDIPINE; RELAXATION; HYPOXIA; DISEASE	Background. Pulmonary hypertension is a hallmark of high-altitude pulmonary edema and may contribute to its pathogenesis. When administered by inhalation, nitric oxide, an endothelium-derived relaxing factor, attenuates the pulmonary vasoconstriction produced by short-term hypoxia. Methods. We studied the effects of inhaled nitric oxide on pulmonary-artery pressure and arterial oxygenation in 18 mountaineers prone to high-altitude pulmonary edema and 18 mountaineers resistant to this condition in a high-altitude laboratory (altitude, 4559 m). We also obtained lung-perfusion scans before and during nitric oxide inhalation to gain further insight into the mechanism of action of nitric oxide. Results. In the high-altitude laboratory subjects prone to high-altitude pulmonary edema had more pronounced pulmonary hypertension and hypoxemia than subjects resistant to high-altitude pulmonary edema. Arterial oxygen saturation was inversely related to the severity of pulmonary hypertension (r=-0.50, P=0.002). In subjects prone to high-altitude pulmonary edema, the inhalation of nitric oxide (40 ppm for 15 minutes) produced a decrease in mean (+/-SD) systolic pulmonary-artery pressure that was three times larger than the decrease in subjects resistant to such edema (25.9+/-8.9 vs. 8.7+/-4.8 mm Hg, P<0.001). Inhaled nitric oxide improved arterial oxygenation in the 10 subjects who had radiographic evidence of pulmonary edema (arterial oxygen saturation increased from 67+/-10 to 73+/-12 percent, P=0.047), whereas it worsened oxygenation in subjects resistant to high-altitude pulmonary edema. The nitric oxide-induced improvement in arterial oxygenation in subjects with high-altitude pulmonary edema was accompanied by a shift in blood flow in the lung away from edematous segments and toward nonedematous segments. Conclusions. The inhalation of nitric oxide improves arterial oxygenation in high-altitude pulmonary edema, and this beneficial effect may be related to its favorable action on the distribution of blood flow in the lungs. A defect in nitric oxide synthesis may contribute to high-altitude pulmonary edema. (C) 1996, Massachusetts Medical Society.	CHU VAUDOIS,DIV CARDIOL,CH-1011 LAUSANNE,SWITZERLAND; INST PHYSIOL,LAUSANNE,SWITZERLAND; UNIV HOSP BERN,DEPT MED,CH-3010 BERN,SWITZERLAND; UNIV HOSP BERN,DEPT RADIOL,CH-3010 BERN,SWITZERLAND; UNIV HOSP BERN,DEPT NUCL MED,CH-3010 BERN,SWITZERLAND; UNIV HEIDELBERG,DEPT SPORTS MED,HEIDELBERG,GERMANY	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Ruprecht Karls University Heidelberg	Scherrer, U (corresponding author), CHU VAUDOIS,DEPT INTERNAL MED,BH 10642,CH-1011 LAUSANNE,SWITZERLAND.		Fikrle, Antonin/U-5022-2017; Ballmer, Peter/AAA-5743-2022	Fikrle, Antonin/0000-0002-5651-9616; 				BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; BLITZER ML, 1994, CIRCULATION, V90, P295; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; FRED HL, 1962, CIRCULATION, V25, P929, DOI 10.1161/01.CIR.25.6.929; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL C, 1991, CIRCULATION, V84, P2212; FROSTELL CG, 1993, ANESTHESIOLOGY, V78, P427, DOI 10.1097/00000542-199303000-00005; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HACKETT PH, 1992, INT J SPORTS MED, V13, pS68, DOI 10.1055/s-2007-1024599; HACKETT PH, 1990, J WILDERNESS MED, V1, P3, DOI 10.1580/0953-9859-1.1.3; HOUSTON CS, 1960, NEW ENGL J MED, V263, P478, DOI 10.1056/NEJM196009082631003; HULTGREN HN, 1964, CIRCULATION, V29, P393, DOI 10.1161/01.CIR.29.3.393; HULTGREN HN, 1978, LUNG BIOL HLTH DISEA, V7, P437; KUBES P, 1993, AM J PHYSIOL, V265, pH1909, DOI 10.1152/ajpheart.1993.265.6.H1909; OELZ O, 1989, LANCET, V2, P1241; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERRELLA MA, 1992, AM J PHYSIOL, V263, pR45, DOI 10.1152/ajpregu.1992.263.1.R45; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; SCHOENE RB, 1985, CLIN CHEST MED, V6, P491; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; STAUB NC, 1980, NEW ENGL J MED, V302, P1085, DOI 10.1056/NEJM198005083021911; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019; WEST JB, 1963, BRIT MED BULL, V19, P53, DOI 10.1093/oxfordjournals.bmb.a070007; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U	25	241	250	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					624	629		10.1056/NEJM199603073341003	http://dx.doi.org/10.1056/NEJM199603073341003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TX693	8592525	Bronze, Green Published			2022-12-28	WOS:A1996TX69300003
J	Selby, JV; Fireman, BH; Swain, BE				Selby, JV; Fireman, BH; Swain, BE			Effect of a copayment on use of the emergency department in a health maintenance organization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OFFICE VISIT COPAYMENTS; INSURANCE EXPERIMENT; CONTROLLED TRIAL; PRIMARY CARE; SERVICES	Background. Use of the emergency department for nonemergency care is frequent and costly. We studied the effect of a copayment on emergency department use in a group-model health maintenance organization (HMO). Methods. We examined the use of the emergency department in 1992 and 1993 by 30,276 subjects who ranged in age from 1 to 63 years at the start of the study and belonged to the Kaiser Permanente HMO in northern California. We assessed their use of various HMO services and their clinical outcomes before and after the introduction of a copayment of $25 to $35 for using the emergency department. This copayment group was compared with two randomly selected control groups not affected by the copayment. One control group, with 60,408 members, was matched for age, sex, and area of residence to the copayment group. The second, with 37,539 members, was matched for these factors and also for the type of employer. Results. After adjustment for age, sex, socioeconomic status, and use of the emergency department in 1992, the decline in the number of visits in 1993 was 14.6 percentage points greater in the copayment group than in either control group (P<0.001 for each comparison). Visits for urgent care did not increase among subjects in any stratum defined by age and sex, and neither did the number of outpatient visits by adults and children. The decline in emergency visits for presenting conditions classified as ''always an emergency'' was small and not significant. For conditions classified as ''often an emergency,'' ''sometimes not an emergency,'' or ''often not an emergency,'' the declines in the use of the emergency department were larger and statistically significant, and they increased with decreasing severity of the presenting condition, Although our ability to detect any adverse effects of the copayment was limited, there was no suggestion of excess adverse events in the copayment group, such as increases in mortality or in the number of potentially avoidable hospitalizations. Conclusions, Among members of an HMO, the introduction of a small copayment for the use of the emergency department was associated with a decline of about 15 percent in the use of that department, mostly among patients with conditions considered likely not to present an emergency. (C)1996, Massachusetts Medical Society.			Selby, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, PERMANENTE MED GRP, 3505 BROADWAY, OAKLAND, CA 94611 USA.							Afilalo Marc, 1995, Journal of Emergency Medicine, V13, P259, DOI 10.1016/0736-4679(94)00157-X; ANDRULIS DP, 1991, ANN EMERG MED, V20, P980, DOI 10.1016/S0196-0644(05)82976-2; BAKER DW, 1995, ANN EMERG MED, V25, P311, DOI 10.1016/S0196-0644(95)70285-7; BAKER LC, 1994, HEALTH AFFAIR, V13, P162, DOI 10.1377/hlthaff.13.5.162; Birnbaum A, 1994, Acad Emerg Med, V1, P213; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; CHERKIN DC, 1990, INQUIRY-J HEALTH CAR, V27, P24; CHERKIN DC, 1992, SOC SCI MED, V34, P33, DOI 10.1016/0277-9536(92)90064-W; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; DALEY W E, 1988, Journal of Emergency Medicine, V6, P333, DOI 10.1016/0736-4679(88)90371-X; DERLET RW, 1995, ANN EMERG MED, V25, P215, DOI 10.1016/S0196-0644(95)70327-6; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; HADDY RI, 1987, J FAM PRACTICE, V24, P389; KEELER E B, 1985, Journal of the American Medical Association, V254, P1926, DOI 10.1001/jama.254.14.1926; KELLERMANN AL, 1994, JAMA-J AM MED ASSOC, V271, P1953, DOI 10.1001/jama.271.24.1953; KRIEGER N, 1991, J EPIDEMIOL COMMUN H, V45, P35, DOI 10.1136/jech.45.1.35; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lohr K N, 1986, Med Care, V24, pS1; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P1677; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P640, DOI 10.2105/AJPH.79.5.640; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Rosen R, 1991, HMO PRACT, V5, P73; SIMON GE, 1994, AM J PSYCHIAT, V151, P908; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388	30	188	191	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1996	334	10					635	641		10.1056/NEJM199603073341006	http://dx.doi.org/10.1056/NEJM199603073341006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TX693	8592528				2022-12-28	WOS:A1996TX69300006
J	Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT				Hicks, RCJ; Golledge, J; MirHasseine, R; Powell, JT			Vasoactive effects of fibrinogen on saphenous vein	NATURE			English	Article							ENDOTHELIUM; SMOKING	Normal plasma fibrinogen concentrations are critical to haemostasis. Higher fibrinogen concentrations are associated with increasing risk of atherosclerotic disease(1) and with graft stenosis and occlusion after saphenous vein bypass surgery(2,3). Vein graft stenosis is characterized by the localized proliferation of intimal smooth muscle cells, causing narrowing of the graft with increased risk of thrombotic occlusion. In rabbit arteries, fibrinopeptide B is reported to have both vasoconstrictor and mitogenic properties(4,5). We report here that fibrinopeptides had no vasoactive effects on saphenous vein rings; however, fibrinogen (0-2 mu M) affected an endothelium-dependent relaxation, followed by recontraction at higher concentrations. The fibrinogen-mediated relaxation was inhibited by K+-channel blockers and antibodies to ICAM-1. Coupled signalling pathways for the synthesis of vasoactive mediators and mitogens could underlie the association between fibrinogen and the development of vein graft pathology.			Hicks, RCJ (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,CARDIOVASC & PULM RES DIV,LONDON W6 8RF,ENGLAND.		golledge, jonathan/I-2371-2013; Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; HICKS RC, 1995, J VASC SURG, V9, P415; HIGMAN DJ, 1993, BRIT J SURG, V80, P1242, DOI 10.1002/bjs.1800801007; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVENSON J, 1995, ARTERIOSCL THROM VAS, V15, P1263, DOI 10.1161/01.ATV.15.9.1263; MOORE PK, 1988, J PHARM PHARMACOL, V40, P558, DOI 10.1111/j.2042-7158.1988.tb05302.x; NAGAO T, 1993, AM J RESP CELL MOL, V8, P1; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; SINGH TM, 1990, AM J SURG, V160, P156, DOI 10.1016/S0002-9610(05)80297-1; WALDMAN SA, 1988, J CARDIOVASC PHARM, V12, pS115; WISEMAN S, 1989, BRIT MED J, V299, P643, DOI 10.1136/bmj.299.6700.643	11	43	46	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					818	820		10.1038/379818a0	http://dx.doi.org/10.1038/379818a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587603				2022-12-28	WOS:A1996TX50100056
J	Berenson, JR; Lichtenstein, A; Porter, L; Dimopoulos, MA; Bordoni, R; George, S; Lipton, A; Keller, A; Ballester, O; Kovacs, MJ; Blacklock, HA; Bell, R; Simeone, J; Reitsma, DJ; Heffernan, M; Seaman, J; Knight, RD				Berenson, JR; Lichtenstein, A; Porter, L; Dimopoulos, MA; Bordoni, R; George, S; Lipton, A; Keller, A; Ballester, O; Kovacs, MJ; Blacklock, HA; Bell, R; Simeone, J; Reitsma, DJ; Heffernan, M; Seaman, J; Knight, RD			Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-CELL MYELOMA; BONE METASTASES; BREAST-CANCER; THERAPY; HYPERCALCEMIA; CHEMOTHERAPY; INHIBITION; ETIDRONATE; ONCOLOGY; CALCIUM	Background. Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone, Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. Methods. Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy. The patients were stratified according to whether they were receiving first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy at entry into the study. Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration greater than or equal to 12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of life were assessed monthly. Results. Among 392 treated patients, the efficacy of treatment could be evaluated in 196 who received pamidronate and 181 who received placebo. The proportion of patients who had any skeletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group (41 percent, P<0.001), and the reduction was evident in both stratum 1 (P=0.04) and stratum 2 (P=0.004). The patients who received pamidronate had significant decreases in bone pain and no deterioration in performance status and quality of life. Pamidronate was well tolerated. Conclusions. Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma. (C) 1996, Massachusetts Medical Society.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90024; ST THOMAS HOSP,NASHVILLE,TN; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; AMER MED RES INST,ATLANTA,GA; SW INST CLIN RES,RANCHO MIRAGE,CA; MILTON S HERSHEY MED CTR,HERSHEY,PA; CANC CARE ASSOCIATES,TULSA,OK; H LEE MOFFITT CANC CTR,TAMPA,FL; VICTORIA HOSP,LONDON,ON N6A 4G5,CANADA; MIDDLEMORE HOSP,AUCKLAND 6,NEW ZEALAND; SCH MED,AUCKLAND,NEW ZEALAND; ST JOHN GOD HOSP,CENT HIGHLANDS ONCOL PROGRAM,BALLARAT,AUSTRALIA; CIBA PHARMACEUT,SUMMIT,NJ; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Saint Thomas Hospital; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; H Lee Moffitt Cancer Center & Research Institute; University of Victoria; Western University (University of Western Ontario); St John of God Health Care; Harvard University; Massachusetts General Hospital	Berenson, JR (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,DIV MED ONCOL,111H,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.		Dimopoulos, Meletios Athanasios/AAD-4130-2019; Kovacs, Michael/G-3315-2011	Dimopoulos, Meletios/0000-0001-8990-3254				ALEXANIAN R, 1983, BLOOD, V62, P572; ALEXANIAN R, 1984, CANCER, V53, P583, DOI 10.1002/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1; ARANKO K, 1995, BONE, V16, P275, DOI 10.1016/8756-3282(95)90127-2; BEAHRS OH, 1988, MANUAL STAGING CANCE; BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397; BERGSAGEL DE, 1985, POSTGRAD MED J, V61, P109, DOI 10.1136/pgmj.61.712.109; Cheung W. K., 1994, Am J Ther, V1, P221, DOI 10.1097/00045391-199410000-00009; COHEN HJ, 1984, BLOOD, V63, P639; COLEMAN RE, 1993, CANCER TREAT REV, V19, P79, DOI 10.1016/0305-7372(93)90028-P; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; FERRETTI JL, 1990, BONE MINER, V11, P111, DOI 10.1016/0169-6009(90)90020-G; FERRETTI JL, 1993, BONE MINER, V20, P265, DOI 10.1016/S0169-6009(08)80007-4; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; KANIS JA, 1991, BONE, V12, pS13, DOI 10.1016/8756-3282(91)90061-M; KELLIHAN MJ, 1992, ANN PHARMACOTHER, V26, P1262, DOI 10.1177/106002809202601015; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; KYLE RA, 1975, NEW ENGL J MED, V293, P1334, DOI 10.1056/NEJM197512252932602; LAHTINEN M, 1992, LANCET, V340, P1420; LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140-6736(92)93075-X; MAN Z, 1990, LANCET, V335, P663, DOI 10.1016/0140-6736(90)90452-B; MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756-3282(91)90057-P; MUNDY GR, 1986, SEMIN ONCOL, V13, P291; MUNDY GR, 1986, SEMIN ONCOL, V13, pR63; NUSSBAUM SR, 1993, AM J MED, V95, P297, DOI 10.1016/0002-9343(93)90282-T; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Salmon S, 1993, CANCER PRINCIPLES PR, V2, P1984; SIRIS ES, 1980, NEW ENGL J MED, V302, P310, DOI 10.1056/NEJM198002073020602; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STASHENKO P, 1987, J IMMUNOL, V138, P1464; THIEBAUD D, 1991, EUR J CANCER, V27, P37, DOI 10.1016/0277-5379(91)90056-J; TONG D, 1982, CANCER, V50, P893, DOI 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y; VANBREUKELEN FJM, 1979, LANCET, V1, P803; WEBER DM, 1993, MED ONCOLOGY COMPREH, P49; 1972, NEW ENGL J MED, V286, P1283	35	792	817	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 22	1996	334	8					488	493		10.1056/NEJM199602223340802	http://dx.doi.org/10.1056/NEJM199602223340802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV686	8559201				2022-12-28	WOS:A1996TV68600002
J	Magid, D; Douglas, JM; Schwartz, JS				Magid, D; Douglas, JM; Schwartz, JS			Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; doxycycline; azithromycin; Chlamydia trachomatis; Chlamydia infections	PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; NONGONOCOCCAL URETHRITIS; NEISSERIA-GONORRHOEAE; DECISION-ANALYSIS; UNITED-STATES; TRENDS; MALES; EPIDEMIOLOGY; ERYTHROMYCIN	Objective: To compare the economic consequences of doxycycline therapy with those of azithromycin therapy for women with uncomplicated cervical chlamydial infections. Design: Decision analysis in which the health outcomes, costs, and cost-effectiveness of two provider-administered treatment strategies for women with uncomplicated cervical chlamydial infections were compared: 1) initial therapy with doxycycline, 100 mg orally twice daily for 7 days (estimated cost, $5.51) and 2) initial therapy with azithromycin, 1 g orally administered as a single dose (estimated cost, $18.75). Results: Under baseline assumptions, the azithromycin strategy incurred fewer major and minor complications and was less expensive overall than the doxycycline strategy despite a higher initial cost for acquiring antibiotic agents. In univariate sensitivity analyses, the azithromycin strategy prevented more major complications but was more expensive than the doxycycline strategy when doxycycline effectiveness was greater than 0.93. In a multivariate sensitivity analysis combining 11 parameter estimates selected so that the cost-effectiveness of the doxycycline strategy would be maximized relative to that of the azithromycin strategy, the azithromycin strategy resulted in fewer complications but was more costly. The incremental cost-effectiveness was $521 per additional major complication prevented. However, if the difference in the cost of azithromycin and doxycycline decreased to $9.80, the azithromycin strategy was less expensive and more effective, even under these extreme conditions. Conclusions: On the basis of the best available data as derived from the literature and experts, the azithromycin strategy was more cost-effective than the doxycycline strategy for women with uncomplicated cervical chlamydial infections. Despite the dominance of the azithromycin strategy over the doxycycline strategy, the adoption of the azithromycin strategy may be limited by the practical financial constraints of our currently fragmented health care system, in which the costs and benefits of preventing chlamydia sequelae are often incurred by different components of the system.	DENVER DEPT PUBL HLTH, DIS CONTROL SERV, DENVER, CO 80204 USA; UNIV WASHINGTON, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, SEATTLE, WA 98195 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Washington; University of Washington Seattle; University of Pennsylvania								[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ARYA OP, 1978, BRIT J VENER DIS, V54, P414; BELL TA, 1987, SEX TRANSM DIS, V14, P195, DOI 10.1097/00007435-198710000-00003; BROOKOFF D, 1992, ANN EMERG MED, V21, P621; BUHAUG H, 1990, BRIT J GEN PRACT, V40, P142; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P2; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; GELMAN CR, 1992, DOXYCYCLINE DRUG EVA, V72; GEN M, 1993, JAMA-J AM MED ASSOC, V270, P2057; GUMP DW, 1983, AM J OBSTET GYNECOL, V146, P153, DOI 10.1016/0002-9378(83)91044-X; HAMMERSCHLAG MR, 1993, J PEDIATR-US, V122, P961, DOI 10.1016/S0022-3476(09)90029-4; HAMMERSCHLAG MR, 1982, PEDIATR INFECT DIS J, V1, P395, DOI 10.1097/00006454-198211000-00007; HOPKINS S, 1991, AM J MED, V91, pS40, DOI 10.1016/0002-9343(91)90401-I; JOHANNISSON G, 1980, OBSTET GYNECOL, V56, P671; JORDAN WC, 1981, SEX TRANSM DIS, V8, P105, DOI 10.1097/00007435-198104000-00019; KATZ BP, 1992, SEX TRANSM DIS, V19, P351, DOI 10.1097/00007435-199211000-00011; KAUFMAN RE, 1974, NEW ENGL J MED, V291, P1175, DOI 10.1056/NEJM197411282912208; LASSUS A, 1990, J ANTIMICROB CHEMOTH, V25, P115, DOI 10.1093/jac/25.suppl_A.115; LAUHARANTA J, 1993, J ANTIMICROB CHEMOTH, V31, P177, DOI 10.1093/jac/31.suppl_E.177; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; LISTER PJ, 1993, J ANTIMICROB CHEMOTH, V31, P185, DOI 10.1093/jac/31.suppl_E.185; MANSOOR GA, 1993, ANN INTERN MED, V119, P636, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00027; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; NETTLEMAN MD, 1991, AM J OBSTET GYNECOL, V164, P1289, DOI 10.1016/0002-9378(91)90701-R; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; NETTLEMAN MD, 1986, ANN INTERN MED, V105, P189, DOI 10.7326/0003-4819-105-2-189; NILSEN A, 1992, GENITOURIN MED, V68, P325; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; ROMANOWSKI B, 1993, ANN INTERN MED, V119, P16, DOI 10.7326/0003-4819-119-1-199307010-00003; SANDE MA, 1990, PHARMACOL BASIS THER, P1117; SCHACHTER J, 1986, NEW ENGL J MED, V314, P276, DOI 10.1056/NEJM198601303140503; SCHACHTER J, 1979, LANCET, V2, P377; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; SCHEIFE RT, 1976, DRUG EFFECTS HOSPITA, P263; SCHMID GP, 1995, JAMA-J AM MED ASSOC, V274, P577; STAMM WE, 1984, NEW ENGL J MED, V310, P545, DOI 10.1056/NEJM198403013100901; STAMM WE, 1987, AM J MED, V82, P307; STEINGRIMSSON O, 1990, J ANTIMICROB CHEMOTH, V25, P109, DOI 10.1093/jac/25.suppl_A.109; SVENSSON L, 1983, FERTIL STERIL, V40, P322; TERHO P, 1978, BRIT J VENER DIS, V54, P251; THOMPSON SE, 1983, EPIDEMIOL REV, V5, P96, DOI 10.1093/oxfordjournals.epirev.a036266; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1984, JAMA-J AM MED ASSOC, V251, P2529, DOI 10.1001/jama.251.19.2529; WASHINGTON AE, 1986, JAMA-J AM MED ASSOC, V255, P1735, DOI 10.1001/jama.255.13.1735; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2056, DOI 10.1001/jama.257.15.2056; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; WESTROM L, 1982, SCAND J INFECT DIS, P157; WESTROM L, 1975, AM J OBSTET GYNECOL, V121, P707, DOI 10.1016/0002-9378(75)90477-9; 1991, 1ST DATA BANK MONTHL, V6, P1; 1996, PRICE ALERT, V7, P27; 1985, MMWR MORB MORTAL S3, V34, pS53	58	92	93	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					389	+		10.7326/0003-4819-124-4-199602150-00002	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554247				2022-12-28	WOS:A1996TV22000002
J	Hirschl, RB; Pranikoff, T; Wise, C; Overbeck, MC; Gauger, P; Schreiner, RJ; Dechert, R; Bartlett, RH				Hirschl, RB; Pranikoff, T; Wise, C; Overbeck, MC; Gauger, P; Schreiner, RJ; Dechert, R; Bartlett, RH			Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-EXPIRATORY PRESSURE; GAS-EXCHANGE; LUNG; SUPPORT; FAILURE	Objective.-To evaluate the safety and efficacy of partial liquid ventilation (PLV). Design.-Before-after trial. Setting.-The surgical intensive care unit at the University of Michigan, Ann Arbor, from April to December 1994. Patients.-A consecutive sample of 10 patients aged 19 to 55 years with the acute respiratory distress syndrome who were receiving extracorporeal life support. Intervention.-Perflubron was administered into the trachea until the dependent zone of the lung was filled. Gas ventilation of the perflubron-filled lung was then performed (PLV). Volatilized perflubron replacement was repeated daily for from 1 to 7 days with a median cumulative dose of 38 mL/kg (range, 15 to 62 mL/kg). Main Outcome Measures.-Physiologic shunt and static pulmonary compliance. Results.-Physiologic shunt decreased from a median of 0.72 (range, 0.37 to 1.0) to 0.46 (range, 0.21 to 0.96) over the 72 hours following initiation of PLV (P=.01 by repeated measures analysis of variance). Static pulmonary compliance corrected for patient weight increased from a median of 0.16 mL/cm H2O per kilogram (range, 0.01 to 0.48 mL/cm H2O per kilogram) to 0.27 mL/cm H2O per kilogram (range, 0.05 to 1.11 mL/cm H2O per kilogram) over the same time period (P=.04 by repeated measures analysis of variance). Overall survival was five (50%) of 10 patients. Complications that were potentially associated with PLV included pneumothorax development in one patient and mucus plug formation in one patient. Conclusions.-Perflubron may be safely administered into the lungs of patients with severe respiratory failure receiving extracorporeal life support and may be associated with improvement in gas exchange and pulmonary compliance.	UNIV MICHIGAN,DEPT RESP CARE,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Hirschl, RB (corresponding author), UNIV MICHIGAN,DEPT SURG,PEDIAT SURG SECT,F3970 MOTT,BOX 0245,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.		Gauger, Paul/W-8176-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON H, 1993, SURGERY, V114, P161; CALDERWOOD HW, 1973, ANESTHESIOLOGY, V38, P141, DOI 10.1097/00000542-197302000-00008; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; CURTIS SE, 1993, J APPL PHYSIOL, V75, P2696, DOI 10.1152/jappl.1993.75.6.2696; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; HERMAN LJ, 1995, CRIT CARE MED S1, V23, pA264; HIRSCHL RB, 1994, SURGERY, V116, P159; HIRSCHL RB, 1995, ANN SURG, V221, P79, DOI 10.1097/00000658-199501000-00010; HIRSCHL RB, 1995, LANCET, V346, P1201, DOI 10.1016/S0140-6736(95)92903-7; HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500; KAZEROONI E, IN PRESS RADIOLOGY; KYLSTRA JA, 1962, T AM SOC ART INT ORG, V8, P378; LACHMANN B, 1980, ACTA ANAESTH SCAND, V24, P231, DOI 10.1111/j.1399-6576.1980.tb01541.x; LEACH CL, 1993, CRIT CARE MED, V21, P1270, DOI 10.1097/00003246-199309000-00008; LOWE C, 1979, J APPL PHYSIOL, V47, P1051, DOI 10.1152/jappl.1979.47.5.1051; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; MODELL JH, 1970, FED PROC, V29, P1731; NESTI FD, 1994, CRIT CARE MED, V22, P1445, DOI 10.1097/00003246-199409000-00015; OVERBECK MC, IN PRESS CRIT CARE M; Pranikoff T, 1994, ASAIO J, V40, pM339, DOI 10.1097/00002480-199407000-00020; RICHMAN PS, 1993, CRIT CARE MED, V21, P768, DOI 10.1097/00003246-199305000-00022; SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208; SHAFFER TH, 1984, PEDIATR RES, V18, P47; SHAFFER TH, 1978, PEDIATR RES, V12, P695, DOI 10.1203/00006450-197806000-00003; SHAPIRO BA, 1984, CRIT CARE MED, V12, P127, DOI 10.1097/00003246-198402000-00011; TOOLEY R, IN PRESS CRIT CARE M; TUTUNCU AS, 1993, AM REV RESPIR DIS, V148, P785; TUTUNCU AS, 1992, CLIN INTENSIVE CAR S, V3, P72	30	203	212	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					383	389		10.1001/jama.275.5.383	http://dx.doi.org/10.1001/jama.275.5.383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569018				2022-12-28	WOS:A1996TT30300032
J	Judd, HL; Wasilauskas, C; Johnson, S; Merino, M; BarrettConnor, E; Trabal, J; Miller, VT; Barnabei, V; Levin, G; Bush, T; Foster, D; Zacur, H; Woodruff, JD; Stefanick, M; Akana, A; Heinrichs, WL; OHanlan, K; Buyalos, RP; Greendale, G; Lozano, K; CarrionPetersen, L; Cavero, C; Langer, R; Schrott, HG; Benda, JA; deProsse, C; Fedderson, D; Johnson, SR; Ahmad, MM; Brown, HP; Schenken, RS; RodriguezSifuentes, M; Valente, PT; Espeland, M; Lane, K; Legault, C; MebaneSims, IL; Kelaghan, J; McGowan, J; Fradkin, J; Sherman, S; Scully, R				Judd, HL; Wasilauskas, C; Johnson, S; Merino, M; BarrettConnor, E; Trabal, J; Miller, VT; Barnabei, V; Levin, G; Bush, T; Foster, D; Zacur, H; Woodruff, JD; Stefanick, M; Akana, A; Heinrichs, WL; OHanlan, K; Buyalos, RP; Greendale, G; Lozano, K; CarrionPetersen, L; Cavero, C; Langer, R; Schrott, HG; Benda, JA; deProsse, C; Fedderson, D; Johnson, SR; Ahmad, MM; Brown, HP; Schenken, RS; RodriguezSifuentes, M; Valente, PT; Espeland, M; Lane, K; Legault, C; MebaneSims, IL; Kelaghan, J; McGowan, J; Fradkin, J; Sherman, S; Scully, R			Effects of hormone replacement therapy on endometrial histology in postmenopausal women - The Postmenopausal Estrogen Progestin Interventions (PEPI) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONJUGATED ESTROGENS; MENOPAUSAL WOMEN; CANCER; RISK; CARCINOMA; ASSOCIATION; DISEASE	Objective.-To report the histological findings of the endometrium of postmenopausal women who were randomized to receive placebo, estrogen only, or one of three estrogen plus progestin (EI-P) regimens in the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. Design.-A 3-year multicenter, randomized, double-masked, placebo-controlled trial. Participants-A total of 596 postmenopausal women aged 45 through 64 years without contraindication to hormone therapy. Intervention.-Participants were randomized and stratified in equal numbers to one of the following treatments in 28-day cycles: placebo, 0.625 mg/d of conjugated equine estrogens (GEE), 0.625 mg/d of CEE plus 10 mg/d of medroxyprogesterone acetate (MPA)for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of micronized progesterone (MP) for the first 12 days. Outcome Measure.-Histology of endometrium collected at baseline, annual, or unscheduled Visits by biopsy, curettage, or hysterectomy. Analysis.-Intention to treat. Results.-During follow-up women assigned to estrogen atone were more likely to develop simple (cystic), complex (adenomatous), or atypical hyperplasia than those given placebo (27.7% vs 0.8%, 22.7% vs 0.8%, and 11.8% vs 0%, respectively) for the same types of hyperplasia (P<.001). Participants administered one of the three E+P regimens had similar rates of hyperplasia as those given placebo (P=.16). The occurrence of hyperplasia was distributed evenly across the 3 years of the trial. Women taking estrogens alone also had more unscheduled biopsies (66.4% vs 8.4%; P<.001) and curettages (17.6% vs 0.8%; P<.001) than women receiving placebo. The number of surgical procedures was similar for women receiving placebo and women receiving the E+P regimens (P=.38). Of the 45 women with complex (adenomatous) or atypical hyperplasia, study medications were discontinued in all, and the biopsy results of 34 (94%) of 36 women with hyperplasia reverted to normal with progestin therapy. The remainder had dilatation and curettage (n=2) or hysterectomy with (n=2) or without (n=6) prior medical therapy, or refused further biopsies (n=1). One woman developed adenocarcinoma of the endometrium while receiving placebo. Conclusions.-At a dosage of 0.625 mg, the daily administration of CEE enhanced the development of endometrial hyperplasia. Combining CEE with cyclic or continuous MPA or cyclic MP protected the endometrium from hyperplastic changes associated with estrogen-only therapy.			Judd, HL (corresponding author), NHLBI,2 ROCKLEDGE CTR,SUITE 10193,6701 ROCKLEDGE DR,MSC,BETHESDA,MD 20892, USA.		zacur, howard/W-2170-2019		NHLBI NIH HHS [U01-HL40154, U01-HL40185, U01-HL40195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040185, U01HL040195, U01HL040154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRINTON LA, 1993, OBSTET GYNECOL, V81, P265; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAMPBELL PE, 1961, J OBSTET GYN BR COMM, V68, P668; GELFAND MM, 1989, OBSTET GYNECOL, V74, P398; GIBBONS WE, 1986, AM J OBSTET GYNECOL, V154, P456, DOI 10.1016/0002-9378(86)90690-3; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GUSBERG SB, 1947, AM J OBSTET GYNECOL, V54, P905, DOI 10.1016/S0002-9378(16)39706-X; HALL KARL VICTOR, 1957, ACTA OBSTET ET GYNECOL SCAND, V36, P306; HENDERSON BE, 1989, AM J OBSTET GYNECOL, V161, P1859, DOI 10.1016/S0002-9378(89)80007-9; HENDRICKSON M, 1980, MAJOR PROBLEMS PATHO, V12, P285; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MOORJANI S, 1991, J CLIN ENDOCR METAB, V73, P373, DOI 10.1210/jcem-73-2-373; PERSSON I, 1989, BRIT MED J, V298, P141; SCHIFF I, 1982, FERTIL STERIL, V37, P79; SHAPIRO S, 1985, NEW ENGL J MED, V313, P969, DOI 10.1056/NEJM198510173131601; SHERMAN AI, 1979, AM J OBSTET GYNECOL, V135, P947, DOI 10.1016/0002-9378(79)90821-4; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STURDEE DW, 1978, BRIT MED J, V1, P1575, DOI 10.1136/bmj.1.6127.1575; THOM M, 1978, LANCET, V1, P455; THOM M, 1979, AM J OBSTET GYNECOL, V135, P947; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; WENTZ WB, 1966, AM J OBSTET GYNECOL, V96, P999, DOI 10.1016/0002-9378(66)90447-9; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1212; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1995, J CONTROLLED CLIN S, V16, pS36; 1995, J CONTROLLED CLIN S, V16, pS20; 1995, JAMA-J AM MED ASSOC, V273, P199; 1995, J CONTROLLED CLIN S, V16, pS54; 1995, J CONTROLLED CLIN S, V16, pS3	34	462	472	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					370	375		10.1001/jama.1996.03530290040035	http://dx.doi.org/10.1001/jama.1996.03530290040035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8569016				2022-12-28	WOS:A1996TT30300030
J	Diehm, C; Trampisch, HJ; Lange, S; Schmidt, C				Diehm, C; Trampisch, HJ; Lange, S; Schmidt, C			Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency	LANCET			English	Article								Background Diseases of the venous system are widespread disorders sometimes associated with modern civilisation and are among the major concerns of social and occupational medicine. This study was carried out to compare the efficacy (oedema reduction) and safety of compression stockings class II and dried horse chestnut seed extract (HCSE, 50 mg aescin, twice daily). Methods Equivalence of both therapies was examined in a novel hierarchical statistical design in 240 patients with chronic venous insufficiency. Patients were treated over a period of 12 weeks in a randomised, partially blinded, placebo-controlled, parallel study design. Findings Lower leg volume of the more severely affected limb decreased on average by 43.8 mL (n=95) with HCSE and 46.7 mL (n=99) with compression therapy, while it increased by 9.8 mL with placebo (n=46) after 12 weeks therapy for the intention-to-treat group (95% CI: HCSE: 21.1-66.4; compression: 30.4-63.0; placebo: 40.0-20.4). Significant oedema reductions were achieved by HCSE (p=0.005) and compression (p=0.002) compared placebo, and the two therapies were shown to equivalent (p=0.001); in this design, however, compression could not be proven as standard with regard to oedema reduction in the statistical test procedure. Both HCSE and compression therapy were well tolerated and no serious treatment-related events were reported. Interpretation These results indicate that compression stocking therapy and HCSE therapy are alternative therapies for the effective treatment of patients with oedema resulting from chronic venous insufficiency.	UNIV HEIDELBERG,AFFILIATED TEACHING HOSP,DEPT INTERNAL MED VASC MED,D-76307 KARLSBAD LANGENST,GERMANY; KLINGE PHARMA GMBH,DEPT CLIN RES,MUNICH,GERMANY; RUHR UNIV BOCHUM,DEPT MED DATA PROC & BIOMATH,BOCHUM,GERMANY	Ruprecht Karls University Heidelberg; Ruhr University Bochum								BISLER H, 1986, DEUT MED WOCHENSCHR, V111, P1321, DOI 10.1055/s-2008-1068628; DIEHM C, 1992, VASA-J VASCULAR DIS, V21, P188; KREYSEL HW, 1983, VASA-J VASCULAR DIS, V12, P377; LONGIAVE D, 1978, PHARMACOL RES COMMUN, V10, P145, DOI 10.1016/S0031-6989(78)80072-1; PARTSCH H, 1991, J DERMATOL SURG ONC, V17, P799, DOI 10.1111/j.1524-4725.1991.tb03263.x; RUDOFSKY G, 1986, PHLEBOL PROKTOL, V15, P47; SENN S, 1993, STAT MED, V12, P2367, DOI 10.1002/sim.4780122412; SMITH PDC, 1994, BRIT J SURG, V81, P1401; STEINER M, 1986, MUNCHEN MED WOCHEN, V31, P551; Thulesius O, 1973, Vasa, V2, P325	10	138	143	1	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					292	294		10.1016/S0140-6736(96)90467-5	http://dx.doi.org/10.1016/S0140-6736(96)90467-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569363				2022-12-28	WOS:A1996TT48500010
J	Peaceman, AM; Sciarra, JJ				Peaceman, AM; Sciarra, JJ			Encouraging trials of labour for patients with previous caesarean birth	LANCET			English	Editorial Material											Peaceman, AM (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.			Peaceman, Alan/0000-0002-4515-4850				FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; 1995, MMWR-MORBID MORTAL W, V44, P303; 1996, INT J GYNECOL OBSTET, V52, P90	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 3	1996	347	8997					278	278		10.1016/S0140-6736(96)90461-4	http://dx.doi.org/10.1016/S0140-6736(96)90461-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT485	8569357				2022-12-28	WOS:A1996TT48500004
J	Rubin, N; Nakayama, K; Shapley, R				Rubin, N; Nakayama, K; Shapley, R			Enhanced perception of illusory contours in the lower versus upper visual hemifields	SCIENCE			English	Article							RANDOM-DOT STEREOGRAMS; STRIATE CORTEX; COMPLETION; MECHANISMS; ANISOTROPY; DYNAMICS; ISOTROPY; FIELD; FORM	The visual world consciously perceived is very different from the spatial array of photoreceptor activation present on our retinae; it is composed of segregated surfaces, organized into distinct objects. An important component of this organizational process, the segmentation of an image into figures and background, is shown to be performed much better in the lower visual field. This finding is demonstrated by the performance in two tasks that involve the perception of illusory contours. This asymmetry indicates a neural specialization that may be related to the anatomical discontinuity along the representation of the horizontal meridian in extrastriate visual cortex.	NYU,CTR NEURAL SCI,NEW YORK,NY 10003	New York University	Rubin, N (corresponding author), HARVARD UNIV,VIS SCI LAB,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.		Rubin, Nava/J-5189-2012		NATIONAL EYE INSTITUTE [R01EY001472] Funding Source: NIH RePORTER; NEI NIH HHS [EY-01472] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON JC, 1993, CEREB CORTEX, V3, P412, DOI 10.1093/cercor/3.5.412; ANGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; BLOMFIELD S, 1973, NATURE-NEW BIOL, V245, P256, DOI 10.1038/newbio245256a0; BREITMEYER B, 1975, SCIENCE, V187, P269, DOI 10.1126/science.1111104; Chernjavsky A, 1990, NEURAL COMPUT, V2, P334, DOI 10.1162/neco.1990.2.3.334; EDELMAN GM, 1987, NEURAL DARWINISM, pCH6; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FINKEL LH, 1992, NEURAL COMPUT, V4, P901, DOI 10.1162/neco.1992.4.6.901; Fletcher R., 1980, PRACTICAL METHODS OP; Gibson JJ, 1950, PERCEPTION VISUAL WO; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; GULYAS B, 1993, FUNCTIONAL ORG HUMAN, P346; HEITGER F, 1993, P INT C COMP VISION, V4, P32; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HOLMES G, 1945, PROC R SOC SER B-BIO, V132, P348, DOI 10.1098/rspb.1945.0002; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; HORTON JC, 1991, BRAIN, V114, P1703, DOI 10.1093/brain/114.4.1703; JULESZ B, 1976, PERCEPTION, V5, P129, DOI 10.1068/p050129; JULESZ B, 1971, F CYCLOPEAN VISION; Kanizsa G., 1979, ORG VISION; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P405; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Nitzberg M., 1993, FILTERING SEGMENTATI; PETERHANS E, 1989, J NEUROSCI, V9, P1749; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; Petry S., 1987, PERCEPTION ILLUSORY; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; RINGACH D, 1993, PERCEPTION S, V22, P51; RUBIN N, UNPUB; Tyler C. W., 1991, BINOCULAR VISION; ULLMAN S, 1976, BIOL CYBERN, V25, P1; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; WASSERSTEIN J, 1984, BRAIN COGNITION, V3, P51, DOI 10.1016/0278-2626(84)90006-X; WASSERSTEIN J, 1987, BRAIN COGNITION, V6, P1, DOI 10.1016/0278-2626(87)90042-X; WILLIAMS LR, 1995, P INT C COMP VIS, V5, P408	40	156	161	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 2	1996	271	5249					651	653		10.1126/science.271.5249.651	http://dx.doi.org/10.1126/science.271.5249.651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT870	8571128				2022-12-28	WOS:A1996TT87000047
J	Abbott, A; Cohen, B; Howlett, R				Abbott, A; Cohen, B; Howlett, R			Complexity limits the powers of prediction	NATURE			English	Editorial Material																			0	4	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					390	390						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559236				2022-12-28	WOS:A1996TT30400016
J	Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU				Mayhew, M; daSilva, ACR; Martin, J; ErdjumentBromage, H; Tempst, P; Hartl, FU			Protein folding in the central cavity of the GroEL-GroES chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; ATP HYDROLYSIS; BINDING; SUBSTRATE; CYCLE	The chaperonin GroEL is able to mediate protein folding in its central cavity. GroEL-bound dihydrofolate reductase assumes its native conformation when the GroES cofactor caps one end of the GroEL cylinder, thereby discharging the unfolded polypeptide into an enclosed cage. Folded dihydrofolate reductase emerges upon ATF-dependent GroES release. Other proteins, such as rhodanese, may leave GroEL after having attained a conformation that is committed to fold. Incompletely folded polypeptide rebinds to GroEL, resulting in structural rearrangement for another folding trial in the chaperonin cavity.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Erdjument-Bromage, Hediye/0000-0003-0224-3594				BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ELLIS RJ, 1994, OPIN STRUCT BIOL, V4, P117; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P615; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HODAN R, 1995, NAT STRUCT BIOL, V2, P587; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, REV BIOPHSY BIOMOL S, V23, P645; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	47	324	330	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 1	1996	379	6564					420	426		10.1038/379420a0	http://dx.doi.org/10.1038/379420a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT304	8559246				2022-12-28	WOS:A1996TT30400050
J	Connolly, DL; Shanahan, CM; Weissberg, PL				Connolly, DL; Shanahan, CM; Weissberg, PL			Water channels in health and disease	LANCET			English	Editorial Material											Connolly, DL (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE,ENGLAND.			Shanahan, Catherine/0000-0002-8352-8171				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; MARPLES D, 1995, J CLIN INVEST, V95, P838; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIELS A, IN PRESS NATURE GENE; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907	13	13	15	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					210	212		10.1016/S0140-6736(96)90399-2	http://dx.doi.org/10.1016/S0140-6736(96)90399-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551876				2022-12-28	WOS:A1996TT06900005
J	GoodrichBlair, H; Shub, DA				GoodrichBlair, H; Shub, DA			Beyond homing: Competition between intron endonucleases confers a selective advantage on flanking genetic markers	CELL			English	Article							BACILLUS-SUBTILIS BACTERIOPHAGE-SPO1; DNA-POLYMERASE GENE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; SITE; MECHANISM; SEQUENCE; PROTEIN; SUBUNIT; RECOMBINATION	The closely related B. subtilis bacteriophages SPO1 and SP82 have similar introns inserted into a conserved domain of their DNA polymerase genes. These introns encode endonucleases with unique properties. Other intron-encoded ''homing'' endonucleases cleave both strands of intronless DNA; subsequent repair results in unidirectional gene conversion to the intron-containing allele. In contrast, the enzymes described here cleave one strand on both intron-containing and intronless targets at different distances from their common intron insertion site. Most surprisingly, each enzyme prefers DNA of the heterologous phage. The SP82-encoded endonuclease is responsible for exclusion of the SPO1 intron and flanking genetic markers from the progeny of mixed infections, a novel selective advantage imparted by an intron to the genome in which it resides.	SUNY ALBANY, CTR GENET MOLEC, DEPT BIOL SCI, ALBANY, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany				Goodrich-Blair, Heidi/0000-0003-1934-2636	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037746] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37746] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYK M, 1995, J MOL BIOL, V247, P197, DOI 10.1006/jmbi.1994.0133; CULL M, 1990, METHOD ENZYMOL, V182, P147; CURRAN JF, 1985, VIROLOGY, V142, P78, DOI 10.1016/0042-6822(85)90424-6; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUJON B, 1989, GENE, V82, P115, DOI 10.1016/0378-1119(89)90035-8; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GLASSBERG J, 1977, J VIROL, V21, P147, DOI 10.1128/JVI.21.1.147-152.1977; GOODRICHBLAIR H, 1994, NUCLEIC ACIDS RES, V22, P3715, DOI 10.1093/nar/22.18.3715; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HARDY KG, 1985, DNA CLONING PRACTICA, V2, P1; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARSHALL P, 1992, NUCLEIC ACIDS RES, V20, P6401, DOI 10.1093/nar/20.23.6401; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUELLER JE, 1993, NUCLEASES, P111; MULBRY WW, 1989, J BACTERIOL, V171, P5322, DOI 10.1128/jb.171.10.5322-5324.1989; NAKAGAWA K, 1992, EMBO J, V11, P2707, DOI 10.1002/j.1460-2075.1992.tb05336.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; RUSSELL RL, 1974, GENETICS, V78, P989; SAYRE MH, 1988, J VIROL, V62, P3455, DOI 10.1128/JVI.62.9.3455-3462.1988; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SHARMA M, 1994, J BACTERIOL, V176, P6439, DOI 10.1128/JB.176.21.6439-6448.1994; SHARMA M, 1992, P NATL ACAD SCI USA, V89, P6658, DOI 10.1073/pnas.89.14.6658; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; SHUB DA, 1987, COLD SPRING HARB SYM, V52, P193, DOI 10.1101/SQB.1987.052.01.024; Shub DA, 1991, CURR OPIN GENET DEV, V1, P478, DOI 10.1016/S0959-437X(05)80195-9; Stewart Charles R., 1993, P813; STEWART CR, 1981, J VIROL, V38, P1081, DOI 10.1128/JVI.38.3.1081-1083.1981; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TURMEL M, 1995, NUCLEIC ACIDS RES, V23, P2519, DOI 10.1093/nar/23.13.2519	40	74	75	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 26	1996	84	2					211	221		10.1016/S0092-8674(00)80976-9	http://dx.doi.org/10.1016/S0092-8674(00)80976-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565067	Bronze			2022-12-28	WOS:A1996TR59500008
J	Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME				Hargreaves, RM; Slack, MPE; Howard, AJ; Anderson, E; Ramsay, ME			Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programme	BRITISH MEDICAL JOURNAL			English	Article									GWYNEDD PUBL HLTH LAB,BANGOR,GWYNEDD,WALES; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND	Public Health England	Hargreaves, RM (corresponding author), JOHN RADCLIFFE HOSP,HAEMOPHILUS REFERENCE UNIT,OXFORD PUBL HLTH LAB,OXFORD OX3 9DU,ENGLAND.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ANDERSON EC, 1995, EPIDEMIOL INFECT, V115, P89, DOI 10.1017/S0950268800058155; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; SLACK MPE, 1993, PHLS MICROBIOL DIG, V10, P122; 1991, PAEDIATRICS, V88, P169	5	77	79	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	1996	312	7024					160	161						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TR325	8563536				2022-12-28	WOS:A1996TR32500024
J	Silverman, WA; Altman, DG				Silverman, WA; Altman, DG			Patients' preferences and randomised trials	LANCET			English	Article							CLINICAL-TRIALS; COMPREHENSIVE COHORT; DESIGN		CTR STAT MED, IMPERIAL CANC RES FUND, MED STAT GRP, OXFORD OX3 7LF, ENGLAND	University of Oxford								ALTMAN DG, IN PRESS EUR J CANCE; [Anonymous], 1982, JUDGMENT UNCERTAINTY; BARNETT HJM, 1987, NEW ENGL J MED, V316, P817, DOI 10.1056/NEJM198703263161320; BRADLEY C, 1988, DIABETIC MED, V5, P107, DOI 10.1111/j.1464-5491.1988.tb00954.x; BRADLEY C, 1993, DIABETES CARE, V2, P509; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; CHALMERS TC, 1975, MED CLIN N AM, V59, P1035, DOI 10.1016/S0025-7125(16)32001-6; ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518; FDEN R, 1986, HIST THEORY INFORMED; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714; HICKISH TF, 1995, LANCET, V345, P857, DOI 10.1016/S0140-6736(95)92993-2; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; JOHNSON L, 1959, AMA J DIS CHILD, V97, P591, DOI 10.1001/archpedi.1959.02070010593009; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; Katz J, 1982, SILENT WORLD DOCTOR; KORN EL, 1991, LANCET, V337, P149, DOI 10.1016/0140-6736(91)90809-4; MACINTYRE IMC, 1991, BRIT MED J, V302, P1099, DOI 10.1136/bmj.302.6785.1099; ODELL GB, 1959, J CLIN INVEST, V38, P823, DOI 10.1172/JCI103864; OLSCHEWSKI M, 1985, METHOD INFORM MED, V24, P131; OLSCHEWSKI M, 1992, CONTROL CLIN TRIALS, V13, P226, DOI 10.1016/0197-2456(92)90005-K; PAULOS JA, 1992, NUMERACY; SILVERMAN WA, 1956, PEDIATRICS, V18, P614; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; SUNDT TM, 1987, NEW ENGL J MED, V316, P814, DOI 10.1056/NEJM198703263161318; Till J E, 1992, Qual Life Res, V1, P31, DOI 10.1007/BF00435433; WENNBERG JE, 1990, MODERN METHODS CLIN; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1995, LANCET, V345, P805; 1995, COCHRANE DATABASE SY	29	103	105	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					171	174		10.1016/S0140-6736(96)90347-5	http://dx.doi.org/10.1016/S0140-6736(96)90347-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544555				2022-12-28	WOS:A1996TQ24400016
J	Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J				Gilbert, L; Nicholl, J; Alex, S; Smethurst, I; Mander, A; Andrews, A; Patrick, J			Ethnic differences in the outcome of serum screening for Down's syndrome	BRITISH MEDICAL JOURNAL			English	Article									OLDHAM NHS TRUST,DEPT OBSTET & GYNAECOL,OLDHAM OL1 2PN,ENGLAND; UNIV SHEFFIELD,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; OLDHAM NHS TRUST,DEPT CLIN PATHOL,OLDHAM OL1 2PN,ENGLAND; ST MARYS HOSP,REG CYTOGENET DEPT,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Sheffield; University of Manchester			Gilbert, Lucy/M-6879-2019; Nicholl, Jon/B-8257-2008	Gilbert, Lucy/0000-0001-8605-5472; 				BOGART MH, 1991, AM J OBSTET GYNECOL, V165, P663, DOI 10.1016/0002-9378(91)90305-B; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; GARDNER MJ, 1989, STATISTICS CONFIDENC; REYNOLDS TN, 1989, NN CLIN BIOCH, V26, P26; RODGERS MS, 1986, BRIT J OBSTET GYNAEC, V93, P587	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	1996	312	7023					94	95						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ168	8555938				2022-12-28	WOS:A1996TQ16800025
J	Joseph, KS; Blais, L; Ernst, P; Suissa, S				Joseph, KS; Blais, L; Ernst, P; Suissa, S			Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEATH; SCHIZOPHRENIA; CHILDHOOD; RISK	Objective - To assess the potentially increased risk of death or near death from asthma in asthmatic patients with psychosis. Design - Case-control study. Setting - The computerised health databases of the Canadian province of Saskatchewan. Subjects - 131 cases of death or near death from asthma identified within a cohort of asthmatic patients; 3930 matched non-cases. Exposure and outcome measures - The exposure of interest was the use of major tranquillisers in the period before an outcome event. Outcomes included death or near death from asthma. Results - Crude analyses showed that asthmatic patients who had used major tranquillisers in the previous 12 months were at a 3.2 (95% confidence interval 1.4 to 7.5) times greater risk of death or near death from asthma than asthmatic patients who did not use major tranquillisers. Past users of major tranquillisers who had recently discontinued use were at a particularly high risk (relative risk 6.6; 2.5 to 17.6). Adjustment for use of antiasthma drugs and other confounders abolished this excess risk. Conclusions - Asthmatic patients who use major tranquillisers seem to be at an increased risk of death or near death from asthma. Physicians treating asthmatic patients with a history of use of major tranquillisers should exercise greater caution with regard to management of such patients.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ H3A 1A2, CANADA	McGill University				Joseph, K.S./0000-0003-2317-5607				BALDESSARINI RJ, 1990, GOODMAN GILMANS PHAR, P391; Banks T, 1993, Aust Fam Physician, V22, P1467; BENNET DR, 1994, DRUG EVALAUTION ANN, P272; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P94; BUDA M, 1988, ARCH GEN PSYCHIAT, V45, P283; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; FRITZ GK, 1987, AM J ORTHOPSYCHIAT, V57, P253, DOI 10.1111/j.1939-0025.1987.tb03535.x; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P257; MASCIA A V, 1974, Journal of Asthma Research, V12, P73, DOI 10.3109/02770907409098935; MASTERSON E, 1984, BRIT J PSYCHIAT, V145, P429, DOI 10.1192/bjp.145.4.429; MCFADDEN ER, 1994, PRINCIPLES INTERNAL, P1172; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MIETTINEN OS, 1989, J CLIN EPIDEMIOL, V42, P491, DOI 10.1016/0895-4356(89)90143-1; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; MORTENSEN PB, 1989, J EPIDEMIOL COMMUN H, V43, P43, DOI 10.1136/jech.43.1.43; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SAUGSTAD LF, 1979, ACTA PSYCHIAT SCAND, V59, P431; SHERMAN S, 1992, EMERGENCY MED COMPRE; SONIN L, 1984, ARCH INTERN MED, V144, P554, DOI 10.1001/archinte.144.3.554; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; TYRER PJ, 1980, DRUGS, V20, P300, DOI 10.2165/00003495-198020040-00004; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1; WEST R, 1987, AM J PREV MED S2, V4, P25; 1992, CLIN EXP ALLERGY S1, V22, P1; 1990, EGRET EPIDEMIOLOGICA, P289	29	54	56	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	1996	312	7023					79	82						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ168	8555932				2022-12-28	WOS:A1996TQ16800019
J	Newrick, DC; Spencer, JA; Jones, KP				Newrick, DC; Spencer, JA; Jones, KP			Collecting data in general practice: Need for standardisation	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Newrick, DC (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT PRIMARY HLTH CARE, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND.							PRINGLE M, 1991, BMJ-BRIT MED J, V302, P741, DOI 10.1136/bmj.302.6779.741; RECORD MC, 1994, BRIT MED J, V309, P849, DOI 10.1136/bmj.309.6958.849; SHANKS J, 1995, BRIT MED J, V310, P480, DOI 10.1136/bmj.310.6978.480; WILKINSON J, 1993, J PUBLIC HEALTH MED, V15, P342, DOI 10.1093/oxfordjournals.pubmed.a042887; WILSON A, 1989, J ROY COLL GEN PRACT, V39, P250	5	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					33	34		10.1136/bmj.312.7022.33	http://dx.doi.org/10.1136/bmj.312.7022.33			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP209	8555857	Green Published			2022-12-28	WOS:A1996TP20900023
J	Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN				Luo, LQ; Hensch, TK; Ackerman, L; Barbel, S; Jan, LY; Jan, YN			Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines	NATURE			English	Article							CALCIUM-BINDING PROTEIN; ELECTRON-MICROSCOPY; CEREBELLAR CORTEX; EXPRESSION; MOUSE; CLONING; BRAIN; GENE; MICE	Neurons contain distinct compartments including dendrites, dendritic spines, axons and synaptic terminals(1). The molecular mechanisms that generate and distinguish these compartments, although largely unknown, may involve the small GTPases Rac and Cdc42 (ref. 2), which appear to regulate actin polymerization(3). Having shown that perturbations of Rad activity block the growth of axons but not dendrites of Drosophila neurons(2), we investigated whether this also applies to mammals by examining transgenic mice expressing constitutively active human Rad in Purkinje cells. We found that these mice were ataxic and had a reduction of Purkinje-cell axon terminals in the deep cerebellar nuclei, whereas the dendritic trees grew to normal height and branched extensively. Unexpectedly, the dendritic spines of Purkinje cells in developing and mature cerebella were much reduced in size but increased in number. These 'mini' spines often form supernumerary synapses. These differential effects of perturbing Rac1 activity indicate that there may be distinct mechanisms for the elaboration of axons, dendrites and dendritic spines.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Luo, LQ (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Hensch, Takao/L-4182-2019	Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BERRY M, 1976, BRAIN RES, V112, P1, DOI 10.1016/0006-8993(76)90331-0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; FAIREN A, 1992, MICROSC RES TECHNIQ, V23, P289, DOI 10.1002/jemt.1070230405; GUENET JL, 1983, J HERED, V74, P105, DOI 10.1093/oxfordjournals.jhered.a109729; HALL AA, 1994, REV CELL BIOL, V10, P31; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HOGAN B, 1986, MANIPULATING MOUSE E; Ito M, 1984, CEREBELLUM NEURAL CO; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JANDE SS, 1981, NATURE, V294, P765, DOI 10.1038/294765a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MOLL J, 1991, ONCOGENE, V6, P863; OBERDICK J, 1993, NEURON, V10, P1007, DOI 10.1016/0896-6273(93)90050-2; Palay S. L., 1974, CEREBELLAR CORTEX CY; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; ROFFLERTARLOV S, 1979, BRAIN RES, V168, P75, DOI 10.1016/0006-8993(79)90129-X; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SOTELO C, 1990, J NEUROCYTOL, V19, P737, DOI 10.1007/BF01188042; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; WOOD TL, 1988, DNA-J MOLEC CELL BIO, V7, P585, DOI 10.1089/dna.1988.7.585	30	380	386	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					837	840		10.1038/379837a0	http://dx.doi.org/10.1038/379837a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587609				2022-12-28	WOS:A1996TX50100062
J	Moxham, CM; Malbon, CC				Moxham, CM; Malbon, CC			Insulin action impaired by deficiency of the G-protein subunit G(i alpha 2)	NATURE			English	Article							PHOSPHATASE-ACTIVITIES; PHOSPHORYLATION STATE; GLUCOSE-TRANSPORT; ANTISENSE RNA; DIABETIC RATS; PHOSPHOTYROSINE	Integration of information between tyrosine kinase(1) and G-protein-mediated pathways(2) is necessary, but remains poorly understood. Here we use cells from transgenic mice harbouring inducible expression of RNA antisense to the gene encoding G(i alpha 2) (refs 3, 4) to show that G(i alpha 2) is critical for insulin action. G(i alpha 2) deficiency in adipose tissue and liver produces hyperinsulinaemia, impaired glucose tolerance and resistance to insulin in vivo. Insulin resistance affects glucose-transporter activity and recruitment, counterregulation of lipolysis, and activation of glycogen synthase, all of which are cardinal responses to insulin(5). G(i alpha 2) deficiency increases protein-tyrosine phosphatase activity and attenuates insulin-stimulated tyrosine phosphorylation of IRS (insulin-receptor substrate 1) in vivo. G(i alpha 2) deficiency creates a model for the insulin resistance characteristic of noninsulin-dependent diabetes mellitus (NIDDM)(6), implicating G(i alpha 2) as a positive regulator of insulin action.			Moxham, CM (corresponding author), SUNY STONY BROOK,UNIV MED CTR,DEPT MOLEC PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794, USA.		malbon, craig/ABF-3604-2020					AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BOYLAN JM, 1992, J CLIN INVEST, V90, P174, DOI 10.1172/JCI115833; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; COHEN P, 1985, MOL BASIS INSULIN AC, P213; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOLEY JE, 1978, AM J PHYSIOL, V234, pE112, DOI 10.1152/ajpendo.1978.234.2.E112; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAWLER D, 1987, NATURE, V327, P224; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; KAMIELI E, 1981, J BIOL CHEM, V256, P4772; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; LAVAN BE, 1994, BIOCHEM SOC T, V22, P676, DOI 10.1042/bst0220676; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAURO LJ, 1993, ADV PROT PHOSPHATASE, V7, P393; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIELAND O, 1974, METHOD ENZYMAT AN, V3, P1404	30	181	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					840	844		10.1038/379840a0	http://dx.doi.org/10.1038/379840a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587610				2022-12-28	WOS:A1996TX50100063
J	Gilsdorf, JR				Gilsdorf, JR			Do you have a minute?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 7	1996	275	5					343	343						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT303	8568996				2022-12-28	WOS:A1996TT30300002
J	Baird, AG; Jewell, D; Walker, JJ				Baird, AG; Jewell, D; Walker, JJ			Management of labour in an isolated rural maternity hospital	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; DELIVERY; UNITS	Objectives-To evaluate the use of a maternity unit run by general practitioners and midwives, describing the outcome of labor in an unselected group of women and quantifying the contribution made by general practitioners. Design-Retrospective population based review of obstetric patients who had access to an isolated rural maternity unit. Setting-Rural area 120 km from a consultant maternity unit. Subjects-997 consecutive women delivered between January 1987 and May 1991. Main outcome measures-Mode of delivery and complications by place of booking and place of delivery; need for medical intervention and transfer. Results-530 women (53%) were booked for delivery in the rural unit; this group had a caesarean section rate of 3.8% and an unplanned transfer rate of 12.8% to the consultant unit in labour. Of the 462 who delivered in the low risk unit, 25 (5%) required a forceps delivery; postnatal complications requiring emergency medical support occurred in a further 33 (7%). Conclusions-Risk characterisation is possible, but medical support from general practitioners and obstetricians is required in almost a third of women at low risk for complications of delivery. Results of this study support the team approach to obstetric management but not the move towards isolated units without organised medical support.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LEEDS,ST JAMES HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TS,W YORKSHIRE,ENGLAND	University of Bristol; Saint James's University Hospital; University of Leeds	Baird, AG (corresponding author), WHITE HOUSE,SANDHEAD,STRANRAER DG9 9JA,WIGTOWN,SCOTLAND.		Baird, Gordon/AAN-8026-2020; Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Baird, Gordon/0000-0002-8803-6520; Walker, James/0000-0002-8922-083X				BROWN DJ, 1994, BRIT MED J, V309, P777, DOI 10.1136/bmj.309.6957.777; Bull M J, 1980, J R Coll Gen Pract, V30, P208; CAVENAGH AJM, 1984, BRIT MED J, V288, P1438, DOI 10.1136/bmj.288.6428.1438; HEMMINKI E, 1985, SCAND J SOC MED, V13, P113, DOI 10.1177/140349488501300308; LOWE SW, 1987, J ROY COLL GEN PRACT, V37, P484; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; ROSENBLATT RA, 1985, LANCET, V1, P429; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; TAYLOR GW, 1980, LANCET, V2, P1287; TUCKER J, 1994, J PUBLIC HEALTH MED, V16, P60, DOI 10.1093/oxfordjournals.pubmed.a042937; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; YOUNG G, 1990, BRIT MED J, V301, P665, DOI 10.1136/bmj.301.6753.665-b; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1990, BRIT MED J, V301, P983; 1993, CHANGING CHILDBIRT 1; 1994, 1988 90 DEP HLTH REP; 1993, PROVISION MATERNITY	19	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	1996	312	7025					223	226						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT486	8563590				2022-12-28	WOS:A1996TT48600030
J	Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV				Hsu, HL; Shu, HB; Pan, MG; Goeddel, DV			TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; KAPPA-B; EXPRESSION; ACTIVATION; PROTEINS; DOMAIN; ALPHA	Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1). TRADD is a TNFR1-associated signal transducer that is involved in activating both pathways. Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively. A TRAF2 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated NF-kappa B activation, but does not affect TNF-induced apoptosis. Conversely, a FADD mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit NF-kappa B activation. Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.			Hsu, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1994, J IMMUNOL, V152, P1751	45	1691	1778	0	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 26	1996	84	2					299	308		10.1016/S0092-8674(00)80984-8	http://dx.doi.org/10.1016/S0092-8674(00)80984-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TR595	8565075	Bronze			2022-12-28	WOS:A1996TR59500016
J	Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ				Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ			Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; GENE; IDENTIFICATION; THREONINE; TYROSINE; PROTEINS; FAMILIES; ENCODES	Mutants of the Saccharomyces cerevisiae ataxia telangiectasia mutated (ATM) homolog MEC1/SAD3/ESR1 were identified that could live only if the RAD53/SAD1 checkpoint kinase was overproduced. MEC1 and a structurally related gene, TEL1, have overlapping functions in response to DNA damage and replication blocks that in mutants can be provided by overproduction of RAD53. Both MEC1 and TEL1 were found to control phosphorylation of Rad53p in response to DNA damage. These results indicate that RAD53 is a signal transducer in the DNA damage and replication checkpoint pathways and functions downstream of two members of the ATM lipid kinase family. Because several members of this pathway are conserved among eukaryotes, it is likely that a RAD53-related kinase will function downstream of the human ATM gene product and play an important role in the mammalian response to DNA damage.	BAYLOR COLL MED, HOWARD HUGHES MED INST, DEPT MOLEC & HUMAN GENET, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute					NIDDK NIH HHS [DK07696] Funding Source: Medline; NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Allen JB, 1994, GENE DEV, V8, P2416; BENTLEY N, COMMUNICATION; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DESANY B, UNPUB; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GIETZ RD, 1994, MOL GENETICS YEAST P, pCH8; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MOORE CW, 1978, MUTAT RES, V51, P165, DOI 10.1016/S0027-5107(78)80016-5; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASIM A, 1977, CAN J GENET CYTOL, V19, P323, DOI 10.1139/g77-035; NASR F, 1994, CR ACAD SCI III-VIE, V317, P607; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; STACK JH, 1994, J BIOL CHEM, V269, P31552; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	36	538	549	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					357	360		10.1126/science.271.5247.357	http://dx.doi.org/10.1126/science.271.5247.357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553072				2022-12-28	WOS:A1996TQ52800043
J	Herendeen, DR; Kelly, TJ				Herendeen, DR; Kelly, TJ			DNA polymerase III: Running rings around the fork	CELL			English	Review							REPLICATION; HOLOENZYME; CLAMP				Herendeen, DR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; WU CA, 1992, J BIOL CHEM, V267, P4064; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAO N, 1996, IN PRESS GENES CELL	18	27	31	3	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					5	8		10.1016/S0092-8674(00)80069-0	http://dx.doi.org/10.1016/S0092-8674(00)80069-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548826	Bronze			2022-12-28	WOS:A1996TQ17000002
J	Berger, M; Jorgens, V; Flatten, G				Berger, M; Jorgens, V; Flatten, G			Health care for persons with non-insulin-dependent diabetes mellitus - The German experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			STRUCTURED TREATMENT; TEACHING PROGRAM	A structured treatment and education program for patients with non-insulin-dependent diabetes mellitus (NIDDM) who are not taking insulin was developed, evaluated, and implemented at the primary health care level throughout Germany. The program is based on the definition of individual and pragmatic therapeutic goals for each patient, primarily using nondrug treatment, which includes systematic glycosuria self-monitoring by the patients and four structured sessions of group education held in a general practitioner's office. After documentation of the program's efficacy in a randomized, controlled trial and several pilot projects, the program has been officially incorporated into the general German health care scheme and includes payment to practicing physicians for each patient treated. More than 12 500 primary health care physicians have participated in special 2-day postgraduate courses given by diabetologists; these courses are a precondition to participating in the program. As part of the primary health care scheme, the NIDDM program will be continuously monitored for quality control and efficiency. Currently, similar structured treatment and education programs targeted to primary health care physicians are being introduced for both insulin-treated NIDDM and arterial hypertension.	CENT INST AMBULATORY HLTH CARE, D-50931 COLOGNE, GERMANY		Berger, M (corresponding author), UNIV DUSSELDORF, DEPT METAB DIS & NUTR, WHO, COLLABORATING CTR DIABET, MOORENSTR 5, D-40225 DUSSELDORF, GERMANY.							BERGER M, 1991, CLIN DIABETES MELLIT, P341; BERGER M, 1994, DIABETES BEHANDLUNG; Bouchardat A., 1875, GLYCOSURIE DIABETE S; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GRUSSER M, 1992, DIABETES STOFFWECH H, V1, P229; JORGENS V, 1991, IDF B, V36, P22; KRONSBEIN P, 1988, LANCET, V2, P1407; MUHLHAUSER I, 1993, CLIN EXP HYPERTENS, V15, P125, DOI 10.3109/10641969309041615; RATZMANN KP, 1991, AKT ENDOKRIN STOFFW, V12, P220; RATZMANN KP, 1993, DIABETOLOGISCHE PRAX, P10; SAWICKI PT, 1993, J HUM HYPERTENS, V7, P571	11	31	33	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				153	155		10.7326/0003-4819-124-1_Part_2-199601011-00014	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554209				2022-12-28	WOS:A1996TL94400014
J	Colwell, JA				Colwell, JA			The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus - Implications of the veterans affairs cooperative study on glycemic control and complications in NIDDM	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			BEDTIME NPH INSULIN; CARDIOVASCULAR MORTALITY; RISK-FACTORS; SULFONYLUREA; GLYBURIDE; GLUCOSE; FAILURE; TRIAL; CELL	Objective: To review the results from the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM (VACSDM) and to discuss the implications of the results from this feasibility trial. Design: A randomized clinical trial comprising 153 men with non-insulin-dependent diabetes mellitus (NIDDM) who remained hyperglycemic on usual pharmacologic therapy. Patients were randomized into two groups receiving either standard or intensive insulin therapy and were followed for 27 months. Setting: Five Veterans Affairs medical centers. Patients: 153 men with NIDDM, aged 40 to 69 years, who had hemoglobin A(1c) (HbA(1c)) levels of greater than 6.55% while receiving sulfonylurea or insulin therapy. Intervention: Standard insulin therapy was one or two insulin injections daily. Intensive insulin therapy was done using a stepwise approach: 1) evening intermediate or long-acting insulin; 2) addition of daytime glipizide; 3) insulin twice daily, with no glipizide; and 4) insulin three to four times daily, with no glipizide. Measurements: Fasting blood glucose and HbA(1c) levels, retinopathy, lipid and urinary albumin levels, cardiovascular events, hypoglycemia, and body mass index. Results: In the intensive group, the HbA(1c) level fell 2.07 percentage points; the mean HbA(1c) level was 7.3% from 6 months onward. The standard group experienced little change. These changes occurred without significant weight gain and with a very low rate of severe hypoglycemia. Sixteen patients (20.5%) in the standard group and 24 patients (32%) in the intensive group had cardiovascular events (P = 0.1). Conclusions: It is feasible to achieve excellent glycemic control in men with NIDDM in whom standard pharmacologic therapy has failed. The benefit/risk ratio of intensive insulin management in this patient group is not established and has been made the subject of a long-term prospective clinical trial.	DEPT VET AFFAIRS, COOPERAT STUDIES PROGRAM, HINES, IL USA									ABRAIRA C, 1992, DIABETES CARE, V15, P1560, DOI 10.2337/diacare.15.11.1560; ABRAIRA C, 1995, IN PRESS DIABETES CA; COLWELL JA, 1994, DIABETES REV, V2, P277; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FIRTH RG, 1986, NEW ENGL J MED, V314, P1280, DOI 10.1056/NEJM198605153142003; GARVEY WT, 1985, DIABETES, V34, P222, DOI 10.2337/diabetes.34.3.222; GROOP L, 1987, DIABETES CARE, V10, P671, DOI 10.2337/diacare.10.6.671; GROOP LC, 1990, DIABETES CARE, V13, P47, DOI 10.2337/diacare.13.3.47; GROOP LC, 1992, DIABETES CARE, V15, P831, DOI 10.2337/diacare.15.7.831; HOLMAN RR, 1981, CLIN ENDOCRINOL, V14, P279, DOI 10.1111/j.1365-2265.1981.tb00196.x; JANKA HU, 1985, HORM METAB RES, V15, P15; JANKA HU, 1992, DIAB STOFFW, V1, P2; KLEIN R, 1987, AM J EPIDEMIOL, V126, P415, DOI 10.1093/oxfordjournals.aje.a114673; KROLEWSKI AS, 1991, AM J MED, V90, pS56, DOI 10.1016/0002-9343(91)90040-5; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MCMAHON M, 1989, DIABETES, V38, P291, DOI 10.2337/diabetes.38.3.291; MEINERT CL, 1970, DIABETES, V19, P789; RIDDLE MC, 1985, LANCET, V1, P192, DOI 10.1016/S0140-6736(85)92029-X; RIDDLE MC, 1990, DIABETES CARE, V13, P676, DOI 10.2337/diacare.13.6.676; RIDDLE MC, 1989, DIABETES CARE, V12, P623, DOI 10.2337/diacare.12.9.623; SEIGLER DE, 1987, DIABETOLOGIA, V30, pA581; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SONERU IL, 1993, DIABETES CARE, V16, P896, DOI 10.2337/diacare.16.6.896; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STOLAR MW, 1988, METABOLISM, V37, P1, DOI 10.1016/0026-0495(88)90180-1; TASKINEN MR, 1989, DIABETES, V38, P580, DOI 10.2337/diabetes.38.5.580; TRISCHITTA V, 1989, DIABETES CARE, V12, P582, DOI 10.2337/diacare.12.8.582; TURNER RC, 1991, DIABETOLOGIA, V34, P877; TURNER RC, 1985, DIABETES, V34, P793; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; VAGUE P, 1982, METABOLISM, V31, P139, DOI 10.1016/0026-0495(82)90125-1; 1982, DIABETES, V31, P14; 1970, DIABETES S2, V19, P747	34	60	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				131	135		10.7326/0003-4819-124-1_Part_2-199601011-00010	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554205				2022-12-28	WOS:A1996TL94400010
J	Harris, MI				Harris, MI			Medical care for patients with diabetes - Epidemiologic aspects	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			UNITED-STATES; BLOOD-GLUCOSE; COMPLICATIONS TRIAL; MELLITUS; ADULTS; INTERVENTIONS; RELIABILITY; INFORMATION; PHYSICIANS; BEHAVIORS	Objective: To describe the epidemiologic characteristics of physician care and self-care for adults with diabetes in the U.S. population. Design and Subjects: Data are drawn from the 1989 National Health Interview Survey, in which a personal household interview was administered to a representative sample of U.S. adults aged 18 years or older. The response rate was 96% (n = 84 572). All subjects identified as having diabetes previously diagnosed by a physician were asked a series of questions about their diabetes. Response rate for this representative sample of U.S. diabetic patients was 95% (n = 2405). Measurements: Self-reported information was obtained about various aspects of diabetes care, including care by physicians and self-care practices of the diabetic persons. Sociodemographic and clinical factors that may influence diabetes care were also determined. Results: More than 90% of diabetic adults had one physician for the usual care of their diabetes, but 32% made fewer than four visits to this physician each year. Most physician visits by diabetic patients were not made to diabetes specialists, and the visit rate to other health care professionals such as ophthalmologists, podiatrists, and nutritionists was low. About half of insulin-treated diabetic subjects used multiple daily insulin injections; and 40% of patients with insulin-dependent diabetes mellitus, 26% of those with non-insulin-dependent diabetes mellitus (NIDDM) who were taking insulin, and 5% of those with NIDDM who were not taking insulin monitored their blood glucose level daily. Diabetes patient education classes had been attended by 35% of diabetic adults. Conclusions: These and other data indicate that medical care for diabetic patients and their self-care practices may not be optimal for prevention of diabetes complications. The Diabetes Control and Complications Trial showed that achieving and maintaining near-normal glycemia, with a concomitant 50% to 70% reduction in diabetes complications, may require close monitoring and ongoing support from a health care team, ample financial resources, and advanced patient knowledge and motivation. Providing this level of diabetes management to all diabetic persons may require major changes in the health care system and in patient self-care practices.			Harris, MI (corresponding author), NIDDKD, NATCHER BLDG, ROOM 5AN24, 45 CTR DR, MSC 6600, BETHESDA, MD 20892 USA.							ADAMS PF, 1990, VITAL HLTH STAT, V176, P1; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; BRANSOME ED, 1992, DIABETES CARE, V15, P1; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BROWN SA, 1990, PATIENT EDUC COUNS, V16, P189, DOI 10.1016/0738-3991(90)90070-2; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Cochran WG, 1977, SAMPLING TECHNIQUES, P319; COONROD BA, 1994, DIABETES CARE, V17, P852, DOI 10.2337/diacare.17.8.852; COWIE CC, 1995, NIH951468 US DEP HLT, P541; DUDL RJ, 1982, DIABETES CARE, V5, P649, DOI 10.2337/diacare.5.6.649; EASTMAN RC, 1993, J CLIN ENDOCR METAB, V77, P1105, DOI 10.1210/jc.77.5.1105; EASTMAN RC, 1993, DIABETES CARE, V16, P1095, DOI 10.2337/diacare.16.8.1095; GONDERFREDERICK LA, 1988, DIABETES CARE, V11, P579, DOI 10.2337/diacare.11.7.579; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GUTHRIE RA, 1991, AM FAM PHYSICIAN, V43, P570; HARRIS MI, 1994, DIABETES CARE, V17, P585, DOI 10.2337/diacare.17.6.585; HARRIS MI, 1994, DIABETES CARE, V17, P761, DOI 10.2337/diacare.17.7.761; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; HARRIS MI, 1994, DIABETES CARE, V17, P1337, DOI 10.2337/diacare.17.11.1337; HARRIS MI, 1990, DIABETES CARE, V13, P419, DOI 10.2337/diacare.13.4.419; HELIOVAARA M, 1993, J CLIN EPIDEMIOL, V46, P181, DOI 10.1016/0895-4356(93)90056-7; Janes GR, 1995, NIH PUBLICATION, P541; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; LASKER RD, 1993, NEW ENGL J MED, V329, P1035, DOI 10.1056/NEJM199309303291410; MIDTHJELL K, 1992, J EPIDEMIOL COMMUN H, V46, P537, DOI 10.1136/jech.46.5.537; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PEYROT M, 1988, DIABETES S1, V37, pA53; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAH BV, 1984, SESUDAAN STANDARD ER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEBERT C, 1993, DIABETES CARE, V16, P759, DOI 10.2337/diacare.16.5.759; SONGER TJ, 1992, DIABETES CARE, V15, P15, DOI 10.2337/diacare.15.1.S15; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; 1993, DIABETES CARE, V16, P113; 1995, DIABETES CARE S1, V18, P1	39	82	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				117	122		10.7326/0003-4819-124-1_Part_2-199601011-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554202				2022-12-28	WOS:A1996TL94400007
J	Hay, BA; Wassarman, DA; Rubin, GM				Hay, BA; Wassarman, DA; Rubin, GM			Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ZINC-FINGER; GENE; EYE; EXPRESSION; ROUGH; DIVERSITY; P35-GENE; MOTIF	Apoptotic cell death is a mechanism by which organisms eliminate superfluous or harmful cells. Expression of the cell death regulatory protein REAPER (RPR) in the developing Drosophila eye results in a small eye owing to excess cell death. We show that mutations in thread (th) are dominant enhancers of RPR-induced cell death and that th encodes a protein homologous to baculovirus inhibitors of apoptosis (IAPs), which we call Drosophila IAP1 (DIAP1). Overexpression of DIAP1 or a related protein, DIAP2, in the eye suppresses normally occurring cell death as well as death due to overexpression of rpr or head in volution defective. IAP death-preventing activity localizes to the N-terminal baculovirus IAP repeats, a motif found in both viral and cellular proteins associated with death prevention.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	Hay, BA (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; ELLIS MC, 1993, DEVELOPMENT, V119, P855; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GOMBART AF, 1989, J GEN VIROL, V70, P1815, DOI 10.1099/0022-1317-70-7-1815; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOLFF T, 1991, DEVELOPMENT, V113, P825; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	53	617	636	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1253	1262		10.1016/0092-8674(95)90150-7	http://dx.doi.org/10.1016/0092-8674(95)90150-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548811	Bronze			2022-12-28	WOS:A1995TM76200020
J	Fazel, M				Fazel, M			Now show me your tongue: A taste of medicine in China	LANCET			English	Editorial Material											Fazel, M (corresponding author), LINCOLN COLL,OXFORD OX1 3DR,ENGLAND.			Fazel, Mina/0000-0001-9342-2365				WILSON A, 1991, BRIT J GEN PRACT, V41, P119	1	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1687	1688		10.1016/S0140-6736(95)92847-2	http://dx.doi.org/10.1016/S0140-6736(95)92847-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551831				2022-12-28	WOS:A1995TL42300017
J	Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT				Bhatia, S; Robison, LL; Oberlin, O; Greenberg, M; Bunin, G; FossatiBellani, F; Meadows, AT			Breast cancer and other second neoplasms after childhood Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							2ND MALIGNANT NEOPLASMS; FOLLOW-UP; ALKYLATING-AGENTS; ACUTE-LEUKEMIA; INCREASED RISK; THERAPY; CHEMOTHERAPY; SPLENECTOMY; RADIOTHERAPY; IRRADIATION	Background. Patients who survive Hodgkin's disease are at increased risk for second neoplasms, As survival times increase, solid tumors are emerging as a serious long-term complication. Methods. The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to deter mine the incidence of second neoplasms and the risk factors associated with them. Results. In this cohort, there were 88 second neoplasms as compared with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidence interval, 14.3 to 22.3), The estimated actuarial incidence of any second neoplasm 15 years after the diagnosis of Hodgkin's disease was 7.0 percent (95 percent confidence interval, 5.2 to 8.8 percent); the incidence of solid tumors was 3.9 percent (95 percent confidence interval, 2.3 to 5.5 percent), Breast cancer was the most common solid tumor (standardized incidence ratio, 75.3; 95 percent confidence interval, 44.9 to 118.4), with an estimated actuarial incidence in women that approached 35 percent (95 percent confidence interval, 17.4 to 52.6 percent) by 40 years of age, Older age (10 to 16 vs, <10 years) at the time of radiation treatment (relative risk, 1.9) and a higher dose (2000 to 4000 vs, <2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer, The estimated actuarial incidence of leukemia reached a plateau of 2.8 percent (95 percent confidence interval, 0.8 to 4.8 percent) 14 years after diagnosis. Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia. Conclusions. The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. Systematic screening for breast cancer could be important in the health care of such women. (C) 1996, Massachusetts Medical Society.	UNIV MINNESOTA, DEPT PEDIAT, DIV PEDIAT EPIDEMIOL & CLIN RES, MINNEAPOLIS, MN 55455 USA; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; NATL TUMOR INST, MILAN, ITALY	University of Minnesota System; University of Minnesota Twin Cities; UNICANCER; Gustave Roussy; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018					ABRAHAMSEN JF, 1993, J CLIN ONCOL, V11, P255, DOI 10.1200/JCO.1993.11.2.255; ANDRIEU JM, 1990, J CLIN ONCOL, V8, P1148, DOI 10.1200/JCO.1990.8.7.1148; ARSENEAU JC, 1972, NEW ENGL J MED, V287, P1119, DOI 10.1056/NEJM197211302872204; BARAL E, 1977, CANCER, V40, P2905, DOI 10.1002/1097-0142(197712)40:6<2905::AID-CNCR2820400621>3.0.CO;2-Y; BEATY O, 1995, J CLIN ONCOL, V13, P603, DOI 10.1200/JCO.1995.13.3.603; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1979, RADIOLOGY, V131, P589, DOI 10.1148/131.3.589; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; CANELLOS GP, 1975, LANCET, V1, P947; CIMINO G, 1991, J CLIN ONCOL, V9, P432, DOI 10.1200/JCO.1991.9.3.432; Coleman C. N., 1982, CANCER SURV, V1, P733; COLTMAN CA, 1982, CANCER TREAT REP, V66, P1023; CURTIS RE, 1988, NEW ENGL J MED, V319, P244; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; GREENE MH, 1985, 852714 NIH PUBL, P191; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HORNING SJ, 1981, NEW ENGL J MED, V304, P1377, DOI 10.1056/NEJM198106043042301; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOLETSKY AJ, 1986, J CLIN ONCOL, V4, P311, DOI 10.1200/JCO.1986.4.3.311; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; MILLER BA, 1993, 932789 NIH PUBL; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; RODRIGUEZ MA, 1993, ANN ONCOL, V4, P125, DOI 10.1093/oxfordjournals.annonc.a058414; ROSENBERG SA, 1985, INT J RADIAT ONCOL, V11, P5, DOI 10.1016/0360-3016(85)90357-8; SHERINS RJ, 1973, ANN INTERN MED, V79, P216, DOI 10.7326/0003-4819-79-2-216; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STORM HH, 1985, 852714 NIH PUBL, P389; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERVELDEN JW, 1988, INT J CANCER, V42, P252, DOI 10.1002/ijc.2910420218; VANLEEUWEN FE, 1987, LANCET, V2, P210; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P312, DOI 10.1200/JCO.1994.12.2.312	44	674	685	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1996	334	12					745	751		10.1056/NEJM199603213341201	http://dx.doi.org/10.1056/NEJM199603213341201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ979	8592547				2022-12-28	WOS:A1996TZ97900001
J	Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E				Bradley, D; Carpenter, R; Copsey, L; Vincent, C; Rothstein, S; Coen, E			Control of inflorescence architecture in Antirrhinum	NATURE			English	Article							FLOWER DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; GENE; MAJUS; TRANSPOSON; MUTATIONS; MERISTEM; CLONING; LOCUS	Flowering plants exhibit two types of inflorescence architecture: determinate and indeterminate. The centroradialis mutation causes the normally indeterminate inflorescence of Antirrhinum to terminate in a flower. We show that centroradialis is expressed in the inflorescence apex a few days after floral induction, and interacts with the floral-meristemidentity gene floricaula to regulate flower position and morphology. The protein CEN is similar to animal proteins that associate with lipids and GTP-binding proteins. We propose a model for how different inflorescence structures may arise through the action and evolution of centroradialis.			Bradley, D (corresponding author), JOHN INNES CTR,DEPT GENET,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Rothstein, Steven J/A-4947-2013	Rothstein, Steven J/0000-0003-0737-1878				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRADLEY D, IN PRESS DEVELOPMENT; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN EA, 1991, REV PL PHYSL PL MOL, V42, P241; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COEN ES, 1994, DEVELOPMENT, P107; COEN ES, 1989, MOBILE DNA, P413; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Hammer K., 1990, Kulturpflanze, V38, P91; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Keeble F, 1910, NEW PHYTOL, V9, P68, DOI DOI 10.1111/J.1469-8137.1910.TB05554.X; KUCKUCK H, 1930, INDUKT ABSTANIM VERE, V51, P51; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; TRIPP ML, 1989, MOL MICROBIOL, V3, P1319, DOI 10.1111/j.1365-2958.1989.tb00113.x; Weberling F, 1989, MORPHOLOGY FLOWERS I; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	34	322	357	4	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 29	1996	379	6568					791	797		10.1038/379791a0	http://dx.doi.org/10.1038/379791a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX501	8587601				2022-12-28	WOS:A1996TX50100048
J	Nightingale, SL				Nightingale, SL			New Reporting requirements for device user facilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5611 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	1996	275	8					585	585		10.1001/jama.275.8.585	http://dx.doi.org/10.1001/jama.275.8.585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW627	8594230				2022-12-28	WOS:A1996TW62700030
J	NobenTrauth, N; Kropf, P; Muller, I				NobenTrauth, N; Kropf, P; Muller, I			Susceptibility to Leishmania major infection in interleukin-4-deficient mice	SCIENCE			English	Article							MURINE LEISHMANIASIS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; BALB/C MOUSE; IFN-GAMMA; T-CELLS; IL-4; TH2; GROWTH; INTERLEUKIN-10	Interleukin-4 (IL-4), a pleiotropic cytokine, is a major regulator of the immune system and is considered crucial for the development of T helper cell type 2 (T(H)2) responses. The susceptibility of BALB/c mice to infection with Leishmania major has been associated with a polarized T(H)2 response and an inability to down-modulate IL-4 production. The role of IL-4 in vivo was examined directly by disrupting the IL-4 gene in BALB/c embryonic stem cells. Despite the absence of IL-4, the genetically pure BALB/c mutant mice remained susceptible to L. major infection, Showed no signs of lesion healing or parasite clearance, and did not switch to a T(H)1 phenotype.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory	NobenTrauth, N (corresponding author), UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA.				NIAID NIH HHS [1R29 AI37636-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037636] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARTER KC, 1989, EUR J IMMUNOL, V19, P779, DOI 10.1002/eji.1830190432; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DING A, 1990, J IMMUNOL, V145, P940; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GERLING IC, 1994, MAMM GENOME, V5, P318, DOI 10.1007/BF00389549; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HJULSTROM S, 1995, EUR J IMMUNOL, V25, P1469, DOI 10.1002/eji.1830250552; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEZAMADAVILA CM, 1992, PARASITE IMMUNOL, V14, P37, DOI 10.1111/j.1365-3024.1992.tb00004.x; LIEW FY, 1989, IMMUNOL TODAY, V10, P40, DOI 10.1016/0167-5699(89)90302-2; LIEW FY, 1993, ADV PARASIT, V32, P162; LOCKSLEY RM, 1991, IMMUNOPARASITOL TOD, pA58, DOI 10.1016/S0167-5699(05)80017-9; MOCK B, 1993, EUR J IMMUNOGENET, V20, P335, DOI 10.1111/j.1744-313X.1993.tb00153.x; MORAWETZ RA, 1994, SCIENCE, V265, P264, DOI 10.1126/science.8023146; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; NABORS GS, 1994, INFECT IMMUN, V62, P5498, DOI 10.1128/IAI.62.12.5498-5504.1994; NACY CA, 1991, RES IMMUNOL, V142, P573, DOI 10.1016/0923-2494(91)90105-R; NOBENTRAUTH N, IN PRESS TRANSGENIC; NOBENTRAUTH N, UNPUB; OSWALD IP, 1992, J IMMUNOL, V148, P3578; POWRIE F, 1993, EUR J IMMUNOL, V23, P2223, DOI 10.1002/eji.1830230926; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1989, EXP PARASITOL, V68, P369, DOI 10.1016/0014-4894(89)90120-3; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SLADE SJ, 1989, IMMUNOBIOLOGY, V179, P353, DOI 10.1016/S0171-2985(89)80041-5; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0	44	258	260	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	1996	271	5251					987	990		10.1126/science.271.5251.987	http://dx.doi.org/10.1126/science.271.5251.987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV704	8584936				2022-12-28	WOS:A1996TV70400049
J	Goodgame, RW				Goodgame, RW			Understanding intestinal spore-forming protozoa: Cryptosporidia, Microsporidia, Isospora, and Cyclospora	ANNALS OF INTERNAL MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; AIDS PATIENTS; TRAVELERS DIARRHEA; BELLI INFECTION; DIAGNOSTIC METHODS; STOOL SPECIMENS; HIV-INFECTION; SMALL-BOWEL; LIFE-CYCLE	Objectives: To summarize recent information about the ''new'' gastrointestinal protozoal pathogens (cryptosporidia, microsporidia, isospora, and cyclospora) and to help practicing clinicians integrate this information into their clinical databases by emphasizing the similarities among these organisms. Data Sources: Relevant English-language articles published between 1988 and 1995 were identified through a MEDLINE search done using the names of the intestinal spore-forming protozoa. Articles cited in the bibliographies of these and other articles were searched manually. Study Selection: Studies that contained information on the history, taxonomy, life cycle, epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of the pathogens were reviewed. Data Extraction: Cryptosporidium parvum, Isospora belli, Cyclospora cayetanensis, Enterocytozoon bieneusi, and Septata intestinalis are intestinal spore-forming protozoa that cause intracellular infections, predominantly in the epithelial cells of the intestine. They are transmitted either by stool from person to person or through contaminated water or food by an infectious particle called a spore or oocyst. Asymptomatic infections occur; the most common symptom of infection is diarrhea. Infections have been associated with intestinal inflammation, disordered architecture (such as villus blunting), and abnormal function (for example, malabsorption). Mild to moderate, self-limited diarrhea is common in healthy persons, but patients with immune dysfunction can have severe intestinal injury and prolonged diarrhea. Diagnosis is made by a microscopic examination of the stool and the use of appropriate staining techniques. Effective antibiotic treatment for prolonged infection in immunocompromised patients is available for most of these infections. Conclusions: The intestinal spore-forming protozoa are four frequently identified gastrointestinal pathogens that have important similarities in epidemiology, disease pathogenesis, clinical manifestations, diagnosis, and treatment.	BEN TAUB GEN HOSP, HOUSTON, TX 77030 USA		Goodgame, RW (corresponding author), BAYLOR COLL MED, 1 BAYLOR PLAZA, ROOM 525-D, HOUSTON, TX 77030 USA.							ADAMS RB, 1994, J INFECT DIS, V169, P170, DOI 10.1093/infdis/169.1.170; ALPERT G, 1986, PEDIATRICS, V77, P152; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; ARGENZIO RA, 1994, GASTROENTEROLOGY, V106, P1418, DOI 10.1016/0016-5085(94)90393-X; ARGENZIO RA, 1990, GASTROENTEROLOGY, V98, P1129, DOI 10.1016/0016-5085(90)90325-U; ARGENZIO RA, 1993, GASTROENTEROLOGY, V104, P440, DOI 10.1016/0016-5085(93)90412-6; ARMITAGE K, 1992, ARCH INTERN MED, V152, P2497, DOI 10.1001/archinte.152.12.2497; ARROWOOD MJ, 1989, J CLIN MICROBIOL, V27, P1490, DOI 10.1128/JCM.27.7.1490-1495.1989; ASHFORD RW, 1979, ANN TROP MED PARASIT, V73, P497, DOI 10.1080/00034983.1979.11687291; ASMUTH DM, 1994, CLIN INFECT DIS, V18, P819, DOI 10.1093/clinids/18.5.819; BEAUGERIE L, 1992, ANN INTERN MED, V117, P401, DOI 10.7326/0003-4819-117-5-401; BEAUVAIS B, 1993, ANN TROP MED PARASIT, V87, P99, DOI 10.1080/00034983.1993.11812742; BENATOR DA, 1994, ANN INTERN MED, V121, P663, DOI 10.7326/0003-4819-121-9-199411010-00006; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BENHAMOU Y, 1993, DIGEST DIS SCI, V38, P1113, DOI 10.1007/BF01295729; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; BIRD RG, 1980, J PATHOL, V132, P217, DOI 10.1002/path.1711320304; BISSUEL F, 1994, CLIN INFECT DIS, V18, P447, DOI 10.1093/clinids/18.3.447; BLANSHARD C, 1992, Q J MED, V85, P813; BRANDBORG LL, 1970, NEW ENGL J MED, V283, P1306, DOI 10.1056/NEJM197012102832403; BRYAN RT, 1993, ARCH PATHOL LAB MED, V117, P1243; CALI A, 1993, J EUKARYOT MICROBIOL, V40, P101, DOI 10.1111/j.1550-7408.1993.tb04889.x; CASEMORE DP, 1985, J CLIN PATHOL, V38, P1321, DOI 10.1136/jcp.38.12.1321; CHANDRASEKAR PH, 1987, AM J MED, V83, P187, DOI 10.1016/0002-9343(87)90524-9; CIANCIO MJ, 1992, ANN NY ACAD SCI, V664, P210, DOI 10.1111/j.1749-6632.1992.tb39762.x; CLEZY K, 1991, AIDS, V5, P1146, DOI 10.1097/00002030-199109000-00020; COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; CORDELL RL, 1994, PEDIATR INFECT DIS J, V13, P310, DOI 10.1097/00006454-199404000-00012; COTTE L, 1993, J ACQ IMMUN DEF SYND, V6, P1024; COZON G, 1994, J INFECT DIS, V169, P696, DOI 10.1093/infdis/169.3.696; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; CURRENT WL, 1994, ANN INTERN MED, V120, P518, DOI 10.7326/0003-4819-120-6-199403150-00012; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DESPORTES I, 1985, J PROTOZOOL, V32, P250; DIETERICH DT, 1994, J INFECT DIS, V169, P178, DOI 10.1093/infdis/169.1.178; DOBBINS WO, 1985, GASTROENTEROLOGY, V88, P738, DOI 10.1016/0016-5085(85)90145-3; Fang G, 1991, Infect Dis Clin North Am, V5, P681; FAUST EC, 1961, AM J TROP MED HYG, V10, P343, DOI 10.4269/ajtmh.1961.10.343; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; FICHTENBAUM CJ, 1993, CLIN INFECT DIS, V16, P298, DOI 10.1093/clind/16.2.298; FIELD AS, 1993, MED J AUSTRALIA, V158, P390, DOI 10.5694/j.1326-5377.1993.tb121832.x; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; GARCIA LS, 1983, J CLIN MICROBIOL, V18, P185, DOI 10.1128/JCM.18.1.185-190.1983; GATHE J, 1990, AIDS 90S SCI POLICY, P384; GENTA RM, 1993, GASTROENTEROLOGY, V105, P1769, DOI 10.1016/0016-5085(93)91075-S; GLASER CA, 1994, CLIN INFECT DIS, V18, P14, DOI 10.1093/clinids/18.1.14; GODIWALA T, 1987, ANN INTERN MED, V106, P908, DOI 10.7326/0003-4819-106-6-908_2; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; GOODGAME RW, 1993, J INFECT DIS, V167, P704, DOI 10.1093/infdis/167.3.704; GOODGAME RW, 1995, GASTROENTEROLOGY, V108, P1075, DOI 10.1016/0016-5085(95)90205-8; GREENBERG RE, 1989, GASTROENTEROLOGY, V97, P1327, DOI 10.1016/0016-5085(89)91708-3; GRIFFITHS JK, 1994, INFECT IMMUN, V62, P4506, DOI 10.1128/IAI.62.10.4506-4514.1994; GRIGORIEW GA, 1994, DIAGN MICR INFEC DIS, V19, P89, DOI 10.1016/0732-8893(94)90118-X; GROSS TL, 1986, AM J GASTROENTEROL, V81, P456; GUARINO A, 1995, J INFECT DIS, V171, P976, DOI 10.1093/infdis/171.4.976; GUARINO A, 1994, GASTROENTEROLOGY, V106, P28, DOI 10.1016/S0016-5085(94)94093-2; HENDERSON HE, 1963, AM J HYG, V78, P302, DOI 10.1093/oxfordjournals.aje.a120349; HINNANT K, 1989, AM J SURG PATHOL, V13, P57, DOI 10.1097/00000478-198901000-00008; HINTERLEITNER TA, 1991, P SOC EXP BIOL MED, V197, P249; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; HOGE CW, 1993, NEW ENGL J MED, V329, P1504, DOI 10.1056/NEJM199311113292019; HUANG P, 1995, ANN INTERN MED, V123, P409, DOI 10.7326/0003-4819-123-6-199509150-00002; JACYNA MR, 1990, GUT, V31, P714, DOI 10.1136/gut.31.6.714; JANOFF EN, 1990, ANN INTERN MED, V112, P75, DOI 10.7326/0003-4819-112-1-75; JEFFERY GM, 1958, AM J HYG, V67, P251, DOI 10.1093/oxfordjournals.aje.a119931; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; JOHNSTON AM, 1990, LANCET, V336, P856, DOI 10.1016/0140-6736(90)92350-Q; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; JURANEK DD, 1995, CLIN INFECT DIS, V21, pS57, DOI 10.1093/clinids/21.Supplement_1.S57; KAPEMBWA MS, 1990, J INFECTION, V21, P43, DOI 10.1016/0163-4453(90)90623-G; KIRKPATRICK CE, 1988, J INFECT DIS, V158, P909, DOI 10.1093/infdis/158.4.909a; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; KOTLER DP, 1994, AM J GASTROENTEROL, V89, P1998; KOTLER DP, 1990, ANN INTERN MED, V113, P444; KOTLER DP, 1993, J CLIN GASTROENTEROL, V16, P10, DOI 10.1097/00004836-199301000-00005; KUHLS TL, 1994, CLIN INFECT DIS, V18, P731, DOI 10.1093/clinids/18.5.731; LASSER KH, 1979, HUM PATHOL, V10, P234, DOI 10.1016/S0046-8177(79)80012-X; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LAXER MA, 1990, AM J TROP MED HYG, V42, P131, DOI 10.4269/ajtmh.1990.42.131; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; MA P, 1985, NEW ENGL J MED, V312, P647; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; MALEBRANCHE R, 1983, LANCET, V2, P873; MCANULTY JM, 1994, JAMA-J AM MED ASSOC, V272, P1597, DOI 10.1001/jama.272.20.1597; MEAD JR, 1988, J PARASITOL, V74, P135, DOI 10.2307/3282489; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MILLER FH, 1971, AM J TROP MED HYG, V20, P23, DOI 10.4269/ajtmh.1971.20.23; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; MOLBAK K, 1994, PARASITE IMMUNOL, V16, P275, DOI 10.1111/j.1365-3024.1994.tb00349.x; MOLBAK K, 1994, AM J EPIDEMIOL, V139, P734, DOI 10.1093/oxfordjournals.aje.a117064; MOLINA JM, 1995, J INFECT DIS, V171, P245, DOI 10.1093/infdis/171.1.245; MORALES MAG, 1992, J INFECTION, V25, P229, DOI 10.1016/0163-4453(92)94219-N; MORALES MAG, 1995, J INFECT DIS, V172, P211, DOI 10.1093/infdis/172.1.211; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; OOI WW, 1995, J CLIN MICROBIOL, V33, P1267, DOI 10.1128/JCM.33.5.1267-1269.1995; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1994, ANN INTERN MED, V120, P973, DOI 10.7326/0003-4819-120-11-199406010-00021; ORENSTEIN JM, 1991, J PARASITOL, V77, P843, DOI 10.2307/3282733; ORENSTEIN JM, 1992, HUM PATHOL, V23, P722, DOI 10.1016/0046-8177(92)90339-5; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Pape J W, 1991, Prog Clin Parasitol, V2, P119; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; Peng C Y, 1991, J Formos Med Assoc, V90, P260; PETERSEN C, 1993, J INFECT DIS, V15, P903; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; POWELL D, 1995, TXB GASTROENTEROLOGY, P820; POWELL DW, 1994, GASTROENTEROLOGY, V106, P1705, DOI 10.1016/0016-5085(94)90430-8; RABENECK L, 1993, ANN INTERN MED, V119, P895, DOI 10.7326/0003-4819-119-9-199311010-00005; RABENECK L, 1994, ANN INTERN MED, V120, P973, DOI 10.7326/0003-4819-120-11-199406010-00022; REESE NC, 1982, AM J TROP MED HYG, V31, P226, DOI 10.4269/ajtmh.1982.31.226; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; ROBERTS WG, 1989, AM J MED, V87, P537, DOI 10.1016/S0002-9343(89)80610-2; SALLON S, 1988, AM J DIS CHILD, V142, P312, DOI 10.1001/archpedi.1988.02150030086027; SANDFORT J, 1994, CLIN INFECT DIS, V19, P514, DOI 10.1093/clinids/19.3.514; SAUDA FC, 1993, J PARASITOL, V79, P454, DOI 10.2307/3283588; SCAGLIA M, 1994, J INFECT DIS, V170, P1349, DOI 10.1093/infdis/170.5.1349; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SCHNEIDERMAN DJ, 1987, ANN INTERN MED, V106, P546, DOI 10.7326/0003-4819-106-4-546; SEARS CL, 1994, GASTROENTEROLOGY, V106, P252, DOI 10.1016/S0016-5085(94)95891-2; SEWANKAMBO N, 1987, AIDS, V1, P9; SHADDUCK JA, 1993, ARCH PATHOL LAB MED, V117, P1215; SHAFFER N, 1989, J INFECT DIS, V159, P596, DOI 10.1093/infdis/159.3.596; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SLEIGH M, 1992, PARASITIC PROTOZOA, V1, P1; SLOPER KS, 1982, GUT, V23, P80, DOI 10.1136/gut.23.1.80; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SOAVE R, 1986, CLIN RES, V34, pA533; SOAVE R, 1985, ARCH INTERN MED, V145, P70, DOI 10.1001/archinte.145.1.70; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; SOGNI P, 1990, GASTROENTEROLOGY, V99, P602, DOI 10.1016/0016-5085(90)91057-D; STERLING C, 1993, PARASITIC PROTOZOA, V6, P156; STERLING CR, 1993, NEW ENGL J MED, V329, P1505; Topazian M, 1994, Gastroenterologist, V2, P147; TRIER JS, 1974, GASTROENTEROLOGY, V66, P923; TZIPORI S, 1986, BRIT MED J, V293, P1276, DOI 10.1136/bmj.293.6557.1276; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1988, J INFECT DIS, V157, P551, DOI 10.1093/infdis/157.3.551; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; VANGOOL T, 1993, J CLIN PATHOL, V46, P694, DOI 10.1136/jcp.46.8.694; VUORIO AF, 1991, REV INFECT DIS, V13, P261; WEBER R, 1992, AM REV RESPIR DIS, V146, P1603, DOI 10.1164/ajrccm/146.6.1603; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; WEBER R, 1994, CLIN INFECT DIS, V19, P342, DOI 10.1093/clinids/19.2.342; WEBER R, 1994, CLIN INFECT DIS, V19, P517, DOI 10.1093/clinids/19.3.517; WEBER R, 1991, J CLIN MICROBIOL, V29, P1323, DOI 10.1128/JCM.29.7.1323-1327.1991; WEBER R, 1994, CLIN MICROBIOL REV, V7, P426, DOI 10.1128/CMR.7.4.426-461.1994; WEISBURGER WR, 1979, AM J CLIN PATHOL, V72, P473; WESTERMAN EL, 1979, ANN INTERN MED, V91, P413; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419; WILLSON R, 1995, GASTROENTEROLOGY, V108, P247, DOI 10.1016/0016-5085(95)90031-4; WITTNER M, 1993, INFECT DIS CLIN N AM, V7, P569; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; WUHIB T, 1994, J INFECT DIS, V170, P494, DOI 10.1093/infdis/170.2.494; WURTZ R, 1994, CLIN INFECT DIS, V18, P620, DOI 10.1093/clinids/18.4.620; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; ZAR F, 1985, J INFECT DIS, V151, P195, DOI 10.1093/infdis/151.1.195; 1991, MMWR-MORBID MORTAL W, V40, P325	170	124	137	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1996	124	4					429	441		10.7326/0003-4819-124-4-199602150-00008	http://dx.doi.org/10.7326/0003-4819-124-4-199602150-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV220	8554253				2022-12-28	WOS:A1996TV22000008
J	Schultz, CH; Koenig, KL; Noji, EK				Schultz, CH; Koenig, KL; Noji, EK			Current concepts - A medical disaster response to reduce immediate mortality after an earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							7.5-PERCENT SODIUM-CHLORIDE; MULTICENTER TRIAL; 1980 EARTHQUAKE; RESUSCITATION; MANAGEMENT; SHOCK; EMERGENCY; SEDATION; RESCUE		UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; UNIV CALIF SAN FRANCISCO, ALAMEDA CTY MED CTR, DEPT EMERGENCY MED, SAN FRANCISCO, CA USA; CTR DIS CONTROL & PREVENT, DIV ENVIRONM HAZARDS & HLTH EFFECTS, ATLANTA, GA 30341 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Schultz, CH (corresponding author), UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, DEPT EMERGENCY MED, 1000 W CARSON ST, TORRANCE, CA 90509 USA.							ARNOLD C, 1983, HOSPITALS SAN FERNAN; ATKINSON W, 1989, NEXT NEW MADRID EART, P7; BARBERA JA, 1991, CRIT CARE CLIN, V7, P321, DOI 10.1016/S0749-0704(18)30308-7; BENSON M, IN PRESS PREHOSP DIS; BETTER OS, 1990, NEW ENGL J MED, V322, P825; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BORDEN F, 1994, NORTHRIDGE EARTHQUAK; BOWSER BH, 1983, J TRAUMA, V23, P916, DOI 10.1097/00005373-198310000-00013; CHEU DH, 1995, NORTHRIDGE EARTHQUAK; COBURN A, 1992, EARTHQUAKE PROTECTIO, P2; DEBRUYCKER M, 1985, INT J EPIDEMIOL, V14, P113, DOI 10.1093/ije/14.1.113; DEBRUYCKER M, 1983, B WORLD HEALTH ORGAN, V61, P1021; DEGOYET CD, 1977, EMERG PLANN DIG, V4, P2; DERHEIDE E, 1989, DISASTER RESPONSE PR, P111; Durkin ME, 1992, EARTHQ SPECTRA, V8, P95, DOI DOI 10.1193/1.1585672; ESTESS PA, 1990, PUBLICATION JOINT CO, V2, P21; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; HALBERT RJ, 1988, ANN EMERG MED, V17, P779, DOI 10.1016/S0196-0644(88)80551-1; HALBERT RJ, 1988, ANN EMERG MED, V17, P775, DOI 10.1016/S0196-0644(88)80550-X; Irwin R. L., 1989, DISASTER RESPONSE PR, P133; JOHANSEN K, 1990, J TRAUMA, V30, P568, DOI 10.1097/00005373-199005000-00007; KERR RA, 1995, SCIENCE, V267, P176, DOI 10.1126/science.267.5195.176; KOENIG KL, 1992, ANN EMERG MED, V21, P929, DOI 10.1016/S0196-0644(05)82930-0; KOHLENBERGER C, 1994, JAMA-J AM MED ASSOC, V271, P1200; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Moore R E 3rd, 1989, J Emerg Med, V7, P657; MOORHEAD GV, 1984, INJURY PATTERNS MAJO; NOJI EK, 1990, ANN EMERG MED, V19, P891, DOI 10.1016/S0196-0644(05)81563-X; NOJI EK, 1987, EVALUATION EFFICACY, P11; NOJI EK, 1989, EARTHQUAKE SPECTRA S, V5, P101; PENICK JL, 1981, NEW MADRID EARTHQUAK, P1; PEPE PE, 1991, CRIT CARE CLIN, V7, P401, DOI 10.1016/S0749-0704(18)30312-9; Pretto E A, 1994, Prehosp Disaster Med, V9, pS39; Pretto E A, 1994, Prehosp Disaster Med, V9, P107; Pretto EA, 1992, PREHOSP DISASTER MED, V7, P327; Quarantelli Enrico L, 1970, AM BEHAV SCI, V13, P325; Safar P., 1986, PREHOSP DISASTER MED, V2, P34, DOI DOI 10.1017/S1049023X00030314; SCHULTZ CH, 1993, WESTERN J MED, V159, P600; SCHULTZ CH, 1991, ANN EMERG MED, V20, P470; SHENG ZY, 1987, J TRAUMA, V27, P1130; STEINBRUGGE KV, 1981, 81113 US GEOL SURV O; STEWART C, 1993, EMERG MED REP, V14, P227; Super G., 1994, START SIMPLE TRIAGE; Thiel C.C., 1992, PREHOSPITAL DISASTER, V7, P348; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vassar MJ, 1991, ARCH SURG-CHICAGO, V126, P43; WAECKERLE JF, 1991, NEW ENGL J MED, V324, P815; YOUNES RN, 1992, SURGERY, V111, P380; 1995, NORTHRIDGE EARTHQUAK; 1983, INCIDENT COMMAND SYS; 1972, STUDY EARTHQUAKE LOS; 1973, STUDY EARTHQUAKE LOS; 1987, CONFRONTING NATURAL, P1	54	188	199	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					438	444		10.1056/NEJM199602153340706	http://dx.doi.org/10.1056/NEJM199602153340706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552147				2022-12-28	WOS:A1996TU69600006
J	Grotzfeld, RM; Branda, N; Rebek, J				Grotzfeld, RM; Branda, N; Rebek, J			Reversible encapsulation of disc-shaped guests by a synthetic, self-assembled host	SCIENCE			English	Article							COMPLEX	Here, the synthesis of a bowl-shaped molecule is described and evidence of its reversible dimerization by means of hydrogen bonds is presented. The dimer features a flattened spherical cavity of peculiar symmetry and acts as a host for the encapsulation of guest molecules of complementary shape. Encapsulation of aromatic guests in chloroform solution and of cyclohexane in p-xylene solution was demonstrated by nuclear magnetic resonance experiments. The passage of guests into and out of the cavity is slow and occurs on a time scale of hours. The system was used to explore the effects of size, shape, and solvation on molecular recognition coupled with assembly.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BARTLE KD, 1965, TETRAHEDRON, V21, P3289, DOI 10.1016/S0040-4020(01)96950-9; BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; BRANDA N, 1995, J AM CHEM SOC, V117, P85, DOI 10.1021/ja00106a010; CHAPMAN KT, 1989, J AM CHEM SOC, V111, P3075, DOI 10.1021/ja00190a058; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4316, DOI 10.1021/ja00089a021; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; QUAN MLC, 1991, J AM CHEM SOC, V113, P2754, DOI 10.1021/ja00007a060; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; SIMARD M, 1991, J AM CHEM SOC, V113, P4696, DOI 10.1021/ja00012a057; VALDES C, 1995, ANGEW CHEM INT EDIT, V34, P1885, DOI 10.1002/anie.199518851; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P939; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991; YANG J, 1993, J AM CHEM SOC, V115, P5314, DOI 10.1021/ja00065a061	19	102	102	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 26	1996	271	5248					487	489		10.1126/science.271.5248.487	http://dx.doi.org/10.1126/science.271.5248.487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR322	8560261				2022-12-28	WOS:A1996TR32200035
J	Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ			Molecular basis of sun-induced premature skin ageing and retinoid antagonism	NATURE			English	Article							IV COLLAGENASE GENE; C-JUN; GLUCOCORTICOID RECEPTOR; ACID; EXPRESSION; GELATINASE; PROMOTER; BINDING; FORMS	DAMAGE to skin collagen and elastin (extracellular matrix) is the hallmark of long-term exposure to solar ultraviolet irradiation(1-3), and is believed to be responsible for the wrinkled appearance of sun-exposed skin(4,5). We report here that matrix-degrading metalloproteinase messenger RNAs, proteins and activities are induced in human skin in vivo within hours of exposure to ultraviolet-B irradiation (UVB). Induction of metalloproteinase proteins and activities occurred at UVB doses well below those that cause skin reddening. Within minutes, low-dose UVB upregulated the transcription factors AP-1 and NF-kappa B, which are known to be stimulators of metalloproteinase genes(6,7). All-trans retinoic acid, which transrepresses AP-1 (ref. 8), applied before irradiation with UVB, substantially reduced AP-1 and metalloproteinase induction, We propose that elevated metalloproteinases, resulting from activation of AP-1 and NF-kappa B by low dose solar irradiation, degrade collagen and elastin in skin, Such damage, if imperfectly repaired would result in solar scars, which through accumulation from a lifetime of repeated low-dose sunlight exposure could cause premature skin ageing (photoageing).	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT DERMATOL,KRESGE 1,R6558,ANN ARBOR,MI 48109, USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; BAILLY C, 1990, J INVEST DERMATOL, V94, P47, DOI 10.1111/1523-1747.ep12873342; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EISEN AZ, 1969, J INVEST DERMATOL, V52, P442, DOI 10.1038/jid.1969.76; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; HU CL, 1978, ANAL BIOCHEM, V88, P638, DOI 10.1016/0003-2697(78)90467-0; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; Lavker RM, 1979, J INVEST DERMATOL, V73, P559; MAUCH C, 1994, ARCH DERMATOL RES, V287, P107, DOI 10.1007/BF00370728; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SATO H, 1993, ONCOGENE, V8, P395; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; WEINSTEIN GD, 1960, J INVEST DERMATOL, V35, P227, DOI 10.1038/jid.1960.109; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	30	1048	1105	8	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					335	339		10.1038/379335a0	http://dx.doi.org/10.1038/379335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552187	Green Submitted			2022-12-28	WOS:A1996TR32300056
J	Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG				Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG			Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes	NATURE			English	Article								DYSREGULATION Of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers(1), or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Recently, we isolated a candidate gene, encoding neuronal apoptosis inhibitor protein (NAIP)(2), for SMA. This gene is homologous to two baculovirus inhibitor of apoptosis proteins(3,4) (Cp-IAP and Op-IAP) and is partly deleted in individuals with type I SMA, A second SMA candidate gene encoding survival motor neuron (SMN), which is contiguous with the NAIP locus on 5q13.1, was also reported(5), Here we demonstrate a NAIP-mediated inhibition of apoptosis induced by a variety of signals, and have identified three additional human complementary DNAs and a Drosophila melanogaster sequence that are also homologous to the baculovirus IAPs, The four open reading frames (ORFs) possess three baculoviral inhibition of apoptosis protein repeat (BIR) domains and a carboxy-terminal RING zinc-finger. The human iap genes have a distinct but overlapping pattern of expression in fetal and adult tissues. These proteins significantly increase the number of known apoptotic suppressors.	CHILDRENS HOSP EASTERN ONTARIO,MOLEC GENET RES LAB,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,APOPTOGEN INC,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA,ON K1H 8M5,CANADA; MED & BIOL LABS CO,NAKA KU,NAGOYA,AICHI 460,JAPAN; TOKAI UNIV,INST MED SCI,KANAGAWA 25911,JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; Tokai University			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUJITA A, 1995, J VIROL, V69, P6180, DOI 10.1128/JVI.69.10.6180-6190.1995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOR H, 1982, J BIOL CHEM, V257, P2419; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	15	855	925	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					349	353		10.1038/379349a0	http://dx.doi.org/10.1038/379349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552191				2022-12-28	WOS:A1996TR32300060
J	Gordon, M				Gordon, M			Government assault on Canada's physicians	LANCET			English	Editorial Material											Gordon, M (corresponding author), UNIV TORONTO,100 COLL ST,TORONTO,ON,CANADA.							1995, LANCET, V345, P333	1	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					137	138		10.1016/S0140-6736(96)90336-0	http://dx.doi.org/10.1016/S0140-6736(96)90336-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544544				2022-12-28	WOS:A1996TQ24400005
J	OBrien, JP				OBrien, JP			Controversies in management - Should backache be treated with spinal fusion? Spinal fusion is the only treatment for discogenic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUMBAR SPINE; POSTERIOR											FARFAN HF, 1981, CLIN ORTHOP RELAT R, P198; Hibbs, 1911, NY MED J, V93, P1013, DOI 10.1097/BLO.0b013e3180686b30; HODGSON AR, 1956, BRIT J SURG, V44, P266, DOI 10.1002/bjs.18004418508; KUSLICH SD, 1991, ORTHOP CLIN N AM, V22, P181; MCCALL IW, 1979, SPINE, V4, P441, DOI 10.1097/00007632-197909000-00009; PARK WM, 1979, BRIT J RADIOL, V52, P382, DOI 10.1259/0007-1285-52-617-382; WEATHERLEY CR, 1986, J BONE JOINT SURG BR, V68, P142, DOI 10.1302/0301-620X.68B1.2934399; WILTSE LL, 1977, CLIN ORTHOP RELAT R, V129, P22; YOSHIZAWA H, 1980, J PATHOL, V132, P95, DOI 10.1002/path.1711320202; 1972, BLAKISTONS GOULD MED, P137	10	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	1996	312	7022					38	39		10.1136/bmj.312.7022.38	http://dx.doi.org/10.1136/bmj.312.7022.38			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP209	8555861	Green Published			2022-12-28	WOS:A1996TP20900027
J	Roberts, I; Kramer, MS; Suissa, S				Roberts, I; Kramer, MS; Suissa, S			Does home visiting prevent childhood injury? A systematic review of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							PRETERM INFANTS; SOCIAL SUPPORT; HEALTH; ABUSE; INTERVENTION; CHILDREN; MOTHERS; PROGRAM; NEGLECT; CARE	Objective-To quantify the effectiveness of home visiting programmes in the prevention of child injury and child abuse. Design-Systematic review of 11 randomised controlled trials of home visiting programmes. Pooled odds ratios were estimated as an inverse variance weighted average of the study specific odds ratios. Setting-Randomised trials that were available by April 1995. Subjects-The trials comprised 3433 participants. Results-Eight trials examined the effectiveness of home visiting in the prevention of childhood injury. The pooled odds ratio for the eight trials was 0.74 (95% confidence interval 0.60 to 0.92). Four studies examined the effect of home visiting on injury in the first year of life. The pooled odds ratio was 0.98 (0.62 to 1.53). Nine trials examined the effect of home visiting on the occurrence of suspected abuse, reported abuse, or out of home placement for child abuse. Because of the potential for bias in outcome reporting in these studies, pooled effect estimates were not calculated. Conclusions-Home visiting programmes have the potential to reduce significantly the rates of childhood injury. The problem of differential surveillance for child abuse between intervention and control groups precludes the use of reported abuse as a valid outcome measure in controlled trials of home visiting.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,FAC MED,DEPT COMMUNITY PAEDIAT RES,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,FAC MED,DEPT PEDIAT,MONTREAL,PQ,CANADA; MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA; ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital								Avery JG, 1933, CHILDREN THEIR ACCID; BARNARD KE, 1988, PSYCHIATRY, V51, P248, DOI 10.1080/00332747.1988.11024399; BARTH RP, 1991, CHILD ABUSE NEGLECT, V15, P363, DOI 10.1016/0145-2134(91)90021-5; BECKWITH L, 1988, PSYCHIATRY, V51, P242, DOI 10.1080/00332747.1988.11024398; BLACK MM, 1994, PEDIATRICS, V94, P440; CASEY PH, 1994, ARCH PEDIAT ADOL MED, V148, P1071, DOI 10.1001/archpedi.1994.02170100069014; CASIRO OG, 1993, PEDIATRICS, V92, P128; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COMBSORME T, 1985, PUBLIC HEALTH REP, V100, P490; CURRIE AL, 1983, J FAM PRACTICE, V17, P635; DAWSON P, 1989, J DEV BEHAV PEDIATR, V10, P63; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; FIELD TM, 1980, CHILD DEV, V51, P426; GRAY JD, 1979, J SOC ISSUES, V35, P127, DOI 10.1111/j.1540-4560.1979.tb00805.x; GREENBERG RA, 1994, J BEHAV MED, V17, P273, DOI 10.1007/BF01857953; HALL LA, 1980, NURS RES, V29, P317; HARDY JB, 1989, J PEDIATR-US, V115, P927, DOI 10.1016/S0022-3476(89)80744-9; Infante-Rivard C, 1989, CHILDRENS HLTH CARE, V18, P102; JOHNSON DL, 1987, AM J COMMUN PSYCHOL, V15, P375, DOI 10.1007/BF00915208; JOHNSON Z, 1993, BRIT MED J, V306, P1449, DOI 10.1136/bmj.306.6890.1449; KEMPE CH, 1976, AM J DIS CHILD, V130, P941, DOI 10.1001/archpedi.1976.02120100031005; LARSON CP, 1980, PEDIATRICS, V66, P191; LEALMAN GT, 1983, LANCET, V1, P1423; LOWE ML, 1970, NURS RES, V19, P59, DOI 10.1097/00006199-197019010-00010; MADDEN J, 1984, CHILD DEV, V55, P636; MARCENKO MO, 1994, AM J ORTHOPSYCHIAT, V64, P468, DOI 10.1037/h0079547; NICOL AR, 1984, J ROY SOC MED, V77, P488; OLDS DL, 1986, PEDIATRICS, V78, P65; OLDS DL, 1990, PEDIATRICS, V86, P108; OLDS DL, 1995, ARCH PEDIAT ADOL MED, V149, P76; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; POWELL C, 1989, Pediatrics, V84, P157; PRENDIVILLE W, 1988, BRIT J OBSTET GYNAEC, V95, P3, DOI 10.1111/j.1471-0528.1988.tb06475.x; SCARR S, 1988, CHILD DEV, V59, P531, DOI 10.1111/j.1467-8624.1988.tb03214.x; SHYNE AW, 1963, NURS OUTLOOK, V11, P56; SIEGEL E, 1980, PEDIATRICS, V66, P183; STANWICK RS, 1982, CAN J PUBLIC HEALTH, V73, P200; THOMPSON RJ, 1982, J DEV BEHAV PEDIATR, V3, P18; VINES SW, 1994, PUBLIC HEALTH NURS, V11, P188, DOI 10.1111/j.1525-1446.1994.tb00400.x; WOLF B, 1965, ANN HUM GENET, V19, P251; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; Yauger R A, 1972, Nurs Outlook, V20, P320; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1990, 017092001045 US ADV	44	108	112	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	1996	312	7022					29	33		10.1136/bmj.312.7022.29	http://dx.doi.org/10.1136/bmj.312.7022.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP209	8555855	Green Published			2022-12-28	WOS:A1996TP20900022
J	Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV				Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV			The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR; ZINC-FINGER; IDENTIFICATION; SEQUENCE; CLONING; MOTIF	The 75 kDa tumor necrosis factor receptor (TNFR2) transduces extracellular signals via receptor-associated cytoplasmic proteins. Two of these signal transducers, TRAF1 and TRAF2, were isolated and characterized previously. We report here the biochemical purification and subsequent molecular cloning of two novel TNFR2-associated proteins, designated c-IAP1 and c-IAP2, that are closely related mammalian members of the inhibitor of apoptosis protein (IAP) family originally identified in baculoviruses. The viral and cellular IAPs contain N-terminal baculovirus IAP repeat (BIR) motifs and a C-terminal RING finger. The c-IAPs do not directly contact TNFR2, but rather associate with TRAF1 and TRAF2 through their N-terminal BIR motif-comprising domain. The recruitment of c-IAP1 or c-IAP2 to the TNFR2 signaling complex requires a TRAF2-TRAF1 heterocomplex.	GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech	Rothe, M (corresponding author), TULARIK INC, DEPT BIOL MOLEC, 270 E GRAND AVE, San Francisco, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAUNAGEL SC, 1992, VIROLOGY, V191, P1003, DOI 10.1016/0042-6822(92)90281-S; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PENNICA D, 1992, J BIOL CHEM, V267, P21172; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROTH E, 1995, M SCIENCE, V269, P1424; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J, 1989, MOL CLONING LABORATO; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	43	1028	1091	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1243	1252		10.1016/0092-8674(95)90149-3	http://dx.doi.org/10.1016/0092-8674(95)90149-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548810	Bronze			2022-12-28	WOS:A1995TM76200019
J	Hanlon, P; McEwen, J; Carey, L; Gilmour, H; Tannahill, C; Tannahill, A; Kelly, M				Hanlon, P; McEwen, J; Carey, L; Gilmour, H; Tannahill, C; Tannahill, A; Kelly, M			Health checks and coronary risk: Further evidence from a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine the effectiveness of a health check and assess any particular benefits resulting from feedback of plasma cholesterol concentration or coronary risk score, or both. Design-Randomised controlled trial in two Glasgow work sites. Subjects-1632 employees (89% male) aged 20 to 65 years. Interventions-At the larger work site, (a) health education; (b) health education and feedback on cholesterol concentration; (c) health education and feedback on risk score; (d) health education with feedback on cholesterol concentration and risk score (full health check); (e) no health intervention (internal control). At the other work site there was no health intervention (external control). Main outcome measures-Changes in Dundee risk score, plasma cholesterol concentration, diastolic blood pressure, body mass index, and self reported behaviours (smoking, exercise, alcohol intake, and diet) in comparison with internal and external control groups. Results-Comparisons between the full health check and the internal control groups showed a small difference (0 . 13 mmol/l) in the change in mean cholesterol concentration (95% confidence interval 0 . 02 to 0 . 22, P=0 . 02) but no significant differences for changes in Dundee risk score (P=0 . 21), diastolic blood pressure (P=0 . 71), body mass index (P=0 . 16), smoking (P=1 . 00), or exercise (P=0 . 41). Significant differences between the two groups were detected for changes in self reported consumption of alcohol (41% in group with full health check v 17% in internal control group, P=0 . 001), fruit and vegetables (24% v 12%, P<0 . 001), and fat (30% v 9%, P<0 . 001). Comparison of all groups showed no advantage from feedback of cholesterol concentration or risk score, or both. Conclusions-The health check only had a small effect on reversible coronary risk. It was effective in influencing self reported alcohol consumption and diet. Feedback on cholesterol concentration and on risk score did not provide additional motivation for a change in behaviour.	GREATER GLASGOW HLTH BOARD, DEPT HLTH PROMOT, GLASGOW G2 4JT, LANARK, SCOTLAND; HLTH EDUC BOARD SCOTLAND, EDINBURGH EH10 5SG, MIDLOTHIAN, SCOTLAND; UNIV GREENWICH, LONDON SE9 2HB, ENGLAND	University of Greenwich	Hanlon, P (corresponding author), UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND.							Hanlon P, 1992, COMMUNITY PREVENTION, P181; LEWIS M, 1994, HLTH B EDINB, V52, P65; SOLONEN JT, 1979, BRIT MED J, V2, P1178; The South-East London Screening Study Group, 1977, INT J EPIDEMIOL, V6, P357; TOON PD, 1995, BRIT MED J, V310, P1083, DOI 10.1136/bmj.310.6987.1083; Tunstall-Pedoe H, 1986, Health Bull (Edinb), V44, P153; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; 1992, SCOTLANDS HLTH CHALL; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1994, BRIT MED J, V38, P308; 1995, BRIT MED J, V310, P1099; 1986, LANCET, V1, P869; 1989, BLOOD CHOLESTEROL ME; 1994, BRIT MED J, V38, P313	15	40	40	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	1995	311	7020					1609	1613		10.1136/bmj.311.7020.1609	http://dx.doi.org/10.1136/bmj.311.7020.1609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL422	8555805	Green Published			2022-12-28	WOS:A1995TL42200024
